EAHP represents over 30,000 hospital pharmacists across 37 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professional
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic, Germany, Italy and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
The Early Career Network aims to empower early-career pharmacists by sharing opportunities, insights, and success stories from across 25 member countries.
Together, we’re building a stronger, more connected hospital pharmacy community: one story, one country, one pharmacist at a time.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Please find below the online abstract Poster Walks of the last EAHP Congresses.
Please select the desired annual Congress to view the posters presented in the different topic categories.
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| 0.05% atropine for myopia treatment for children in Estonia: Development of a protocol to prepare eye drops and the effect and tolerability in a twelve-month treatment in East Tallinn Central Hospital | NP-001 | |
| Impact of pharmacist interventions on hospitalizations in heart failure: a systematic review and meta-analysis | NP-002 | |
| Clinical Laboratory Pharmacy Aspects of Precision Vancomycin Therapy | NP-003 | |
| Effect of High-Dose Intravitreal Aflibercept in Patients With Neovascular Age-Related Macular Degeneration: Comparison of Real-World Outcomes with Pharmacokinetic Model | NP-004 | |
| Salt or base? Clear labeling of the reference value to prevent dosing errors: A case study | NP-005 | |
| Hospital pharmacist’s consulting activities | NP-006 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ENVIROMENTAL IMPACT OF PHARMACEUTICALS: A SURVEY ON KNOWLEDGE OF PATIENTS ATTENDING A HOSPITAL PHARMACY DISPENSING SERVICE | 1ISG-001 | |
| ESTIMATION OF THE HIDDEN COSTS OF DRUG PREPARATIONS IN EARLY ACCESS AUTHORIZATION AND COMPASSIONATE USE AUTHORIZATION OVER 18 MONTHS | 1ISG-001 | |
| HIGH STABILITY, HIGH RISK: THE DUAL CHALLENGE OF EXPERIENCE RETENTION VERSUS DEMOGRAPHIC DECLINE IN ESTONIAN HOSPITAL PHARMACIES | 1ISG-002 | |
| COST-EFFECTIVENESS OF BEMPEDOIC ACID VERSUS EZETIMIBE IN STATIN-INTOLERANT PATIENTS: A PAYER PERSPECTIVE | 1ISG-004 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| TERRITORIAL AND SIZE-BASED ANALYSIS OF DETERMINANTS OF MEDICATION EXPENDITURE IN NURSING HOMES | 2SPD-001 | |
| PRE-EXPOSURE PROPHYLAXIS (PrEP) IN SPAIN: ACCESS, FINANCING AND ECONOMIC IMPACT OF A POTENTIAL TRANSITION TO FROM HOSPITAL PHARMACY TO COMMUNITY PHARMACY DISPENSING | 2SPD-002 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ORAL VANCOMYCIN: VIALS VS CAPSULES | 3PC-001 | |
| COMPLIANCE OF STANDARDIZED PARENTERAL NUTRITION WITH INDIVIDUALIZED PRESCRIPTIONS IN A NEONATAL INTENSIVE CARE UNIT | 3PC-002 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IMPLEMENTATION OF A VALUE-BASED TELEPHARMACY MODEL FOR MONITORING SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS | 4CPS-001 | |
| IMPORTANCE OF INDIVIDUALIZING RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE | 4CPS-002 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| STATIN POTENTIAL DEPRESTSCRIPTION IN INSTITUTIONALIZED ELDERLY PATIENTS | 5PSQ-001 | |
| TWELVE YEARS OF CLINICAL PHARMACIST-LED ADVERSE DRUG REACTION REPORTING IN ONCOLOGY PATIENTS AT A UNIVERSITY HOSPITAL | 5PSQ-002 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ASSESSMENT OF HERBAL AND NON-PRESCRIPTION DRUG USE IN AN UNDERSERVED PATIENT POPULATION | 6ER-001 | |
| Evolving the “E” in Entrustable Professional Activities: mapping entrustment across the pharmacy degree | 6ER-002 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
 | DEVELOPING AN IN-HOUSE COMPREHENSIVE MEDICATION REVIEW TRAINING PROGRAMME FOR CLINICAL PHARMACISTS IN A FINNISH HOSPITAL PHARMACY | NP-001 |
| IMPACT OF BLOOD SAMPLE HANDLING DURING 99MTC-CERETEC LEUKOCYTE LABELING ON IMAGE QUALITY AND INTERPRETATION | NP-002 |
| IMPACT OF BLOOD SAMPLE HANDLING DURING 99MTC-CERETEC LEUKOCYTE LABELING ON IMAGE QUALITY AND INTERPRETATION | NP-002 | |
| LEARNING PROGRESS OF ARTIFICIAL INTELLIGENCE IN ANSWERING CLINICAL-PHARMACEUTICAL QUESTIONS | NP-003 |
| IMPACT OF ANTIBIOTIC STEWARDSHIP PROGRAM (ASP) ON ANTIBIOTIC USE AND CLINICAL OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP): RETROSPECTIVE OBSERVATIONAL BEFORE-AFTER STUDY | NP-004 | |
| PENICILLIN ALLERGY AWARENESS AND DE-LABELLING | NP-005 |
| PREVENTION MEASURES AGAINST CANDIDA AURIS DIFFUSION IN NOCOSOMIAL SETTINGS | NP-006 |
| INFANT BOTULISM – EXPERIENCE OF 3 CASES-REPORT IN A PAEDIATRIC HOSPITAL | NP-007 |
| COMPATIBILITY OF INTRAVENOUS MEDICATIONS ADMINISTERED VIA Y-SITE | NP-008 |
| DEVELOPMENT AND VALIDATION OF A POPULATION PHARMACOKINETIC MODEL OF TEICOPLANIN IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES | NP-009 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| USE OF A GOVERNMENT DIGITAL TOOL IN DRUG EVALUATION FOR HOSPITAL PHARMACIES | 1ISG-001 |
| COMPARATIVE PHARMACOECONOMIC ANALYSIS OF COST-EFFECTIVENESS BETWEEN ERENUMAB, FREMANEZUMAB, AND GALCANEZUMAB IN THE PREVENTIVE TREATMENT OF EPISODIC AND CHRONIC MIGRAINE | 1ISG-002 | |
| COST EVALUATION OF OFF-LABEL THERAPY OF METHICILLIN-RESISTANT S. AUREUS OSTEOMYELITIS (MRSA) WITH DALBAVANCIN VS STANDARD OF CARE IN AN HEALTCARE COMPANY | 1ISG-003 |
| PHARMACOECONOMIC ANALYSIS OF LIPOSOMAL IRINOTECAN AS SECOND-LINE TREATMENT FOR ADVANCED PANCREATIC CANCER VERSUS STANDARD THERAPY FOLFIRINOX | 1ISG-004 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN A MULTIDISCIPLINARY TELEPHARMACY PROGRAMME | 1ISG-005 |
| GENDER DIFFERENCES IN WORK ENVIRONMENT PERCEPTIONS AMONG HOSPITAL PHARMACISTS | 1ISG-006 |
| COST ANALYSIS OF REMDESIVIR AND NIRMATRELVIR/RITONAVIR FOR THE EARLY TREATMENT OF COVID19 VULNERABLE PATIENTS | 1ISG-007 |
| COMPASSIONATE USE AND NOMINAL THERAPEUTIC USE: ACCESS TO INNOVATIVE TREATMENTS AND ECONOMIC IMPACT ON THE NATIONAL HEALTH SERVICE | 1ISG-008 | |
| OPTIMIZING NON-CLINICAL DRUG MANAGEMENT PROCESSES THROUGH ROOT CAUSE ANALYSIS | 1ISG-009 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ENVIRONMENTAL IMPACT MANAGEMENT OF INHALERS FROM THE HOSPITAL PHARMACY: THE GIMAFH PROJECT | 2SPD-001 |
| DEVELOPMENT AND IMPACT OF A DASHBOARD FOR DRUG SHORTAGE PREDICTION AND MANAGEMENT: A BEFORE-AND-AFTER STUDY | 2SPD-002 |
| EVOLUTION OF TREATMENT CONSUMPTION IN SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS (2018-2023) | 2SPD-003 |
| IMPACT ON CONSUMPTION AND BUDGET DUE TO SUPPLY SHORTAGES | 2SPD-004 |
| CEMIPLIMAB PLUS CHEMOTHERAPY AS FIRST-LINE TREATMENT IN LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PDL-1 EXPRESSION ≥1%: COMPARISON VS. CURRENT ALTERNATIVES | 2SPD-005 |
| BUDGETARY IMPACT OF AZTREONAM SHORTAGE IN THE TREATMENT OF METALLO-BETA-LACTAMASE-PRODUCING GRAM-NEGATIVE BACTERIA | 2SPD-006 |
| CHARACTERISTICS OF PERIOPERATIVE IMMUNOTHERAPY CLINICAL TRIALS IN NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW | 2SPD-007 |
| FIVE YEARS OF THE FALSIFIED MEDICINES DIRECTIVE: A COMPARATIVE ANALYSIS OF COMPLIANCE AND IMPACT IN HOSPITAL PHARMACY | 2SPD-008 |
| IMPACT OF HOSPITAL TRANSPORT SYSTEMS, INCLUDING PNEUMATIC TUBES, ON PROTEIN STABILITY IN IV BAGS AND SYRINGES | 2SPD-009 |
| AN ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF EFGARTIGIMOD-ALFA, RAVULIZUMAB, AND ECULIZUMAB FOR TREATING ACETYLCHOLINE RECEPTOR AUTO-ANTIBODY-POSITIVE (AChR-Ab+) GENERALIZED MYASTHENIA GRAVIS | 2SPD-010 |
| COMPARATIVE ANALYSIS OF EXPIRY MANAGEMENT OF MEDICATIONS AFTER THE IMPLEMENTATION OF AUTOMATED DRUG DISPENSING SYSTEMS | 2SPD-011 |
| AUTOMATION OF NARCOTIC DRUG PROCESS: AN OPPORTUNITY FOR IMPROVEMENT | 2SPD-012 |
| EFFECTIVENESS AND EFFICIENCY OF PCSK9 INHIBITORS: CLINICAL PRACTICE EXPERIENCE | 2SPD-013 |
| REDUCTION OF CARBON FOOTPRINT BY IMPLEMENTING AUTOMATED MEDICINE DISPENSING SYSTEMS IN HOSPITALIZATION UNITS | 2SPD-014 |
| MEDICO-ECONOMIC EVALUATION OF SINGLE-USE VERSUS REUSABLE HYSTEROSCOPES IN OUTPATIENT GYNECOLOGICAL CONSULTATIONS | 2SPD-015 |
| SMART COUNTING: THE ROLE OF ARTIFICIAL INTELLIGENCE IN CONTROLLED MEDICATION MANAGEMENT | 2SPD-016 |
| ECONOMIC IMPACT OF ORPHAN DRUGS ON A THIRD-LEVEL HOSPITAL | 2SPD-017 | |
| ADJUSTED INDIRECT COMPARISON BETWEEN PLOZASIRAN AND ZODASIRAN IN MIXED HYPERLIPIDEMIA | 2SPD-018 |
| HOSPITAL PHARMACISTS ADDRESSING MEDICATION SHORTAGES IN THE EUROPEAN UNION: A COMPARATIVE ANALYSIS OF CAUSES AND SOLUTIONS IN BULGARIA AND THE EU | 2SPD-019 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| STORAGE OF FARICIMAB AND HIGH-DOSE AFLIBERCEPT IN POLYPROPYLENE SYRINGES DOES NOT IMPAIR ANTIBODY INTEGRITY AFTER 28 DAYS | 3PC-001 |
| EVALUATION STUDY OF A PEDIATRIC NON-HAZARDOUS ROBOTIC COMPOUNDING SYSTEM: IS IT SAFE AND DOSE ACCURATE? | 3PC-002 |
| FORMULATION OF AN ORAL PEDIATRIC SUSPENSION OF AMLODIPINE 1 mg/mL: ADAPTATION TO THE NATIONAL FORMULARY AND STABILITY TESTING | 3PC-003 |
| IMPLEMENTATION OF AN ASEPTIC TECHNIQUE VALIDATION PROTOCOL IN A PHARMACY DEPARTMENT | 3PC-004 |
| COMPOUNDING IMIQUIMOD SUPPOSITORIES FOR CONDILOMA ACUMINATA | 3PC-005 |
| SWITCHING TO SILICONE OIL FREE SYRINGES FOR INTRAVITREAL APPLICATION: DESIGN OF A REGULATORY COMPLIANT CONTAINER CLOSURE INTEGRITY TEST REALIZABLE IN A HOSPITAL PHARMACY | 3PC-006 |
| ACCURACY AND STERILITY PERFORMANCE OF A NEW PHARMACY ROBOT-CLOSED SYSTEM TRANSFER DEVICE COMBINATION | 3PC-007 |
| PHYSICOCHEMICAL STABILITY OF FIVE BETA-LACTAM ANTIBIOTICS UNDER SIMULATED REAL-LIFE CONDITIONS IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY (OPAT) | 3PC-008 |
| ECONOMICAL IMPACT ASSOCIATED WITH A FARICIMAB VIAL SHARING PROTOCOL IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION IN THE HOSPITAL OF SAGUNTO | 3PC-009 |
| MICROBIOLOGICAL EVALUATION OF COMPOUNDED HOSPITAL PARENTERAL SOLUTIONS FOR PRETERM INFANTS | 3PC-010 | |
| ANALYSIS OF ALERTS IN THE PRODUCTION OF PERSONALIZED DOSAGE SYSTEMS FOR PATIENTS IN NURSING HOMES: A QUALITY STUDY | 3PC-011 | |
| SODIUM PENTOBARBITAL RECTAL PREPARATIONS: OPTIMISATION OF A MANUFACTURING PROCESS, AND DEVELOPMENT OF FORMULATION | 3PC-012 |
| IN THIS ABSTRACT WE EXPLAIN THE COMPOUNDING OF BEVACIZUMAB EYE DROPS FOR NEOVASCULARIZACION, SOME STUDIES HAVE DEMONSTRATED THEIR EFFICACY, IT HAS 1 MONTH STABILITY | 3PC-013 |
| APPLICATION OF 3D PRINTING TO THE FORMULATION OF A NOVEL ANTICANCER AGENT FOR PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA | 3PC-014 |
| DEVELOPMENT AND PREPARATION OF A GEL FOR URETHRAL ADMINISTRATION OF 5-FLUOROURACIL AND LIDOCAINE FOR THE TREATMENT OF CONDYLOMA ACUMINATUM | 3PC-015 |
| STABILITY EVALUATION OF FOUR METHADONE INTRAVENOUS MIXTURES USED IN PALLIATIVE SEDATION | 3PC-016 |
| ASSESSING THE CARBON IMPACT RELATED TO THE PRODUCTION OF ANTICANCER DRUGS IN ISOLATOR AND AUTOMATED CHEMOTHERAPY PREPARATION ROBOT | 3PC-017 |
| POORLY WATER-SOLUBLE DRUGS: IS THE COMPOUNDING OF ADAPTED DOSES BETTER THAN PHARMACEUTICAL MARKETED SPECIALTIES? EXAMPLE OF DIAZOXIDE | 3PC-018 |
| DEVELOPMENT OF A SODIUM THIOSULPHATE 15% + ZINC OXIDE 15% TOPICAL FORMULATION FOR THE TREATMENT OF CALCINOSIS CUTIS | 3PC-019 | |
| COMPARISON OF ROBOTIC AND MANUAL RECONSTITUTION: STABILITY ASSESSMENT OF PROTEIN DRUGS IN HOSPITAL COMPOUNDING | 3PC-020 |
| ANAKINRA EYE DROPS FOR THE TREATMENT OF DRY EYE ASSOCIATED WITH GRAFT-VERSUS-HOST DISEASE (GVHD): CASE REPORT | 3PC-021 |
| OPTIMIZATION OF QUALITY CONTROL FOR 68GA-EDOTREOTIDE (SOMAKIT®): TIME IS OF THE ESSENCE… | 3PC-022 |
| FORMULATION AND CHARACTERIZATION OF FLUORESCEIN SODIUM SOLUTION FOR INJECTION FOR DIAGNOSTIC ANGIOGRAPHY | 3PC-023 |
| EFFECTIVENESS OF PLERIXAFOR IN HEMATOPOIETIC STEM CELL MOBILISATION AND REPACKAGING STRATEGY TO REDUCE COST | 3PC-024 |
| IMPLEMENTATION OF FULLY AUTOMATIZED IN-HOUSE SYNTHESIS OF THERAPEUTIC RADIOPHARMACEUTICAL [177LU]LU-DOTA-TOC | 3PC-025 |
| LEACHABLES IN SYRINGES CONTAINING ETHANOL, PROPOFOL OR MRNA VACCINE | 3PC-026 |
| OPTIMIZATION OF THE LIQUID ORAL FORMS PROCESS: EXAMPLE OF A SEMI-AUTOMATED DEVICE AND ITS QUALIFICATION | 3PC-027 |
| EVALUATION AND ANALYSIS OF HUMAN HEALTH HAZARDS OF RAW MATERIALS USED FOR COMPOUNDING IN THE HOSPITAL PHARMACY DEPARTMENT. | 3PC-028 |
| COMPATIBILITY OF AGE-APPROPRIATE COMPOUNDED ORAL SUSPENSIONS | 3PC-029 |
| DESIGN AND DEVELOPMENT OF A MAGISTRAL FORMULATION OF MOUTHWASH FOR THE TREATMENT OF MUCOSITIS: A CASE REPORT. | 3PC-030 |
| STUDY ON THE ADSORPTION OF RADIOPHARMACEUTICALS ON SYRINGE WALLS AND STERILIZATION FILTERS | 3PC-031 |
| METRONIDAZOLE 2%+ LIDOCAINE 2% GEL IN CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK – CASE REPORT | 3PC-032 |
| STABILITY OF TENECTEPLASE SYRINGES AFTER FRACTIONATION | 3PC-033 |
| DEVELOPMENT OF A DENSITY MEASUREMENT PROTOCOL FOR INJECTABLE STERILE DRUGS: APPLICATION TO AMSACRINE IN A HOSPITAL PHARMACY | 3PC-034 |
| THE STABILITY OF CYCLOPHOSPHAMIDE (CPA) AND MESNA MIXTURE IS SHORTENED BY CYCLOPHOSPHAMIDE INSTABILITY CAUSING QUICK PH DECREASE IN SOLUTION | 3PC-035 |
| NEW THERAPEUTIC APPROACH FOR DIFFUSE MIDLINE GLIOMA: 3-YEAR EVALUATION OF ACCESS TO ONC201 IN FRANCE AND EUROPE | 3PC-036 |
| STABILITY STUDY OF HYDROCORTISONE 1MG/ML ORAL SUSPENSION FOR NEONATAL USEINSTABILITY CAUSING QUICK PH DECREASE IN SOLUTION | 3PC-037 |
| COMPOUNDING AND PHYSICOCHEMICAL STABILITY STUDY OF DEXAMETHASONE MOUTHWASH 0.1 MG/ML TO PREVENT STOMATITIS ASSOCIATED WITH EVEROLIMUS | 3PC-038 |
| PREPARATION AND STABILITY OF READY-TO-ADMINISTER DEXAMETHASONE DIHYDROGEN PHOSPHATE 8 MG/ML / 0.02% HYALURONIC ACID INTRATYMPANAL INJECTION SOLUTION | 3PC-039 |
| ORAL SUSPENSION OF DAPSONE 2 MG/ML. EFFICACY, SAFETY AND FORMULATION IN PEDIATRIC PATIENT WITH LINEAR Ig A DERMATOSIS: A CASE REPORT. | 3PC-040 |
| EPICUTANEOUS PATCH TEST PREPARATION IN IDENTIFYING ALLERGENIC COMPONENTS IN A COSMETIC CREAM: A CASE REPORT | 3PC-041 |
| CYBER RESILIENCE : DEVELOPMENT OF A DIGITAL CLINICAL CONTINUITY SOLUTION TO MAINTAIN SAFE PRESCRIPTION AND COMPOUNDING ASSISTANCE IN ONCOLOGY | 3PC-042 |
| HOW RELIABLE IS PATCH TESTING? APPLICABILITY IN REAL-LIFE PRACTICE FOR THE DIAGNOSIS OF ALLERGIC REACTIONS | 3PC-043 |
| NOVEL METHOD OF COMPOUNDING AN ORAL TEMOZOLOMIDE SUSPENSION FOR PAEDIATRIC CANCER PATIENTS | 3PC-044 |
| COMPARISON OF HYDROCHLOROTHIAZIDE DOSAGE FORMS : EVALUATION OF 3D PRINTED TABLETS VERSUS CAPSULES AND SUSPENSIONS IN HOSPITAL PHARMACY | 3PC-045 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| MONITORIZATION OF OFF-LABEL USE OF MONOCLONAL ANTIBODIES | 4CPS-001 |
| MICRO-ELIMINATION OF HEPATITIS C IN A MIGRANT AREA: DECENTRALISATION OF THE OUTPATIENT CLINIC | 4CPS-002 |
| ANALYSIS OF THE RESULTS OF ASSISTED REPRODUCTION TREATMENTS | 4CPS-003 | |
| REAL-WORLD OUTCOMES OF ALPELISIB: IMPLICATIONS OF PIK3CA VARIANTS. | 4CPS-004 |
| REAL-LIFE USE OF CEFTAZIDIME-AVIBACTAM | 4CPS-005 |
| CLINICAL PHARMACIST INTERVENTIONS WITHIN A GERIATRIC MOBILE TEAM | 4CPS-006 |
| EFFICACY AND SAFETY OF AVELUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | 4CPS-007 |
| IS LINEZOLID PENETRATION IN THE MEDIASTINUM ADEQUATE?: A CASE REPORT | 4CPS-008 |
| RESOLUTION OF ELECTRONIC PRESCRIBING ERRORS AFTER INTERVENTION FROM A SPECIALIZED HOSPITAL PHARMACIST OR NON-SPECIALIZED HOSPTIAL PHARMACIST: A RETROSPECTIVE CROSS-SECTIONAL STUDY | 4CPS-009 |
| RECONCILIATION OF EYE DROPS FOR GLAUCOMA IN THE EMERGENCY DEPARTMENT | 4CPS-010 |
| ANTIMICROBIAL STEWARDSHIP RECOMMENDATIONS IN PATIENTS WITH RESPIRATORY TRACT INFECTIONS IN AN INTERMEDIATE CARE HOSPITAL | 4CPS-011 |
| CLASSIFICATION AND ASSESSMENT OF THE COMPLEXITY OF ONCO-HAEMATOLOGY CLINICAL TRIALS FROM A PHARMACY SERVICE PERSPECTIVE | 4CPS-012 |
| OPTIMIZATION OF EMPIRICAL USE OF CEFTAZIDIME/AVIBACTAM IN A MEDIUM-COMPLEXITY HOSPITAL: IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAM MULTIDISCIPLINARY TEAM INTERVENTIONS | 4CPS-013 |
| SAFETY PROFILE OF ENZALUTAMIDE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER: REAL LIFE DATA | 4CPS-014 |
| THERAPEUTIC OPTIMISATION IN OLDER INPATIENTS : IS MELATONIN A REAL DEAL ? | 4CPS-015 |
| EVALUATION OF A PHARMACIST-LED DEPRESCRIBING INTERVENTION IN A POLYMEDICATED ELDERLY POPULATION USING THE CLEO TOOL: OPTIMISING PHARMACOTHERAPY IN CHRONIC PATIENTS. | 4CPS-016 |
| EVALUATION OF EFFECTIVENESS AND SAFETY OF ALIROCUMAB AND EVOLOCUMAB IN REAL-WORLD SETTINGS | 4CPS-017 |
| AVOIDED COST IN COAGULATION FACTORS IN CONGENITAL COAGULOPATIES CLINICAL TRIALS | 4CPS-018 |
| ANALYSIS OF CLINICAL TRIAL SITE SELECTION VISITS | 4CPS-019 |
| EVALUATION OF CHANGES TO PHARMACIST-LED SERVICE FOR ELECTIVE VASCULAR SURGERY PATIENTS IN THE PERIOPERATIVE TIMEFRAME. | 4CPS-020 | |
| ANALYSIS OF GLYCEMIC CONTROL IN ELDERLY TYPE 2 DIABETIC PATIENTS INSTITUTIONALIZED IN SOCIO-HEALTHCARE CENTERS | 4CPS-021 |
| CONTROVERSIES IN THE PREOPERATIVE MANAGEMENT OF SGLT2 INHIBITORS | 4CPS-022 |
| OCCURRENCE OF POTENTIAL PRESCRIBING CASCADES AFTER HOSPITAL DISCHARGE: A COHORT STUDY | 4CPS-023 |
| IMPLEMENTATION OF A PATIENT STRATIFICATION METHOD TO PRIORITIZE MEDICATION RECONCILIATION AT ADMISSION IN THE EMERGENCY DEPARTMENT | 4CPS-024 |
| MEDICATION EXTRAVASATION MANAGEMENT AND OUTCOMES IN PATIENTS WHO EXPERIENCED AN EXTRAVASATION OF MEDICATION DURING HOSPITAL ADMISSION: A MIXED-METHOD STUDY | 4CPS-025 |
| CLINICAL EVOLUTION COMPARED BETWEEN SINGLE-TABLET REGIMENS AND LONG-ACTING ANTIRETROVIRALS AFTER 12 MONTHS OF TREATMENT | 4CPS-026 |
| NEOADJUVANT DOUBLE ANTI-HER2 BLOCKADE COMBINED WITH ANTHRACYCLINE-FREE CHEMOTHERAPY, RESULTS IN LOCALLY ADVANCED BREAST CANCER. | 4CPS-027 |
| REAL-LIFE STUDY OF THE USE OF CYCLIN-DEPENDENT KINASE INHIBITORS IN HORMONE-RECEPTOR POSITIVE BREAST CANCER | 4CPS-028 |
| COST-EFFECTIVENESS OF ECULIZUMAB FOR ACTIVE ANTIBODY-MEDIATED REJECTION IN EARLY POST-KIDNEY TRANSPLANTATION PATIENTS | 4CPS-029 | |
| PATIENT-REPORTED OUTCOMES IN INTERSTITIAL LUNG DISEASE AND ADHERENCE TO ANTIFIBROTIC THERAPY | 4CPS-030 |
| EVALUATION OF PHARMACIST’S CONTRIBUTION TO THE PREVENTION OF SURGICAL SITE INFECTIONS (SSI) | 4CPS-031 |
| PALBOCICLIB AND RIBOCICLIB: DOSE ADJUSTMENT BY TOXICITY AND ITS IMPACT IN HEALTH OUTCOMES. | 4CPS-032 |
| ABIRATERONE OFF LABEL USE IN COMBINATION WITH DOCETAXEL AND ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH METASTASIC HORMONE SENSITIVE PROSTATE CANCER: A REAL WORLD EXPERIENCE | 4CPS-033 |
| REAL-WORLD STUDY OF TRIFLURIDINE/TIPIRACIL-BEVACIZUMAB IN METASTATIC COLORECTAL CANCER | 4CPS-034 |
| PERSISTENCE OF UPADACITINIB TREATMENT IN ITS DIFFERENT INDICATIONS | 4CPS-035 |
| ANALYSIS OF PHARMACOTHERAPEUTIC INTERVENTIONS AT EMERGENCY DEPARTMENT | 4CPS-036 |
| PRESCRIBING PATTERNS OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS (SGLT2i) IN HEART FAILURE: A RETROSPECTIVE STUDY IN A MEDICAL CENTER | 4CPS-037 |
| REAL-LIFE STUDY OF THE USE OF TUMOR NECROSIS FACTOR INHIBITORS IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE | 4CPS-038 |
| SIX-MONTH EVALUATION OF THE CLINICAL AND ECONOMIC IMPACT OF PHARMACEUTICAL COUNSELING IN MULTIDISCIPLINARY DAY HOSPITALS FOR GERIATRICS. | 4CPS-039 |
| EVALUATION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN LOW, MODERATE, AND HIGH EMETIC CHEMOTHERAPY BETWEEN SEXES | 4CPS-040 |
| ANALYSIS OF ADHERENCE TO JANUS KINASE INHIBITORS IN PATIENTS WITH AUTOINMMUNE DISEASES: INFLUENCING FACTORS AND OUTCOMES | 4CPS-041 |
| EXPERIENCE WITH INTRANASAL ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION | 4CPS-042 |
| ASSOCIATIONS BETWEEN ROUTINE BLOOD TESTS AND MEDICATION USE WITH ADVERSE CLINICAL OUTCOMES IN ACUTELY ADMITTED MEDICAL PATIENTS | 4CPS-043 |
| PROACTIVE MONITORING OF INFLIXIMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE OVER A 4-YEAR PERIOD. | 4CPS-044 |
| LONG-TERM EFFECTIVENESS AND SAFETY OF PROACTIVE THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY | 4CPS-045 |
| THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN PAEDIATRIC SEVERE VERY EARLY-ONSET INFLAMMATORY BOWEL DISEASE | 4CPS-046 |
| TREATMENT OF WARM ANTIBODIES HEMOLYTIC ANEMIA WITH ABATACEPT – CASE REPORT | 4CPS-047 |
| BROLUCIZUMAB: EFFECTIVENESS AND SAFETY IN ROUTINE CLINICAL PRACTICE. | 4CPS-048 | |
| EFFECTIVENESS AND SAFETY OF RISANKIZUMAB AS INDUCTION THERAPY FOR CROHN’S DISEASE. | 4CPS-049 |
| MULTICENTRE EVALUATION OF MIGRAINE PREVENTIVE TREATMENT WITH CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTIBODIES EFFICACY AFTER A THERAPEUTIC HOLIDAY. | 4CPS-050 |
| EVALUATION OF THE RESPONSE OF MONOCLONAL ANTIBODIES AGAINST MIGRAINE AFTER THE APPLICATION OF A TREATMENT INTERRUPTION PROTOCOL | 4CPS-051 |
| IDENTIFYING HIV PRE-EXPOSURE PROPHYLAXIS CANDIDATES AMONG PATIENTS WHO RECEIVED POST-EXPOSURE PROPHYLAXIS. PHARMACEUTICAL INTERVENTION IN THE OUTPATIENT PHARMACY AREA. | 4CPS-052 |
| PHARMACISTS’ AND PHYSICIANS’ VIEWS ON THE ROLE OF PHARMACISTS IN PALLIATIVE CARE AND DEPRESCRIBING: A CROSS-SECTIONAL SURVEY | 4CPS-053 |
| PERSISTENCE OF INHIBITORS OF INTERLEUKIN-17 (ANTI-IL-17) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (MSPS) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS | 4CPS-054 |
| IMPACT OF EXTRACORPOREAL MEMBRANE OXYGENATION CIRCUIT ON FENTANYL PHARMACOKINETICS IN CRITICALLY ILL PATIENTS | 4CPS-055 |
| EFFICACY OF ANTI-CALCITONIN GENE RELATED PEPTIDE THERAPIES IN CHRONIC MIGRAINE: AN INDIRECT TREATMENT COMPARISON. | 4CPS-056 |
| IS THE SWITCH FROM INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB TO FARICIMAB AN EFFICIENT AND SAFE STRATEGY? | 4CPS-057 |
| REAL-LIFE STUDY OF EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE/SEVERE HIDRADENITIS SUPPURATIVA TREATED WITH MONOCLONAL ANTIBODIES | 4CPS-058 | |
| PREDICTIVE MARKERS OF RESPONSE TO ADJUVANT TREATMENT IN LOCALLY ADVANCED OVARIAN CANCER. | 4CPS-059 |
| COMPARISON OF THREE-YEAR PERSISTENCE IN PSORIASIS PATIENTS TREATED WITH GUSELKUMAB OR SECUKINUMAB IN REAL-WORLD SETTING | 4CPS-060 | |
| ASSESMENT OF THE EFFECTIVENESS AND SAFETY OF MEPOLIZUMAB IN A REAL-WORLD LONG-TERM STUDY | 4CPS-061 |
| CLINICAL AND ECONOMIC IMPACT OF INAPPROPRIATE USE OF TOTAL PARENTERAL NUTRITION IN ADULTS | 4CPS-062 |
| PATIENT SATISFACTION SURVEY ABOUT INTRAMUSCULAR INJECTIONS OF LONG-ACTING ANTIRETROVIRAL TREATMENT FOR HIV | 4CPS-063 |
| PHARMACOKINETIC MONITORING OF SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE | 4CPS-064 |
| OPPORTUNITIES FOR THE INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) IN ONCO-HEMATOLOGY PHARMACY: EXPLORING AI APPLICATIONS AND THEIR INCORPORATION INTO IN CLINICAL PRACTICE | 4CPS-065 | |
| INFLUENCE OF JAK1 GENE POLYMORPHISMS ON TREATMENT RESPONSE TO JAK INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS. | 4CPS-066 |
| DEVELOPMENT AND MANAGEMENT OF ICANS: RISK FACTORS FOLLOWING CD19 CAR-T THERAPY IN LYMPHOPROLIFERATIVE DISORDERS | 4CPS-067 |
| INTRAVENOUS LEVOMEPROMAZINE IN THE TREATMENT OF CUTANEOUS RASH DUE TO SUSPECTED DRUG HYPERSENSITIVITY: A CASE REPORT | 4CPS-068 |
| CALCULATION OF THE THERAPEUTIC COMPLEXITY OF THE INSTITUTIONALIZED PATIENT IN A TERTIARY HOSPITAL | 4CPS-069 |
| PHARMACOGENETICS OF FLUOROPYRIMIDIDINE TOXICITY BEYOND DPYD VARIANTS | 4CPS-070 | |
| WHAT GETS MEASURED, GETS MANAGED! ANALYSIS OF ANTIMICROBIAL STEWARDSHIP PROCESS QUALITY INDICATORS AT A UNIVERSITY HOSPITAL | 4CPS-071 |
| NEBULIZED ANTIBIOTIC-THERAPY VERSUS INSTILLED ANTIBIOTIC-THERAPY IN PATIENTS WITH TRACHEOBRONCHITIS | 4CPS-072 |
| IMPACT OF ANTIBIOTIC STEWARDSHIP PROGRAM (ASP) ON ANTIBIOTIC USE AND CLINICAL OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP): PRE- AND POST-INTERVENTION STUDY | 4CPS-073 |
| OPTIMISING MEDICATION SAFETY: THE ROLE OF PHARMACIST-LED INTERVENTIONS IN REDUCING DRUG-RELATED PROBLEMS IN GERIATRIC VASCULAR SURGERY PATIENTS | 4CPS-074 |
| EPTINEZUMAB SUCCES IN SHORT-LASTING UNILATERAL NEURALGIFORM HEADACHE ATTACKS WITH CONJUNCTIVAL INJECTION AND TEARING: A CASE REPORT | 4CPS-075 |
| AVELUMAB IN FIRST-LINE TREATMENT OF UROTHELIAL CARCINOMA: REAL-WORLD EFFECTIVENESS ANALYSIS | 4CPS-076 | |
| REAL-WORLD COMPARISON OF PEMBROLIZUMAB AND ATEZOLIZUMAB IN FIRST-LINE THERAPY OF NON-SMALL CELL LUNG CANCER (NSCLC) | 4CPS-077 | |
| THE ROLE OF ADMINISTRATION ROUTE IN ACHIEVING THERAPEUTIC VORICONAZOLE PLASMA LEVELS | 4CPS-078 |
| IMPACT OF ANTIBIOTIC USE OPTIMIZATION PROGRAM AUDITS ON THE USE OF CARBAPENEMS IN OUR HOSPITAL | 4CPS-079 | |
| ECONOMIC IMPACT ASSOCIATED TO BIOLOGICAL THERAPY OPTIMISATION IN PATIENTS WITH PSORIASIS | 4CPS-080 |
| DISCONTINUATION OF TYROSINE KINASE INHIBITOR THERAPY IN CHRONIC MYELOID LEUKEMIA IN FIRST OR SECOND LINE | 4CPS-081 |
| DETECTION OF MEDICATION ERRORS AND UNMET NEEDS OF ONCOLOGY PATIENTS DURING THE ONCOLOGY PHARMACY PRACTICE VISIT | 4CPS-082 |
| DISCONTINUATION OF LENALIDOMIDE TREATMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH 5Q DELETION | 4CPS-083 |
| EFFICACY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: A MULTICENTRE STUDY IN REAL-LIFE | 4CPS-084 |
| EVALUATION OF THE INCIDENCE OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS TREATED WITH PEMBROLIZUMAB | 4CPS-085 |
| OBSERVATIONAL STUDY TO ASSESS GUSELKUMAB ADHERENCE IN CLINICAL PRACTICE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS | 4CPS-086 |
| EXPLORING THE ROLE OF COMMUNITY PHARMACISTS IN PERIOPERATIVE ANTITHROMBOTIC MANAGEMENT: BARRIERS, FACILITATORS, AND FUTURE DIRECTIONS | 4CPS-087 |
| SUSTAINABLE EYECARE: EVALUATING THE CARBON FOOTPRINT OF INTRAVITREAL INJECTIONS | 4CPS-088 |
| IMPACT OF THE ANTIMICROBIAL STEWARDSHIP PROGRAM’S RECOMMENDATIONS ON THE ANNUAL CONSUMPTION OF CARBAPENEMS | 4CPS-089 |
| CONSUMPTION-BASED INDICATORS IN AN INTENSIVE CARE UNIT AFTER AN ANTIMICROBIAL STEWARDSHIP PROGRAM IMPLEMENTATION | 4CPS-090 |
| COST SAVING IMPACT FROM CHOOSING INTRAVENOUS OR SUBCUTANEOUS DARATUMUMAB BASED ON WEIGHT PATIENT FOR THE TREATMENT OF MULTIPLE MYELOMA | 4CPS-091 |
| TREATMENTS FOR RET-ALTERED ADVANCE OR METASTATIC THYROID CANCER: A SYSTEMATIC REVIEW | 4CPS-092 |
| ANALYSIS OF THE IMPACT OF THE OMALIZUMAB SHORTAGE IN THE ALLERGY DEPARTMENT | 4CPS-093 |
| EVALUATION OF ADHERENCE AND VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS B INFECTION | 4CPS-094 |
| MEDICATION MANAGEMENT IN ACUTE ADMISSIONS: A TEMPORARY HOLD OF NON-ESSENTIAL MEDICATION USING A PHARMACIST-DEVELOPED POCKET CARD | 4CPS-095 |
| TEDUGLUTIDE VERSUS HOME PARENTERAL NUTRITION IN PAEDIATRIC POPULATION WITH SHORT BOWEL SYNDROME | 4CPS-096 |
| ONCOGERIATRIC PHARMACEUTICAL CONSULTATION: IMPACT OF CLINICAL PHARMACIST INTERVENTIONS BASED ON STOPP/START CRITERIA. | 4CPS-097 | |
| CYTOKINE RELEASE SYNDROME INCIDENCE AND MANAGEMENT IN CAR-T THERAPIES: A COMPARATIVE STUDY OF AXICABTAGEN CILOLEUCEL AND TISAGENLECLEUCEL | 4CPS-098 |
| COMPARISON OF TRASTUZUMAB-DERUXTECAN AND TRASTUZUMAB-EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER: REAL-LIFE OBSERVATIONAL STUDY AT A UNIVERSITY POLYCLINIC | 4CPS-099 |
| A SINGLE-CENTRE, RETROSPECTIVE, OBSERVATIONAL COHORT STUDY TO EVALUATE THE IMPACT OF CEFIDEROCOL IN PATIENTS WITH INFECTIONS CAUSED BY MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA | 4CPS-100 |
| SUCCESSFUL MANAGEMENT OF ERYTHROMELALGIA SYMPTOMS WITH TOPICAL KETAMINE AND CLONIDINE: A CASE REPORT | 4CPS-101 |
| ASSESSING THE IMPACT OF SPECIALIST PHARMACIST REVIEW ON THE SAFETY OF MEDICATIONS IN PATIENTS RECENTLY DISCHARGED FROM INTENSIVE CARE | 4CPS-102 |
| COST MODEL OF LONG-TERM PROPHYLAXIS TREATMENT IN VON WILLEBRAND DISEASE. | 4CPS-103 |
| CORRELATION BETWEEN HYPERIMMUNE ANTI-HEPATITIS B IMMUNOGLOBULIN LEVELS AND CLINICAL PARAMETERS IN LIVER TRANSPLANT RECIPIENTS WITH HBV INFECTION | 4CPS-104 |
| EVALUATION OF ADHERENCE AND VIRAL LOAD ACCORDING TO THE ANTIRETROVIRAL TREATMENT REGIMEN IN PATIENTS WITH HIV | 4CPS-105 |
| NOVEL APPROACH TO AN UNCOMMON CASE: ACINIC CELL CARCINOMA OF THE SALIVARY GLANDS TREATED WITH LENVATINIB | 4CPS-106 | |
| EVALUATION OF EARLY ORAL SWITCH IN ANTIMICROBIAL THERAPY INTERVENTIONS THROUGH THE WASPSS® PROGRAM IN THE WORK OF PROA TEAMS | 4CPS-107 |
| EFFECTIVENESS OF BOTULINUM TOXIN TREATMENT IN PATIENTS WITH BLEPHAROSPASM | 4CPS-108 |
| PERSISTENCE EVALUATION OF SECOND-LINE TREATMENT FOR MULTIPLE SCLEROSIS | 4CPS-109 |
| USE OF ASPARAGINASE IN A TERTIARY CARE HOSPITAL. HOW TO DEAL WITH HYPERSENSITIVITIES? | 4CPS-110 |
| PERSPECTIVES OF PHYSICIANS ON THE INTEGRATION OF HOSPITAL PHARMACISTS IN MULTIDISCIPLINARY HEALTHCARE TEAMS | 4CPS-111 |
| EFFICACY OF FARICIMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | 4CPS-112 |
| IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMS AUTOMATIC ALERTS IN IMPROVING THE DURATION OF ANTIMICROBIAL TRETAMENT | 4CPS-113 |
| INCIDENCE OF SEXUALLY TRANSMITTED INFECTIONS IN PrEP USERS: IS THERE AN INCREASE? | 4CPS-114 |
| STUDY OF EFFECTIVENESS AND SAFETY OF CYTOREDUCTIVE SURGERY ASSOCIATED WITH HIPEC IN PATIENTS WITH PERITONEAL CARCINOMATOSIS | 4CPS-116 |
| EFFICACY AND SAFETY OF ESKETAMINE THERAPY IN TREATMENT-RESISTANT DEPRESSION IN ADULTS, REAL WORLD DATA | 4CPS-117 | |
| IMPLEMENTATION OF QUALITY INDICATORS FOR HOSPITAL PHARMACY SERVICES IN A UNIVERSITY HOSPITAL | 4CPS-118 |
| PREDICTIVE VALUE OF THE ARCTIC SCORE AND ESTIMATED GLOMERULAR FILTRATION RATE EQUATIONS ON LEVETIRACETAM PLASMA CONCENTRATIONS IN CRITICALLY ILL NEUROTRAUMA PATIENTS | 4CPS-119 |
| ROLE OF PHARMACISTS IN IMPROVING THERAPEUTIC DRUG MONITORING AND DOSING OF VANCOMYCIN | 4CPS-120 |
| RETROSPECTIVE OBSERVATIONAL STUDY ON DULOXETINE USE FOR THE TREATMENT OF URINARY INCONTINENCE | 4CPS-121 |
| ANALYSIS OF THE APPROPRIATENESS OF TAFAMIDIS PRESCRIPTION FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS | 4CPS-122 |
| TERRITORIAL CLINICAL PHARMACY MANAGED BY A LOCAL HEALTH UNIT | 4CPS-123 |
| ALGORITHM FOR PRIORITISATION OF PATIENTS FOR CLINICAL PHARMACY MEDICATION CHECK: PROOF OF CONCEPT | 4CPS-124 |
| EFFECTIVENESS AND SAFETY OF TRASTUZUMAB-DERUXTECAN FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER | 4CPS-125 | |
| PHARMACIST ON ACUTE FRAILTY POST TAKE WARD ROUND (PTWR) | 4CPS-126 | |
| CLIMATE IMPACT OF DRUGS IN THE HEALTHCARE SECTOR | 4CPS-127 |
| ANTICHOLINERGIC LOAD: A BETTER SCORE FOR A GOLD PRESCRIPTION? | 4CPS-128 |
| THE USEFULNESS OF BROLUCIZUMAB IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION NOT RESPONDING TO RANIBIZUMAB OR AFLIBERCEPT. A RETROSPECTIVE CHART REVIEW | 4CPS-129 |
| R-START: EFFECTIVENESS OF FREMANEZUMAB AFTER 18 MONTHS OF TREATMENT IN PATIENTS WITH CHRONIC MIGRAINE | 4CPS-130 |
| DEVELOPMENT OF AN AUGMENTED INTELLIGENCE TOOL TO PREDICT RISK OF UNCONTROLLED TYPE 2 DIABETES MELLITUS FOR PERSONALIZED PHARMACEUTICAL CARE AT THE OUTPATIENT SETTING | 4CPS-131 |
| POPULATION PHARMACOKINETIC MODEL OF FLUDARABINE IN PATIENTS UNDERGOING CHIMERIC ANTIGEN RECEPTOR T CELLS THERAPY | 4CPS-132 |
| PREVALENCE OF THIRD LINE TREATMENT QUETIAPINE AND OVERWEIGHT/OBESITY IN HOSPITALIZED PSYCHIATRIC PATIENTS: A CROSS-SECTIONAL STUDY | 4CPS-133 |
| REAL-LIFE EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE FOR THE TREATMENT OF HYPERKALEMIA | 4CPS-134 |
| PHARMACEUTICAL INTERVENTIONS ON DIRECT ORAL ANTICOAGULANTS IN EMERGENCY DEPARTMENT | 4CPS-135 |
| MEDICATION RECONCILIATION IN PATIENTS ADMITTED TO A NEUROLOGY WARD | 4CPS-136 | |
| EVALUATION OF POST-EXPOSURE PROPHYLAXIS EFFECTIVENESS IN PREVENTING SEXUALLY TRANSMITTED DISEASES AND UNWANTED PREGNANCIES IN SEXUAL ASSAULT VICTIMS IN A TERTIARY UNIVERSITY HOSPITAL | 4CPS-137 |
| NUMBER OF ANNUAL INJECTIONS WITH RANIBIZUMAB OR AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD). A COMPARISON USING REAL WORLD DATA | 4CPS-138 |
| EVALUATION OF ANTIFUNGAL PRESCRIPTION PRACTICES IN A HOSPITAL WITH AN ANTIMICROBIAL STEWARDSHIP PROGRAM | 4CPS-139 |
| IMPACT OF ORAL SEQUENTIAL THERAPY ON ANTIMICROBIAL PRESCRIBING AT A TERTIARY CARE HOSPITAL | 4CPS-140 |
| INDIRECT COMPARISON OF RISANKIZUMAB VERSUS UPADACITINIB FOR THE MAINTENANCE OF MODERATE TO SEVERE CROHN’S DISEASE | 4CPS-141 | |
| PHARMACOTHERAPEUTIC RECOMMENDATIONS AND DEPRESCRIPTION IN ELDERLY PATIENTS ADMITTED TO AN ACUTE A GERIATRIC UNIT | 4CPS-142 |
| REAL-WORLD PERSISTENCE OF ANTI‐IL5 THERAPIES IN UNCONTROLLED ASTHMA | 4CPS-143 |
| OPTIMIZING MEDICATIONS IN GERIATRIC PATIENTS: INSIGHTS FROM THE ASPIRE RANDOMIZED CONTROLLED TRIAL ON PHARMACIST-LED MEDICATION REVIEWS | 4CPS-144 |
| MAKING THE RIGHT NOISES: IMPACT OF A PHARMACIST IN THE EMERGENCY ROOM | 4CPS-145 |
| STREAMLINING AND SUSTAINABILITY OF POYC SCHEME WHICH ENSURES PATIENT ACCESS TO MEDICATIONS | 4CPS-146 | |
| EVALUATION OF THE EFFECTIVENESS AND SAFETY OF ANTI-CGRP ANTIBODIES IN THE TREATMENT OF MIGRAINE | 4CPS-147 |
| REAL-WORLD USE OF BULEVIRTIDE: A RETROSPECTIVE STUDY ON QUALITY OF LIFE, ADHERENCE, AND SAFETY IN A COHORT OF ADULT PATIENTS WITH HEPATITIS DELTA VIRUS | 4CPS-148 |
| EXTERNAL VALIDATION OF POPULATION PHARMACOKINETIC MODELS OF HIGH DOSING METHOTREXATE IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA | 4CPS-149 |
| GLOBAL EVOLUTION OF CLINICAL TRIALS AND PHARMACY ACTIVIES DEVELOPED IN A CENTRAL PORTUGUESE HOSPITAL FROM 2016 TO 2023 | 4CPS-150 |
| VALIDATION OF AN ALGORITHM FOR PRIORITIZING MEDICATION RECONCILIATION AT ADMISSION USING AN ARTIFICIAL INTELLIGENCE METHOD | 4CPS-151 |
| EFFECTIVENESS AND SAFETY OF BROLUCIZUMAB IN AGE-RELATED MACULAR DEGENERATION | 4CPS-152 |
| COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB EMTAMSINE IN PATIENTS WITH HER2-POSITIVE BREAST CANCER | 4CPS-153 |
| MEDICATION ERRORS AT DISCHARGE : SEVERITY AND ROOT CAUSES. WHAT DO OUR DOCTORS THINK? | 4CPS-154 | |
| DAPAGLIFOZIN REAL-WORLD DATA IN PATIENTS WITH HEART FAILURE COMPARED TO CLINICAL TRIALS: A RETROSPECTIVE OBSERVATIONAL STUDY | 4CPS-155 |
| ANALYSIS OF ANTIRETROVIRAL THERAPY SWITCH IN 2022 IN PEOPLE LIVING WITH HUMAN INMUNODEFICIENCY VIRUS: REASONS AND IMMUNOVIROLOGICAL EFFICACY | 4CPS-156 |
| STUDY OF SERUM CONCENTRATIONS OF SUBCUTANEOUS INFLIXIMAB IN INFLAMATORY BOWEL DESEASE AND THEIR CORRELATION WITH ANALYTIC RESPONSE | 4CPS-157 |
| MANAGEMENT OF A SECOND VISCERAL LEISHMANIA RECURRENCE IN A HIV PATIENT WITH MILTEFOSINE: A CASE REPORT | 4CPS-158 |
| COMPARATIVE EVALUATION OF CHATGPT-4O AND CHATGPT-3.5 IN CLINICAL RULE-GUIDED DOSE INTERVENTIONS IN HOSPITALIZED PATIENTS WITH RENAL DYSFUNCTION | 4CPS-159 |
| IMPROVING PATIENT SAFETY : THE CLINICAL IMPACT OF MEDICATION RECONCILIATION AT ADMISSION IN TRAUMA AND ORTHOPAEDIC SURGERY | 4CPS-160 |
| DOSE-DEPENDENT RELATIONSHIPS IN PRESCRIBING CASCADES: A COHORT STUDY | 4CPS-161 |
| EVALUATION OF ANTIHYPERTENSIVE PRESCRIPTIONS OF PATIENTS OF A GERIATRIC DAY HOSPITAL | 4CPS-162 |
| LEACHABLE ANALYSIS OF DENTAL MATERIALS | 4CPS-163 |
| PHARMACEUTICAL DECISION SUPPORT SYSTEM FOR SALT ACETAMINOPHEN USE: RAISING AWARENESS AMONG CARDIOVASCULAR PATIENTS | 4CPS-164 |
| REAL LIFE EFFECTIVENESS AND SAFETY OF PARPis IN FIRST-LINE MAINTENANCE OVARIAN CANCER: A MULTICENTER STUDY. | 4CPS-165 | |
| REASONS AND CLINICAL OUTCOMES OF SWITCHING STRATEGY BETWEEN DUPILUMAB AND TRALOKINUMAB IN ATOPIC DERMATITIS IN CLINICAL PRACTICE | 4CPS-166 |
| MEDICATION ADHERENCE OF THROMBOPOIETIN RECEPTOR AGONISTS IN IMMUNE THROMBOCYTOPENIC PURPURA: IDENTIFYING BARRIERS, CHALLENGES AND SOLUTIONS THROUGH PATIENTS FEEDBACK | 4CPS-167 |
| STUDY OF ANTIBIOTIC THERAPY AND EVOLUTION OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS IN A BURN INTENSIVE CARE UNIT | 4CPS-168 | |
| SHOULD WE TAKE THE SERUM ALBUMIN VALUE INTO ACCOUNT WHEN ADJUSTING THE VANCOMYCIN DOSAGE? | 4CPS-169 |
| HEALTH OUTCOMES ASSESSMENT OF AN INTERDISCIPLINARY PHARMACEUTICAL ONCO-HAEMATOLOGY COMMITTEE | 4CPS-170 | |
| AN ANALYSIS ON POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN PRIMARY CARE | 4CPS-171 | |
| RELATIONSHIP BETWEEN ANTICHOLINERGIC BURDEN ASSOCIATED WITH MEDICATIONS AND FUNCTIONAL CHRONIC CONSTIPATION IN PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENTS | 4CPS-172 |
| ANALYSIS OF THE EVOLUTION OF NUTRITIONAL STATUS USING THE C-REACTIVE PROTEIN/PREALBUMIN RATIO IN CRITICALLY ILL PATIENTS WITH PARENTERAL NUTRITION | 4CPS-173 |
| ADJUSTMENT TO THE PROTOCOL OF NIRMATRELVIR/RITONAVIR AND REMDESIVIR TREATMENT IN IMMUNOCOMPROMISED PATIENTS AT HIGH RISK OF PERSISTENT COVID AT A SECOND-LEVEL HOSPITAL | 4CPS-174 |
| NIKI-TAG (NEPHROTOXIC INJURY IN KIDS-TAG): SCREENING OF PEDIATRIC HOSPITALIZED PATIENTS EXPOSED TO NEPHROTOXIC DRUGS AND EDUCATION FOR REDUCING THE RISK OF ACUTE KIDNEY INJURY | 4CPS-176 |
| ANALYSIS OF DOSE REDUCTION OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA | 4CPS-177 |
| DESCRIPTIVE ANALYSIS IN REAL-WORLD OF TREAT AND EXTEND TREATMENT OF FARICIMAB IN PATIENTS FAILING PRIOR INTRAVITREAL TREATMENTS | 4CPS-178 |
| CONCORDANCE ANALYSIS BETWEEN THE CONUT INDEX AND INDIVIDUAL MARKERS: EVALUATING NUTRITIONAL STATUS THROUGH UNWEIGHTED AND WEIGHTED KAPPA MEASURES | 4CPS-179 |
| ASSESSMENT OF CAPIVASERTIB FOR TREATMENT OF ADVANCED BREAST CANCER | 4CPS-180 | |
| HIV PRE‐EXPOSURE PROPHYLAXIS IN REAL-WORLD SETTING: TOLERANCE AND ADHERENCE. | 4CPS-181 |
| NUTRITIONAL ASSESSMENT OF NON-SMALL CELL LUNG CANCER PATIENTS UNDERGOING TREATMENT WITH OSIMERTINIB | 4CPS-182 |
| MULTICENTER STUDY: EVALUATION OF THE EFFECTIVENESS AND SAFETY OF UPADACITINIB IN INFLAMMATORY BOWEL DISEASE | 4CPS-183 |
| DETERMINATION OF VORICONAZOLE METABOLISER PHENOTYPE IN THE ABSENCE OF GENETIC TESTING | 4CPS-184 |
| EVALUATE THE IMPACT OF A PHARMACEUTICAL INTERVENTION TO IMPROVE THE ADEQUACY OF ANTIBIOTIC CONSUMPTION | 4CPS-185 |
| OPTIMIZATION OF A HIGH-PRIORITY DRUG LIST FOR PHARMACEUTICAL VALIDATION: IMPACT ON PATIENT CARE BY PHARMACY DEPARTMENT | 4CPS-186 | |
| IMMUNIZATION WITH NIRSEVIMAB: IMPACT ON RSV SEASON IN A PEDIATRIC HOSPITAL | 4CPS-187 |
| THERAPEUTIC DRUG MONITORING FOR DALBAVANCIN SUPPRESSIVE THERAPY : OPTIMIZING INFUSION SPACING BASED ON MINIMUM INHIBITORY CONCENTRATION | 4CPS-188 |
| REAL-WORLD EFFECTIVENESS, SAFETY AND ADHERENCE OF LONG ACTING CABOTEGRAVIR AND RILPIVIRINA IN A TERTIARY HOSPITAL | 4CPS-189 |
| OPTIMIZATION OF ADALIMUMAB IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: KEY FACTORS FOR DOSE ESCALATION | 4CPS-190 |
| EVALUATION OF AUC/MIC AS A PREDICTOR OF MICROBIOLOGICAL AND CLINICAL OUTCOMES IN STAPHYLOCOCCUS GRAM-POSITIVE BACTEREMIA TREATED WITH VANCOMYCIN | 4CPS-191 |
| TRANSFORMING DRUG SHORTAGES INTO OPPORTUNITIES FOR OPTIMAL USE OF AZTREONAM | 4CPS-192 |
| LONG-TERM IMPACT OF A PHARMACEUTICAL INTERVENTION ON BENZODIAZEPINE USE: A GENDER PERSPECTIVE | 4CPS-193 |
| SELECTIVE DIGESTIVE DECONTAMINATION IN CRITICALLY ILL PATIENTS | 4CPS-194 |
| EVALUATION OF THE EFFECTIVENESS AND SAFETY OF THE BEVACIZUMAB-TRIFLURIDINE-TYPIRACYL REGIMEN IN A MULTICENTRIC STUDY | 4CPS-195 | |
| ANALYSIS OF ANTIBIOTIC CONSUMPTION DUE TO THE IMPLEMENTATION OF FRONT-END AND BACK-END STRATEGIES OF ANTIMICROBIAL STEWARDSHIP: AN INTERRUPTED TIME SERIES ANALYSIS | 4CPS-196 |
| REAL WORLD PROSPECTIVE ANALYSIS OF THE EFFICACY OF COUNSELING AND STRUCTURED PATIENT INFORMATION IN IMPROVING SAFETY OF CARE AND PHARMACOLOGICAL THERAPY ADHERENCE IN ONCOLOGY | 4CPS-197 | |
| CLOZAPINE MONITORING: EFFICACY, SAFETY AND THE INFLUENCE OF SMOKING ON PLASMA LEVELS | 4CPS-198 |
| BEZAFIBRATE FOR PRIMARY BILIARY CHOLANGITIS: EFFICACY, SAFETY, AND EFFICIENCY OF AN OFF-LABEL USE PROTOCOL IN REAL WORLD PRACTICE | 4CPS-199 |
| CASE REPORT: TREATMENT OF DIGOXIN INTOXICATION IN A HAEMODIALYSIS PATIENT USING ANTI-DIGOXIN ANTIBODIES AND PLASMAPHERESIS. | 4CPS-200 |
| AUDIT OF INTRAVENOUS INFUSION SETUPS IN CONTINUOUS CARE UNITS | 4CPS-201 | |
| FORMULATION OF CLOBETASOL AND TACROLIMUS URETHRAL SYRINGES AND EFFICACY IN BALANITIS XEROTICA OBLITERANS: A CASE REPORT | 4CPS-202 |
| REAL-LIFE ANALYSIS OF THE DEVELOPMENT OF ANTI-DRUG ANTIBODIES IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THERAPEUTIC APPROACH | 4CPS-203 |
| OPTIMIZING PHARMACEUTICAL CARE IN HOSPITAL TELEPHARMACY: IMPACT ASSESSMENT OF THE CHRONIC PATIENT STRATIFICATION MODEL | 4CPS-204 | |
| ALECTINIB FOR ALK-POSITIVE UTERINE LEIOMYOSARCOMAL: SUSTAINED RESPONSE AFTER TREATMENT RESISTANCE – A CASE REPORT | 4CPS-205 |
| EFFECTIVENESS OF TREATMENT WITH MEPOLIZUMAB AND RESLIZUMAB IN DIAGNOSED PATIENTS OF SEVERE UNCONTROLLED ASTHMA ACCORDING TO BODY WEIGHT | 4CPS-206 | |
| COMPARATIVE STUDY OF ADHERENCE RATES TO COMPUTERIZED INJECTABLE ANTIBIOTIC PROTOCOLS | 4CPS-207 |
| MACHINE LEARNING-DRIVEN EARLY PREDICTION OF VORICONAZOLE PLASMA LEVELS: ENHANCING PRECISION DOSING AND PATIENT SAFETY IN ANTIFUNGAL THERAPY | 4CPS-208 | |
| LONG-TERM OUTCOMES AND RETREATMENT PATTERNS IN ANTI-CGRP THERAPY | 4CPS-209 |
| ANALYSIS OF THE EFFECTIVENESS OF GEPANTS IN NAIVE PATIENTS VERSUS PATIENTS PREVIOUSLY TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES | 4CPS-210 | |
| CLEAR CELL RENAL CELL CARCINOMA, WITH LUNG METASTASES – CLINICAL CASE | 4CPS-211 |
| CROSS-SECTIONAL STUDY TO ASSESS THE USE AND RATIONALITY OF PHARMACOGENOMICS IN PSYCHIATRIC WARDS. | 4CPS-212 |
| IMPACT OF THE ANTIMICROBIAL STEWARDSHIP PROGRAM ON ANTIBIOTIC CONSUMPTION IN TWO INTERNAL MEDICINE UNITS | 4CPS-213 |
| GENDER ANALYSIS OF PATIENTS TREATED WITH “RESERVE” ANTIBIOTICS IN A UNIVERSITY HOSPITAL | 4CPS-214 | |
| REAL-LIFE ANALYSIS OF THE DEVELOPMENT OF ANTI-DRUG ANTIBODIES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THERAPEUTIC APPROACH | 4CPS-215 |
| CASE SERIES: REAL WORLD EFFECTIVENESS AND SAFETY OF TISAGENLECLEUCEL FOR THE TREATMENT OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN PEDIATRICS | 4CPS-216 |
| EFFECTIVENESS AND SAFETY OF ORAL VISCOUS BUDESONIDE IN COMPOUNDED FORMULATION: REAL-WORLD DATA | 4CPS-217 |
| ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIPTION IN PATIENTS ADMITTED TO AN EMERGENCY DEPARTMENT | 4CPS-218 | |
| REAL-WORLD EFFECTIVENESS OF IBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA | 4CPS-219 |
| PRESCRIBING ERRORS IN PARENTERAL NUTRITIONAL SUPPORT FOR ADOLESCENT PEDIATRIC PATIENT | 4CPS-220 |
| COMPARATIVE ANALYSIS OF ANTICHOLINERGIC SCALES IN OLDER PATIENTS: A SYSTEMATIC REVIEW TOWARDS A GOLD STANDARD TOOL | 4CPS-221 |
| DESIGN OF HYDROXYCOBALAMINE MICROCAPSULES FOR INJECTABLES IN THE OCULAR TREATMENT OF HOMOCYSTINURIA WITH METHYLMALONIC ACIDURIA | 4CPS-222 | |
| COMPARED REAL-LIFE PERSISTENCE BETWEEN FREMANEZUMAB, ERENUMAB AND GALCANEZUMAB. | 4CPS-223 |
| EXPERIENCE OF USING DALBAVANCIN IN OSTEOARTICULAR PROSTHETIC INFECTION | 4CPS-224 |
| EPTINEZUMAB IN PATIENTS REFRACTORY TO OTHER INHIBITOR OF CALCITONIN GENE-RELATED PEPTIDE | 4CPS-225 |
| EFFICACY OF ENZALUTAMIDE IN ABIRATERONE-NAÏVE PATIENTS VERSUS ABIRATERONE-PRETREATED PATIENTS IN mCRPC NOT CANDIDATES FOR CHEMOTHERAPY | 4CPS-226 | |
| MANAGEMENT OF OSTEOPOROSIS IN RHEUMATOLOGY DAY HOSPITAL: DOES THE CLINICAL PHARMACIST HAVE A ROLE TO PLAY? | 4CPS-227 |
| ACUTE HEPATITIS AFTER PARACETAMOL POISONING: ANALYSIS OF POTENTIALLY INFLUENCING FACTORS. | 4CPS-228 |
| IMPLEMENTATION OF A STRATIFICATION MODEL FOR CHRONIC PAEDIATRIC PATIENTS IN OUTPATIENT PHARMACY | 4CPS-229 |
| TIME COURSE OF HYPERCHOLESTEROLAEMIA TREATMENT WITH PCSK9 INHIBITORS MONOCLONAL ANTIBODIES (IPCSK9) | 4CPS-230 |
| ANALYSIS OF DRUG INTERACTIONS RELATED TO THE INITIATION OF NIRMATRELVIR/RITONAVIR IN A GERIATRIC POPULATION | 4CPS-231 |
| USTEKINUMAB TROUGH LEVELS AND THEIR IMPACT ON CLINICAL AND ANALYTICAL RESULTS IN CROHN’S DISEASE | 4CPS-232 |
| EFFECT OF HIGH-DOSE INTRAVITREAL AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: COMPARISON OF REAL-WORLD OUTCOMES WITH PHARMACOKINETIC MODEL | 4CPS-233 |
| RESULTS OF THE IMPLEMENTATION OF AN EFFICIENCY-BASED AGE-RELATED MACULAR DEGENERATION TREATMENT PROTOCOL | 4CPS-234 | |
| ASSESSMENT OF THERAPEUTIC DRUG MONITORING IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY (OPAT) IN PAEDIATRIC PATIENTS | 4CPS-235 |
| ASSESSMENT OF THERAPEUTIC DRUG MONITORING IN ADULT CYSTIC FIBROSIS PATIENTS ON OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY | 4CPS-236 |
| SPECIAL PHARMACEUTICAL CARE AND TELECONSULTATION FOR THE GERIATRIC ONCOHEMATOLOGICAL PATIENT | 4CPS-237 |
| ROLE OF HLA-DQA1*05 IN THE PERSISTENCE OF ADALIMUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE | 4CPS-238 |
| PHARMACY-LED MEDICATION RECONCILIATION TO OPTIMIZE LEVODOPA MANAGEMENT AND MINIMIZE CONTRAINDICATED DRUG USE IN HOSPITALIZED PARKINSON’S DISEASE PATIENTS: A QUASI-EXPERIMENTAL STUDY | 4CPS-239 |
| CLINICAL PHARMACY IN PSYCHIATRIC DEPARTMENT. A QUALITATIVE STUDY FROM USERS OF MEDICIN REVIEWS PERFORMED BY PHARMACISTS | 4CPS-240 |
| PROACTIVE VERSUS RETROACTIVE MODELS IN MEDICATION RECONCILIATION – ARE THERE BENEFITS? | 4CPS-241 |
| EFFECTIVENESS OF PHARMACIST BASED MEDICATION RECONCILIATION ON PATIENT SAFETY | 4CPS-242 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| POTENTIAL AND CLINICALLY MANIFESTED DRUG-DRUG INTERACTIONS IN PATIENTS ADMITTED TO THE HOSPITAL: A CROSS-SECTIONAL STUDY | 5PSQ-001 |
| ATEZOLIZUMAB PLUS CHEMOTHERAPY IN EXTENSIVE-STAGE SMALL-CELL LUNG CANCER | 5PSQ-002 |
| IMPACT OF PHARMACIST INTERVENTIONS IN ELDERLY PATIENTS WITH POLYPHARMACY | 5PSQ-003 |
| ANALYSIS OF SYMPTOMATIC RESCUE THERAPY IN PATIENTS WITH GALCANEZUMAB FOR MIGRAINE PROPHYLAXIS | 5PSQ-004 |
| EVALUATING RENAL DRUG DOSING APPROPRIATENESS IN PATIENTS WITH REDUCED GLOMERULAR FILTRATION RATE: A CONSENSUS ACROSS MULTIPLE DRUG INFORMATION SOURCES | 5PSQ-005 |
| AN EXPLORATION OF NON-CONSULTANT DOCTORS’ VIEWS, AND CURRENT PRACTICES, OF PRESCRIBING THROMBOPROPHYLAXIS, FOR PATIENTS WITH CHRONIC LIVER DISEASE | 5PSQ-006 |
| MOLECULAR ADSORVENT RECIRCULATING SYSTEM (MARS) IN A CRITICAL CARE UNIT FOR HEPATIC FAILURE | 5PSQ-007 |
| STUDY OF PATIENT SATISFACTION IN A PHARMACY UNIT FOR CLINICAL TRIALS | 5PSQ-008 |
| CHANGES OF INFLAMMATORY PROFILE AFTER ANTI-CGRP ANTIBODY TREATMENT IN MIGRAINE PATIENTS | 5PSQ-009 |
| PEMBROLIZUMAB IN METASTATIC NON-SMALL CELL LUNG CANCER AND POOR PROGNOSTIC FACTORS IN CLINICAL PRACTICE | 5PSQ-010 |
| ASSESSING THE MISUSE OF THROMBOPROPHYLAXIS IN HOSPITALIZED PATIENTS: A RETROSPECTIVE STUDY | 5PSQ-011 |
| “FRAILTY INDEX: A PARAMETER TO CONSIDER IN PHARMACEUTICAL VALIDATION?” | 5PSQ-012 |
| ECONOMIC EVALUATION OF THE PEMBROLIZUMAB DOSING REGIMEN BY BODY WEIGHT IN A SECOND-LEVEL PRIVATE HOSPITAL | 5PSQ-013 |
| IMPACT OF ROBOTIC DISPENSING SYSTEMS ON MEDICATION ERRORS IN TELEPHARMACY PROCEDURE: A COMPARATIVE ANALYSIS | 5PSQ-014 |
| EVALUATION OF HERBAL AND NON-PRESCRIPTION DRUG USE IN AN UNDERSERVED PATIENT POPULATION | 5PSQ-015 | |
| SIMULATION OF A CYBERATTACK IN A HOSPITAL PHARMACY: DEVELOPMENT OF TOOLS TO ENSURE CONTINUITY OF CARE | 5PSQ-016 |
| HEDGEHOG PATHWAY INHIBITORS IN BASAL CELL CARCINOMA: REAL-LIFE EXPERIENCE | 5PSQ-017 | |
| ADEQUACY OF OMEGA-3-ACID ETHYL ESTERS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASES OR CARDIOVASCULAR RISK FACTORS | 5PSQ-018 |
| PREVENTION OF DISPENSING MEDICATION ERRORS IN ELECTRONIC PRESCRIPTIONS | 5PSQ-019 |
| MULTIDISCIPLINARY PROTOCOL FOR THE USE OF MEDICINES: LET’S TALK ABOUT INTRAVITREAL THERAPY | 5PSQ-020 |
| CLINICAL IMPACT OF SWITCHING BIOLOGICAL THERAPIES IN SEVERE ASTHMA ON A THIRD LEVEL HOSPITAL | 5PSQ-021 | |
| FOLLOW UP THE EFFECTIVENESS AND SAFETY OF SACITUZUMAB-GOVITECAN IN A COHORT OF PATIENTS WITH TRIPLE NEGATIVE METASTATIC BREAST CANCER: A MULTICENTER STUDY | 5PSQ-022 |
| LITMUS TEST METHOD FOR CLOSED SYSTEM TRANSFER DEVICE DRY DISCONNECTION VALIDATION | 5PSQ-023 |
| ANALYSIS OF THE USE OF PERIOPERATIVE ANTIBIOTIC PROFPHYLAXIS | 5PSQ-024 |
| A PAIR PHARMACY TECHNICIAN AND NURSE, KEY TO SUCCESS BEFORE CARRYING OUT A CLINICAL AUDIT ON THE CORRECT USE OF NASOGASTRIC TUBES AND ADMINISTERED DRUGS | 5PSQ-025 |
| COMPARISON OF PERIOPERATIVE CHEMOTHERAPY AND PREOPERATIVE CHEMORADIOTHERAPY IN GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: ANALYSIS FROM THE AGAMENON-SEOM REGISTRY | 5PSQ-026 |
| ORAL TOLERANCE INDUCTION TO COTRIMOXAZOLE IN IMMUNOSUPPRESSED PATIENTS WITH A HISTORY OF A NON-SEVERE HYPERSENSITIVITY REACTION | 5PSQ-027 |
| THE HOSPITAL PHARMACIST FACING THE NATIONAL AZTREONAM SHORTAGE | 5PSQ-028 | |
| EVALUATION OF THE EFFICACY OF INCLISIRAN FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA O MIXED DYSLIPIDAEMIA: ANALYSIS OF AIFA MONITORING REGISTERS | 5PSQ-029 |
| EFFECTIVENESS AND SAFETY OF SEMAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES: REAL-WORLD USAGE DATA | 5PSQ-030 |
| CONCORDANCE BETWEEN GLOMERULAR FILTRATION RATE EQUATIONS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TREATED WITH HEPARIN AND THEIR RELATIONSHIP WITH BLEEDING RISK | 5PSQ-031 |
| EFFECTIVENESS AND SAFETY IN THE USE OF SOFOSBUBIR/VELPATASVIR IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION | 5PSQ-032 |
| OFF-LABEL USE OF INTERFERON ALPHA 2B EYE DROPS IN CORNEAL INTRAEPITHELIAL NEOPLASIA: A CASE REPORT | 5PSQ-033 |
| EVALUATION OF ANTIBIOTICS CONSUMPTION IN THE INTENSIVE CARE UNIT OF A SECOND LEVEL HOSPITAL | 5PSQ-034 |
| USING FAILURE MODE AND EFFECTS ANALYSIS TO IMPROVE PRODUCTION OF NON-STERILE PREPARATIONS | 5PSQ-035 |
| CLINICAL PHARMACIST INTERVENTIONS IN ANTIMICROBIAL THERAPY STEWARDSHIP: PREVENTION OF MEDICATION ERRORS ENHANCED BY ACCESS TO THE PATIENT’S ELECTRONIC HEALTH RECORD | 5PSQ-036 |
| EVALUATION OF THE COMPLETENESS OF PATIENTS’ MEDICATION REPORTS AND DISCHARGE SUMMARIES AT DISCHARGE FROM TWO WARDS USING COMPLETE MEDICATION DOCUMENTATION AT DISCHARGE MEASURE (CMDD-M) | 5PSQ-037 |
| COMPLIANCE AND APPLICABILITY OF PRO RE NATA PRESCRIBING IN A FRENCH UNIVERSITY HOSPITAL | 5PSQ-038 |
| PROFILE OF INTRAVENOUS IMMUNE GLOBULIN UTILIZATION IN A PORTUGUESE POLYVALENT HOSPITAL | 5PSQ-039 |
| DIMETHYL FUMARATE SAFETY IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS | 5PSQ-040 |
| PRIORITISATION OF PHARMACEUTICAL INTERVENTIONS WITHIN THE MULTIDISCIPLINARY TEAM IN THE INTENSIVE CARE UNIT | 5PSQ-041 |
| CLINICAL INTERVENTIONS IN THE CARDIOLOGY SERVICE PERFORMED BY A HOSPITAL PHARMACY RESIDENT | 5PSQ-042 |
| EXPERIENCE OF USING BEMPEDOIC ACID ONE YEAR SINCE ITS FUNDING IN THE NATIONAL HEALTH SYSTEM | 5PSQ-043 |
| IMPACT OF ADVERSE DRUG REACTIONS ON LENGTH OF STAY AND MORTALITY IN HOSPITALIZED PATIENTS THROUGH A CLINICAL ADMINISTRATIVE NATIONAL DATASET | 5PSQ-044 |
| ANALYSIS OF CARDIOVASCULAR RISK ASSOCIATED WITH JANUS KINASE INHIBITORS TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS | 5PSQ-045 |
| ANALYSIS OF DESENSITIZATION PROTOCOLS USED IN ONCOLOGY PATIENTS IN A TERTIARY HOSPITAL | 5PSQ-046 |
| DYNAMICS OF HIV PRE-EXPOSURE PROPHYLAXIS USE AND EVALUACION OF ITS IMPACT IN THE INCIDENCE OF SEXUAL TRANSMITTED DISEASES | 5PSQ-047 |
| REAL-WORLD DATA ON INFECTION PREVALENCE IN PATIENTS ON IMMUNOSUPPRESSIVE TREATMENT WITH USTEKINUMAB, GOLIMUMAB AND GUSELKUMAB | 5PSQ-048 |
| COST-SAVING IMPACT AND SAFETY EVALUATION OF BIOSIMILAR NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS | 5PSQ-049 |
| REVIEW OF THE USE OF NEUROLEPTICS IN A NURSING HOME ASSOCIATED WITH HOSPITAL PHARMACY | 5PSQ-050 |
| ANALYSIS OF USE AND THERAPEUTIC ADHERENCE AMONG PATIENTS TREATED WITH BEMPEDOIC ACID AT A LOCAL HEALTH AUTHORITY | 5PSQ-051 | |
| PERSISTENCE OF BARICITINIB IN A REAL-WORLD SETTING OF RHEUMATOID ARTHRITIS PATIENTS | 5PSQ-052 |
| PREVALENCE OF MEDICATION-RELATED HOSPITAL ADMISSIONS AT AN AUSTRIAN TERTIARY CARE CENTER | 5PSQ-053 |
| REAL-WORLD OUTCOMES OF ENZALUTAMIDE, ABIRATERONE, AND APALUTAMIDE IN PATIENTS WITH PROSTATE CANCER | 5PSQ-054 |
| EFFECTIVENESS, SAFETY, AND MONITORING OF PIRFENIDONE AND NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS | 5PSQ-055 |
| PHARMACOGENETIC INFLUENCE OF MTHFR VARIANTS ON METHOTREXATE TOXICITY: UNVEILING PREDICTIVE BIOMARKERS FOR PERSONALIZED THERAPY | 5PSQ-056 | |
| SCREENING FOR HIV IN PATIENTS DIAGNOSED WITH HERPES ZOSTER IN THE EMERGENCY DEPARTMENT | 5PSQ-057 |
| MEDICINES RECONCILIATION OF HOME ORAL ANTICOAGULANTS UPON ADMISSION, ARE WE DOING IT WELL? | 5PSQ-058 |
| CASE REPORT: UNEXPECTED ADVERSE REACTION TO [68Ga]Ga-DOTATOC | 5PSQ-059 |
| LEVERAGING THE WHO PHARMACOVIGILANCE DATABASE VIGIBASE®: EXAMPLE OF THE SAFETY ANALYSIS OF [177Lu]Lu-DOTATATE | 5PSQ-060 |
| APPROPRIATENESS, EFFICACY AND SAFETY OF LORLATINIB IN REAL-WORLD PATIENTS | 5PSQ-061 | |
| COMPARISON OF THE EFFICACY AND SAFETY BETWEEN TICAGRELOR AND CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | 5PSQ-062 |
| EFFICACY AND SAFETY OF BENRALIZUMAB IN SEVERE EOSINOPHILIC ASTHMA IN A TERTIARY HOSPITAL | 5PSQ-063 |
| EFFICACY AND SAFETY OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA IN A TERTIARY HOSPITAL | 5PSQ-064 | |
| EVALUATION OF RESPIRATORY FUNCTION AND SAFETY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS FOLLOWED AT A REGIONAL REFERENCE CENTER | 5PSQ-065 |
| EVALUATION OF CEFTAZIDIME/AVIBACTAM USE AND CLINICAL OUTCOMES IN PATIENTS WITH MULTIDRUG-RESISTANT GRAM-NEGATIVE INFECTIONS | 5PSQ-066 |
| ANALYSIS OF THE HIV (HUMAN IMMUNODEFICIENCY VIRUS) POST-EXPOSURE PROPHYLAXIS PROGRAM (PEP) IN A TERTIARY HOSPITAL | 5PSQ-067 |
| ANALYSIS OF RELAPSES AFTER DISCONTINUATION OF PROPHYLACTIC BIOLOGIC TREATMENT IN MIGRAINE | 5PSQ-068 |
| QT-PROLONGING DRUGS IN HIGH-RISK POST-SURGICAL PATIENTS: ARE WE AWARE OF THEIR RISKS? | 5PSQ-069 |
| PROMPT SWITCHING OF INTRAVENOUS TO ORAL ANTIBIOTICS- A QUALITY IMPROVEMENT APPROACH | 5PSQ-070 |
| SAFETY PROFILE OF APALUTAMIDE FOR THE TREATMENT OF PROSTATE CANCER IN CLINICAL PRACTICE | 5PSQ-071 |
| DRUG PRESCRIPTION IN HEPATIC CIRRHOSIS: PITFALLS AND ROOM FOR IMPROVEMENT | 5PSQ-072 |
| ASSOCIATION BETWEEN ATORVASTATIN TREATMENT AND ELEVATED PLASMA LACTATE LEVELS | 5PSQ-073 |
| SEQUENTIAL MONOCLONAL ANTIBODY THERAPY IN PSORIASIS MANAGEMENT: EVALUATING CLINICAL OUTCOMES AND TREATMENT DURABILITY | 5PSQ-074 |
| EFFICACY AND PATIENT-REPORTED OUTCOMES OF TENECTEPLASE AND ALTEPLASE IN ACUTE STROKE MANAGEMENT: A COMPARATIVE ANALYSIS | 5PSQ-075 | |
| COMPREHENSIVE ASSESSMENT OF PHARMACOTHERAPY IN THE COMPLEX CHRONIC PATIENT AS A SECURITY STRATEGY | 5PSQ-076 |
| MICROBIOLOGICAL CONTAMINATION FOLLOWING THE USE OF TWO COMPOUNDED FORMULATIONS OF TACROLIMUS EYE DROPS | 5PSQ-077 |
| EXTRAVASATION MANAGEMENT AWARENESS IN NURSING STAFF IN A TERTIARY CARE HOSPITAL | 5PSQ-078 |
| CONTINUED USE OF POTENTIALLY INAPPROPRIATE MEDICATION AFTER HOSPITAL DISCHARGE: A RETROSPECTIVE COHORT STUDY | 5PSQ-079 |
| CISPLATIN-INDUCED NEPHROTOXICITY AND ELECTROLYTE IMBALANCES IN HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) | 5PSQ-080 |
| DOCETAXEL, ABIRATERONE AND ANDROGEN DEPRIVATION THERAPY: EFFICACY AND SAFETY ANALYSIS | 5PSQ-081 |
| USE, EFFICACY AND SAFETY OF CEFIDEROCOL IN INFECTIONS CAUSED BY MULTIDRUG-RESISTANT GRAM-NEGATIVE MICROORGANISMS | 5PSQ-082 |
| ADVERSE EFFECTS OF LONG-TERM ORAL ANTIBIOTICS IN OSTEOARTICULAR INFECTIONS: PRELIMINARY RESULTS OF THE PROSPECTIVE STUDY | 5PSQ-083 | |
| ADEQUACY OF AMIKACIN PRESCRIPTION IN OVERWEIGHT AND OBESE CRITICALLY ILL PATIENTS | 5PSQ-084 |
| SAFETY AND TOLERANCE PROFILE OF OSIMERTINIB FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | 5PSQ-085 |
| HOSPITALIZATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER RECEIVING IMMUNOTHERAPY | 5PSQ-086 |
| CLINICAL EXPERIENCE WITH BEZLOTOXUMAB IN A THIRD-LEVEL HOSPITAL | 5PSQ-087 |
| CONCILIATION FROM HOSPITAL PHARMACY EXTERNAL CONSULTATIONS IN COLLABORATION WITH PRIMARY CARE PHARMACY | 5PSQ-088 |
| IMPACT OF ANTIMICROBIAL RESISTANCE ON HOSPITAL MORTALITY, LENGTH OF HOSPITAL STAY AND LENGTH OF ICU STAY IN PATIENTS WITH BACTERIAL PNEUMONIA ADMITTED TO ICU | 5PSQ-089 |
| IMPACT OF VEDOLIZUMAB LEVELS ON CLINICAL RESPONSE IN CROHN’S DISEASE: A RETROSPECTIVE STUDY | 5PSQ-090 |
| FACILITATORS AND BARRIERS IN UTILIZING BARCODE TECHNOLOGY IN DRUG PREPARATION AND ADMINISTRATION – A FOCUS GROUP STUDY FOR WARD PHARMACISTS | 5PSQ-091 |
| IMMUNOTHERAPY IN NEOADJUVANT TRIPLE-NEGATIVE BREAST CANCER: EFFECTIVENESS AND SAFETY | 5PSQ-092 |
| EFFECTIVENESS AND SAFETY OF DURVALUMAB IN UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA | 5PSQ-093 |
| EFFICACY OF BASILIXIMAB VERSUS THYMOGLOBULIN IN RENAL TRANSPLANT INDUCTION THERAPY | 5PSQ-094 |
| IMPACT OF ANTIBIOTIC THERAPY ON CLINICAL OUTCOMES OF CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICIs): A REAL-PRACTICE ANALYSIS | 5PSQ-095 | |
| DIFFERENCES IN GFR ESTIMATION BASED ON CREATININE AND CYSTATIN C IN A COHORT OF OLDER MEDICAL PATIENTS, AGE-MATCHED CONTROLS, AND HEALTHY YOUNG ADULTS | 5PSQ-096 |
| EVALUATION OF EFFECTIVENESS AND SAFETY OF ELADOCAGENE EXUPARVOVEC IN THE TREATMENT OF AROMATIC L-AMINO ACID DECARBOXYLASE (AADC) DEFICIENCY IN UNIVERSITY HOSPITAL: A CASE REPORT | 5PSQ-097 |
| EFFECTIVENESS AND SAFETY OF OSIMERTINIB IN EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER WITH BRAIN METASTASES : A RETROSPECTIVE OBSERVATIONAL STUDY | 5PSQ-098 |
| ENHANCING PATIENT SAFETY: ANALYSIS AND MITIGATION OF MEDICATION ERRORS IN CRITICAL CARE UNITS DURING 2024 | 5PSQ-099 |
| SAFETY IN THE USE OF JAK INHIBITORS IN CHRONIC INFLAMMATORY DISEASES | 5PSQ-100 |
| STRATEGIES TO REDUCE THE RISK OF INFUSION REACTIONS TO FOSAPREPITANT IN HIGHLY EMETOGENIC CHEMOTHERAPY | 5PSQ-101 |
| EVALUATION OF THE CORRELATION BETWEEN PROCALCITONIN (PCT) LEVEL AND OTHER BIOMARKERS, SEPSIS DIAGNOSIS AND ANTIBIOTIC PRESCRIPTION PATTERN AT AN EMERGENCY DEPARTMENT (ED) | 5PSQ-102 |
| EXTRAVASATION AND ONCO-HEMATOLOGICAL BIOLOGICAL DRUGS: ANALYSIS OF REPORTS IN THE NATIONAL ITALIAN PHARMACOVIGILANCE NETWORK | 5PSQ-103 |
| ATEZOLIZUMAB TOGETHER WITH CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG CANCER IN A TERTIARY HOSPITAL | 5PSQ-104 |
| EVALUATION OF A CHRONIC MEDICATION ADEQUACY PROGRAM AT HOSPITAL DISCHARGE FOR FRAIL PATIENTS ADMITTED TO THE EMERGENCY SHORT-STAY UNIT OF A TERTIARY HOSPITAL | 5PSQ-105 |
| ANALYSIS OF ADVERSE DRUG REACTIONS LEADING TO HOSPITAL ADMISSION IN A REGIONAL HOSPITAL | 5PSQ-106 |
| ANALYSIS OF BETA-LACTAM ALLERGIES: “DE-LABEL YOUR ALLERGY” PROJECT | 5PSQ-107 |
| COMPARISON OF THE FRENCH PRESCRIPTION GUIDE ADAPTED FOR THE ELDERLY (PAPA guide) WITH THE EUROPEAN STOPP/START (S/S) LIST | 5PSQ-108 |
| ROLE OF THE PHARMACIST IN THE APPROACH TO VACCINATION OF IMMUNOCOMPROMISED PATIENTS TREATED WITH BIOLOGIC DRUGS | 5PSQ-109 |
| ANTIBIOTIC STEWARDSHIP IN AN EMERGENCY DEPARTMENT | 5PSQ-110 |
| RISK ANALYSIS OF ADVANCED THERAPY MEDICAL PRODUCTS (ATMPs) CIRCUITS WITHIN A UNIVERSITY HOSPITAL | 5PSQ-111 |
| EVALUATION OF THE USE OF INFLIXIMAB IN IMMUNE-CHECKPOINT INHIBITOR-INDUCED ADVERSE REACTIONS | 5PSQ-112 |
| VITAMIN D PRESCRIPTION IN COMPLEX CHRONIC PATIENTS AND PHARMACEUTICAL INTERVENTIONS TO TRATMENT OPTIMIZATION | 5PSQ-113 |
| ADALIMUMAB IN PATIENTS WITH IMMUNE-MEDIATED DISEASES: EVALUATING THE TRANSITION TO THE BIOSIMILAR AND PATIENT-REPORTED OUTCOME MEASURES (PROM) | 5PSQ-114 |
| INFLUENCE OF THE PHARMACY IN ADHERENCE TO TREATMENT IN PATIENTS WITH MULTIPLE SCLEROSIS | 5PSQ-115 |
| ANALYSING UNIVERISTY HOSPITALS’ CLINICAL DECISION SUPPORT SYSTEM ALERTS FOR MEDICATION ORDERING PROCESS | 5PSQ-116 |
| EFFECTIVENESS OF BARICITINIB IN ALOPECIA AREATA | 5PSQ-117 |
| INTELLIGENT INFUSION PUMPS FOR CYTOSTATIC DRUG DELIVERY: DEVELOPMENT OF A DRUG LIBRARY AND FIRST STEPS OF IMPLEMENTATION | 5PSQ-118 |
| ENCEPHALOMYELITIS AFTER RABIES VACCINATION: A REPORT OF TWO CASES | 5PSQ-119 |
| USE OF DIRECT ORAL ANTICOAGULANTS IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL: A RETROSPECTIVE REVIEW OF CLINICAL PRACTICE | 5PSQ-120 |
| SEVERE BONE MARROW APLASIA INDUCED BY ENFORTUMAB VEDOTIN IN A PATIENT WITH METASTATIC UROTHELIAL CARCINOMA: A CASE REPORT AND MULTIDISCIPLINARY MANAGEMENT | 5PSQ-121 | |
| EVALUATION AND INFLUENCE OF VITAMIN D LEVELS IN THE CRITICALLY CARE PATIENT | 5PSQ-122 |
| REPORTED SERIOUS ADVERSE DRUG EVENTS: A KNOWLEDGE SOURCE FOR PHARMACEUTICAL DECISION SUPPORT SYSTEMS LEARNING | 5PSQ-123 |
| EXCEEDING SAFE EXCIPIENT LIMITS IN NEONATOLOGY UNIT MEDICATIONS: A CALL FOR SAFER PHARMACEUTICAL ALTERNATIVES | 5PSQ-124 |
| EVALUATION OF PATIENT SAFETY CULTURE AMONG HEALTHCARE PROFESSIONALS IN A PHARMACY DEPARTMENT | 5PSQ-125 |
| PHARMACEUTICAL INTERVENTION IN INTRAVITREAL THERAPY | 5PSQ-126 |
| OPIOID WITHDRAWAL IN PATIENTS WITH FIBROMYALGIA | 5PSQ-127 | |
| CASE REPORT: “ADVERSE REACTION FOLLOWING INTRAVITEAL ADMINISTRATION OF AFLIBERCEPT” | 5PSQ-128 |
| CHATGPT’S PERFORMANCE AND PHARMACEUTICAL INTERVENTION IN DOSING HIGH-RISK MEDICATIONS IN THE OPERATING ROOM | 5PSQ-129 |
| IMPACT OF DPYD GENE POLYMORPHISMS AND TOXICITY ON FLUOROPYRIMIDINE TREATMENT | 5PSQ-130 |
| EVALUATION OF THE FINANCIAL IMPACT OF COLD CHAIN BREAKS IN A BURNS INTENSIVE CARE UNIT | 5PSQ-131 | |
| ADVERSE DRUGS EVENTS ATTENDED IN EMERGENCY DEPARTMENT: ANALYSIS, ECONOMIC IMPACT AND PREVENTIVE MEASURES ADOPTED | 5PSQ-132 |
| DISCREPANCIES BETWEEN OBSERVED VORICONAZOLE CLEARANCE AND PREDICTED ACCORDING TO CYP2C19 GENETIC POLYMORPHISM. IMPORTANCE OF THERAPEUTIC DRUG MONITORING | 5PSQ-133 |
| IMPROVING ACCESS TO INNOVATIVE MEDICINES: A REVIEW OF THE “ACCESS PROGRAM” EXPERIENCE | 5PSQ-134 | |
| LONG-TERM ACTIVITY-FREE STATUS IN MULTIPLE SCLEROSIS WITH OCRELIZUMAB: REAL WOLRD EVIDENCE | 5PSQ-135 |
| APPROPRIATENESS OF DAPAGLIFLOZIN PRESCRIPTION IN HEART FAILURE | 5PSQ-136 |
| PROGNOSTIC ROLE OF HAEMATOLOGICAL PARAMETERS IN EXTENDED-STAGE SMALL-CELL LUNG CANCER PATIENTS TREATED WITH ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY | 5PSQ-137 |
| SATISFACTION WITH CABOTEGARVIR AND RILPIVIRINE LONG-ACTING IN A REAL WORLD SETTING: PRELIMINARY DATA | 5PSQ-138 |
| DUPILUMAB-ASSOCIATED SCARRING ALOPECIA IN A PATIENT WITH ATOPIC DERMATITIS: A CASE REPORT | 5PSQ-139 |
| CLASSIFICATION OF DRUG-RELATED PROBLEMS IN PEDIATRIC PATIENTS AND ACCEPTANCE OF PHARMACEUTICAL INTERVENTIONS | 5PSQ-140 |
| IMPACT OF CABOTEGARVIR AND RILPIVIRINE LONG-ACTING IN QUALITY OF LIFE OF SUBJECTS IN A REAL WORLD SETTING: PRELIMINARY DATA | 5PSQ-141 |
| MULTISITE CLINICAL TRIALS: WHAT ABOUT THE EXPERIMENTAL DRUG CIRCUIT? FAILURE MODE, EFFECTS AND CRITICALITY ANALYSIS | 5PSQ-142 |
| ASSESSING CARDIOVASCULAR SAFETY OF ANTI-CGRP TREATMENTS: INSIGHTS FROM REAL WORLD DATA IN ELDERLY AND CARDIOVASCULAR PATIENTS | 5PSQ-143 |
| THE VALUE OF THERAPEUTIC ADHERENCE IN THE TREATMENT OF DRUG-RESISTANT EPILEPSY | 5PSQ-144 |
| THE USE OF MEAN KINETIC TEMPERATURE TO MANAGE TEMPERATURE EXCURSION IN HOSPITAL PHARMACY | 5PSQ-145 | |
| MAINTENANCE OF RESPONSE AT 52-WEEK IN MODERATE TO SEVERE ATOPIC DERMATITIS: A NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES | 5PSQ-146 |
| ALGORITHMS TO ENHANCE SAFETY OF HIGH ALERT MEDICATIONS’ PRESCRIBING IN HOSPITALIZED PATIENTS | 5PSQ-147 |
| MEDICAL DEVICES VIGILANCE NETWORK: EXPERIENCE IN AN ITALIAN LOCAL HOSPITAL | 5PSQ-148 |
| EFFICACY AND SAFETY OF AVATROMBOPAG IN SEVERE THROMBOCYTOPENIA SECONDARY TO CHRONIC LIVER DISEASE IN A PATIENT WITH HISTORY OF THROMBOSIS: A CASE REPORT | 5PSQ-149 |
| MONITORING OF PERSONALIZED THERAPIES DISPENSED THROUGH AUTOMATED UNIT DOSE DRUG DISPENSING SYSTEM | 5PSQ-150 |
| INCIDENCE OF NEPHROTOXICITY IN CISPLATIN ADMINISTRATION ASSOCIATED WITH A HYDRATION PROTOCOL | 5PSQ-151 |
| PATIENT-ORIENTED CARE IN PHARMACY CONSULTATION CENTRE: CHANGES OF TRENDS IN CONSULTATIONS IN LAST 12 YEARS – ANALYSIS OF ACTIVITIES IN CONSULTATION CENTRE | 5PSQ-152 |
| AN EVALUATION OF ADHERENCE TO HYPERKALEMIA GUIDELINES WITH A REVISED SODIUM POLYSTYRENE SULFONATE DOSING | 5PSQ-153 |
| CO-ADMINISTRATION OF RIBOCICLIB/PALBOCICLIB AND PROTON PUMP INHIBITORS (PPI): A REAL-WORLD ANALYSIS IN AN ITALIAN ONCOLOGY CENTER | 5PSQ-154 |
| PK-RULES: CLINICAL RULES TO ENHANCE THE SAFETY AND EFFICACY OF TREATMENTS THROUGH PHARMACOKINETIC MONITORING | 5PSQ-155 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EFFICACY OF BIOLOGICS AND SMALL MOLECULE INHIBITORS IN TREATING GENITAL PSORIASIS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS | 6ER-001 | |
| VALIDATION OF ICD-10 DIAGNOSIS CODES FOR GUILLAIN-BARRÉ SYNDROME IN TAIWAN’S NATIONAL HEALTH INSURANCE CLAIMS DATABASE | 6ER-002 | |
| INFLUENZA VACCINATION AND ITS ASSOCIATION WITH DEMENTIA RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS | 6ER-003 |
| USE OF ARTIFICIAL INTELLIGENCE TO IMPROVE MEDICAL CARE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. INFLAMMATORY BOWEL DISEASE. PRELIMINARY MODELS | 6ER-004 |
| THE IMPACT OF TYPE OF DELIVERY METHOD ON MEDICINE WASTE IN HOUSEHOLDS: A QUESTIONNAIRE-BASED STUDY ON OUTPATIENTS RECEIVING COST-FREE MEDICINE | 6ER-005 |
| ANALYSIS OF THE ANTIMICROBIAL USE IN NEONATAL POPULATION BASED ON A DEFINED DAILY DOSE METHOD | 6ER-006 |
| RALOXIFENE AS AN ADJUVANT THERAPY FOR PATIENTS WITH SCHIZOPHRENIA | 6ER-007 |
| AFICAMTEN AND MAVACAMTEN: WHEN SIDE EFFECTS AFFECT EFFICACY | 6ER-008 |
| SCIENTIFIC ACTIVITY OF HOSPITAL PHARMACY SPECIALISTS TRAINED AT VIRGEN DEL ROCÍO UNIVERSITY HOSPITAL | 6ER-009 |
| METFORMIN FOR PREVENTION AND TREATMENT OF ANTIPSYCHOTIC-INDUCED WEIGHT GAIN | 6ER-010 |
| EVALUATING THE POTENTIAL OF CHATGPT TO SIMULATE CLINICAL TRIAL DATA: IMPLICATIONS FOR THE INTEGRITY OF SCIENTIFIC RESEARCH | 6ER-011 |
| ESTIMATING MEDICATION ADHERENCE IN HEART FAILURE USING ELECTRONIC HEALTH RECORDS: A SYSTEMATIC REVIEW | 6ER-012 |
| EVOLUTION OF PHARMACISTS’ PARTICIPATION AS PRINCIPAL INVESTIGATORS IN REGISTERED CLINICAL TRIALS: A LONGITUDINAL STUDY FROM 2004 TO 2024 | 6ER-013 |
| EVALUATION OF BARICITINIB IN PEDIATRIC PATIENTS WITH ALOPECIA AREATA | 6ER-014 |
| HARNESSING OPENAI AS A STRATEGIC TOOL FOR HORIZON SCANNING IN HOSPITAL PHARMACY PRACTICE | 6ER-015 | |
| THE TECHNICIAN: A KEY PILLAR IN STAFF TRAINING FOR COMPOUNDING | 6ER-016 |
| IMPLEMENTING DIVERSE EDUCATIONAL MODELS TO ENHANCE PHARMACISTS’ PRESCRIPTION EVALUATION SKILLS | 6ER-017 | |
| ATTITUDES TOWARDS DEPRESCRIBING AMONG OLDER PATIENTS WITH RHEUMATIC DISEASES | 6ER-018 |
| COLCHICINE : HOSPITAL-WIDE EVALUATION AND BENEFITS OF A VIDEO COURSE | 6ER-019 |
| LARGE LANGUAGE MODEL: METHODOLOGY PROPOSAL FOR AN ASSISTED META-ANALYSIS TO CATALOG MEDICAL DEVICES USED IN PREOPERATIVE PROGRESSIVE PNEUMOPERITONEUM FOR THE MANAGEMENT OF COMPLEX VENTRAL HERNIAS | 6ER-020 |
| PROGNOSTIC FACTORS OF CLINICAL OUTCOME IN REAL-WORLD ADVANCED CERVICAL CANCER PATIENTS RECEIVING PEMBROLIZUMAB TREATMENT: A RETROSPECTIVE STUDY | 6ER-021 |
| ANALYSIS OF THE PERFORMANCE OF GENERATIVE ARTIFICIAL INTELLIGENCE IN THE CRITICAL EVALUATION OF ARTICLES | 6ER-022 |
| ANALYSIS OF THE INCIDENCE OF SEXUALLY TRANSMITTED DISEASES IN USERS OF HIV-1 PRE-EXPOSURE PROPHYLAXIS | 6ER-023 |
| ADHERENCE TO INHALED TREATMENT IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA ON TREATMENT WITH BIOLOGICAL THERAPY | 6ER-024 |
| WOMEN IN FOCUS: FEMALE REPRESENTATION IN HOSPITAL PHARMACY CONFERENCES | 6ER-025 |
| A NETWORK META-ANALYSIS OF BIOLOGICAL AND TARGETED SYNTHETIC DRUGS IN REFRACTORY PSORIATIC ARTHRITIS | 6ER-026 |
| MANAGEMENT OF HEART FAILURE IN 16 SUB-SAHARAN AFRICAN COUNTRIES: DRUGS STRATEGIES AND 8-YEAR TRENDS (THE FEBRUARY STUDY 2016-2023) | 6ER-027 |
| A COMPARATIVE ANALYSIS OF THE EFFICACY OF ADJUVANT TREATMENT WITH PEMBROLIZUMAB OR NIVOLUMAB IN PATIENTS WITH STAGE IIB/IIC MELANOMA | 6ER-028 |
| LONG-TERM EXPERIENCE WITH ERENUMAB, GALCANEZUMAB AND FREMANEZUMAB IN THE TREATMENT OF CHRONIC MIGRAINE | 6ER-029 |
| EXPERIENCE WITH NATALIZUMAB IN THE TREATMENT OF MULTIPLE SCLEROSIS | 6ER-030 |
| EFFECTIVENESS OF ABEMACICLIB, PALBOCICLIB AND RIBOCICLIB IN METASTATIC BREAST CANCER | 6ER-031 |
| ASSESSING THE RELATIONSHIP BETWEEN JOB-RELATED FACTORS AND PHARMACISTS’ PERCEPTION OF SATISFACTION WITH WORK CONDITIONS | 6ER-032 | |
| EVALUATING ADHERENCE IN HIV PRE-EXPOSURE PROPHYLAXIS (PREP): A RETROSPECTIVE ANALYSIS | 6ER-033 |
| ESTABLISHING PHARMACOEPIDEMIOLOGICAL CURRICULUM TO ENHANCE PHARMACIST’S RESEARCH CORE COMPETENCIES: A EVIDENCE-BASED KNOWLEDGE TRANSLATION | 6ER-034 | |
| A COMPARATIVE ANALYSIS OF THE EFFICACY OF BIOLOGICAL DRUGS AND ORAL SMALL MOLECULES IN THE TREATMENT OF ATOPIC DERMATITIS | 6ER-035 |
| SUBSTANCE ABUSE IN PATIENTS WITH SCHIZOPHRENIC OR BIPOLAR DISORDER | 6ER-036 |
| PERFORMANCE AND CONCORDANCE OF ARTIFICIAL INTELLIGENCE IN THE BPS | 6ER-037 |
| INVESTIGATING CO-MEDICATION-RELATED TOXICITY IN CANCER PATIENTS TREATED WITH IMMUNOTHERAPY: AN OBSERVATIONAL STUDY | 6ER-038 |
| CONCOMITANT USE OF PROTON PUMP INHIBITORS AND ABEMACICLIB, PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER | 6ER-039 |
| EFFICACY AND SAFETY OF ANTIBODY-DRUG CONJUGATES FOR LUNG CANCER THERAPY: A SYSTEMATIC REVIEW OF RANDOMIZED AND NON-RANDOMIZED CLINICAL TRIALS | 6ER-040 |
| SWITCHING CALCITONINE GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES (CGRP-mAb) IN PATIENTS WITH REFRACTORY MIGRAINE: REAL WORLD DATA | 6ER-041 |
| REPORTED DRUG INDUCED ACUTE KIDNEY INJURY: A PHARMACOVIGILANCE ANALYSIS | 6ER-042 |
| CASE REPORT: SPINAL CORD INFARCT SECONDARY TO VAPING? | 6ER-043 |
| DOCTORS’, NURSES’, AND MIDWIVES’ VIEWS OF HOSPITAL PHARMACIST PRESCRIBING: A CROSS-SECTIONAL SURVEY STUDY | 6ER-044 |
| EFFECTIVENESS AND SAFETY OF FIRST LINE CHEMOIMMUNOTHERAPY WITH PEMBROLIZUMAB FOR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | 6ER-045 |
| DURVALUMAB AS CONSOLIDATION THERAPY FOLLOWING CHEMORADIOTHERAPY IN UNRESECTABLE STAGE III NON-SMALL-CELL LUNG CANCER: REAL-WORLD SURVIVAL OUTCOMES | 6ER-046 |
| IMPACT OF BIOLOGIC THERAPY ON CARDIO-METABOLIC PARAMETERS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: A SYSTEMATIC REVIEW | 6ER-047 |
| COMPARISON OF PEMBROLIZUMAB + CHEMOTHERAPY AND NIVOLUMAB + IPILIMUMAB + CHEMOTHERAPY IN METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER WITH PD-L1 < 1% | 6ER-048 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EXTEMPORANEOUS FLUCYTOSINE 15,5% INTRAVAGINAL GEL TO TREAT REFRACTORY CANDIDA GLABRATA VULVOVAGINTIS – CASE REPORT | NP-001 |
| MEDICATION SAFETY: STRATEGIES & OPPORTUNITIES IN CLINICAL PHARMACY PRACTICE | NP-002 | |
| PATIENT MEDICINE GUIDES SUPPORT SAFE MEDICATION TREATMENT AND DISCHARGE FROM THE HOSPITAL IN PAEDIATRIC SPECIALISED MEDICAL CARE | NP-003 |
| PALL-OLU.DE: A NEW DATABASE ON THE OFF-LABEL USE OF DRUGS IN PALLIATIVE MEDICINE | NP-004 |
| UNAUTHORISED MEDICATION USE IN ESTONIAN HOSPITALS | NP-005 |
| DRUGHOST, THE FIRST DATABASE OF UNAVAILABLE DRUGS IN EUROPE—AN ITALIAN MODEL: DATA ONE YEAR AFTER THE START OF THE PLATFORM | NP-006 |
| VALIDATION OF ANTIMICROBIAL DEFINED DAILY DOSE (DDD) FOR THE PAEDIATRIC POPULATION: FINAL RESULTS OF KIDDDS PROJECT | NP-007 | |
| CASE REPORT : SINGLE-USE CRANIAL DRILLS, HIGH-RISK DEVICES! | NP-008 |
| BARRIERS AND FACILITATORS TO PHARMACY PROFESSIONALS’ SPECIALIST PUBLIC HEALTH SKILLS: A MIXED METHODS UK-WIDE PHARMACEUTICAL PUBLIC HEALTH EVIDENCE REVIEW | NP-009 | |
| COMPATIBILITY OF LOCAL ANESTHETIC AND CORTICOSTEROID MIXTURES IN TRANSFORAMINAL EPIDURAL STEROID INJECTIONS | NP-010 |
| LINEZOLID THERAPEUTIC DRUG MONITORING AMONG CRITICALLY ILL ADULT PATIENTS AFTER CARDIOVASCULAR SURGERY | NP-011 | |
| IMPROVING THE CLINICAL PHARMACIST HANDOVER PROCESS USING AN ADAPTED ISBAR COMMUNICATION TOOL WHEN TRANSFERRING PATIENTS FROM CORK UNIVERSITY MATERNITY HOSPITAL (CUMH) TO AN INTENSIVE CARE UNIT (ICU) WITHIN CORK UNIVERSITY HOSPITAL (CUH). | NP-012 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ANALYSIS OF THE USE OF ORAL ONCOLOGY TARGETED THERAPIES IN A REGION OF SPAIN | 1ISG-001 |
| PHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE | 1ISG-002 |
| PHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE | 1ISG-002 |
| DIGITAL TRANSFORMATION OF THE HOSPITAL/TERRITORIAL PHARMACY – TELEPHARMACY NEW DIMENSION OF PATIENT CARE MODELS | 1ISG-003 |
| MULTIDISCIPLINARY MANAGEMENT OF CENTRAL VENOUS CATHETERS (CVCS) IN HEMODIALYSIS PATIENTS. | 1ISG-004 |
| ASSESSMENT OF A MANAGEMENT TOOL REGARDING MEDICAL DEVICE VIGILANCE | 1ISG-005 | |
| ECONOMIC SAVING OF THE PREPARATION OF SUBCUTANEOUS FORMULATIONS COMPARED TO INTRAVENOUS: FOCUS ON DARATUMUMAB IN THREE HEALTHCARE COMPANIES | 1ISG-006 |
| HTA ANALYSIS FOR THE INCLUSION OF ANDEXANET ALFA (AA) WITHIN THE HOSPITAL THERAPEUTIC HANDBOOK (HTH) – THE EXPERIENCE OF AN ITALIAN CENTER SPECIALIZING IN CARDIOVASCULAR DISEASES | 1ISG-007 |
| USABILITY EVALUATION OF AN INSULIN MANAGEMENT SOLUTION WITHIN AN ELECTRONIC PATIENT RECORD | 1ISG-008 | |
| PHARMACOECONOMIC ANALYSIS OF AN ALTERNATIVE DOSAGE REGIMEN FOR PALIVIZUMAB | 1ISG-009 |
| ECONOMIC IMPACT OF THE CLINICAL PHARMACIST ON THE REDUCTION OF DRUG-RELATED PROBLEMS BEFORE THE INITIATION OF AN ANTI-TUMOR TREATMENT – A PROSPECTIVE MULTICENTER TRIAL | 1ISG-010 |
| OPPORTUNITY FOR DAILY HOME-BASED MANAGEMENT OF CHRONIC PATIENTS FROM THE SAME AREA USING AN INTERPROFESSIONAL NETWORK MODEL DEVISED, SET UP AND IMPLEMENDET FOR THE COVID-19 | 1ISG-011 |
| BALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS | 1ISG-012 |
| BALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS | 1ISG-012 | |
| REAL-LIFE DATA OF CDK4/6 INHIBITORS PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER: EFFECTIVENESS EVALUATION | 1ISG-013 |
| SUSTAINABLE HEALTHCARE: AN EXAMPLE OF PHARMACEUTICAL INTERVENTION | 1ISG-014 |
| ASSESSMENT OF PREPARATORY STAFF’S KNOWLEDGE OF CARCINOGENIC, MUTAGENIC AND REPROTOXIC (CMR) RISKS | 1ISG-015 |
| OCRELIZUMAB FOR THE TREATMENT OF RECAPTING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN NATIONAL HEALTH SYSTEM: A COST EFFECTIVENESS ANALYSIS | 1ISG-016 |
| THE THREE HORIZONS METHOD AS A TOOL FOR DEFINING THE HOSPITAL PHARMACY RESIDENT OF THE FUTURE(HPRF) | 1ISG-017 |
| TEN-YEAR DRUG SURVIVAL ANALYSIS IN MODERATE TO SEVERE PLAQUE PSORIASIS FIRST-LINE TREATMENT | 1ISG-018 | |
| DO ALL SURGICAL SPECIALTIES HAVE AN IDENTICAL CARBON FOOTPRINT WHITIN AN AMBULATORY UNIT ? | 1ISG-019 |
| DRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT | 1ISG-020 |
| DRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT | 1ISG-020 | |
| 1 YEAR-REVIEW OF THE EKOSONIC® ENDOVASCULAR SYSTEM (BOSTON SCIENTIFIC) IN THE MANAGEMENT OF PULMONARY EMBOLISM IN AN INTERVENTIONAL CARDIOLOGY DEPARTMENT | 1ISG-021 |
| HOSPITAL PHARMACISTS’ PERCEPTIONS OF THEIR PROFESSION IN TWO EUROPEAN COUNTRIES | 1ISG-022 |
| ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL | 1ISG-023 |
| ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL | 1ISG-023 | |
| SINGLE-USE MEDICAL DEVICES IN THE TREATMENT OF CHRONIC DISEASES: WHAT IS THE ENVIRONMENTAL IMPACT? | 1ISG-024 |
| ANALYSIS OF THE COMPLEXITY OF THE CLINICAL TRIALS CARRIED OUT IN A THIRD-LEVEL HOSPITAL | 1ISG-025 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CLINICAL IMPACT AND COST SAVINGS OF AN OUTPATIENT ANTIMICROBIAL THERAPY PROGRAMME: A FOCUS ON SELF-ADMINISTRATION | 2SPD-001 |
| EVALUATION OF THE EFFECTIVENESS AND RELATED COST OF ONCOLOGY DRUGS USED IN SPECIAL SITUATIONS, IN A THIRD-LEVEL UNIVERSITY HOSPITAL | 2SPD-002 |
| PROPER MANAGEMENT AND ECONOMIC BURDEN OF UNUSED MEDICATIONS DISPOSAL IN A SUSTAINABLE LATIN AMERICAN HOSPITAL: A RETROSPECTIVE STUDY | 2SPD-003 | |
| BUDGETARY IMPACT OF THE INTRODUCTION OF CABOTEGRAVIR PLUS RILPIVIRINE LONG-ACTING IN A THIRD LEVEL HOSPITAL | 2SPD-004 | |
| ALTERNATIVE TO THE TREATMENT OF POOR GRAFT FUNCTION AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION: ELTROMBOPAG | 2SPD-005 |
| IMPACT AND CONSEQUENCES OF THE USE OF HUMAN POLYVALENT IMMUNOGLOBULIN DURING THE COVID-19 PANDEMIC (2019-2022) | 2SPD-006 | |
| USE AND COST EVOLUTION OF ADALIMUMAB OVER EIGHT YEARS IN A LOCAL HOSPITAL | 2SPD-007 |
| SWITCHING TO A BIOSIMILAR ADALIMUMAB IN DUTCH UNIVERSITY MEDICAL CENTERS: IT IS NOT THAT HARD! | 2SPD-008 |
| A FIVE-YEAR RETROSPECTIVE REPORT ON COMPREHENSIVE MEDICINE PROCUREMENT WITHIN A PUBLIC GROUP PROCUREMENT ORGANISATION | 2SPD-009 | |
| IDENTIFYING AND QUANTIFYING DRUG-RELATED WASTE IN A HEALTHCARE ESTABLISHMENT | 2SPD-010 |
| AVAILABILITY OF LIQUID ANTIMICROBIALS – A NATIONAL ANALYSIS OF THE CURRENT SUPPLY SITUATION | 2SPD-011 |
| APPLICATION OF FAILURE MODE AND EFFECTS ANALYSIS TO IMPROVE AUTOMATED DISPENSING CABINETS’ DRUG STOCK MANAGEMENT PROCESSES | 2SPD-012 |
| A COMPARATIVE LIFE CYCLE ASSESSMENT OF DIFFERENT PACKAGING OPTIONS FOR ALBUMIN DISTRIBUTION | 2SPD-013 |
| ECO-CONSCIOUS HEALTHCARE PRODUCTS SUPPLY: INVESTIGATING THE EFFECTS OF FEWER ORDERS | 2SPD-014 |
| INTEGRATED HEALTHCARE LOGISTICS: KANBAN SOLUTION FOR MANAGEMENT OF DIALYSIS WAREHOUSES PILOT CASE | 2SPD-015 | |
| DATA-DRIVEN SELECTION OF A MEDICATION MANAGEMENT MODEL IN HOSPITALISATION WARDS | 2SPD-016 |
| RISK IDENTIFICATION IN ANTIDOTE AND EMERGENCY PREPAREDNESS | 2SPD-017 | |
| IMPACT OF INHALERS ON CO2 EMISSION IN A HEALTH AREA | 2SPD-018 |
| TOWARDS A SUSTAINABLE OPERATING ROOM : FEEDBACK ON ACTIONS CARRIED OUT AROUND MEDICAL DEVICES | 2SPD-019 |
| DESIGN AND EVALUATION OF AN INNOVATIVE AIRBORNE TRANSPORT SYSTEM FOR BLOOD-DERIVED DRUGS UNDER EMERGENCY CONDITIONS | 2SPD-020 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| TOPICAL COMPOUNDED CLINDAMYCIN SOLUTION MADE FROM ORAL DOSAGE FORMS, CONTROL AND STABILITY STUDY | 3PC-001 |
| STABILITY OF TENECTEPLASE SYRINGES AFTER FRACTIONATION | 3PC-002 | |
| SUITABILITY OF ELASTOMERIC PUMPS FOR DRUG STORAGE | 3PC-003 |
| DRUG WASTE OF READY-TO-ADMINISTER SYRINGES IN THE INTENSIVE CARE UNIT: ASEPTICALLY PREPARED SYRINGES VERSUS PREFILLED STERILISED SRYINGES | 3PC-004 |
| PREPARATION OF EPICUTANEOUS TESTS WITH MINOXIDIL AT 2% AND 5%. | 3PC-005 |
| STABILITY STUDY OF CLOBAZAM LIQUID ORAL FORMS FOR PEDIATRIC PATIENTS | 3PC-006 |
| CONTAINMENT PERFORMANCE ASSESSMENT OF CHEMFORT® (ONGUARD®2) CLOSED SYSTEM TRANSFER DEVICE ACCORDING TO 2016 DRAFT NIOSH PROTOCOL AT FIRST AND TENTH ACTIVATIONS END OF SHELF LIFE. | 3PC-007 |
| STABILITY OF PARENTERAL NUTRITION ADMIXTURES: FOCUS ON PRECIPITATION. | 3PC-008 |
| THE EFFECT OF ACCELERATED LIGHT (STRESS) AND NATURAL SUNLIGHT EXPOSURES ON CETUXIMAB (ERBITUX®): EVALUATION OF AGGREGATE FORMATION AND FUNCTIONALITY | 3PC-009 |
| DEVELOPMENT OF A STABLE PARENTERAL SOLUTION OF TOPIRAMATE FOR EMERGENCY TREATMENT OF STATUS EPILEPTICUS | 3PC-010 |
| MUCOSECTOMY : FEASIBILITY STUDY OF THE AUTOMATED PREPARATION OF A STERILE SOLUTION OF 5/10% FRUCTOSE GLYCEROL. | 3PC-011 |
| CONTENT UNIFORMITY OF SODIUM BENZOATE CAPSULES: VALIDATION OF A METHOD USING QCPREP® | 3PC-012 |
| RADIOPHARMACEUTICAL SINGLE-VIAL COLD KIT FORMULATION OF FAPI-04, AN EXPERIMENTAL VECTOR FOR GALLIUM-68 PET IMAGING IN ONCOLOGY | 3PC-013 |
| PHYSICOCHEMICAL STABILITY OF BEVACIZUMAB 25 MG/ML CONCENTRATE (VEGZELMA®) IN ORIGINAL GLASS VIALS AFTER FIRST OPENING | 3PC-014 |
| MICROBIOLOGICAL PERFORMANCE QUALIFICATION OF THE ROBOTIC SYSTEMS APOTECASYRINGE AND APOTECAUNIT | 3PC-015 |
| PHYSICOCHEMICAL STABILITY OF MOXIFLOXACIN 1 MG/0,2 ML SYRINGES FOR INTRACAMERAL ADMINISTRATION | 3PC-016 |
| ELABORATION OF DEFEROXAMINE EMULSION 0.5% FOR HYPERPIGMENTATION DUE TO INTRAVENOUS IRON EXTRAVASATION | 3PC-017 |
| GLASS AMPOULE HANDLING PRACTICES IN DUTCH HEALTHCARE: A COMPREHENSIVE ASSESSMENT | 3PC-018 |
| DEVELOPMENT A TOPICAL EMULSION FOR THE TREATMENT OF THIRD-DEGREE BURN PATIENTS CANDIDATES FOR SKIN GRAFT | 3PC-019 |
| PREVENTION OF INFECTIOUS RISK IN PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ALPHA INHIBITORS (ANTI-TNFΑ) | 3PC-020 |
| FORMULATION OF VORICONAZOLE OVULES AND EFFICACY IN VULVOVAGINAL CANDIDIASIS BY CANDIDA GLABRATA: A CASE REPORT. | 3PC-021 |
| DESIGN AND STABILITY STUDY OF AN ISONIAZID AND PYRIDOXINE ORAL LIQUID FORMULATION | 3PC-022 |
| NEW ACTIVITIES WITHIN A CLINICAL TRIAL MANAGEMENT UNIT: WHAT NEW RISKS FOR THE STAFF? | 3PC-023 |
| IMPLEMENTATION OF A STRATEGY TO OVERCOME THE POTENTIAL TOXIC EFFECTS OF PROPYLENE GLYCOL IN NEONATES | 3PC-024 |
| STABILITY STUDY OF STANDARDISED FLUID THERAPY PREPARED BY THE PHARMACY DEPARTMENT TO TREAT PEDIATRIC DIABETIC KETOACIDOSIS | 3PC-025 |
| COST SAVINGS ASSOCIATED WITH ROMIPLOSTIM REPACKAGING IN PATTIENT WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA | 3PC-026 |
| USE OF AUTOMATED COMPOUNDING DEVICES IN PEDIATRIC PARENTERAL NUTRITION: A GOOD WAY TO ENSURE SAFETY | 3PC-027 | |
| FOR A MORE ECONOMICAL AND ECOLOGICAL CENTRAL STERILE SERVICES DEPARTMENT (CSSD) : BACK TO THE CONTAINER | 3PC-028 | |
| PH MEASUREMENT: NOT AS SIMPLE AS WE THINK? A CASE OF SODIUM PERCHLORATE INJECTIONS | 3PC-029 |
| STABILITY STUDY OF AN EPIDURAL ANALGESIC CONCENTRATE FOR INFUSION USED DURING CHILDBIRTH | 3PC-030 |
| USABILITY OF SEMI-SOLID EXTRUSION 3D PRINTING IN HOSPITAL PHARMACY SETTINGS TO PRODUCE PERSONALISED ORAL MEDICATIONS FOR PEDIATRIC PATIENTS | 3PC-031 |
| OPTIMIZATION OF AN INSULIN 1 IU/ML EYE DROP FORMULATION FOR THE TREATMENT OF CORNEAL ULCERS | 3PC-032 |
| KIRO ISOLATOR®: A NEW, RELIABLE, ROBOTIC DEVICE FOR THE COMPOUNDING OF INJECTABLE ANTICANCER DRUGS | 3PC-033 | |
| FORMULATION OF KETAMINE 1% AND AMITRIPTYLINE 1% GEL IN PRURITIC EPIDERMOLYSIS BULLOSA: A CASE REPORT | 3PC-034 |
| PATCH TESTS WITH HAZARDOUS DRUGS: IS IT POSSIBLE TO ENSURE SAFETY DURING PRODUCTION? | 3PC-035 |
| RISK ANALYSIS OF THE PHARMACEUTICAL CIRCUIT FOR INJECTABLE CHEMOTHERAPIES AFTER IMPLEMENTATION OF DRUGLOG ®. | 3PC-036 |
| ALUMINIUM IN PEDIATRIC PARENTERAL NUTRITION: ARE MULTICHAMBER-BAGS THE SAFER CHOICE? | 3PC-037 | |
| AUTOLOGOUS SERUM EYE DROPS PREPARATION: APPROACH TO THE FILTRATION STEP IMPACT ON THE CONCENTRATION OF ACTIVE MOLECULES | 3PC-038 |
| EARLY DE-RISKING OF THE STABILITY OF A PERSONALISED, STERILE BACTERIOPHAGE SUSPENSION ON THE BASIS OF ADVANCED KINETIC MODELING | 3PC-039 | |
| RADIOCHEMICAL PURITY DETERMINATION OF 177LU-PSMA-617: DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYTICAL METHOD | 3PC-040 |
| PUBLIC PRODUCTION OF THERAPEUTIC BACTERIOPHAGES | 3PC-041 | |
| STERILE AND NON-STERILE COMPOUNDING: RISK ANALYSIS AND IMPROVEMENT MEASURES | 3PC-042 |
| INTRAVITREAL PREPARATION OF LIPOSOMAL B AMPHOTERICIN: FROM FORMULATION STUDY TO PREPARATION | 3PC-043 |
| A PHYSICO-CHEMICAL STABILITY STUDY OF VANCOMYCIN EYE DROP AFTER DIFFERENT THAWING TIMES | 3PC-044 | |
| RETROSPECTIVE STUDY OVER 6 YEARS OF THE TREND IN FUNGAL CONTAMINATION OF CONTROLLED ATMOSPHERE AREAS WITHIN A CELL THERAPY UNIT. | 3PC-045 |
| RISK OF PERSONNEL EXPOSURE TO HAZARDOUS DRUGS IN ROBOTIC COMPOUNDING | 3PC-046 |
| PEDIATRIC IV ANTIFUNGAL ADMIXTURES: CENTRALISATION’S ECONOMIC CONSEQUENCES | 3PC-047 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| COMPARATIVE ANALYSIS OF TWO PHARMACOKINETIC PROGRAMMES FOR LITHIUM ADJUSTMENT | 4CPS-001 |
| PHARMACEUTICAL CARE IN POSTOPERATIVE PAIN MANAGEMENT AT ADMISSION AND DISCHARGE | 4CPS-002 | |
| EVALUATION OF CLINICAL VARIABLES IMPACT ON ENOXAPARIN DOSING AND ANTIXA CONCENTRATION | 4CPS-003 |
| IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS | 4CPS-004 |
| DRUG PERSISTENCE OF JAK INHIBITORS COMPARED TO BIOLOGIC DRUGS IN REAL-WORLD PRACTICE IN PATIENTS WITH RHEUMATOID ARTHRITIS | 4CPS-005 |
| ADHERENCE TO NEBULIZED ANTIBIOTICS IN CYSTIC FIBROSIS PATIENTS AFTER STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR | 4CPS-006 |
| ADALIMUMAB IN THE TREATMENT OF RECALCITRANT SWEET SYNDROME: A CASE REPORT | 4CPS-007 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO ANTITHROMBOTIC DRUGS IN EMERGENCY DEPARTMENT | 4CPS-008 |
| NEONATAL DIAGNOSIS AND TREATMENT OF STIFF BABY SYNDROME: A CASE REPORT | 4CPS-009 |
| CAN ERENUMAB IMPROVE QUALITY OF LIFE PERCEIVED BY PATIENTS? | 4CPS-010 | |
| REAL-WORLD EFFECTIVENESS AND SURVIVAL OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIASIC ARTRHITIS: MULTICENTER ANALYSIS IN DAILY CLINICAL PRACTICE BY THE VALENCIAN COMMUNITY PSORIASIS GROUP. | 4CPS-011 |
| IMPROVING PARENTAL MEDICATION LITERACY BY PHARMACIST-LED DISCHARGE COUNSELLING IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | 4CPS-012 |
| INTRAVENOUS LEVETIRACETAM SUPPLETION DURING HAEMODIALYSIS PRESERVED STABLE THERAPEUTIC SERUM CONCENTRATIONS: A CASE REPORT | 4CPS-013 |
| REAL WORLD DATA ON THE USE OF PCSK9 INHIBITOR TREATMENTS IN HYPERCHOLESTEROLEMIA | 4CPS-014 |
| ASSESSMENT OF IN-HOSPITAL ANTIBIOTICS CONSUMPTION PATTERN ACCORDING TO THE WHO AWARE CLASSIFICATION IN A LOCAL HEALTH AUTHORITY | 4CPS-015 |
| EXPERIENCES, VIEWS AND ATTITUDES OF HOSPITAL NURSING STAFF TOWARDS THE IMPLEMENTATION OF THE UNIT DOSE DISPENSING SYSTEM FOR INPATIENTS: A QUALITATIVE INTERVIEW STUDY | 4CPS-016 |
| COMPARATIVE STUDY BETWEEN TIXAGEVIMAB/CILGAVIMAB AND SOTROVIMAB IN PATIENTS WITH COVID-19: A MONOCENTRIC EXPERIENCE AT UNIVERSITY HOSPITAL | 4CPS-017 |
| SWITCHING BETWEEN CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN THE PROPHYLAXIS OF MIGRAINE | 4CPS-018 |
| DIFFERENCES IN MEROPENEM DOSE ADJUSTMENT WITH CALCULATION OF GLOMERULAR FILTRATION RATE THROUGH DIFFERENT FORMULAS. | 4CPS-019 |
| EVALUATION OF THE EFFECTIVENESS OF MONOCLONAL ANTIBODIES AGAINST MIGRAINE HEADACHE | 4CPS-020 |
| PERFORMANCE OF MULTIPLE TRIGGER TOOLS IN IDENTIFYING MEDICATION-RELATED HOSPITAL READMISSIONS | 4CPS-021 |
| THE EFFECT OF DIGITAL CLINICAL DECISION SUPPORT ON PHARMACOTHERAPY IN HOSPITALISED (MORBIDLY) OBESE PATIENTS: A PROSPECTIVE INTERVENTION STUDY | 4CPS-022 | |
| OPTIMISING BIOLOGIC THERAPY IN SEVERE UNCONTROLLED ASTHMA PATIENTS ON OMALIZUMAB TREATMENT | 4CPS-023 |
| ANALYSIS OF POLYMEDICATION AND ADEQUACY TREATMENT RECOMMENDATIONS IN PATIENTS WITH MULTIPLE SCLEROSIS IN A TERTIARY LEVEL HOSPITAL. | 4CPS-024 |
| MANAGEMENT OF COVID-19 WITH NIRMATRELVIR/RITONAVIR AND TACROLIMUS MONITORING IN RENAL TRANSPLANTATION: A CASE REPORT | 4CPS-025 |
| ACCEPTABILITY AND WILLINGNESS TO SWITCH ANTIRETROVIRAL TREATMENT IN PATIENTS WITH LONG-ACTING INJECTABLE THERAPY CRITERIA. | 4CPS-026 |
| ANALYSIS OF CARDIOVASCULAR RISK ASSOCIATED WITH IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE TREATMENT IN PATIENTS WITH CHRONIC LYMPHOID LEUKEMIA | 4CPS-027 |
| ANALYSIS OF INTERACTIONS DETECTED IN THE CONCOMITANT USE OF ANTINEOPLASTIC AGENTS AND PHYTOTHERAPY IN ONCOHEMATOLOGY PRACTICE AND INTERVENTIONS CARRIED OUT. | 4CPS-028 |
| USE OF TOPICAL 1% CIDOFOVIR ON SKIN LESIONS IN A PATIENT WITH MONKEYPOX | 4CPS-029 |
| ANALYSIS OF ADHERENCE TO GROWTH HORMONE TREATMENT IN PAEDIATRIC PATIENTS. | 4CPS-030 |
| A POPULATION PHARMACOKINETIC MODEL OF VEDOLIZUMAB IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PRELIMINARY ANALYSIS | 4CPS-031 | |
| PHARMACEUTICAL INTERVENTIONS FOR MEDICATION RECONCILIATION IN COMPLEX CHRONICALLY ILL PATIENTS | 4CPS-032 |
| REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF SELECTIVE CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS UTILISATION IN METASTATIC BREAST CANCER – REVEAL STUDY | 4CPS-033 |
| REAL-WORLD SAFETY AND TOLERABILITY IN PATIENTS TREATED WITH ABEMACICLIB AND ENDOCRINE THERAPY: A RETROSPECTIVE OBSERVATIONAL STUDY | 4CPS-034 |
| IMPACT OF ANTIBIOTIC STEWARDSHIP PROGRAMME (ASP) ON ANTIBIOTIC USE AND CLINICAL OUTCOMES IN PATIENTS HOSPITALISED WITH COMMUNITYACQUIRED PNEUMONIA (CAP): RETROSPECTIVE OBSERVATIONAL BEFORE-AFTER STUDY | 4CPS-035 |
| EVALUATION OF THE DIAGNOSIS AND ANTIBIOTIC PRESCRIPTION PATTERN IN PATIENTS HOSPITALISED WITH URINARY TRACT INFECTIONS (UTIS) | 4CPS-036 |
| INTEGRATION OF THE PHARMACIST IN THE MULTIDISCIPLINARY COMMITTEE OF URO ONCOLOGICAL PATHOLOGY | 4CPS-037 |
| CASE REPORT ON AUTONOMIC NEUROPATHY INDUCED BY BORTEZOMIB | 4CPS-038 |
| DRUG-RELATED PROBLEMS AT HOSPITAL ADMISSION IN ELDERLY PATIENTS WITH CARDIOVASCULAR DISEASES | 4CPS-039 | |
| ADHERENCE TO GUIDELINES AND PRESCRIBING TRENDS OF STATINS IN PATIENTS WITH ACUTE CORONARY SYNDROME | 4CPS-040 |
| SILENCE SPEAKS LOUDER THAN WORDS: OMISSION OF PRESCRIPTION IN THE EMERGENCY ROOM | 4CPS-041 | |
| OVERDOSE OF DARBEPOETIN IN PATIENTS WITH CHRONIC KIDNEY FAILURE. ROOM FOR IMPROVEMENT WITH PHARMACIST INTERVENTIONS | 4CPS-042 |
| EFFICACY AND SAFETY OF ANTI-CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES FOR MIGRAINE PROPHYLAXIS: ONE-YEAR REAL-LIFE EXPERIENCE | 4CPS-043 |
| PRE-EXPOSURE PROPHYLAXIS DROP-OUT: FOLLOW-UP AND RELINKING THROUGH TELEPHONE CONTACT | 4CPS-044 |
| OPTIMISATION OF OMALIZUMAB FOR SEVERE ALLERGIC ASTHMA IN PEDIATRIC POPULATION | 4CPS-045 |
| EVALUATION OF HEALTH IMPACT IN INFLIXIMAB-TREATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: INCORPORATION OF PATIENT REPORTED OUTCOME MEASURES (PROMS) | 4CPS-046 |
| EVALUATION OF ANTIRESORPTIVE AGENT-RELATED OSTEONECROSIS THERAPY BY MEASURING CONCENTRATIONS OF PENICILLIN G IN JAWBONE | 4CPS-047 |
| A COMPLEX, ADHERENCE-IMPROVING PHARMACIST INTERVENTION TO REDUCE HYPERPHOSPHATEMIA IN HEMODIALYSIS PATIENTS | 4CPS-048 |
| TREATMENT OF ROSAI DORFMAN’S HISTIOCYTOSIS: CASE REPORT | 4CPS-049 |
| PRE-EXPOSURE PROPHYLAXIS FOR HIV INFECTION: PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS (STIS) AND ADHERENCE DURING THE PROGRAMME | 4CPS-050 |
| COST SAVING IMPACT OF BIOSIMILAR TRASTUZUMAB FOR THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN A HOSPITAL | 4CPS-051 |
| EVALUATION OF USTEKINUMAB USE IN INFLAMMATORY BOWEL DISEASES | 4CPS-052 |
| OUTCOMES OF INFRADOSED ANTIMICROBIALS PATIENTS WITH BACTEREMIA IN THE EMERGENCY DEPARTMENT | 4CPS-053 |
| NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES FOR MODERATE TO SEVERE ULCERATIVE COLITIS | 4CPS-054 |
| PHARMACOGENETICS AND ITS APPLICATIONS IN PERSONALISED MEDICINE: A SYSTEMATIC REVIEW | 4CPS-055 |
| EFFECTIVENESS AND SAFETY OF ERIBULIN THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER. | 4CPS-056 | |
| EFFECTIVENESS, SAFETY, AND PATIENT-REPORTED OUTCOME OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE | 4CPS-057 |
| ANALYSIS OF ANTIFUNGAL CONSUMPTION IN AN INTENSIVE CARE UNIT OVER 5 YEARS | 4CPS-058 |
| SEVENTEEN DRUGS, ONE SAMPLE: ANALYSING MULTIPLE ANTI-TUBERCULOSIS DRUGS SIMULTANEOUSLY USING ONE METHOD | 4CPS-059 | |
| IMPACT OF OBESITY ON VANCOMYCIN PHARMACOKINETIC PARAMETERS IN ADULT PATIENTS | 4CPS-060 |
| SAFETY AND EFFECTIVENESS OF THE OFF-LABEL USE OF CANGRELOR IN PERIOPERATIVE BRIDGING: A CASE SERIES | 4CPS-061 |
| POSITIVE IMPACT OF EXTENDING NATALIZUMAB DOSAGE INTERVAL FROM EVERY 4 WEEKS TO EVERY 6 WEEKS IN MULTIPLE SCLEROSIS PATIENTS | 4CPS-062 |
| CLINICAL PHARMACIST IN THE MULTIDISCIPLINARY TEAM IN THE INTENSIVE CARE UNIT IMPROVE THE QUALITY OF MEDICINE THROUGHOUT THE PATIENT’S HOSPITAL STAY | 4CPS-063 |
| REVIEW OF USE OF IMMUNOGLOBULINS IN TERTIARY HOSPITAL | 4CPS-064 |
| EXPERIENCE OF IMMUNOCHEMOTHERAPY VERSUS STANDARD TREATMENT IN SMALL-CELL LUNG CANCER | 4CPS-065 |
| THERAPEUTIC DRUG MONITORING OF ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE. | 4CPS-066 |
| EFFECTIVENESS AND SAFETY OF 1 IU/ML TOPICAL INSULIN TO TREAT PERSISTENT CORNEAL ULCERS | 4CPS-067 | |
| TARGET THERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE ANALYSIS TO GUARANTEE THE APPROPRIATENESS OF THE PRESCRIPTIONS IN OUR HOSPITAL | 4CPS-068 |
| OUTPATIENT SATISFACTION IN THE TELEPHARMACY PROGRAMME OF A TERTIARY HOSPITAL PHARMACY SERVICE | 4CPS-069 |
| EVALUATION OF AVOIDED COST IN CLINICAL TRIALS WITH IMMUNOTHERAPY IN LUNG CANCER | 4CPS-070 |
| ANTIBIOTIC CONSUMPTION MONITORING BY AWARE CLASSIFICATION: A SIX MONTHS ANALYSIS | 4CPS-071 |
| SETMELANOTIDE IN MONOGENIC OBESITY: A CASE REPORT | 4CPS-072 |
| ANALYSIS OF THE REASONS FOR CHANGING TREATMENT IN PATJENTS WITH MULTIPLE SCLEROSIS | 4CPS-073 |
| DRUG CLASSES COMMONLY RELATED TO MEDICATION ERRORS AT TRANSITION OF CARE | 4CPS-074 |
| A SYSTEMATIC REVIEW OF THE TARGET PHARMACOKINETIC/PHARMACODYNAMIC PARAMETERS OF ANTIBIOTICS TREATING GRAM-NEGATIVE INFECTIONS | 4CPS-075 |
| EFFECTIVENESS AND SAFETY OF DUPILUMAB AND TRALOKINUMAB IN ATOPIC DERMATITIS IN CLINICAL PRACTICE | 4CPS-076 |
| PHARMACEUTICAL INTERVENTIONS AFTER DETECTION OF NON-HANDLING MEDICATIONS IN PATIENTS WITH DYSPHAGIA | 4CPS-077 |
| QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES WITH MULTIPLE MYELOMA TREATEDS WITH DARATUMUMAB | 4CPS-078 |
| INDIRECT COMPARISON OF IL-13 INHIBITORS PLUS TOPICAL CORTICOSTEROIDS IN MODERATE TO SEVERE ATOPIC DERMATITIS | 4CPS-079 |
| METASTATIC HER2-POSITIVE BREAST CARCINOMA CASE REPORT: ANTI-HER2 TREATMENT MAINTENANCE DESPITE OLIGOPROGRESSION | 4CPS-080 |
| CONSENSUS ON INDICATORS FOR MEDICATION-RELATED READMISSIONS: A DELPHI STUDY | 4CPS-081 |
| DESCRIPTIVE STUDY OF POST-SURGERY ANALGESIC PRESCRIPTIONS | 4CPS-082 | |
| MEDICATION RECONCILIATION INTERVENTIONS IN AN EMERGENCY DEPARTMENT AT ADMISSION | 4CPS-083 |
| GENOTYPING ANALYSIS OF POLYMORPHISMS IN THE DIAHYDROPYRHYDROMIDINE DEHYDROGENASE (DPYD) GENE PRIOR TO ADMINISTRATION OF FLUOROPIRMIDINES | 4CPS-084 |
| LONG-TERM PERSISTENCE IN PSORIASIS PATIENTS WITH HIGH RESPONSE TO GUSELKUMAB: A REAL-WORLD RETROSPECTIVE STUDY. | 4CPS-085 | |
| ASSESSMENT OF THE CLINICAL RELEVANCE OF LEVETIRACETAM MONITORING | 4CPS-086 |
| ADALIMUMAB PERSISTENCE IN CLINICAL PRACTICE AT A REGIONAL HOSPITAL | 4CPS-087 |
| FOLIC ACID, FOLINIC ACID AND HEMATOTOXIC TREATMENTS: A REVIEW AT A UNIVERSITY HOSPITAL CENTRE | 4CPS-088 |
| CLINICAL PHARMACIST EFFECTIVENESS IN HOSPITALISED PATIENTS: ANALYSIS OF THE INTERVENTION RECORD IN A SECONDARY ACUTE HOSPITAL | 4CPS-089 |
| REAL-WORLD PERSISTENCE WITH FREMANEZUMAB VERSUS ERENUMAB AMONG MIGRAINE PATIENTS | 4CPS-090 |
| REAL-LIFE PERSISTENCE, EFFECTIVENESS AND SAFETY OF FREMANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE | 4CPS-091 |
| ANALYSIS OF ANTIBIOTICS CONSUMPTION AT AN ITALIAN CARDIOLOGY CENTRE: PHARMACOUSE PROFILE ACCORDING TO THE AWARE CLASSIFICATION | 4CPS-092 |
| ANTIBIOTIC RESISTANCE IN THE HOSPITAL CONTEXT: RETROSPECTIVE ANALYSIS OF ANTIBIOGRAMS, RESISTANCE AND SENSITIVITY PROFILES AT AN ITALIAN HEART CENTER | 4CPS-093 |
| RISK FACTORS FOR EMERGENCY DEPARTMENT RE-VISIT IN ELDERLY PATIENTS WITH GASTROINTESTINAL BLEEDING SECONDARY TO DIRECT ORAL ANTICOAGULANTS | 4CPS-094 | |
| EXPLORATORY ANALYSIS OF CARDIOVASCULAR EVENTS IN AN ASTHMATIC COHORT | 4CPS-095 | |
| USE OF COVID-19 ANTIVIRALS IN PATIENTS PREVIOUSLY TREATED WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS: EXPERIENCE OF AN ITALIAN HOSPITAL | 4CPS-096 |
| REAL-WORLD STUDY OF APALUTAMIDE TREATMENT IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN NINE HOSPITALS OF VALENCIAN COMMUNITY. | 4CPS-097 |
| EFECTIVENESS AND SAFETY OF LONG-ACTING CABOTEGRAVIR/RILPIVIRINE IN REAL-LIFE POPULATION | 4CPS-098 |
| CHIMERIC ANTIGEN RECEPTOR-T CELLS (CAR-T CELLS) AND ANTIBIOTICS : A NOT-SO-INNOCENT ASSOCIATION | 4CPS-099 |
| THE UTILITY OF EARLY PHARMACEUTICAL VALIDATION OF SELECTED HIGH-RISK DRUGS IN A HOSPITAL EMERGENCY DEPARTMENT | 4CPS-100 |
| MONITORING METABOLIC SYNDROME IN OLANZAPINE TREATED PATIENTS | 4CPS-101 |
| AMIODARONE AND LITHIUM-INDUCED THYROID DYSFUNCTION: WHO INITIATES THE PRESCRIBING CASCADE? | 4CPS-102 |
| ANALYSIS OF PNEUMONIA ASSOCIATED WITH MECHANICAL VENTILATION IN CRITICALLY ILL PATIENTS UNDERGOING SELECTIVE DIGESTIVE DECONTAMINATION. | 4CPS-103 |
| COMORBIDITY PATTERNS IN THE OLDER HIV PATIENT | 4CPS-104 |
| MEDICINES OPTIMISATION FOR PATIENTS IN A NURSING HOME | 4CPS-105 |
| AUC-SURVIVAL REANALYSIS OF TROPICS-02 TRIAL WITH SACITUZUMAB GOVITECAN FOR METASTATIC LUMINAL BREAST CANCER. | 4CPS-106 |
| ADHERENCE TO DAILY ORAL TREATMENT IN MULTIPLE SCLEROSIS | 4CPS-107 |
| CLINICAL IMPACT OF PHARMACOKINETIC MONITORING OF INFLIXIMAB AND ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE | 4CPS-108 |
| SEX-RELATED DIFFERENCES IN THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS TREATMENT | 4CPS-109 |
| SYSTEMATIC REVIEW AND E-QUESTIONNAIRE ON THE SERVICE CHARACTERISTICS, OPERATIONS AND ACTIVITIES OF CENTRES FOR MEDICINES INFORMATION (CMI) | 4CPS-110 |
| PHARMACEUTICAL INTERVENTIONS IN PATIENTS UNDER CHRONIC OPIOID TREATMENT ADMITTED TO TRAUMATOLOGY UNITS | 4CPS-111 |
| ANTIMICROBIAL STEWARDSHIP PROGRAMME INTERVENTIONS IN INTENSIVE CARE UNIT | 4CPS-112 |
| THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS | 4CPS-113 |
| SUBLINGUAL ADMINISTRATION OF TACROLIMUS IN LIVER TRANSPLANT PATIENT WITH INTESTINAL MALABSORPTION: A CASE REPORT | 4CPS-114 |
| CHRONIC MIGRAINE REVERSION AND SYMPTOMATIC MEDICATION REDUCTION WITH FREMANEZUMAB | 4CPS-115 |
| REAL-WORLD EFFECTIVENESS AND COSTS OF USTEKINUMAB IN PATIENTS DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE | 4CPS-116 |
| UPDATE OF STOPP/START CRITERIA IN 2023: WHAT ARE THE IMPACTS ON OUR PHARMACEUTICAL INTERVENTIONS? | 4CPS-117 |
| MEDICATION ADHERENCE TO PSORIASIS TREATMENTS: A POPULATION-BASED STUDY | 4CPS-118 |
| A REAL-LIFE STUDY OF PHARMACOKINETIC MONITORING: NEPHROTOXIC IMPACT OF AMINOGLYCOSIDES AND VANCOMYCIN | 4CPS-119 |
| EFFICACY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY REAL-WORLD ANALYSIS AND COMPARISON WITH THE PIVOTAL STUDY (PS) | 4CPS-120 |
| OPTIMISING ANTIDIABETIC TREATMENT FOR ELDERLY PATIENTS ACCORDING TO THEIR FUNCTIONAL STATUS | 4CPS-121 |
| ANALYSIS OF THE USE AND EFFECTIVENESS OF FIDAXOMICIN IN CLOSTRIDIOIDES DIFFICILE INFECTION | 4CPS-122 |
| SARGRAMOSTIM AND LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF CHRONIC VISCERAL LEISHMANIASIS IN HIV CO-INFECTED PATIENT: A CASE REPORT | 4CPS-123 |
| MONITORING OF HIGH-COST ANTIBIOTIC’S PRESCRIPTIONS IN ORDER TO ENSURE PRESCRIPTIVE APPROPRIATENESS, PATIENT SAFETY AND CONTAINING EXPENDITURE | 4CPS-124 |
| PHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTER PROSPECTIVE STUDY | 4CPS-125 |
| ADHERENCE, PERSISTENCE, AND SWITCHING MEDICATION IN PATIENTS WITH MULTIPLE SCLEROSIS INITIATING ORAL DISEASE MODIFYING THERAPIES: A RETROSPECTIVE REAL-WORLD STUDY | 4CPS-126 | |
| PERSISTENCE OF BIOLOGICAL DISEASE-MODIFYING DRUGS AND PHOSPHODIESTERASE-4- INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITHIS | 4CPS-127 |
| POTENTIAL DRUG-DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS | 4CPS-128 |
| EVALUATION OF THE BENEFIT OF CAROB FLOUR ON NINTEDANIB DIARRHEA IN THE TREATMENT OF DIFFUSE INTERSTITIAL LUNG DISEASE | 4CPS-129 |
| RISK OF HYPOKALAEMIA IN HOSPITALIZED PATIENTS ASSOCIATED WITH THE COMBINATION OF DIURETICS | 4CPS-130 |
| UTILIZATION AND SAFETY PROFILE OF UPADACITINIB IN A TERTIARY HOSPITAL | 4CPS-131 | |
| RIBOCICLIB IN METASTASIC BREAST CANCER TREATMENT: FRECUENCY AND ANALYSIS OF DIFFERENTS ADVERSE EFFECTS WHICH REQUIRED INTERVENTION | 4CPS-132 |
| EFFECTIVENESS AND SAFETY OF ANTI IL-5 DRUGS BENRALIZUMAB AND MEPOLIZUMAB IN SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA PATIENTS | 4CPS-133 |
| REAL WORLD EVIDENCE OF CEFIDEROCOL IN CLINICAL PRACTICE | 4CPS-134 | |
| EVALUATION AND MANAGEMENT OF CONSTIPATION IN THE CRITICALLY ILL PATIENT | 4CPS-135 |
| ANALYSIS OF THE SITUATION OF PHARMACEUTICAL CARE FOR PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES BEFORE AND AFTER THE COVID-19 PANDEMIC | 4CPS-136 |
| CEFIDEROCOL: UTILIZATION PROFILE IN THE TREATMENT OF MULTIDRUG-RESISTANT BACTERIA, A RETROSPECTIVE OVERVIEW. | 4CPS-137 |
| CEFIDEROCOL: EFFECTIVENESS AND MORTALITY OF MULTIDRUG-RESISTANT BACTERIA INFECTIONS, A RETROSPECTIVE OVERVIEW. | 4CPS-138 |
| VORICONAZOLE SERUM CONCENTRATIONS MONITORING | 4CPS-139 |
| EXPERIENCE OF USING PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN A TERTIARY HOSPITAL | 4CPS-140 |
| REAL-LIFE IMPACT OF INCLUDING MONTELUKAST AS PREMEDICATION ON THE INCIDENCE OF INFUSION-RELATED REACTIONS TO ISATUXIMAB AND DESCRIPTION OF RISK FACTORS | 4CPS-141 |
| COMMUNITY PHARMACY-BASED HBA1C SCREENING FOR EARLY DETECTION OF DIABETES AND PRE-DIABETES | 4CPS-142 | |
| A DESCRIPTION OF PHARMACISTS’ INTERVENTIONS TO OPTIMISE THE TREATMENT OF ADULTS WITH ORALLY AVAILABLE COVID-DRUG PAXLOVID® | 4CPS-143 |
| BIOLOGICAL TREATMENTS IN THE PREVENTION OF MIGRAINE: RESTART AND DURATION OF THERAPEUTIC REST | 4CPS-144 | |
| COLLABORATIVE IMPLEMENTATION OF ‘WALANT’ (LOCAL ANESTHETIC) TECHNIQUE IN A HAND SURGERY WARD | 4CPS-145 |
| ECONOMIC IMPACT ON MULTIPLE MYELOMA CLINICAL TRIALS IN THE PHARMACY SERVICE | 4CPS-146 |
| OSIMERTINIB: A PROMISING TREATMENT FOR EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER | 4CPS-147 |
| EAVLUATION OF DAILY DOSE MANUAL DRUG DISPENSING ACCURACY | 4CPS-148 |
| CENTRAL VENOUS CATHETER-RELATED BLOODSTREAM INFECTIONS IN PATIENTS ON TOTAL PARENTERAL NUTRITION | 4CPS-149 |
| PHARMACEUTICAL INTERVENTIONS IN OBESE PATIENTS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION | 4CPS-150 |
| ANALYSIS OF ANTIBIOTIC TREATMENT IN PATIENTS WITH VENTILATOR-ASSOCIATED PNEUMONIA | 4CPS-151 |
| THE INCLUSION OF TRAMADOL FOR PARENTERAL USE IN THE NARCOTIC TABLE OF PHARMACOPOEIA: ANALYSIS OF EFFECTS AND CONSUMPTION IN A GENERAL HOSPITAL SETTING | 4CPS-152 |
| ECONOMIC BENEFIT ANALYSIS ON LUNG CANCER CLINICAL TRIALS: MEDICATION AND MEDICAL TESTS | 4CPS-153 |
| THERAPEUTIC DRUG MONITORING OF AMIKACIN IN NEONATES: ABOUT A NEW PROTOCOL | 4CPS-154 |
| PERCEPTION OF HOSPITAL PHARMACIES ABOUT TELEPHARMACY IN THE PROVISION OF HEALTHCARE FOR PEOPLE LIVING WITH HIV | 4CPS-155 |
| ANALYSIS OF THE PRESCRIPTION PATTERN AND DAYS OF HOSPITALIZATION AVOIDED BY OUTPATIENT INTRAVENOUS ANTIBIOTIC THERAPY AND THE SAFETY OF THIS PRACTICE | 4CPS-156 |
| PERSPECTIVES OF PATIENTS AND MEDICAL PROVIDERS ON MULTIDISCIPLINARY MEDICATION RECONCILIATIONS SERVICE IN ADULT PATIENTS UNDERGOING THORACIC AND CARDIOVASCULAR SURGERY (MERITS STUDY) | 4CPS-157 |
| RELAPSED/REFRACTORY MULTIPLE MYELOMA AND NEW THERAPEUTIC OPTIONS: EXPERIENCE IN A PHASE I CLINICAL TRIALS UNIT | 4CPS-158 |
| ANALYSIS OF THE INTERVENTIONS CARRIED OUT IN THE GERIATRIC SERVICE IN COLLABORATION WITH THE INTERNAL MEDICINE AND MICROBIOLOGY SERVICES | 4CPS-159 | |
| LONG-TERM EFFECTIVENESS AND SAFETY RESULTS OF GALCANEZUMAB IN REAL-WORLD DATA IN MIGRAINE PROPHYLAXIS | 4CPS-160 |
| VANCOMYCIN PHARMACOKINETIC MONITORING IN CRITICALLY ILL NEONATAL PATIENTS | 4CPS-161 |
| “TO ERR IS HUMAN“: PRESENTING CASES OF MEDICATION ERRORS FROM REAL CLINICAL PRACTICE | 4CPS-162 | |
| EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN HOSPITALISED PATIENTS WITH HYPERKALAEMIA | 4CPS-163 |
| ANALYSIS OF USTEKINUMAB INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE ACCORDING TO LINE OF TREATMENT | 4CPS-164 |
| DETERMINATION OF PREDICTIVE FACTORS FOR IMMUNE-RELATED TOXICITY IN LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPY | 4CPS-165 |
| COMPREHENSIVE ASSESSMENT OF PHARMACOTHERAPY IN THE COMPLEX CHRONIC PATIENT: COLLABORATION BETWEEN DIFFERENT LEVELS OF CARE | 4CPS-166 |
| USE OF STANDARD- AND HIGH-DOSE LIPOSOMAL AMPHOTERICIN B AND ITS RELATIONSHIP WITH HYPOMAGNESEMIA | 4CPS-167 | |
| EFFECTIVENESS, SAFETY AND ADHERENCE TO EVOLOCUMAB IN REAL CLINICAL PRACTICE | 4CPS-168 |
| EVALUATION OF ANTICHOLINERGIC DRUG PRESCRIPTION USING A CLINICAL DECISION SUPPORT SYSTEM: A PROSPECTIVE STUDY IN A GERIATRIC REHABILITATION CENTER | 4CPS-169 |
| CLINICAL PHARMACY PRIORITISATION ALGORITHM FOR PATIENTS IN PSYCHIATRIC LONG-TERM CARE: A PILOT STUDY | 4CPS-170 |
| FIXED-DOSE VERSUS WEIGHT-BASED DOSING REGIMEN OF PEMBROLIZUMAB | 4CPS-171 |
| IMPROVING POST-OPERATIVE ANALGESIA AND ASSOCIATED PRESCRIBING IN THE ORTHOPAEDIC SETTING | 4CPS-172 |
| PRESCRIPTION OF PSYCHOTROPIC DRUGS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION ON INTEGRASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY | 4CPS-173 |
| NASAL ESKETAMINE USE FOR MAYOR DEPRESSIVE DISORDER, FROM A THIRD LEVEL HOSPITAL TO PERIPHERAL MENTAL CENTERS | 4CPS-174 |
| EFFECTIVENESS OF IMMUNOTHERAPY AS A FUNCTION OF AGE: METHA-ANALYSIS OF THE APPROVED COMBINATIONS IN FIRST LINE METASTASIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITHOUT MUTATIONS. | 4CPS-175 |
| USE AND PERSISTENCE OF GUSELKUMAB IN TREATMENT FOR RHEUMATIC AND DERMATOLOGICAL DISEASE | 4CPS-176 |
| LONG-ACTING INTRAMUSCULAR ANTIRETROVIRALS: WHAT REAL-WORLD DATA DO WE HAVE? | 4CPS-177 |
| EFFECT OF PCSK9 INHIBITORS ON HYPERCHOLESTEROLEMIA | 4CPS-178 |
| REAL-LIFE ANALYSIS OF THE DEVELOPMENT OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THERAPEUTIC APPROACH. | 4CPS-179 | |
| SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: COMPARISON OF OUR DATA TO THE ASCENT TRIAL AFTER TWO YEARS OF EXPERIENCE | 4CPS-180 |
| ELECTRONIC PRESCRIBING IN THE NEONATAL INTENSIVE CARE UNIT: ANALYSIS OF PRESCRIBING ERRORS AND RISK FACTORS | 4CPS-181 |
| DESCRIPTION OF A CLINICAL PHARMACIST INTERVENTION FOCUSED ON MANAGEMENT OF A CHRONIC DISEASE AT HOSPITAL: THE EXAMPLE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | 4CPS-182 |
| PHARMACIST-LED OPT-OUT CESSATION TREATMENT PROTOCOL FOR COMBUSTIBLE TOBACCO SMOKING | 4CPS-183 | |
| THERAPIES IN ENDOMETRIAL CANCER WITH DNA MISMATCH REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY: A SYSTEMATIC REVIEW | 4CPS-184 |
| ANALYSIS OF THE USE OF MEDICATION NOT INCLUDED IN THE PHARMACOTHERAPEUTIC GUIDE OF A TERTIARY HOSPITAL | 4CPS-185 |
| IMPLEMENTATION OF A PATIENT STRATIFICATION MODEL IN OUTPATIENT PHARMACY FOR IMMUNE-MEDIATED DERMATOLOGICAL DISEASES | 4CPS-186 |
| DEVELOPMENT OF A POPULATION PHARMACOKINETIC MODEL OF CYCLOSPORINE | 4CPS-187 |
| IMPLEMENTATION OF THIOPURINE PHARMACOGENETICS TO IMPROVE PEDIATRIC SAFETY AT A TERTIARY HOSPITAL | 4CPS-188 | |
| LOCAL EXPERIENCE ON THE USE OF CANNABIDIOL FOR THE TREATMENT OF REFRACTORY EPILEPSY. SAFETY AND EFFICACY ON A 10 PATIENT’S COHORT | 4CPS-189 |
| DEVELOPMENT OF TRANSMURAL PHARMACEUTICAL CARE IN A GENERAL HOSPITAL | 4CPS-190 |
| PRE-RADIOIODINE THERAPY SURGICAL MODALITIES: COMPARION OF POST-OPERATIVE THYROGLOBULIN LEVELS IN PATIENTS UNDERGOING 1- OR 2-STEP THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER | 4CPS-191 |
| ASTHMA AND RISK OF CARDIOVASCULAR EVENTS: A RETROSPECTIVE STUDY | 4CPS-192 |
| EFFECTIVENESS AND SAFETY OF INTRAVENOUS USTEKINUMAB INTENSIFICATION IN CROHN’S DISEASE WITH LOSS OF RESPONSE OR PARTIAL RESPONSE TO SUBCUTANEOUS THERAPY | 4CPS-193 |
| EVOLUTION OF HOSPITAL CLINICAL PHARMACY SERVICES IN FINLAND DURING YEARS 2017-2022: A FOLLOW-UP SURVEY | 4CPS-194 |
| CHARACTERIZATION OF INJECTABLE FORMULATIONS AND OPTIMIZATION OF THEIR DELIVERY BY ENTERAL TUBE: A PHYSICOCHEMICAL AND PHYSIOLOGICAL APPROACH | 4CPS-195 |
| ASSESSMENT OF ORAL DRUG THERAPY REGARDING ABSORPTION DISORDERS IN PATIENTS WITH INTESTINAL OSTOMIES – AN OBSERVATIONAL STUDY | 4CPS-196 |
| THE KTIA-SCORAC STUDY : SECURING THE MEDICATION MANAGEMENT OF ELDERLY PATIENTS BY THE SYSTEMATIC EVALUATION OF ANTICHOLINERGIC LOAD SCORES VIA A CLINICAL DECISION SUPPORT SYSTEM | 4CPS-197 |
| EVALUATION OF PROA TEAM INTERVENTION ACCEPTANCE RATES THROUGH AN AUTOMATED MEASUREMENT SYSTEM | 4CPS-198 | |
| COMPARATIVE EVALUATION OF ENZYME-LINKED IMMUNOSORBENT ASSAY VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS | 4CPS-199 |
| TRIPLE THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS BASED ON A PHARMACOLOGICAL TREATMENT ALGORITHM | 4CPS-200 |
| CLINICAL EXPERIENCE OF TYROSINE-KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA | 4CPS-201 |
| EVALUATION OF THE EXCHANGE OF ANTICGRP MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CHRONIC REFRACTORY MIGRAINE | 4CPS-202 |
| DEVELOPMENT AND VALIDATION OF A DATA COLLECTION TOOL TO EVALUATE PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT | 4CPS-203 |
| MONITORING OF LINEZOLID IN HEMODIALYSIS: A CLINICAL CASE | 4CPS-204 |
| RESULTS OF ANTIBIOTIC PROPHYLAXIS IN ACUTE BRONCHOASPIRATION PNEUMONITIS | 4CPS-205 |
| PRE-EXPOSURE PROPHYLAXIS, ARE WE DOING IT RIGHT? | 4CPS-206 |
| EVALUATION OF PROSTATIC SPECIFIC ANTIGEN DEPLETION WITH ABIRATERONE AS A PRONOSTATIVE FACTOR FOR SURVIVAL IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | 4CPS-207 | |
| ANALYSIS OF THE IMPLEMENTATION OF A MULTIDISCIPLINARY PHARMACEUTICAL CARE PROJECT FOR GERIATRIC HEMATO-ONCOLOGY PATIENTS | 4CPS-208 |
| COMPARISON OF TWO PHARMACOKINETIC/PHARMACODYNAMIC INDICES IN CRITICALLY ILL PATIENTS TREATED WITH AMIKACIN | 4CPS-209 |
| HOME INFUSION CHEMOTHERAPY TREATMENT FOR PATIENTS WITH MALIGNANT HAEMATOLOGICAL DISORDERS | 4CPS-210 |
| TITLE: ANALYSIS OF THE PRESCRIPTION OF VITAMIN D SUPPLEMENTS IN A SOCIAL HEALTH CENTER. | 4CPS-211 |
| MANAGEMENT OF POST CAR-T NEUROTOXICITY USING ANAKINRA. A CASE REPORT | 4CPS-212 |
| RESULTS OF ANTIBIOTIC TREATMENT OF AORTIC ENDOPROSTHESIS INFECTIONS IN PATIENTS NOT CANDIDATES FOR SURGERY | 4CPS-213 |
| MONITORING OF TACROLIMUS IN A KIDNEY TRANSPLANTED COHORT | 4CPS-214 |
| ADJUSTMENT OF ANTIBIOTICS THROUGH THE HEMOFILTER: A CASE REPORT | 4CPS-215 |
| EFFICACY AND SAFETY ANALYSIS OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS: REAL-LIFE DATA. | 4CPS-216 |
| A COMPARATIVE EVALUATION OF THE LONG-TERM EFFECTIVENESS OF GUSELKUMAB AND RISANKIZUMAB IN THE CLINICAL MANAGEMENT OF PLAQUE PSORIASIS. | 4CPS-217 |
| OPIOID PRESCRIBING FOR ACUTE NON-CANCER PAIN, POST-OPERATIVE PAIN AND POST-PROCEDURE PAIN BY SURGICAL TEAMS AT A TERTIARY HOSPITAL: 1-DAY AUDIT | 4CPS-218 |
| BEYOND THE EXPECTED: THE ENHANCED DETECTION OF DRUG RELATED PROBLEMS, THE MOST OF A PHARMACEUTICAL DECISION SUPPORT SYSTEM | 4CPS-219 |
| EVALUATION OF THE IMPLEMENTATION OF A PRE-EXPOSURE PROPHYLAXIS PROGRAM. 2 YEARS EXPERIENCE IN OUR REGION | 4CPS-220 |
| EVALUATION OF THE RELEVANCE OF STATINS PRESCRIPTION IN THE ELDERLY : TOWARDS A DEPRESCRIPTION ? | 4CPS-221 |
| THE REAL LIFE OF BENZODIAZEPINES IN GERIATRIC DEPARTMENT : CAN THE PHARMACIST HAVE AN IMPACT ? | 4CPS-222 | |
| A STUDY ON THE PERCEPTION OF ELDERLY PATIENTS ON THE EXPIRATION DATE AND STORAGE OF PRESCRIBED MEDICATION: A QUESTIONNAIRE STUDY | 4CPS-223 |
| MEDICATION RECONCILIATION IN A SURGERY DEPARTMENT: 6-MONTHS EXPERIENCE | 4CPS-224 |
| DEFINING INTERNATIONAL CRITICAL CARE PHARMACIST ASPIRATIONS TO THE MANAGEMENT OF SEPSIS | 4CPS-225 |
| PHARMACEUTICAL INTERVENTION ON THE ADEQUACY OF THE INDICATION OF SEMAGLUTIDE IN DIABETES MELLITUS 2 | 4CPS-226 |
| PHARMACEUTICAL REVIEW AND PHARMACEUTICAL INTERVENTION IN A NURSING HOME TO ENHANCE THE MEDICATION MANAGEMENT OF RESIDENTS. | 4CPS-227 |
| IMPACT AND ACCEPTANCE OF PHARMACEUTICAL INTERVENTIONS FOR EARLY MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT | 4CPS-228 |
| SUSTAINABILITY: A PERSON-CENTRED, WHOLE SYSTEMS APPROACH TO MEDICINES OPTIMISATION | 4CPS-229 |
| CLINICAL PHARMACOGENOMICS FOR A SAFER USE OF FLUOROPYRIMIDINES | 4CPS-230 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| INCIDENCE OF HEPATITIS B VIRUS REACTIVATION IN PSORIASIS PATIENTS TREATED WITH CYTOKINE INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS | 5PSQ-001 | |
| PRESCRIBING TREND OFFLUOROQUINOLONES FOLLOWING LATEST EMA RECOMMENDATIONS | 5PSQ-002 | |
| IMPROVING MEDICINES MANAGEMENT OF INPATIENT PARKINSON’S DISEASE PATIENTS BY MAKING PHARMACY INTERVENTIONS | 5PSQ-003 |
| COMPARISON BETWEEN BEERS 2019 CRITERIA AND THE EURO-FORTA 2018 LIST IN THE IDENTIFICATION OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY PATIENTS IN THE PRIMARY HEALTHCARE CONTEXT | 5PSQ-004 | |
| UTILITY OF THE THERAPEUTIC COMPLEXITY INDEX ADAPTED TO CRITICALLY ILL PATIENTS AS A METHOD OF STRATIFICATION FOR PHARMACEUTICAL CARE | 5PSQ-005 |
| FREQUENCY OF CREATININE TESTING AND ACUTE KIDNEY INJURY IDENTIFICATION AND STAGING. | 5PSQ-006 |
| A REVIEW ON MEDICATION RECONCILIATION IN THE PERIOPERATIVE PERIOD: VARIABLES THAT LEAD TO MEDICATION ERRORS. | 5PSQ-007 |
| IMMUNE-MEDIATED HEPATITIS SECONDARY TO TREATMENT WITH PEMBROLIZUMAB. A CASE REPORT. | 5PSQ-008 |
| OFF-LABEL USE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS ACUTE LUPUS PNEUMONITIS: A CASE REPORT | 5PSQ-009 |
| NATIONAL STANDARDISATION OF PRETERM PARENTERAL NUTRITION IN NEONATAL UNITS | 5PSQ-010 |
| TOXICITY OF IMMUNOTHERAPY TREATMENT IN CLINICAL PRACTICE | 5PSQ-011 |
| TOOLS OFFERED BY REGENERATIVE MEDICINE FOR THE TREATMENT OF OSTEOARTHRITIS – PLATELET RICH PLASMA (PRP). | 5PSQ-012 |
| NEW METHOD FOR ASSESSMENT OF ENVIRONMENTAL VIRAL CONTAMINATION OF LIQUIDS PREPARED IN CLOSED-SYSTEM DRUG TRANSFER DEVICES | 5PSQ-013 |
| ELECTRONIC COMMUNICATION OF THE DISCONTINUATION OF HOME TREATMENT PRESCRIBED TO PATIENTS IN A TERTIARY LEVEL HOSPITAL. | 5PSQ-014 |
| ANALYSIS OF THE OCCURRENCE OF ATRIAL FIBRILLATION WITH THE ADMINISTRATION OF IBRUTINIB: SHOULD WE BE CAREFUL WITH THIS DRUG? | 5PSQ-015 |
| ASSESSMENT OF THE ACCREDITATION AND CONTINUOUS EDUCATION TESTS FOR PHARMACY TECHNICIANS WITHIN A CYTOTOXIC RECONSTITUTION UNIT | 5PSQ-016 |
| PHARMACEUTICAL INTERVENTIONS IN ORAL AND SUBCUTANEOUS MTX PRESCRIBING ERRORS | 5PSQ-017 |
| ANALYSIS OF ERRORS IN THE MANUAL PREPARATION OF STERILE DRUGS FROM STOCK. | 5PSQ-018 |
| VALIDATION PRIOR TO THE DISPENSING OF MEDICINES AS A TOOL TO IMPROVE THE QUALITY OF THE PRESCRIPTION | 5PSQ-019 |
| EVALUATION OF THE EFFICACY AND SAFETY OF EPCORITAMAB-BYSP IN PATIENTS WITH FOLLICULAR B LYMPHOMA: A CASE REPORT. | 5PSQ-020 |
| EVALUATION OF THE PREVALENCE OF MULTI-RESISTANT BACTERIA IN THE INTENSIVE CARE UNIT AFTER SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT. | 5PSQ-021 |
| DRUG-INDUCED APLASTIC ANAEMIA: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) | 5PSQ-022 |
| SAFETY AND TOLERABILITY OF VORICONAZOLE TREATMENT: A RETROSPECTIVE OBSERVATIONAL STUDY | 5PSQ-023 |
| ENHANCING SAFETY AND EFFICIENCY IN CHEMOTHERAPY PREPARATION AND ADMINISTRATION IN A SMALL ONCOLOGY HOSPITAL | 5PSQ-024 |
| AUDIT ON THE CORRECT USE OF MEDICAL DEVICES FOR URINARY CATHETERISATION | 5PSQ-025 |
| THE POTENTIAL OF PHARMACOVIGILANCE DATABASES TO ASSESS TOXICOLOGICAL RISK OF DIETARY SUPPLEMENTS AND OTHER UNSUPERVISED HEALTH PRODUCTS USED BY PATIENTS | 5PSQ-026 | |
| VARIABILITY IN VANCOMYCIN PLASMA CONCENTRATION IN NEUTROPENIC PATIENTS | 5PSQ-027 | |
| CASE REPORT: ANTITUMOR ACTIVITY AND TOXICITIES OF ENTRECTINIB IN A PATIENT WITH A PRIMARY CENTRAL NEUROCYTOMA | 5PSQ-028 | |
| THE OVERRIDING OF DRUG SAFETY ALERTS FIRED BY THE CLINICAL DECISION SUPPORT TOOL: EVALUATION OF APPROPRIATE RESPONSES AND ALERT FATIGUE SOLUTIONS | 5PSQ-029 | |
| CONCORDANCE OF MEDICATION PRESCRIPTION RECORDS IN THE HOSPITALISED SURGICAL PATIENT | 5PSQ-030 |
| “ASSESSING HEALTHCARE PROFESSIONALS “VIEWS ON DEPRESCRIPTION | 5PSQ-031 | |
| USE OF THE “PRECAUTIONARY ANNULMENTS” TOOL BY A HOSPITAL PHARMACY SERVICE | 5PSQ-032 | |
| TEMPORAL TRENDS OF ATYPICAL DRUG ACCESS AT AN ACADEMIC ONCOLOGY UNIT: THE VERONA UNIVERSITY HOSPITAL EXPERIENCE | 5PSQ-033 | |
| COMPARISON OF TOXICITY IN CLINICAL PRACTICE OF ANTI-PD-1/PD-L1 ANTIBODIES IN MONOTHERAPY IN NON-SMALL CELL LUNG CANCER | 5PSQ-034 |
| SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A MULTICENTER EFFECTIVENESS AND SAFETY STUDY | 5PSQ-035 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON ANTIMICROBIAL PRESCRIPTIONS IN THE POSTOPERATIVE RESUSCITATION UNIT | 5PSQ-036 |
| PERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER | 5PSQ-037 |
| REAL-WORLD SAFETY OF IBRUTINIB IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | 5PSQ-038 |
| IMPACT OF TAILORED SCREENING INTERVALS ON THE BURDEN OF DRUG-DRUG INTERACTION ALERTS: AN INTERRUPTED TIME SERIES ANALYSIS | 5PSQ-039 |
| VOLUNTARY MEDICATION ERRORS REPORTING SYSTEM IN AN ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT | 5PSQ-040 |
| IMPACT OF INTRODUCING PREFILLED ATROPINE SYRINGES IN OCULAR SURGERY: PROACTIVE ASSESSMENT OF DRUG COSTS AND MEDICATION SAFETY | 5PSQ-041 |
| FOCUS ON MEDICATION ERRORS ON HIGH-RISK MEDICATIONS IN A HOSPITAL’S ELECTRONIC INCIDENT REPORTING SYSTEM | 5PSQ-042 |
| DESCRIPTIVE STUDY OF MARKETED MEDICINES CONTAINING ASPARTAME | 5PSQ-043 |
| SAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL-CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE | 5PSQ-044 |
| ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS WITH DEMENTIA AND IN TREATMENT WITH HIGH ANTICHOLINERGIC ACTIVITY DRUGS | 5PSQ-045 |
| SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE INDUCED BY ALPRAZOLAM: A CASE REPORT | 5PSQ-046 | |
| THE PERCEIVED IMPACT ON PATIENT SAFETY AND QUALITY OF CARE OF PHARMACEUTICAL TECHNICAL ASSISTANTS ON NURSING WARDS: A QUALITATIVE STUDY | 5PSQ-047 |
| COST-SAVING IMPACT OF USING NUSINERSEN BY CLINICAL TRIALS FOR SPINAL MUSCULAR ATROPHY | 5PSQ-048 |
| MEDICATION PRESCRIBING ERRORS PROSPECTIVE OBSERVATIONAL STUDY IN AN INTENSIVE CARE UNIT | 5PSQ-049 |
| IT IS POSSIBLE TO IMPROVE THE HIPOPOTASEMIC MANAGMENT IN THE HOSPITAL? | 5PSQ-050 |
| EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19. | 5PSQ-051 |
| ANALYSIS OF POTENTIAL PROGNOSTIC FACTORS OF EFFICACY IN TISAGENLECLEUCEL TREATMENT IN A COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA | 5PSQ-052 |
| EFFECTIVENESS AND SAFETY OF GALCANEZUMAB. REAL-LIFE RESULTS. | 5PSQ-053 | |
| EVALUATION OF AN APPLICATION TO HELP FOR THE ADEQUACY OF THE DOSAGE OF ANTIBIOTICS IN RENAL FAILURE | 5PSQ-054 |
| EFFICACY AND SAFETY OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS TREATMENT | 5PSQ-055 |
| VACCINATION COVERAGE AGAINST PENUMOCOCCUS FOR PEOPLE LIVING WITH HIV BEFORE AND AFTER THE COVI-19 PANDEMIC | 5PSQ-056 |
| ANTICHOLINERGIC BURDEN ASSESSMENT IN INSTITUTIONALIZED PATIENTS | 5PSQ-057 |
| EFFICACY EVALUATION OF ANTI-PCSK9 DRUGS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA. | 5PSQ-058 |
| STUDY OF THE USE OF CEFTAZIDIME/AVIBACTAM IN A FIRST LEVEL HOSPITAL | 5PSQ-059 |
| REAL-LIFE DATA ON THE EFFECTIVENESS AND SAFETY OF CABOTEGRAVIR/RILPIVIRINE IN A THIRD-LEVEL HOSPITAL | 5PSQ-060 |
| CURRENT PRACTICE OF PEDIATRIC OFF-LABEL PRESCRIPTIONS IN A PEDIATRIC HOSPITAL | 5PSQ-061 |
| SAFETY EVALUATION OF PEMBROLIZUMAB IN MONOTHERAPY | 5PSQ-062 | |
| ADJUVANTE ANALGESICS INTERACTIONS: HOW TO MANAGE PAIN IN PATIENTS RECEIVING ORAL THERAPY FOR BREAST CANCER TREATMENT | 5PSQ-063 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON DIRECT ACTING ORAL ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL. | 5PSQ-064 |
| INTESTINAL PERFORATION AFTER CRS AND ICANS IN A CAR-T TREATED PATIENT: A CLINICAL CASE REPORT. | 5PSQ-065 |
| SURVIVAL ANALYSIS OF REGORAFENIB IN PATIENTS WITH COLORECTAL CANCER. FIRST RESULTS OF REGORAFENIB USE IN REAL CLINICAL PRACTICE | 5PSQ-066 |
| DRUG UTILIZATION PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS: A REAL WORLD EVIDENCE STUDY | 5PSQ-067 |
| THE HOSPITAL PHARMACIST’S INTERVENTIONS IN THE POST-MARKETING PHARMACOVIGILANCE OF ANTI-ASTHMATIC BIOLOGICS: A REAL LIFE ANALYSIS | 5PSQ-068 |
| COMPARISON OF RENAL GLOMERULAR FILTRATION ESTIMATION FORMULAS IN VANCOMYCIN PHARMACOKINETIC MONITORING | 5PSQ-069 |
| DUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF ATOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE. DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE. | 5PSQ-070 |
| MULTIDISCIPLINARY MANAGEMENT OF DRESS SYNDROME: A CASE REPORT | 5PSQ-071 |
| TREATMENT WITH GALCANEZUMAB IN REAL WORLD DATA: SAFETY. | 5PSQ-072 |
| RISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS | 5PSQ-073 |
| PHARMACEUTICAL INTERVENTIONS IN PAIN MANAGEMENT | 5PSQ-074 |
| ADHERENCE TO LOCAL ANTIBIOTIC PRESCRIBING GUIDELINES WITHIN 48 HOURS OF INPATIENT ADMISSION | 5PSQ-075 |
| EFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY VS NIVOLUMAB PLUS IPILIMUMAB IN RENAL CELL CARCINOMA IN CLINICAL PRACTICE | 5PSQ-076 |
| ADEQUATE NUTRITIONAL THERAPY IN CRITICAL PATIENTS WITH CORONAVIRUS DISEASE (COVID-19) | 5PSQ-077 |
| HYPOPHOSPHATEMIA AFTER FERRIC CARBOXYMALTOSE ADMINISTRATION IN A COHORT OF ELDERLY PATIENTS WITH HIP FRACTURE | 5PSQ-078 |
| PHARMACEUTICAL INTERVENTIONS IN A HEALTH MANAGEMENT AREA | 5PSQ-079 |
| CLINICAL INTERVENTIONS IN PATIENTS UNDERGOING ANTIPARKINSONIAN TREATMENT: THE IMPORTANCE OF CORRECT RECONCILIATION | 5PSQ-080 |
| SATISFACTION OF PHYSICIANS AND HOSPITAL PHARMACISTS OF A HYPERSENSITIVITY DOCUMENTATION TOOL WITH DE-LABELING FEATURE IN CLINICAL PRACTICE | 5PSQ-081 |
| THIRD-GENERATION HOSPITAL-EXCLUSIVE CEPHALOSPORINS: DIFFERENT SAFETY PROFILES? | 5PSQ-082 |
| MARIBAVIR-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A LIVER TRANSPLANT PATIENT: A CASE REPORT. | 5PSQ-083 |
| EROSIVE BALANITIS AS A POSSIBLE ADVERSE EFFECT TO TREATMENT WITH TOFACITINIB. A CASE REPORT. | 5PSQ-084 |
| SAFETY ASSESSMENT OF JANUS KINASE INHIBITORS IN CLINICAL PRACTICE | 5PSQ-085 |
| ADMINISTRATION OF TYROSINE KINASE INHIBITOR DRUGS IN PATIENTS WITH ENTERAL FEEDING TUBES | 5PSQ-086 | |
| ANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS | 5PSQ-087 |
| ADHERENCE TO ANTIRETROVIRAL THERAPY IN VIH PATIENTS | 5PSQ-088 |
| OUTCOME OF MOLNUPIRAVIR TREATMENT IN RENAL TRANSPLANT PATIENTS WITH COVID-19 | 5PSQ-089 |
| CAPSAICIN 8% PATCH IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | 5PSQ-090 |
| SUITABILITY OF TERIPARATIDE AND LEVEL OF ACCEPTANCE OF PHARMACOTHERAPEUTIC RECOMMENDATIONS IN AN AREA OF HEALTH MANAGEMENT | 5PSQ-091 |
| ALTERED PHARMACOKINETICS PARAMETERS OF VANCOMYCIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY WITH FEBRILE NEUTROPENIA, A BAYESIAN SOFTWARE ESTIMATION | 5PSQ-092 | |
| DOES EXPOSURE TO ANTIBIOTICS PRIOR TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AFFECT THEIR EFFECTIVENESS? | 5PSQ-093 |
| INCIDENCE OF HYPERSENSITIVITY REACTIONS IN PACLITAXEL INFUSIONS FOLLOWING THE DISCONTINUATION OF RANITIDINE. | 5PSQ-094 | |
| HOSPITAL PHARMACISTS ENGAGEMENT IN PHARMACOVIGILANCE PRACTICES DURING COVID-19 IN THE NORTH MACEDONIA | 5PSQ-095 |
| DESCRIPTION OF INMMUNOGLOBULIN REPLACEMENT THERAPY IN MULTIPLE MYELOMA PATIENTS WITH ANTI-BCMA CART | 5PSQ-096 |
| AN APPROACH TO THE USE OF MACHINE LEARNING TOOLS FOR THE PREDICTION OF ADVERSE EVENTS IN CANCER PATIENTS ON IMMUNOTHERAPY | 5PSQ-097 |
| PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: OPTIMIZATION OF ACCESS TO THERAPY IN ACCORDANCE WITH EUROPEAN GUIDELINES | 5PSQ-098 | |
| DRUG-RELATED PROBLEMS ASSOCIATED WITH THE TREATMENT OF POLYCYSTIC OVARY SYNDROME | 5PSQ-099 | |
| SURVEY OF PATIENT INVOLVEMENT IN ADVERSE DRUG REACTION MONITORING: THEIR INFORMATION SOURCES AND NEEDS | 5PSQ-100 |
| MEDICAL DEVICES INCIDENT REPORTS: AN ITALIAN EXPERIENCE | 5PSQ-101 | |
| ANALYSIS OF REPEATED EMERGENCY DEPARTMENT VISITS AND THEIR RELATIONSHIP TO MEDICATION | 5PSQ-102 |
| VANCOMYCIN-INDUCED RENAL TOXICITY THROUGH THERAPEUTIC DRUG MONITORING IN DAILY PRACTICE | 5PSQ-103 |
| REAL WORLD EVIDENCE: IS IBRUTINIB AS SAFE AS EVIDENCE TELLS? | 5PSQ-104 |
| PATTERNS OF USE AND APPROPRIATENESS OF ANTICOAGULATION IN ATRIAL FIBRILLATION: AN OBSERVATIONAL STUDY AMONG GERIATRIC INPATIENTS | 5PSQ-105 | |
| FALL-INCREASING RISK DRUGS (FRIDS) AND FALL-RELATED FRACTURES | 5PSQ-106 |
| COMPLIANCE OF FLUOROQUINOLONES PRESCRIPTIONS : A HOSPITAL ACQUIRED RESISTANCE ? | 5PSQ-107 |
| EFFICACY AND SAFETY OF INFLIXIMAB IN NF-KB ESSENTIAL MODULATOR DELETED EXON 5 AUTO-INFLAMMATORY SYNDROME: A CASE REPORT | 5PSQ-108 |
| HAEMOASSIST: A DIGITAL BRIDGE BETWEEN HAEMOPHILIA PATIENTS AND PHARMACISTS | 5PSQ-109 |
| DESENSITIZATION TO MONOCLONAL ANTIBODIES IN ONCOHEMATOLOGICAL PATIENTS | 5PSQ-110 |
| SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AFTER HEART TRANSPLANTATION | 5PSQ-111 |
| A SURVEY OF HOME STORAGE TEMPERATURE OF IN-USE INSULINS AND ANALYSIS OF THEIR STABILITIES UNDER THE SIMULATED HIGHEST HOME TEMPERATURE | 5PSQ-112 |
| ROOT CAUSE ANALYSIS: STATEGY FOR A SUSTAINABLE ANTIBLASTIC THERAPY MANAGEMENT SYSTEM | 5PSQ-113 |
| HEAD AND NECK ERYTHEMA ASSOCIATED WITH THE USE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS | 5PSQ-114 |
| EVALUATION OF HYPOTHYROIDISM ASSOCIATED WITH APALUTAMIDE AND ENZALUTAMIDE TREATMENT IN METASTATIC PROSTATE CANCER USING THE EUROPEAN ADVERSE EFFECT DATABASE (EUDRAVIGILANCE) | 5PSQ-115 | |
| REAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS | 5PSQ-116 |
| TRACEABILITY OF IMPLANTABLE MEDICAL DEVICES / PATIENT INFORMATION: WHERE DO WE STAND? | 5PSQ-117 |
| NON-ACTIVE PRESCRIPTIONS IN AMBULATORY PATIENTS: ANALYSIS AND EFFECT IN CONSULTATION WAITING TIME | 5PSQ-118 |
| REVIEW OF REAL-WORLD MANAGEMENT OF NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS: A DOUBLE-EDGED WEAPON | 5PSQ-119 |
| PEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY | 5PSQ-120 |
| A REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE | 5PSQ-121 |
| SEQUENTIAL CHANGE OF DOSING INTERVAL OF PALIPERIDONE PALMITATE BASED ON PLASMA CONCENTRATION MONITORING | 5PSQ-122 | |
| SIMUALTION OF A DISCHARGE CONTROL: AN EFFECTIVE TOOL FOR QUALIFYING STAFF | 5PSQ-123 | |
| THE TREATMENT OF PRESSURE ULCERS WITH BACTERIA BINDING MEDICATION AS A VALID THERAPEUTIC OPPORTUNITY | 5PSQ-124 |
| ANALYSIS OF INTRODUCING PROBIOTICS FOR THE PREVENTION OF NECROTIZING ENTEROCOLITIS IN PREMATURE NEONATES IN A NEONATAL UNIT | 5PSQ-125 | |
| THE ANALYSIS OF INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN HOSPITALIZED SENIORS | 5PSQ-126 |
| MEDICATION-RELATED FALLS IN A NURSING HOME: IDENTIFICATION AND HOSPITAL PHARMACY INTERVENTIONS | 5PSQ-127 |
| COST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS | 5PSQ-128 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HEALTHCARE RESOURCE UTILIZATION AND COSTS OF INTRAVITREAL RANIBIZUMAB OR AFLIBERCEPT VS. DEXAMETHASONE FOR DIABETIC MACULAR EDEMA IN TAIWAN | 6ER-001 |
| POSITIVE PREDICTIVE VALUES OF ANAPHYLAXIS DIAGNOSIS IN CLAIMS DATA: A MULTI-INSTITUTIONAL STUDY IN TAIWAN | 6ER-002 | |
| ASSESSMENT OF OVERALL SURVIVAL AND SAFETY IN NEWLY APPROVED ONCOHEMATOLOGIC DRUGS | 6ER-003 |
| VISION RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR OEDEMA AND AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR GROWTH FACTOR THERAPY OR DEXAMETHASONE | 6ER-004 |
| DRUG WASTAGE: A HIDDEN COST OF CANCER CARE | 6ER-005 |
| LABOUR PRODUCTIVITY GROWTH IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES UNDERGOING BIOLOGICAL OR JANUS KINASE INHIBITORS TREATMENT | 6ER-006 |
| QUALITY, GAPS AND OPPORTUNITIES IN SMARTPHONE APPLICATIONS FOR PULMONARY HYPERTENSION: AN EVALUATION FROM HOSPITAL PHARMACISTS AND PATIENTS PERSPECTIVE | 6ER-008 |
| PRESCRIBING PATTERNS AND EFFECTIVENESS OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION: A RETROSPECTIVE COHORT STUDY IN TAIWAN | 6ER-009 |
| INVESTIGATING NEED AND APPROPRIATENESS FOR PHARMACIST-LED VACCINATION SERVICES WITHIN A HEALTHCARE SYSTEM | 6ER-010 |
| AN ASSESSMENT OF PHARMACISTS’ CONFIDENCE AND BEHAVIORS IN DISPENSING OPIOID MEDICATIONS | 6ER-011 |
| EVALUATION OF THE EFFECT OF CLOSED SYSTEM TRANSFER DEVICE SYRINGE ADAPTOR CONNECTION IN THE ISOLATOR ON CYTOTOXIC RESIDUE CONTAMINATION DURING INTRAVENOUS ADMINISTRATION | 6ER-012 |
| ENHANCING PATIENT-CENTERED CARE THROUGH PREDICTIVE MODELING OF PATIENT-REPORTED OUTCOMES IN HOSPITAL PHARMACY SETTING | 6ER-013 |
| ASSESSING ADHERENCE TO ESC/ERS GUIDELINES FOR VASOREACTIVITY TESTING AND PRESCRIPTION OF CALCIUM CHANNEL BLOCKERS IN PULMONARY HYPERTENSION PATIENTS | 6ER-014 |
| RETRACTED PHARMACOLOGY ARTICLES: A CROSS-SECTIONAL STUDY USING THE RETRACTION WATCH DATABASE | 6ER-015 |
| REAL-WORLD EFFECTIVENESS OF ALECTINIB AS FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER PATIENTS : AN EVIDENCE FROM TAIWAN | 6ER-016 | |
| FACTORS PREDICTIVE OF CLINICAL OUTCOME IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING OSIMERTINIB TREATMENT: A REAL-WORLD EXPERIENCE | 6ER-017 |
| THE EFFECTIVENESS OF ADRENERGIC ALPHA ANTAGONISTS ON REDUCING RE-CATHETERIZATION RATES IN ADULTS WITH URINARY CATHETERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. | 6ER-018 |
| TREATMENT BEYOND PROGRESSION WITH PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER | 6ER-019 |
| WOULD CHATGPT PASS THE RESIDENT INTERNAL PHARMACIST EXAM? | 6ER-020 |
| OPIOID-SPARING STRATEGIES FOR DISCHARGE ANALGESIA PRESCRIBING IN NON-COMPLEX SURGERIES – A MISSED OPPORTUNITY. | 6ER-021 |
| KNOWLEDGE, ATTITUDE AND PRACTICE ABOUT PHARMACEUTICALS IN THE ENVIRONMENT AMONG HOSPITAL PHARMACISTS IN SPAIN | 6ER-022 |
| A MULTI-SECTOR SIMULATED EXPERIENTIAL PRACTICE EVENT FOR YEAR ONE PHARMACY STUDENTS | 6ER-023 | |
| LYELL’S SYNDROME IN CAR-T TREATED PATIENTS: A CASE STUDY | 6ER-024 |
| ANTIMICROBIAL ACTIVITY OF SUBCRITICAL CO2 EXTRACT OBTAINED FROM UNDERGROUND FERULA ASAFOETIDA L. | 6ER-025 | |
| THE IMPORTANCE OF PHARMACY DEPARTMENT CLINICAL TRIALS UNIT INTERVENTION IN A CENTRE OF REFERENCE FOR THE TREATMENT OF PARAMYLOIDOSIS | 6ER-026 |
| ECONOMIC BENEFIT AND CLINICAL ADVANTAGES WITH THE INCLUSION OF PATIENTS IN CLINICAL TRIALS RELATED TO PARAMYLOIDOSIS | 6ER-027 |
| REAL-WORLD TREATMENT PATTERN AND EFFECTIVENESS OF PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: A MULTI-INSTITUTIONAL STUDY IN TAIWAN | 6ER-028 |
| A SYSTEMATIC REVIEW OF COMBINED POLY (ADP-RIBOSE) POLYMERASE INHIBITOR AND ANDROGEN RECEPTOR ANTAGONISTS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. | 6ER-029 |
| EVALUATION OF A GROUP-BASED ONLINE INFORMED CONSENT CONVERSATION (ECONSENT) IN PARTICIPANTS FROM A VACCINATION CLINICAL TRIAL: A MIXED METHOD STUDY | 6ER-030 |
| EXCLUSION OF PEOPLE LIVING WITH HIV FROM ONCOHAEMATOLOGICAL CLINICAL TRIALS WITH IMMUNE CHECKPOINT INHIBITORS | 6ER-031 |
| ADJUSTED INDIRECT COMPARISON OF CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VS. IMMUNOTHERAPY ALONE IN THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PD-L1≥50% | 6ER-032 |
| ADJUSTED INDIRECT COMPARISON OF CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VS. IMMUNOTHERAPY ALONE IN THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PD-L1≥1% | 6ER-033 |
| EFFICACY OF NEOADJUVANT TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER IN EARLY STAGES: A SYSTEMATIC REVIEW | 6ER-034 |
| EXAMINING THE PERCEPTIONS OF PHARMACISTS OF JOB SATISFACTION, ACHIEVMENTS, AND PREPRDNESS | 6ER-035 | |
| EVALUATION OF THE EFFICACY OF NEOADJUVANCE TREATMENT WITH IMMUNOTHERAPY IN EARLY STAGE BREAST CANCER: A SYSTEMATIC REVIEW | 6ER-036 |
| PHARMACO-UTILISATION OF IBRUTINIB IN CLL: A SINGLE CENTRE STUDY | 6ER-037 | |
| ELABORATION OF A COMPETENCY FRAMEWORK FOR PATIENTS UNDERGOING PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE OR ATRIAL SEPTAL DEFECT | 6ER-038 | |
| PAIN MANAGEMENT: OPIOID USE IN HOSPITALS | 6ER-039 |
| A TOOL PROPOSAL FOR IDENTIFYING THE RISK OF POLYPHARMACY IN NURSING HOMES FOR ELDERLY PEOPLE | 6ER-040 |
| ROLE OF CHECKPOINT INHIBITORS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA | 6ER-041 |
| THE DISASTER PREPAREDNESS AND MANAGEMENT OF HEALTHCARE PRACTITIONERS: A SYSTEMATIC REVIEW OF THE ASSESSMENT INSTRUMENTS | 6ER-042 | |
| DEVELOPING AND VALIDATING A DISASTER MANAGEMENT ASSESSMENT TOOL FOR HEALTHCARE PRACTITIONERS | 6ER-043 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| DEVELOPING THE ROLE OF PRIMARY CARE CLINICAL PHARMACIST | NP-001 |
| “CAPSULE PHARMA”, AN INNOVATIVE DIGITAL TRAINING TOOL TO LEARN ABOUT IMPORTANT STERILE MEDICAL DEVICE (SMD) CONCEPTS | NP-002 |
| PHARMACEUTICAL INFUSION SCHEDULES AS A TOOL TO IMPROVE FLUID RESTRICTION IN PICU PATIENTS | NP-003 | |
| RETROSPECTIVE STUDY ON INDIVIDUALISED MEDICATION OF DEMENTIA PATIENTS RECEIVING CHRONIC HOSPITAL CARES | NP-004 |
| SELF-ASSESSMENT ON THE IMPLEMENTATION OF RECOMMENDATIONS OF THE PERIOPERATIVE PROCESS: INFECTIOUS RISK MANAGEMENT IN SURGERY SETTING | NP-005 |
| IMMUNOTHERAPY IN SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER | NP-006 |
| RECOMMENDATIONS FOR ADMINISTRATION OF IMMUNOSUPPRESSANTS VIA ENTERAL FEEDING TUBE ACCORDING TO THEIR IN-VITRO ADMINISTRATION | NP-007 |
| EMERGENCY DEPARTMENT REVISIT SOCORE BASED ON PHARMACOTHERPAY | NP-008 |
| ASSESSMENT OF MEDICATION DISCREPANCIES BY PHARMACIST-LED MEDICATION RECONCILIATION AT ADMISSION : A PROSPECTIVE STUDY IN TRAUMATOLOGY | NP-009 |
| DEVELOPMENT OF A 2% LIDOCAINE GEL FOR LOCAL ANAESTHESIA OF THE EYE PRIOR TO INTRAVITREAL INJECTION | NP-010 |
| Around one-third of people with diabetes will develop foot ulcers in their lifetime | Student Science Award |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ECONOMIC IMPACT GENERATED BY NATALIZUMAB OPTIMIZATION | 1ISG-001 |
| MEDICATION WASTE IN AN ORTHOPAEDIC DEPARTMENT: EFFECT OF PATIENT’S OWN MEDICATION USE AND SELF-ADMINISTRATION DURING HOSPITALISATION AND THE VIEWS OF PATIENTS AND HOSPITAL STAFF | 1ISG-002 |
| PROTOCOL FOR THE OPTIMISATION OF PHARMACEUTICAL VALIDATION IN HOSPITALIZED PATIENTS | 1ISG-003 |
| HOME DELIVERY – EFFICIENCY, ECONOMY AND CUSTOMER SATISFACTION OUTCOMES – COMPARISON OF ASSISTANCE MODELS | 1ISG-004 | |
| DEPARTMENT COMPUTERISED PHARMACEUTICAL CABINET: RESULTS OF DEMATERIALIZATION AND TRACEABILITY OF DRUGS IN OBSTETRICS AND GYNECOLOGY | 1ISG-005 | |
| OPPORTUNITY TO STUDY ADHERENCE AND PERSISTENCE WITH HOME DELIVERY (HD) – REAL WORLD DATA (RWD) AND REAL WORLD EVIDENCE (RWE) ANALYSIS | 1ISG-006 | |
| OPPORTUNITIES FOR LOGISTIC REORGANISATION OF THE HOSPITAL PHARMACY WITH NEW CARE MODES: STOCK MANAGEMENT (SM) AND HOME DELIVERY (HD) | 1ISG-007 | |
| THE MULTIDISCIPLINARY ASSESSMENT OF RAPID ANTIGEN TESTS FOR THE DETECTION OF THE OMICRON VARIANT: THE ROLE OF THE HOSPITAL PHARMACIST IN A UNIVERSITY HOSPITAL | 1ISG-008 |
| A FRAMEWORK FACILITATING ACCESS TO MEDICINES IN THE EUROPEAN UNION | 1ISG-009 |
| PHARMACY STAFF SATISFACTION AND OPINION OF NEW WEBSITE APPLICATION FOR OUTPATIENT CARE | 1ISG-010 |
| MANAGEMENT OF UNADMINISTERED THERAPIES: IMPACT OF PHARMACIST-DOCTOR COLLABORATION TO OPTIMIZE THE PROCESS OF PREPARING CANCER THERAPIES | 1ISG-011 |
| COST-MINIMISATION ANALYSIS: PROPHYLACTIC TREATMENT OF HAEMOPHILIA TYPE A, WHAT TO CHOOSE BETWEEN FACTOR VIII, RECOMBINANT FACTORS VIII (MOROCTOCOG-ALFA AND OCTOCOG) AND EMICIZUMAB? | 1ISG-012 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| USE AND COST EVOLUTION OF INFLIXIMAB AND ADALIMUMAB OVER 8 YEARS IN A TERTIARY HOSPITAL | 2SPD-001 |
| COST SAVINGS IMPACT OF GENERICS: A LOCAL EXPERIENCE ON LENALIDOMIDE | 2SPD-002 | |
| ERRORS DETECTED IN THE TELEPHARMACY PROCEDURE | 2SPD-003 |
| ECONOMIC EVALUATION AND BUDGET IMPACT FOR A REGIONAL HEALTH SERVICE ASSOCIATED WITH THE INCLUSION OF THE FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN A REGIONAL PHARMACOTHERAPEUTIC GUIDELINE | 2SPD-004 |
| NEW CLOSED SYSTEM TRANSFER DEVICE CONTAINS REAL DRUG VAPOURS FOR UP TO 28 DAYS | 2SPD-005 |
| ARE ALL BIOLOGIC AGENTS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS EQUIVALENT ALTERNATIVES? | 2SPD-006 |
| USE OF DRUGS IN SPECIAL SITUATIONS | 2SPD-007 |
| BUDGETARY IMPACT DUE TO THE REPLACEMENT OF ORIGINAL LENALIDOMIDE INTO GENERIC LENALIDOMIDE | 2SPD-008 | |
| AVOIDED COSTS FROM THE INCLUSION OF BREAST CANCER PATIENTS IN CLINICAL TRIALS | 2SPD-009 |
| REVIEW OF THE ENVIRONMENTAL CRITERIA INTRODUCED IN THE TENDERING OF DRUGS, MEDICAL DEVICES AND NON-MEDICAL EQUIPMENT IN A HEALTH GROUP PROCUREMENT ORGANIZATION | 2SPD-010 |
| COMPARATIVE EFFICACY OF EPTINEZUMAB, GALCANEZUMAB, FREMANEZUMAB AND ERENUMAB IN THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE | 2SPD-011 |
| COMPARATIVE EFFICACY OF ABROCITINIB, BARICITINIB AND UPADACITINIB IN MONOTHERAPY FOR THE TREATMENT OF ATOPIC DERMATITIS | 2SPD-012 |
| INTERVENTIONAL CARDIOLOGY: ANALYSIS OF STERILE MEDICAL DEVICE’S CONSUMPTION AND ASSESSMENT OF DIFFERING PRACTICES | 2SPD-013 |
| COST STUDY: REUSABLE FLEXIBLE URETEROSCOPES VERSUS SINGLE-USE IN A HEALTHCARE FACILITY | 2SPD-014 |
| INDIRECT COMPARISON OF ANIFROLUMAB VS BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS | 2SPD-015 | |
| COMPARATIVE EFFICACY OF BIMEKIZUMAB, IXEKIZUMAB AND BRODALUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | 2SPD-016 | |
| TELEPHARMACY AND HOME DELIVERY PROGRAMME FOR OUTPATIENTS THROUGH THE COMMUNITY PHARMACY | 2SPD-017 |
| BEZLOTOXUMAB: STRATEGIES TO REDUCE ECONOMIC IMPACT | 2SPD-018 |
| EXPLORING ECONOMIC AND QUALITATIVE ASPECTS OF DRUG USE IN A PENITENTIARY INSTITUTE | 2SPD-019 |
| IMPACT OF COVID-19 TREATMENT OPTIONS ON HOSPITAL PHARMACY’S WORKLOAD: LESSONS LEARNED | 2SPD-020 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PREPACKED BOXES FOR OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT) – A QUESTIONNAIRE SURVEY ON KNOWLEDGE, OPINION AND WISHES | 3PC-001 |
| HAZARDOUS DRUG AND ANTIBIOTIC RESIDUE SURFACE CONTAMINATION – IS THERE A NEED TO REDUCE EXPOSURE? | 3PC-002 |
| 99m-Tc- HMPAO LABELED LEUKOCITES: STUDYING ACUTE INFECTION OUTBREAKS – NUCLEAR PHARMACIST IN NUCLEAR MEDICINE | 3PC-003 | |
| ECONOMIC SAVINGS OF ERENUMAB REDOSING IN A THIRD LEVEL HOSPITAL | 3PC-004 |
| CLOSED SYSTEM TRANSFER DEVICE (CSTD) EXTENDS PRACTICAL IN-USE SHELF LIFE TO 28 DAYS AFTER FIRST PUNCTURE OF NON-PRESERVED SINGLE-USE-VIALS IN BOTH CONTROLLED AND UNCONTROLLED ENVIRONMENTS | 3PC-005 |
| CONTAINER CLOSURE INTEGRITY TESTING AND PROCES VALIDATION OF CLOSED SYSTEM TRANSFER DEVICES FOR ASEPTIC RECONSTITUTION OF DRUG VIALS CONNECTED TO FLUID BAGS | 3PC-006 |
| IMPACT OF A SUSTAINABILITY STRATEGY IN THE DEVELOPMENT OF STANDARDIZED NEONATAL PARENTERAL NUTRITION ON DEMAND | 3PC-007 | |
| SLOW ANAKINRA DESENSITIZATION PROTOCOL DESIGN FOR DELAYED HYPERSENSIBILITY REACTION | 3PC-008 |
| CYCLOPHOSPHAMIDE SURFACE CONTAMINATION IN A ROBOTIC CHEMOTHERAPY COMPOUNDING PROCESS | 3PC-009 |
| FORMULATION OF TACROLIMUS SOLUTION FOR SUBLINGUAL USE | 3PC-010 |
| A VIRTUAL STERILISATION AREA : AN INTERACTIVE TRAINING TOOL | 3PC-011 |
| IMPACT AND SATISFACTION IN DRUG ADDICTS ATTENTION CENTERS AFTER INCREASING THE STABILITY OF METHADONE ORAL SOLUTION | 3PC-012 |
| FORMULATION AND ELABORATION OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF A MENINGEAL CARCINOMATOSIS | 3PC-013 |
| METAMORPHINE INSTEAD OF POLYSUBSTANCE USE? | 3PC-014 |
| IN-USE STABILITY OF COMIRNATY AND SPIKEVAX CLINICAL SOLUTIONS: PFIZER-BIONTECH AND MODERNA COVID-19 VACCINES. A COMPARATIVE STUDY FROM A HOSPITAL PHARMACY PERSPECTIVE | 3PC-015 |
| DOES A HOSPITAL COMPRESSOR SYSTEM CONTINOUSLY DELIVER MEDICINAL AIR ACCORDING TO THE EUROPEAN PHARMACOPAEIA? | 3PC-016 |
| IMPACT OF AGITATION ON PEMBROLIZUMAB (KEYTRUDA®) SAFETY AND EFFICACY: AGGREGATION AND FUNCTIONALITY. | 3PC-017 |
| TIME TO AVAILABILITY OF INJECTABLE ANTICANCER DRUGS FOR OUTPATIENTS: REASSESSMENT IN A FRENCH COMPREHENSIVE CANCER CENTER | 3PC-018 | |
| INDIGO CARMINE SOLUTION AND ADRENALINE IN SUBMUCOSAL CHROMOENDOSCOPY | 3PC-019 |
| CLOBETASOL PETROLATUM OINTMENT 0.015% FOR THE TREATMENT OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS: A CASE REPORT. | 3PC-020 |
| AMPHOTERICIN AND COLISTIN GELS FOR NECROTIZING WOUNDS: GALENIC AND MICROBIOLOGICAL VALIDATION. | 3PC-021 |
| FORMULATION AND QUALITY CONTROL OF A BISOPROLOL 0.5 MG/ML ORAL SOLUTION FOR PAEDIATRIC USE | 3PC-022 |
| PATCH TESTS WITH ETHAMBUTOL 10%, ISONIAZID 15% AND PYRAZINAMIDE 25%: A CASE REPORT. | 3PC-023 |
| THE PREPARATION PERSONALIZED OF IMMUNOGLOBULIN BAGS TO IMPROVE THE TREATMENT PATH OF NEUROLOGICAL PATIENTS | 3PC-024 |
| OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT): AN EXAMPLE DURING THE COVID-19 HEALTH EMERGENCY. | 3PC-025 | |
| EFFECTIVENESS AND SAFETY OF INSULIN 1UI/ml EYE DROPS | 3PC-026 |
| STABILITY OF TACROLIMUS ORAL SUSPENSION IN DISPOSABLE POLYPROPYLENE SYRINGE | 3PC-027 |
| FORMULATION OF AN ORAL PLATELET LYSATE GEL TO TREAT CHRONIC GRAFT VERSUS HOST DISEASE ASSOCIATED ORAL MUCOSITIS. EFFECTIVENESS IN A SERIES OF CASES | 3PC-028 |
| MANAGEMENT OF A CHEMOTHERAPY PRODUCTION AFTER A CYBER-ATTACK IN A PUBLIC HOSPITAL | 3PC-029 |
| EVALUATION OF EXCIPIENTS USED IN PAEDIATRIC COMPOUNDED FORMULATIONS PRESCRIBED IN A NEONATAL INTENSIVE CARE UNIT | 3PC-030 |
| A DELPHI METHOD TO STANDARDIZE THE PREPARATION OF AUTOLOGOUS SERUM EYE DROPS ? | 3PC-031 |
| USE OF ORAL KETAMINE FORMULATION IN PATIENTS WITH CHRONIC REFRACTORY PAIN | 3PC-032 | |
| ECONOMIC IMPACT OF CENTRALIZING PEDIATRIC INTRAVENOUS ADMIXTURES | 3PC-033 |
| USE OF A MIXTURE OF BLEOMYCIN, LIDOCAINE AND EPINEPHRINE IN THE TREATMENT OF KELOID SCARS.ON THE SUBJECT OF A CASE. | 3PC-034 | |
| GALENIC DEVELOPMENT OF A GENERIC SPECIALTY WITH CONVENTIONAL RELEASE BASED ON ACARBOSE | 3PC-035 |
| CENTRALIZED AND PERSONALIZED PREPARATION OF INTRAVENOUS KETAMINE FOR PATIENTS WITH RESISTANT DEPRESSION | 3PC-036 |
| LIQUID CHROMATOGRAPY MASS SPECTROMETRY ANALYSIS OF DOXORUBICIN AND EPIRUBICIN AFTER FREEZING | 3PC-037 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EMICIZUMAB IN ACQUIRED HAEMOPHILIA TYPE A: A CASE REPORT. | 4CPS-001 |
| SAFETY AND EFFECTIVENESS OF MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION AFTER TWO AND A HALF YEARS OF CLINICAL EXPERIENCE | 4CPS-002 |
| EXPERIENCES WITH A BEST POSSIBLE MEDICATION HISTORY (BPMH) CONDUCTED BY PHARMACY STUDENTS IN THE HOSPITAL SETTING: A SCOPING REVIEW | 4CPS-003 |
| TRENDS IN TREATMENTS DURING COVID-19 PANDEMIA IN A UNIVERSITY TERTIARY HOSPITAL | 4CPS-004 |
| SUCCESSFUL TREATMENT OF OSTEOMYELITIS CAUSED BY DIFFICULT-TO-TREAT RESISTANT PSEUDOMONAS AERUGINOSA WITH CEFIDEROCOL AS MONOTHERAPY: A CASE REPORT | 4CPS-005 |
| COMPLETE CLINICAL RESPONSE IN METASTATIC BREAST CANCER AFTER FRONT-LINE TREATMENT WITH RIBOCICLIB/TAMOXIFEN | 4CPS-006 |
| TARGETING PATIENTS WITH PNEUMONIA BY COVID-19 THAT COULD BE BENEFICIATED BY COLCHICINE. | 4CPS-007 |
| DOES COMORBIDITY AFFECT ADHERENCE TO INHALERS IN SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS? | 4CPS-008 |
| Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY : EVALUATION OF EFFECTIVENESS AND SAFETY | 4CPS-009 |
| DUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS: EVALUATION OF EFFECTIVENESS AND SAFETY | 4CPS-010 |
| CLINICAL AND ECONOMIC IMPACT OF PHARMACIST ANTIMICROBIAL INTERVENTIONS IN A SMALL HOSPITAL | 4CPS-011 |
| PLATELET TO LYMPHOCYTE RATIO (PLR) AS BIOLOGICAL MARKER OF INTEREST IN INMUNOTHERAPY | 4CPS-012 |
| TREOSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE. EFFICACY AND SAFETY. | 4CPS-013 | |
| COMPARISON OF TWO PROTOCOLS FOR THE ADMINISTRATION OF LEUCOVORIN RESCUES AFTER HIGH DOSE METHOTREXATE INFUSION OF 24 HOURS | 4CPS-014 |
| ROLE OF CLINICAL PHARMACIST IN THE OPTIMISATION OF NIRMATRELVIR/RITONAVIR PRESCRIPTION IN THE EMERGENCY DEPARTMENT | 4CPS-015 |
| PREDICTIVE PERFORMANCE OF GLOMERULAR FILTRATION RATE EQUATIONS BASED ON CYSTATIN C, CREATININE AND THEIR COMBINATION IN CRITICALLY ILL PATIENTS | 4CPS-016 |
| REAL-WORLD EVIDENCE ON RHEUMATOID ARTHRITIS TREATMENT PERSISTENCE: JANUS KINASE INHIBITORS VERSUS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS. | 4CPS-017 |
| EVOLUTION OF ANTIMICROBIAL USE IN COVID-19 PATIENTS | 4CPS-018 |
| QUALITY ASSESSMENT OF THE EVIDENCE UNDERPINNING PHARMACIST-LED ANTIMICROBIAL STEWARDSHIPS INTERVENTIONS | 4CPS-019 |
| TREATMENT PERSISTENCE AND DISCONTINUATION REASONS OF JANUS KINASE INHIBITORS IN A REAL-WORLD SETTING OF RHEUMATOID ARTHRITIS PATIENTS. | 4CPS-020 |
| EFFECTIVENESS, PERSISTENCE, AND ADHERENCE OF BARICITINIB IN RHEUMATOID ARTHRITIS: LONG-TERM REAL-WORLD EVIDENCE STUDY | 4CPS-021 | |
| ADHERENCE TO EVOLOCUMAB AND ITS IMPACT ON LDL CHOLESTEROL REDUCTION | 4CPS-022 |
| TOPICAL RAPAMYCIN IN RARE TUBEROUS SCLEROSIS DISEASE: LIPOSOMAL FORMULATION STABILITY | 4CPS-023 |
| COMPARISON OF CHANGES IN CLINICAL VALUES OF INTENSIVE CARE PATIENTS AT VETERANS HOSPITAL ACCORDING TO VARIOUS FAT EMULSIONS FOR PARENTERAL NUTRITION | 4CPS-024 |
| FREMANEZUMAB UTILISATION STUDY AND EFFECTIVENESS IN THE ‘REAL WORLD’ | 4CPS-025 | |
| EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN REDUCING POTASSIUM CONCENTRATIONS IN HOSPITALISED PATIENTS | 4CPS-026 |
| COST SAVINGS IMPACT AND EFFECTIVENESS OF OMALIZUMAB OPTIMISATION IN REFRACTORY CHRONIC URTICARIA. | 4CPS-027 |
| DRUG BURDEN INDEX EVALUATION IN INSTITUTIONALIZED GERIATRIC PATIENTS AS A DEPRESCRIPTION STRATEGY | 4CPS-028 | |
| ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES | 4CPS-029 |
| IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES | 4CPS-030 |
| THERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET ACHIEVEMENT AND CLINICAL OUTCOMES | 4CPS-031 |
| THE USE OF LEAN METHODOLOGY IN CLINICAL PHARMACOKINETICS – A RETROSPECTIVE ANALYSIS | 4CPS-032 | |
| EVALUATION OF THE EFFECTIVENESS OF REINDUCTION OR INTENSIFICATION WITH USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE | 4CPS-033 |
| ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19 | 4CPS-034 |
| ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE | 4CPS-035 |
| SUCCESSFUL TREATMENT OF POSTSURGICAL MENINGITIS CAUSED BY BACILLUS CEREUS: A CASE REPORT | 4CPS-036 |
| INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN PSORIATIC ARTHRITIS | 4CPS-037 |
| CHALLENGES RELATED TO TRANSITIONING FROM HOSPITAL TO TEMPORARY CARE AT A SKILLED NURSING FACILITY | 4CPS-038 |
| CLINICAL AND ECONOMIC IMPACT OF MULTISWITCHING FROM ORIGINAL ADALIMUMAB TO BIOSIMILARS. | 4CPS-039 |
| ELECTRONIC CLINICAL DECISION SUPPORT FOR PHARMACOTHERAPEUTIC INTERVENTIONS TO REDUCE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS | 4CPS-040 |
| ASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING ANTIMIGRAINE TREATMENT | 4CPS-041 |
| OFF-LABEL USE OF USTEKINUMAB IN NONBULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA: A CASE REPORT | 4CPS-042 |
| DRUG-DRUG INTERACTIONS WITH NIRMATRELVIR/RITONAVIR FOR COVID-19 AND THE ROLE OF HOSPITAL PHARMACISTS | 4CPS-043 |
| EFFECTIVENESS AND SAFETY OF DIFFERENT INITIAL DOSES OF ARIPIPRAZOLE INTRAMUSCULAR DEPOT | 4CPS-044 |
| ECOLOGICAL AND CLINICAL IMPACT OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME ON THE INCIDENCE OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE | 4CPS-045 | |
| A QUALITATIVE STUDY OF FEASABILITY AND ACCEPTABILITY OF A PHARMACY PRIORITISATION TOOLKIT BY A FRAILTY FOCUSED MULTIDICIPLINARY TEAM IN AN ACUTE HOSPITAL EMERGECY DEPARTMENT | 4CPS-046 | |
| IMPACT OF CORTICOSTEROID ON THE EFFECTIVENESS OF IMMUNOTHERAPY | 4CPS-047 |
| ANALYSIS OF PAXLOVID® FOR THE TREATMENT OF COVID-19 IN ARAGÓN, SPAIN | 4CPS-048 |
| TELEPHARMACY AND NEW HEALTHCARE MODELS: CLOSER TO PATIENTS | 4CPS-049 |
| ANALYSIS OF REAL-LIFE USE OF IBRUTINIB AFTER RELAPSE TO CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | 4CPS-050 |
| IMPACT OF THE NEW ANTIEPILEPTIC DRUG MONITORING PROGRAMME ON THE ACTIVITY OF THE PHARMACY AND NEUROLOGY DEPARTMENTS | 4CPS-051 | |
| LONG-TERM MONITORING OF UREA AS TREATMENT FOR HYPONATREMIA ASSOCIATED TO INADEQUATE SECRETION OF ANTIDIURETIC HORMONE (ISADH) | 4CPS-052 |
| KOUNIS SYNDROME SECONDARY TO METAMIZOLE: A CASE REPORT | 4CPS-053 |
| USE OF INTRATHECAL LIPOSOMAL-AMPHOTERICIN B FOR CANDIDA MENINGITIS: A CASE REPORT. | 4CPS-054 |
| EFFECTIVENESS AND SAFETY OF RIBOCICLIB IN THE FIRST LINE OF LUMINAL METASTATIC BREAST CANCER. | 4CPS-055 |
| A CLINICAL AND COST ANALYSIS OF MEDICINES RECONCILIATION BY CLINICAL PHARMACISTS ON HOSPITAL DISCHARGE | 4CPS-056 | |
| SEARCHING FOR A TREATMENT FOR PERIPHERAL TISSUE ISCHEMIA IN NEWBORNS. A CASE REPORT. | 4CPS-057 |
| SYMBALOO AS DIGITAL TOOL FOR HEMOPHILIA | 4CPS-058 |
| EFFICACY AND SAFETY OF EARLY SWITCH TO ORAL ANTIBIOTHERAPY IN PNEUMOLOGY: PROPENSITY SCORE-MATCHED ANALYSIS | 4CPS-059 | |
| EFFECTIVENESS AND ECONOMIC ANALYSIS OF WEIGHT-BASED VERSUS FIXED DOSING OF PEMBROLIZUMAB IN NON SMALL CELL LUNG CANCER | 4CPS-060 |
| APPLICATION OF PROPORTION OF DAY COVERED (PDC) TO EVALUATE ADHERENCE AND PERSISTENCE TO TREATMENT WITH FINGOLIMOD IN PATIENTS WITH MULTIPLE SCLEROSIS | 4CPS-061 |
| EVALUATION AND FOLOW-UP OF PEDIATRIC PATIENT WITH SHORT BOWEL SYNDROME ON TREATMENT WITH TEDUGLUTIDE: CASE REPORT | 4CPS-062 |
| USING MACHINE LEARNING TO PREDICT PHARMACEUTICAL INTERVENTIONS IN A HOSPITAL SETTING | 4CPS-063 |
| EFFECTIVENESS OF RIBOCICLIB AND ABEMACICLIB AS FIRST LINE TREATMENT FOR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN. | 4CPS-064 |
| SIMULATION OF THE IMPACT OF PHARMACOGENETIC MONITORING OF CYTOCHROME P450 2C19 IN PATIENTS ON CLOPIDOGREL TREATMENT | 4CPS-065 | |
| BIOLOGICAL TREATMENTS USED TO TREAT HIDRADENITIS SUPPURATIVA IN A TERTIARY HOSPITAL | 4CPS-066 |
| A CROSS-SECTORAL PHARMACIST INTERVENTION FOR PATIENTS IN TRANSITION BETWEEN HOSPITAL AND GENERAL PRACTICE: A PILOT STUDY | 4CPS-067 |
| CONDUCTION OF AN AUDIT TO REDUCE THE ECONOMIC LOSS DUE TO UNUTILIZED ONCOLOGICAL DRUG PREPARATIONS | 4CPS-068 |
| EXPERIENCE OF ONCOHEMATOLOGY PATIENTS IN OUTPATIENT THERAPY WITH COMPREHENSIVE MEDICATION MANAGEMENT IN THE CONTEXT OF A COVID 19 PANDEMIC | 4CPS-069 |
| THE CLINICAL PHARMACIST : AN ESSENTIAL ACTOR IN TIMES OF CRISIS | 4CPS-070 |
| IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS | 4CPS-071 | |
| REAL-WORLD EXPERIENCE IN HEMOPHILLIA B PATIENTS AFTER SWITCHING TO FIX EXTENDED HALF LIFE USING PHARMACOKINETIC POBLACIONAL SOFTWARE AND MONOCOMPARTIMENTAL MODEL | 4CPS-072 |
| ANALYSIS OF EFFECTIVENESS AND POSITIVE PREDICTIVE VALUE OF ANTIMICROBIAL STEWARDSHIP ALERTS USING A CLINICAL-DECISSION SUPPORT SYSTEM | 4CPS-073 |
| EFFICACY AND SAFETY OF SOTROVIMAB: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY IN A FRENCH HOSPITAL | 4CPS-074 |
| PERSISTENCE AND COST ANALYSIS OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS | 4CPS-075 |
| EFFECTIVENESS AND TOLERABILITY OF CYCLIN-DEPENDENT KINASE INHIBITOR TREATMENT IN METASTATIC BREAST CANCER: REAL-LIFE DATA. | 4CPS-076 |
| CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS TREATED WITH DORAVIRINE | 4CPS-077 |
| ASSESSMENT OF THE QUALITY OF A HOSPITAL’S CLINICAL TRIAL INITIATION VISIT | 4CPS-078 |
| COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM ADMINISTERED BY INTERMITTENT INFUSION VERSUS CONTINUOUS INFUSION | 4CPS-079 |
| OPTIMIZATION OF ANTIRETROVIRAL THERAPY: RESULTS AFTER SIMPLIFICATION TO BITHERAPY WITH DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/RILPIVIRINE. | 4CPS-080 |
| EVALUATION OF EFFECTIVENESS, SAFETY AND ADHERENCE OF PRE-EXPOSURE PROPHYLAXIS AGAISNT HIV | 4CPS-081 | |
| MOST FREQUENT ERRORS IN THE INHALATION TECHNIQUE OF ASTHMATIC CHILDREN | 4CPS-082 |
| CREATININE AND CYSTATIN-BASED ESTIMATED RENAL FUNCTION IN VANCOMYCIN MONITORING | 4CPS-083 |
| EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH VERY HIGH VS HIGH PD-L1 EXPRESSION | 4CPS-084 |
| PHARMACEUTICAL INTERVENTIONS IN A NEONATOLOGY UNIT | 4CPS-085 | |
| COMPARISON OF A TRADITIONAL ELISA TECHNIQUE VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. | 4CPS-086 | |
| PERSISTENCE IN THE METHADONE MAINTENANCE PROGRAMME AND ITS RELATIONSHIP WITH THE MEDICATION REGIMEN COMPLEXITY INDEX IN OPIOID DEPENDENT PATIENTS | 4CPS-087 |
| CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL CELL LUNG CANCER TREATED WITH NIVOLUMAB | 4CPS-088 |
| CURRENT STATUS OF HEPATITIS C VIRUS INFECTION | 4CPS-089 |
| A REVIEW OF PHARMACY HOMECARE SERVICES WITHIN A GROUP OF UK HOSPITAL PHARMACIES | 4CPS-090 | |
| WHAT YOU NEED TO KNOW ABOUT BRUGADA SYNDROME IF YOU ARE A HOSPITAL PHARMACIST | 4CPS-091 |
| STATISTICAL RELATIONSHIP BETWEEN BIOMARKERS WITH PROGNOSTIC VALUE IN ANTI-PDL1 TREATMENTS IN CANCER PATIENTS | 4CPS-092 |
| POLYPHARMACY AND INAPPROPRIATE DRUGS IN PATIENTS WITH OROPHARYNGEAL DYSPHAGIA | 4CPS-093 |
| ANALYSIS OF INTERVENTIONS ON ANTIBIOTIC PRESCRIPTIONS BY THE ANTIMICROBIAL STEWARDSHIP PROGRAMS AT THE EMERGENCY DEPARTMENT | 4CPS-094 |
| INFUSION AUDIT IN HEMATOLOGY: IMPORTANCE OF EVALUATION AND OPTIMIZATION OF PROFESSIONAL PRACTICES | 4CPS-095 |
| EVOLUTION OF SELECTIVE IMMUNOMODULATE THERAPY IN SPECIAL SITUATIONS | 4CPS-096 | |
| COMPARATIVE EFFECTIVENESS OF RISANKIZUMAB AND SECUKINUMAB IN MODERATE TO SERIOUS PSORIASIS. | 4CPS-097 |
| NIRMATRELVIR-RITONAVIR EFFECTIVENESS ANALYSIS AND INTERACTION PROFILE ANALYSIS | 4CPS-098 |
| NINTEDANIB AND PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: COMPARATIVE EFFECTIVENESS AND SAFETY IN A THIRD-LEVEL HOSPITAL | 4CPS-099 |
| VALIDITY, RELIABILITY AND USER-PRACTICABILITY OF A CLASSIFICATION TOOL FOR DRUG-RELATED PROBLEMS AND PHARMACIST INTERVENTIONS WITHIN AN UPPER AUSTRIAN HOSPITAL TRUST | 4CPS-100 |
| CAUSALITY OF ADVERSE DRUG REACTIONS IN HIV-PATIENTS TREATED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE | 4CPS-101 |
| DRUG RELATED PROBLEMS SECONDARY TO HEPARIN TREATMENT IN PATIENTS DISCHARGED FROM THE EMERGENCY DEPARTMENT | 4CPS-102 |
| PHARMACOKINETIC INTERACTION STUDY OF OSIMERTINIB AND DIGOXIN: A CASE REPORT | 4CPS-103 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN A UNIT DOSE AREA | 4CPS-104 |
| CEFIDEROCOL TREATMENT IN COVID-19 POSITIVE PATIENTS CO-INFECTED WITH PAN-RESISTANT PSEUDOMONAS AERUGINOSA | 4CPS-105 |
| BEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD | 4CPS-106 |
| EFFECT OF PATIENT BODY WEIGHT ON THE PHARMACOKINETIC BEHAVIOR OF AMIKACIN | 4CPS-107 |
| PATIENT AND PHYSICIANS’S SATISFACTION WITH CLINICAL PHARMACY SERVICES ON A HEMATOLOGY WARD IN A LARGE TERTIARY CARE HOSPITAL | 4CPS-108 |
| THERAPEUTIC DRUG MONITORING OF VANCOMYCIN IN ONCOLOGIC AND HEMATOLOGIC PATIENTS: REAL-WORLD DATA | 4CPS-109 |
| ASSOCIATION BETWEEN BASELINE CHARACTERISTICSTS AND FIRST LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER PATIENTS | 4CPS-110 |
| IMPORTANCE OF IMPLEMENTING A CLINICAL PHARMACOKINETIC UNIT IN HOSPITAL PHARMACY SERVICE | 4CPS-111 |
| SURVEY OF DIETARY SUPPLEMENT USE AND VACCINATION STATUS AMONG RHEUMATOID ARTHRITIS PATIENTS DURING THE COVID-19 PANDEMIC | 4CPS-112 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS AND ACTIVITY IN THE ARTHROPATHY PHARMACEUTICAL CARE PRACTICE IN A REGIONAL HOSPITAL | 4CPS-113 |
| DEVELOPMENT AND PROSPECTIVE VALIDATION OF A PREDICTION MODEL TO IDENTIFY CLINICALLY RELEVANT MEDICATION DISCREPANCIES AT THE EMERGENCY DEPARTMENT | 4CPS-114 |
| DEVELOPMENT AND IMPLEMENTATION OF A REVIEW PROGRAMME ASSISTED BY THE PHARMACIST TO IMPROVE THE ADEQUACY OF TREATMENT IN POLYMEDICATED PATIENTS IN HOSPITAL OUTPATIENT SETTING | 4CPS-115 |
| THE EFFICIENCY AND COST-EFFECTIVENESS OF HEALTHCARE AND NUTRITIONAL INTERVENTIONS IN THE MANAGEMENT OF POST-STROKE OROPHARYNGEAL DYSPHAGIA, RESULTS OF A SYSTEMATIC REVIEW | 4CPS-116 |
| USE OF ERYTHROMYCIN AS PROKINETIC IN CRITICALLY HOSPITALIZED PATIENTS | 4CPS-117 |
| HEALTH OUTCOMES IN A COHORT OF HIV+ PATIENTS STRATIFIED USING THE KAISER PERMANENTE PYRAMID POPULATION-BASED RISK STRATIFICATION MODEL | 4CPS-118 |
| PNEUMONOLOGY-PHARMACY COLLABORATION IN THE PHARMACOTHERAPEUTIC OPTIMIZATION OF MONOCLONAL ANTIBODIES IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA | 4CPS-119 |
| ADVERSE EFFECTS OF ANTIRETROVIRALS: EXPERIENCE OF PATIENTS. «TALK ABOUT IT TO BETTER MANAGE IT» | 4CPS-120 |
| ANALYSIS OF THE USE OF INTRAVENOUS IRON IN OUTPATIENTS | 4CPS-121 |
| CLINICAL FOLLOW-UP IN PATIENTS WITH MIGRAINE AFTER DISCONTINUATION OF PROPHYLACTIC BIOLOGICAL TREATMENT: A REAL-WORLD EXPERIENCE | 4CPS-122 |
| CASE-CONTROL STUDY ON THE ASSOCIATION BETWEEN NOSOCOMIAL BLOODSTREAM INFECTIONS AND GLUCOCORTICOIDS, TOCILIZUMAB, SYSTEMIC ANTIBIOTICS, MECHANICAL VENTILATION AND LENGTH OF HOSPITAL STAY IN COVID-19 HOSPITALISED PATIENTS | 4CPS-123 |
| EFFICACY AND SAFETY OF ERENUMAB IN A SECOND-LEVEL HOSPITAL | 4CPS-124 |
| PREEXPOSURE PROPHYLAXIS IN MEN AT HIGH RISK FOR HIV-1 INFECTION | 4CPS-125 |
| LINEZOLID STUDY USE AND ASSESSMENT THE APPROPRIATENESS OF ITS PRESCRIPTION IN A REGIONAL HOSPITAL | 4CPS-126 |
| PHARMACOKINETIC MONITORING OF VANCOMYCIN, GENTAMICIN AND AMIKACIN IN PAEDIATRIC POPULATION | 4CPS-127 |
| CLINICAL PRACTICE: ANTI-VEGF THERAPY FOR RESISTANT MACULAR EDEMA. | 4CPS-128 |
| REAL-LIFE EFFECTIVENESS AND SAFETY OF NIRAPARIB AND OLAPARIB IN HIGH-GRADE OVARIAN CANCER | 4CPS-129 |
| EVALUATION OF TIXAGEVIMAB-CILGAVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-130 |
| SOCIAL FUNCTION OF THE TELEPHARMACY: A SOCIOECONOMIC ANALYSIS | 4CPS-131 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS REGARDING ADMISSION RECONCILIATION | 4CPS-132 |
| SAFETY AND EFFECTIVENESS OF GUSELKUMAB ON MODERATE TO SEVERE PLAQUE PSORIASIS | 4CPS-133 |
| PERSISTENCE AND SHIFT IN THE TREATMENT OF PSORIASIS IN THE PERIOD 2019 – 2021 | 4CPS-134 | |
| MELANOMA ADJUVANT THERAPY: from trials to clinical practice215 | 4CPS-135 |
| STANDARD FIRST DAY OF LIFE CENTRAL PARENTERAL NUTRITION, EXPERIENCE IN REAL CLINICAL PRACTICE | 4CPS-136 |
| EVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL | 4CPS-137 |
| USE OF SODIUM ZIRCONIUM CYCLOSILICATE IN HYPERKALEMIC EMERGENCIES | 4CPS-138 |
| THE PHARMACEUTICAL NEWSLETTER AS AN INFORMATION TOOL: USEFUL OR FUTILE ? | 4CPS-139 |
| MEDICAL CANNABIS: PRESCRIPTION ANALYSIS IN TERMS OF FORMULATION AND THERAPEUTIC NEED IN AN HOSPITAL PHARMACY | 4CPS-140 | |
| PHARMACEUTICAL INTERVENTIONS IN A MEDICAL EMERGENCY DEPARTMENT: 6-MONTHS EXPERIENCE | 4CPS-141 |
| EVALUATION OF PREMEDICATION USE IN ADVERSE DRUG REACTIONS OCCURENCE IN PATIENTS WHO RECEIVED INFLIXIMAB TO TREAT INFLAMMATORY BOWEL DISEASE | 4CPS-142 |
| CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA FOLLOWING IMMUNE CHECKPOINT INHIBITION FOR SOLID TUMORS: TWO CASE REPORTS AND LITERATURE STATE OF THE ART. | 4CPS-143 |
| EXPERIENCE OF USING REMDESIVIR IN THE TREATMENT OF PATIENTS WITH SARS-COV2 INFECTION | 4CPS-144 |
| CONSENSUS VALIDATION OF A SCREENING TOOL FOR CARDIOVASCULAR PHARMACOTHERAPY IN GERIATRIC PATIENTS: THE RASP_CARDIO LIST | 4CPS-145 |
| ‘REAL WORLD’ EXPERIENCE OFELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN THE TREATMENT OF CYSTIC FIBROSIS: EFFECTIVENESS AND SAFETY EVALUATION | 4CPS-146 |
| REAL WORLD DATA (RWD) ANALYSIS ON USE OF IMMUNECHECKPOINT INHIBITORS (ICI) FOR NON-SMALL CELL LUNG CANCER (NSCLC) | 4CPS-147 |
| USE OF ANTIVIRALS AUTHORIZED FOR THE TREATMENT OF COVID-19 IN PATIENTS NOT SUBJECT TO HOSPITAL ADMISSION | 4CPS-148 | |
| PAIN MANAGEMENT IN MENTAL HEALTH. | 4CPS-149 |
| THE ROLE OF CLINICAL PHARMACIST IN EMERGENCY DEPARTMENT | 4CPS-150 |
| ACETYLSALICYLIC ACID DESENSITIZATION IN PATIENTS WITH CORONARY ARTERY SYNDROME: LITERATURE REVIEW, RETROSPECTIVE ANALYSIS AND PATIENT FOLLOW-UP PROCEDURE IN AN ITALIAN CARDIOLOGICAL CENTER | 4CPS-151 |
| PERSISTENT CYTOPENIA AFTER CAR-T CELLS: TREATMENT WITH ELTROMBOPAG. A CASE REPORT. | 4CPS-152 |
| OFF-LABEL USE OF KETAMINE FOR RESISTANT DEPRESSION: ROLE OF THE HOSPITAL PHARMACIST | 4CPS-153 |
| IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITS: INCIDENCE IN A PATIENT SAMPLE AND POSSIBLE CHEMIOTHERAPY PROTOCOL REVIEW | 4CPS-154 |
| CREATION AND VALIDATION OF A MEDICATION REVIEW SUPPORT TOOL FOR POTASSIUM CHLORIDE INJECTION (KCl-inj) PRESCRIPTIONS | 4CPS-155 |
| ANALYSIS OF EFECTIVENESS AND COSTS OF DRUG THERAPY PRESCRIBED IN SPECIAL SITUATIONS IN OUR HOSPITAL | 4CPS-156 |
| COMPARISON OF THE EFFECTIVENESS BETWEEN INTERLEUKIN-23 INHIBITORS FOR TREATMENT OF PSORIASIS IN A THIRD LEVEL HOSPITAL | 4CPS-157 |
| IMPROVEMENT IN PATIENT CARE BY PHARMACIST PHONE CALL AFTER STARTING TREATMENT | 4CPS-158 |
| ESTIMATING RENAL FUNCTION FOR DRUG DOSING: CORRELATION BETWEEN CKD-EPI AND COCKCROFT-GAULT IN AN ELDERLY POPULATION | 4CPS-159 |
| REAL-WORLD PERSISTENCE WITH DOLUTEGRAVIR/LAMIVUDINE VERSUS BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS | 4CPS-160 |
| NEGATIVE PRESSURE WOUND THERAPY IMPORTANCE IN WOUND CARE | 4CPS-161 |
| TRIPLE WHAMMY DRUG-DRUG INTERACTION: CLINICAL RELEVANCE AND RESULTS OF PHARMACEUTICAL INTERVENTION. | 4CPS-162 |
| CYTOCHROME P450 2C19 GENOTYPING FOR PERSONALISATION OF PROTON PUMP INHIBITOR THERAPY | 4CPS-163 |
| ADEQUACY REVIEW IN THE USE OF DAPAGLIFLOZIN FOR THE TREATMENT OF HEART FAILURE. | 4CPS-164 |
| ADAPTATION OF MARKETED PARENTERAL NUTRITION TO THE NEEDS OF A HOSPITAL. | 4CPS-165 |
| IMPLEMENTATION OF A LINEZOLID PHARMACOKINETIC MONITORING PROGRAMME | 4CPS-166 |
| CURRENT TRENDS IN THE USE OF CHECK-POINT INHIBITORS FOR NON-SMALL CELL LUNG CANCER | 4CPS-167 |
| RESULTS OF THE USE OF GALCANEZUMAB IN ROUTINE CLINICAL PRACTICE | 4CPS-168 |
| PHYSICOCHEMICAL CHARACTERIZATION OF ORAL LIQUID FORMS AND REVIEW OF THE LITERATURE FOR SAFE AND EFFECTIVE ADMINISTRATION BY ENTERAL FEEDING TUBES | 4CPS-169 |
| THE HOSPITAL PHARMACIST ROLE IN MULTIDISCIPLINARY TEAM DURING THE VACCINATION CAMPAIGN | 4CPS-170 | |
| METHADONE DRUG-DRUG INTERACTIONS POTENTIALLY RELATED TO CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE | 4CPS-171 |
| BRODALUMAB’S EFFECTIVENESS ON MODERATE TO SEVERE PLAQUE PSORIASIS IN REAL PRACTISE | 4CPS-172 |
| EVALUATION OF INCLUSION CRITERIA OF OUTPATIENTS INCLUDED AT HOSPITAL MEDICATION DISPENSING PROGRAMME THROUGH COMMUNITY PHARMACIES | 4CPS-173 |
| EFFECTIVITY AND SAFETY OF CYCLIN-DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER PATIENTS | 4CPS-174 | |
| SEPSIS CODE: IMPROVING OUTCOMES FOR PATIENTS WITH SEPSIS | 4CPS-175 |
| EVALUATION OF NIRMATRELVIR/RITONAVIR USE AND EFFECTIVENESS | 4CPS-176 |
| OPTIMIZATION OF THE THERAPEUTIC MANAGEMENT OF PATIENTS ON ECMO IN THE PEDIATRIC INTENSIVE CARE UNIT | 4CPS-177 |
| DURABILITY OF TREATMENT AND REASONS FOR DISCONTINUATION OF DIMETHYL FUMARATE AND TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS | 4CPS-178 |
| REVERSAL OF ANTICOAGULATION IN ORTHOGERIATRIC PATIENTS WITH HIP FRACTURE REQUIRING EARLY SURGICAL INTERVENTION | 4CPS-179 | |
| VANCOMYCIN: CONCORDANCE OF DOSAGE ADJUSTMENT ACCORDING TO MINIMUM PLASMA CONCENTRATION AND AREA UNDER THE CURVE/MINIMUM INHIBITORY CONCENTRATION | 4CPS-180 |
| FOLLOW-UP OF EXPOSED NEWBORNS TO HIV IN PREGNANCY IN A TERTIARY HOSPITAL | 4CPS-181 |
| EXPERIENCE OF DISCONTINUATION TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE | 4CPS-182 |
| EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING | 4CPS-183 |
| WHAT IS THE ADDITIONNAL VALUE OF PHARMACEUTICAL INTERVENTIONS ON [123I]-METAIODOBENZYLGUANIDINE SCINTIGRAPHY? | 4CPS-184 |
| COMPOUNDED INSULIN EYE DROPS: POPULATION CHARACTERISTICS, USE IN CLINICAL PRACTICE AND SAFETY | 4CPS-185 | |
| EFFECTIVENESS AND SAFETY OF CILGAVIMAB/TIXAGEVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-186 |
| PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH MONOCLONAL ANTIBODIES FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-187 |
| QUALITY OF LIFE IN PATIENTS ON GALCANEZUMAB LONG TERM TREATMENT | 4CPS-188 |
| ANALYSIS OF MEDICATION PERSISTANCE IN MIGRAINE PATIENTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES | 4CPS-189 |
| ANALYSIS OF IBRUTINIB DOSE REDUCTION IN PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA. ARE WE DOING IT RIGHT? | 4CPS-190 |
| IMPACT OF THE COVID-19 PANDEMIC ON THE ADHERENCE OF HIV PATIENTS | 4CPS-191 |
| ANALYSIS OF ADHERENCE AND ASSOCIATED RISK FACTORS IN MULTIPLE SCLEROSIS PATIENTS UNDER DISEASE-MODIFYING THERAPY | 4CPS-192 |
| SUITABILITY OF THE DUAL ANTIPLATELET THERAPY TO THE GUIDELINES OF EUROPEAN SOCIETY OF CARDIOLOGY IN ACUTE CORONARY SYNDROME | 4CPS-193 |
| BASELINE AUDIT OF POTENTIAL TO OPTIMISE THERAPY THROUGH USE OF SGLT2i IN A COHORT OF PATIENT ADMITTED WITH AN ACUTE MYOCARDIAL INFARCTION | 4CPS-194 |
| E-LUNGING: EVALUATION OF AN E-LEARNING PROGRAM INTENDED FOR HEALTHCARE PROFESSIONALS REGARDING THE MEDICATION OF LUNG TRANSPLANT PATIENTS | 4CPS-195 |
| POTENTIALLY INAPPROPIATE MEDICATIONS AND POTENTIALLY PRESCRIBING OMISSIONS IN OLDER PEOPLE LIVING WITH HIV | 4CPS-196 |
| CONCOMITANT USE OF PROTON PUMP INHIBITORS AND PALBOCICLIB: ¿IS THERE A REAL IMPACT ON RESPONSE? | 4CPS-197 |
| ANALYSIS OF ANTIPSYCHOTIC DRUGS USE AT A SPANISH TERTIARY HOSPITAL | 4CPS-198 |
| PHARMACO-ECONOMIC IMPACT OF DRUG INTOXICATIONS IN CHILDREN | 4CPS-199 |
| SUSTAINING A PHARMACEUTICAL DECISION SUPPORT SYSTEM BY DETERMINING THE CLINICAL RISK’S LEVEL OF DETECTED DRUG-RELATED PROBLEMS | 4CPS-200 |
| PHARMACEUTICAL CARE TO OPTIMIZE TREATMENT FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PRISON | 4CPS-201 |
| THE USEFULNESS OF A PHARMACY RESIDENT STAGE IN THE CRITICAL CARE UNIT | 4CPS-202 |
| ANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A THIRD LEVEL HOSPITAL IN SPAIN: A ONE-YEAR REVIEW | 4CPS-203 |
| NATIONAL SURVEY ON CLONIDINE PRESCRIBING PRACTICES IN COMPLEX TRAUMA IN CHILD PSYCHIATRY | 4CPS-204 |
| PHARMACIST’S INTERVENTION IN THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH HEART FAILURE – AN OPPORTUNITY FOR IMPROVEMENT | 4CPS-205 |
| EVALUATION OF IRON CARBOXYMALTOSE VS IRON SUCROSE ADMINISTRATION FOR THE CONTROL OF ANAEMIA IN HOSPITALISED PATIENTS | 4CPS-206 |
| PHARMACEUTlCAL INTERVENTIONS IN AN INTENSIVE CARE UNIT OF EMERGENCY TRAUMA | 4CPS-207 | |
| TELEPHARMACY INTERVENTIONS IN PATIENTS WITH CHRONIC DISEASES | 4CPS-208 |
| EXPERIENCE OF THE NOCEBO EFFECT IN PATIENTS WITH SWITCH TO BIOSIMILARS IN RHEUMATOID ARTHRITIS. | 4CPS-209 |
| EFFICACY OF MONOCLONAL ANTIBODIES TO PREVENT PROGRESSION TO SEVERE COVID-19 DISEASE: REAL-LIFE DATA OF A UNIVERSITY HOSPITAL | 4CPS-210 |
| DESIGN AND VALIDATION OF A QUESTIONNAIRE IN ARABIC LANGUAGE EVALUATING CHRONIC RENAL FAILURE PATIENTS’S KNOWLEDGE | 4CPS-211 | |
| SPECIALIST PHARMACIST-LED MULTIDISCIPLINARY CARE PATHWAY FOR OPTIMISING LIPID THERAPY – SIX MONTHS INTERIM ANALYSIS | 4CPS-212 |
| CHARACTERISTICS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN VERSUS KAWAZAKI ON CLINICAL ASPECTS, SPECIFICITIES AND TREATMENT | 4CPS-213 |
| REAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER | 4CPS-214 |
| DESCRIPTION OF THE PRE-EXPOSURE PROPHYLAXIS COVERAGE AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS. | 4CPS-215 |
| OFF-LABEL USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN JEHOVAH’S WITNESS PATIENTS WITH HIP FRACTURE SUBJECTED TO MAJOR ORTHOPAEDIC SURGERY: A THREE CASES REPORT | 4CPS-216 | |
| THE USE OF CYSTIC FIBROSIS CONDUCTANCE REGULATOR MODULATORS IN PATIENTS WITH RARE MUTATION | 4CPS-217 |
| TNF GENE POLYMORPHISMS PREDICTORS OF RESPONSE TO ANTI-TNF DRUGS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS | 4CPS-218 | |
| AGAMENON-SEOM MODEL FOR THE PREDICTION OF SURVIVAL IN PATIENTS WITH HER2-POSITIVE ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA RECEIVING TRASTUZUMAB-BASED FIRST-LINE TREATMENT | 4CPS-219 |
| COMPARATIVE ANALYSIS OF SKIN TOXICITY ON PATIENTS WITH METASTATIC COLON CANCER TREATED WITH EPIDERMAL GROWTH RECEPTOR BLOCKING DRUGS. | 4CPS-220 |
| ASSESSMENT OF CLINICAL BENEFIT OF CANCER TREATMENTS ACCORDING TO THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SCALE | 4CPS-221 |
| HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED > 55 YEARS WITH ACUTE MYELOID LEUKAEMIA | 4CPS-222 |
| BOTULINUM TOXIN TYPE A: THE NON-INVASIVE SUCCESS FOR OVERACTIVE BLADDERS | 4CPS-223 |
| IMPACT OF AUGMENTED RENAL CLEARANCE ON ANTIMICROBIAL DOSING IN SEVERELY BURNED PATIENTS | 4CPS-224 |
| HEALTH IMPACT OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH BIOLOGICAL AGENTS FROM THE PATIENT’S PERSPECTIVE: A CROSS-SECTIONAL STUDY USING PATIENT REPORTED OUTCOME MEASURES (PROMs) | 4CPS-225 |
| CONTINUOUS INFUSION OF VANCOMICYN: WHO ARE THE PATIENT CANDIDATES AND HOW SAFE IT IS? | 4CPS-226 |
| REAL WORLD EVIDENCE OF THE USE OF DEFIBROTIDE FOR PROPHYLAXIS OF VENO-OCCLUSIVE DISEASE AFTER POST-HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN | 4CPS-227 |
| HIGH DOSE PHENOBARBITAL COMA IN PAEDIATRIC REFRACTORY STATUS EPILEPTICUS | 4CPS-228 |
| THE ADDED VALUE OF A NATIONAL ELECTRONIC HEALTH RECORD FOR THE BEST POSSIBLE MEDICATION HISTORY OBTAINED BY A CLINICAL PHARMACIST | 4CPS-229 |
| ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED <60 YEARS WITH ACUTE MYELOID LEUKEMIA | 4CPS-230 |
| EVALUATION OF CLINICAL DATA OF PATIENTS TREATED WITH ANTI-PCSK9 DRUGS IN TWO HEALTH DISTRICTS | 4CPS-231 | |
| COMPARATIVE EFFICACY OF RISANKIZUMAB AND GUSELKUMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS | 4CPS-232 |
| PD-L1 EXPRESSION AND HISTOLOGICAL TYPE AS PREDICTORS OF RESPONSE IN METASTASIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PEMBROLIZUMAB IN FIRST LINE | 4CPS-233 |
| DEVELOPMENT AND VALIDATION OF A RAPID HIGH PERFORMANCE CHROMATOGRAPHY METHOD (HPLC) FOR THE DETERMINATION OF LINEZOLID IN HUMAN PLASMA | 4CPS-234 |
| IMPACT OF TELEPHARMACY ON BIOLOGIC THERAPIES ADHERENCE AND CLINICAL OUTCOMES IN PATIENTS WITH PSORIASIS | 4CPS-235 | |
| LOSS TO FOLLOW-UP FACTORS OF PEOPLE LIVING WITH HIV | 4CPS-236 |
| HYPERKALEMIA AND RISK FACTORS: SCREENING AND ASSESSSMENT IN HOSPITAL PATIENTS. | 4CPS-237 |
| PROFILE OF ELDERLY PATIENTS AT HIGH FALL RISK AND POLYPHARMACY IN THE EMERGENCY DEPARTMENT. | 4CPS-238 |
| POPULATION PHARMACOKINETICS OF ISAVUCONAZOLE BASED ON PHAMACOGENETICS IN IMMUNOSUPPRESSED PATIENTS | 4CPS-239 |
| FINGOLIMOD: ANALYSIS OF USE AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | 4CPS-240 | |
| FINAL VALIDITY OF A TOOL FOR RATING SIGNIFICANCE OF PHARMACISTS’ CLINICAL CONTRIBUTIONS IN HOSPITAL | 4CPS-241 |
| ISAVUCONAZOLE TREATMENT IN TWO PEDIATRIC PATIENTS DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: THE ROLE OF THERAPEUTIC DRUG MONITORING. | 4CPS-242 |
| DELAYED HIV TREATMENT AND FACTORS ASSOCIATED | 4CPS-243 |
| ANALYSIS AND COMPARISON OF OLANZAPINE ADMINISTRATION IN SMOKING AND NON-SMOKING PATIENTS | 4CPS-244 |
| PREVENTION OF REFEEDING SYNDROME IN PATIENTS ON PARENTERAL NUTRITION: A REVIEW OF APPROPRIATENESS | 4CPS-245 |
| TREATMENT AND NURSING CARE OF MUCORMYCOSIS IN PAEDIATRICS: A CASE REPORT | 4CPS-246 |
| INITIATIVES TO IMPROVE THE MANAGEMENT OF PATIENTS WITH HEREDITARY ANGIOEDEMA BY HOSPITAL PHARMACY | 4CPS-247 |
| THERAPEUTIC DRUG MONITORING OF LINEZOLID IN SOFT-TISSUE AND OSTEOARTICULAR INFECTIONS: A RETROSPECTIVE ANALYSIS | 4CPS-248 |
| RELATIONSHIP BETWEEN RENAL FUNCTION AND ERTAPENEM PLASMA CONCENTRATION IN ADULT PATIENTS. | 4CPS-249 |
| EXPERIENCE OF TECOVIRIMAT AND CIDOFOVIR USE IN A PATIENT WITH MONKEYPOX: A CASE REPORT | 4CPS-250 |
| HEREDITARY ANGIOEDEMA: IMPACT OF THE BURDEN OF DISEASE IN SPAIN | 4CPS-251 |
| OPTIMIZATION OF ERTAPENEM POSOLOGY IN A CRITICALLY ILL PATIENT BY THERAPEUTIC DRUG MONITORING: A CASE REPORT | 4CPS-252 |
| DESCRIPTIVE STUDY OF THE ONCOLOGY AND HAEMATOLOGY POPULATION, DIAGNOSIS, AND IMMUNOTHERAPY IN PATIENTS OVER 65 YEARS OLD IN A THIRD LEVEL HOSPITAL | 4CPS-253 | |
| DAPAGLIFOZIN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE | 4CPS-254 |
| ANTIPARKINSONIAN MEDICATION RECONCILIATION: HOW PREVENTING MEDICATION ERRORS PROMOTES THERAPEUTIC QUALITY AND SAFETY | 4CPS-255 |
| ENHANCING THE SAFETY OF INJECTABLE CYTOTOXIC CHEMOTHERAPY AT A TERTIARY CARE HOSPITAL: A RETROSPECTIVE ANALYSIS OF PHARMACISTS’ INTERVENTIONS IN CHEMOTHERAPY PREPARATION SERVICES | 4CPS-256 |
| PREOPERATIVE INTRAVENOUS IRON TO TREAT ANEMIA BEFORE MAJOR ORTHOPEDIC SURGERY | 4CPS-257 |
| PHARMACOKINETICS ALTERATIONS IN FIVE CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL | 4CPS-258 |
| MANAGEMENT OF VORICONAZOLE-INDUCED LIVER TOXICITY IN A PEDIATRIC PATIENT | 4CPS-259 |
| PERSISTENCE, SAFETY AND ASSOCIATED LYMPHOPENIA OF DIMETHYL FUMARATE IN RELAPSING REMITTING MULTIPLE SCLEROSIS, REAL WORLD DATA | 4CPS-260 |
| ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ONCOLOGICAL TREATMENT OF PROSTATE CANCER AND CHRONIC MEDICATION. | 4CPS-261 | |
| A NOVEL ARTIFICIAL INTELLIGENCE-BASED TOOL TO ASSESS ANTICHOLINERGIC BURDEN: A SURVEY | 4CPS-262 |
| THE PHARMACIST’S ROLE IN OPTIMIZING SURGICAL ANTIBACTERIAL PROPHYLAXIS (SAP) | 4CPS-263 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT | 5PSQ-001 |
| PHARMACIST IN SECURING DRUG CIRCUIT : FROM PRESCRIPTION TO ADMINISTRATION (ANALYSIS AND ACTIONS) | 5PSQ-002 |
| PERFORMANCE OF A COLD MAINTENANCE DEVICE DURING THE IMPLEMENTATION OF A PNEUMATIC CIRCUIT | 5PSQ-003 |
| EPCLUSA RELATED SLEEPINESS: A CASE REPORT | 5PSQ-004 |
| ANALYSIS OF ANTI-ANGIOGENESIS-RELATED ADVERSE EVENTS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (VEGFR-TKIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA | 5PSQ-005 |
| IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: A 7-MONTHS ANALYSIS | 5PSQ-006 |
| IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: WHAT’S NEW AND WHAT’S LEFT? | 5PSQ-007 |
| A DIGITAL ASSISTANT TO SUPPORT PATIENTS IN PREPARING MEDICATION RECONCILIATION: PATIENT EXPERIENCES. | 5PSQ-008 |
| EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS | 5PSQ-009 |
| DIGOXIN ADJUSTMENT: COMPARATIVE ANALYSIS OF THREE PHARMACOKINETIC SOFTWARE | 5PSQ-010 |
| PHARMACOKINETIC EVALUATION OF DRUGS WITH A NARROW THERAPEUTIC RANGE AND THEIR INFLUENCE ON CLINICAL DECISION | 5PSQ-011 |
| CASE REPORT: INHALED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR MILD-TO-MODERATE AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS – 24 MONTHS OF FOLLOW-UP | 5PSQ-012 |
| PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: NEUTROPENIA MANAGEMENT IN CLINICAL PRACTICE. | 5PSQ-013 |
| IMPACT OF HISTAMINE-2 ANTAGONIST SHORTAGE ON THE INCIDENCE OF HYPERSENSITIVITY REACTIONS TO PACLITAXEL – TOWARDS CRISIS MANAGEMENT AND A PREMEDICATION RECONSIDERATION IN FRANCE (PACLIREACT STUDY) | 5PSQ-014 |
| PERSISTENCE OF TREATMENT WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN PATIENTS ALREADY TREATED WITH THEM | 5PSQ-015 |
| HUMAN FACTORS ROLE IN MEDICATION ERRORS: DILUTING INTRAVENOUS MEDICATIONS AT HOSPITAL WARDS – A STUDY BASED ON INCIDENT REPORTS | 5PSQ-016 |
| IMMUNE-MEDIATED ADVERSE EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) THERAPY IN REAL LIFE POPULATION: WE CONTINUE TO LEARN. | 5PSQ-017 |
| PRESCRIBING ERRORS IN CHILDREN: WHAT IS THE IMPACT OF A COMPUTERIZED PHYSICIAN ORDER ENTRY? | 5PSQ-018 |
| ANALYSIS OF THE USE OF IDARUCIZUMAB IN A TERTIARY HOSPITAL | 5PSQ-019 |
| ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS TO INCREASE THE SAFETY AND ADEQUACY OF THEIR TREATMENT | 5PSQ-020 | |
| AUTOMATION MEETS TRACEABILITY TO OPTIMIZE DRUGS AND MEDICAL DEVICES LOGISTICS GUARANTEEING PATIENT SAFETY AND HOSPITAL STAFF WELL-BEING | 5PSQ-021 |
| ANALYSIS OF HEALTHCARE VISITS TO EMERGENCY SERVICES FROM PATIENTS WITH PAINFUL VASCULAR ULCERS TREATED WITH TOPICAL SEVOFLURANE | 5PSQ-022 |
| SEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT | 5PSQ-023 |
| HAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING | 5PSQ-024 |
| IMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE. | 5PSQ-025 |
| MEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS | 5PSQ-026 |
| APPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA | 5PSQ-027 |
| CDK 4/6 INHIBITORS – ANALYSIS OF POTENTIAL DRUG INTERACTIONS | 5PSQ-028 |
| PERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME | 5PSQ-029 |
| SAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA | 5PSQ-030 |
| ANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED | 5PSQ-031 |
| PHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM | 5PSQ-032 |
| ANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B | 5PSQ-033 |
| FIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING | 5PSQ-034 |
| MASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA | 5PSQ-035 |
| MEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA | 5PSQ-036 |
| IMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION | 5PSQ-037 |
| DRUG RELATED VISITS TO THE EMERGENCY DEPARTMENT IN NURSING HOME PATIENTS | 5PSQ-038 |
| RAF-KINASI PATHWAY INHIBITORS IN TREATMENT OF METASTATIC MELANOMA: WHEN COMPLIANCE DOESN’T MATCH WITH TOLERANCE. | 5PSQ-039 |
| ANALYSIS OF THE IMPACT OF THE COVID-19 PANDEMIC ON PSYCHOTROPIC DRUG USE | 5PSQ-040 | |
| STERILE INTRAOCULAR INFLAMMATION AFTER INTRAVITREAL AFLIBERCEPT | 5PSQ-041 |
| PREVALENCE OF MEDICATION PRESCRIPTION WITH A POTENTIAL NEGATIVE EFFECT ON SWALLOWING IN OUTPATIENTS WITH COGNITIVE IMPAIRMENT AND A DIAGNOSIS OF DYSPHAGIA. | 5PSQ-042 |
| UNSUPPORTED PRESCRIPTION OF POLYVALENT IMMUNOGLOBULINS IN A UNIVERSITY HOSPITAL CENTER: FREQUENCY AND COST | 5PSQ-043 | |
| REAL-LIFE SAFETY AND SATISFACTION OF CFTR PROTEIN MODULATORS IN CYSTIC FIBROSIS | 5PSQ-044 |
| IMPACT OF PHARMACEUTICAL INTERVENTIONS IN CRITICAL PATIENTS | 5PSQ-045 |
| FMEA (FAILURE MODE AND EFFECT ANALYSIS) APPLICATION TO PARENTERAL NUTRITION BAGS MANUFACTURING PROCESS: ROLE OF HOSPITAL PHARMACIST | 5PSQ-046 |
| PRECAUTIONARY CANCELLATION: TOOL TO IMPROVE PATIENT SAFETY | 5PSQ-047 |
| WHAT DO ONCOLOGISTS AND PHARMACISTS THINK AND WANT FROM A CAHM-DRUG INTERACTION CHECKER? A BROADSCALE SURVEY TO ASSESS EXPECTATIONS. | 5PSQ-048 |
| ASSESSMENT AND OPTIMISATION OF THE MANAGEMENT OF HIGH RISK MEDICINES IN A GENERAL HOSPITAL | 5PSQ-049 |
| ANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE | 5PSQ-050 |
| PARKINSONISM INDUCED BY TAKING TRAZODONE AS A HYPNOTIC: A CASE REPORT | 5PSQ-051 |
| CHANGES IN POLYMEDICATED PATIENTS’ PRESCRIPTIONS AFTER OUTPATIENT HOSPITAL CONSULTATIONS IN REAL LIFE SITUATIONS | 5PSQ-052 |
| DESIGN OF A PRIORIZATION SYSTEM BY COMPLEXITY OF THE REVIEW IN POLYMEDICATED PATIENTS: POTENTIAL INADECUACY INDEX | 5PSQ-053 |
| ASSESSEMENT OF OCCUPATIONAL PRACTICES: ANALYSIS OF THE PRESCRIPTIONS OF TRANSCATHETER AORTICVALVE IMPLANTATION (TAVI) | 5PSQ-054 |
| SAFETY TESTING ASSESSMENT FOR THE ADHERENCE OF DOSE REDUCTION IN ONCOLOGY TREATMENT FOLLOWING CLINICAL GUIDELINES RECOMMENDATIONS IN PATIENTS PRIOR RECEIVING FLUOROPYRIMIDINES (5-FLUOROURACIL, CAPECITABINE AND TEGAFUR) | 5PSQ-055 | |
| HETEROGENEITY OF DEXMEDETOMIDINE TREATMENT EFFECT ON MORTALITY ACCORDING TO AGE | 5PSQ-056 |
| EFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE | 5PSQ-057 |
| MANAGEMENT OF SOLID ORAL PHARMACEUTICAL FORMS WITH UNIT DOSE | 5PSQ-058 |
| REAL-WORLD CLINICAL DATA OF PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER PATIENT | 5PSQ-059 |
| GLUTEN IN MEDICINES. A PRESCRIPTION HELPING TOOL. | 5PSQ-060 |
| NEW-ONSET MULTIPLE SCLEROSIS ASSOCIATED WITH ADALIMUMAB TREATMENT: ABOUT TWO CASE REPORTS | 5PSQ-061 |
| REVIEW AND DEPRESCRIPTION OF MEDICATION IN POLYMEDICATED PATIENTS WITH PSYCHOACTIVE DRUGS. | 5PSQ-062 |
| A CROSS-SECTIONAL STUDY ON THE POTENTIALLY INAPROPIATE PRESCRIBED AND CONTRAINDICATED HIGH-RISK MEDICATION IN HOSPITALIZED CHRONIC COMPLEX PATIENTS | 5PSQ-063 |
| CONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT | 5PSQ-064 |
| BE A HUMAN, NOT A CASE REPORT! HOSPITAL PHARMACISTS MAKE THE DIFFERENCE | 5PSQ-065 |
| ADEQUACY TO PROTOCOL OF USE OF TOCILIZUMAB FOR MANAGEMENT OF COVD-19 DISEASE | 5PSQ-066 |
| TRACKING THE OVERAL IN USE AND STRESS STABILITY OF ROMIPLISTIM (N-PLATE®) BY THE EVALUATION OF A SELECTED SET OF CRITICAL QUALITY ATTRIBUTES | 5PSQ-067 | |
| DIARRHEA OCCURRENCE ANALYSIS IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS | 5PSQ-068 |
| ANALYSIS AND MONITORING OF ERRORS ASSOCIATED WITH ELECTRONIC PRESCRIPTION SYSTEMS: PRESCRIPTIONS WITH INCORRECT DRUG SCHEDULES. | 5PSQ-069 |
| PHARMACEUTICAL CARE IN AN ONCO-HEMATOLOGICAL CLINICAL TRIALS UNIT | 5PSQ-070 |
| ANALYSIS OF MEDICATION PROVIDED BY PATIENTS | 5PSQ-071 |
| ANALYSIS OF THE DURATION AND COMPLICATIONS ASSOCIATED WITH PERIPHERAL PARENTERAL NUTRITION: A COHORT STUDY. | 5PSQ-072 |
| IS THERE A SAFETY DIFFERENCE? JANUS KINASE INHIBITORS IN REAL CLINICAL PRACTICE | 5PSQ-073 |
| INTERACTIONS DETECTED WITH THE USE OF NIRMATRELVIR/RITONAVIR IN A TERTIARY HOSPITAL | 5PSQ-074 |
| PROPOSAL FOR THE ADJUSTMENT AND OPTIMISATION OF THE MEDICATION PROVIDED BY THE PATIENT | 5PSQ-075 |
| PATIENTS’ SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION | 5PSQ-076 |
| CYCLIN DEPENDENT KINASES 4 AND 6 INHIBITORS – REAL-WORLD DATA ANALYSIS | 5PSQ-077 | |
| ANALYSIS OF CASIRIVIMAB AND IMDEVIMAB USE IN OUTPATIENTS WITH COVID-19 | 5PSQ-078 |
| FONDAPARINUX IN AN INFANT WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA. A CASE REPORT. | 5PSQ-079 |
| IDENTIFICATION OF PHARMACOLOGICAL INTERACTIONS BETWEEN IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND DIETARY SUPPLEMENTS/HERBS IN PATIENTS WITH CYSTIC FIBROSIS IN AN OUTPATIENT PHARMACEUTICAL CARE UNIT | 5PSQ-080 |
| ASSESSMENT OF THE IMPACT OF THE PHARMACEUTICAL INTERVENTION IN MEDICATION RECONCILIATION AT PATIENT ADMISSION IN A SURGICAL PRE-HOSPITALIZATION CLINIC | 5PSQ-081 |
| GRAVIMETRIC CONTROL OF PARENTERAL NUTRITION IN NEONATOLOGY AND PEDIATRICS. | 5PSQ-082 | |
| FOUR YEARS OF A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY | 5PSQ-083 |
| ASSESSING QUALITY OF LIFE OF PATIENTS WITH SEVERE ASTHMA MEASURED BY PATIENT REPORTED OUTCOMES | 5PSQ-084 |
| MEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA: SEARCHING FOR THE BEST PHARMACEUTICAL FORM | 5PSQ-085 |
| ANALYSIS OF POTENCIALLY INAPPROPRIATE PRESCRIPTION IN A NURSING HOME | 5PSQ-086 |
| EVALUATION OF THE EFFECTIVENESS OF LAMIVUDINE IN THE PROPHYLAXIS OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL DISEASES | 5PSQ-087 |
| EXPLORING THE NEED FOR A CHECK OF COMPOUNDING APPROPRIATENESS SERVICE: EVALUATION OF SPONTANEOUS CHECKS BEFORE COMPOUNDING AT A LARGE TERTIARY CARE HOSPITAL | 5PSQ-088 |
| CHRONIC NON-CANCER PAIN, WHAT ABOUT THIS PATIENTS? | 5PSQ-089 | |
| STUDY OF THE USE OF RESTRICTED ANTIBIOTICS DURING COVID-19 PANDEMIC: CEFTAROLINE, CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM. | 5PSQ-090 |
| TRIFECTA™ BIOPROSTHESES : EVALUATION OF THE SAFETY BASED ON THE STUDY OF DEGENERATIONS ACCORDING TO THE VARC-3 CLASSIFICATION | 5PSQ-091 |
| PHARMACOVIGILANCE OF BIOLOGICAL THERAPIES FROM THE OUTPATIENT DEPARTMENT | 5PSQ-092 |
| PHARMACEUTICAL INTERVENTION AFTER INAPPROPRIATE PRESCRIPTION OF ZOLPIDEM | 5PSQ-093 |
| TOXICITY IN PATIENTS TREATED WITH VENETOCLAX. A SAFETY STUDY IN REAL-WORLD PRACTICE | 5PSQ-094 |
| CARDIAC CONDUCTION DISORDERS ASSOCIATED WITH THE USE OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY | 5PSQ-095 | |
| A PROSPECTIVE OBSERVATIONAL STUDY OF MEDICATION PRESCRIBING ERRORS IN AN EMERGENCY DEPARTMENT. | 5PSQ-096 |
| HEALTH ALERT OF TOFACITINIB AND PHARMACEUTICAL INTERVENTION | 5PSQ-097 |
| SAFETY AND PERSISTENCE OF ANTI-FIBROTIC DRUGS IN INTERSTITIAL LUNG DISEASES | 5PSQ-098 |
| ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL | 5PSQ-099 |
| UTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW | 5PSQ-100 |
| ANALYSIS OF HIP PROSTHESES OVER A YEAR | 5PSQ-101 | |
| SAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY | 5PSQ-102 |
| PARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS | 5PSQ-103 |
| ERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT | 5PSQ-104 |
| DEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE | 5PSQ-105 |
| SAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT | 5PSQ-106 |
| SAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE | 5PSQ-107 |
| COMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW | 5PSQ-108 |
| RANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW? | 5PSQ-109 |
| IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS | 5PSQ-110 | |
| MEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL | 5PSQ-111 |
| RELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER | 5PSQ-112 |
| REAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS | 5PSQ-113 |
| PERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB | 5PSQ-114 |
| DEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE. | 5PSQ-115 |
| PERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS. | 5PSQ-116 |
| EVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE | 5PSQ-117 |
| PATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY | 5PSQ-118 |
| A NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED | 5PSQ-119 |
| ANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION | 5PSQ-120 |
| CYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT | 5PSQ-121 |
| COVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA | 5PSQ-122 |
| IMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV | 5PSQ-123 |
| EFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS | 5PSQ-124 |
| BRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY? | 5PSQ-125 |
| EFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA | 5PSQ-126 |
| PHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW | 5PSQ-127 |
| THROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION. | 5PSQ-128 |
| SWITCHING BETWEEN ANTI-CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN MIGRAINE | 5PSQ-129 |
| OFF-LABEL USE OF CIDOFOVIR INTRALESIONAL INJECTIONS IN EXTENSIVE ANOGENITAL CONDYLOMATOSIS: A CASE REPORT | 5PSQ-130 |
| LETERMOVIR, GANCICLOVIR AND IMMUNOGLOBULINS COMBINATION TREATMENT IN AN IMMUNOCOMPROMISED PATIENT WITH CYTOMEGALOVIRUS INFECTION: A CASE REPORT | 5PSQ-131 |
| PHARMACOGENETIC-GUIDED TREATMENT IN PATIENTS WITH DYHYDROPIRYMIDINE DEHYDROGENASE DEFICIENCY | 5PSQ-132 |
| PHARMACISTS – GENERAL PRACTIONERS (GPs) COLLABORATION TO IDENTIFY DRUG-RELATED PROBLEMS (DRPs) IN PATIENTS IN POLYTHERAPY | 5PSQ-133 |
| UNIT DOSE IN A CYBERATTACK SCENARIO | 5PSQ-134 |
| HAS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME HAD AN IMPACT ON THE ANTIBIOTIC CONSUMPTION? | 5PSQ-135 |
| ANALYSIS OF ANTIRETROVIRAL THERAPY POTENCY IN HIV- NAÏVE PATIENTS | 5PSQ-136 |
| ANALYSIS OF THE DPYD GENE MUTATIONS IN CANCER PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH FLUOROPYRIMIDINES | 5PSQ-137 |
| CHEMOTHERAPY ERRORS DETECTED DURING PHARMACEUTICAL VALIDATION | 5PSQ-138 |
| USING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs) | 5PSQ-139 |
| FREQUENCY OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS UNDERGOING HOME TREATMENT WITH DIRECT-ACTING ORAL ANTICOAGULANTS (DOACs) | 5PSQ-140 |
| FALLS IN ELDERLY PATIENTS AND CHRONIC CONSUMPTION OF ANXIOLYTIC BENZODIAZEPINES. | 5PSQ-141 |
| EVALUATION OF ADEQUACY, ADHERENCE AND SAFETY OF HUMAN IMMUNODEFICIENCY VIRUS POST-EXPOSURE TREATMENT | 5PSQ-142 |
| THE ROLE OF THE PHARMACIST IN INCREASING HEALTH VIGILANCE AMONG HEALTH PROFESSIONALS: QUINCKE’S EDEMA FOLLOWING THE ADMINISTRATION OF RITUXIMAB | 5PSQ-143 |
| ELECTRONIC PATIENT-REPORTED OUTCOME (PROM) MEASUREMENT USING PRO-CTCAE®QUESTIONNAIRE TO IMPROVE QUALITY OF LIFE ASSESSMENT AND HEALTHCARE RESOURCES MANAGEMENT IN PATIENTS WITH LYMPHOMA RECEIVING INTRAVENOUS CHEMOTHERAPY | 5PSQ-144 |
| A PATIENT SATISFACTION SURVEY ON UNIT DOSE DRUG DISTRIBUTION IN HOSPITAL | 5PSQ-145 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| THE USE OF GAMIFICATION TO EVALUATE PUBLIC UNDERSTANDING OF ADVERSE DRUG REACTIONS | 6ER-001 |
| WHAT’s ANOTHER PEER? EXPLORING THE USE OF NEAR PEER TEACHING OF MEDICATION HISTORY TAKING IN PHARMACY UNDERGRADUATES IN THE UK | 6ER-002 |
| THE CLIMATE EMERGENCY, HOW CAN PHARMACY MAKE A DIFFERENCE? | 6ER-003 | |
| EFFECTIVENESS AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED DISEASES ON BIOLOGICAL THERAPY | 6ER-004 |
| EFFECTS OF ADHERENCE TO THE MEDITERRANEAN DIET IN PATIENTS WITH AUTOIMMUNE DISEASES | 6ER-005 |
| CURRENT PERFORMANCE OF HOSPITAL PHARMACY SPECIALISTS TRAINED AT A TERTIARY HOSPITAL IN SPAIN | 6ER-006 |
| PHYSICO-CHEMICAL PARAMETERS OF TOBACCO OIL AND PREPARATION OF A DOSAGE FORM BASED ON IT | 6ER-007 | |
| CORRELATES OF ONE-YEAR MORTALITY AMONG PATIENTS LIVING WITH HIV ACCORDING TO THE STRATIFICATION LEVEL OF THE PHARMACEUTICAL CARE MODEL | 6ER-008 |
| COMPARATIVE EFFICACY OF ABEMACICLIB AND PALBOCICLIB AS ADJUVANT TREATMENT IN PATIENTS WITH EARLY BREAST CANCER | 6ER-009 |
| EVOLUTION OF ONCOHAEMATOLOGICAL CLINICAL TRIALS FROM 2016 TO 2021: EXPERIENCE FROM A TERTIARY HOSPITAL | 6ER-010 |
| EFFICACY OF THERAPIES IN NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS: A SYSTEMATIC REVIEW | 6ER-011 |
| TREATMENT DECISIONS ACCORDING TO 1-YEAR RISK MORTALITY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY. | 6ER-012 |
| 1 YEAR-MORTALITY RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY. | 6ER-013 |
| EFFECTIVENESS AND SAFETY OF THE ADMINISTRATION OF MURPHY’S ENEMA FOR THE TREATMENT OF REFRACTORY CONSTIPATION IN A TERTIARY HOSPITAL | 6ER-014 |
| AZACITIDINE IN THE TREATMENT OF JUVENILE MYELOMONOCYTIC LEUKAEMIA: AN UP-TO-DATE PHARMACY PROTOCOL | 6ER-015 |
| IDENTIFICATION OF NEW GENES OF EARLY RESPONSE TO ANTI-TNFS BY RNASEQ IN PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE. | 6ER-016 | |
| STRUCTURED OBJECTIVE CLINICAL EVALUATION FOR PHARMACY STUDENTS ON INTERNSHIPS AT THE HOSPITAL | 6ER-017 |
| OFF-LABEL USE OF USTEKINUMAB IN REFRACTORY EPIDERMOLYTIC ICHTHYOSIS: A CASE REPORT | 6ER-018 |
| THE STUDENT PHARMACIST EXPERIENCE OF ENHANCED CLINICAL PLACEMENTS | 6ER-019 |
| PRESCRIPTION AND USE OF LIPOSOMAL AMPHOTERICIN B DURING THE COVID-19 PANDEMIC | 6ER-020 |
| RETROSPECTIVE OF DRUG INNOVATION DURING THE SARS-Cov2 PANDEMIC : DEVELOPMENT OF A GAME-BASED TRAINING | 6ER-021 |
| CLINICAL IMPACT OF THE USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF COVID-19 IN INTERMEDIATE RESPIRATORY CARE UNITS | 6ER-022 |
| THE ASSOCIATION BETWEEN NADROPARIN DOSE AND ANTI-XA LEVELS IN RENAL INSUFFICIENCY: A MULTICENTER STUDY | 6ER-023 | |
| COMPARISON OF REDUCTIONS IN MONTHLY MIGRAINE DAYS BETWEEN NEW SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS (GEPANTS) AND MONOCLONAL ANTIBODIES TARGETING CGRP/CGRP RECEPTOR | 6ER-024 | |
| EFECTIVENESS AND SAFETY OF 20% AUTOLOGOUS SERUM EYE DROPS IN PATIENTS WITH CORNEAL SURFACE PATHOLOGIES | 6ER-025 | |
| SPECTRUM OF HEART FAILURE IN 16 SUB-SAHARAN AFRICAN COUNTRIES: TREATMENTS AND IN-HOSPITAL OUTCOME | 6ER-026 | |
| ASSESSMENT OF ATTITUDES AND PERCEIVED SKILLFULNESS OF PHARMACY STUDENTS IN CARING FOR UNDERSERVED POPULATIONS | 6ER-027 |
| ASSESSMENT OF SYMPTOMS AND SIGNS SEVERITY IN PSORIASIS PATIENTS | 6ER-028 |
| EYE DROPS OF INTERFERON ALPHA-2B TO TREAT OCULAR PATHOLOGIES | 6ER-029 |
| USING A PHARMACIST-LED ASTHMA SERVICE TO ASSESS THE CONCORDANCE BETWEEN PATIENT-REPORTED ICS ADHERENCE AND OBJECTIVE E-MONITORING OF ICS THERAPY | 6ER-030 |
| KWOLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION IN PEOPLE LIVING WITH HIV IN ANTIRETROVIRAL THERAPY | 6ER-031 |
| HOW CAN DUTCH UNIVERSITY HOSPITALS CONTRIBUTE TO AFFORDABLE MEDICINES AND COST CONTAINMENT OF TOTAL HOSPITAL DRUG EXPENDITURE: A DELPHI STUDY | 6ER-032 |
| PEMBROLIZUMAB AND ATEZOLIZUMAB AS POSSIBLE EQUIVALENT FIRST-LINE THERAPEUTIC ALTERNATIVES IN PDL1-EXPRESSING TRIPLE-NEGATIVE BREAST CANCER | 6ER-033 |
| USE OF CLOSED SYSTEM TRANSFER DEVICES WITH INVESTIGATIONAL DRUG PRODUCTS | 6ER-034 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| The appropriateness review FOR HOSPITAL MEDICATION ORDERS IN FINLAND | NP-01 |
| Usage of falls-risk-increasing drugs among patients with high risk of falls in the nursing ward of Tartu University Hospital | NP-02 |
| From basic to advanced computerized IV to oral switch for paracetamol and antibiotics: an interrupted time series analysis | NP-03 |
| MONITORING OF GRAM-NEGATIVE (G-) MULTIDRUG RESISTANT (MDR) PATIENS AT POLICLINICO UMBERTO I OF ROME WITH THE AIM OF CONTROLLING HEALTHCARE ASSOCIATED INFECTIONS, COUNTERACTING THE PHENOMENON OF ANTIMICROBIAL RESISTANCE AND… | NP-04 |
| INTRAVESICAL EPIRUBICIN ADMINISTRATION IN A UROLOGY DEPARTMENT | NP-05 |
| RELATIONSHIP BETWEEN SERUM VEDOLIZUMAB CONCENTRATIONS IN INDUCTION PHASE AND EARLY AND SUSTAINED RESPONSE ON PATIENTS WITH ULCERATIVE COLITIS | NP-06 |
| Integrating pharmacogenetic information into medication reviews – an interprofessional challenge | NP-08 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS | 1ISG-003 |
| ASSESSMENT OF CUSTOMER SATISFACTION WITH HOSPITAL PHARMACY SERVICES IN ESTONIA | 1ISG-004 |
| ESTIMATION OF DRUG COST AVOIDANCE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER | 1ISG-006 | |
| ECONOMIC SAVINGS FROM WEIGHT-BASED DOSING OF PEMBROLIZUMAB: WHAT IS THE IMPACT IN A TERTIARY HOSPITAL? | 1ISG-007 |
| OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA | 1ISG-008 |
| IMPLEMENTATION AND EVALUATION OF TELEPHARMACY DURING COVID-19 PANDEMIC IN AN ACADEMIC MEDICAL CITY : PAVING THE WAY FOR TELEPHARMACY | 1ISG-009 |
| ECONOMIC EVALUATION OF DOSE BANDING IN INMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB | 1ISG-012 |
| Users’ expectations and opinions on a computerised physician order entry (CPOE) system before and after its implementation | 1ISG-013 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HOW CAN WE BEST MANAGE SUPPLY SHORTAGES OF EXCLUSIVELY HUMAN MOLECULES FOR SUBSTITUTION ? THE EXAMPLE OF IMMUNOGLOBULINS | 2SPD-001 |
| TELEPHARMACY IN ONCO-HEMATOLOGIC PATIENTS: A SEVEN MONTH EXPERIENCE | 2SPD-003 |
| SIGNIFICANT DISCONTINUATION RATES IN PATIENTS INITIATING OR SWITCHING FROM CT-P13: A RETROSPECTIVE COHORT STUDY IN A UNIVERSITY HOSPITAL | 2SPD-005 |
| DEVELOPMENT OF A PRIORITATION PROTOCOL FOR THE USE OF IMMUNOGLBULINS IN VIEW OF THE GLOBAL SUPPLY PROBLEM | 2SPD-006 |
| NETWORK META-ANALYSIS OF IMMUNOTHERAPIES IN UNTREATED ADVANCED OR METASTARIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA | 2SPD-008 |
| RIVAROXABAN VERSUS ENOXAPARIN IN TRAUMATOLOGY: A PHARMACO-ECONOMIC STUDY | 2SPD-011 |
| IMMUNOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY IN REAL LIFE | 2SPD-012 |
| INCREASE IN HEALTHCARE COSTS WITH FIDAXOMICIN INSTEAD OF VANCOMYCINFOR CLOSTRIDIUM DIFFICLIE TREATMENT | 2SPD-013 |
| APPROPRIATENESS OF USTEKINUMAB THERAPY PRESCRIPTION AND REAL-LIFE CONDITION USE IN CROHN’S DISEASE | 2SPD-014 |
| LOGISTICS AUTOMATION AND PROCESS REENGINEERING: IMPACT ON INTER-HOSPITAL LOAN MANAGEMENT | 2SPD-015 |
| APPLICATION OF FAILURE MODE AND EFFECT ANALYSIS TO IMPROVE CYTOSTATIC DRUG STOCK MANAGEMENT | 2SPD-016 |
| ANALYSIS AND MONITORING OF THE WORKLOAD AND FINANCIAL BURDEN OF DISPENSING HIGHCOST MEDICINES WITH ITEM-BASED REIMBURSEMENT IN HUNGARIAN HOSPITAL PHARMACIES | 2SPD-017 |
| INVENTORY MANAGEMENT DURING THE COVID-19 PANDEMIC: OUR CASE FOR THE THIRD WAVE | 2SPD-019 |
| INTRODUCTION OF A NEW PRESENTATION OF HYALURONIC ACID FOR INTRAARTICULAR INFILTRATION | 2SPD-020 |
| ASSESSMENT OF FORECAST ACCURACY FOR CONTRACTUAL PURCHASES | 2SPD-021 |
| RELEVANCE OF UNIVERSAL KIT COMPOSITION AND ECONOMIC VALUE OF NON-USED MEDICAL DEVICES | 2SPD-022 |
| CHOOSING THE RIGHT FORECASTING METHOD: WHICH PRACTICE IS BEST FOR OUR CASE? | 2SPD-023 |
| RETROSPECTIVE EVALUATION OF THE SAFETY STOCK LEVEL DETERMINED FOR THE PANDEMIC IN TERMS OF SERVICE LEVEL | 2SPD-024 |
| ACALABRUTINIB + OBINUTUZUMAB VERSUS IBRUTINIB + OBINUTUZUMAB AS FIRST LINEIN CHRONIC LYMPHOCYTIC LEUKEMIA | 2SPD-025 |
| Medication storage temperatures inside emergency vehicles A pilot study in a temperate climate country | 2SPD-027 |
| STABILITY OF NIVOLUMAB SOLUTIONS AFTER TRANSPORT THROUGH PNEUMATIC TUBE SYSTEMS | 2SPD-029 |
| How to assess the impact of medicines shortages in the European Union? | 2SPD-030 |
| THE ECONOMIC IMPACT OF ANTIMICROBIAL SHORTAGES IN ANTIMICROBIAL STEWARDSHIP PROGRAMMES | 2SPD-031 |
| DRUG EXCHANGE NETWORK | 2SPD-032 |
| Making the case for Prefilled Syringes (PFS): Development and utilisation of an economic model | 2SPD-033 |
| METHODOLOGICAL ANALYSIS OF PHARMACOECONOMIC STUDIES IN CAR-T: A SYSTEMATIC REVIEW | 2SPD-034 |
| COST MINIMISATION ANALYSIS IN CLINICAL PRACTICE OF RIBOCICLIB VERSUS PALBOCICLIB IN THE TREATMENT OF METASTASTIC BREAST CANCER | 2SPD-035 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CHOLESTEROL 2%/SIMVASTATIN 1% OINTMENT FOR THE TREATMENT OF POROKERATOSIS PTYCHOTROPICA: A CASE REPORT | 3PC-001 |
| GLASS AMPOULES AND DRUG FILTRATION: ¿HOW MUCH DO WE KNOW ABOUT IT? | 3PC-002 |
| SODIUM THIOSULPHATE GEL 25% FOR THE TREATMENT OF CALCIPHYLAXIS | 3PC-003 | |
| INSULIN EYE DROP FORMULATION: EFFECTIVENESS, SAFETY AND PATIENT SATISFACTION | 3PC-004 |
| SELECTION OF AN OSMOLARITY VALIDATION MODEL FOR NOMINATIVE PARENTERAL NUTRITION | 3PC-005 |
| EVALUATION OF PARENTERAL NUTRITION COMPOUNDING THROUGH A CHECKLIST | 3PC-006 |
| TIMES AND ERRORS FOR DISPENSING NARCOTICS DRUGS IN AUTOMATED SYSTEM VERSUS MANUAL SYSTEM | 3PC-008 |
| STANOZOLOL RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) QUANTIFICATION METHOD FOR QUALITY CONTROL | 3PC-009 |
| Assessment of Chemfort (OnGuard, US) Syringe Adaptor Lock Fitted With Luer Lock Syringes to Container Integrity Standards (NHS, UK) Supporting Dose Banding of Cytotoxic Drugs | 3PC-010 |
| STUDY OF THE CONTAINERCONTENT INTERACTION BETWEEN ETOPOPHOS POLYVINYL CHLORIDE (PVC) PERFUSION | 3PC-011 |
| IMPACT OF PRELIMINARY WIPING OF EQUIPMENT INTRODUCED INTO A CLEANROOM ON THE CONTROL OF THE ENVIRONMENT | 3PC-012 |
| PHARMACEUTICAL COMPOUNDING IN PAEDIATRIC PATCH TESTING: ARE WE SURE ABOUT THE ACTUAL ACTIVE INGREDIENT CONCENTRATION? | 3PC-013 |
| EVALUATION OF THE MICROBIOLOGICAL QUALITY OF NONSTERILE DRUGS PREPARED IN A HOSPITAL PHARMACY | 3PC-014 |
| VANCOMYCIN EYE DROPS AT 50 MG/ML : PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS | 3PC-016 |
| Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days | 3PC-017 |
| COMPATIBILITY AND 30-DAY STABILITY OF FOUR INTRAVENOUS MIXTURES FOR MULTIMODAL ANALGESIA | 3PC-018 |
| EVALUATION OF THE IMPACT OF MACHINE-AIDED DEBLISTERING IN UNIT DOSE BLISTER PRODUCTION ON THE FUNCTIONALITY OF TABLET COATING | 3PC-019 |
| CHEMICAL STABILITY AND PHYSICAL COMPATIBILITY OF INSULIN EYE DROPS USED IN CLINICAL PRACTICE | 3PC-020 |
| DESIGN AND ELABORATION OF METRONIDAZOLE 1% TOPICAL SOLUTION FOR TREATMENT OF ULCERS INFECTED BY ANAEROBIC BACTERIA | 3PC-021 |
| PH STABILITY OF TETRACAINE SOLUTIONS FOR SURFACE ANAESTHESIA | 3PC-022 | |
| Investigation of Leachable Compounds In water for injection used in hospital pharmacy | 3PC-023 |
| IMPACT OF PH MODIFICATION ON THE AGGREGATION OF NIVOLUMAB (OPDIVO) IN CLINICAL SOLUTIONS AT 1 AND 5 MG/ML MEASURED BY DYNAMIC LIGHT SCATTERING (DLS) AND SIZEEXCLUSION HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-DIODE ARRAY DETECTION (SE/HPLC-DAD) | 3PC-024 | |
| Rainer Trittler, Brigitte Altmann, Manuel Garcia-Käufer, Richard Gminski, Martin J. Hug | 3PC-026 |
| DIGITALIZATION SUPPORT SYSTEM FOR INTRAVENOUS MIXTURES ELABORATION IN A BIOLOGICAL SAFETY CABINET | 3PC-027 |
| PHARMACEUTICAL INTERVENTIONS IN PAEDIATRIC PARENTERAL NUTRITION | 3PC-028 |
| STUDY OF PSMA11-68GA ADSORPTION ON MEDICAL DEVICES USED FOR RADIOSYNTHESIS AND MEDIA FILL TEST | 3PC-029 |
| Different substrates for orodispersible films: You have the choice! | 3PC-030 |
| PHYSICOCHEMICAL STABILITY OF helen.linxweiler@unimedizin-mainz.de DILUTED ‘THIOTEPA RIEMSER’ INFUSION SOLUTIONS IN PREFILLED 5% GLUCOSE INFUSION BAGS | 3PC-031 |
| Optimising Analgosedation in the Intensive Care Unit during the SARS-COV-2 Pandemic | 3PC-032 |
| Y-site Compatibility of Intravenous Nefopam with Medications Commonly Used in Intensive Care Units | 3PC-033 |
| DEVELOPMENT AND VALIDATION OF A METHOD FOR THE DETERMINATION OF VANCOMYCIN EYE DROPS BY ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRY | 3PC-034 |
| Minimising Waste In Oncology | 3PC-035 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| COVID-19 HOSPITAL VACCINATION CENTER: PATIENT AND NURSE SATISFACTION | 4CPS-002 |
| OUTPATIENT-REPORTED EXPERIENCE IN HOSPITAL PHARMACY AMBULATORY CARE DURING THE COVID19 PANDEMIC | 4CPS-003 | |
| IMPACT OF THE SARS-COV PANDEMIC ON THE TRAINING OF HOSPITAL PHARMACY RESIDENTS | 4CPS-004 |
| Evaluating pharmaceutical logistics automated technologies in the hospital setting: a Health Technology Assessment (HTA) approach | 4CPS-005 | |
| EVALUATION STUDY OF THE CHAGE IN ADMINISTRATION TIMING OF FIXED COMBINATION: NETUPITANT AND PALONOSETRON IN ONCOHEMATOLOGIC PATIENTS WITH HIGH DOSES OF CARBOPLATIN | 4CPS-006 |
| The role of the pharmacist in the management of Intravenous fluids & electrolytes in adult patients | 4CPS-008 |
| ASSESSMENT OF KNOWLEDGE, ATTITUDES AND PRACTICES REGARDING ANTIBIOTIC RECONSTITUTION AMONG HEALTHCARE PROFESSIONALS IN 12 SOUTHEASTERN EUROPEAN HOSPITALS: A MULTICENTRE CROSS-SECTIONAL STUDY | 4CPS-011 |
| MERGING THE MEDICATION RECONCILIATION AND THE HOSPITALIZATION REPORT TO FORM THE LIAISON LETTER IN A DEPARTMENT OF OTOLARYNGOLOGY | 4CPS-013 |
| CLINICAL RELEVANCE OF PHARMACISTS’ INTERVENTIONS IN THE ACUTE WARD | 4CPS-014 |
| SATISFACTION AND INDIRECT IMPACT OF AN OUTPATIENTS’ TELEPHARMACY PROGRAMME | 4CPS-015 |
| Factors influencing the attitudes and opinions of Czech physicians and citizens toward influenza vaccination in Czech pharmacies | 4CPS-016 |
| THE DECISION-MAKING PROCESS IN HEALTH POLICY IMPACTS CLINICAL PRACTICES: A QUALITATIVE STUDY | 4CPS-017 |
| Perceptions of young people regarding pharmaceutical care provided by pharmacists | 4CPS-018 |
| REACTOGENICITY OF THE BNT162B2 (PFIZERBIONTECH) MRNA VACCINE AGAINST COVID-19 IN TERTIARY HOSPITAL WORKERS | 4CPS-019 |
| COMPARISON OF DEPRESCRIBING STRATEGIES: LESSCHRON CRITERIA VERSUS THE GOOD PALLIATIVEGERIATRIC ALGORITHM IN A NURSING HOME | 4CPS-020 |
| POST-STERNOTOMY MEDIASTINITIS: A MEDICOECONOMIC STUDY COMPARING TWO PREVENTIVE STRATEGIES IN CARDIAC SURGERY | 4CPS-021 |
| To vaccinate or not to vaccinate : Impact of a public health action on vaccine hesitancy | 4CPS-022 |
| INDIVIDUALIZATION OF TREATMENT WITH TOCILIZUMAB IN GRAVES ORBITHOPATHY | 4CPS-023 |
| PHARMACEUTICAL INTERVIEWS DEDICATED TO VACCINATION: WHAT ROLE FOR THE CLINICAL PHARMACIST IN MONITORING THE VACCINATION COVERAGE OF AT-RISK PATIENTS ? | 4CPS-024 |
| Adequacy of hepatitis B reactivation prophylaxis in patients treated with rituximab | 4CPS-025 |
| OPTIMISATION OF DIRECT ORAL ANTICOAGULANT TREATMENTS: ANALYSIS OF PRESCRIPTIONS AND PHARMACEUTICAL INTERVIEWS (PI) | 4CPS-026 |
| DESENSITISATION PROTOCOL FOR LIPOSOMAL AMPHOTHERICIN B: A CASE REPORT | 4CPS-027 |
| EFFECTIVENESS AND SAFETY OF CENOBAMATE: EXPERIENCE IN A THIRD-LEVEL HOSPITAL | 4CPS-028 |
| PEMBROLIZUMAB, NIVOLUMAB AND ATEZOLIZUMAB: INCREMENTAL COST-EFFECTIVENESS RATIO | 4CPS-029 |
| SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT IN PREVENTING VENTILATOR-ASSOCIATED PNEUMONIA IN AN INTENSIVE CARE UNIT | 4CPS-030 |
| EFFICACY AND SAFETY OF HIGH-DOSE TWICE WEEKLY SEBELIPASE ALFA IN SEVERE-ONSET WOLMAN DISEASE: A CASE REPORT | 4CPS-031 |
| Medication errors in prescribing antithrombotics for patients admitted to the hospital in the weekend. A pilot-study | 4CPS-032 |
| Development and evaluation of an amitriptyline topical form for the treatment of cancer-related neuropathy | 4CPS-033 |
| DEPRESCRIBING ORAL IRON IN ELDERLY PATIENTS: EXPERIENCE FROM A NURSING HOME ASSOCIATED WITH A THIRD LEVEL HOSPITAL | 4CPS-034 |
| PHARMACIST-LED MEDICATION RECONCILIATION AT DISCHARGE SHALL NOT BE SUFFICIENT TO REDUCE UNPLANNED HEALTHCARE UTILIZATION: HEAR THE PATIENT EXPERIENCE! | 4CPS-035 |
| IS OUR PROTOCOL FOR THE USE OF TOCILIZUMAB IN COVID PATIENTS ADEQUATE? | 4CPS-036 |
| The 5P-study: Patient and healthcare Provider Perspectives on Potential Preventability of hospital admission for acute exacerbations of Chronic Obstructive Pulmonary Disease | 4CPS-037 |
| Intrapleural colistin for pleural empyema caused by extensively drug-resistant Pseudomonas aeruginosa: A case report | 4CPS-038 |
| EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE TREATMENT OF MIGRAINE | 4CPS-039 |
| INTERINDIVIDUAL VARIABILITY OF LINEZOLID IN CRITICALLY ILL PATIENTS | 4CPS-040 |
| SACUBITRIL/ VALSARTAN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE | 4CPS-041 |
| PHARMACOKINETIC MONITORING OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS | 4CPS-042 |
| EFFECTIVENESS, SAFETY AND ADHERENCE OF GUSELKUMAB IN MODERATE TO SEVERE PSORIASIS | 4CPS-043 |
| PATIENTS’ PERCEPTIONS OF HEALTHCARE ASSOCIATED-INFECTIONS AND USE OF ANTIBIOTICS IN SURGICAL CONTEXT | 4CPS-044 |
| HEALTHCARE EVALUATION OF HOSPITAL PHARMACY SERVICES BY PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A MULTICENTRE STUDY | 4CPS-045 |
| CARDIOVASCULAR RISK OF HIV PATIENTS | 4CPS-046 |
| IMPROVING SAFETY IN THE USE OF MONOCLONAL ANTIBODIES IN PATIENTS WITH MIGRAINE: AN INTERDISCIPLINARY STUDY | 4CPS-048 |
| MANAGEMENT OF PAN-RESISTANT STENOTROPHOMONAS MALTOPHILIA | 4CPS-049 |
| USE OF GALCANEZUMAB IN PATIENTS WITH MIGRAINE IN A TERTIARY HOSPITAL: HEALTH RESULTS | 4CPS-050 |
| PHARMACOKINETICS ALTERATIONS IN TWO CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL | 4CPS-051 |
| GALCANEZUMAB IN PROPHYLAXIS OF REFRACTORY HIGH-FREQUENCY EPISODIC MIGRAINE IN CLINICAL PRACTICE | 4CPS-053 |
| ANALYSIS OF REAL-WORLD DATA FOR ERENUMAB UTILISATION AND PATIENT-RELATED OUTCOMES | 4CPS-054 |
| SUCCESSFUL SOFOSBUVIR/VELPATASVIR TREATMENT IN A HEPATITIS C PATIENT RECEIVING CHRONIC ANTIEPILEPTIC THERAPY: A CASE REPORT | 4CPS-055 |
| POLYPHARMACY AND POTENTIALLY INAPPROPIATE MEDICATIONS IN OLDER PEOPLE LIVING WITH HIV | 4CPS-056 |
| DISCONTINUATION OF PROTON PUMP INHIBITORS DURING HOSPITALISATION: A RANDOMISED CONTROLLED TRIAL | 4CPS-057 |
| REAL-WORLD EXPERIENCE WITH PROLONGED TEDIZOLID TREATMENT: EFFECTIVENESS AND SAFETY | 4CPS-058 |
| CASE REPORT OF SEVERE HYPERBILIRRUBINEMIA IN A PATIENT CARRYING POLYMORPHISMS IN CES1P1, CDA, SLC22A7 AND ENOSF1 TREATED WITH FLUOROPYRIMIDINES | 4CPS-059 |
| INFLUENCE OF GENETIC POLYMORPHISMS ON THE RESPONSE AND TOXICITY OF CAPECITABINE THERAPY IN PATIENTS WITH BREAST CANCER | 4CPS-060 |
| IMPACT OF PHARMACOGENETICS ON THE TOXICITY OF HIGH-DOSE METHOTREXATE IN A PAEDIATRIC POPULATION | 4CPS-061 |
| RITUXIMAB PHARMACOKINETICS CHARACTERIZATION IN PLASMA AND URINE IN A PATIENT WITH NEPHOTIC SYNDROME | 4CPS-062 |
| ERENUMAB VERSUS GALCANEZUMAB, EFFECTIVENESS IN REAL-LIFE EXPERIENCE | 4CPS-063 |
| QUALITY OF LIFE STUDY: GALCANEZUMAB IN THE TREATMENT OF MIGRAINE | 4CPS-064 |
| SAFETY OF BEVACIZUMAB BIOSIMILAR IN CLINICAL PRACTICE IN NEW AND SWITCHED TREATMENTS | 4CPS-065 |
| PHARMACIST INTERVENTIONS IN SEQUENTIAL ANTIMICROBIAL THERAPY INSIDE AN ANTIMICROBIAL STEWARDSHIP PROGRAMME (ASP) | 4CPS-067 |
| IMPACT OF PHARMACOGENETICS IN SEVERE ALLERGIC ASTHMA PATIENTS TREATED WITH OMALIZUMAB | 4CPS-068 |
| INFLUENCE OF GENETIC VARIANTS IN THE VITAMIN D HYDROXYLATION PATHWAY AS A RESPONSE FACTOR TO PLATINUM-BASED CHEMOTHERAPY IN NONSMALL CELL LUNG CANCER | 4CPS-069 |
| STUDY OF CARDIOVASCULAR TOXICITY ASSOCIATED WITH IBRUTINIB TREATMENT | 4CPS-070 |
| CYP27B1 GENETIC VARIANTS’ INFLUENCE IN NEPHROTOXICITY DUE TO PLATINUMBASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER | 4CPS-071 |
| BEZLOTOXUMAB FOR THE PREVENTION OF CLOSTRIDIOIDES DIFFICILE RECURRENCE: STUDY IN THE REAL WORLD | 4CPS-072 |
| DESENSITISATION TO IBRUTINIB IN A PATIENT WITH SERIOUS LATE REACTION: A CASE REPORT | 4CPS-073 |
| EVALUATION OF THE COST OF MANAGING ADVERSE EVENTS RELATED TO CYTOTOXIC DRUGS IN CHILDREN | 4CPS-075 |
| GENETICVARIANTSAFFECTINGBISOPROLOL RESPONSEINCARDIOVASCULARDISEASES | 4CPS-077 |
| MOTIVATIONAL INTERVIEWING IN CLINICAL PHARMACIST INTERVENTIONS: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS | 4CPS-078 |
| ANALYSIS OF CURRENT RESEARCH IN WEAREABLES : TOWARD A MORE DIGITAL HEALTH | 4CPS-079 |
| EFFICACY AND SAFETY OF THE CONTINUOUS INFUSION OF VANCOMYCIN IN PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW | 4CPS-080 | |
| SUBCUTANEOUS FUROSEMIDE INFUSION USING ELASTOMERIC INFUSION PUMPS IN A TERTIARY HOSPITAL | 4CPS-081 |
| ENVIRONMENTAL POLLUTION WITH QUINOLONES IN SPAIN | 4CPS-082 | |
| Cost-effectiveness analysis of adalimumab and its clinical alternatives in immunemediated inflammatory diseases in Spain | 4CPS-083 |
| STABILITY OF MEROPENEM AND PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION FOR HOME ADMINISTRATION | 4CPS-085 |
| Inhaled sedation with halogenated agents in the Intensive Care Unit: A literature mini-review | 4CPS-086 |
| THE USE OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN IMMUNE CHECKPOINT INHIBITOR THERAPY FOR CANCER IN CLINICAL PRACTICE: A SYSTEMATIC REVIEW | 4CPS-087 |
| INDIRECT COMPARISON OF NIVOLUMAB, PEMBROLIZUMAB AND CAMRELIZUMAB IN PATIENTS WITH UNRESECTABLE AND/OR ADVANCED SQUAMOUS CELL CARCINOMA OF ESOPHAGUS IN SECOND-LINE SETTING | 4CPS-088 |
| RISANKIZUMAB IN REFRACTORY HIDRADENITIS SUPPURATIVA TO ANTI-TNFa A CASE REPORT | 4CPS-089 |
| EFFICACY AND SAFETY OF PANGENOTYPS TREATMENTS IN HCV PATIENTS | 4CPS-090 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO HIGH-RISK-DRUGS IN THE EMERGENCY DEPARTMENT | 4CPS-091 |
| BIOLOGICAL THERAPIES FOR THE TREATMENT OF PSORIASIS: EFFECTIVENESS, SAFETY AND ECONOMIC IMPACT OF OPTIMISATION STRATEGIES | 4CPS-092 |
| DRUG-INDUCED SOMNOLENCE IN FRAILTY PATIENTS ATTENDED IN AN EMERGENCY DEPARTMENT | 4CPS-093 |
| APPROPRIATENESS OF EMPIRICAL ANTIBIOTIC THERAPY FOR CERVICITIS AND URETHRITIS PRESCRIBED AT THE EMERGENCY DEPARTMENT | 4CPS-095 |
| CLINICALLY RELEVANT DRUG-DRUG INTERACTION EVENTS IN PATIENTS WITH ABIRATERONE, ENZALUTAMIDE OR APALUTAMIDE TREATMENT | 4CPS-099 |
| INTRADIALYTIC PARENTERAL NUTRITION EFFECTS ON ALBUMIN LEVELS IN MALNOURISHED HAEMODIALYSIS PATIENTS | 4CPS-100 |
| BIOLOGIC AGENTS IN RHEUMATOLOGICAL DISEASES: IMPACT OF ‘TREAT TO TARGET’ IN CLINICAL PRACTICE | 4CPS-101 |
| Drug-related hospital admissions in older adults: comparison of the Naranjo algorithm and an adjusted version of the Kramer algorithm | 4CPS-102 |
| IMPROVING MEDICATION RECONCILIATION REPORTS: EVALUATION THROUGH QUALITY AUDITS | 4CPS-103 |
| PERSISTENCE WITH DISEASE-MODIFYING THERAPY IN MULTIPLE SCLEROSIS PATIENTS | 4CPS-104 |
| CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH HIV INFECTION WITH ANTIRETROVIRAL TREATMENT | 4CPS-105 |
| SAFETY OF ADJUVANT TRASTUZUMAB EMTANSINA FOR RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER | 4CPS-106 |
| IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA: EFFECTIVENESS AND SAFETY IN CLINICAL PRACTICE | 4CPS-107 |
| BIOMARKERS EVOLUTION IN PATIENTS WITH SARSCOV-2 PNEUMONIA TREATED WITH BARICITINIB | 4CPS-108 |
| DESCRIPTIVE ANALYSIS OF PATIENTS CO-INFECTED WITH HIV AND HEPATITIS C VIRUS (HCV) TREATED WITH ANTIVIRALS FOR HCV AND ITS EFFICACY IN A PRISON FROM 2002 TO 2020 | 4CPS-109 |
| INITIAL EXPERIENCE OF THE USE OF CEFIDEROCOL FOR MULTIDRUG RESISTANT INFECTIONS IN A UNIVERSITY HOSPITAL | 4CPS-110 |
| RUXOLITINIB FOR REFRACTORY GRAFT-VERSUS-HOST DISEASE IN PAEDIATRIC PATIENTS | 4CPS-111 |
| VORICONAZOLE THERAPEUTIC DRUG MONITORING: RELATIONSHIP WITH LIVER TOXICITY | 4CPS-112 |
| REAL-LIFE DATA ON THE USE OF ABIRATERONE/ ENZALUTAMIDE IN CASTRATION-RESISTANT PROSTATE CANCER | 4CPS-113 |
| INTEGRATION OF A PHARMACIST INTO A GERIATRIC DEPARTMENT | 4CPS-114 |
| NABPACLITAXEL PLUS GEMCITABINE VERSUS FOLFIRINOX IN METASTATIC PANCREATIC CANCER: REAL WORLD DATA EXPERIENCE | 4CPS-115 |
| ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE | 4CPS-116 | |
| APPROPRIATENESS OF ANTIBIOTIC PRESCRIPTIONS IN A LONG-TERM CARE FACILITY | 4CPS-117 |
| REAL-WORLD EXPERIENCE WITH PCSK9 INHIBITORS PROTOCOL FOR HYPERCHOLESTEROLEMIA | 4CPS-119 |
| ADVERSE DRUG REACTION (ADR) NOTICATIONS’ IMPACT ON PATIENTS FOLLOWED AT AN AMBULATORY CARE PHARMACY UNIT | 4CPS-120 |
| CLINICAL PHARMACIST INTERVENTIONS IN THE EMERGENCY DEPARTMENT AND THEIR IMPACT ON PREVENTABLE ADVERSE DRUG EVENTS | 4CPS-121 |
| OVERVIEW OF THE IMPACT OF PENICILLIN ALLERGY LABELS ON ANTIBIOTIC USE IN THE EMERGENCY DEPARTMENT | 4CPS-122 |
| PERFORMANCE OF MOST COMMONLY USED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN CRITICALLY ILL PATIENTS | 4CPS-123 |
| COST OPTIMISATION PLAN IN IMMUNOTHERAPY | 4CPS-124 |
| SINGLE-AGENT BEVACIZUMAB IN OFF-LABEL TREATMENT OF RECURRENT OR REFRACTORY GLIOMA | 4CPS-125 |
| REAL-WORLD PERSISTENCE WITH FAMPRIDINE AMONG MULTIPLE SCLEROSIS PATIENTS | 4CPS-126 |
| THERAPEUTIC DRUG MONITORING WITH BIOLOGICAL DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | 4CPS-127 |
| ADJUST DOSES OF ANTIBIOTICS IN PATIENTS WITH RENAL INSUFFICIENCY | 4CPS-129 |
| Analysis of the Different Cardioversion Strategies in the Emergency Department in a Secondary Hospital | 4CPS-130 |
| SWITCHING AND DISCONTINUATION OF DISEASE-MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS: EXPERIENCE IN AN UNIVERSITY HOSPITAL | 4CPS-131 |
| ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT | 4CPS-133 |
| OPTIMIZATION OF DENOSUMAB PRESCRIPTION IN OSTEOPOROSIS PATIENTS | 4CPS-134 |
| PERSISTENCE OF FIRST-LINE BIOLOGICAL THERAPY IN PATIENTS WITH CROHN’S DISEASE | 4CPS-136 |
| Prospective analysis of clinical pharmacist interventions for QT drug-drug interactions alongside clinical decision support | 4CPS-137 |
| THERAPEUTIC DRUG MONITORING OF INTRAVENOUSBUSULFANINPAEDIATRICPATIENTS | 4CPS-138 |
| ANTIMICROBIAL STEWARDSHIP PROGRAM IN ONCOLOGY PATIENTS THROUGH A MULTIDISCIPLINARY TEAM | 4CPS-140 | |
| ASSESSMENT OF TEDIZOLID FOR USE IN GRAM-POSITIVE BACTERIAL INFECTIONS BACKGROUND: REAL WORLD DATA | 4CPS-141 |
| EFFECTIVENESS AND SAFETY OF ATEZOLIZUMAB IN METASTATIC UROTHELIAL CARCINOMA | 4CPS-142 |
| EFFECTIVENESS AND SAFETY OF BARICITINIB AND TOFACITINIB IN REUMATOID ARTHRITIS IN CLINICAL PRACTICE | 4CPS-145 |
| Development and validation of a rapid High Performance Liquid Cromatography method (HPLC) for the determination of triazoles in human plasma | 4CPS-146 |
| EXPERIENCE OF USE OF BIOLOGICAL ANTIMIGRAINE TREATMENTS IN CLINICAL PRACTICE | 4CPS-147 |
| Use of remdesivir in severe Sars-CoV-2 pneumonia in critically and non-critically ill patients | 4CPS-148 |
| HOSPITAL AT HOME COVID UNIT: MULTIDISCIPLINARY STRATEGIES | 4CPS-149 |
| Ability to assess acute kidney injury in patients admitted to hospital | 4CPS-150 |
| CHARACTERIZATION OF A COMPOUNDED VORICONAZOLE SOLUTION FOR NEBULIZATION AND DESCRIPTION OF ITS USE IN THE CLINICAL SETTING | 4CPS-152 |
| STEVENS–JOHNSON SYNDROME IN A PREGNANT WOMAN CAUSED BY PYRIMETHAMINE AND SULFADIZINE | 4CPS-154 |
| APPROPRIATENESS OF PHARMACOTHERAPY IN NURSING HOMES: PHARMACY AND GERIATRICS SERVICES COORDINATION PROJECT | 4CPS-155 |
| ANTIMICROBIAL STEWARDSHIP PROGRAMME IN A GENERAL SURGERY SERVICE: ROLE OF THE PHARMACIST | 4CPS-156 |
| IMPACT OF COVID-19 PANDEMIC ON PATIENTS TREATED WITH BIOLOGICAL DRUGS AND ENZYME REPLACEMENT THERAPIES | 4CPS-157 |
| BUDGETARY IMPACT OF PCSK9I DOSES REGIMEN OPTIMISATION | 4CPS-161 |
| CYTOKINE RELEASE SYNDROME IN ONCOHAEMATOLOGICAL PATIENTS TREATED WITH TOCILIZUMAB | 4CPS-162 |
| EARLY EXPERIENCES IN SWITCHING BETWEEN MONOCLONAL ANTIBODIES IN CHRONIC MIGRAINE PREVENTIVE THERAPY | 4CPS-163 |
| DURABILITY OF ORAL DUAL ANTIRETROVIRAL THERAPY IN HIV PATIENTS | 4CPS-164 |
| HAS COVID AFFECTED THE TREATMENT OF ONCOLOGY PATIENTS?: A DESCRIPTIVE STUDY OF TREATMENTS FROM 2019 TO 2021 | 4CPS-165 |
| ASSOCIATION BETWEEN IMMUNE-RELATED EFFECTS AND EFFECTIVENESS OF FIRST-LINE PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER | 4CPS-166 |
| SODIUM AND MAGNESIUM ALTERATIONS IN THE CRITICAL PATIENT WITH SARS-CoV-2 AND PARENTERAL NUTRITION | 4CPS-167 |
| Review of new biomarkers that predict the pharmacokinetics of biologic drugs in inflammatory bowel disease | 4CPS-170 |
| EFFECT OF LIPIDIC COMPOSITION OF PARENTERAL NUTRITION ON THE DEVELOPMENT OF HYPERTRIGLYCERIDAEMIA AND CHOLESTASIS | 4CPS-171 |
| POSACONAZOL THERAPEUTIC DRUG MONITORING IN A PAEDIATRIC TERTIARY HOSPITAL | 4CPS-172 |
| PHARMACEUTICAL INTERVENTION IN BROAD-SPECTRUM ANTIBIOTIC PRESCRIPTION IN HOSPITALIZED PATIENTS | 4CPS-173 |
| EFFECTIVENESS OF OBETICOLIC ACID TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS E | 4CPS-174 | |
| MEDICATION REGIMEN COMPLEXITY INDEX AMONG SOLID ORGAN TRANSPLANT PATIENTS | 4CPS-175 |
| ORAL IVERMECTIN EFFECTIVENESS IN THE TREATMENT OF PERMETHRIN-RESISTANT SCABIES: A DESCRIPTIVE AND RETROSPECTIVE OBSERVATIONAL STUDY | 4CPS-176 |
| A QUALITATIVE STUDY ON PHARMACIST PRESCRIBING FOR PATIENTS WITH CHRONIC KIDNEY DISEASE | 4CPS-177 |
| THERAPEUTIC DRUG MONITORINGOF GENTAMICIN AFTER PRE-DIALYSIS ADMINISTRATION | 4CPS-178 |
| “Description and Follow-up of the Use of Emtricitabin/ Tenofovir for HIV Pre-Exposure Prophylaxis | 4CPS-179 |
| INCREASE IN THE PRESCRIPTION OF BENZODIAZEPINES IN THE CONTEXT OF THE SARSCOV-2 PANDEMIC | 4CPS-182 |
| Prevention of coronavirus contamination from the environment using an air-cleaning closed system drug-transfer device | 4CPS-183 |
| A toll for Hospital Pharmacist Interventions optimization | 4CPS-185 |
| 2020 ANTIMICROBIAL CONSUMPTION INDICATORS: ANALYSIS COMPARED WITH PREVIOUS YEARS | 4CPS-186 |
| Pharmacist-clinician Collaborative Study for Prospective Identification of Drug Interactions on HIV Patients | 4CPS-187 |
| TELEPHARMACY: A PILOT EXPERIENCE IN TIMES OF COVID-19 IN A TERTIARY HOSPITAL | 4CPS-190 |
| SWITCH TO BENRALIZUMAB FOR SEVERE EOSINOPHILIC ASTHMA | 4CPS-191 |
| IMPACT OF THE SARS-COV-2 PANDEMIC ON THE USE OF ANTIFUNGALS IN AN INTENSIVE CARE UNIT IN A THIRD-LEVEL HOSPITAL | 4CPS-192 |
| Selection of clinical rules for the screening of high-risk situations in paediatric medicine | 4CPS-193 |
| CLINICAL IMPACT OF A PHARMACIST-LED DISCHARGE MEDICATION REVIEW SERVICE: AN ANALYSIS OF PREVALENCE AND ACCEPTANCE OF INTERVENTIONS | 4CPS-194 |
| Medication-related readmissions: documentation and communication to the next healthcare providers and patients | 4CPS-195 |
| Evaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs | 4CPS-197 |
| THE IMPACT OF A PHARMACIST-LED MEDICATION REVIEW ON THE MEDICINE RISK SCORE: A NONRANDOMISED CONTROLLED STUDY | 4CPS-198 |
| EVALUATION OF FREMANEZUMAB RESPONSE IN MIGRAINE PROPHYLAXIS | 4CPS-199 |
| EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE PREVENTION OF MIGRAINE | 4CPS-200 |
| Audit on the prescription and administration of Parkinson’s Disease medication on admission to hospital | 4CPS-201 |
| OPTIMISATION OF SUBCUTANEOUS BIOLOGICAL THERAPIES IN RHEUMATIC AND DERMATOLOGICAL DISEASES | 4CPS-202 |
| COMPARISON OF PIRFENIDONE VERSUS NINTENDANIB IN IDIOPATHIC PULMONARY FIBROSIS | 4CPS-203 |
| AN EXPLORATION OF PATIENTS’ PERCEPTIONS OF COLORECTAL CANCER AND ITS MANAGEMENT: A QUALITATIVE STUDY AT INITIATION OF TREATMENT WITH CHEMOTHERAPY | 4CPS-204 |
| RIBOCICLIB AS FIRST LINE FOR METASTASIC BREAST CANCER: ANALISIS OF USE AND SECURITY | 4CPS-206 |
| IMPROVING THE SAFETY OF PHARMACOTHERAPY IN PAEDIATRIC HAEMATO-ONCOLOGY BY CLINICAL PHARMACY SERVICES | 4CPS-207 |
| Benefit of Medication Reviews by a Renal Pharmacist in the Setting of a Computerized Physician Order Entry System | 4CPS-209 |
| IMPACT OF THE ANTIBIOTIC THERAPY USED DURING THE SARS-COV-2 PANDEMIC ON THE INCIDENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION | 4CPS-210 |
| Reduction of flushing volume and incompatibilities by a clinical pharmacist in a paediatric intensive care unit | 4CPS-211 |
| INSTRUCTIONS GIVEN BY THE ANAESTHETIST ON THE MANAGEMENT OF CHRONIC TREATMENTS PREOPERATIVELY: WHAT DOES THE PATIENT REALLY UNDERSTAND AND RETAIN? AN OBSERVATIONAL STUDY | 4CPS-212 |
| A COMPARATIVE RISK ANALYSIS COMPARING THE CONVENTIONAL AND FULLY AUTOMATED MANAGEMENT OF CLINICAL TRIALS IN AN ONCOLOGY PHARMACY | 4CPS-213 |
| EXPERIENCE OF USE OF CANNABIDIOL IN PAEDIATRIC PATIENTS | 4CPS-214 |
| PERSISTENCE AND THERAPEUTIC ADHERENCE TO FIRST GENERATION JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS | 4CPS-215 |
| CLINICAL, ECONOMIC AND ORGANISATIONAL IMPACT OF PHARMACISTS’ INTERVENTIONS IN ONCOLOGICAL CARE PATIENTS | 4CPS-217 |
| EVALUATION OF THE IMPACT OF INCORPORATING A PHARMACIST INTO A HOSPITAL EMERGENCY DEPARTMENT | 4CPS-218 |
| POTENTIALLY INAPPROPRIATE MEDICINES IN OLDER PATIENTS | 4CPS-221 |
| ADHERENCE IN POLYMEDICATED ELDERLY PATIENTS ADMITTED TO A TRAUMA WARD | 4CPS-222 |
| ADHERENCE TO ABIRATERONE AND CORTICOID IN PATIENTS WITH PROSTATE CANCER | 4CPS-223 |
| IMPACT OF PROACTIVE MEDICATION RECONCILIATION PRIOR TO PRE-ANAESTHESIC CONSULTATION | 4CPS-224 |
| Integration of a clinical pharmacist in a therapeutic education team for diabetic patients: an initiative that is worth gold! | 4CPS-225 |
| THE ROLE OF THE CLINICAL PHARMACIST IN THE SCREENING OF CANDIDATES FOR ONCOHAEMATOLOGICAL CLINICAL TRIALS | 4CPS-226 |
| Feedback from a French region on the use of e – Therapeutic Patient Education during the health crisis: high-speed interviews! | 4CPS-227 |
| Implementation of an interprofessional pre-operative medication management program in cardiac surgery – a pre post quality improvement study | 4CPS-229 |
| ARE WE SUSTAINABLE? A BASELINE QUESTIONNAIRE REGARDING THE ENVIRONMENTAL IMPACT OF PHARMACY PRACTICE ACROSS THE COUNTRY | 4CPS-231 |
| Pharmacist-led medication review unveiled more medication-related problems in possibly medication-related hospitalisations than in unlikely medication-related hospitalisations in elderly patients | 4CPS-232 | |
| THERAPEUTIC SWITCH OF ANTIRETROVIRAL TREATMENTS: EFFICACY, TOLERABILITY AND REASON FOR CHANGE | 4CPS-233 |
| IMPACT OF AN INTENSIVE MONITORING PROGRAM ON METHOTREXATE ELIMINATION | 4CPS-234 |
| PROFILE OF USE OF PHARMACOTHERAPY IN PSORIASIS, BIOLOGICAL DRUGS AND BIOSIMILARS | 4CPS-235 |
| MEASURING ADHERENCE TO ANTIRETROVIRAL TREATMENT: CORRELATION AND CONCORDANCE BETWEEN TWO INDIRECT METHODS | 4CPS-237 |
| IMPACT OF KNOWLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION ON THE QUALIY OF LIFE OF PEOPLE LIVING WITH HIV | 4CPS-239 |
| DEVELOPMENT OF A 25% BENZYL BENZOATE LOTION FOR A CASE OF RESISTANT NORWEGIAN SCABIES | 4CPS-240 |
| Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Tenofovir alafenamide, Emtricitabine and Bictegravir in a Real-Life Cohort of HIV-Infected Adults | 4CPS-241 |
| HUMAN IMMUNODEFICIENCY VIRUS PRE-EXPOSURE PROPHYLAXIS: ANALYSIS, FOLLOW-UP AND PANDEMIC EFFECT | 4CPS-242 |
| INFLUENCE OF VENOVENOUS EXTRACORPOREAL MEMBRANE OXYGENATION ON THE PHARMACOKINETICS OF VANCOMYCIN IN ADULTS: CAN AN OPTIMAL PHARMACODYNAMIC TARGET BE ACHIEVED? | 4CPS-243 |
| CARDIOVASCULAR, RENAL AND BONE EVALUATION OF A HIV POPULATION OVER 60 YEARS OLD | 4CPS-244 |
| INAPPROPRIATE ANTIBIOTIC DOSAGE ADJUSTMENTS IN PATIENTS WITH RENAL IMPAIRMENT: A CROSS-SECTIONAL ANALYSIS | 4CPS-245 |
| MEDICATION-RELATED ADMISSION WAS MORE FREQUENT IN ELDERLY PATIENTS HOSPITALISED IN AN ORTHOPEDIC UNIT THAN IN AN EMERGENCY DEPARTMENT IN TWO FRENCH HOSPITALS | 4CPS-246 |
| EVALUATION OF THE CLINICAL IMPACT OF MEDICATION RECONCILIATION ON ADMISSION USING THE CLEO TOOL | 4CPS-247 |
| ELTROMBOPAG FOR TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA ASSOCIATED WITH COVID-19 VACCINE: A CASE REPORT | 4CPS-249 |
| HOME DELIVERY FOR OUTPATIENTS WITH IMMUNEMEDIATED DISEASES: EXPERIENCE AND PATIENT SATISFACTION | 4CPS-250 |
| INFLUENCE OF POLYPHARMACY AND COMORBIDITIES IN THE QUALITY OF LIFE OF PATIENTS WHO SUFFER HIP FRACTURE | 4CPS-251 |
| ORAL AND INTRAVENOUS IRON IN THE TREATMENT OF PERIOPERATIVE ANAEMIA | 4CPS-252 |
| DIFFERENCES BETWEEN PHARMACEUTICAL INTERVENTIONS PERFORMED ON ANTIMICROBIALS IN MEDICAL AND SURGICAL SERVICES | 4CPS-253 |
| EFFECTIVENESS AND SAFETY OF NINTEDANIB AND PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | 4CPS-257 |
| ACTIVATION, ADHERENCE AND HEALTH OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH BIOLOGICAL DRUGS | 4CPS-258 |
| ANALYSIS OF THE ANTICHOLINERGIC LOAD IN POLYMEDICATED ELDERLY PATIENTS WHO HAVE SUFFERED A FALL | 4CPS-259 |
| PERSISTENCE AND SAFETY OF CALCITONIN GENERELATED PEPTIDE INHIBITORS IN CHRONIC MIGRAINE | 4CPS-260 |
| EVALUATION OF DRY EYE SEVERITY AND THERAPEUTIC ADHERENCE OF PATIENTS ON AUTOLOGOUS SERUM EYE DROPS | 4CPS-262 |
| EVALUATION OF THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS TOCILIZUMAB | 4CPS-263 |
| ANALYSIS OF MEDICAL TREATMENT, RISK FACTORS AND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE NOSOCOMIAL DIARRHOEA | 4CPS-264 |
| CHRONIC COMPLEX PALLIATIVE PAEDIATRIC PATIENT AT-HOME CARE UNIT: PHARMACOTHERAPEUTIC PROFILE AND ANALYSIS OF SIALORRHEA TREATMENT | 4CPS-265 |
| Detection and follow-up of drug related problems for patients with cardiovascular disease: A study of the Medicine Start Service in hospital pharmacies | 4CPS-266 |
| Design, implementation, and evaluation of a medication counselling service provided by pharmacists using teach-back at hospital discharge | 4CPS-267 |
| ANALYSIS OF RECURRENCES AND RISK FACTORS IN INFECTION BY CLOSTRIDIUM DIFFICILE | 4CPS-269 |
| Investigating the Use of Patient Frailty to Guide Pharmacist-led Medication Review | 4CPS-270 |
| ADHERENCE TO MEPOLIZUMAB AND BENRALIZUMAB IN REAL CLINICAL PRACTICE | 4CPS-271 |
| INTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY DYSPHAGIA SCREENING TEAM IN AN INTERMEDIATE AND LONG STAY HOSPITAL | 4CPS-272 |
| IMPACT OF A SPECIALIST PHARMACIST ON HEPATOPANCREATICO-BILIARY (HPB) SURGICAL WARD ROUNDS AT A LARGE TERTIARY LIVER CENTRE | 4CPS-273 |
| Evaluation of pharmaceutical interventions documented by a pharmacy technician: Where do pharmacy technicians have the biggest impact to avoid drug-related problems? | 4CPS-274 |
| ASSOCIATION BETWEEN THE DEVELOPMENT OF IMMUNE-RELATED ADVERSE EVENTS AND THE EFFECTIVENESS OF IPILIMUMAB IN ADVANCED MELANOMA | ACPS-189 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ADVERSE EVENTS REPORTED AFTER ADMINISTRATION OF BNT162B2 AND MRNA-1273 COVID-19 VACCINES AMONG HEALTHCARE-WORKERS | 5PSQ-002 |
| DEVELOPMENT AND APPLICABILITY OF THE MEDHIPPRO-Q: A QUESTIONNAIRE ASSESSING MEDICAL DOCTORS’ EXPERIENCE WITH MEDICATION MANAGEMENT IN THE HIP FRACTURE PATIENT PATHWAY | 5PSQ-003 |
| ANALYSIS OF ADVERSE DRUG REACTIONS OF DISEASE -MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS | 5PSQ-004 |
| DOSING LOW MOLECULAR WEIGHT HEPARINS IN RENAL IMPAIRMENT: A NATIONWIDE SURVEY | 5PSQ-006 |
| ASSESSMENT OF PATIENTCONTROLLED ANALGESIA (PCA) PRACTICES IN A PUBLIC HOSPITAL | 5PSQ-008 |
| Patient Safety and Medication Safety Culture in a Hospital Pharmacy Department: A Mixed Methods Study | 5PSQ-009 |
| Identification of incorrect dosing of direct oral anticoagulants: an important intervention to improve patient safety | 5PSQ-010 |
| INTRAVENOUS POTASSIUM CHLORIDE: HOSPITALWIDE EVALUATION AND BENEFITS OF A VIDEO COURSE | 5PSQ-011 |
| ARE 12 MONTHS OF TREATMENT WITH MONOCLONAL ANTIBODIES SUFFICIENT FOR MIGRAINE ATTACK PREVENTION? | 5PSQ-012 |
| ANTINEOPLASTIC DRUGS AND THROMBOSIS: ANALYSIS OF A COHORT OF PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS | 5PSQ-013 |
| SAFETY AND TOLERANCE PROFILE OF NIVOLUMAB AND PEMBROLIZUMAB | 5PSQ-014 |
| ANTIBIOTIC DESENSITIZATION IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH POTENTIALLY ALLERGY-TRIGGERING MOLECULES | 5PSQ-015 |
| ACE INHIBITORS AND ARBs AS RISK FACTORS FOR COVID-19 INFECTION: FAKE NEWS OR EVIDENCE-BASED MEDICINE? | 5PSQ-016 |
| MAPPING OF PHARMACOLOGICAL RISK FACTORS AND COMORBIDITY IN PATIENTS WITH SEVERE COVID-19: A RETROSPECTIVE OBSERVATIONAL CASE-CONTROL STUDY | 5PSQ-017 |
| ANALYSIS OF THE USE OF FONDAPARINUX IN SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA | 5PSQ-018 |
| ASSESSMENT OF THE LEVEL OF KNOWLEDGE AND MOTIVATION IN A HOSPITAL CENTER STAFF FOR GETTING VACCINATED AGAINST SARS-CoV-2 | 5PSQ-019 |
| Patient´s and physician´s acceptance of a pharmacist-led intervention to reduce anticholinergic burden | 5PSQ-021 |
| DESENSITISATION PROTOCOL FOR ADALIMUMAB IN ARTHROPATHIC PSORIASIS: A CASE REPORT | 5PSQ-022 |
| Neutropenia as an indicator of trifluridinetipiracil efficacy in metastatic colorectal cancer | 5PSQ-023 |
| Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non small cell lung cancer (LANSCLC) | 5PSQ-024 |
| ANTICHOLINERGIC RISK IN OLDER PEOPLE LIVING WITH HIV | 5PSQ-025 |
| CLINICAL IMPORTANCE OF GENETIC VARIANTS IN CAPECITABINE BIOACTIVATION PATHWAY FOR THE PREDICTION OF RESPONSE IN COLORECTAL CANCER PATIENTS | 5PSQ-026 |
| Misuse assesment and risks of NSAIDs prescriptions for elderly patients in surgical units | 5PSQ-027 |
| ASSESSMENT OF SUSPICION OF ALLERGY TO CORONAVIRUS DISEASE 2019 VACCINE BY SKIN TESTING: RESULTS FROM A MONOCENTRIC COHORT | 5PSQ-028 |
| EVALUATION OF THE EFFICACY AND SAFETY OF ERENUMAB IN THE PROFILAXIS OF CHRONIC AND EPISODIC MIGRAINE | 5PSQ-029 |
| USE OF CEFIDEROCOL FOR MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII IN PATIENTS WITH SARS-COV-2: TWO CASE REPORTS | 5PSQ-030 |
| EVALUATION OF THE SAFETY AND TOLERANCE OF THE COMMERCIAL PRESENTATION OF CICLOSPORINE 0.1% COLLYRIUM | 5PSQ-031 |
| COMPLIANCE ANALYSIS OF PEDIATRIC ANTICANCER DRUG DOSING | 5PSQ-032 |
| Positive Impact of an Implemented Ward Pharmacist in a Multiprofessional Cancer Care Team in Germany | 5PSQ-033 |
| HOMOGENEITY OF OPINION EXPERT ON CLEO SCALE WHEN APPLIED TO 50 MODELED PHARMACEUTICAL INTERVENTIONS | 5PSQ-034 |
| INTENSIFICATING THERAPY WITH USTEKINUMAB IN NON-FIRST LINE CROHN’S DISEASE: CLINICAL EXPERIENCE, SAFETY AND EFFECTIVENESS IN THE “REAL WORLD” | 5PSQ-035 |
| IMPROVEMENT IN POSTOPERATIVE PAIN CONTROL BY THE INTRODUCTION OF ELASTOMETRIC LOCAL ANAESTHESIC LEVOBUPIVACAINE PUMPS IN PATIENTS UNDERGOING ARTHROPLASTY | 5PSQ-036 |
| DEPRESCRIBING INTERVENTIONS PERFORMED BY HOSPITAL PHARMACISTS REDUCE POTENTIALLY INAPPROPRIATE MEDICATION AT HOSPITAL DISCHARGE | 5PSQ-038 |
| PHARMACEUTICALS IN HOSPITAL WASTEWATER: A REVIEW | 5PSQ-040 |
| SAFETY AND EFFICACY OF HIGH DOSES OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FOLFIRI SCHEME BASED ON UGT1A1 GENOTYPE: A SYSTEMATIC REVIEW | 5PSQ-041 |
| TOXICITY OF REMDESIVIR AS TREATMENT OF NON-CRITICALLY ILL COVID-19 PATIENTS | 5PSQ-042 |
| BENZODIAZEPINES AND HYPNOTIC ANTIPSYCHOTICS IN A PSYCHIATRIC HOSPITAL | 5PSQ-043 |
| CONCILIATION AND PHARMACEUTICAL CARE ON DISCHARGE IN THE PSYCHIATRIC PATIENT | 5PSQ-044 |
| ANALYSIS OF ANTIPSYCHOTIC POLYTHERAPY IN A PSYCHIATRIC HOSPITAL | 5PSQ-045 |
| IMPACT OF THE COVID-19 PANDEMIC ON A NOTIFICATION AND LEARNING SYSTEM FOR PATIENT SAFETY IN A PSYCHIATRIC HOSPITAL | 5PSQ-046 |
| ANALYSIS OF THE UNIT DOSE SYSTEM OF MEDICATION DISTRIBUTION IN MENTAL HEALTH PHARMACY | 5PSQ-048 |
| STARTING POINT TO PROMOTE A POTENTIALLY INAPPROPRIATE PRESCRIPTION ASSESSMENT PROJECT | 5PSQ-049 |
| COST-EFFECTIVENESS OF A PRESURGICAL PHARMACEUTICAL CARE CONSULTATION | 5PSQ-051 |
| INFLUENCE OF AUGMENTED RENAL CLEARANCE IN THE LOWER INCIDENCE OF LINEZOLID-RELATED HAEMATOLOGICAL TOXICITY | 5PSQ-053 |
| ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH ANTIANGIOGENIC DRUGS: A RARE BUT SERIOUS COMPLICATION | 5PSQ-054 |
| LONG-TERM EFFECTIVENESS OF ADALIMUMAB IN SECONDLINE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS AND INFLUENCE OF THE FIRST-LINE TREATMENT | 5PSQ-055 |
| LOT QUALITY ASSURANCE SAMPLING (LQAS) OF A TELEPHARMACY PROGRAMME FROM THE HOSPITAL PHARMACY TO THE OUTPATIENT THROUGH THE COMMUNITY PHARMACY | 5PSQ-056 |
| ACTIVE PHARMACOVIGILANCE OF PATIROMER IN A CENTRAL HOSPITAL PHARMACEUTICAL CONSULTATION SETTING | 5PSQ-057 |
| EFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS | 5PSQ-058 |
| CHARACTERISATION OF MEDICATION ERRORS IN A PUBLIC HOSPITAL | 5PSQ-059 |
| LONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE | 5PSQ-060 |
| REAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS | 5PSQ-062 |
| PERSISTENCE OF TYROSINE KINASE INHIBITORS IN ADVANCED RENAL CELL CARCINOMA | 5PSQ-063 |
| INMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS | 5PSQ-065 |
| PATIENT OUTCOMES AFTER THE IMPLEMENTATION OF A HUMANISED ENHANCED RECOVERY AFTER KNEE JOINT REPLACEMENT SURGERY PROGRAMME | 5PSQ-066 | |
| ARE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS WELL TOLERATED BY OUR PATIENTS? A SAFETY STUDY IN REAL-WORD PRACTICE | 5PSQ-067 | |
| INCIDENCE OF POST-ARTESUNATE-INDUCED HAMOLYSIS AFTER SEVERE MALARIA | 5PSQ-068 |
| DOES THE TREATMENT LINE HAVE AN IMPACT ON THE TOXICITY PRODUCED BY OFF-LABEL ONCOLOGICAL TREATMENTS? | 5PSQ-069 |
| USEFULNESS OF PHARMACEUTICAL VALIDATION IN CHEMOTHERAPY PRESCRIPTION | 5PSQ-070 |
| REAL-WORLD RESULTS OF EFFECTIVENESS AND SECURITY OF ERENUMAB AND GALCANEZUMAB IN MIGRAINE PATIENTS | 5PSQ-071 |
| COVID-19 VACCINES: ADVERSE EVENTS AFTER A SECOND DOSE OF PFIZER OR ASTRAZENECA VACCINES IN HEALTHCARE WORKERS WHO RECEIVED A FIRST DOSE OF ASTRAZENECA VACCINE | 5PSQ-074 |
| EVALUATION AND MONITORING OF BIOCHEMICAL PARAMETERS IN PATIENTS ON PARENTERAL NUTRITION | 5PSQ-076 |
| BEVACIZUMAB BIOSIMILARUSE IN OPHTHALMOLOGY | 5PSQ-077 |
| THROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA | 5PSQ-078 |
| ERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING | 5PSQ-080 |
| IMPACT OF PHARMACY INTERVENTION ON REDUCTION OF MEDICATION-RELATED PROBLEMS IN ELDERLY PATIENTS IN A NURSING HOME | 5PSQ-081 |
| EFFECTIVENESS IN REAL LIFE OF BIOLOGICAL DRUGS USED IN MIGRAINE PROPHYLAXIS | 5PSQ-082 |
| USE OF ISAVUCONAZOLE IN PATIENTS WITH COVID19 IN AN INTENSIVE CARE UNIT | 5PSQ-083 |
| HOME DELIVERY AND TELEPHARMACY PROGRAMME: SATISFACTION OF PATIENTS | 5PSQ-084 |
| REAL-WORLD SAFETY AND TOLERABILITY OF PALBOCICLIB AS FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER | 5PSQ-085 |
| EVALUATION OF THE EFFECTIVENESS OF BEZLOTOXUMAB ON PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION | 5PSQ-086 |
| LONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES | 5PSQ-087 |
| ANTI SARS-CoV-2 MONOCLONAL ANTIBODIES: FROM CLINICAL TRIAL TO REAL WORLD EVIDENCE | 5PSQ-088 |
| USE OF MONOCLONAL ANTIBODIES AGAINST THE CALCITONIN GENERELATED PEPTIDE PATHWAY IN CHRONIC MIGRAINE IN CLINICAL PRACTICE | 5PSQ-090 |
| DALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS | 5PSQ-091 |
| TREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB | 5PSQ-092 |
| PERSISTENCE OF TREATMENT WITH INTERLEUKIN -17 INHIBITORS IN SKIN DISORDERS | 5PSQ-093 |
| REASONS FOR DISCONTINUATION OF SELECTIVE IMMUNOSUPPRESSIVE BIOLOGICAL TREATMENTS AGAINST PSORIASIS | 5PSQ-094 |
| COMPARISON BETWEEN THE MAXIMUM RECOMMENDED DOSE OF AZATHIOPRINE ACCORDING TO THE ENZYMATIC ACTIVITY OF THIOPURINE METHYLTRANSFERASE AND 6-THIOGUANINE LEVELS WITH THE MAXIMUM TOLERATED DOSE | 5PSQ-095 |
| USE AND PERSISTENCE OF FIRST-LINE BIOLOGICAL TREATMENTS FOR PSORIASIS | 5PSQ-097 |
| EXPERIENCE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | 5PSQ-098 |
| MEDICATION ERRORS IN UNIT-DOSE DRUG DISTRIBUTION SYSTEM: QUALITY CONTROL | 5PSQ-101 |
| DEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS | 5PSQ-103 |
| VOLUNTARY ELECTRONIC REPORTING OF MEDICATION ERRORS AND ADVERSE DRUGS EVENTS DURING THE FIRST YEAR OF THE COVID-19 PANDEMIC | 5PSQ-104 |
| INSULIN PERFUSION IN NEONATOLOGY. WHICH ONE IS THE SAFEST? | 5PSQ-105 |
| IMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) RECONSTITUTION IN A UNIVERSITY TEACHING HOSPITAL IN FRANCE : PROPOSAL OF A DECISION-MAKING ALGORITHM | 5PSQ-106 |
| SECURIZING OF TISAGENLECLEUCEL THAWING AND DELIVERING | 5PSQ-107 |
| SECURIZING OF TISAGENLECLEUCEL (KYMRIAH®) STORAGE | 5PSQ-108 |
| OMEPRAZOLE DEPRESCRIPTION PROJECT IN A SOCIAL HEALTH CENTER WITH A DEPOSIT OF MEDICINES ASSOCIATED WITH A HOSPITAL PHARMACY SERVICE | 5PSQ-110 |
| PHARMACEUTICAL INTERVENTION: AVOIDING INTERACTIONS BETWEEN ANTIRETROVIRALS AND VITAMIN SUPPLEMENTS/ ANTIACIDS | 5PSQ-111 |
| HIDDEN HARM? ASSESSING MAGNITUDE AND COSTS OF INTRAVENOUS THERAPY ADMINISTRATION ERRORS VIA SMART PUMP REPORTS | 5PSQ-112 |
| ANALYSIS OF MEDICATION ERRORS INVOLVING HIGH-RISK PATIENTS IN THE PERIOPERATIVE SETTING | 5PSQ-115 |
| Medication-related follow-up of older patients after hospital discharge: a multicentre retrospective chart review | 5PSQ-116 |
| DETERMINATION OF GENETIC POLYMORPHISMS IN THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN A PATIENT WITH GASTRIC ADENOCARCINOMA TREATED WITH FLUOROPYRIMIDINES: A CASE REPORT | 5PSQ-117 |
| LITHIUM THERAPY ON HOSPITAL ADMISSION | 5PSQ-118 |
| IMPACT OF THE COVID-19 PANDEMIC ON THE USE OF ANTIMICROBIALS IN PRIMARY AND HOSPITAL CARE | 5PSQ-120 |
| IMPORTANCE OF CONCILIATION IN IMMUNOSUPPRESSANT TREATMENT | 5PSQ-121 |
| EXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION | 5PSQ-122 |
| ORPHAN OFF-LABEL DRUG: IS IT REALLY COMMON PRACTICE? | 5PSQ-123 |
| THE ROLE OF THE CLINICAL PHARMACIST AVOIDING MEDICATION ERRORS IN A CLINICAL RESEARCH ONCO-HEMATOLOGIC UNIT | 5PSQ-124 |
| THE IDENTIFICATION OF HEALTH CONSEQUENCES ASSOCIATED WITH COUNTERFEIT MEDICINE AND ILLEGAL HEALTH PRODUCT APPLICATION USING PHARMACOVIGILANCE DATA | 5PSQ-125 |
| CLINICAL INTERVENTIONS IN THE AREA OF INPATIENT PRESCRIPTIONS PERFORMED BY HOSPITAL PHARMACY RESIDENT | 5PSQ-128 |
| DOSE BANDING OF INTRAVENOUS 5-FLUOROURACIL, OXALIPLATIN, PACLITAXEL AND GEMCITABIN: EVALUATION OF EFFICIENCY AND SAFETY SUBSEQUENT TO AN IMPLEMENTATION PROGRAMME | 5PSQ-130 |
| PARENTERAL NUTRITION IN ACUTE PANCREATITIS: A REVIEW OF APPROPRIATENESS | 5PSQ-131 |
| ANALYSIS OF CHEMICAL CONTAMINATION BY HAZARDOUS DRUGS WITH SEMIQUANTITATIVE SYSTEM IN A TERTIARY HOSPITAL | 5PSQ-132 |
| ANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER | 5PSQ-133 |
| PATIENTS’ SATISFACTION TOWARD PHARMACEUTICAL CARE AT A UNIVERSITY HOSPITAL | 5PSQ-134 |
| NEW SECURITY WARNINGS FOR TOFACITINIB: ANALYSIS OF PATIENTS IN RISK | 5PSQ-135 |
| MEDICATION ERRORS RELATING TO ISOAPPEARANCES IN THE EMERGENCY ROOM | 5PSQ-137 |
| IMPACT OF HIGH TEMPERATURE, SHAKING AND LIGHT ON QUALITY OF THE THERAPEUTIC PEPTIDE TEDUGLUTIDE (REVESTIVE®) EVALUATED BY LC/MS/MS (ORBITRAP) PEPTIDE MAPPING ANALYSIS AND STRESS | 5PSQ-138 |
| ANTICHOLINERGIC RISK EVALUATION IN HOSPITALISED PATIENTS | 5PSQ-139 |
| PATIENT SAFETY CLIMATE IN A HOSPITAL PHARMACY DEPARTMENT | 5PSQ-140 |
| Personalized therapy for interstitial lung diseases in caused by ABCA3 mutations | 5PSQ-141 |
| Development and validation of clinical rules to address risk prescriptions | 5PSQ-144 | |
| MEDICINAL PLANTS USE AMONG TUNISIAN PATIENTS: PREVALENCE AND PERCEPTION | 5PSQ-145 |
| RISK MAPPING OF DRUG MANAGEMENT IN A PRISON | 5PSQ-146 |
| A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO THE MEDICAL DEVICES MANAGEMENT PROCESS IN A HOSPITAL PHARMACY | 5PSQ-147 |
| TANDEM PROJECT: TRANSITIONS OF CARE AND MEDICATION RECONCILIATION IN HIGH-RISK PATIENTS | 5PSQ-148 | |
| DURVALUMAB FOR THE TREATMENT OF NONSMALL CELL LUNG CANCER: REAL-WORLD EXPERIENCE | 5PSQ-149 | |
| Implementation of a Programme for Optimising the Use of Antibiotics (PROA) in the Paediatrics Emergency Care Unit of a third level hospital | 5PSQ-150 |
| OPTIMIZATION OF THE SUBCUTANEOUS ADMINISTRATION OF DARATUMUMAB | 5PSQ-151 |
| EFFECTIVENESS AND SAFETY OF ERENUMAB IN MIGRAINE PROPHYLAXIS | 5PSQ-152 |
| PERSISTENCE AND REASONS FOR DISCONTINUATION OF TREATMENT WITH APREMILAST IN DERMATHOLOGICAL DISEASES | 5PSQ-153 |
| Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Antimicrobial Resistance | 5PSQ-154 |
| HOW IS CHEMOTHERAPY USED AT THE END OF LIFE IN A SECONDARY HOSPITAL? | 5PSQ-155 |
| REASONS FOR SECUKINUMAB TREATMENT DISCONTINUATION | 5PSQ-156 |
| SEVERE NEUROTOXICITY OF ORAL IVERMECTIN: A SYSTEMATIC REVIEW OF CASES AND CASE SERIES | 5PSQ-157 |
| Food and drink management as part of medicaton administration safety | 5PSQ-158 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CAN PHARMACISTS IMPROVE THEIR PATIENT COMMUNICATION BY READING FICTION? | 6ER-001 | |
| Applying reflective Multicriteria Decision Analysis to understand the value of therapeutic alternatives in the management of anaemia in gynaecologic surgery | 6ER-002 |
| REDUCING INVASIVE DEVICE-RELATED BLOODSTREAM INFECTIONS: A CHALLENGE FOR THE PREVENTION OF HEALTH-CARE ASSOCIATED INFECTIONS | 6ER-005 |
| PARACETAMOL VERSUS IBUPROFEN FOR TREATMENT OF PERSISTENT DUCTUS ARTERIOSUS CLOSURE IN PRETERM INFANTS: IBUPAR-TRIAL | 6ER-006 |
| REAL-WORLD EFFECTIVENESS OF GENE THERAPY ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA) FOR SPINAL MUSCULAR ATROPHY: A REVIEW | 6ER-007 |
| DEVELOPMENT OF A RISK-SHARING MODEL BASED ON THE CLINICAL PERFORMANCE OF ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA) | 6ER-008 |
| COTRIMOXAZOL: HOW FOLATE SUPPLEMENTATION COULD AFFECT TREATMENT EFFICACY | 6ER-011 |
| EFFECTIVENESS OF IL-23 INHIBITORS IN PATIENTS WITH MODERATE–SEVERE CHRONIC PLAQUE PSORIASIS | 6ER-012 |
| ANALYSIS OF PATIENTS’ MORTALITY IN SARS-COV-2 INFECTION DURING THE FIRST MONTH OF HOSPITAL ADMISSION | 6ER-013 |
| ANALYSIS OF THE EVOLUTION OF INTERLEUKIN-6 IN COVID-19 PATIENTS AFTER BEING TREATED WITH DEXAMETHASONE | 6ER-014 |
| MUTATIONS IN THE FACTOR VIII GENE IN OUR HAEMOPHILIA A POPULATION | 6ER-015 |
| PREVENTION OF EXTRAVASATION BY THE LOCAL APPLICATION OF HYBRID AEROGEL MICROPARTICLES AS DRUG DELIVERY SYSTEMS FOR CERVICAL CANCER CHEMOTHERAPY | 6ER-017 |
| USE OF ELTROMBOPAG IN ROUTINE CLINICAL PRACTICE | 6ER-018 |
| DETERMINATION OF DOXORUBICIN FROM THE EFLUATE OF CELLS USING THE DRUGLOG® SYSTEM | 6ER-019 |
| The occurrence of fluid overload in critically ill patients: is there a need for fluid stewardship? | 6ER-020 |
| EVALUATION OF COVID MORTALITY DURING HOSPITAL ADMISSION IN PATIENTS RECEIVING ONCOLOGIC TREATMENT | 6ER-021 |
| PHARMACOLOGICAL FACTORS RELATED TO HOSPITAL ADMISSIONS IN POLYMEDICATED ELDERLY PATIENS | 6ER-022 |
| STUDY OF THE USE OF CEFTAZIDIMA-AVIBACTAM IN A THIRDLEVEL UNIVERSITY HOSPITAL | 6ER-023 |
| POTENTIALLY DRUG-RELATED PROBLEMS IN A POLYMEDICATED POPULATION | 6ER-024 |
| Real-life use of remdesivir in hospitalized COVID-19 patients with severe pneumonia: an observational study from an Italian University Hospital | 6ER-025 |
| EFFECTIVENESS AND SAFETY OF APREMILAST IN A THIRD-LEVEL HOSPITAL | 6ER-026 |
| BLOOD CYTOKINE EVALUATION IN PATIENTS WITH INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION | 6ER-027 |
| BLOOD CYTOKINE EVALUATION IN PATIENTS WITH INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION | 6ER-027 | |
| MARKET EXCLUSIVITY EXPIRY HAS LIMITED EFFECT ON PRICES OF BRAND-NAME ORPHAN DRUGS | 6ER-028 |
| Game-based training: play instead of reading boring procedures! | 6ER-029 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IMPACT OF AN ORAL NUTRITION PROTOCOL IN PATIENTS TREATED WITH ELECTIVE RADICAL CYSTECTOMY: A LONG TERM FOLLOW-UP (submitted in 2019) | NP-001 | |
| MEDICATION SAFETY IN PATIENTS TREATED WITH ORAL ANTITUMOR AGENTS: A PROSPECTIVE, RANDOMIZED INVESTIGATION TO IMPROVE PATIENT SAFETY AND WELL-BEING BY INTENSIFIED CLINICAL PHARMACEUTICAL/ PHARMACOLOGICAL CARE (submitted in 2019) | NP-002 |
| STEADY-STATE PHARMACOKINETICS AND EARLY SAFETY DATA IN HIV-INFECTED AFRICAN CHILDREN WEIGHING ≥25KG AFTER SWITCHING TO 50MG FILM-COATED DOLUTEGRAVIR TABLETS IN THE ODYSSEY TRIAL (submitted in 2019) | NP-003 | |
| INITIATION OF A CLINICAL PHARMACIST LED, PROSPECTIVE AUDIT ON ANTIBIOTIC PRESCRIBING (submitted in 2019) | NP-004 |
| IMPLEMENTING MEDICATION RECONCILIATION ON HOSPITAL ADMISSION: A MULTICENTER PILOT STUDY IN ESTONIA AND FINLAND (submitted in 2019) | NP-005 |
| A PAIR OF PHARMACY TECHNICIAN / NURSE TO TRAIN ON THE ANTI-RETURN VALVES (submitted in 2019) | NP-006 | |
| A MIXED METHODS EVALUATION OF THE CROSS-SECTOR PHARMACIST VOCATIONAL TRAINING FOUNDATION PROGRAMME: IS THE TRAINING PROGRAMME FIT FOR PURPOSE? (submitted in 2019) | NP-007 | |
| MONITORING OF PRESCRIPTIONS ON PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL PATIENTS IN BEATRIZ ÂNGELO HOSPITAL (submitted in 2019) | NP-008 |
| THE IMPACT OF TNFa INHIBITORS ON GLUCOCORTICOIDS USE AMONG PATIENTS WITH ARTHRITIDES (submitted in 2019) | NP-009 | |
| CLINICAL AND PHARMACOKINETIC RESULTS AFTER THE SWITCH TO INFLIXIMAB BIOSIMILAR IN INFLAMMATORY BOWEL DISEASE: 2 YEARS OF REAL-LIFE EXPERIENCE (submitted in 2019) | NP-010 | |
| MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT – PROCESS ASSESSMENT FOR A MORE EFFICIENT SERVICE (submitted in 2019) | NP-011 | |
| COST EFFECTIVENESS ANALYSIS AND INDIRECT COMPARISON CAN SUPPORT THE PRICE’ DEFINITION OF A DRUG? THE CASE OF ENCORAFENIB AND BINIMETINIB IN METASTATIC MELANOMA, THE PHARMACIST’POINT OF VIEW (submitted in 2019) | NP-012 | |
| THE NEOCHECK PROJECT: DEVELOPMENT OF A PRESCRIPTION-SCREENING TOOL SPECIFIC TO NEONATOLOGY (submitted in 2019) | NP-013 |
| MEDICINE BOXES FOR DISTRIBUTION OF PAID PHARMACEUTICALS TO OUTPATIENTS IN THE FUTURE (submitted in 2019) | NP-014 | |
| QUALITY ASSESSMENT OF 3D PRINTED SILDENAFIL AND FUROSEMIDE TABLETS FOR THE PAEDIATRIC POPULATION USING AN INNOVATIVE EXTRUSIONBASED TECHNIQUE | NP-015 |
| EPIDEMIOLOGY AND RESISTANCE MAP TO AID ANTIBIOTIC GUIDELINE DEVELOPMENT SINGLE CENTRE RETROSPECTIVE STUDY FROM AN EMERGENCY DEPARTMENT | NP-016 |
| RISK ASSESSMENT OF OCCUPATIONAL EXPOSURE TO CYTOTOXIC DRUGS IN AN OUTPATIENT HOSPITAL PHARMACY | NP-017 |
| BUILDING CAPACITY WITHIN A HEPATITIS C TREATMENT MODEL. THE VALIDATION PROCESS FOR A HEPATITIS C PRE-TREATMENT PHARMACIST ASSESSMENT COMPLEX INTERVENTION TOOLKIT | NP-018 | |
| DEVELOPMENT OF A CONVERSION FACTOR BETWEEN DEFINED DAILY DOSES OF ADULTS AND NEONATES | NP-019 |
| ANTINEOPLASTIC AND OTHER HAZARDOUS DRUGS: RISK POTENTIAL AND EXPOSURE – LESS IS MORE! | NP-020 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CAN RIVAROXABAN BECOME COST SAVING COMPARED WITH VITAMIN K ANTAGONISTS IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN FRANCE? (submitted in 2019) | 1ISG-001 | |
| BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS: A COST ANALYSIS AND AN APPLICATION OF A CORRELATION ANALYSIS TO INVESTIGATE COST EFFECTIVENESS (submitted in 2019) | 1ISG-002 |
| STUDY OF THE USE OF INTRAVENOUS IMMUNOGLOBULINS DURING THE FOURTH QUARTER OF 2018 AND ANALYSIS OF ITS OFF-LABEL USE (submitted in 2019) | 1ISG-003 | |
| ECONOMIC COMPARISON OF THERAPEUTIC ALTERNATIVES FOR FIRSTLINE OF TREATMENT MULTIPLE MYELOMA (submitted in 2019) | 1ISG-004 |
| ABC-VEN CROSSTAB ANALYSIS: A DECISION MAKING SYSTEM APPLIED FOR ANTICANCER MEDICINES (submitted in 2019) | 1ISG-005 | |
| EFFECTIVENESS EVALUATION OF HIGHCOST DRUGS FOR ADVANCED NON-SMALL-CELL LUNG CANCER: REAL WORLD EVIDENCE, COMPLIANCE WITH CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION (submitted in 2019) | 1ISG-006 | |
| NEW CANCER DRUGS APPROVALS IN PORTUGAL (submitted in 2019) | 1ISG-007 | |
| COST EFFICACY ANALYSIS OF ABIRATERONE IN NEWLY DIAGNOSED HIGH RISK METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (submitted in 2019) | 1ISG-008 | |
| BUDGET IMPACT ANALYSIS OF A NATALIZUMAB EXTENDED INTERVAL DOSING REGIMEN (submitted in 2019) | 1ISG-009 |
| INTRODUCTION OF RITUXIMAB BIOSIMILAR: AN OPPORTUNITY TO IMPROVE HEALTH SYSTEM EFFICIENCY? (submitted in 2019) | 1ISG-010 | |
| ASSESSMENT OF ASTHMA DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY AND RELATED COST IN THE VENETO REGION (submitted in 2019) | 1ISG-011 | |
| NATIONAL REPORTING SYSTEM FOR DRUG SHORTAGES : CLASSIFICATION AND TRENDS IN REPORTED CAUSES FROM 2015 TO 2018 (submitted in 2019) | 1ISG-012 |
| SMARTPHONE APPLICATIONS FOR PATIENTS DIAGNOSED WITH GENITOURINARY TUMOURS: ANALYSIS OF THE QUALITY USING THE MOBILE APPLICATION RATING SCALE (submitted in 2019) | 1ISG-013 | |
| COST EFFECTIVENESS ANALYSIS OF PATIENTS’ SELF-ADMINISTRATION OF MEDICATION (SAM) DURING HOSPITALISATION IN A CARDIOLOGY UNIT (submitted in 2019) | 1ISG-014 |
| EVALUATION OF BISPECTRAL INDEX MONITORING IN GENERAL ANAESTHESIA THROUGH A HEALTH TECHNOLOGY ASSESSMENT METHOD: A POSSIBLE INTRODUCTION IN CLINICAL PRACTICE IN AN ITALIAN HOSPITAL? (submitted in 2019) | 1ISG-015 | |
| ENVISIONING SUSTAINABILITY IN PERSONALISED MEDICINE: FONDO AIFA 5% AND THE ITALIAN EXAMPLE (submitted in 2019) | 1ISG-016 | |
| IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE (submitted in 2019) | 1ISG-017 | |
| APPLICATION OF A TIME SLOT MODEL IN ONCOLOGY: DELIVERY PLANNING AND PROCESS OPTIMISATION (submitted in 2019) | 1ISG-018 | |
| HOSPITAL PHARMACISTS AGED <45 YEARS: AN EMPLOYMENT STATUS AND JOB SATISFACTION SURVEY IN ITALY (submitted in 2019) | 1ISG-019 | |
| COST SAVINGS IMPACT OF BIOSIMILARS: A LOCAL EXPERIENCE ON TRASTUZUMAB | 1ISG-020 |
| INDIRECT COMPARISON OF BRIGATINIB VERSUS ALECTINIB IN THE ALK-POSITIVE NON-SMALL CELL LUNG CANCER | 1ISG-021 |
| ECONOMIC ANALYSIS AFTER THE INCORPORATION OF BEVACIZUMAB BIOSIMILAR IN A THIRD LEVEL HOSPITAL | 1ISG-022 |
| PHARMACOECONOMIC ANALYSIS OF REFERENCE BEVACIZUMAB: OPPORTUNITY FOR IMPROVED EFFICIENCY | 1ISG-023 |
| BIOLOGICAL DRUGS IN THE TREATMENT OF IMMUNE MEDIATED INFLAMMATORY DISEASES: MONITORING OF PRESCRIPTION APPROPRIATENESS | 1ISG-024 |
| BUDGET IMPACT ANALYSIS OF BIOSIMILAR ADALIMUMAB VERSUS REFERENCE ADALIMUMAB | 1ISG-025 |
| MULTIDISCIPLINARY DOCTOR-PHARMACIST COLLABORATION IN THE MANAGEMENT OF REFUNDS POLICIES OF OPHTHALMIC DRUGS AT SANT’ANDREA HOSPITAL , VERCELLI | 1ISG-026 |
| CARBON FOOTPRINT OF A STERILISATION UNIT | 1ISG-027 |
| BECOMING OF GRADUATE HOSPITAL PHARMACISTS: A FRENCH NATIONAL SURVEY | 1ISG-028 |
| CRANIOPLASTY: A REVIEW OF CUSTOMISED CRANIOPLASTY IMPLANTS | 1ISG-029 |
| ECONOMIC IMPACT OF BIOLOGICAL MEDICINES ON A THIRD LEVEL HOSPITAL | 1ISG-030 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IMPLEMENTATION OF HOME DELIVERY AND TELEPHARMACY SYSTEMS IN A THIRD LEVEL HOSPITAL (submitted in 2019) | 2SPD-001 | |
| IMPROVEMENT IN AN ANTIMICROBIAL STEWARDSHIP PROGRAMME AFTER IMPLEMENTING A SCREENING ALERT SYSTEM (submitted in 2019) | 2SPD-002 | |
| ECONOMIC IMPACT OF THE INTRODUCTION OF LAMIVUDINE PLUS DOLUTEGRAVIR BITHERAPY IN HIV NAIVE PATIENTS (submitted in 2019) | 2SPD-003 | |
| EFFICIENCY OF PRECISION DOSING WITH INTRAVENOUS IMMUNOGLOBULINS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES (submitted in 2019) | 2SPD-004 |
| ECONOMIC ANALYSIS OF OSIMERTINIB IN PREVIOUSLY UNTREATED EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (submitted in 2019) | 2SPD-005 | |
| ASSESSMENT OF REGORAFENIB, RAMUCIRUMAB AND CABOZANTINIB AS SECONDLINE THERAPY IN HEPATOCARCINOMA AND ALFA-FETOPROTEIN VALUE ≥400 NG/ML (submitted in 2019) | 2SPD-006 | |
| OUT OF SUPPLY OF CHEMOTHERAPY INJECTABLE MEDICINES OVER 9 MONTHS: PATIENT IMPACT (submitted in 2019) | 2SPD-007 | |
| IMPACT OF FRENCH EXPERIMENT FOR INCENTIVISING ETANERCEPT BIOSIMILAR USE AFTER 10 MONTHS (submitted in 2019) | 2SPD-008 | |
| COST MINIMISATION STUDY OF THE BIOLOGICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE: USTEKINUMAB VERSUS VEDOLIZUMAB (submitted in 2019) | 2SPD-009 | |
| ECONOMIC IMPACT OF SWITCHING THE ADMINISTRATION ROUTE OF TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (submitted in 2019) | 2SPD-010 | |
| TRANS-INTERFACE GAIN SHARE PROGRAMME FOR BIOSSIMILAR INFLIXIMAB (submitted in 2019) | 2SPD-011 | |
| COST MINIMISATION STUDY IN SEVERE ASTHMA TREATMENT (submitted in 2019) | 2SPD-012 | |
| APPLICATION OF THE ABC ANALYSIS METHOD FOR OPTIMIZING THE STOCK MANAGEMENT OF MEDICAL DEVICES IN COMMON USE (submitted in 2019) | 2SPD-013 | |
| EVALUATING THE METHODOLOGICAL QUALITY OF PIVOTAL CLINICAL TRIALS´S PUBLICATIONS FOR ORPHAN DRUGS AUTHORISED IN 2018. ARE THEY RELIABLE? (submitted in 2019) | 2SPD-014 | |
| COST OF STOCKOUT. A GROWING PROBLEM (submitted in 2019) | 2SPD-015 | |
| FUTURE DISTRIBUTION MODELTS FOR PAID PHARMACEUTICALS: THE PATIENT’S PERSPECTIVE (submitted in 2019) | 2SPD-016 | |
| IMPACT OF THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE AT THE LISBON PORTUGUESE INSTITUTE OF ONCOLOGY (FG, EPE) (submitted in 2019) | 2SPD-017 | |
| FOUR YEAR STUDY OF DRUGS SHORTAGES IN TWO PUBLIC HOSPITALS (submitted in 2019) | 2SPD-018 | |
| FOUR YEARS OF SHORTAGES REGARDING THE ANATOMIC, THERAPEUTIC AND CHEMICAL CLASSIFICATION (submitted in 2019) | 2SPD-019 | |
| IMPACT OF MEDICINE SHORTAGES ON AN OUTPATIENT CLINIC OF A GENERAL HOSPITAL (submitted in 2019) | 2SPD-020 | |
| SURVEY OF DRUG SHORTAGES IN HUNGARIAN HOSPITALS (submitted in 2019) | 2SPD-021 | |
| DRUG SHORTAGES AND DRUG UNAVAILABILITY: ANALYSIS FROM AN ITALIAN HOSPITAL (submitted in 2019) | 2SPD-022 | |
| HOW MUCH DOES FALSIFIED MEDICINES DIRECTIVE ACTUALLY COSTS? DETAILED COST EVALUATION OF SERIALISATION IN A REPRESENTATIVE SAMPLE OF HUNGARIAN HOSPITAL PHARMACIES (submitted in 2019) | 2SPD-023 | |
| SHORTAGES OF MEDICINES IN HOSPITAL: RESULTS OF A SURVEY ON THE PERCEPTION OF HEALTH WORKERS IN THE WARDS VSV REAL WORLD (submitted in 2019) | 2SPD-024 | |
| APPLICATION OF HAZARD VULNERABILITY ANALYSIS TO EVALUATE THE RISK LEVEL OF MEDICINE SHORTAGES (submitted in 2019) | 2SPD-025 | |
| MANAGEMENT OF DRUG SHORTAGES (submitted in 2019) | 2SPD-026 | |
| ECONOMIC IMPACT OF DRUG SHORTAGES (submitted in 2019) | 2SPD-027 | |
| REFERENCING A MIDLINE: HOW TO MAKE A CHOICE? (submitted in 2019) | 2SPD-028 | |
| OFF-LABEL DRUGS: USE ANALYSIS AND PHARMACOEPIDEMIOLOGY IN A COVID CENTRE IN ROME | 2SPD-029 |
| POSITIONING OF DORAVIRINE IN THE PHARMACOTHERAPEUTIC GUIDE OF A THIRD LEVEL HOSPITAL. | 2SPD-030 |
| SUBGROUP ANALYSIS ABOUT EFFICACY OF EARLY USE OF REMDESIVIR IN COVID-19 | 2SPD-031 |
| NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES IN UNTREATED METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER | 2SPD-032 |
| EVALUATION OF DOCETAXEL IN LOW AND HIGH BURDEN METASTATIC HORMONE SENSITIVE PROSTATE CANCER | 2SPD-033 |
| USE OF DARATUMUMAB BASED TREATMENTS IN PATIENTS WITH MULTIPLE MYELOMA AND HEPATIC IMPAIRMENT | 2SPD-034 |
| BIOLOGICAL THERAPIES EFFECTIVENESS COMPARISON FOR PATIENTS WITH SEVERE-MODERATE PSORIASIS | 2SPD-035 |
| CENTRALISED PROPOFOL RECONDITIONING PROCEDURE DURING COVID-19 | 2SPD-036 |
| ANALYSIS OF DRUG DISPENSES OUTSIDE THE HOSPITAL GUIDE IN A PSYCHIATRIC HOSPITAL | 2SPD-037 |
| BEVACIZUMAB VERSUS RANIBIZUMAB IN OPHTHALMOLOGY OUTPATIENT SURGERY | 2SPD-038 | |
| MAKE OR BUY: PHARMACOECONOMIC EVALUATION OF GARGLE SOLUTIONS USED FOR SARS-CoV-2 SAMPLE COLLECTION | 2SPD-039 |
| IMPACT OF AUTOMATED DISPENSING CABINETS ON DISPENSING ERRORS, INTERRUPTIONS AND PILLBOX PREPARATION TIME | 2SPD-040 |
| QUANTITATIVE EVALUATION AND ECONOMIC IMPACT OF MEDICINE SHORTAGES IN A TEACHING HOSPITAL | 2SPD-041 |
| MEDICAL DEVICE’S ACTIVE VIGILANCE OF THE PHARMACIST IN THE DIGITALISATION OF INTRAOCULAR LENSES (IOLs) LOGISTIC PATH | 2SPD-042 |
| PROCEDURE FOR DELIVERY OF RETROCESSION DRUGS BY THE HOSPITAL PHARMACIST TO THE COMMUNITY PHARMACY DURING THE COVID-19 CRISIS: SATISFACTION SURVEY OF PHARMACIES | 2SPD-043 |
| DruGhost: web based platform of drugs’ unavailability | 2SPD-044 |
| OPTIMISATION OF THE BUYING PROCESS: BUILDING A TIME EARNING COMPARATOR TO EASE THE CHOICE BETWEEN EQUIVALENT SPECIALTIES | 2SPD-045 |
| ORGANISATIONAL CHALLENGES OF THE PHARMACY SERVICE AS A CONSEQUENCE OF THE COVID-19 PANDEMIC | 2SPD-046 |
| NEW REQUIREMENTS OF OUTPATIENTS IN THE COVID-19 ERA: ADAPTING PHARMACEUTICAL CARE | 2SPD-047 |
| POLITICAL REPORT–OPTIONS TO BREAK THROUGH MEDICINE SHORTAGES | 2SPD-048 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| COMPATIBILITY AND STABILITY ASSESSMENT OF A SODIUM GLYCEROPHOSPHATE FORMULATION MIXED IN BAGS FOR NEONATAL TOTAL PARENTERAL NUTRITION (submitted in 2019) | 3PC-001 | |
| MICROBIOLOGICAL STABILITY TEST OF 15% TOPICAL RESORCINOL FOR QUALITY CONTROL (submitted in 2019) | 3PC-002 | |
| TERLIPRESSIN PH STABILITY FOR CONTINUOUS INFUSION (submitted in 2019) | 3PC-003 | |
| PHYSICOCHEMICAL STABILITY OF CEFEPIME IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES. (submitted in 2019) | 3PC-004 | |
| PHYSICOCHEMICAL STABILITY OF CEFAZOLIN IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES. (submitted in 2019) | 3PC-005 | |
| PHYSICOCHEMICAL STABILITY OF AZTREONAM IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATION FOR INTENSIVE CARE UNITS. (submitted in 2019) | 3PC-006 | |
| LEVOFLOXACIN 0.05 % EYEDROPS ELABORATION: A CASE OF STUDY (submitted in 2019) | 3PC-007 | |
| INTRAVENOUS PERFUSION OF CEFTOLOZANE-TAZOBACTAM USING ELASTOMERIC INFUSION PUMPS (submitted in 2019) | 3PC-008 | |
| TREATMENT OF RECURRENT OTOMYCOSIS WITH LOCAL APPLICATION OF A COMPOUNDED FORMULATION OF VORICONAZOLE EAR DROPS: CASE SERIES (submitted in 2019) | 3PC-009 | |
| EVALUATION OF THE PRODUCTION ACCURACY AND ERROR RATE IN THE AUTOMATED COMPOUNDING OF CYTOTOXIC PREPARATIONS BY A ROBOT (submitted in 2019) | 3PC-010 | |
| CLOSED SYSTEM TRANSFER DEVICE BASED ON AIR FILTRATION: THE DRUG VAPOUR CHALLENGE (submitted in 2019) | 3PC-011 | |
| MANAGEMENT OF NON-ADMINISTERED CHEMOTHERAPY PREPARATION: AN OPPORTUNITY TO MINIMISE DRUG WASTE IN ONCOLOGY PHARMACY (submitted in 2019) | 3PC-012 | |
| COMPARATIVE BIOPHYSICAL STABILITY STUDY OF ZIV-AFLIBERCEPT (ZALTRAP, OPENED VIALS) STORED AT 4ºC AND ROOM TEMPERATURE FOR 2 WEEKS (submitted in 2019) | 3PC-013 |
| USE OF CABAZITAXEL AND REDUCTION OF WASTE: THE POTENTIAL OF DRUG-DAY. (submitted in 2019) | 3PC-014 | |
| SHORT TERM STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY DARATUMUMAB (submitted in 2019) | 3PC-015 | |
| STABILITY OF COMPOUNDED NIVOLUMAB SOLUTION AFTER PNEUMATIC SYSTEM TRANSPORTATION (submitted in 2019) | 3PC-016 | |
| INCREASING PHARMACY PRODUCTIVITY BY EXPANDING THE ROLE OF THE INTRAVENOUS COMPOUNDING ROBOT IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019) | 3PC-017 | |
| MITOMYCIN C STABILITY ACCORDING TO PH AND TEMPERATURE CONDITIONS (submitted in 2019) | 3PC-018 | |
| IN USE PHYSICOCHEMICAL AND MICROBIOLOGICAL STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY NIVOLUMAB (submitted in 2019) | 3PC-019 | |
| PHYSICOCHEMICAL STABILITY OF 25 MG/ML PEMETREXED DIARGININE IN PARTIALLY-USED VIALS AND 3 AND 12 MG/ML DILUTED IN DEXTROSE 5% IN POLYOLEFIN BAG. (submitted in 2019) | 3PC-020 | |
| STORAGE OF NIVOLUMAB, PEMBROLIZUMAB AND DARATUMUMAB FOR 14 DAYS AFTER COMPOUNDING IN THE HOSPITAL PHARMACY: A MICROBIOLOGICAL STABILITY STUDY (submitted in 2019) | 3PC-021 | |
| PARTICULATE QUALITY OF A CONTROLLED ATMOSPHERE AREA. COMPLIANCE WITH GOOD MANUFACTURING PRACTICES AT REST AND DURING ACTIVITY, HIGHLIGHTING OF FACTORS IMPACTING ON CONTAMINATION (submitted in 2019) | 3PC-022 | |
| DEVELOPMENT AND VALIDATION OF A DISCRIMINATIVE METHOD FOR ANTHRACYCLINES DRUGS USED IN ONCOLOGY BY VISIBLE SPECTROMETER (submitted in 2019) | 3PC-023 | |
| THE EFFECTS OF FREEZE-THAW CYCLING ON THE STABILITY OF THE ADALIMUMAB BIOSIMILAR SB5 (submitted in 2019) | 3PC-024 | |
| MAGISTRAL FORMULATION FOR A PATIENT WITH MULTIPLE FOOD ALLERGY (submitted in 2019) | 3PC-025 | |
| FORMULATION AND GALENIC CHARACTERISATION OF A TACROLIMUS ADHESIVE GEL FOR TREATMENT OF ULCERATIVE PROCTITIS (submitted in 2019) | 3PC-026 | |
| LONG TERM STABILITY OF A READY TO USE TOPICAL ANAESTHETIC GEL KIT (submitted in 2019) | 3PC-027 | |
| COMPOUNDING AN ORAL LIQUID FORMULATION OF DIAZEPAM ALCOHOL FREE (submitted in 2019) | 3PC-028 | |
| PAEDIATRIC DRUG RESISTANT EPILEPSY: NITRAZEPAM 1MG/ML SOLUTIONS TO AVOID CLINICAL THERAPEUTIC ERROR (submitted in 2019) | 3PC-029 | |
| ANALYTICAL METHOD VALIDATION TO CARRY OUT PHYSICOCHEMICAL STABILITY STUDIES OF METHADONE ORAL SOLUTIONS. (submitted in 2019) | 3PC-030 |
| CURRENT STATE OF THE ANTI-INFECTIVE OPHTHALMIC COMPOUNDING FORMULATION IN PHARMACY SERVICES: A NATIONAL SURVEY (submitted in 2019) | 3PC-031 | |
| AUTOLOGOUS TISSUE ADHESIVE IN OPHTHALMOLOGICAL SURGERY (submitted in 2019) | 3PC-032 | |
| INTRACAMERAL AND INTRASTROMAL VORICONAZOLE ADMINISTRATION IN FUSARIUM KERATITIS (submitted in 2019) | 3PC-033 | |
| CONTENT UNIFORMITY OF EXTEMPORANEOUS COMPOUNDED SUSPENSIONS (submitted in 2019) | 3PC-034 | |
| 93% OXYGEN SELF-PRODUCTION: EXPERIENCE IN NA ITALIAN HOSPITAL (submitted in 2019) | 3PC-035 | |
| CASE STUDY: DEVELOPMENT OF AN OINTMENT ACCORDING TO THE PHARMACEUTICAL INSPECTION CONVENTION GUIDELINE (submitted in 2019) | 3PC-036 | |
| STERILITY OF SINGLE USE VIALS WHEN ACCESSED USING A CLOSED SYSTEM TRANSFER DEVICE (submitted in 2019) | 3PC-037 | |
| PHYSICOCHEMICAL STABILITY OF THE BEVACIZUMAB BIOSIMILAR, ABP 215, IN INTRAVENOUS BAGS AFTER PREPARATION AND STORAGE (submitted in 2019) | 3PC-038 | |
| OPTIMISATION OF MIXING AN ORAL POWDER MIXTURE OF CODEINE PREPARED IN THE HOSPITAL PHARMACY FOR FILLING INTO HARD CAPSULES (submitted in 2019) | 3PC-039 | |
| GALENIC VALIDATION OF A DEXAMETHASONE 0.01% MOUTHWASH SOLUTION TO PREVENT EVEROLIMUS RELATED STOMATITIS (submitted in 2019) | 3PC-040 | |
| SURFACE CONTAMINATION WITH CYTOTOXIC DRUGS IN EUROPEAN HOSPITAL WARDS (submitted in 2019) | 3PC-041 | |
| THE SIGNIFICANCE OF PHARMACY PREPARATION IN PAEDIATRICS: MAKING INDIVIDUAL THERAPIES FOR CRITICALLY ILL CHILDREN POSSIBLE (submitted in 2019) | 3PC-042 | |
| HAZARDOUS DRUGS: IMPACT OF MEASURES FOR SAFE HANDLING (submitted in 2019) | 3PC-043 | |
| IN USE PHYSICOCHEMICAL STABILITY OF PEMBROLIZUMAB UNDER THE DILUTION CONDITION REQUIRED FOR USE IN A DAY HOSPITAL (submitted in 2019) | 3PC-044 | |
| IMPACT OF THE PREPARATION OF A CLINICAL SOLUTION OF RITUXIMAB 1.0 MG/ML ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: SODIUM CHLORIDE AND GLUCOSE CONCENTRATION, AND AGITATION EFFECT (submitted in 2019) | 3PC-045 |
| PARENTERAL NUTRITION ADMIXTURES: REVIEW OF THE MICROBIOLOGICAL SAMPLING PLAN (submitted in 2019) | 3PC-046 | |
| STUDY OF THE TRIGON DEPOT ALLERGY TEST (TRIAMCINOLONE AND EXCIPIENTS: CARBOXYMETHYLCELLULOSE, POLYSORBATE 80) DEVELOPED IN THE PHARMACY DEPARTMENT (submitted in 2019) | 3PC-047 | |
| IMPORTANCE OF NON-STERILE FORMULATION IN A PAEDIATRIC HOSPITAL (submitted in 2019) | 3PC-048 | |
| IMIPENEM-CILASTATIN FORTIFIED EYE DROPS FOR THE TREATMENT OF CORNEAL ULCERS CAUSED BY: CONTACT LENSES. DEVELOPMENT AND CHARACTERISATION (submitted in 2019) | 3PC-049 | |
| IMPORTANCE OF COMPOUNDING IN THE PAEDIATRIC HOSPITAL PHARMACY (submitted in 2019) | 3PC-050 | |
| CIRCUIT TO PREPARE AND CONDITION ORAL HAZARDOUS MEDICINES (submitted in 2019) | 3PC-051 | |
| HAZARDOUS MEDICINES IN A PAEDIATRIC HOSPITAL (submitted in 2019) | 3PC-052 | |
| IMPACT OF SERIALISATION ON RECEPTION OF MEDICINES AND ACTIVITY SMOOTHING (submitted in 2019) | 3PC-053 | |
| SODIUM BENZOATE SUSPENSION IN NON-KETOTIC HYPERGLYCINAEMIA: A CASE REPORT (submitted in 2019) | 3PC-054 | |
| STABILITY OF UROKINASE IN CITRATE BASED SOLUTIONS | 3PC-055 | |
| A STABLE READY-TO-USE FORMULATION OF PHENYLEPHRINE HCL IN SYRINGES | 3PC-056 | |
| USING DIFFERENT TECHNIQUES TO PREPARE ORODISPERSIBLE FILMS IN A HOSPITAL PHARMACY | 3PC-057 |
| PHYSICOCHEMICAL STABILITY OF MEROPENEM IN POLYPROPYLENE SYRINGES AT 41.7 mg/mL FOR INTENSIVE CARE UNITS | 3PC-058 |
| PHYSICOCHEMICAL STABILITY OF CEFTOLOZANE/TAZOBACTAM IN POLYPROPYLENE SYRINGES AT 61.5/31.25 mg/mL AND IN ELASTOMERIC DEVICES AT 25.0/12.5 mg/mL | 3PC-059 |
| PHYSICOCHEMICAL STABILITY OF VANCOMYCIN SOLUTION IN ELASTOMERIC DEVICES AT 37.5 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER | 3PC-060 |
| PHYSICOCHEMICAL STABILITY OF CLOXACILLIN SOLUTION IN POLYPROPYLENE SYRINGES AT 125 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER | 3PC-061 |
| IMPACT OF THE PREPARATION OF THE 1.0 MG/ML NIVOLUMAB CLINICAL SOLUTION ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: NaCl AND GLUCOSE CONCENTRATION AND AGITATION EFFECT | 3PC-062 |
| PERFORMANCE QUALIFICATION OF ROBOTIC SYSTEM FOR CYTOTOXIC DRUG PREPARATION IN A FULLY GMP COMPLIANT HOSPITAL PHARMACY | 3PC-063 |
| A MULTICENTRE STUDY COMPARING CHEMOTHERAPY PREPARATIONS USING A DIGITAL VIDEO MONITORING | 3PC-064 |
| IMPACT OF LIGHT STRESS ON THE ISOFORM PROFILE OF NIVOLUMAB (OPDIVO) IN OPENED VIALS ESTIMATED BY (RP)UHPLC-UV-(HESI/ORBITRAP)-MS | 3PC-065 |
| COMPOUNDING AN EYE DROP FORMULATION OF TOPICAL INSULIN FOR CORNEAL DEFECTS REFRACTORY TO PREVIOUS TREATMENT: EXPERIENCE IN REAL CLINICAL PRACTICE | 3PC-066 |
| KEY ROLE OF HOSPITAL PHARMACY IN A NON-PROFIT STUDY INVOLVING RUXOLITINIB 5mg CPS: IMPLEMENTATION AND QUALITY ASSURANCE OF AN INVESTIGATIONAL MANUFACTURING PRODUCT | 3PC-067 |
| LONG TERM STABILITY OF CO-ADMINISTRATION OF BUMETANIDE AND SCOPOLAMINE FOR THE PALLIATIVE CARE UNIT | 3PC-068 | |
| IMPROVING SAFETY AND QUALITY FOR ASEPTIC TRANSFER PROCEDURES IN HOSPITAL PHARMACIES | 3PC-069 |
| EVALUATION OF COMPATIBILITY OF ACETYLSALICYLIC ACID AND ATENOLOL WITH MEDICATIONS COMMONLY USED IN INTENSIVE CARE UNITS | 3PC-070 |
| FULLY AUTOMATED CENTRAL INTRAVENOUS ADDITIVE SERVICE (CIVAS): A 12 MONTH ANALYSIS OF PERFORMANCES AND IMPACT OF COVID-19 ON STERILE ANTIBIOTICS PRODUCTION | 3PC-071 |
| WHICH MODEL TO ESTIMATE AT BEST THE THEORETICAL OSMOLARITY OF NOMINATIVE PARENTERAL NUTRITION? | 3PC-072 |
| EVALUATION OF ANTIOBIOTICS’ PHYSICOCHEMICAL INCOMPATIBILITY WITH THE PRESENCE OF DIVALENT CATIONS | 3PC-073 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EXPERIENCE WITH THE NEW DIRECT ACTING ANTIVIRAL AGENTS IN A THIRD LEVEL HOSPITAL IN 2018 (submitted in 2019) | 4CPS-001 | |
| ANTICHOLINERGIC BURDEN IN CONSTIPATED PATIENT ADMITTED TO AN EMERGENCY DEPARTMENT (submitted in 2019) | 4CPS-002 | |
| LIRAGLUTIDE IN CHRONIC INTESTINAL FAILURE: OVERVIEW AND CASE REPORT (submitted in 2019) | 4CPS-003 | |
| EVALUATION OF THE USE OF HYDROCORTISONE, VITAMIN C AND THIAMINE FOR THE TREATMENT OF SEPTIC SHOCK (submitted in 2019) | 4CPS-004 | |
| RISK FACTORS FOR PERSISTENCE AND TOLERANCE OF COW’S MILK ALLERGY (submitter in 2019) | 4CPS-005 | |
| USE OF AMMONIUM TETRATHIOMOLYBDATE IN WILSON DISEASE (submitted in 2019) | 4CPS-006 | |
| PHARMACEUTICAL CARE AS A MEANS OF PREVENTION AGAINST DRUG IATROGENESIS: CASE OF ORAL ANTICOAGULANTS (submitted in 2019) | 4CPS-007 | |
| RISK FACTORS ASSOCIATED WITH RE-ADMISSION TO THE EMERGENCY DEPARTMENT, IN PATIENTS WITH PREVIOUS GASTROINTESTINAL HAEMORRHAGE SECONDARY TO ORAL ANTICOAGULANT THERAPY (submitted in 2019) | 4CPS-008 | |
| DURATION OF DUAL ANTIPLATELET THERAPY IN CORONARY ARTERY DISEASE: IS PHARMACIST INTERVENTION NECESSARY TO IMPROVE PATIENT SAFETY? (submitted in 2019) | 4CPS-009 | |
| SAFETY AND EFFICACY OF LOW MOLECULAR WEIGHT HEPARINS IN PATIENTS WITH PORTAL VEIN THROMBOSIS (submitted in 2019) | 4CPS-010 | |
| PRESCRIPTION ANALYSIS OF DIRECT ACTING ORAL ANTICOAGULANTS (submitted in 2019) | 4CPS-011 | |
| AUDIT OF ORAL ANTICOAGULANT PRESCRIBING; WHAT HAS CHANGED IN 4 YEARS? (submitted in 2019) | 4CPS-012 |
| EFFECT OF 2MG INTRAVENOUS PHYTONADIONE TREATMENT ON INTERNATIONAL NORMALISED RATIO IN THE HOSPITALISED ADULT (submitted in 2019) | 4CPS-013 | |
| CLINICAL AND ASSISTED IMPACT OF ISCHAEMICAL ICTUS IN PATIENTS TREATED WITH ORAL ANTICOAGULANTS (submitted in 2019) | 4CPS-014 | |
| SITUATIONAL ANALYSIS OF POSTOPERATIVE IRON SUPPLEMENTATION PRESCRIPTIONS IN A PLASTIC SURGERY DEPARTMENT (submitted in 2019) | 4CPS-015 | |
| INAPPROPRIATE USE OF HUMAN ALBUMIN IN A TEACHING HOSPITAL (submitted in 2019) | 4CPS-016 | |
| EFFICACY AND SAFETY OF TOLVAPTAN IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE (submitted in 2019) | 4CPS-017 | |
| EFFICACY OF UREA IN THE TREATMENT OF HYPONATRAEMIA IN SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (submitted in 2019) | 4CPS-018 | |
| ALIROCUMAB AND EVOLOCUMAB: EFFECTIVENESS AFTER 3 YEARS OF FOLLOW-UP IN A REAL WORLD SETTING (submitted in 2019) | 4CPS-019 | |
| USE, EFFICACY AND ADHERENCE TO TREATMENT WITH PCKS9 INHIBITORS IN REAL CLINICAL PRACTICE (submitted in 2019) | 4CPS-020 | |
| ALIROCUMAB AND EVOLOCUMAB: RESULTS IN CLINICAL PRACTICE. (submitted in 2019) | 4CPS-021 | |
| PCSK9 INHIBITORS: EVALUATION OF EFFECTIVENESS IN OUR CENTRE IN RELATION TO THE OFFICIAL CLINICAL ENDPOINTS (submitted in 2019) | 4CPS-022 | |
| LONG-TERM EFFICACY, SAFETY AND ADHERENCE TO ALIROCUMAB IN PATIENTS WITH DYSLIPIDAEMIA FROM A TERTIARY HOSPITAL COHORT (submitted in 2019) | 4CPS-023 | |
| EFFECTIVENESS OF ANTI-INTERLEUKIN-17 DRUGS IN PSORIASIS IN CLINICAL PRACTICE (submitted in 2019) | 4CPS-024 | |
| DUPILUMAB IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS: CASE REPORTS (submitted in 2019) | 4CPS-025 | |
| DALBAVANCIN OFF-LABEL USE: EFFECTIVENESS AND SAFETY (submitted in 2019) | 4CPS-026 | |
| ANTIBIOTIC THERAPY REASSESSMENT AND ITS DOCUMENTATION: CAN VIRTUAL TOOLS IMPROVE PRACTICES? (submitted in 2019) | 4CPS-027 | |
| EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL (submitted in 2019) | 4CPS-028 | |
| PRELIMINARY RESULTS OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN ONCOLOGY DEPARTMENT (submitted in 2019) | 4CPS-029 | |
| INCIDENCE AND RISK FACTORS FOR PROSTHETIC JOINT INFECTION WITHIN 90 DAYS AFTER HEMIARTHROPLASTY FOR FEMORAL NECK FRACTURES IN THE ELDERLY (submitted in 2019) | 4CPS-030 |
| AUDIT OF ANTIBIOTIC PROPHYLAXIS PRACTICE IN VISCERAL SURGERY IN AN AFRICAN COUNTRY (submitted in 2019) | 4CPS-031 | |
| ANTIBIOTIC PRESCRIPTION THROUGH MOTIVATED REQUEST: CLINICAL PHARMACY TOOL TO IMPROVE APPROPRIATENESS AND LIMIT RESISTANT BACTERIAl STRAINS. A FOLLOW-UP AFTER A YEAR OF MONITORING IN A LOCAL HOSPITAL (submitted in 2019) | 4CPS-032 | |
| OFF-LABEL USE OF NEBULISED AZTREONAM LYSINE IN PATIENTS WITH CHRONIC GRAM-NEGATIVE BACTERIAL LUNG COLONISATION (submitted in 2019) | 4CPS-033 | |
| IS IT POSSIBLE TO RATIONALISE THE ANTIBIOTIC USE AMONG HOSPITALISED PATIENTS BY CLINICAL PHARMACISTS’ ACTIVITY? (submitted in 2019) | 4CPS-034 |
| CLINICAL PHARMACOKINETICS OF VANCOMYCIN IN NEUTROPENIC PATIENTS (submitted in 2019) | 4CPS-035 | |
| PHARMACEUTICAL INTERVENTIONS IN A SMALL HOSPITAL (submitted in 2019) | 4CPS-036 | |
| CLINICAL OUTCOME IN PAEDIATRIC INTENSIVE CARE UNIT PATIENTS TREATED WITH VANCOMYCIN (submitted in 2019) | 4CPS-037 | |
| STABILITY TO HIGH TEMPERATURES OF THE ANTIMICROBIALS USED IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY PROGRAMMES (submitted in 2019) | 4CPS-038 | |
| NOSOCOMIAL INFECTION BY MULTIRESISTANT PATHOGENS IN KIDNEY TRANSPLANTED PATIENTS (submitted in 2019) | 4CPS-039 | |
| ADEQUACY OF ANTIBIOTIC PRESCRIPTIONS IN A NURSING HOME (submitted in 2019) | 4CPS-040 | |
| PHARMACIST LED ANTIMICROBIAL STEWARDSHIP PROGRAMME (submitted in 2019) | 4CPS-041 | |
| PHARMACIST’S MISSION IN INFECTION MANAGEMENT : EVALUATION OF IMPROVEMENT ACTIONS (submitted in 2019) | 4CPS-042 | |
| EFFECTIVENESS OF A NEW INTERNAL PROTOCOL FOR DOSAGE OF VANCOMYCIN IN NEONATES (submitted in 2019) | 4CPS-043 | |
| THE ROUTINE USE OF ANTIBIOTICS AFTER INSERTION OF A CARDIAC IMPLANTABLE ELECTRONIC DEVICE (CIED): EVIDENCE AND CURRENT PRACTICE (submitted in 2019) | 4CPS-044 | |
| COST EFFECTIVENESS ANALYSIS OF MEROPENEM DOSE OPTIMISATION IN CRITICAL PATIENTS (submitted in 2019) | 4CPS-045 | |
| MONITORING THE PRESCRIPTION OF NEW ANTIBIOTICS: THE WORK OF THE ANTIMICROBIAL STEWARDSHIP TEAM IN A THIRD LEVEL HOSPITAL (submitted in 2019) | 4CPS-046 | |
| ASSESSING THE IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS: ROLE OF HOSPITAL PHARMACISTS. (submitted in 2019) | 4CPS-047 | |
| BETA-LACTAM ANTIBIOTICS IN CRITICAL ILL PATIENTS: ARE WE DOSING CORRECTLY OUR PATIENTS CORRECTLY? (submitted in 2019) | 4CPS-048 | |
| UNDERDOSING WITH HIGH DOSE PIPERACILLIN/TAZOBACTAM ADMINISTERED VIA CONTINUOUS INFUSION IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY: A STABILITY OR VISCOSITY PROBLEM? (submitted in 2019) | 4CPS-049 | |
| CONFORMITY OF ANTIBIOTIC THERAPY DURATION IN PATIENTS WITH FEBRILE NEUTROPENIA, HOSPITALISED IN THE HAEMATOLOGY DEPARTMENT OF A UNIVERSITY HOSPITAL (submitted in 2019) | 4CPS-050 | |
| ANTIBIOTICS IN THE EMERGENCY DEPARTMENT: IS IT POSSIBLE TO IMPROVE THE PRESCRIPTIONS FOR INFECTIOUS RESPIRATORY DISEASES IN AMBULATORY PATIENTS? (submitted in 2019) | 4CPS-051 | |
| EVALUATION OF PIPERACILIN/TAZOBACTAM DOSAGE IN SEPTIC PATIENTS ATTENDING THE EMERGENCY DEPARTMENT (submitted in 2019) | 4CPS-052 | |
| ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN INTENSIVE CARE UNIT (submitted in 2019) | 4CPS-053 | |
| A MULTIDISCIPLINARY AND EDUCATIONAL APPROACH TO ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN THE EMERGENCY DEPARTMENT (submitted in 2019) | 4CPS-054 | |
| EVALUATION OF USE, EFFECTIVENESS AND SAFETY OF ISAVUCONAZOL (submitted in 2019) | 4CPS-055 | |
| PROPER USE OF ANTIFUNGALS: IMPLEMENTATION OF OPERATIONAL MULTIDISCIPLINARY TEAMS DEDICATED TO ANTIFUNGALS (submitted in 2019) | 4CPS-056 | |
| THERAPEUTIC DRUG MONITORING OF VORICONAZOLE (submitted in 2019) | 4CPS-057 | |
| MANAGEMENT OF THE HOSPITALISED PATIENT WITH FLU (submitted in 2019) | 4CPS-058 | |
| STRATEGY FOR CHANGE IN ANTIRETROVIRAL THERAPY: LOOKING FOR BETTER RESULTS (submitted in 2019) | 4CPS-059 | |
| PRESCRIPTION ANALYSIS OF TENOFOVIR DISPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE FUMARATE IN A THIRD LEVEL HOSPITAL (submitted in 2019) | 4CPS-060 | |
| ADHERENCE TO ANTIRETROVIRAL TREATMENT AS A FUNCTION OF THE COMPLEXITY OF THE TREATMENT (submitted in 2019) | 4CPS-061 | |
| PATIENTS WITH DARUNAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE TREATMENT IN A THIRD LEVEL HOSPITAL (submitted in 2019) | 4CPS-062 | |
| USE OF OSELTAMIVIR IN THE TREATMENT OF INFLUENZA A (submitted in 2019) | 4CPS-063 | |
| ADHERENCE TO ANTIRETROVIRAL TREATMENT IN PATIENTS WITH HIV (submitted in 2019) | 4CPS-064 | |
| SWITCHING TO EQUIVALENT ALTERNATIVES: ANTIRETROVIRAL OPTIMISATION STRATEGY (submitted in 2019) | 4CPS-065 | |
| CHANGING FROM COBICISTAT TO A RITONAVIR BOOSTED REGIMEN IN HIV POSITIVE PATIENTS (submitted in 2019) | 4CPS-066 | |
| ANALYSIS OF USAGE OF DIRECT ACTIN ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C. (submitted in 2019) | 4CPS-067 | |
| EFFECTIVENESS OF DOLUTEGRAVIR AND LAMIVUDINE THERAPY IN A TWO DRUG REGIMEN IN A THIRD LEVEL HOSPITAL. (submitted in 2019) | 4CPS-068 | |
| EVALUATION OF PALIVIZUMAB AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION (submitted in 2019) | 4CPS-069 | |
| ANALYSIS OF THE USE OF NON-SPECIFIC INTRAVENOUS IMMUNOGLOBULINS IN A TERTIARY HOSPITAL. (submitted in 2019) | 4CPS-070 | |
| ANALYSIS OF EFFECTIVENESS: USE OF PERTUZUMAB AND TRASTUZUMAB IN NEOADJUVANT TREATMENT IN PATIENTS WITH HER2 POSITIVE BREAST CANCER AND ITS CORRELATION WITH PLASMA LEVELS OF TRASTUZUMAB (submitted in 2019) | 4CPS-071 | |
| COMPARISON OF IMMUNE CHECKPOINT INHIBITORS (NIVOLUMAB, PEMBROLIZUMAB, ATÉZOLIZUMAB AND DURVALUMAB) IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: TOLERANCE AND FINANCIAL IMPACT (submitted in 2019) | 4CPS-072 | |
| EFFECTIVENESS AND SAFETY OF PLATIN/PERMETREXED COMBINATION IN NON-SMALL CELL LUNG CANCER. (submitted in 2019) | 4CPS-073 | |
| CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER: POTENTIAL DRUG INTERACTIONS (submitted in 2019) | 4CPS-074 | |
| IBRUTINIB ASSOCIATED ATRIAL FIBRILLATION: INCIDENCE AND MANAGEMENT IN THE REAL LIFE CLINICAL SETTING (submitted in 2019) | 4CPS-075 | |
| INDIRECT COMPARISON BETWEEN PEMBROLIZUMAB MONOTHERAPY AND PEMBROLIZUMAB CHEMOTHERAPY REGIMENE IN SQUAMOUS LUNG CANCER (submitted in 2019) | 4CPS-076 | |
| DETECTION AND COMMUNICATION OF CONCOMITANT USE OF CAPECITABINE AND PROTON PUMP INHIBITORS (submitted in 2019) | 4CPS-077 | |
| EFFECTIVENESS AND SAFETY OF ERIBULIN FOR ADVANCED BREAST CANCER TREATMENT (submitted in 2019) | 4CPS-078 | |
| SEQUENCING OF IBRUTINIB, IDELALISIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019) | 4CPS-079 | |
| REAL LIFE TYROSINE KINASE INHIBITOR DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (submitted in 2019) | 4CPS-080 | |
| GEFITINIB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY. (submitted in 2019) | 4CPS-081 | |
| RISK OF MYELOTOXICITY IN NON-CANCER PATIENTS TREATED WITH CHEMOTHERAPY (submitted in 2019) | 4CPS-082 | |
| SAFETY AND TOLERABILITY OF PALBOCICLIB IN CLINICAL PRACTICE IN A TERTIARY HOSPITAL (submitted in 2019) | 4CPS-083 | |
| ANTHRACYCLINES DOSAGE IN PAEDIATRIC OBESE PATIENTS (submitted in 2019) | 4CPS-084 | |
| IMPROVED ACCESS TO CHEMOTHERAPEUTIC TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (submitted in 2019) | 4CPS-085 | |
| IMATINIB DOSE OPTIMISATION THROUGH THERAPEUTIC MONITORING IN CHRONIC MYELOID LEUKAEMIA AS PART OF PHARMACEUTICAL CARE (submitted in 2019) | 4CPS-086 | |
| OPTIMISATION OF RESOURCES IN THE USE OF IMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB IN WEIGHT-BASED DOSING INSTEAD OF FLAT DOSE. (submitted in 2019) | 4CPS-087 | |
| CHECKPOINT INHIBITORS IN NON-MICROCYTIC LUNG CANCER: RESULTS IN COMMON CLINICAL PRACTICE (submitted in 2019) | 4CPS-088 | |
| COMPARATIVE EFFECTIVENESS OF NINTEDANIB PLUS DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN ADENOCARCINOMA NON-SMALL CELL LUNG CANCER (submitted in 2019) | 4CPS-089 | |
| EFFICACY AND SAFETY OF ERLOTINIB IN NON-SMALL CELL LUNG CANCER (submitted in 2019) | 4CPS-090 | |
| EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH PANCREATIC CANCER (submitted in 2019) | 4CPS-091 | |
| EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH METASTATIC NON-MICROCYTIC LUNG CANCER (submitted in 2019) | 4CPS-092 | |
| EFFECTIVENESS OF DEXAMETHASONE MOUTHWASH 0.1MG/ML FOR PREVENTION OF EVEROLIMUS RELATED STOMATITIS (submitted in 2019) | 4CPS-093 | |
| CHARACTERISATION OF POTENTIAL DRUG-DRUG INTERACTIONS IN ONCOLOGICAL PATIENTS TREATED WITH ORAL ANTICANCER DRUGS (submitted in 2019) | 4CPS-094 | |
| REVIEWING THE LATEST CLINICAL RESEARCH FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER: SELECTION OF RANDOMISED CONTROLLED TRIALS PUBLISHED IN 2018 (submitted in 2019) | 4CPS-095 | |
| EVALUATION OF CLINICAL PHARMACY SERVICES IN A HAEMATOLOGY OUTPATIENT SETTING. (submitted in 2019) | 4CPS-096 |
| SECOND LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WITH IMMUNE CHECKPOINT INHIBITORS (submitted in 2019) | 4CPS-097 | |
| INDIRECT TREATMENT COMPARISONS OF IBRUTINIB-OBINOTUZUMAB VERSUS VENETOCLAX-OBINOTUZUMAB IN NAIVE CHRONIC LYMPHOCYTIC LEUKAEMIA (submitted in 2019) | 4CPS-098 | |
| REAL WORLD EVIDENCE OF PEMBROLIZUMAB AS MONOTHERAPY IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY STUDY (submitted in 2019) | 4CPS-099 | |
| ANTHRACYCLINE DOSING IN OBESE ADULT PATIENTS: A SYSTEMATIC REVIEW (submitted in 2019) | 4CPS-100 | |
| TRIFLURIDINE-TIPIRACIL FOR METASTATIC COLORECTAL CANCER: REAL WORLD DATA EXPERIENCE (submitted in 2019) | 4CPS-101 | |
| INFLUENCE OF PALBOCICLIB TOXICITY IN THE REAL WORLD CLINICAL PRACTICE (submitted in 2019) | 4CPS-102 | |
| IS THERE A ROLE FOR THE PHARMACIST IN SCREENING FOR METABOLIC SYNDROME? (submitted in 2019) | 4CPS-103 | |
| SWITCHING ORAL ANTIANDROGENIC TREATMENT IN PATIENTS WITH CASTRATE METASTATIC PROSTATE CANCER: AN ANALYSIS. (submitted in 2019) | 4CPS-104 | |
| TOLERANCE PROFILE TO ANTI-THYMOCYTE IMMUNOGLOBULIN TREATMENT AND ITS RELATION TO INFECTIOUS PARAMETERS IN PAEDIATRIC PATIENTS (submitted in 2019) | 4CPS-105 | |
| ANALYSIS OF THE PRESCRIPTION AND SAFE DRUG ADMINISTRATION OF OCRELIZUMAB (submitted in 2019) | 4CPS-106 | |
| IMPACT OF A TOOL IN THE ELECTRONIC CLINICAL HISTORY FOR THE OPTIMISATION OF BIOLOGIC DRUGS IN RHEUMATOLOGY (submitted in 2019) | 4CPS-107 | |
| A REVIEW OF INFLIXIMAB BIOSIMILAR TO BIOSIMILAR SWITCH: REMSIMA TO FLIXABI (submitted in 2019) | 4CPS-108 | |
| ANALYSIS OF CHANGES IN DISEASE MODIFYING TREATMENT IN THE MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS (submitted in 2019) | 4CPS-109 | |
| VEDOLIZUMAB: OUTCOMES AND THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE (submitted in 2019) | 4CPS-110 | |
| CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB BIOSIMILAR INFLECTRA IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS NAÏVE AND SWITCHED PATIENTS: AFTER 5 YEARS OF FOLLOW-UP (submitted in 2019) | 4CPS-111 | |
| ADHERENCE TO ADALIMUMAB, GOLIMUMAB AND USTEKINUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE (submitted in 2019) | 4CPS-112 | |
| INOTUZUMAB OZOGAMIZIN FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN AN ADULT PATIENT: A CASE REPORT. (submitted in 2019) | 4CPS-113 | |
| BELIEFS ABOUT MEDICATION AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB (submitted in 2019) | 4CPS-114 | |
| THERAPEUTIC DRUG MONITORING OF ETANERCEPT BIOSIMILAR IN PSORIATIC PATIENTS (submitted in 2019) | 4CPS-115 | |
| TEN YEARS OF EXPERTISE IN USTEKINUMAB USE FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS (submitted in 2019) | 4CPS-116 | |
| CASE REPORT: USEFULNESS OF THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN MANAGING ACUTE GRAFT VERSUS HOST DISEASE (submitted in 2019) | 4CPS-117 | |
| REAL CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS OF IMMUNOSUPPRESSANTS IN TRANSPLANT PATIENTS. (submitted in 2019) | 4CPS-118 | |
| “REAL WORLD” EXPERIENCE OF TOFACITINIB AND BARICITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: EFFECTIVENESS AND SAFETY EVALUATION (submitted in 2019) | 4CPS-119 | |
| TEN YEAR ANALYSIS OF THE USE OF INFLIXIMAB IN ULCERATIVE COLITIS (submitted in 2019) | 4CPS-120 | |
| EVALUATION OF COST AND EFFICACY OF ECULIZUMAB IN COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY IN THE CLINICAL SETTING (submitted in 2019) | 4CPS-121 | |
| POTENTIAL OPTIMISATION OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE (submitted in 2019) | 4CPS-122 | |
| EVALUATION OF ADHERENCE TO ORAL DISEASE MODIFYING THERAPIES (ORAL-DMT) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (submitted in 2019) | 4CPS-123 | |
| ADHERENCE TO SELECTIVE IMUNOSUPPRESSIVE DRUGS TREATMENTS IN PATIENTS WITH INFLAMMATORY IMMUNE-MEDIATED DISEASES (submitted in 2019) | 4CPS-124 | |
| ACCEPTANCE OF PHARMACOKINETIC RECOMMENDATIONS FOR EVEROLIMUS IN RENAL TRANSPLANT PATIENTS (submitted in 2019) | 4CPS-125 | |
| A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWOL DISEASE: A PRELIMINARY ANALYSIS (submitted in 2019) | 4CPS-126 | |
| ECONOMIC IMPACT OF INTENSIFICATION REGIMENS IN INFLAMMATORY BOWEL DISEASE (submitted in 2019) | 4CPS-127 | |
| LIVER TRANSPLANT AND DIABETES MELLITUS (submitted in 2019) | 4CPS-128 | |
| PILOT STUDY TO SURVEY THE ATTITUDE, SUPPLEMENT USE AND STORAGE CONDITIONS OF DRUG PRODUCTS AMONG PATIENTS RECEIVING BIOLOGICAL THERAPY (submitted in 2019) | 4CPS-129 | |
| ONE IN A MILLION: A TNF RECEPTOR-1 ASSOCIATED SYNDROME RESISTANT TO ANTI-TNF-ALPHA THERAPY. (submitted in 2019) | 4CPS-130 | |
| EFFECTIVENESS OF NUSINERSEN IN PAEDIATRIC PATIENTS SMA1 AND SMA2 (submitted in 2019) | 4CPS-131 | |
| INDIRECT TREATMENT COMPARISON OF ANTICALCITONIN GENE RELATED PEPTIDE PATHWAY ANTIBODIES IN CHRONIC MIGRAINE (submitted in 2019) | 4CPS-132 | |
| IS PARACETAMOL A REAL ALTERNATIVE IN THE MANAGEMENT OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTS? (submitted in 2019) | 4CPS-133 | |
| PREVALENCE ANALYSIS OF PATIENTS TREATED WITH TRIPTANS AT RISK OF DEVELOPING MEDICATION OVERUSE HEADACHE AND DEVELOPMENT OF A PRESCRIPTION OPTIMISATION STRATEGY. (submitted in 2019) | 4CPS-134 | |
| PERPHENAZINE AND PROPRANOLOL POISONING: A CASE REPORT. (submitted in 2019) | 4CPS-135 | |
| DEXMEDETOMIDINE TREATMENT FOR THE SEDATION OF PRETERM NEONATES (submitted in 2019) | 4CPS-136 |
| REVIEW OF 3 MONTH PRESCRIPTIONS CONTAINING DRUGS INDUCING QT PROLONGATION AND TORSADE DE POINTE (submitted in 2019) | 4CPS-137 | |
| AN OBSERVATIONAL RETROSPECTIVE STUDY ON TREATMENT ADHERENCE OF LONG ACTING INJECTABLE ANTIPSYCHOTICS (submitted in 2019) | 4CPS-138 | |
| PSYCHOTROPIC DRUG USAGE IN OCTOGENARIAN AND NONAGENARIAN COMPLEX CHRONIC PATIENTS (submitted in 2019) | 4CPS-139 | |
| CURRENT STATUS OF CLINICAL TRIALS FOR ALZHEIMER’S DISEASE (submitted in 2019) | 4CPS-140 | |
| EFFECTIVENESS OF IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA (submitted in 2019) | 4CPS-141 | |
| EFFECTIVENESS AND SAFETY OF ANTI-IL-5 BIOLOGIC AGENTS IN SEVERE EOSINOPHILIC ASTHMA (submitted in 2019) | 4CPS-142 | |
| TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTION PULMONARY DISEASE: ARE OUR HOSPITAL NURSES AND PHYSICIANS READY TO TREAT AND EDUCATE IN-PATIENTS? (submitted in 2019) | 4CPS-143 | |
| SAFETY AND EFFECTIVENESS OF REDUCED DOSE OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA (submitted in 2019) | 4CPS-144 | |
| EVALUATION OF A PHARMACEUTICAL CARE PROGRAMME FOR PATIENTS BEING TREATED WITH OMALIZUMAB (submitted in 2019) | 4CPS-145 | |
| EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN THE TREATMENT OF SEVERE UNCONTROLLED ASTHMA (submitted in 2019) | 4CPS-146 |
| THERAPEUTIC POSITIONING AND USE OF INTRAVITREAL RANIBIZUMAB AND AFLIBERCEPT (submitted in 2019) | 4CPS-147 | |
| CLINICAL EVALUATION AND SATISFACTION OF PATIENTS TREATED WITH PRGF-ENDORET (PLASMA RICH IN GROWTH FACTORS) (submitted in 2019) | 4CPS-148 | |
| INITIAL THERAPY FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION: ARE THE GUIDELINES MET IN CLINICAL PRACTICE? (submitted in 2019) | 4CPS-149 | |
| ASSESSMENT OF BURDEN OF DISEASE IN TERMS OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (submitted in 2019) | 4CPS-150 | |
| THE IMPACT OF AN INTEGRATED ELECTRONIC MEDICAL RECORD ON THERAPEUTIC DRUG MONITORING (submitted in 2019) | 4CPS-151 | |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN THE EXCHANGE OF THERAPEUTIC EQUIVALENTS (submitted in 2019) | 4CPS-152 | |
| INTENSIFICATION IN BIOLOGICAL TREATMENT IN ULCERATIVE COLITIS (submitted in 2019) | 4CPS-153 | |
| POTENTIALLY INAPPROPRIATE MEDICATION FOR ELDERLY HOSPITALISED PATIENTS IN A TRAUMA AND ORTHOPAEDIC SURGERY DEPARTMENT (submitted in 2019) | 4CPS-154 | |
| REAL LIFE EXPERIENCE OF HOME CARE ADMINISTRATION OF 5-AZACITIDINE AND DOMICILIARY MANAGEMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (submitted in 2019) | 4CPS-155 | |
| ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (submitted in 2019) | 4CPS-156 | |
| INTRAVENOUS BIOSIMILAR PRESCRIBING TRENDS IN A THIRD LEVEL SPANISH HOSPITAL (submitted in 2019) | 4CPS-157 | |
| PRESCRIBING TRENDS OF ADALIMUMAB AND ETANERCEPT BIOSIMILAR DRUGS IN A THIRD LEVEL HOSPITAL (submitted in 2019) | 4CPS-158 | |
| MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL (submitted in 2019) | 4CPS-159 | |
| MANAGEMENT OF DRUGS IN PATIENTS WITH SWALLOWING DIFFICULTIES IN A PUBLIC RESIDENTIAL CARE HOME: ROLE OF THE HOSPITAL PHARMACIST (submitted n 2019) | 4CPS-160 | |
| PHARMACIST INTERVENTIONS IN A HOSPITAL AT HOME UNIT (submitted in 2019) | 4CPS-161 |
| PHARMACEUTICAL INTERVENTIONS IN DRUGS PROVIDED TO THE OUTPATIENT HOSPITAL PHARMACY (submitted in 2019) | 4CPS-162 |
| CLINICAL PHARMACIST RESIDENCE IN AN INTENSIVE CARE UNIT: SCOPE AND RELEVANCE (submitted in 2019) | 4CPS-163 | |
| A SAFE HANDLING HAZARDOUS DRUGS STRATEGY TO IMPROVE THE SAFETY OF HEALTH PROFESSIONALS: REDUCING EXPOSURE BY MEDICAL PRESCRIPTION REVIEW IN NURSING HOMES (submitted in 2019) | 4CPS-164 | |
| ANALYSIS OF ANTIBIOTIC CONSUMPTION IN A NURSING HOME (submitted in 2019) | 4CPS-165 |
| ANALYSIS OF THE MAINTENANCE RATE OF LONG ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT IN OUTPATIENTS (submitted in 2019) | 4CPS-166 | |
| EVALUATION OF PHARMACEUTICAL INTERVENTIONS: IMPROVEMENT PLANS (submitted in 2019) | 4CPS-167 | |
| DEVELOPMENT OF A BELGIAN CLASSIFICATION SYSTEM FOR CLINICAL PHARMACY ACTIVITIES (submitted in 2019) | 4CPS-168 | |
| EFFECT OF ABIRATERONE VERSUS ENZALUTAMIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (submitted in 2019) | 4CPS-169 | |
| ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL (submitted in 2019) | 4CPS-170 | |
| PHARMACISTS AT THE HEALTH CENTRE (submitted in 2019) | 4CPS-171 | |
| OFF-LABEL USE OF INTRALESIONAL CIDOFOVIR IN RECURRENT RESPIRATORY PAPILLOMATOSIS: A CASE REPORT. (submitted in 2019) | 4CPS-172 | |
| ROLE OF THE PHARMACIST IN THE MULTIDISCIPLINARY MANAGEMENT OF OSTEOMYELITIS: FROM MEDICATION RECONCILIATION TO SUPPORT IN CLINICAL DECISION MAKING. (submitted in 2019) | 4CPS-173 | |
| FACILITATORS AND BARRIERS TO PERFORMING COMPREHENSIVE MEDICATION REVIEWS AND FOLLOW-UP IN OLDER HOSPITALISED PATIENTS BY MULTIPROFESSIONAL WARD TEAMS INCLUDING A CLINICAL PHARMACIST (submitted in 2019) | 4CPS-174 | |
| EVOLUTION OF ANTIMICROBIAL CONSUMPTION IN A TRAUMA INTENSIVE CARE UNIT USING DEFINED DAILY DOSES PER 100 OCCUPIED BED DAYS (submitted in 2019) | 4CPS-175 | |
| ELECTROLYTE DISTURBANCES IN PREMATURE INFANTS WITH INTRAUTERINE GROWTH RESTRICTION RECEIVING PARENTERAL NUTRITION (submitted in 2019) | 4CPS-176 | |
| COMPARATIVE STUDY OF PATIENT PROFILES AND INITIAL ANTIRETROVIRAL TREATMENT IN 2014 VERSUS 2018 (submitted in 2019) | 4CPS-177 | |
| TRANSCRIPTION OF SUPPORTIVE MEDICATION FOR INPATIENT CHEMOTHERAPY BY DESIGNATED ONCOLOGY WARD PHARMACISTS (submitted in 2019) | 4CPS-178 | |
| THE WIDE REVIEW OF POLYPHARMACY IN THE FRAIL OLDER PERSON (submitted in 2019) | 4CPS-179 | |
| FROM EVIDENCE BASED MEDICINE TO PRACTICE: GUM CHEWING FOR POSTOPERATIVE RECOVERY OF GASTROINTESTINAL FUNCTION AFTER COLORECTAL SURGERY WITH INTERPROFESSIONAL TEAMWORK (submitted in 2019) | 4CPS-180 | |
| BUDGETARY IMPACT OF BIOSIMILAR PRESCRIPTION IN THE TREATMENT OF RHEUMATIC DISEASES (submitted in 2019) | 4CPS-181 | |
| PRELIMINARY DESIGN OF HOSPITAL TELEPHARMACY (submitted in 2019) | 4CPS-182 | |
| SELECTION OF A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SUITABLE FOR THERAPEUTIC DRUG MONITORING (submitted in 2019) | 4CPS-183 | |
| EVALUATION OF A CLINICAL PHARMACY SERVUCE ON AN INPATIENT WARD IN AN ACUTE HOSPITAL (submitted in 2019) | 4CPS-184 | |
| ADMINISTRATION OF ORAL ANTICANCER DRUGS FOR PATIENTS WITH SWALLOWING DIFFICULTIES (submitted in 2019) | 4CPS-185 | |
| DESCRIPTION OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT (submitted in 2019) | 4CPS-186 | |
| PROGNOSTIC VALUE OF HAEMATOLOGICAL INFLAMMATORY MARKERS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH PEMBROLIZUMAB (submitted in 2019) | 4CPS-187 | |
| PHARMACEUTICAL INTERVENTION TO REDUCE THE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS (submitted in 2019) | 4CPS-188 | |
| FALL INCIDENTS IN NURSING HOME PATIENTS: DEVELOPMENT OF A PREDICTIVE CLINICAL RULE (FINDER) (submitted in 2019) | 4CPS-189 |
| EVALUATION OF A NEW CLINICAL PHARMACY SERVICE WITHIN A NEWLY LAUNCHED SURGICAL ADMISSION PROCESS (submitted in 2019) | 4CPS-190 | |
| PHARMACEUTICAL INTERVENTIONS IN A MEDICATION RECONCILIATION PROGRAMME UPON ADMISSION IN SURGICAL PATIENTS (submitted in 2019) | 4CPS-191 | |
| ESTIMATING THE SURVIVAL PROGNOSIS OF PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCY ON HOME PARENTERAL NUTRITION: A RETROSPECTIVE, MONOCENTRE STUDY (submitted in 2019) | 4CPS-192 | |
| MEASURING THE IMPACT OF HOSPITAL PHARMACIST PRESCRITION REVIEWING IN AN ONCOLOGY SETTING ON THE PHARMACOVIGILANCE REPORTING IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019) | 4CPS-193 | |
| THE UNDERREPORTING RATE AS A PHARMACOVIGILANCE PROCESS INDICATOR IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019) | 4CPS-194 |
| PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION FOR CRITICALLY ILL PATIENTS (submitted in 2019) | 4CPS-195 | |
| STABILITY OF LIPID EMULSION IN PAEDIATRIC PARENTERAL NUTRITION WITH HIGH ELECTROLYTIC LOAD (submitted in 2019) | 4CPS-196 | |
| MONITORING OF OFF-LABEL USE: ANALYSIS OF PRESCRIPTIONS IN THE PHARMACY’S ANTIBLASTIC DRUGS UNIT (submitted in 2019) | 4CPS-197 | |
| RESULTS OF A MEDICATION RECONCILIATION PROGRAMME IN COMPLEX CHRONIC PATIENTS AT HOSPITAL DISCHARGE (submitted in 2019) | 4CPS-198 | |
| PHARMACEUTICAL INTERVENTIONS IN HAEMODIALYSIS PATIENTS: A 2 YEAR OVERVIEW (submitted in 2019) | 4CPS-199 | |
| DIFFERENCES IN ALLELIC FREQUENCIES OF RELEVANT PHARMACOGENETIC POLYMORPHISMS MAY LEAD TO LOCAL GENE PANEL DEVELOPMENT (submitted in 2019) | 4CPS-200 | |
| IDENTIFICATION OF HAZARDOUS DRUGS AND PROCESS IN A UNIVERSITY HOSPITAL (submitted in 2019) | 4CPS-201 | |
| NUTRITIONAL RISK EVALUATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A PUBLIC NURSING HOME (submitted in 2019) | 4CPS-202 | |
| NURSES: WHAT DO YOU THINK ABOUT A PHARMACEUTICAL PRESENCE IN THE EMERGENCY WARD? (submitted in 2019) | 4CPS-203 | |
| MEDICINE RECONCILIATION AT HOSPITAL DISCHARGE (submitted in 2019) | 4CPS-204 | |
| ASSESSMENT OF THE PALATABILITY OF ANTIBIOTIC ORAL SUSPENSIONS: A LITERATURE REVIEW. (submitted in 2019) | 4CPS-205 | |
| IMPACT OF MEDICATION RECONCILIATION IN COMPLEX CHRONIC PATIENTS (submitted in 2019) | 4CPS-206 | |
| TREATMENT ADEQUACY IN DOMICILIARY CARE PROGRAMME PATIENTS (submitted in 2019) | 4CPS-207 | |
| NUTRITIONAL SUPPORT IN ONCOLOGY: A CROSS SECTIONAL STUDY AMONG CANCER PATIENTS (submitted in 2019) | 4CPS-208 | |
| AN EXPLORATION INTO A PHARMACIST-LED MEDICINES RECONCILIATION SERVICE IN AN ACUTE HOSPITAL SETTING. (submitted in 2019) | 4CPS-209 | |
| PHARMACISTS’ COMMUNICATION WITH FOREIGN LANGUAGE SPEAKING PATIENTS IN A FOREIGNER SETTLEMENT AREA, JAPAN (submitted in 2019) | 4CPS-210 | |
| ADHERENCE AND INTERACTIONS IN PATIENTS TREATED WITH ABIRATERONE AND ENZALUTAMIDE (submitted in 2019) | 4CPS-211 | |
| HEALTHCARE PROVIDERS’ VIEWS OF PHARMACY TEAM INVOLVEMENT IN THE PREPARATION AND ADMINISTRATION OF MEDICINES ON INPATIENTS WARDS: AN EXPLORATORY STUDY (submitted in 2019) | 4CPS-212 | |
| PATIENT PERCEPTIONS OF GENERIC MEDICINES 20 YEARS AFTER THE RIGHT OF SUBSTITUTION BY PHARMACISTS (submitted in 2019) | 4CPS-213 | |
| IMPROVING INTRAVENOUS TO ORAL SWITCH BY IDENTIFYING AND TACKLING BARRIERS PERCEIVED BY PHYSICIANS AND NURSES (submitted in 2019) | 4CPS-214 | |
| THE IMPACT OF CLINICAL PHARMACIST DRIVEN INTERVENTIONS ON PATIENT SAFETY IN HOSPITALISED PATIENTS: PRELIMINARY RESULTS OF A POINT PREVALENCE STUDY (submitted in 2019) | 4CPS-215 | |
| PROMOTION OF THE QUALITY OF DRUG EDUCATION FOR THE PATIENTS USING NASOGASTRIC TUBE FEEDING BEFORE DISCHARGE (submitted in 2019) | 4CPS-216 | |
| NETUPITANT-PALONOSETRON IN BREAST CANCER: POTENTIAL DRUGS INTERACTIONS | 4CPS-217 |
| ANTIDIABETIC TREATMENT IN FRAIL PATIENTS WITH TYPE II DIABETES ADMITTED TO THE EMERGENCY DEPARTMENT FOR ALTERED GLYCAEMIA | 4CPS-218 | |
| COMPARISON OF THE NUMBER OF PARENTAL NUTRITION PRESCRIPTIONS IN 2020 DURING THE COVID-19 PANDEMIC WITH THE SAME TIME PERIOD IN 2019 | 4CPS-219 | |
| PATIENT SATISFACTION WITH PHARMACIST EDUCATION ON ORAL ANTICOAGULANT MEDICATION | 4CPS-220 |
| EFFECT OF SARS-CoV-2 PANDEMIC ON DIRECT ORAL ANTICOAGULANTS USE IN THE PRIMARY CARE SETTING | 4CPS-221 |
| CONCORDANCE BETWEEN GUIDELINES ON PERIOPERATIVE MANAGEMENT OF NOVEL ORAL ANTICOAGULANTS AND ITS IMPLEMENTATION AND PREVENTABLE CAUSES OF THE OCCURRENCE OF ISCHAEMIC STROKE | 4CPS-222 |
| REAL WORLD EXPERIENCE OF SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION | 4CPS-223 |
| THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS: ASSESSMENT OF THE CURRENT PRACTICES IN A 950 BED HOSPITAL GROUP | 4CPS-224 | |
| IMPLEMENTATION OF A COMPUTER ALGORITHM IN THE ELECTRONIC HEALTH RECORD TO IDENTIFY INPATIENTS WITH UNTREATED ATRIAL FIBRILLATION TO OPTIMISE STROKE PREVENTION | 4CPS-225 |
| EFFECTIVENESS OF CARBOXYMALTOSE IRON IN PREOPERATIVE ANAEMIA TREATMENT | 4CPS-226 |
| HUMAN SERUM ALBUMIN: ANALYSIS OF USE | 4CPS-227 |
| VERNAKALANT VERSUS FLECAINIDE FOR CONVERSION OF RECENT ONSET ATRIAL FIBRILLATION IN PATIENTS ATTENDING THE EMERGENCY DEPARTMENT | 4CPS-228 |
| ANALYSIS OF CLINICAL PHARMACIST INTERVENTIONS IN THE HEART FAILURE DAY HOSPITAL. | 4CPS-229 |
| ANTIARRHYTHMIC THERAPY EVALUATION IN A HOSPITAL SETTING | 4CPS-230 |
| REAL WORLD DATA OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HYPERLIPIDAEMIA: ANALYSIS 3 YEARS AFTER INTRODUCTION IN CLINICAL PRACTICE | 4CPS-231 |
| USE OF DUPILUMAB IN THE TREATMENT OF ATOPIC DERMATITIS IN REAL CLINICAL PRACTICE | 4CPS-232 |
| HOME MANAGEMENT OF ACUTE MULTIPLE SCLEROSIS OUTBREAK: ADAPTATION TO CORONAVIRUS PANDEMIC | 4CPS-233 |
| GLUCOCORTICOID INDUCED HYPERGLYCAEMIA IN NON-DIABETIC PATIENTS IN AN EMERGENCY DEPARTMENT | 4CPS-234 |
| SYSTEMIC CORTICOSTEROIDS IN THE TREATMENT OF SARS-CoV-2 INFECTION | 4CPS-235 |
| USE OF ETELCALCETIDE IN PATIENTS UNDERGOING HAEMODIALYSIS | 4CPS-236 | |
| FEASIBILITY OF CONTINUOUS ADMINISTRATION OF ANTIMICROBIALS IN HOSPITAL: NOTHING IS EVER AS IT SEEMS? | 4CPS-237 |
| EVALUATION OF EFFECTIVENESS OF COMPOUNDED ORAL VANCOMYCIN CAPSULES FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | 4CPS-238 |
| THERAPEUTIC DRUG MONITORING OF GENTAMICIN IN NEONATES | 4CPS-239 |
| THERAPEUTIC MONITORING OF VANCOMYCIN IN A COHORT OF PAEDIATRIC PATIENTS | 4CPS-240 |
| IMPACT OF ANTIBIOTIC PRESCRIBING IN AN EMERGENCY DEPARTMENT ON HOSPITAL STAYS, READMISSION AND MORTALITY | 4CPS-241 |
| ACUTE RESPIRATORY INFECTIONS: AN ANALYSIS OF HOSPITAL ANTIBIOTHERAPY PRESCRIPTION QUALITY FOR THE PAEDIATRIC POPULATION | 4CPS-242 |
| HEALHCARE ASSOCIATED CLOSTRIDIOIDES DIFFICILE INFECTION IN SURGICAL AND MEDICAL PATIENTS | 4CPS-243 |
| THERAPEUTIC DRUG MONITORING GUIDED PHARMACY INTERVENTIONS TO OPTIMISE THE DOSAGE OF BETA-LACTAMS ADMINISTERED IN CONTINUOUS INFUSION IN NON-CRITICALLY ILL PATIENTS. | 4CPS-244 |
| DURATION OF ANTIBIOTIC TREATMENT IN PATIENTS DISCHARGED FROM A SHORT STAY HOSPITALISATION UNIT | 4CPS-245 | |
| CORONAVIRUS FIRST WAVE EFFECT ON ANTIBIOTIC CONSUMPTION AND ANTIMICROBIAL RESISTANCE | 4CPS-246 |
| VARIATIONS IN CONSUMPTION OF ANTIMICROBIALS IN INTERNAL MEDICINE WARDS OF HOSPITALS | 4CPS-247 |
| APPROPRIATENESS OF THE CLOSTRIDIUM DIFFICILE INFECTION PRESCRIPTION PRIOR TO THE IMPLEMENTATION OF A PROTOCOL FOR ITS MANAGEMENT | 4CPS-248 |
| SECOND GENERATION β-LACTAM/ β-LACTAMASE INHIBITOR COMBINATIONS: CEFTAZIDIME-AVIBACTAM AND CEFTOLOZANE-TAZOBACTAM EXPERIENCE OF USE | 4CPS-249 |
| EVALUATION OF PRESCRIPTION ADEQUACY TO THE ANTIBIOTHERAPY PROTOCOL IN INTRA-ABDOMINAL INFECTION IN A REGIONAL HOSPITAL | 4CPS-250 |
| EVALUATION OF CLOSTRIDIUM DIFFICILE INFECTION MANAGEMENT PRIOR TO IMPLEMENTATION OF A PROTOCOL FOR IMPROVEMENT | 4CPS-251 |
| STUDY OF THE IMPLEMENTATION OF A VANCOMYCIN PHARMACOKINETIC MONITORING PROGRAMME IN PAEDIATRICS | 4CPS-252 |
| THE IMPORTANCE OF THE PHARMACOKINETIC PROFILE IN PATIENTS WITH ULTRA-RARE DISEASES:A CASE REPORT | 4CPS-253 |
| A RETROSPECTIVE STUDY OF ANTIMICROBIAL STEWARDSHIP IN A UNIVERSITY HOSPITAL | 4CPS-254 |
| CLINICAL EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL | 4CPS-255 |
| HEPATITIS C RETREATMENT OF A PATIENT WHO FAILED MULTIPLE TREATMENTS INCLUDING PROTEASE INHIBITOR AND NON-STRUCTURAL PROTEIN 5A INHIBITORS: A CASE REPORT | 4CPS-256 |
| RELEVANCE OF RITONAVIR INTERACTIONS IN HIV TREATMENTS THAT INVOLVE TREATMENT MODIFICATION | 4CPS-257 |
| EVALUATION OF MEDICINES ADHERENCE AND ASSOCIATED FACTORS IN PATIENTS WITH CHRONIC HEPATITIS B | 4CPS-258 |
| ONE YEAR WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE | 4CPS-259 |
| ANALYSIS OF DRUGS INTERACTIONS BETWEEN CORONAVIRUS (COVID-19) ANTIVIRAL TREATMENT AND CONCOMITANT MEDICATION | 4CPS-260 |
| USE OF INTRAVENOUS IMMUNOGLOBULIN: BY THE BOOK? | 4CPS-261 |
| CLINICAL EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN NEUROLOGY: A RETROSPECTIVE COHORT STUDY AT THE MATER MISERICORDIAE UNIVERSITY HOSPITAL | 4CPS-262 |
| CASE REPORT OF KAWASAKI DISEASE AND SARS-COV-2 INFECTION IN A PAEDIATRIC HOSPITAL | 4CPS-263 |
| AUTOIMMUNE MYOPATHY RESULTING FROM A THERAPY WITH NIVOLUMAB FOR METASTATIC NON-SMALL CELL LUNG CANCER: A CASE REPORT | 4CPS-264 |
| CEMIPLIMAB FOR THE TREATMENT OF RELAPSE OF A CUTANEOUS SQUAMOUS CELL CARCINOMA IN AN ADULT PATIENT: A CASE REPORT | 4CPS-265 |
| AFATINIB AS FIRSTLINE TREATMENT FOR ADVANCED LUNG ADENOCARCINOMA IN A PATIENT HARBOURING EXON 19 DELETION IN EGFR: A CASE REPORT | 4CPS-266 |
| RETROSPECTIVE ANALYSIS OF CARBOPLATIN DOSING PRESCRIBED IN A CHEMOTHERAPY REGIMEN AND ITS RELATIONSHIP WITH TOXICITY | 4CPS-267 |
| NIVOLUMAB VERSUS PEMBROLIZUMAB IN SECONDLINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER IN CLINICAL PRACTICE | 4CPS-268 |
| HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY ASSOCIATED WITH CYTOREDUCTIVE SURGERY IN PERITONEAL CANCER TREATMENTS: A MULTIDISCIPLINARY EXPERIENCE TO EVALUATE ITS EFFICACY | 4CPS-269 |
| RESULTS OF EFFECTIVENESS AND SAFETY IN REAL CLINICAL PRACTICE OF NIVOLUMAB, PEMBROLIZUMAB AND ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER | 4CPS-270 |
| EVALUATION OF THE EFFICACY OF ANTI-PD-L1 IMMUNOTHERAPY IN NON-MICROCRITICAL LUNG CANCER IN CLINICAL PRACTICE | 4CPS-271 |
| PHARMACIST ROLE IN HEALTH OUTCOME OF VD-PACE SAVAGE REGIMEN IN AN ADULT FEMALE PATIENT WITH RARE RELAPSED AND REFRACTORY IgD LAMBDA MULTIPLE MYELOMA | 4CPS-272 |
| DOES AGE REALLY MATTERS ON THE PREVALENCE OF DRUG-DRUG INTERACTIONS WITH ENDOVENOUS CHEMOTHERAPY? | 4CPS-273 |
| REAL WORLD EFFECTIVENESS OF PALBOCICLIB AND RIBOCICLIB IN WOMEN WITH METASTATIC BREAST CANCER. | 4CPS-274 |
| EFFICACY AND SAFETY OF TRIFLURIDINE/TIPIRACIL IN PATIENTS WITH METASTATIC COLORECTAL CANCER: REAL WORLD DATA | 4CPS-275 |
| ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY REAL WORLD DATA STUDY. | 4CPS-276 |
| CETUXIMAB VERSUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: A COMPARATIVE EFFECTIVENESS AND PATIENT REPORTED OUTCOMES MULTI-COHORT STUDY | 4CPS-277 |
| EFFECTIVENESS AND SAFETY OF CISPLATIN PLUS GEMCITABINE IN METASTATIC BREAST CANCER | 4CPS-278 |
| CANCER PAIN MANAGEMENT APPROACH CONSIDERING POTENTIAL DRUG INTERACTIONS IN PATIENTS RECEIVING ORAL ANTITUMOUR TREATMENT | 4CPS-279 |
| BENEFITS OF PHARMACOKINETIC ESTIMATION OF METHOTREXATE LEVELS IN PAEDIATRIC OSTEOSARCOMA PATIENTS | 4CPS-280 |
| HIGH DOSE METHOTREXATE IN PEDIATRIC OSTEOSARCOMA PATIENTS: EFFECTIVENESS AND SAFETY. | 4CPS-281 |
| EPIDEMIOLOGY AND CLINICAL COURSE OF PATIENTS WITH CANCER DIAGNOSED WITH SARS-COV-2 INFECTION | 4CPS-282 |
| ONCOHAEMATOLOGICAL PHARMACEUTICAL CARE CONSULTATION. IS THE INFORMATION ON THE EUROPEAN PUBLIC ASSESSMENT REPORT OF DRUGS ENOUGH? | 4CPS-283 |
| TREATMENT OF CYCLIN INHIBITOR INDUCED NEUTROPENIA: IMPACT ON PROGRESSION FREE SURVIVAL | 4CPS-284 |
| MULTIDISCIPLINARY ORAL THERAPY OUTPATIENT CLINIC: AN ITALIAN SINGLE CENTRE EXPERIENCE | 4CPS-285 |
| EARLY IMPACT OF COVID ON THE ACTIVITY OF A CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT AT A TERTIARY CARE HOSPITAL | 4CPS-286 |
| IMPACT OF SARS-COV-2 INFECTION IN ACUTE MYELOID LEUKAEMIA PATIENTS: EXPERIENCE OF THE PETHEMA REGISTRY | 4CPS-287 |
| CLINICAL PHARMACIST’S IMPACT IN IMPROVING THE SAFETY OF THERAPIES FOR PATIENTS USING ORAL ANTICANCER AGENTS: A PROSPECTIVE SINGLE CENTRE STUDY | 4CPS-288 |
| ANALYSIS OF ANTINEOPLASTIC DRUG CONTAMINATION LEVEL IN THE HOSPITAL PHARMACY: PROBLEM MONITORING AND SOLVING | 4CPS-289 |
| BORTEZOMIB INDUCED ACUTE NECROHAEMORRHAGIC PANCREATITIS: A CASE REPORT | 4CPS-290 |
| PALBOCICLIB: EARLY NEUTROPENIA AS A PHARMACODYNAMIC MARKER IN A REAL WORLD SETTING? | 4CPS-291 |
| EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHATIC LEUKAEMIA: MULTICENTRE STUDY | 4CPS-292 |
| EFFICACY AND SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER | 4CPS-293 | |
| EFFICACY AND SAFETY PROFILE OF TRIFLURIDINE TIPIRACIL AND REGORAFENIB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER | 4CPS-294 | |
| IMMUNOTHERAPY FOR CANCER THERAPEUTIC POSITIONING REPORTS: KNOWLEDGE, EXPECTATIONS AND EXPERIENCES THROUGH A NATIONAL SURVEY. | 4CPS-295 |
| IMPACT OF THE COVID-19 PANDEMIC ON CLINICAL LUNG CANCER MANAGEMENT | 4CPS-296 |
| SPINAL CORD APLASIA CAUSED BY 6-MERCAPTOPURINE IN A CAUCASIAN GIRL WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND HOMOZYGOUS MUTATION IN NUDIX HYDROLASE 15: CASE REPORT | 4CPS-297 |
| EFFICACY AND SAFETY PROFILE OF ANTI-EGFR TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER | 4CPS-298 | |
| PATIENTS’ MISCONCEPTIONS FOLLOWING INITIATION OF ANTINEOPLASTIC TREATMENT FOR COLORECTAL CANCER | 4CPS-299 |
| EFFECTIVENESS AND SAFETY OF CEMIPLIMAB IN SQUAMOUS CELL CARCINOMA OF THE SKIN IN A THIRD LEVEL HOSPITAL | 4CPS-300 |
| ASSOCIATION OF ANTIBIOTICS AND PROTON PUMP INHIBITORS ON CLINICAL ACTIVITY OF FIRSTLINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER: 2 YEARS OF REAL WORLD DATA | 4CPS-301 |
| SORAFENIB IN HEPATOCARCINOMA: RESULTS IN A REAL WORLD SETTING | 4CPS-302 |
| EFFICACY AND SAFETY OF MONOTHERAPY WITH PEMBROLIZUMAB IN NON-MICROCYTIC METASTATIC LUNG CANCER IN CLINICAL PRACTICE. | 4CPS-303 |
| RITUXIMAB AS AN ALTERNATIVE IN NEUROLOGIC DISORDERS: LONG TERM STUDY | 4CPS-304 |
| EFFECTIVENESS AND SAFETY OF BRAF/MEK INHIBITORS IN ADVANCED OR METASTATIC MELANOMA IN TWO TERTIARY HOSPITALS | 4CPS-305 |
| DAROLUTAMIDE, ENZALUTAMIDE AND APALUTAMIDE: PLACE IN THERAPEUTICS OF CASTRATION RESISTANT NON METASTATIC PROSTATE CANCER | 4CPS-306 |
| SAFETY EVALUATION OF NEW ANTIANDROGENIC DRUGS IN CASTRATION RESISTANT NON-METASTATIC PROSTATE CANCER | 4CPS-307 |
| EXPERIENCE WITH TERIFLUNOMIDE TREATMENT FOR MULTIPLE SCLEROSIS IN A UNIVERSITY HOSPITAL | 4CPS-308 |
| BARRIERS TO ADHERENCE WITH PRESCRIBED TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS | 4CPS-309 |
| TOFACITINIB EFFECTIVENESS AND SAFETY RESULTS: REAL WORLD DATA | 4CPS-310 |
| REAL WORLD TOXICITY AND MANAGEMENT OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES TARGETING CD19 IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES | 4CPS-311 |
| PHARMACEUTICAL INTERVENTIONS IN A NON-ONCOHAEMATOLOGICAL DAILY HOSPITAL | 4CPS-312 |
| EXPERIENCE OF THE USE OF BARICITINIB IN COVID-19 PNEUMONIA | 4CPS-313 |
| 3 DAY COURSE OF LOW DOSE SUBCUTANEOUS ANAKINRA IN PATIENTS WITH REFRACTORY MODERATE-SEVERE COVID-19: A PROOF-OF-CONCEPT STUDY | 4CPS-314 |
| EVALUATION OF THE EFFECTIVENESS OF EARLY ADMINISTRATION OF TOCILIZUMAB IN PATIENTS WITH COVID-19 | 4CPS-315 |
| MULTIPLE SCLEROSIS OUTPATIENT PHARMACEUTICAL CARE BY AN IMPLANTED TELEPHARMACY TOOL DURING SARS-COV-2 PANDEMIC | 4CPS-316 |
| IMMUNOSUPPRESSIVE TREATMENT MANAGEMENT IN A COHORT OF HOSPITALIZED SOLID ORGAN RECIPIENTS AFFECTED BY COVID-19 | 4CPS-317 | |
| COMPOUNDING TACROLIMUS OPHTHALMIC OINTMENT 0,02% IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE OPHTHALMIC SYNDROMES: EFFECTIVENESS AND SAFETY ASSESSMENT | 4CPS-318 |
| PIRFENIDONE AND NINTEDANIB FOR THE TREATMENT OF THE IDIOPATHIC PULMONARY FIBROSIS: AN ITALIAN HOSPITAL EXPERIENCE | 4CPS-319 |
| IMPROVING MEDICATION ADHERENCE AND PATIENTS’ EXPERIENCE AFTER HEART TRANSPLANT USING A MULTILEVEL eHEALTH INTERVENTION: THE mHEART CLINICAL TRIAL | 4CPS-320 |
| ANAKINRA IN SEVERE COVID-19 PNEUMONIA: RETROSPECTIVE STUDY | 4CPS-321 |
| ADALIMUMAB CONCENTRATIONS PRIOR TO THE IMPLEMENTATION OF THERAPEUTIC DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE | 4CPS-322 |
| EVALUATION OF THE USE, ADHERENCE AND TOLERANCE OF 0.03% TACROLIMUS EYE DROPS | 4CPS-323 |
| EFFECTIVENESS AND SAFETY OF IXEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS | 4CPS-324 |
| EFFECTS ON ADHERENCE IN PATIENTS WITH ARTHROPATHIES CHANGING TREATMENT | 4CPS-325 |
| ADALIMUMAB’S PERSISTENCE IN RHEUMATHOLOGICAL DISEASES | 4CPS-326 |
| EFFECTIVENESS, SAFETY AND ADHERENCE OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS | 4CPS-327 |
| BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS ACCORDING TO THE MECHANISM OF ACTION | 4CPS-328 |
| DO PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES THINK THEY KNOW THEIR MEDICATION? | 4CPS-329 |
| INDIVIDUALISING THERAPIES THROUGH PHARMACOKINETICS: ADALIMUMAB FOR INFLAMMATORY BOWEL DISEASE | 4CPS-330 |
| MMATORY PARAMETERS ANALYSIS IN SEVERE COVID-19 PATIENTS TREATED WITH TOCILIZUMAB | 4CPS-331 |
| TOCILIZUMAB FOR TREATING COVID PNEUMONIA: ANALYSIS OF EFFECTIVENESS AND SECURITY | 4CPS-332 |
| TREATING MULTIPLE SCLEROSIS PATIENTS WITH INFUSION OF DISEASE MODIFYING TREATMENTS DRUGS DURING THE COVID-19 PANDEMIC | 4CPS-333 |
| INFLUENCE OF ANTHROPOMETRIC, DEMOGRAPHIC AND THERAPEUTIC FACTORS ON SERUM CONCENTRATIONS OF ANTI-TNF DRUGS | 4CPS-334 |
| EXPERIENCE IN THE USE OF TOCILIZUMAB IN PATIENTS WITH COVID-19. HAS IT REALLY BEEN EFFECTIVE? | 4CPS-335 |
| IMPACT OF CHECK OF MEDICATION APPROPRIATENESS (CMA) IN OPTIMISING ANALGESIC PRESCRIBING | 4CPS-336 |
| PERSISTENCE OF BIOSIMILAR TREATMENT FOR IMMUNE MEDIATED INFLAMMATORY DISEASES IN CLINICAL PRACTICE | 4CPS-337 |
| USE AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA | 4CPS-338 |
| INTRATHECAL ADMINISTRATION OF BACLOFEN FOR THE REDUCTION OF SPASTICITY | 4CPS-339 |
| PROFILE OF PATIENTS WITH ABUSIVE CONSUMPTION OF QUICK RELEASE FENTANYL IN A HEALTHCARE AREA | 4CPS-340 |
| THE ROLE OF PHARMACISTS IN PROVIDING PHARMACEUTICAL CARE FOR PATIENTS WITH HEADACHES | 4CPS-341 |
| TRANSIENT VALPROIC ACID TOXICITY: HYPERAMMONAEMIA IN A PAEDIATRIC PATIENT | 4CPS-342 |
| PREGABALIN AND GABAPENTIN DRUG UTILISATION REVIEW | 4CPS-343 |
| PRESCRIPTION AUDITING OF THE 3 MONTHLY FORMULATION OF PALIPERIDONE PALMITATE IN ADULT PATIENTS WITH SCHIZOPHRENIA | 4CPS-344 |
| MANAGEMENT OF BRONCHIOLITIS IN HOSPITALISED CHILDREN | 4CPS-345 |
| EVALUATION OF THE IMPLEMENTATION OF “INHALER INTERVIEWS” DURING MEDICATION RECONCILIATION IN THE PNEUMOLOGY SERVICE | 4CPS-346 | |
| CLINICAL TRIAL DRUGS: DISPENSING OPTIMISATION FOR OUTPATIENTS OF A CANCER CENTRE | 4CPS-347 |
| THE HOSPITAL PHARMACY IN THE CREATION OF CLEAN CIRCUITS IN THE FACE OF COVID-19 | 4CPS-348 |
| ROLE OF HOSPITAL PHARMACISTS IN ONCOGERIATRIC CONSULTATIONS: A RETROSPECTIVE STUDY | 4CPS-349 |
| ROLE OF THE PHARMACIST IN INTERNAL MEDICINE: ANALYSIS OF PHARMACEUTICAL INTERVENTIONS DURING A ROTATION IN AN INTERNAL MEDICINE DEPARTMENT | 4CPS-350 |
| MEDICATION DELIVERY CONFIRMATION TO AMBULATORY PATIENTS BY INSTANT MESSAGING APP | 4CPS-351 |
| PATIENTS IN CHARGE: WHY WE SHOULD IMPLEMENT AN ONLINE PERSONAL HEALTH RECORD AS A TOOL FOR MEDICATION RECONCILIATION | 4CPS-352 |
| COLLABORATION BETWEEN HOSPITAL AND COMMUNITY PHARMACISTS ABOUT DISCHARGED PATIENTS: A PILOT STUDY | 4CPS-353 |
| EFFICACY AND SAFETY WITH ERENUMAB AND GALCANEZUMAB: OUR EXPERIENCE | 4CPS-354 |
| EVALUATION OF PATIENTS CONSULTING THE EMERGENCY DEPARTMENT FOR BRADYCARDIA RELATED TO MEDICATION | 4CPS-355 |
| COST-MINIMISATION ANALYSIS OF THE USE OF NIVOLUMAB AND PEMBROLIZUMAB | 4CPS-356 |
| CLINICAL CHARACTERISTICS AND MORTALITY OF COVID-19 IN A LONG TERM CARE FACILITY | 4CPS-357 |
| POINT PREVALENCE REVIEW OF MEDICINES RECONCILIATION FOLLOW-UP BY MEDICAL TEAMS | 4CPS-358 |
| DEVELOPMENT AND VALIDATION OF A 30 DAY REVISIT RISK PREDICTION MODEL IN PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENT DUE TO DRUG RELATED PROBLEMS | 4CPS-359 |
| RISK OF MALNUTRITION IN PATIENTS WITH COVID-19 DISEASE WHO RECEIVE ORAL NUTRITIONAL SUPPLEMENTS | 4CPS-360 |
| INTERVENTIONS OF A CLINICAL PHARMACIST IN AN INTENSIVE CARE UNIT | 4CPS-361 |
| NONAGENARIANS VERSUS NON-NONAGENARIANS IN THE HIP FRACTURE PATIENT: FROM A PHARMACOTHERAPEUTIC POINT OF VIEW | 4CPS-362 |
| DOES PATIENT CENTRED CARE PRACTICE IMPROVE MEDICATION ADHERENCE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS? | 4CPS-363 | |
| PERSONALISED QT RISK ASSESSMENT – TO INFORM MEDICATION PRESCRIBING? | 4CPS-364 |
| INTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY COMPLEX CHRONIC PATIENT CARE TEAM | 4CPS-365 | |
| COMPARING THE MEDICATION PROCESS ACROSS COUNTRIES USING THE FUNCTIONAL RESONANCE ANALYSIS METHOD | 4CPS-366 |
| IMPACT OF PHARMACEUTICAL CONSULTATION IMPLEMENTATION ON THE PHARMACEUTICAL INTERVENTIONS AND THE ROLE OF PHARMACISTS IN MULTIDISCIPLINARY TEAMS | 4CPS-367 |
| SYSTEMATIC REVIEW OF THE ASSOCIATION BETWEEN ANTICHOLINERGIC BURDEN AND XEROSTOMIA AND XEROPHTHALMIA | 4CPS-368 |
| PHARMACHECK AS A SCREENING TOOL TO INTERCEPT HIGH RISK SITUATIONS IN INTERNAL MEDICINE THAT COULD LEAD TO ADVERSE DRUG EVENTS | 4CPS-369 |
| PHARMACISTS´ INTERVENTIONS BEFORE AND AFTER THE USE OF A CLINICAL DECISION SUPPORT TOOL TO DETECT DRUG RELATED PROBLEMS | 4CPS-370 |
| USABILITY EVALUATION OF A PERSONALISED HEALTH RECORD FOR DETECTING MEDICATION DISCREPANCIES | 4CPS-371 |
| PHARMACEUTICAL INTERVENTIONS IN HOSPITALIZED PATIENTS DURING THE FIRST WAVE OF SARS-COV-2 PANDEMIC | 4CPS-372 |
| PHARMACEUTICAL CARE IN HOSPITALISATION UNITS: ANALYSIS OF INTERVENTIONS | 4CPS-373 |
| A SCREENING MODEL TO IDENTIFY ELDERLY POLYPHARMACY PATIENTS THAT MAY BENEFIT FROM PHARMACIST LED MEDICATION REVIEW DURING HOSPITAL ADMISSION | 4CPS-374 |
| EXCESSIVE POLYPHARMACY AND OTHER DETERMINANTS FOR UNPLANNED HOSPITAL ADMISSIONS | 4CPS-375 |
| ANTIRETROVIRAL THERAPY OPTIMISATION STRATEGIES IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS: A DECISIVE TASK FOR HOSPITAL PHARMACISTS | 4CPS-376 |
| APPROPRIATENESS OF NUTRITIONAL SUPPORT FOR PATIENTS WITH INVASIVE MECHANICAL VENTILATION WITH COVID-19 DISEASE REQUIRING INTENSIVE CARE | 4CPS-377 |
| ORAL THERAPY ADHERENCE AND SATISFACTION IN PATIENTS WITH MULTIPLE MYELOMA | 4CPS-378 |
| PARENTERAL NUTRITION MANAGEMENT IN CORONAVIRUS CRITICAL PATIENTS: CASE REPORT | 4CPS-379 |
| AN INTEGRATED PHARMACIST LED MEDICATION REVIEW SERVICE FOR ELECTIVE SURGERY PATIENTS AT THE PRE-ANAESTHESIA OUTPATIENT CLINIC | 4CPS-380 |
| PROACTIVE MEDICATION RECONCILIATION AND PATIENT FLOW IN THE EMERGENCY DEPARTMENT ADMISSIONS | 4CPS-381 |
| IMPACT OF A CLINICAL PHARMACIST AT TRANSITION OF CARE: A PROSPECTIVE STUDY IN AN ORTHOPAEDIC WARD OF A REGIONAL HOSPITAL | 4CPS-382 |
| DRUG PRESCRIPTION IN THE ELDERLY. ARE WE DOING WELL? | 4CPS-383 |
| POTENTIAL DRUG-RELATED PROBLEMS IN THE TIME OF COVID-19 | 4CPS-384 |
| IMPACT OF FULLY AUTOMATISED CENTRAL INTRAVENOUS ADDITIVE SERVICE (CIVAS) ON DAILY NURSING PRACTICE | 4CPS-385 |
| ONE YEAR EXPERIENCE OF A NEW PROGRAMME OF TELEMATIC PHARMACEUTICAL CONSULTATION AND DELIVERY OF HOSPITAL DISPENSING MEDICATION | 4CPS-386 |
| COVID-19 TREATMENT: A FOLLOW-UP OF INPATIENTS DURING THE SECOND WAVE OF THE PANDEMIC | 4CPS-387 |
| TELEPHARMACY DURING SARS-COV-2 | 4CPS-388 |
| GOVERNANCE OF CLINICAL TRIALS BETWEEN HEALTH NEEDS, ACCESS TO CARE, INNOVATION AND SUSTAINABILITY IN THE COVID-19 PANDEMIC ERA | 4CPS-389 |
| DISPENSING OF ANTICANCER INVESTIGATIONAL DRUGS DURING THE LOCKDOWN FOR THE SARS-COV-2 PANDEMIC: EXPERIENCE IN AN ONCOLOGICAL CENTRE | 4CPS-390 |
| NON-ADHERENCE IN RHEUMATOLOGICAL IMMUNE MEDIATED DISEASES | 4CPS-391 |
| EFFECT OF COVID 19 PANDEMIC ON ANTIRETROVIRAL THERAPY ADHERENCE | 4CPS-392 |
| IMPACT OF MULTIDISCIPLINARY TEAM INTERVENTION IN MEDICATION RECONCILIATION FOR GERIATRIC PATIENTS | 4CPS-393 |
| EVALUATION OF THE DEGREE OF THERAPEUTIC KNOWLEDGE IN LUNG TRANSPLANT RECIPIENTS | 4CPS-394 |
| PHARMACY SERVICE’S ADAPTATION TO THE COVID-19 PANDEMIC: TELEPHARMACY AND HOME DRUG DELIVERY | 4CPS-395 |
| EFFECT OF PATIENT’S OWN MEDICATION USE ON PATIENT SELF-REPORTED MEDICATION KNOWLEDGE DURING HOSPITALISATION: A PRE-POST INTERVENTION STUDY | 4CPS-396 |
| ASSESSMENT OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT AFTER COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEM IMPLEMENTATION | 4CPS-397 |
| USE OF INTRAVENOUS IRON IN HEART FAILURE OCTOGENARIANS AND NONAGENARIANS WITH IRON DEFICIENCY | 4CPS-398 |
| EVALUATING CLINICAL PHARMACY SERVICES ON AN INTENSIVE CARE UNIT: A SATISFACTION SURVEY | 4CPS-399 |
| THE ROLE AND VALUE OF A WARD BASED PHARMACIST IN THE INTENSIVE CARE UNIT: THE CRITICAL CARE PHYSICIANS’ AND NURSES’ PERCEPTIONS | 4CPS-400 |
| TELEPHARMACY PROGRAMME IMPLEMENTATION DURING THE COVID-19 PANDEMIC | 4CPS-401 |
| COVID-19 AND DIGESTIVE SURGERY: MEDICAL DEVICES FOR SURGICAL SMOKE FILTRATION | 4CPS-402 |
| CHRONIC KIDNEY DISEASE (CKD) PATIENTS AND POLYPHARMACY: HOW TO OPTIMISE AND SIMPLIFY PRESCRIPTIONS? | 4CPS-403 |
| MULTIDISCIPLINARY TEAM AIMED TO OPTIMISE INDIVIDUALISED SPECIAL DRUGS PRESCRIPTIONS AND AUTHORISATION BY HOSPITAL MEDICAL DIRECTOR THROUGH AN INFORMATIC APPLICATION | 4CPS-404 |
| STRONGYLOIDES STERCORALIS PROPHYLAXIS WITH IVERMECTIN IN COVID-19 PATIENTS | 4CPS-405 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PHARMACIST INTERVENTION TO IMPROVE THE SAFETY OF PATIENTS TREATED WITH PROTON PUMP INHIBITORS (submitted in 2019) | 5PSQ-001 | |
| HYPOMAGNESAEMIA ALERT! MONITOR CLOSELY THE PROTON PUMP INHIBITORS FOR CHRONIC TREATMENT IN ELDERLY PATIENTS (submitted in 2019) | 5PSQ-002 | |
| EFFECTIVENESS OF ANTIEMETIC THERAPY DURING CHEMOTHERAPY IN A REGIONAL HOSPITAL (submitted in 2019) | 5PSQ-003 | |
| ADEQUACY OF ANTIEMETIC TREATMENT DURING CHEMOTHERAPY IN A REGIONAL HOSPITAL (submitted in 2019) | 5PSQ-004 | |
| ANALYSIS OF THE ADEQUACY OF VITAMIN D PRESCRIPTIONS (submitted in 2019) | 5PSQ-005 | |
| PARENTERAL NUTRITION IN A NEONATOLOGY INTENSIVE CARE UNIT: DURATION AND COMPLICATIONS (submitted in 2019) | 5PSQ-006 | |
| THE PHARMACEUTICAL GOVERNANCE OF LOW MOLECULAR WEIGHT HEPARINS: APPROPRIATENESS ANALYSIS (submitted in 2019) | 5PSQ-007 | |
| RESISTANCE TO SODIUM HEPARIN TREATMENT OR TREATMENT FAILURE TO THE EQUIVALENT ANALOGUE? (submitted in 2019) | 5PSQ-008 | |
| EVALUATION OF DIRECT ORAL ANTICOAGULANT USE IN PATIENTS ADMITTED FOR UPPER GASTROINTESTINAL AND INTRACRANIAL HAEMORRHAGES IN THE EMERGENCY SERVICE (submitted in 2019) | 5PSQ-009 | |
| BENEFITS PROVIDED BY RECOMBINANT LONG HALF-LIFE COAGULATION FACTORS IN PATIENTS WITH SEVERE HAEMOPHILIA “A” IN PROPHYLAXIS (submitted in 2019) | 5PSQ-010 | |
| COMPLICATIONS OF DRUG CONTAINING PARENTERAL NUTRITION: A COHORT STUDY. (submitted in 2019) | 5PSQ-011 | |
| DRUG INTERACTIONS AND POLYPHARMACY IN A COHORT OF HIV POSITIVE HAEMOPHILIAC PATIENTS (submitted in 2019) | 5PSQ-012 | |
| ANALYSIS OF THE RISK OF QT INTERVAL PROLONGATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A NURSING HOME (submitted in 2019) | 5PSQ-013 | |
| RETROSPECTIVE EVALUATION OF RESUSCITATION MEDICATION UTILISATION IN HOSPITALISED ADULT PATIENTS WITH CARDIAC ARREST (submitted in 2019) | 5PSQ-014 |
| COMPARING THREE CRITERIA FOR ASSESSMENT OF WHAT MEDICINES INCLUDED IN NATIONAL HOSPITAL FORMULARY ARE CLASSIFIED AS POTENTIALLY INAPPROPRIATE MEDICATIONS FOR OLDER PATIENTS (submitted in 2019) | 5PSQ-015 | |
| TOLVAPTAN ASSOCIATED CREATINE KINASE ELEVATION IN TWO PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (submitted in 2019) | 5PSQ-016 | |
| PCSK-9 INHIBITORS: REAL WORLD EFFECTIVENESS (submitted in 2019) | 5PSQ-017 | |
| ADALIMUMAB IN PALMOPLANTAR PUSTULOSIS (submitted in 2019) | 5PSQ-018 | |
| EFFICACY OF SECUKINUMAB IN MODERATE-SEVERE PSORIASIS WITH A REDUCED TREATMENT REGIMEN (submitted in 2019) | 5PSQ-019 | |
| ANALYSIS OF THE EFFECTIVENESS OF SECUKINUMAB AND IXEKIZUMAB IN THE TREATMENT OF MODERATE-SEVERE PSORIASIS (submitted in 2019) | 5PSQ-020 | |
| TRANSVAGINAL MESH IN PELVIC ORGAN PROLAPSES: 2017-2019 RETROSPECTIVE ANALYSIS (submitted in 2019) | 5PSQ-021 | |
| ANALYSIS OF INFECTIONS ASSOCIATED WITH CENTRAL VENOUS CATHETERS USED FOR ADMINISTRATION OF PARENTERAL NUTRITION IN A THIRD LEVEL HOSPITAL (submitted in 2019) | 5PSQ-022 | |
| EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM IN INFECTIONS BY MULTIRESISTANT MICROORGANISMS. (submitted in 2019) | 5PSQ-023 | |
| PHARMACOLOGIC INTERVENTION BY HOSPITAL PHARMCIST FOR LEUCOPENIA DUE TO TAZOBACTAM/PIPERACILLIN IN THE POSTPARTUM PERIOD: A CASE REPORT (submitted in 2019) | 5PSQ-024 |
| PHARMACEUTICAL INTERVENTION FOR THE OPTIMISATION THE USE OF ANTIBIOTICS IN A TERTIARY HOSPITAL (submitted in 2019) | 5PSQ-025 | |
| IMPACT OF THE EARLY SWITCHING FROM INTRAVENOUS TO ORAL ANTIBIOTICS IN A TERTIARY HOSPITAL (submitted in 2019) | 5PSQ-026 | |
| OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY WORKING GROUP IN A HOSPITAL AT HOME UNIT: THE ESSENTIAL ROLE OF PHARMACISTS (submitted in 2019) | 5PSQ-027 |
| PRESCRIPTION PROFILE OF ISAVUCONAZOLE IN THE REAL WORLD CLINICAL PRACTICE (submitted in 2019) | 5PSQ-028 | |
| SAFE ADMINISTRATION OF SOFOSBUVIR/VELPATASVIR IN A PATIENT WITH PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (submitted in 2019) | 5PSQ-029 | |
| ADVERSE DRUG REACTIONS DUE TO INTERACTION WITH COBICISTAT OR RITONAVIR IN HIV POSITIVE PATIENTS: A CASE SERIES (submitted in 2019) | 5PSQ-030 | |
| CLINICAL AND ECONOMIC IMPACT AFTER BREAKING THE SINGLE TABLET ABACAVIR/LAMIVUDINE/DOLUTEGRAVIR COMBO TREATMENT INTO TWO DRUG REGIMENES (submitted in 2019) | 5PSQ-031 |
| SUCCESSFUL TREATMENT OF CHRONIC HEPATITIS C INFECTION WITH CRUSHED SOFOSBUVIR/VELPATASVIR (submitted in 2019) | 5PSQ-032 | |
| GLECAPREVIR/PIBRENTASVIR USE IN CHRONIC HEPATITIS C: EFFECTIVENESS AND SAFETY (submitted in 2019) | 5PSQ-033 | |
| EVALUATION OF OSELTAMIVIR USE IN CLINICAL PRACTICE IN A SECOND LEVEL HOSPITAL. (submitted in 2019) | 5PSQ-034 | |
| DUAL THERAPY WITH DOLUTEGRAVIR AND LAMIVUDINE: EFFICACY AND SAFETY. (submitted in 2019) | 5PSQ-035 | |
| STOPP/START CRITERIA IN PATIENTS WITH HIV (submitted in 2019) | 5PSQ-036 | |
| DOCETAXEL INDUCED NEUTROPENIC ENTEROCOLITIS: A CASE REPORT (submitted in 2019) | 5PSQ-037 | |
| SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF BREAST CANCER WITH POSITIVE HORMONAL RECEPTORS AND NEGATIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2. (submitted in 2019) | 5PSQ-038 | |
| PANCREATITIS INDUCED BY IMMUNOTHERAPY? TWO CASE REPORTS (submitted in 2019) | 5PSQ-039 | |
| SECURITY PROFILE OF IBRUTINIB AS MONOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019) | 5PSQ-040 | |
| CONSUMPTION OF HERBAL MEDICINE IN PATIENTS ON ORAL ANTICANCER DRUGS: STILL A LONG WAY TO GO! (submitted in 2019) | 5PSQ-041 |
| EVALUATION OF AN INFORMATION CHECKLIST FOR VALIDATION OF ANTINEOPLASTIC PRESCRIPTIONS (submitted in 2019) | 5PSQ-042 | |
| IMPLEMENTATION OF A PREPARATION PROTOCOL FOR CHEMOTHERAPY ADMIXTURES OF HIGH ECONOMIC IMPACT (submitted in 2019) | 5PSQ-043 | |
| IMPACT OF DRUG INTERACTIONS IN HIGH DOSE METHOTREXATE ELIMINATION (submitted in 2019) | 5PSQ-044 | |
| OLARATUMAB: WHAT IS THE ECONOMIC IMPACT ON THE NATIONAL HEALTH SYSTEM? (submitted in 2019) | 5PSQ-045 | |
| PREVALENCE OF NIVOLUMAB ADVERSE EVENTS IN ROUTINE CLINICAL PRACTICE (submitted in 2019) | 5PSQ-046 | |
| RIBOCICLIB SAFETY IN METASTATIC BREAST CANCER (submitted in 2019) | 5PSQ-047 | |
| ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ANTINEOPLASTIC AGENTS AND CONCURRENT MEDICATIONS (submitted in 2019) | 5PSQ-048 | |
| PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: REAL LIFE TOXICITY AND FREQUENCY OF DOSE REDUCTION OR PERMANENT DISCONTINUATION. (submitted in 2019) | 5PSQ-049 | |
| SUCCESSFUL DESENSITISATION IN A PATIENT WITH DASATINIB HYPERSENSITIVITY (submitted in 2019) | 5PSQ-050 | |
| IMMUNE RELATED ADVERSE EVENTS IN CANCER PATIENTS TREATED WITH CONTROL POINT INHIBITORS (submitted in 2019) | 5PSQ-051 | |
| EARLY RESULTS FROM THE EFFECTIVENESS AND SAFETY EVALUATION OF BIOSIMILAR RITUXIMAB AND BRAND-RITUXIMAB IN GLOMERULAR INFLAMMATORY DISEASE (submitted in 2019) | 5PSQ-052 |
| OFF-LABEL USE OF RITUXIMAB IN SYSTEMIC AUTOIMMUNE DISEASES (submitted in 2019) | 5PSQ-053 | |
| EXAMINATION OF A NEW METHOD FOR ANALYSING IDENTITY AND CONCENTRATION OF DRUGS IN READY TO USE PREPARATIONS: PROOF OF CONCEPTS OF THE DRUGLOG SYSTEM (submitted in 2019) | 5PSQ-054 | |
| FILGRASTIM IN EARLY STAGE BREAST CANCER: DIFFERENCES BETWEEN TWO SMALL HOSPITALS (submitted in 2019) | 5PSQ-055 | |
| EXPERIENCE WITH TOFACINITIB AND BARICITINIB IN RHEUMATOID ARTHRITIS (submitted in 2019) | 5PSQ-056 | |
| ANALYSIS OF INCIDENCE OF HEPATOTOXICITY ASSOCIATED WITH THE USE OF TOCILIZUMAB (submitted in 2019) | 5PSQ-057 |
| THE IMPORTANCE OF MONITORING ADVERSE DRUG REACTIONS: DATA FROM THE TREATMENT OF A RARE DISEASE (submitted in 2019) | 5PSQ-058 | |
| PHARMACIST-LED OBSERVATIONAL STUDY ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: EVIDENCES FROM THE QOSMOS STUDY (submitted in 2019) | 5PSQ-059 | |
| EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN CLINICAL PRACTICE FOR CROHN’S DISEASE (submitted in 2019) | 5PSQ-060 | |
| ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: EFFECTIVENESS AND SAFETY (submitted in 2019) | 5PSQ-061 | |
| EFFECTIVENESS OF ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE AND INFLUENCE OF RESPONSE TO FIRSTLINE TREATMENT (submitted in 2019) | 5PSQ-062 | |
| SERIOUS CELLULITIS IN A PATIENT WITH ATOPIC DERMATITIS TREATED WITH BARICITINIB: A CASE REPORT (submitted in 2019) | 5PSQ-063 | |
| RELATED RISK OF BIOLOGIC DRUGS FOR CROHN’S DISEASE IN PREGNANCY: A CASE REPORT AND REVISION OF THE LITERATURE (submitted in 2019) | 5PSQ-064 | |
| PREDICTION OF TOXICITY OF METHOTREXATE BY MEANS OF GENETIC TESTS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS (submitted in 2019) | 5PSQ-065 | |
| ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN ELDERLY ONCOLOGIC PATIENTS BY THE CHECK THE MEDS APP (submitted in 2019) | 5PSQ-066 | |
| SAFETY PROFILE OF PIRFENIDONE AND NINTEDANIB IN A REAL LIFE SETTING: ASSESSMENT OF SUSPECTED ADVERSE DRUG REACTIONS IN THE EMILIA ROMAGNA REGION, ITALY (submitted in 2019) | 5PSQ-067 | |
| INCIDENCE OF FUNGAL INFECTIONS IN PATIENTS TREATED WITH IXEKIZUMAB (submitted in 2019) | 5PSQ-068 | |
| CONCOMITANT PRESCRIPTION OF DRUGS FOR OSTEOPOROSIS AND MEDICATION THAT INCREASE THE OF RISK FALLS (submitted in 2019) | 5PSQ-069 | |
| SAFETY STRATEGIES TO IMPROVE DRUG LABELLING IN OPERATING ROOMS (submitted in 2019) | 5PSQ-070 | |
| AN ADVERSE DRUG REACTION IN A PAEDIATRIC PATIENT WITH DRAVET SYNDROME: CANNABIDIOL AND VALPROATE DRUG-DRUG INTERACTION (submitted in 2019) | 5PSQ-071 | |
| ADEQUACY OF ANTIDEPRESSANT MEDICATION IN ELDERLY PATIENTS (submitted in 2019) | 5PSQ-072 | |
| USEFULNESS OF SALIVA IN THERAPEUTIC DRUG MONITORING OF CAFFEINE IN PRETERM INFANTS (submitted in 2019) | 5PSQ-073 | |
| FAMPRIDINE RELATED ATRIAL FIBRILLATION: TWO CASE REPORTS (submitted in 2019) | 5PSQ-074 | |
| SAFETY PROFILE OF FINGOLIMOD IN REAL WORLD CLINICAL PRACTICE: A PRELIMINARY STUDY (submitted in 2019) | 5PSQ-075 | |
| PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A CROSS-SECTIONAL SURVEY STUDY. (submitted in 2019) | 5PSQ-076 | |
| PERCEPTIONS ABOUT PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A QUALITATIVE STUDY. | 5PSQ-077 | |
| HEALTHCARE PROVIDERS’ PERCEPTIONS OF PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A QUALITATIVE STUDY. (submitted in 2019) | 5PSQ-078 | |
| IMMUNOTHERAPY IN METASTATIC MELANOMA: A MIRACLE OR POISON (submitted in 2019) | 5PSQ-079 | |
| ASSESSMENT OF DOSE PREPARATION PRACTICES FROM LIQUID ORAL FORMS BY MOTHERS OF CHILDREN HOSPITALISED IN OUR PAEDIATRIC DEPARTMENT (submitted in 2019) | 5PSQ-080 | |
| THE BENEFITS-RISKS BALANCE OF LEECH THERAPY IN ONE HOSPITAL : A RETROSPECTIVE STUDY (submitted in 2019) | 5PSQ-081 | |
| EVALUATING AN ELECTRONIC CLINICAL DECISION SUPPORT SYSTEM FOR DRUG-DRUG INTERACTIONS IN A LARGE ACUTE TEACHING HOSPITAL (submitted in 2019) | 5PSQ-082 | |
| A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO STEAM STERILISATION PROCESS IN A TEACHING HOSPITAL (submitted in 2019) | 5PSQ-083 | |
| POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN GERIATRIC HIV PATIENTS (submitted in 2019) | 5PSQ-084 | |
| MEDICATION ERRORS AND PHARMACEUTICAL INTERVENTIONS FOR DRUGS ADMINISTERED BY FEEDING TUBE (submitted in 2019) | 5PSQ-085 | |
| MANAGEMENT OF A CONTAMINATION EPISODE IN A PARENTERAL NUTRIENT MIXTURE PREPARATION UNIT (submitted in 2019) | 5PSQ-086 | |
| SEVERE MALARIA: 3 YEAR REVIEW OF INTRAVENOUS ARTESUNATE USE IN A UNIVERSITY HOSPITAL (submitted in 2019) | 5PSQ-087 | |
| MONITORING OF THE INTRODUCTION OF CHLORHEXIDINE RELEASING POLYURETHANE MEDICATION IN PILOT WARDS OF A LARGE CITY HOSPITAL (submitted in 2019) | 5PSQ-088 | |
| CYTOKINE RELEASE SYNDROME REACTION: THE CLINICAL PHARMACIST IN THE CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY TEAM (submitted in 2019) | 5PSQ-089 | |
| PHARMACIST’S CONTRIBUTION TO IMPROVING CUSTOMERS SATISFACTION AT HOSPITALS CARE UNITS (submitted in 2019) | 5PSQ-090 |
| ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN CHRONIC COMPLEX PATIENTS AND IN PATIENTS WITH ADVANCED CHRONIC DISEASE IN THE EMERGENCY DEPARTMENT (submitted in 2019) | 5PSQ-091 | |
| HOW DOES THE ON-SCREEN DESIGN OF ELECTRONIC PRESCRIBING SYSTEMS AFFECT SAFE PRESCRIBING? A QUALITATIVE STUDY USING A THINK ALOUD APPROACH. (submitted in 2019) | 5PSQ-092 | |
| EXPLORING EYE TRACKING AS A METHOD TO STUDY USERS’ INTERACTIONS WITH A HOSPITAL ELECTRONIC PRESCRIBING SYSTEM: A DESCRIPTIVE STUDY (submitted in 2019) | 5PSQ-093 | |
| HOW CAN PATIENT HELD INFORMATION ABOUT MEDICATION IMPROVE PATIENT SAFETY? (submitted in 2019) | 5PSQ-094 | |
| ANALYSIS OF THE TOXICITIES ASSOCIATED WITH TYROSINE KINASE INHINITORS IN PATIENTS WITH CHRINIC MYELOID LEUKAEMIA (submitted in 2019) | 5PSQ-095 | |
| HAZARD VULNERABILITY ANALYSIS TO EVALUATE RISK OF DRUG SHORTAGES ACCORDING TO THE THERAPEUTIC CLASS (submitted in 2019) | 5PSQ-096 | |
| POTENTIALLY HARMFUL EXCIPIENTS IN NEONATAL AND PAEDIATRIC PATIENTS (submitted in 2019) | 5PSQ-097 | |
| ALLERGIES AND INTOLERANCES: AN OPPORTUNITY FOR IMPROVEMENT (submitted in 2019) | 5PSQ-098 | |
| POTENTIALLY INADEQUATE MEDICATION– DETECTED DIFFERENTLY BY PRISCUS, FORTA OR EU(7)-PIM – IS ASSOCIATED WITH REDUCED COGNITIVE FUNCTION IN MULTIMORBID ELDERLY PATIENTS (submitted in 2019) | 5PSQ-099 | |
| COMPARATIVE ANALYSIS OF THE SAFETY AND TOLERABILITY PROFILE OF PIRFENIDONE AND NINTEDANIB IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (submitted in 2019) | 5PSQ-100 | |
| DRUG-DRUG INTERACTIONS AND POTENTIALLY RELATED ADVERSE CLINICAL EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASES (submitted in 2019) | 5PSQ-101 | |
| AMBULATORY SUBCUTANEOUS BIOLOGIC THERAPY OPTIMISATION IN RHEUMATOLOGY: IMPLEMENTATION OVER TIME (submitted in 2019) | 5PSQ-102 | |
| EXPERIENCE OF ANTIFIBROTIC AGENTS IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (submitted in 2019) | 5PSQ-103 | |
| DESCRIPTION OF A PHARMACOVIGILANCE PROGRAMME IN A TERTIARY HOSPITAL (submitted in 2019) | 5PSQ-104 | |
| PREVENTING FALLS IN ORTHOGERIATRIC PATIENTS BY MANAGING THEIR THERAPEUTIC PROFILES (submitted in 2019) | 5PSQ-105 | |
| ANALYSIS OF HANDLING OF HAZARDOUS DRUGS IN A NURSING HOME (submitted in 2019) | 5PSQ-106 | |
| ACTIVE PHARMACOVIGILANCE AND DEDICATED PHARMACIST: THE EXPERIENCE OF A TERRITORIAL HEALTHCARE HOSPITAL (submitted in 2019) | 5PSQ-107 | |
| INFECTION WITH CLOSTRIDIUM DIFFICILE: RISK FACTORS AND PHARMACOTHERAPEUTIC MANAGEMENT (submitted in 2019) | 5PSQ-108 | |
| READMISSIONS OF OLDER PATIENTS PRESENTING TO HOSPITAL WITH A FALL (RELIEF): A SYSTEMATIC REVIEW (submitted in 2019) | 5PSQ-109 | |
| NUTRITIONAL ASSESSMENT IN A LONG TERM CARE FACILITY (submitted in 2019) | 5PSQ-110 | |
| ADVERSE DRUG REACTIONS DUE TO MEDICINES UNDER ADDITIONAL MONITORING (submitted in 2019) | 5PSQ-111 | |
| IMPACT OF HIGH TEMPERATURE AND SHAKING ON CHARGE VARIANTS OF ADALIMUMAB (HUMIRA) ASSESSED BY LIQUID CHROMATOGRAPHY COUPLED MASS SPECTROMETRY (submitted in 2019) | 5PSQ-112 |
| COMPATIBILITY AND STABILITY OF ONDANSETRON AND MIDAZOLAM MIXTURES USED IN PALLIATIVE CARE (submitted in 2019) | 5PSQ-113 | |
| IMPROVING MEDICATION ADMINISTRATION FOR PATIENTS WITH DYSPHAGIA (submitted in 2019) | 5PSQ-114 | |
| NEAR MISS DISPENSING ERRORS DURING WORKING HOURS IN INPATIENT DISPENSARIES AT A LARGE UK TEACHING HOSPITAL (submitted in 2019) | 5PSQ-115 |
| SAFER HANDLING OF ORAL HAZARDOUS DRUGS IN HOSPITAL UNITS (submitted in 2019) | 5PSQ-116 | |
| ANALYSIS OF MEDICATION ERRORS AN ONCOLOGY SETTING USING AN INTERNAL REPORTING SYSTEMS (submitted in 2019) | 5PSQ-117 | |
| DESCRIPTIVE COMPARATIVE SAFETY ANALYSIS OF PALBOCICLIB AND RIBOCICLIB IN METASTATIC BREAST CANCER HER2 NEGATIVE WITH POSITIVE HORMONAL RECEPTORS (submitted in 2019) | 5PSQ-118 | |
| PROTON PUMP INHIBITOR PRESCRIPTION PATTERNS AND ASSOCIATED COMPLICATIONS IN THE PAEDIATRIC INTENSIVE CARE UNIT | 5PSQ-119 |
| USE OF PROTON PUMP INHIBITORS IN A GERIATRIC HEALTHCARE CENTRE | 5PSQ-120 |
| FIDAXOMICIN RELATED METABOLIC ACIDOSIS: A CASE REPORT | 5PSQ-121 |
| HEALTH RESULTS AFTER INFLIXIMAB PHARMACOKINETIC MONITORING IN INFLAMMATORY BOWEL DISEASE | 5PSQ-122 |
| SGLT2 INHIBITORS IN TYPE 2 DIABETES PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASES: AN UMBRELLA REVIEW OF SYSTEMATIC REVIEWS | 5PSQ-123 | |
| ANTICOAGULATION MANAGEMENT WITHIN A HOSPITAL SETTING: IDENTIFYING RISK FACTORS AFFECTING PATIENT SAFETY | 5PSQ-124 |
| EFFECT OF A MULTIFACETED CLINICAL DECISION SUPPORT INTERVENTION ON ADHERENCE TO THROMBOPROPHYLAXIS GUIDELINES IN NON-SURGICAL PATIENTS | 5PSQ-125 |
| AVICENNE AS A CLINICAL DECISION SUPPORT IN THROMBOPROPHYLAXIS: JUST BECAUSE THE PATIENT’S SITUATION IS IMPROVING DOESN’T MEAN THERE’S NO DRUG RELATED PROBLEM! | 5PSQ-126 |
| ASSESSING APPROPRIATE DOSING OF NEW ORAL ANTICOAGULANTS: APIXABAN, DABIGATRAN AND RIVAROXABAN IN A TERTIARY HOSPITAL | 5PSQ-127 |
| WHICH ENOXAPARIN PREVENTIVE DOSAGE TO CHOOSE FOR OBESE PATIENTS IN ORTHOPAEDIC SURGERY ? | 5PSQ-128 |
| MANAGEMENT OF MULTIFACTORIAL ANAEMIA WITH SUBCUTANEOUS DARBEPOETIN WITH INITIAL MONTHLY DOSAGE, OMITTING INDUCTION ACCORDING TO THE TECHNICAL DATA SHEET, IN ELDERLY PATIENTS | 5PSQ-129 |
| INTRAVENOUS POTASSIUM CHLORIDE: IS THE MEDICATION USE PROCESS SECURE? | 5PSQ-130 |
| ADHERENCE OF THE HOSPITAL CLINICAL MANAGEMENT UNITS TO THE CENTRE’S PROTOCOL FOR THE SAFE USE OF INTRAVENOUS POTASSIUM | 5PSQ-131 |
| FAILURE MODE AND EFFECT ANALYSIS APPLIED TO THE PARENTERAL NUTRITION PREPARATION PROCESS IN A MATERNITY AND NEONATAL HOSPITAL | 5PSQ-132 |
| EVALUATION OF A QUALITY MONITORING PROGRAMME FOR INTRAVENOUS FLUID MANAGEMENT | 5PSQ-133 |
| ANALYSIS OF FACTORS RELATED TO THE CLINICAL COURSE OF COVID-19 INFECTION IN PATIENTS WITH HYPERTENSION | 5PSQ-134 |
| ADEQUACY OF HYPOLIPEMIANT TREATMENT IN PRIMARY HEALTHCARE | 5PSQ-135 |
| DISPROPORTIONALITY ANALYSIS OF THE SKIN TOXICITY OF INGENOL MEBUTATE USING THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE | 5PSQ-136 |
| ADEQUACY OF DIAGNOSIS AND TREATMENT OF PHARYNGOTONSILLITIS | 5PSQ-137 |
| INFLUENCE OF ANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A HOSPITAL AT HOME UNIT | 5PSQ-138 |
| PRESCRIPTIVE APPROPRIATENESS OF ANTIBIOTIC THERAPIES: CRUCIAL ROLE OF THE HOSPITAL PHARMACIST | 5PSQ-139 |
| UNIT DOSE SYSTEM: MODEL OF IMPLEMENTATION OF THE ANTIMICROBIAL STEWARDSHIP | 5PSQ-140 |
| ANALYSIS OF THE CEFTAROLINE ASSOCIATED NEUTROPENIA | 5PSQ-141 |
| SAFETY OF AZOLE ANTIFUNGALS IN TRANSPLANTED PATIENTS RECEIVING TACROLIMUS | 5PSQ-142 |
| DRUG RESISTANT TUBERCULOSIS IN A HIGH COMPLEXITY SPECIALISED UNIT: EPIDEMIOLOGY, TREATMENT AND MAIN ADVERSE REACTIONS | 5PSQ-143 |
| PHARMACOTHERAPY OPTISMISATION IN PATIENTS OVER 50 YEARS OF AGE WITH HIV INFECTION: FIRST STEPS | 5PSQ-144 |
| ANALYSIS OF THERAPEUTIC REGIMENS CONTAINING TENOFOVIR DISOPROXIL AND TENOFOVIR ALAFENAMIDE IN THE 4 YEAR PERIOD 2016-2019 IN A RESEARCH, HOSPITALISATION AND HEALTHCARE INSTITUTE | 5PSQ-145 |
| “REAL LIFE” EFFECTIVENESS AND SAFETY ASSESSMENT OF FOSCARNET | 5PSQ-146 |
| IMMUNOGLOBULIN SHORTAGE : PRACTICE MODIFICATIONS AND CLINICAL OUTCOMES IN A REFERENCE CENTRE | 5PSQ-147 |
| IMPROVING SAFETY IN THE VACCINE CIRCUIT | 5PSQ-148 |
| DRUGE INTERACTION IN BREAST CANCER TRIPLE NEGATIVE THERAPY: DOCETAXEL AND FLUVOXAMINE. A CASE REPORT | 5PSQ-149 |
| DISSEMINATED INTRAVASCULAR COAGULATION AFTER PD-1 BLOCKADE WITH NIVOLUMAB IN ADVANCED MELANOMA: A CASE REPORT | 5PSQ-150 |
| SEVERE TOXICITY IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKAEMIA RESULTING FROM SUBSTITUTION OF DAUNORUBICIN WITH DOXORUBICIN DUE TO MEDICINE SHORTAGE: A CASE REPORT | 5PSQ-151 |
| REAL-WORLD EFFICACY AND COST DATA ON PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH CHECKPOINT INHIBITORS IN AN ITALIAN UNIVERSITY HOSPITAL IN SEPTEMBER 2016-2020 | 5PSQ-152 |
| CARBOPLATIN AUC DOSING IN PAEDIATRIC PATIENTS: INFLUENCE OF GLOMERULAR FILTRATION RATE MEASUREMENT | 5PSQ-153 |
| DETERMINATION OF GENETIC POLYMORPHISMS OF THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN REAL CLINICAL PRACTICE AS PREDICTORS OF SEVERE FLUOROPYRIMIDINE ASSOCIATED TOXICITY | 5PSQ-154 |
| ASSISTANCE PRESSURE IN ONCOHAEMATOLOGICAL DISPENSATION AREA DURING THE COVID PANDEMIC | 5PSQ-155 |
| COMPLIANCE OF RECOMMENDATIONS FOR THE PREVENTION OF HEPATITIS B VIRUS REACTIVATION DURING DARATUMUMAB TREATMENT | 5PSQ-156 |
| EXPENDITURE AND CONSUMPTION DESCRIPTIVE ANALYSIS: RITUXIMAB ORIGINATOR VERSUS BIOSIMILAR IN AN ITALIAN DISTRICT | 5PSQ-157 |
| OFF-LABEL USE OF PEMBROLIZUMAB IN PD-L1 POSITIVE METASTATIC ANAPLASTIC THYROID CARCINOMA: A CASE REPORT | 5PSQ-158 |
| PALBOCICLIB SAFETY IN METASTATIC BREAST CANCER | 5PSQ-159 |
| MOGAMULIZUMAB EXPERIENCE IN ADVANCED SEZARY SYNDROME: A CASE REPORT | 5PSQ-160 |
| EFFECTIVENESS AND SAFETY OF PALBOCICLIB AND RIBOCICLIB | 5PSQ-161 |
| METHOTREXATE-INDUCED MYELITIS IN A CAUCASIAN GIRL WITH LYMPHOBLASTIC LYMPHOMA AND PHARMACOGENETIC STUDY: CASE REPORT | 5PSQ-162 |
| INCIDENCE OF NEUTROPENIA AND EFFECTIVENESS OF PALBOCICLIB IN CLINICAL PRACTICE IN METASTATIC BREAST CANCER AFTER 4 YEARS OF USE | 5PSQ-163 |
| REAL SAFETY OF DARATUMUMAB IN MYELOMA MULTIPLE | 5PSQ-164 |
| INCIDENCE AND MANAGEMENT OF ETOPOSIDE HYPERSENSITIVITY IN PAEDIATRIC PATIENTS | 5PSQ-165 |
| MANAGEMENT OF TOXICITIES RELATED TO CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN METASTATIC BREAST CANCER | 5PSQ-166 |
| ANALYSIS OF FIRSTLINE TREATMENT IN THE ELDERLY WITH METASTATIC COLORECTAL CANCER | 5PSQ-167 |
| INTEREST AND IMPLEMENTATION OF RAPID DARATUMUMAB INFUSION DURING THE HEALTH CRISIS | 5PSQ-168 |
| SAFETY AND SEVERE NEUTROPENIA IN PATIENTS TREATED WITH PALBOCICLIB AND RIBOCICLIB IN REAL WORLD CLINICAL PRACTICE | 5PSQ-169 |
| PEMBROLIZUMAB IN NON-SMALL CELL LUNG CANCER: ANALYSIS IN REAL LIFE OF TOXICITY AND EFFECTIVENESS | 5PSQ-170 |
| TOCILIZUMAB IN PATIENTS WITH COVID19: RESULTS IN CLINICAL PRACTICE | 5PSQ-171 |
| EXPERIENCE WITH TOCILIZUMAB IN SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) INFECTION | 5PSQ-172 |
| PERSISTENCE OF ABATACEPT TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS | 5PSQ-173 |
| EFFECTIVENESS AND SAFETY OF ABATACEPT THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER PREVIOUS FAILURE WITH TNFi TREATMENT | 5PSQ-174 |
| CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MUTATIONS ON T REG AND ABATACEPT: A PAEDIATRIC CASE REPORT | 5PSQ-175 |
| DISCONTINUATION OF ETANERCEPT DUE TO ADVERSE EVENTS IN PATIENTS WITH RHEUMATIC DISEASES | 5PSQ-176 |
| CARDIOVASCULAR RISK AND ALTERED LIPID PROFILE ASSOCIATED WITH TREATMENT WITH THE KINASE-JAK INHIBITORS, TOFACITINIB AND BARICITINIB | 5PSQ-177 | |
| HEPATOTOXICITY ASSOCIATED WITH ACUTE TOCILIZUMAB TREATMENT IN PATIENTS WITH SARS-CoV-2 INFECTION | 5PSQ-178 | |
| REASON FOR DISCONTINUATION OF BIOLOGICAL DRUG TREATMENT IN RHEUMATOID ARTHRITIS | 5PSQ-179 |
| IMPACT OF SEDATIVE DRUGS ON VITAL SIGNS DURING PROCEDURAL SEDATION AND ANAESTHESIA: A RETROSPECTIVE COHORT ANALYSIS | 5PSQ-180 |
| IS INSTANT ALWAYS BETTER? PHARMACOKINETICS OF TABLET VERSUS GRANULATE FORMULATION OF PARACETAMOL IN FRAIL OLDER ADULTS | 5PSQ-181 |
| ANTICHOLINERGIC BURDEN IN PATIENTS ADMITTED TO A PSYCHIATRIC HOSPITAL | 5PSQ-182 |
| CONCOMITANT USE OF ACETYLCHOLINESTERASE INHIBITORS AND DRUGS WITH ANTICHOLINERGIC PROPERTIES AT ADMISSION BY EMERGENCY DEPARTMENT | 5PSQ-183 |
| KNOWLEDGE AND ATTITUDE ASSESSMENT OF PHARMACISTS TOWARD TELEPHARMACY IN RIYADH CITY, SAUDI ARABIA | 5PSQ-184 |
| ARE ADHERENCE TESTS IN ASTHMA STILL RELIABLE WHEN THE PATIENTS KNOWS WHAT WE WANT TO HEAR? | 5PSQ-185 |
| MAIN POTENTIAL INTERACTIONS DETECTED IN THE OUTPATIENT CONSULTATION | 5PSQ-186 |
| ALTERNATIVE TREATMENT TO ORAL IVERMECTIN IN STRONGYLOIDES STERCORALIS HYPERINFECTION IN THE SETTING OF SMALL BOWEL OBSTRUCTION AND PARALYTIC ILEUS | 5PSQ-187 |
| AN AUDIT OF PRESCRIBING, ADMINISTRATION AND STORAGE OF CONCENTRATED ELECTROLYTES | 5PSQ-188 |
| NEAR MISS LOOKALIKE AND SOUNDALIKE INTRAVENOUS MEDICATION ERROR: A 12 MONTH RETROSPECTIVE STUDY | 5PSQ-189 |
| EXPERIENCE AND SATISFACTION OF OUTPATIENTS IN THE DEVELOPMENT OF A PROGRAMME FOR HOME MEDICATION DELIVERY | 5PSQ-190 |
| NEW GENERAL DRUG CHART, POST-IMPLEMENTATION CLINICAL AUDIT | 5PSQ-191 |
| MEDICATION REVIEW OF POLYMEDICATED PATIENTS IN A HEALTH MANAGEMENT AREA | 5PSQ-192 |
| PATIENT SAFETY IN MEDICATION DISPENSING PERFORMED BY PHARMACONOMISTS: A BEFORE AND AFTER STUDY | 5PSQ-193 |
| MANAGEMENT OF EXPERIMENTAL HEALTH PRODUCTS IN HOSPITAL PHARMACIES: A NATIONAL SURVEY | 5PSQ-194 |
| IMPACT OF INTENSIFIED CLINICAL DECISION SUPPORT SYSTEMS ON PRESCRIBING ERRORS: AN INTERRUPTED TIME SERIES ANALYSIS IN TAIWAN | 5PSQ-195 | |
| ASSOCIATION BETWEEN PHOSPHODIESTERASE 5 INHIBITOR USE AND INCIDENT DEMENTIA IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY | 5PSQ-196 | |
| CONTRAINDICATED DRUG-DRUG INTERACTIONS WITH PAN-GENOTYPIC DIRECT ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C PATIENTS IN TAIWAN | 5PSQ-197 | |
| VARIATIONS IN EFFECTIVENESS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR AMONG HEPATITIS C PATIENTS WITH DIFFERENT GENOTYPES: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN | 5PSQ-198 | |
| USE OF SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS AND RISK OF FRACTURE IN TYPE 2 DIABETES PATIENTS: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN. | 5PSQ-199 | |
| COMPARATIVE CARDIOVASCULAR EVENTS ASSOCIATED WITH DENOSUMAB VERSUS ZOLEDRONATE IN THE ELDERLY: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN | 5PSQ-200 | |
| EFFECT OF SACUBITRIL/VALSARTAN ON GLYCAEMIC CONTROL AND RENAL FUNCTION IN PATIENTS WITH DIABETES AND HEART FAILURE: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN | 5PSQ-201 | |
| BIOSIMILARS IN THE REAL WORLD: RESULTS FROM AN ACTIVE PHARMACOVIGILANCE PROGRAMME IN A PORTUGUESE ONCOLOGY HOSPITAL | 5PSQ-202 |
| POLYPHARMACY AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN ELDERLY ONCOHAEMATOLOGICAL PATIENTS REFERRED TO PALLIATIVE CARE: APPLICATION OF THE STOPPFrail CRITERIA | 5PSQ-203 |
| DIFFERENCE IN ADHERENCE ASSOCIATED WITH THE ROUTE OF ADMINISTRATION | 5PSQ-204 |
| MANIPULATING TABLETS CONTAINING POORLY SOLUBLE PREDNISOLONE TO OBTAIN PAEDIATRIC DOSES | 5PSQ-205 |
| SATISFACTION OF PATIENTS WITH PHARMACEUTICAL TELECARE | 5PSQ-206 |
| ANALYSIS OF THE MEDICINES UNDER ADDITIONAL MONITORING AUTHORISED IN THE EUROPEAN UNION FROM 2017 TO 2019 | 5PSQ-207 |
| PHARMACEUTICAL ALGORITHMS TARGETING ANTICOAGULANT THERAPY: IMPACT OF AVICENNE CLINICAL DECISION SUPPORT IN PATIENT SAFETY | 5PSQ-208 |
| ANTICHOLINERGIC BURDEN AND RISK OF ADVERSE EVENTS IN PATIENTS FROM A SPANISH NURSING HOME | 5PSQ-209 |
| RETROSPECTIVE EVALUATION OF THE DOCUMENTATION OF ALLERGIC AND IDIOSYNCRATIC ADVERSE DRUG REACTIONS IN THE CONTEXT OF THE REQUIREMENTS CONCERNING A CLINICAL DECISION SUPPORT SYSTEM | 5PSQ-210 |
| MEDICATION ERRORS RELATING TO SIMILAR OR MISLEADING MANUFACTURER SPECIFIC DRUG PACKAGING AND LABELLING | 5PSQ-211 |
| NUTRITIONAL SUPPORT AND INTERACTION WITH ONCOLOGICAL TREATMENT IN BREAST CANCER | 5PSQ-212 |
| HOSPITAL ADMISSIONS AFTER DISCHARGED FROM THE EMERGENCY DEPARTMENT TO HOME WITH COVID-19 TREATMENT | 5PSQ-213 |
| “UNIT DOSE”: CLINICAL RISK MANAGEMENT OF COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE | 5PSQ-214 | |
| CLINICAL RISK MANAGEMENT THROUGH THE “UNIT DOSE” SYSTEM | 5PSQ-215 |
| IMPLEMENTATION OF A MEDICATION RECONCILIATION PROGRAMME AS A PATIENT SAFETY STRATEGY | 5PSQ-216 |
| MEDICATION RECONCILIATION PROGRAMME OF THE COMPLEX CHRONIC PATIENT IN A TRAUMATOLOGY AND ORTHOPAEDIC SURGERY SERVICE AT HOSPITAL ADMISSION | 5PSQ-217 |
| HAEMORRHAGIC TRANSFORMATION AFTER MECHANICAL THROMBECTOMY ISCHAEMIC STROKE MANAGEMENT: OVERVIEW OF MEDICAL DEVICE VIGILANCE DECLARATIONS | 5PSQ-218 |
| THE ROLE OF THE HOSPITAL PHARMACIST IN MONITORING DRUGS AND MEDICATIONS PRESCRIPTION IN THE HOME CARE SERVICE: A GUARANTEE OF APPROPRIATENESS | 5PSQ-219 |
| DISCREPANCIES BETWEEN PRESCRIPTION AND DISPENSING OF MEDICATION IN AUTOMATIC DISPENSING CABINET | 5PSQ-220 |
| SAFETY PROFILE OF EXPERIMENTAL THERAPIES USED IN THE COVID-19 PANDEMIC BASED ON DATA FROM THE NATIONAL MINIMUM DATA SET | 5PSQ-221 |
| ANTICHOLINERGIC RISK IN THE ELDERLY | 5PSQ-222 |
| DRUGS TO AVOID. AN OPPORTUNITY IN HEALTHCARE PATIENTS: CHECKING PRESCRIRE’S RECOMMENDATIONS | 5PSQ-223 |
| CLINICAL EXPERIENCE OF PEMBROLIZUMAB WITH AXITINIB IN RENAL CELL CARCINOMA | 5PSQ-224 |
| ELDER FALLERS: A GROUP AT RISK OF READMISSION? | 5PSQ-225 | |
| ANALYSIS OF HIGH ALERT MEDICATION PRESCRIPTIONS IN A NURSING HOME | 5PSQ-226 |
| CLINICAL TRIALS: A STANDARDISED SELF-ASSESSMENT TOOL TO REDUCE THE MULTIPLE RISKS OF THE PHARMACEUTICAL CIRCUIT | 5PSQ-227 |
| PHARMACIST MEDICINES OPTIMISATION AND ERROR MITIGATION AT PAEDIATRIC CRITICAL CARE DISCHARGE: A HUMAN SOLUTION TO AN ELECTRONIC RISK | 5PSQ-228 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PCSK9 INHIBITORS: VARIATION IN THE LIPID PROFILE IN A REAL WORLD SETTING (submitted in 2019) | 6ER-001 | |
| A COMPARATIVE REVIEW OF THE IMPACT OF THE INTRODUCTION OF ON-SITE MOLECULAR TESTING ON THE MANAGEMENT OF ADULT PATIENTS HOSPITALISED WITH SUSPECTED INFLUENZA VIRUS INFECTION (submitted in 2019) | 6ER-002 | |
| EFFECTIVENESS OF NEOADJUVANT TREATMENT IN LOCALLY ADVANCED BREAST CANCER (submitted in 2019) | 6ER-003 | |
| PRELIMINARY CLINICAL RESPONSE OF RIBOCICLIB AS A SINGLE AGENT IN ADVANCED BREAST CANCER: IN SEARCH OF NEW THERAPEUTIC INDICATIONS (submitted in 2019) | 6ER-004 | |
| EFFECTIVENESS OF OMALIZUMAB AND BEE VENOM IMMUNOTHERAPY COMBINATION: CASE REPORT (submitted in 2019) | 6ER-005 | |
| DIGITAL LITERACY IN MULTIPLE SCLEROSIS (submitted in 2019) | 6ER-006 | |
| PERSISTENCE AND SAFETY OF ADALIMUMAB IN PSORIASIS (submitted in 2019) | 6ER-007 | |
| STUDY OF THE USE OF DIMETHYL FUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN A THIRD LEVEL HOSPITAL (submitted in 2019) | 6ER-008 | |
| TREATMENT PATTERNS IN MULTIPLE SCLEROSIS WITH DISEASE MODIFYING DRUGS (submitted in 2019) | 6ER-009 | |
| THERAPEUTIC DRUG MONITORING OF TUMOUR NECROSIS FACTOR a INHIBITORS IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM A REAL WORLD SETTING (submitted in 2019) | 6ER-010 | |
| REAL WORLD ADHERENCE TO MULTIPLE SCLEROSIS THERAPY (submitted in 2019) | 6ER-011 | |
| PERSISTENCE FOR DISEASE MODIFYING DRUGS FOR MULTIPLE SCLEROSIS (submitted in 2019) | 6ER-012 | |
| ENRICHED DEVELOPMENTAL BIOLOGY MOLECULAR PATHWAYS: IMPACT ON ANTIPSYCHOTIC INDUCED WEIGHT GAIN (submitted in 2019) | 6ER-013 | |
| EDUCATION OF PATIENTS RECEIVING OXYGEN THERAPY (submitted in 2019) | 6ER-014 | |
| RISKS OF PHARMACIST RECOMMENDED ANTIBIOTIC USE: GENERAL PUBLIC PERCEPTION (submitted in 2019) | 6ER-015 | |
| ECONOMIC VALUE OF UNUSED HIGH COST EXPERIMENTAL INFUSION DRUGS: A POTENTIAL SAVING FOR THE NATIONAL HEALTH SYSTEM (submitted in 2019) | 6ER-016 | |
| DIGITAL LITERACY OF PATIENTS IN A DAY HOSPITAL ONCOLOGY UNIT (submitted in 2019) | 6ER-017 | |
| THE IMPACT OF HOSPITAL PHARMACY SPECIALISATION ON THE PATIENTS’ OUTCOME: A LITERATURE REVIEW (submitted in 2019) | 6ER-018 |
| TEACHING AND LEARNING EFFECT ANALYSIS OF AN INTERPROFESSIONAL TRAINING PROGRAMME FOR UNDERGRADUATE PHARMACY INTERNS (submitted in 2019) | 6ER-019 | |
| STANDARDISATION OF PROCESSES BY ELECTRONIC ASSISTED PRESCRIPTION PROGRAMME IN A UNIVERSITY PAEDIATRIC HOSPITAL (submitted in 2019) | 6ER-020 | |
| DEGREE OF BURNOUT AMONG PHARMACISTS IN ISRAEL (submitted in 2019) | 6ER-021 | |
| PERCEPTION OF RARE DISEASES AND ORPHAN MEDICINES (submitted in 2019) | 6ER-022 |
| THE ROLE OF INSTITUTIONAL REVIEW BOARDS, AND HOSPITAL PHARMACISTS AS MEMBERS, IN THE INFORMED CONSENT PROCESS IN CLINICAL RESEARCH: A RETROSPECTIVE OBSERVATIONAL STUDY (submitted in 2019) | 6ER-023 | |
| WHAT OUR PATIENTS KNOW ABOUT ANTIBIOTICS AND ANTIMICROBIAL RESISTANCE. ARE THEY AWARE OF HOW TO MAKE GOOD USE OF THEM? | 6ER-024 |
| IMPORTANCE OF APPROPRIATE BEFORE-AND-AFTER QUASI-EXPERIMENTAL DESIGN TO EVALUATE THE IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES: COMPARATIVE RESULTS USING STATISTICAL HYPOTHESIS TESTING OR INTERRUPTED TIME SERIES ANALYSIS | 6ER-025 |
| CREDIBILITY OF SUBGROUP CLAIMS IN HAEMATOLOGY CLINICAL TRIALS | 6ER-026 |
| IMPROVEMENT IN SELF-MANAGEMENT OF BIOLOGICAL DMARDS FOR PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS WHEN A PHARMACIST PARTICIPATES IN A MULTIDISCIPLINARY CONSULTATION | 6ER-027 |
| BARICITINIB AGAINST SEVERE COVID-19: EFFECTIVENESS AND SAFETY IN HOSPITAL CARE | 6ER-028 |
| IMPACT OF MEDICINES INFORMATION APP ON MEDICATION KNOWLEDGE AND WORRY IN POST-MYOCARDIAL INFARCTION PATIENTS | 6ER-029 |
| AN ANNUAL REVIEW OF DRUG SHORTAGES MANAGED BY THE MMUH PHARMACY DEPARTMENT | 6ER-030 |
| DEVELOPMENT OF PATIENT CENTRED VIDEO ON MEDICATION MANAGEMENT AND A QUALITATIVE EXPLORATION OF PATIENTS’ OPINIONS TOWARDS THE VIDEO | 6ER-031 |
| PUBLIC OPINION AND PERSONAL SITUATION IN TIMES OF THE COVID-19 PANDEMIC | 6ER-032 |
| PHARMACIST LED DEPRESCRIBING AND FOLLOW-UP IN A SUBACUTE MULTIDISCIPLINARY OUTPATIENT CLINIC: A PILOT RANDOMISED CONTROLLED TRIAL | 6ER-033 |
| MEDICATION DEPRESCRIBING AND FOLLOW-UP: A SURVEY AMONG SUBACUTE MULTIMORBID PATIENTS IN A MULTIDISCIPLINARY OUTPATIENT CLINIC | 6ER-034 |
| AN EVALUATION OF HEALTH PROMOTION AND DISEASE PREVENTION KNOWLEDGE IN PATIENTS ATTENDING A HOSPITAL OUTPATIENT PHARMACY | 6ER-035 |
| DEPRESCRIBING TOOLS FOR THE ELDERLY: A SYSTEMATIC REVIEW | 6ER-036 |
| DRUG – DRUG INTERACTIONS WITH QT PROLONGING DRUGS IN PATIENTS ADMITTED TO A CARDIOVASCULAR DEPARTMENT: A RETROSPECTIVE ANALYSIS | 6ER-037 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH HIGH DOSES OF BIOTIN: PREVENTION OF SIGNIFICANT BIOLOGICAL EXAMINATION DISTURBANCES BY HOSPITAL PHARMACISTS | NP-001 |
| MEDICATION RECONCILIATION AND MEDICATION REVIEW IN THE UROLOGICAL-ONCOLOGICAL OUTPATIENT CLINIC | NP-002 |
| ANTIBIOTIC RESISTANCE IN COMMUNITY-ACQUIRED PNEUMONIA: A ROMANIAN EXPERIENCE | NP-003 |
| IMPLEMENTATION OF CLINICAL PHARMACY SERVICES IN LONG-TERM CARE WARDS | NP-004 |
| ESTIMATING RENAL FUNCTION FOR DRUG DOSING: EQUATIONS MATTER | NP-005 |
| EARLY DETECTION OF RETINOPATHY IN PREMATURE INFANTS USING MIXTURE OF EYE DROPS WITH 2.5% PHENYLEPHRINE HYDROCHLORIDE AND 0.5% TROPICAMIDE | NP-006 |
| MEDICATION ANALYSIS FOR HOSPITAL PATIENTS WITH RENAL INSUFFICIENCY: FROM DEVELOPMENT PHASE TO STANDARD PRACTICE | NP-007 |
| STABILITY OF CEFTOLOZANE/TAZOBACTAM IN SOLUTION AS INFUSION FOR PROLONGED OR CONTINUOUS APPLICATION | NP-008 |
| PATIENTS’ PERSONAL TREATMENT MANAGEMENT IN A UNIVERSITY HOSPITAL | NP-009 |
| WHAT IS THE EFFECT OF INTERPROFESSIONAL STUDENT PLACEMENTS IN PRIMARY CARE? A RETROSPECTIVE PRE-POST STUDY | NP-010 | |
| MEDISCREEN: IMPLEMENTATION OF A TOOL FOR DETECTING PATIENTS AT RISK OF ADVERSE DRUG EVENTS VIA THE ELECTRONIC MEDICAL RECORD | NP-011 |
| STANDARDISATION OF ANALGESIA AND SEDATION INFUSION SOLUTIONS IN PAEDIATRIC PALLIATIVE PATIENTS RECEIVING END-OF-LIFE CARE AT HOME | NP-012 |
| IMPLEMENTING THE EUROPEAN STATEMENTS OF HOSPITAL PHARMACY IN ITALY: RESULTS OF A WORKING GROUP | NP-013 |
| DEVELOPMENT OF NEW PRODUCTION WHEN NEITHER PACKAGING NOR SOME OF THE RAW MATERIALS CONFORM TO EUROPEAN STANDARDS | NP-014 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS ONE YEAR AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRALS | 1ISG-001 | |
| BUDGETARY IMPACT OF ALIROCUMAB REPACKAGING IN A THIRD-LEVEL HOSPITAL | 1ISG-002 |
| BIOSIMILAR GROWTH HORMONE: DEFINED DAILY DOSE IN AN ITALIAN DISTRICT AFTER THE REGIONAL TENDER | 1ISG-003 |
| ABSTRACT WITHDRAWN | 1ISG-004 | |
| A COST EFFECTIVE STRATEGY: SWITCHING FROM ONE TO TWO TABLETS, IN A ONCE-DAILY REGIMEN IN HIV PATIENTS | 1ISG-005 |
| HEPATITIS C TREATMENT: COST AND EFFECTIVENESS | 1ISG-006 |
| PEMETREXED´S LESSON | 1ISG-007 |
| FLAT DOSES OF ANTI-PD1: WHAT IS THE ECONOMIC IMPACT? | 1ISG-008 |
| AVOIDED COST STUDY OF DRUGS IN CLINICAL TRIALS AT A TERTIARY HOSPITAL | 1ISG-009 |
| REAL-WORLD EVIDENCE OF HIGH-COST DRUGS FOR METASTATIC MELANOMA: EFFECTIVENESS, COMPLIANCE TO CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION | 1ISG-010 |
| REDUCTION OF THE PATIENT WAITING TIME: WHAT COST FOR THE CHEMOTHERAPIES PREPARATION UNIT? | 1ISG-011 |
| COST-EFFECTIVENESS OF AZACITIDINE IN THE REAL-WORLD: ANALYSIS IN HIGH-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM THE PERSPECTIVE OF A EUROPEAN PUBLIC HOSPITAL | 1ISG-012 |
| BUDGET IMPACT ANALYSIS OF LUNG CANCER IMMUNOTHERAPY: A HOSPITAL PERSPECTIVE | 1ISG-013 |
| RHEUMATOID ARTHRITIS: BIOLOGICAL DRUGS PHARMACEUTILISATION ANALISYS IN AN ITALIAN DISTRICT | 1ISG-014 |
| OPTIMISATION OF BIOLOGICAL THERAPIES IN THE TREATMENT OF PSORIASIS | 1ISG-015 |
| COST-EFFECTIVENESS OF MORPHINE VERSUS FENTANYL IN MANAGING VENTILATED NEONATES WITH RESPIRATORY DISTRESS SYNDROME IN THE INTENSIVE CARE SETTING | 1ISG-016 |
| CLINICAL AND ECONOMIC EVALUATIONS OF MORPHINE AND FENTANYL WITH MECHANICAL VENTILATION IN INTENSIVE CARE SETTINGS: A SYSTEMATIC REVIEW OF METHODOLOGICAL TRENDS, AND REPORTING QUALITY | 1ISG-017 |
| ORGANISATIONAL COMMITMENT OF HOSPITAL PHARMACISTS, RELATING TO THE SUPPORTIVE ORGANISATIONAL ENVIRONMENT | 1ISG-018 |
| INSIGHT INTO PHARMACY AND THERAPEUTICS COMMITTEES’ STRUCTURE AND ACTIVITIES AMONG HOSPITALS IN X: MIXED-METHODS APPROACH | 1ISG-019 |
| CHEMICAL RISK ASSESSEMENT IN A QUALITY CONTROL LABORATORY BY A TOOL USING ACTIVITY ANALYSIS | 1ISG-020 |
| A COMPREHENSIVE REGIONAL STRATEGY ADDRESSING GUIDANCE ON SAFE HANDLING OF HAZARDOUS DRUGS | 1ISG-021 |
| FINANCIAL IMPACT OF THIRD-GENERATION CEPHALOSPORINES RESISTANCE IN HOSPITAL SETTINGS – AN EXAMPLE WITH CEFTRIAXONE | 1ISG-022 |
| CYSTIC FIBROSIS OUTPATIENT TREATMENT COSTS: A RETROSPECTIVE ANALYSIS | 1ISG-023 |
| BIOSIMILARS SWITCH: DO DOCTORS AND PATIENTS REVERT BACK AFTER SWITCHING? | 1ISG-024 |
| A CONNECTED APPLICATION FOR BETTER FORMATION | 1ISG-025 | |
| ABSTRACT WITHDRAWN | 1ISG-026 | |
| INTRODUCTION OF SELF-MANAGEMENT IN A HOSPITAL PHARMACY | 1ISG-027 |
| AN ASSESSMENT OF HOSPITAL PHARMACISTS’ JOB SATISFACTION: APPLICATION OF THE JOB SATISFACTION SURVEY | 1ISG-028 |
| IMPACT OF THE IMPLEMENTATION OF THE ENFIT SYSTEM ON THE ADMINISTRATION OF ENTERAL MEDICATION | 1ISG-029 |
| BIOLOGICS UTILISATION AND ITS EFFICIENCY THROUGH A HOSPITAL PHARMACY CENTRALISED MANAGEMENT SYSTEM | 1ISG-030 |
| ABSTRACT WITHDRAWN | 1ISG-031 | |
| SURGICAL SUTURE TO REDUCE NEEDLE-HOLE LEAKAGE: COMPARISON OF TWO SUTURES | 1ISG-032 |
| INFLAMMATORY BOWEL DISEASE: BIOLOGICAL PRESCRIBING TRENDS IN AN ITALIAN HOSPITAL | 1ISG-033 |
| A CRITICAL LOOK AT ERRONEOUS INCENTIVES AND LACKING LEGAL FRAMEWORK AS DRIVERS OF MEDICINES SHORTAGES AND OBJECTORS TO PROBLEM-SOLVING APPROACHES | 1ISG-034 |
| URETERAL MAGNETIC CATHETER: AN EASY AND ECONOMICAL WAY TO REMOVE THE DEVICE | 1ISG-035 |
| THE IMPACT OF HOSPITAL PHARMACY INFRASTRUCTURE AND HUMAN RESOURCES ON MEDICINES OPTIMISATION AND INTEGRATED CARE | 1ISG-036 |
| HEALTH-RELATED QUALITY OF LIFE IN HEPATITIS C PATIENTS WHO ACHIEVE SUSTAINED VIROLOGICAL RESPONSE TO DIRECT-ACTING ANTIVIRALS: A COMPARISON WITH THE GENERAL POPULATION | 1ISG-037 |
| CRITICAL ANALYSIS OF THE INFORMATION AND COMMUNICATION TECHNOLOGIES’ TOOLS MOST USED IN CLINICAL PRACTICE BY THE PHARMACIST | 1ISG-038 |
| THE COST-SAVINGS POTENTIAL OF BIOSIMILAR DRUGS: A BUDGET IMPACT ANALYSIS | 1ISG-039 | |
| EMERGENCY AND DISASTER SITUATIONS : HOW ARE HOSPITAL PHARMACIES PREPARED IN EUROPE? | 1ISG-040 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| DESCRIBING A THICKENER HOME DELIVERY PROTOCOL AND THE BENEFITS OF ITS IMPLEMENTATION | 2SPD-001 |
| COMPARATIVE EFFICACY OF DIMETHYLFUMARATE AND OTHER TREATMENTS FOR MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS | 2SPD-002 |
| MONITORING THE USE OF LINEZOLID IN A THIRD-LEVEL HOSPITAL | 2SPD-003 |
| DRUG CONSUMPTION DATA FOR GUIDING ANTIBIOTIC USE RATIONALISATION IN A SURGICAL DEPARTMENT | 2SPD-004 | |
| ECONOMICAL ANALYSIS OF TENOFOVIR ALAFENAMIDE VERSUS TENOFOVIR-DISOPROXIL FURAMATE | 2SPD-005 |
| ECONOMIC IMPACT OF INLFLIXIMAB BIOSIMILAR REFERENCING IN THE HOSPITAL | 2SPD-006 |
| COST-MINIMISATION ANALYSIS OF LUNG CANCER PD-L1 POSITIVE TREATMENT | 2SPD-007 |
| RISK ANALYSIS ON CYTOTOXIC CIRCUIT IN A CENTRAL PHARMACY | 2SPD-008 |
| ANALYSIS OF OLAPARIB AND TALAZOPARIB AS POSSIBLE THERAPEUTIC ALTERNATIVES IN ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION | 2SPD-009 |
| INDIRECT COMPARISON OF PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN LUNG CANCER | 2SPD-010 |
| NETWORK META-ANALYSIS OF FIRST-LINE ANTIANGIOGENIC DRUGS IN ADVANCED RENAL CELL CARCINOMA | 2SPD-011 |
| RELATIVE VALUE UNITS AS A PRODUCTIVITY SCORE OF MANAGEMENT OF ONCOLOGY MEDICATION IN SPECIAL SITUATIONS | 2SPD-012 |
| ECONOMIC IMPACT OF THE USE OF FLAT DOSE VS PERSONALISED DOSE OF PEMBROLIZUMAB | 2SPD-013 |
| MULTIDISCIPLINARY STOCK MANAGEMENT AND REDUCED DISTRIBUTION OF MEDICINE UP TO A DRUG PATENT EXPIRY REDUCED EXPENSES WITHOUT COMPROMISING MEDICINE SUPPLY IN A HOSPITAL SETTING | 2SPD-014 |
| RISK-ADAPTED MANAGEMENT OF DRUG SHORTAGES TO ENSURE PROPER CARE FOR PATIENTS IN MEDICAL NEED | 2SPD-015 |
| BIOSIMILARS OF INFLIXIMAB AND RITUXIMAB: DOES THE INITIAL STRATEGY OF SELECTION HELP THEIR PRESCRIPTIONS? | 2SPD-016 |
| ECHO-ENDOSCOPY : FOR A SOURCING AS SHARP AS A NEEDLE | 2SPD-017 |
| AUDIT ON THE MANAGEMENT OF PERSONAL TREATMENT OF PATIENTS AT THE HOSPITAL | 2SPD-018 |
| EVALUATION OF THE INTRODUCTION OF A MEDICAL DEVICE FOR MECHANICAL INDUCTION OF LABOUR IN WOMEN WITH UNFAVOURABLE CERVIX | 2SPD-019 |
| EXPIRED MEDICINES AND MEDICAL DEVICES, AN ACROBATIC MANAGEMENT | 2SPD-020 |
| NONCOMPLIANCE OF DATAMATRIX CODES, AN OBSTACLE TO IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE | 2SPD-021 |
| ON THE ROAD TO SERIALISATION: A PRATICAL APPLICATION | 2SPD-022 | |
| INTEREST IN CONSIGNMENT INVENTORY MANAGEMENT OF ARTICULAR PROSTHESES AT A UNIVERSITY HOSPITAL | 2SPD-023 | |
| IMPLEMENTED STRATEGIES TO SOLVE MEDICINES SHORTAGES | 2SPD-024 |
| OPTIMISING OF PLANNED DRUGS ORDERS AND RECEPTION PLATFORM ACTIVITY | 2SPD-025 |
| AUTOMATED UNIT DOSE-DISPENSING DEVICE: ASSESSMENT OF THE CONTROL METHOD | 2SPD-026 |
| MULTI-CRITERIA DECISION ANALYSIS FOR EVALUATING NEW MEDICINES IN HEALTH TECHNOLOGY ASSESSMENT FRAMEWORK ANALYSIS | 2SPD-027 | |
| OPTIMISATION OF SURGICAL PROCEDURAL-KIT SETTING | 2SPD-028 |
| MEDICAL DEVICES MANAGEMENT: CONSUMPTION IN SURGICAL PRACTICE WITH RADIO FREQUENCY IDENTIFICATION SYSTEM | 2SPD-029 |
| OPTIMISING INVENTORY MANAGEMENT IN A HOSPITAL PHARMACY | 2SPD-030 |
| MANAGEMENT OF DRUG SHORTAGES IN A TERTIARY HOSPITAL | 2SPD-031 |
| PHARMACY, CLINICAL SERVICES: COMMUNICATE WELL TO SERVE BETTER! EXAMPLE OF THE CARDIOLOGY CENTRE OF A UNIVERSITY HOSPITAL | 2SPD-032 | |
| IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE | 2SPD-033 |
| DRUG SHORTAGES. ANALYSIS OF THE ECONOMIC IMPACT | 2SPD-034 |
| MEDICINE SHORTAGES: IMPACT ON A THIRD-LEVEL HOSPITAL PHARMACY DEPARTMENT ACTIVITY | 2SPD-035 |
| STORAGE AND DISPENSING OF SOLID ORAL DOSAGE FORMS FROM MULTIPLE UNIT CONTAINERS | 2SPD-036 |
| OVER 5 YEARS OF MEDICINES SHORTAGES IN A UNIVERSITY HOSPITAL | 2SPD-037 |
| HOW LONG DO HOSPITAL PHARMACISTS SPEND IN MANAGING MEDICINES SHORTAGES? | 2SPD-038 | |
| MEDICINE SHORTAGES IN A GENERAL COUNTY HOSPITAL: EVALUATION AND ESSENTIAL QUALITY | 2SPD-039 |
| IS PNEUMATIC TUBE DELIVERY SAFE FOR MEDICINES? | 2SPD-040 |
| DRUG SHORTAGES ANALYSIS FROM AN ITALIAN HOSPITAL PHARMACY PERSPECTIVE | 2SPD-041 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| MAGISTRAL FORMULATION OF 10% SUCRALFATE ENEMAS IN PROCTITIS | 3PC-001 |
| PRELIMINARY RESULTS ON THE USE OF ORAL REHYDRATION SOLUTION IN THE FORM OF GELATO FOR REHYDRATION OF CHILDREN WITH ACUTE GASTROENTERITIS | 3PC-002 |
| WEIGHT-LOWERING PSEUDOEPHEDRINE-BASED PRESCRIPTIONS: MONITORING PATIENT FEEDBACK AFTER UPDATE OF NATIONAL PRICE LIST OF MEDICINES AND MAGISTRAL PREPARATION | 3PC-003 |
| WHAT HAPPENS WHEN INSULIN ASPART IS DILUTED IN DEXTROSE? | 3PC-004 |
| STABILITY STUDY OF A 10% SODIUM BENZOATE ORAL SOLUTION | 3PC-005 |
| ANALYSIS OF THE REGIMENS ESTABLISHED AT THE PHARMACY SERVICE FOR TOTAL PARENTERAL NUTRITION AND THE USE OF GLUTAMINE AS SOURCE OF NITROGEN | 3PC-006 |
| IMPLEMENTATION AND QUALITY CONTROL OF A 5% FRUCTOSE AND 10% GLYCEROL STERILE SOLUTION FOR DIGESTIVE ENDOSCOPY | 3PC-007 |
| PHYSICOCHEMICAL STABILITY OF NOREPINEPHRINE BITARTRATE IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS | 3PC-008 |
| SUCCESSFUL TREATMENT OF HAMARTOMA IN CHILD SYNDROME AFTER 30 MONTHS WITH TOPICAL ADMINISTRATION OF SIMVASTATIN/CHOLESTEROL CREAM: A CASE REPORT | 3PC-009 |
| STABILITY OF CHLORHEXIDINE 0.05% EYE DROPS COMPOUNDING DRUG | 3PC-010 |
| EFFECTIVENESS OF 3% TOPICAL IMIQUIMOD IN OFF-LABEL USE FOR ORAL FLORIDA PAPILLOMATOSIS: A CASE REPORT | 3PC-011 |
| TOPICAL CIDOFOVIR COMPOUNDING CREAM FOR THE TREATMENT OF DISSEMINATED INFECTION BY MOLLUSCUM CONTAGIOSUM | 3PC-012 |
| FEEDBACK FROM A FEASIBILITY STUDY OF ALLERGY TEST PREPARATIONS IN DAY HOSPITALISATION | 3PC-013 |
| STABILITY OF 1 MG/ML AND 4 MG/ML HYDROCORTISONE SOLIUM SUCCINATE SOLUTIONS IN 0.9% SODIUM CHLORIDE AND 5% GLUCOSE | 3PC-014 |
| PHYSICOCHEMICAL STABILITY OF CEFOTAXIME IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS | 3PC-015 |
| PHYSICOCHEMICAL STABILITY OF VANCOMYCIN HYDROCHLORIDE IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS | 3PC-016 |
| PHYSICAL COMPATIBILITY OF INTRAVENOUS ANTI-INFECTIVE DRUGS WITH MEDICATIONS COMMONLY USED IN INTENSIVE CARE UNITS | 3PC-017 |
| IMPLEMENTATION OF QUALITY CONTROL OF PAEDIATRIC CYTOTOXIC DRUG PREPARATIONS: PILOT TRIAL WITH ETOPOSIDE. | 3PC-018 |
| RISK MANAGEMENT OF CROSS-CONTAMINATION OF PAEDIATRIC ANTI-CANCER PREPARATIONS USING FAILURE MODE AND EFFECTS CRITICALITY ANALYSIS | 3PC-019 |
| NIVOLUMAB WEIGHT-BASED DOSING VS FLAT DOSE ECONOMIC ANALYSIS | 3PC-020 |
| IMPACT OF A CENTRALISED INTRAVENOUS ADDITIVE SERVICE IN PATIENTS AND HEALTHCARE WORKERS RISK REDUCTION | 3PC-021 |
| PRELIMINARY MICROBIOLOGICAL STUDY OF INJECTABLE CHEMOTHERAPY DOSE-BANDING | 3PC-022 |
| A RISK ANALYSIS METHOD TO EVALUATE THE IMPACT OF A CHEMOTHERAPY COMPOUNDING WORKFLOW MANAGEMENT SYSTEM ON CANCER PATIENTS’ SAFETY | 3PC-023 |
| THE VALIDATION OF CONTROL METHOD : THE GRAVIMETRIC ANALYSIS IN CYTOTOXIC DRUG PREPARATION | 3PC-024 |
| OPTIMISATION OF COMPOUNDING ORGANISATION AFTER IMPLEMENTING A ROBOTIC SYSTEM FOR AUTOMATED PREPARATION OF ONCOLOGIC DRUGS | 3PC-025 |
| WHAT IS THE BEST CHEMICAL DECONTAMINATION SOLUTION FOR CONVENTIONAL ANTI-NEOPLASTIC DRUGS IN A HOSPITAL COMPOUNDING UNIT? | 3PC-026 |
| PRODUCTIVITY ANALYSIS OF AN AUTOMATED COMPOUNDING SYSTEM FOR INTRAVENOUS CHEMOTHERAPY | 3PC-027 |
| DOSE-BANDING GEMCITABINE AND STANDARDISATION OF CHEMOTHERAPY PROTOCOLS PRODUCTION | 3PC-028 |
| QUALITY OF GEMCITABINE READY TO ADMINISTER PREPARATIONS | 3PC-029 |
| PHYSICAL, CHEMICAL AND MICROBIOLOGICAL STABILITY OF SIROLIMUS 0.4% IN TOPICAL FORMULATIONS | 3PC-030 |
| THE TRANSITION FROM THE USE OF BUPIVACAINE TO ROPIVACAINE IN THE DELIVERY ROOM, IN ORDER TO ACHIEVE A BETTER ANALGESIC EFFECT | 3PC-031 |
| LOW-DOSE MORPHINE SOLUTION FOR SPINAL ANAESTHESIA – READY TO USE TO IMPROVE PATIENT SAFETY IN DRUG THERAPY | 3PC-032 |
| LABELLING WITHOUT STRENGTH FOR A PHARMACEUTICAL PREPARATION USED IN A BLINDED DOSAGE ADJUSTMENT OF CLOZAPINE | 3PC-033 |
| IMIPENEM-FORTIFIED EYE DROPS FOR THE TREATMENT OF BACTERIAL KERATITIS: DEVELOPMENT AND CHARACTERISATION | 3PC-034 |
| GALENIC FORMULATIONS FOR OPHTALMOLOGISTS: NEW FORMULATIONS, PRESCRIBING PATHWAYS AND PATIENT INFORMATION | 3PC-035 |
| COMPARISON OF METABOLITE LEVELS IN SERUM AND TEARS: IMPLICATIONS FOR THE DILUTION OF AUTOLOGOUS-SERUM-EYE-DROPS | 3PC-036 | |
| DEVELOPMENT OF VIRTUAL DRUG INFORMATION CENTRE FOR PHARMACY COMPOUNDING AREA | 3PC-037 |
| ABSTRACT WITHDRAWN | 3PC-038 | |
| STABILITY STUDY OF (99MTC)DOTATOC AND (68GA)DOTATOC IN SYRINGES | 3PC-039 |
| HEALTH HAZARDS OF RAW MATERIALS USED IN THE COMPOUNDING OF PHARMACEUTICALS FORMULATIONS | 3PC-040 | |
| AUTOMATION OF PARENTERAL NUTRITION COMPOUNDING: RESULTS OF GRAVIMETRIC QUALITY CONTROL BEFORE AND AFTER ITS IMPLEMENTATION | 3PC-041 |
| A SCIENCE- AND RISK-BASED STRATEGY TO QUALIFY STERILISED PREFILLED SYRINGES AS PRIMARY PACKAGING MATERIAL IN A HOSPITAL PHARMACY | 3PC-042 |
| NEW FORMULATION OF NOREPINEPHRINE SOLUTION IN PREFILLED CYCLIC OLEFIN STERILISED SYRINGES | 3PC-043 |
| PARAFFIN OIL-BASED EMULSION: INFLUENCE OF GUM ARABIC AND THE MIXING RATE ON EMULSION STABILITY | 3PC-044 |
| FORMULATION AND STABILITY STUDY OF EXTEMPORANEOUS ORAL LIQUID DOSAGE FORMS CONTAINING FLECAINIDE ACETATE 2MG/ML FOR PAEDIATRIC USE | 3PC-045 |
| STUDY OF STABILITY OF TWO LIQUID FORMULATIONS OF OMEPRAZOLE ELABORATED IN THE PHARMACEUTICAL SERVICE | 3PC-046 |
| EVALUATION OF THE EFFECTIVENESS AND SATISFACTION OF THE MASTER SUSPENSION FORMULA FOR MUCOSITIS ELABORATED IN A TERTIARY HOSPITAL | 3PC-047 |
| ORAL MUCOADHESIVE DEXAMETHASONE 0.1% (M / M) GEL: A STRATEGY FOR MOTOR INHIBITORS MUCOSITIS | 3PC-048 | |
| MOBILE APPLICATIONS RELATED TO PARENTERAL NUTRITION: QUALITATIVE AND QUANTITATIVE ANALYSIS | 3PC-049 |
| APPLICATION OF HAZARD VULNERABILITY ANALYSIS TO EVALUATE POTENTIAL RISKS OF PHARMACY COMPOUNDING | 3PC-050 |
| IMPACT OF OPHTHALMOLOGICAL PREPARATIONS IN THE PHARMACY SERVICE OF A REFERENCE HOSPITAL | 3PC-051 |
| CHEMICAL DISINFECTANTS VS STERILE WATER AND COMPOSITE FIBRE: THE EFFECT OF CLEANING METHODS ON MICROBIAL CONTAMINATION IN A CLASS A PHARMACEUTICAL COMPOUNDING ENVIRONMENT | 3PC-052 |
| NEW FORMULATIONS FOR THE TREATMENT OF ANTINEOPLASTIC AND RADIOTHERAPY-INDUCED MUCOSITES | 3PC-053 |
| ADDED VALUE FROM AN INFORMATION AND COMMUNICATION TECHNOLOGY-ASSISTED INTERVENTION IN A TOTAL PARENTERAL UNIT OF A PAEDIATRIC HOSPITAL PHARMACY | 3PC-054 |
| CYTOTOXIC AGENTS: SKIN TESTS FOR THE DIAGNOSIS OF DRUG HYPERSENSITIVITY | 3PC-055 |
| PERFORMANCE ANALYSIS OF A FULLY AUTOMATED ONCOLOGY PHARMACY PRODUCTION: A 2018 UPDATE | 3PC-056 |
| ECONOMIC IMPACT AFTER THE IMPLEMENTATION OF A RISK MATRIX IN THE PREPARATION OF CHEMOTHERAPY | 3PC-057 | |
| ROBOTIC COMPOUNDING: SAFETY AND PRODUCTIVITY ACHIEVEMENTS IN THE PREPARATION OF HAZARDOUS DRUGS | 3PC-058 |
| USE OF EXTEMPORANEOUS ORAL SUSPENSIONS OF OXYBUTININ AND PRAZOSINE IN NEONATES | 3PC-059 |
| HOT-MELT RAM EXTRUSION 3D PRINTING: A SMART METHOD FOR COMPOUNDING ORODISPERSIBLE FILMS IN HOSPITAL PHARMACIES | 3PC-060 |
| OPTIMISATION OF INTRACAMERAL CEFUROXIME CONSUMPTION IN THE PREVENTION OF POSTOPERATIVE ENDOPHTALMITIS | 3PC-061 |
| ABSTRACT WITHDRAWN | 3PC-062 | |
| GALENIC PREPARATION OF 40% DEXTROSE GEL: NEW APPROACH TO MANAGEMENT OF NEONATAL HYPOGLYCAEMIA | 3PC-063 |
| FEEDBACK FROM LEAN MANAGEMENT IN A STERILISATION UNIT | 3PC-064 |
| ORODISPERSIBLE FILMS – AN INTERESTING DOSAGE FORM! | 3PC-065 | |
| PT-SMELL TEST: A NOVEL HOSPITAL COMPOUNDING AND ITS CLINICAL VALIDATION TO DIAGNOSE OLFACTORY DYSFUNCTION | 3PC-066 | |
| ABSTRACT WITHDRAWN | 3PC-067 | |
| ABSTRACT WITHDRAWN | 3PC-068 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| A REVISION OF PRESCRIBING PUMP INHIBITOR PRESCRIPTIONS IN INTERNAL MEDICINE AND ADDICTOLOGY DEPARTMENT | 4CPS-001 |
| ANALYSIS AND IMPROVEMENT OF PROFESSIONNAL PRACTICES: PRESCRIPTION’S EVALUATION OF PROTON PUMP INHIBITORS IN ORAL ROUTES | 4CPS-002 |
| AN EVALUATION OF GASTROINTESTINAL PROPHYLAXIS IN ELDERLY PATIENTS ON ASPIRIN THERAPY | 4CPS-003 |
| PERTINENCE OF THE PRESCRIPTION OF STRESS ULCER PROPHYLAXIS IN INTENSIVE CARE MEDICINE | 4CPS-004 |
| GLP-1 AGONIST LIRAGLUTIDE AS ADD-ON THERAPY IN TYPE 2 DIABETES | 4CPS-005 |
| PHARMACIST-LED MEDICINE RECONCILIATION AT DIABETES OUTPATIENT CLINIC | 4CPS-006 |
| COST MINIMISATION STUDY: SWITCH VIAL TO PEN IN GERIATRICS | 4CPS-007 |
| IMPACT OF PHARMACEUTICAL INTERVIEW IN PATIENT ACCEPTANCE OF INSULIN GLARGINE’S BIOSIMILAR 100UI/ML | 4CPS-008 |
| EVALUATION OF THE SAFETY OF INHIBITORS OF THE CO-TRANSPORTER 2 IN A UNIVERSITY CARE HOSPITAL | 4CPS-009 |
| INSULIN PRESCRIPTION ANALYSIS IN A THIRD-LEVEL HOSPITAL | 4CPS-010 |
| PREVALENCE AND RELATIONSHIP BETWEEN HYPOVITAMINOSIS D AND INSULIN RESISTANCE IN OBESE PATIENT CANDIDATES FOR BARIATRIC SURGERY | 4CPS-011 |
| PREVALENCE OF NUTRITIONAL COMPLICATIONS ACCORDING TO THE REQUESTED HOSPITALISATION SERVICE OF TOTAL PARENTERAL NUTRITION | 4CPS-012 |
| ORAL ANTICOAGULANT PRESCRIPTION PRACTICE AFTER AN ISCHAEMIC STROKE | 4CPS-013 |
| ABSTRACT WITHDRAWN | 4CPS-014 | |
| EVALUATION OF ANTICOAGULANTS MISUSE IN PATIENTS ADMITTED FOR ISCHAEMIC STROKE IN A NEUROLOGY UNIT | 4CPS-015 |
| ABSTRACT WITHDRAWN | 4CPS-016 | |
| EVALUATION OF PHARMACISTS’ INPUT IN ANTICOAGULATION CLINIC REVIEWING DIRECT ORAL ANTICOAGULANTS INITIATED IN A SECONDARY CARE HOSPITAL IN LONDON | 4CPS-017 | |
| EVALUATION OF ANTIPLATELET AGENT PRESCRIBING IN PATIENTS ON DIRECT ORAL ANTICOAGULANT | 4CPS-018 | |
| MEDICATION USE EVALUATION OF EDOXABAN IN A TERTIARY HOSPITAL | 4CPS-019 |
| ANTICOAGULATION THERAPY IN HAEMODIALYSIS – A CLINICAL PHARMACIST EXPERIENCE IN A PRIMARY CARE TEAM | 4CPS-020 |
| ABSTRACT WITHDRAWN | 4CPS-021 | |
| HIGH INPUT IN PATIENT SAFETY – DOCUMENTATION OF CARDIOVASCULAR SYSTEM DRUGS | 4CPS-022 |
| SACUBITRIL/VALSARTAN (ENTRESTO) IN REAL LIFE: AN OBSERVATIONAL STUDY IN A HOSPITAL CENTRE | 4CPS-023 | |
| EFFICACY, SAFETY AND ACCEPTANCE OF TREATMENT WITH ALIROCUMAB OR EVOLOCUMAB IN PATIENTS WITH DYSLIPIDAEMIA | 4CPS-024 |
| LIPID MODIFICATION THERAPY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE | 4CPS-025 |
| ADHERENCE AND EFFECTIVENESS OF PCSK9 INHIBITORS IN ROUTINE CLINICAL PRACTICE | 4CPS-026 |
| REAL-WORLD EFFECTIVENESS OF EVOLOCUMAB AND ALIROCUMAB AT 12 MONTHS OF TREATMENT | 4CPS-027 |
| STATIN OVERUSE? EVALUATION OF STATIN INITIATION FOR PRIMARY PREVENTION DURING HOSPITALISATION BETWEEN TWO NEIGHBOURING COUNTRIES IN EUROPE IN HIGH-RISK PATIENTS | 4CPS-028 |
| CLINICAL EXPERIENCE OF NEW LIPID-LOWERING THERAPIES: EVOLOCUMAB AND ALIROCUMAB | 4CPS-029 |
| ANALYSIS OF ADAPTATION TO A PROTOCOL OF USE OF THE PCSK9 INHIBITORS | 4CPS-030 |
| THE PRIMARY EFFICACY ENDPOINT FOR ALIROCUMAB, REDUCTIONS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL | 4CPS-031 |
| SKIN PROTECTION AND PREVENTION OF CUTANEOUS MYCOSIS | 4CPS-032 |
| THE USE OF ORAL APREMILAST FOR THE TREATMENT OF PLAQUE PSORIASIS | 4CPS-033 |
| USE OF USTEKINUMAB IN REFRACTORY PATIENTS OF PSORIASIS | 4CPS-034 |
| PERSISTENCE AND SAFETY OF APREMILAST IN PSORIASIS | 4CPS-035 | |
| APREMILAST ADHERENCE IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS | 4CPS-036 |
| THE IMPACT OF MULTIDISCIPLINARY COLLABORATION IN OPTIMISING THE PRESCRIPTION OF ANTIBIOTICS IN A PAEDIATRIC HOSPITAL | 4CPS-037 | |
| QUALITY OF LIFE OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS UNDERGOING OUT-PATIENT TREATMENT WITH DUPILUMAB | 4CPS-038 |
| DUPILUMAB TREATMENT DISCONTINUATION DUE TO LIMITING ADVERSE EFFECTS: A CASE REPORT | 4CPS-039 |
| OPTIMISING OF ANTIBIOTIC PROPHYLAXIS AT CARDIAC SURGERY CLINIC | 4CPS-040 |
| IMPLEMENTATION OF AN EMPIRICAL ANTIBIOTIC TREATMENT GUIDE: IMPACT ON ANTIOBITIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT | 4CPS-041 |
| SWITCH FROM CLARITHROMYCIN TO AZITHROMYCIN – ONE OPTION TO OPTIMISE MACROLIDE USE THROUGH CLINICAL PHARMACISTS | 4CPS-042 |
| EXTENSIVELY PANDRUG-RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS: ANALYSIS AND OUTCOMES | 4CPS-043 |
| IMPACT OF CLINICAL PHARMACIST-VANCOMYCIN MONITORING ON PATIENT SAFETY OUTCOME | 4CPS-044 |
| VALUE OF THE CLINICAL PHARMACIST IN THE PHARMACOKINETIC MONITORING OF ANTIMICROBIALS: HEALTH OUTCOMES | 4CPS-045 |
| PHARMACEUTICAL INTERVENTIONS IN ANTIMICROBIAL TREATMENT IN A 150-BED HOSPITAL | 4CPS-046 |
| FEASIBILITY OF PHARMACY FOLLOW-UP OF ANTIBIOTIC RE-EVALUATION IN A UNIVERSITY HOSPITAL: DAY-2 OR/AND DAY-7? | 4CPS-047 |
| QUALITY OF THE EMPIRIC ANTIBIOTIC TREATMENT IN COMMUNITY-ACQUIRED PNEUMONIA | 4CPS-048 |
| CEFTOBIPROLE IN EMPIRICAL TREATMENT OF BONE AND JOINT INFECTIONS: SURVEY OF THE PRESCRIPTIONS, RESPECT OF THE PROTOCOL AND ECONOMIC EVALUATION OVER 6 MONTHS | 4CPS-049 |
| ANALYSIS OF ANTIBIOTIC ADMINISTRATION IN SURGICAL PROPHYLAXIS | 4CPS-050 | |
| ABSTRACT WITHDRAWN | 4CPS-051 | |
| FROM THE SURVEILLANCE OF ANTIBIOTICS PRESCRIPTIONS TO LIMITATION OF MULTIDRUG RESISTANT BACTERIA STRAINS: THE ROLE OF THE HOSPITAL PHARMACY IN DEFINING A CARBAPENEM-SPARING-STRATEGY | 4CPS-052 |
| STUDY ON DAPTOMYCIN USE AS A FIRST STEP TOWARDS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME | 4CPS-053 |
| USE OF ANTIMICROBIAL AGENTS IN THE EMERGENCY DEPARTMENT IN A THIRD-LEVEL HOSPITAL | 4CPS-054 |
| EFFICACY AND SAFETY OF ARTEMISININE DERIVATIVES IN THE TREATMENT OF MALARIA | 4CPS-055 |
| MAPPING ANTIBIOTIC USE PATTERNS IN A SEPTIC ORTHOPAEDIC WARD | 4CPS-056 |
| HOW WELL IS THE TARGET CONCENTRATION OF VANCOMYCIN ACHIEVED IN INTENSIVE CARE UNIT PATIENTS? | 4CPS-057 |
| AVOID SIMULTANEUS PRESCRIPTION BETWEEN LINEZOLID AND VORICONAZOLE: PHARMACOKINETIC STUDY | 4CPS-058 |
| EFFECTIVENESS OF MEROPENEM TREATMENT IN CRITICAL PATIENTS: PHARMACOKINETIC STUDY | 4CPS-059 |
| PREVALENCE OF VANCOMYCIN-RELATED NEUTROPAENIA, THROMBOCYTOPAENIA AND ACUTE KIDNEY INJURY | 4CPS-060 |
| EXTENDED INFUSION OF MEROPENEM IN A NEONATE WITH COMPLICATED KLEBSIELLA PNEUMONIAE MENINGITIS | 4CPS-061 |
| IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMME ON CARBAPENEMS RESISTANCE AND CONSUMPTION IN A TERTIARY HOSPITAL: A BEFORE-AND-AFTER INTERVENTIONAL STUDY | 4CPS-062 |
| IMPACT OF PHARMACEUTICAL CARE IN THE RATIONAL USE OF DAPTOMYCIN | 4CPS-063 |
| EVALUATION OF BROAD-SPECTRUM BETA-LACTAM PRESCRIPTIONS (EXCEPTCARBAPENEMS) IN THE MILITARY HOSPITAL OF INSTRUCTION MOHAMMED V RABAT | 4CPS-064 | |
| CLINICAL IMPACT EVALUATION OF IMPLEMENTING ANTIBIOTHERAPY CONTROL OF MORE THAN 7 DAYS | 4CPS-065 | |
| ADHERENCE OF PATIENTS RECEIVING ANTIBIOTIC THERAPY AFTER HOSPITALISATION | 4CPS-066 |
| EFFECTIVENESS AND SAFETY OF THE EARLY SWITCH FROM INTRAVENOUS TO ORAL ANTIBIOTICS TREATMENT IN THE PNEUMOLOGY WARD | 4CPS-067 |
| IMPACT OF THE PHARMACEUTICAL RECOMMENDATIONS FOR THE IMPROVEMENT IN ANTIBIOTICS PRESCRIPTION | 4CPS-068 |
| IMPACT OF IMPLEMENTING A GLOBAL COLLABORATIVE PHYSICIAN-PHARMACIST STRATEGY ON PROPHYLACTIC ANTIBIOTIC PRACTICES IN A UNIVERSITY HOSPITAL CENTRE | 4CPS-069 |
| DOES ANTIBIOTIC CONSUMPTION PREDICT THE INCIDENCE DENSITY OF HEALTHCARE-ASSOCIATED INFECTIONS? | 4CPS-070 |
| SHORTAGE OF DRUGS ERA: IMPACT OF PIPERACILIN/TAZOBACTAM SHORTAGE | 4CPS-071 |
| ABSTRACT WITHDRAWN | 4CPS-072 | |
| FOLLOW-UP OF RECOMMENDATIONS ON DOSE ADJUSTMENT OF CEFTOLOZANE/TAZOBACTAM IN RENAL FAILURE | 4CPS-073 |
| ROLE OF THE PHARMACIST IN THE EVALUATION OF THE PRESCRIPTIVE APPROPRIATENESS IN ANTIBIOTIC THERAPY AS A “SINGLE DOSE” | 4CPS-074 |
| CREATION OF AN INNOVATIVE AND ATTRACTIVE TRAINING PROGRAMME FOR PRESCRIBERS TO PROMOTE THE CORRECT USE OF FLUOROQUINOLONES | 4CPS-075 |
| ENCOURAGING THE RESPONSIBLE USE OF ANTIBIOTICS: AWARENESS AND UNDERSTANDING AMONG A UNIVERSITY STUDENT POPULATION OF A COMMUNITY PHARMACY PUBLIC HEALTH CAMPAIGN IN SCOTLAND | 4CPS-076 |
| INHALED COLISTIN AS CHRONIC SUPPRESSOR THERAPY IN PATIENTS WITH BRONCHIECTASIAS WITH NON-CYSTIC FIBROSIS | 4CPS-077 |
| ADEQUACY OF SYSTEMATIC ANTIFUNGAL AGENT PRESCRIPTIONS IN A TEACHING HOSPITAL | 4CPS-078 |
| PATIENT WITH COMPLICATED FUNGAL ENDOCARDITIS : A CASE REPORT | 4CPS-079 |
| APPROPRIATE USE OF ANTIFUNGALS: IMPACT OF AN ANTIFUNGAL STEWARDSHIP PROGRAMME ON THE CLINICAL OUTCOME OF CANDIDAEMIA IN A UNIVERSITY HOSPITAL | 4CPS-080 |
| EVALUATION OF THE STANDARD DOSAGE REGIMEN OF VORICONAZOLE IN A PAEDIATRIC AND ADULT POPULATION THROUGH THERAPEUTIC DRUG MONITORING | 4CPS-081 |
| NEPHROGENIC DIABETES INSIPIDUS INDUCED BY LIPOSOMAL AMPHOTERICIN B: A CASE REPORT | 4CPS-082 |
| AGING WITH HIV: OPTIMISING PHARMACOTHERAPY BEYOND INTERACTIONS | 4CPS-083 |
| EVOLUTION OF NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS USE SINCE 2010 IN A THIRD-LEVEL HOSPITAL | 4CPS-084 |
| STEWARDSHIPS OF HEPATITIS C VIRUS PATIENTS IN PRISONS | 4CPS-085 |
| A FULLY INTEGRATED CLINICAL TRIAL-LIKE SYSTEM TO MANAGE AND MONITOR PERSISTENCE IN PLANNED HEPATITIS C TREATMENT | 4CPS-086 |
| EVOLUTION OVER TIME OF ANTIRETROVIRALS | 4CPS-087 |
| EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C | 4CPS-088 |
| RETREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION AFTER VIROLOGICAL FAILURE TO DIRECT-ACTING ANTIVIRALS | 4CPS-089 |
| HEALTH OUTCOMES USING DIRECT-ACTING ANTIVIRAL DRUGS FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS AND F0-F1 LIVER FIBROSIS STAGE | 4CPS-090 |
| CURRENT STATE OF RETREATMENT OF HEPATITIS C INFECTION IN PATIENTS WHOM PRIOR THERAPY FAILED IN A HEPATITIS REFERRAL CENTRE | 4CPS-091 |
| PREVALENCE OF POLYPHARMACY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION | 4CPS-092 |
| PERSISTENCE OF AN ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS PATIENTS IN A TERTIARY LEVEL HOSPITAL | 4CPS-093 |
| EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR IN REAL-WORLD CLINICAL PRACTICE FOR CHRONIC HEPATITIS C INFECTION | 4CPS-094 |
| RESCUE OF PATIENTS INFECTED WITH HEPATITIS C VIRUS NOT RESPONDING TO INTERFERON-FREE THERAPIES | 4CPS-095 |
| ABSTRACT WITHDRAWN | 4CPS-096 | |
| COBICISTAT INTERACTIONS WITH CHRONIC TREATMENTS | 4CPS-097 |
| INFLUENCE OF PHARMACOLOGICAL INTERACTIONS IN HEPATITIS C TREATMENT SELECTION IN OPIATE-DEPENDENT PATIENTS | 4CPS-098 |
| PALIVIZUMAB OFF LABEL USE IN TERTIARY REFERRAL HOSPITAL | 4CPS-099 |
| QUALITY OF INTRATECT: IN VITRO EVALUATION OF BIOLOGICAL ACTIVITIES | 4CPS-100 |
| INTRAVENOUS IMMUNOGLOBULINS USE FOR CHILDREN’S NEUROLOGICAL AND NEURODEVELOPMENTAL DISORDERS | 4CPS-101 |
| MEASUREMENT OF HEALTH OUTCOMES OF POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE COMBINATION IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA | 4CPS-102 |
| EVALUATION OF HEALTH OUTCOMES OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | 4CPS-103 |
| CHEMOTHERAPY TREATMENT IN COLORECTAL CANCER PATIENTS OLDER THAN 70 YEARS AT A TERTIARY HOSPITAL | 4CPS-104 |
| PRESCRIBED ANTINEOPLASTIC AGENTS IN PAEDIATRIC PATIENTS | 4CPS-105 |
| MULTI-STATE MODEL TO ESTIMATE THE OPTIMAL DURATION OF FIRST-LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER: DATA FROM THE NATIONAL REGISTRY AGAMENON | 4CPS-106 |
| EFFECTIVENESS AND SAFETY STUDY OF NIVOLUMAB IN THE SECOND LINE OF ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER | 4CPS-107 |
| DABRAFENIB AND TRAMETINIB: COMBINATION THERAPY FOR METASTATIC MELANOMA | 4CPS-108 |
| POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA TREATED AT A UNIVERSITY HOSPITAL | 4CPS-109 |
| SAFETY AND EFFECTIVENESS OF OBINUTUZUMAB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: OUR EXPERIENCE | 4CPS-110 |
| TREATMENT OF FOLLICULAR LYMPHOMA IN ROUTINE CLINICAL PRACTICE. | 4CPS-111 |
| ASSESSMENT OF AGGRESSIVE CARE IN ONCOLOGY PATIENTS AT THE END OF LIFE IN CLINICAL PRACTICE | 4CPS-112 |
| DRUG COST SAVING RESULTING FROM METASTATIC MELANOMA CLINICAL TRIALS | 4CPS-113 |
| DOSING OF PLATINUM AND TAXANES IN OBESE PATIENTS: A SYSTEMATIC REVIEW | 4CPS-114 |
| RITUXIMAB IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS | 4CPS-115 | |
| VEMURAFENIB-INDUCED STEVENS-JOHNSON SYNDROME IN A PATIENT WITH METASTATIC MELANOMA: A CASE REPORT | 4CPS-116 |
| DOSE BANDING – OPTIMISING DOSES IN CETUXIMAB OR BEVACIZUMAB REGIMENS | 4CPS-117 |
| EXPERIENCE OF DUAL TARGETING USE OF NEOADJUVANT HER2-POSITIVE BREAST CANCER | 4CPS-118 |
| EXPERIENCE OF NAB-PACLITAXEL AND GEMCITABINE USE IN METASTATIC PANCREATIC CANCER | 4CPS-119 |
| ERLOTINIB IN NON-SMALL-CELL LUNG CANCER WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS | 4CPS-120 |
| COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPY OF ANTINEUTROPHIL CYTOPLASM ANTIBODY-ASSOCIATED VASCULITIDES | 4CPS-121 |
| EFFICACY AND SAFETY OF COBIMETINIB USED IN MONOTHERAPY FOR ERDHEIM-CHESTER DISEASE | 4CPS-122 | |
| EFFICACY AND SAFETY OF COBIMETINIB USED IN MONOTHERAPY FOR ERDHEIM-CHESTER DISEASE | 4CPS-123 |
| SAFETY AND EFFECTIVENESS OF TRASTUZUMAB EMTANSIN IN LOCALLY ADVANCED OR METASTATIC HER2 POSITIVE BREAST CANCER | 4CPS-124 |
| TOLERANCE TO CHEMORADIOTHERAPY TREATMENT: COMPARING CAPECITABINE WITH 5-FLUOROURACIL IN NEOADJUVANT THERAPY FOR STAGE II-III RECTAL CANCER | 4CPS-125 |
| EFFECTIVENESS AND SAFETY OF NAB-PACLITAXEL IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN A REAL-WORLD SETTING | 4CPS-126 |
| DEVELOPMENT OF A STRATIFICATION MODEL FOR AMBULATORY ONCOLOGY PHARMACY PATIENTS | 4CPS-127 |
| ADEQUACY OF NIVOLUMAB AND PEMBROLIZUMAB IN NON-SMALL-CELL LUNG CANCER | 4CPS-128 |
| CHEMOTHERAPY NEAR THE END OF LIFE IN ONCO-HAEMATOLOGICAL ADULT PATIENTS | 4CPS-129 |
| PALBOCICLIB COMBINED WITH HORMONAL THERAPY FOR METASTATIC BREAST CANCER TREATMENT | 4CPS-130 |
| RUXOLITINIB AS SALVAGE THERAPY IN PAEDIATRIAC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE | 4CPS-131 |
| INTERACTIONS BETWEEN ALTERNATIVE THERAPIES AND PRODUCTS IN CLINICAL TRIAL IN ONCO-HAEMATOLOGY | 4CPS-132 |
| DARATUMUMAB (DARZALEX) FOR THE TREATMENT OF MULTIPLE MYELOMA IN A THIRD-LEVEL HOSPITAL: VARIABILITY OF USE AND EFFECTIVENESS | 4CPS-133 |
| HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH DISEASE-MODIFYING THERAPIES | 4CPS-134 |
| TERIFLUNOMIDE AND DIMETHYLFUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | 4CPS-135 |
| ANALYSIS OF THE USE OF OMALIZUMAB IN ORAL TOLERANCE INDUCTION FOR HIGH-RISK FOOD ALLERGIES IN CHILDREN | 4CPS-136 |
| NATALIZUMAB: A REVIEW OF ITS USE IN THE MANAGEMENT OF MULTIPLE SCLEROSIS, EXPERIENCE IN A UNIVERSITY HOSPITAL | 4CPS-137 |
| BIOSIMILARS’ UTILISATION UNDER HOSPITAL PHARMACY MANAGEMENT POLICY | 4CPS-138 |
| THE PIRAMID STUDY: PATIENTS TREATED BY MYELOMA ORAL MEDICATION HAVE A BAD COMPLIANCE | 4CPS-139 |
| HOW PHARMACISTS CAN IMPROVE PATIENTS’ CARE MANAGEMENT IN SUBCUTANEOUS ANTIPSORIATIC BIOLOGIC THERAPY | 4CPS-140 |
| ECONOMIC IMPACT OVER THE PAST 4 YEARS ASSOCIATED WITH BIOLOGICAL THERAPY OPTIMISATION IN RHEUMATIC DISEASES PATIENTS | 4CPS-141 |
| ADJUVANT CHEMOTHERAPY AND RELAPSE-ASSOCIATED PROGNOSTIC FACTORS IN OPERABLE BREAST CANCER | 4CPS-142 |
| EVALUATION OF KNOWLEDGE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY THE REFERENCE PRODUCT CONCERNING BIOSIMILARS: ROLE OF CLINICAL PHARMACISTS | 4CPS-143 |
| ESTABLISHMENT OF A PHARMACEUTICAL STANDARDISED INTERVIEW CONCERNING BIOSIMILARS OF INFLIXIMAB IN THE DAYCARE CLINIC OF A GASTROENTEROLOGY DEPARTMENT FOR PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE | 4CPS-144 |
| PHARMACOGENETICS AS A TOOL IN DOSE ADJUSTMENT OF IMMUNOSUPPRESSIVE DRUGS: A CASE REPORT | 4CPS-145 |
| SUBLINGUAL AND ENTERIC TACROLIMUS WHOLE BLOOD LEVELS IN AN INTENSIVE CARE UNIT | 4CPS-146 | |
| CLINICAL EXPERIENCE OF OPTIMISING CO-ADMINISTRATION THERAPY OF LOW-DOSE ALLOPURINOL WITH LOW-DOSE THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS ATTENDING A VIRTUAL PHARMACIST CLINIC | 4CPS-147 |
| ANALYSIS OF INTRA-PATIENT VARIABILITY OF PLASMATIC LEVELS OF TACROLIMUS IN EARLY MAINTENANCE OF RENAL POST-TRANSPLANT | 4CPS-148 |
| EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN THE DIFFERENT PERIODS OF THE KIDNEY POST-TRANSPLANT | 4CPS-149 |
| EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN DIFFERENT PERIODS AFTER LIVER TRANSPLANT | 4CPS-150 |
| INFLUENCE OF THE ROUTE AND PHARMACEUTICAL PREPARATION IN INTRA-PATIENT VARIABILITY OF TACROLIMUS SERUM LEVELS IN THE LIVER TRANSPLANT PATIENT | 4CPS-151 |
| CHEMOTHERAPY PHARMACEUTICAL CONSULTATION: PHARMACEUTICAL INTERVENTIONS AFTER 18 MONTHS OF IMPLEMENTATION | 4CPS-152 | |
| COMPARATIVE ANALYSIS BETWEEN ORIGINATOR AND BIOSIMILAR INFLIXIMAB ACCORDING TO TROUGH LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE | 4CPS-153 |
| ABSTRACT WITHDRAWN | 4CPS-154 | |
| A NEW MULTIDISCIPLINARY MODEL WITH THE CLINICAL PHARMACIST FOR MEDICATION RECONCILIATION IN THE PATIENT WITH ADVANCED RENAL DISEASE | 4CPS-155 |
| SAFETY PROFILE OF APREMILAST IN PSORIASIS AND PSORIATIC ARTHRITIS | 4CPS-156 |
| TUMOUR NECROSIS FACTOR INHIBITORS: UTILITY OF PHARMACOKINETICS MONITORING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT | 4CPS-157 |
| CLINICAL BENEFIT OF INFLIXIMAB MONITORING IN INFLAMMATORY BOWEL DISEASE | 4CPS-158 |
| PERIOPERATIVE MANAGEMENT OF ANTIRHEUMATIC MEDICATION IN REAL PRACTICE: IS MISMANAGEMENT RELATED TO POST-SURGICAL COMPLICATIONS? | 4CPS-159 |
| EFFICACY AND SAFETY OF ANAKINRA AND CANAKINUMAB FOR THE TREATMENT OF IL-36R ANTAGONIST DEFICIENCY | 4CPS-160 |
| SCOPING REVIEW ON THE USE OF CANAKINUMAB AND ANAKINRA IN INTERLEUKIN-1 ANTAGONIST RECEPTOR DEFICIENCY | 4CPS-161 |
| MEDICATION COUNSELLING BY CLINICAL PHARMACISTS IN NEWLY GRAFTED RENAL TRANSPLANT RECIPIENTS | 4CPS-162 |
| BONE METASTASIS TREATMENT IN PROSTATE CANCER: EFFICACY AND SAFETY | 4CPS-163 |
| ORAL KETAMINE IN UNMANAGEABLE CHRONIC PAIN: A CASE REPORT | 4CPS-164 |
| LIDOCAINE 5% PLASTER: IS IT WORTH THE PAIN? | 4CPS-165 | |
| IS THERE STILL A PLACE FOR CHLORAL HYDRATE SYRUP IN HOSPITAL? | 4CPS-166 |
| STUDY OF THE USE OF TAPENTADOL | 4CPS-167 |
| POSTOPERATIVE PAIN MANAGEMENT AND PAIN REFERRED BY ADULT PATIENTS 24 HOURS AFTER SURGERY AND ONE MONTH AFTER DISCHARGE | 4CPS-168 |
| COMPARATIVE ANALYSIS OF EFFECTIVENESS BETWEEN A PATIENT-CONTROLLED ANALGESIA MORPHINE DEVICE AND A SUBLINGUAL SUFENTANIL TABLET SYSTEM | 4CPS-169 |
| ESTIMATING THE ECONOMIC IMPACT OF PHARMACIST-LED PRESCRIPTION ORDER VALIDATION OF OPIOID PRESCRIPTIONS IN A TERTIARY UNIVERSITY HOSPITAL | 4CPS-170 |
| THE CHOICE OF ANTIEPILEPTIC DRUG TREATMENT AFTER STATUS EPILEPTICUS | 4CPS-171 | |
| IMPACT OF MEDICATION RECONCILIATION IN PATIENTS ON ADMISSION TO AN EXPERT CENTRE FOR PARKINSON’S DISEASE | 4CPS-172 |
| 8 YEARS’ EVOLUTION OF ANTIPSYCHOTICS PRESCRIPTIONS IN A MENTAL HEALTH PUBLIC INSTITUTION | 4CPS-173 |
| A NEW BREATH FOR CLOZAPINE … | 4CPS-174 |
| OPTIMISATION OF ANTIPSYCHOTIC TREATMENT IN A PATIENT UNDERGOING DIALYSIS: A CASE REPORT | 4CPS-175 |
| A SYSTEMATIC REVIEW OF META-ANALYSES OF THE EFFICACY OF ORAL ANTIPSYCHOTIC LURASIDONE FOR THE TREATMENT OF ADULT PATIENTS WITH SCHIZOPHRENIAA SYSTEMATIC REVIEW OF META-ANALYSES OF THE EFFICACY OF ORAL ANTIPSYCHOTIC LURASIDONE FOR THE TREATMENT OF ADULT PA | 4CPS-176 |
| DEALING WITH IATROGENIC CARDIAC ARREST IN PSYCHIATRY, DO NOT OVERLOOK MONITORING! | 4CPS-177 |
| ABSTRACT WITHDRAWN | 4CPS-178 | |
| USE OF SPECIFIC DRUGS FOR DEMENTIA IN PEOPLE AT THE END OF LIFE IN NURSING HOMES | 4CPS-179 |
| THE PRACTICE OF USING DEXMEDETOMIDINE IN A PAEDIATRIC INTENSIVE CARE UNIT: RETROSPECTIVE CHART REVIEW | 4CPS-180 |
| EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN CHRONIC IDIOPATHIC URTICARIA | 4CPS-181 |
| EXPERIENCE WITH OMALIZUMAB IN THE TREATMENT OF UNCONTROLLED PERSISTENT ASTHMA | 4CPS-182 |
| COLLABORATION WITH THE OPHTHALMOLOGY SERVICE IN A PUBLIC RESIDENTIAL CARE HOME | 4CPS-183 |
| OFF-LABEL USES OF BEVACIZUMAB IN OPHTHALMOLOGY IN A MOROCCAN UNIVERSITY HOSPITAL | 4CPS-184 |
| THE EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY IN THE MANAGEMENT OF GAUCHER DISEASE | 4CPS-185 | |
| THERAPEUTIC DRUG MONITORING OF TYROSINE KINASE INHIBITORS: KEY TO PERSONALISED MEDICINE IN ONCOLOGY | 4CPS-186 |
| EVALUATION OF EXIT PRESCRIPTIONS USING COMPUTERISED PROVIDER ORDER-ENTRY SYSTEM FOR OUTPATIENTS | 4CPS-187 |
| GALENIC PREPARATIONS AND RARE DISEASES: GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY: EXPERIENCE IN A LOCAL HOSPITAL | 4CPS-188 |
| ADEQUACY OF THE PRESCRIPTION OF PARENTERAL NUTRITION IN NEONATOLOGY | 4CPS-189 |
| RITUXIMAB USE IN CHILDREN, A SINGLE HOSPITAL EXPERIENCE | 4CPS-190 |
| EFFECTIVENESS AND SAFETY OF RADIUM-223 CHLORIDE IN BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | 4CPS-191 |
| IDENTIFYING MEDICATION HISTORY ERRORS AT HOSPITAL ADMISSION USING THE LUND INTEGRATED MEDICINES MANAGEMENT MODEL | 4CPS-192 |
| A THEORETICALLY BASED CROSS-SECTIONAL SURVEY ON THE BEHAVIOURS AND EXPERIENCES OF CLINICAL PHARMACISTS CARING FOR CHRONIC KIDNEY DISEASE PATIENTS | 4CPS-193 |
| CLINICAL IMPACT OF GENOMIC BIOMARKERS PREDICTORS OF RESPONSE AND THE THERAPEUTIC STRATEGY IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL | 4CPS-194 |
| PHARMACIST INTERVENTIONS: THE SUCCESS OF AN ANTIMICROBIAL STEWARDSHIP TEAM | 4CPS-195 |
| ABSTRACT WITHDRAWN | 4CPS-196 | |
| DETERMINING THE NECESSARY COMPONENTS OF A PHARMACEUTICAL CARE COMPLEXITY SCREENING TOOL: AN e-DELPHI STUDY | 4CPS-197 |
| CLINICAL EXPERIENCE WITH DALBAVANCIN IN A TERTIARY HOSPITAL | 4CPS-198 |
| ASSESSMENT OF MEDICATION RECONCILIATION IN CHRONIC COMPLEX PATIENTS | 4CPS-199 | |
| USE OF PROHEMOSTATIC DRUGS IN MASSIVE HAEMORRHAGE EPISODES | 4CPS-200 |
| ACCULTURATION OF PRESCRIBERS TO RECOMMENDATIONS ON THE MANAGEMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS TWO YEARS’ AFTER AN ANTIMICROBIAL STEWARDSHIP PROGRAMME IN A UNIVERSITY HOSPITAL | 4CPS-201 |
| ANTICHOLINERGICAL RISK IN CHRONIC COMPLEX PATIENTS | 4CPS-202 |
| PHARMACOECONOMIC ANALYSIS OF THE MANAGEMENT OF GAUCHER DISEASE IN A PAEDIATRICS HOSPITAL | 4CPS-203 | |
| MEDICATION RECONCILIATION AND PHARMACOTHERAPEUTIC REVIEW IN AN ORTHOGERIATRIC UNIT OF A CENTRAL HOSPITAL | 4CPS-204 |
| ENOXAPARIN DOSE ADJUSTMENT IN THE ELDERLY – THE INTERVENTION OF THE CLINICAL PHARMACIST | 4CPS-205 |
| IMPACT OF PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION | 4CPS-206 |
| SCREENING FOR PAINFUL DIABETIC NEUROPATHY | 4CPS-207 |
| CHOOSING THE RIGHT WOUND DRESSING FOR THE RIGHT PRESSURE ULCER: THE DEVELOPMENT OF A COLOUR-BASED CHART HELPING HEALTHCARE PROVIDERS | 4CPS-208 |
| OUTCOMES RESEARCH ON NEW TYROSINE KINASE INHIBITORS FOR NON-SMALL CELL LUNG CANCER | 4CPS-209 |
| PATIENTS IN CLINICAL TRIALS AND THEIR TREATMENT: DID THE PRESCRIPTION SUPPORT A FIRST-LINE INFORMATION TOOL? | 4CPS-210 |
| IMPACT OF THE ELECTRONIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT | 4CPS-211 |
| PRESCRIPTION AND ADMINISTRATION OF ORAL MEDICATION THROUGH THE JEJUNOSTOMY AND THE NASOGASTRIC TUBE IN AN INTENSIVE CARE UNIT: IMPACT OF GOOD PRACTICES GUIDELINES ON CLINICAL PRACTICE | 4CPS-212 |
| ABSTRACT WITHDRAWN | 4CPS-213 | |
| ASSESSMENT OF THE MEDICATION ERROR RATE PRE-PRESCRIPTION DURING THE MEDICATION RECONCILIATION PROCESS | 4CPS-214 |
| ACCESS TO ‘FONDO AIFA 5%’ AS AN INSTRUMENT SUPPORTING THE SUSTAINABILITY IN A SHARED CLINICAL MANAGEMENT OF RARE AND DIFFICULT-TO-TREAT DISEASES | 4CPS-215 |
| PRESCRIPTION OF FALL-RISK-INCREASING DRUGS IN PATIENTS SUFFERING A FALL WITH MAJOR LESIONS DURING ADMISSION AT AN INTERMEDIATE CARE CENTRE | 4CPS-216 |
| ASSESSING MEDICATION ADHERENCE AND CONDITION-RELATED KNOWLEDGE OF HEART FAILURE PATIENTS | 4CPS-217 |
| ASSESSMENT OF CLINICAL PHARMACIST INTERVENTIONS IN AN INTENSIVE CARE UNIT | 4CPS-218 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN AN EMERGENCY DEPARTMENT | 4CPS-219 |
| THERAPEUTIC DRUG MONITORING: ARE WE GETTING IT RIGHT AND OPTIMISING THERAPY? | 4CPS-220 |
| IMPACT OF HOSPITAL-CITY COMMUNICATION BASED ON THE MULTIPROFESSIONAL AND COLLABORATIVE DEVELOPMENT OF THE DISCHARGE LETTER ON THE CONTINUITY OF PATIENTS’ MEDICATION MANAGEMENT-CITY STUDY | 4CPS-221 |
| IMPACT OF THE ESTABLISHMENT OF THE ASSISTED ELECTRONIC PRESCRIPTION ON THE IMPROVEMENT OF THE UNIT-DOSE DRUG DISPENSATION SYSTEM | 4CPS-222 |
| ANTICOAGULANT THERAPY IN CHRONIC COMPLEX PATIENTS WITH ATRIAL FIBRILLATION | 4CPS-223 |
| EVALUATION OF SYSTEMIC ANTIBIOTICS AND ANTIFUNGAL USE IN AN INTENSIVE PAEDIATRIC CARE UNIT : A FIVE-YEARS STUDY IN A FRENCH UNIVERSITY HOSPITAL | 4CPS-224 |
| THE ROLE OF CLINICAL PHARMACISTS MONITORING REGARDING THE EFFECTIVENESS AND TOLERANCE OF EXPENSIVE DRUGS PRESCRIBED OFF-LABEL | 4CPS-225 |
| ADHERENCE TO TREATMENT IN OLDER ADULTS ADMITTED TO AN ACUTE GERIATRIC UNIT AND ASSOCIATED FACTORS | 4CPS-226 |
| EVALUATION OF ADHERENCE TO INHALED MEDICATIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 4CPS-227 |
| AN EVALUATION OF A PHARMACIST-MANAGED PAEDIATRIC TOXICOLOGY CONSULTATION SERVICE | 4CPS-228 | |
| CLINICAL MANAGEMENT OF MALIGNANT MESOTHELIOMA IN AN ASBESTOS-ENDEMIC AREA | 4CPS-229 |
| ABSTRACT WITHDRAWN | 4CPS-230 | |
| ABSTRACT WITHDRAWN | 4CPS-231 | |
| REORGANISATION IN HOSPITAL OUTPATIENT DRUG DELIVERY: ANY PROGRESS? | 4CPS-232 |
| ANALYSIS OF DRUG PRESCRIPTIONS OF INCOMPATIBLE DRUGS THROUGH DRUG UTILISATION REVIEW | 4CPS-233 |
| PHARMACIST INTERVENTIONS IN NEONATAL INTENSIVE CARE UNIT AND ASSOCIATED COST AVOIDANCE AND COST SAVINGS | 4CPS-234 |
| PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS AS AN EARLY-ONSET ADVERSE EFFECT IN ADULT PATIENTS | 4CPS-235 |
| THE IMPACT OF A WARD-BASED PHARMACY TECHNICIAN SERVICE | 4CPS-236 | |
| STUDY OF PATIENT SATISFACTION WITH PHARMACEUTICAL INTERVIEW IN AN OUTPATIENT ONCOLOGY MEDICAL UNIT | 4CPS-237 |
| MEDICATION AND CONFUSION IN ACUTE HOSPITAL OLDER PATIENTS | 4CPS-238 | |
| A COMPARISON OF CLINICAL PHARMACY ACTIVITY BETWEEN TWO METHODS OF CLINICAL PHARMACY SERVICE DELIVERY IN AN ACUTE PSYCHIATRIC HOSPITAL | 4CPS-239 |
| A QUALITATIVE STUDY ON HOW CLINICAL PHARMACISTS PREFORM MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT | 4CPS-240 |
| DDI-PREDICTOR: A NOVEL CLINICAL PHARMACY DECISION-MAKING TOOL FOR DOSE ADAPTATION? | 4CPS-241 |
| REGULATORY VALIDATION OF PRESCRIPTIONS AT A TEACHING HOSPITAL | 4CPS-242 |
| EFFECTIVENESS AND USE OF OFF-LABEL TREATMENTS IN A GENERAL HOSPITAL | 4CPS-243 |
| TIME TO PERFORM MEDICATION RECONCILIATION AT ADMISSION IN A NEUROLOGY UNIT: COMPARISON BETWEEN PROACTIVE AND RETROACTIVE PROCESSES | 4CPS-244 |
| EVALUATION OF THE DEGREE OF ADHERENCE TO THE INTRAVENOUS TREATMENT OF AMBULATORY PATIENTS | 4CPS-245 |
| PALATABILITY ASSESSMENT OF ORAL MEDICATION | 4CPS-246 |
| LOCAL ASSESSMENT OF THE IMPACT OF PHARMACIST-LED MEDICATION RECONCILIATION ON HOSPITALISED ELDERLY PATIENTS | 4CPS-247 |
| ANTIMICROBIAL POINT PREVALENCE SURVEY | 4CPS-248 |
| IMPLEMENTATION OF AN INTEGRATED SOFTWARE FOR CLINICAL TRIALS MANAGEMENT AND AUTOMATED PREPARATION OF INVESTIGATIONAL DRUGS IN A HOSPITAL PHARMACY | 4CPS-249 |
| INFLUENCE OF TIME AND STORAGE CONDITIONS IN THE STABILITY OF NEONATAL TOTAL PARENTERAL NUTRITION ADMIXTURES | 4CPS-250 |
| IMPACT OF A MULTIDISCIPLINARY TEAM IN REDUCING POLYPHARMACY AND TREATMENT COMPLEXITY IN HOME CARE PATIENTS | 4CPS-251 |
| ABSTRACT WITHDRAWN | 4CPS-252 | |
| COMMUNITY PHARMACY-BASED eGFR SCREENING FOR EARLY DETECTION OF CHRONIC KIDNEY DISEASE IN HIGH-RISK PATIENTS | 4CPS-253 |
| BIOSIMILAR RITUXIMAB – A YEAR BEYOND | 4CPS-254 |
| THE EFFECT OF AN ENHANCING MEDICATION ADHERENCE PROGRAMME FOR A TYPE 2 DIABETES MELLITUS NETWORK | 4CPS-255 |
| LINEZOLID USAGE AND COST ANALYSISAFTER A HOSPITAL TRANSFER | 4CPS-256 |
| DETERMINING FACTORS AFFECTING PATIENTS’ CLARITY ON DISPENSED MEDICATION INSTRUCTIONS: A CASE STUDY AT COPPERBELT UNIVERSITY HEALTH FACILITY IN KITWE, ZAMBIA | 4CPS-257 | |
| IMPACT OF A TEAM OF CLINICAL PHARMACISTS IN A PAEDIATRIC SURGERY UNIT: RESULTS AFTER 6 MONTHS | 4CPS-258 |
| EVALUATION OF PATIENTS’, DOCTORS’ AND COMMUNITY PHARMACISTS’ SATISFACTION CONCERNING PHARMACEUTICAL CONSULTATIONS FOR PATIENTS RECEIVING ORAL ANTI-CANCER DRUGS | 4CPS-259 |
| PRE-ANAESTHESIA BEST POSSIBLE MEDICATION HISTORY FOR ORTHOPAEDIC SURGERY-PROGRAMMED PATIENTS | 4CPS-260 |
| ANALYSIS OF THE METHODOLOGY TO COMMUNICATE POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN INPATIENTS TO AN INTERNAL MEDICINE SERVICE OF A THIRD-LEVEL HOSPITAL | 4CPS-261 |
| PLACE OF CLINICAL PHARMACIST IN THE MANAGEMENT OF PATIENTS UNDERGOING BARIATRIC SURGERY | 4CPS-262 |
| ANALYSIS OF CLINICAL PHARMACIST INTERVENTIONS CARRIED OUT IN AN INTENSIVE CARE UNIT | 4CPS-263 |
| ANALYSIS OF THE DISCREPANCIES FOUND IN THE RECONCILIATION OF CONCOMITANT MEDICATION IN A COHORT OF ELDERLY PATIENTS INFECTED WITH HIV | 4CPS-264 |
| EFFECT OF DEDICATED PHARMACIST INTERVENTION IN NEUROCRITICAL CARE UNIT: BEFORE AND AFTER PARTICIPATING IN MULTIDISCIPLINARY ROUNDS | 4CPS-265 |
| Clone of ANALYSIS OF AN EPIDEMIOLOGICAL MODEL FOR THE TREATMENT OF HEPATITIS C VIRUS IN CO-INFECTED HIV/HCV DRUG ADDICTIONS VIA PARENTERAL | 4CPS-266 |
| ANALYSIS OF AN EPIDEMIOLOGICAL MODEL FOR THE TREATMENT OF HEPATITIS C VIRUS IN CO-INFECTED HIV/HCV DRUG ADDICTIONS VIA PARENTERAL | 4CPS-266 | |
| LACK OF HEPATITIS C VIRUS UPTAKE IN HIV/HCV CO-INFECTED PATIENTS | 4CPS-267 |
| EVALUATION OF THE SATISFACTION OF THE IMPLEMENTATION OF A PHARMACEUTICAL LETTER OF HOSPITAL DISCHARGE TRANSMITTED TO PATIENTS AND COMMUNITY HEALTH PROFESSIONALS | 4CPS-268 |
| ARE PATIENTS AND HEALTHCARE PROFESSIONALS WILLING TO EXCHANGE ON THE PRICE OF TREATMENTS TO CHOOSE A BIOSIMILAR? EXPERIENCE BASED ON THE DELPHI METHOD | 4CPS-269 |
| A SIMULATION PILOT STUDY OF HEALTH OPTIMISATION FOR PATIENTS WITH BIPOLAR DISORDERS: AN EMERGING ROLE FOR CLINICAL PHARMACISTS AS DECISION COACHES | 4CPS-270 |
| DEVELOPMENT OF PHARMACIST MEDICATION REVIEW IN PAEDIATRIC DISCHARGE PROCESS | 4CPS-271 |
| ANALYSIS OF ADVERSE REACTION REPORTS BEFORE AND AFTER THE USE OF EQUIVALENT IMATINIB IN A TERTIARY HOSPITAL | 4CPS-272 |
| PHARMACY INTERVENTION AND DRUG PRESCRIPTION REGULATIONS IN A TERTIARY HOSPITAL | 4CPS-273 |
| ABSTRACT WITHDRAWN | 4CPS-274 | |
| A SYSTEMATIC REVIEW OF PHARMACIST INPUT IN THE SCREENING, MANAGEMENT AND PREVENTION OF METABOLIC SYNDROME | 4CPS-275 |
| ANTIMICROBIAL STEWARDSHIP PROGRAMME IMPLEMENTATION IN THE GULF COOPERATION COUNCIL STATES: A SYSTEMATIC REVIEW | 4CPS-276 |
| ABSTRACT WITHDRAWN | 4CPS-277 | |
| ABSTRACT WITHDRAWN | 4CPS-278 | |
| THE EFFECT OF CONTINUATION OF HOME MEDICATION BY HOSPITALISED PATIENTS ON MEDICATION WASTE AND PATIENT SATISFACTION, A MULTICENTRE, QUASI-EXPERIMENTAL STUDY WITH A PRE-POST DESIGN | 4CPS-279 |
| DOES PLATELET-RICH PLASMA COMPOSITION MATTER IN HIP OSTEOARTHRITIS? | 4CPS-280 |
| A COMPARATIVE STUDY OF THE SATISFACTION OF CLIENTS WITH THE SERVICES OF AN OUTPATIENT PHARMACY IN A TERTIARY HOSPITAL | 4CPS-281 |
| ABSTRACT WITHDRAWN | 4CPS-282 | |
| ABSTRACT WITHDRAWN | 4CPS-283 | |
| BINARY LOGISTIC REGRESSION ANALYSIS TO EVALUATE THE INFLUENCE OF DIFFERENT BASAL FACTORS ON THE EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR | 4CPS-284 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EFFICACY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID | 5PSQ-001 |
| IATROGENIC HYPOGLYCAEMIA: FREQUENCY AND IMPACT ON QUALITY OF LIFE AMONG TYPE 2 DIABETES MELLITUS PATIENTS | 5PSQ-002 |
| A QUALITATIVE ANALYSIS OF BARRIERS TO MEDICATION ADHERENCE IN UNCONTROLLED DIABETES – FOCUS ON INSULIN AND SUGGESTIONS FOR PRACTICE IMPROVEMENTS | 5PSQ-003 |
| OBSERVATIONAL STUDY OF THE EVOLUTION OF BLOOD GLUCOSE LEVELS AFTER THE CHANGE TO INSULIN DEGLUDEC | 5PSQ-004 |
| SAFETY AND EFFICACY OF FAST-ACTING INSULIN ADDED TO TOTAL PARENTERAL NUTRITION | 5PSQ-005 |
| USE OF SUBSTITUTE ENZYMATIC TREATMENT AND SUBSTRATE REDUCTION IN GAUCHER DISEASE | 5PSQ-006 |
| SEBELIPASE ALFA AS ENZYME REPLACEMENT THERAPY IN THREE PAEDRIATRIC PATIENTS | 5PSQ-007 |
| CYP2C19 SNP´S INFLUENCE ON CLOPIDOGREL RESPONSE IN PERIPHERAL ARTERY DISEASE PATIENTS | 5PSQ-008 |
| CYP2C19 SNP´S INFLUENCE ON CLOPIDOGREL RESPONSE IN CEREBROVASCULAR DISEASE PATIENTS: FINAL RESULTS | 5PSQ-009 |
| MANIPULATION OF WARFARIN TABLETS IN PAEDIATRIC CARE: DO WE GIVE THE RIGHT DOSE? | 5PSQ-010 |
| VENOUS THROMBOEMBOLIC EVENTS AND TOTAL HIP OR KNEE ARTHROPLASTY: INCIDENCE AND ASSOCIATED FACTORS | 5PSQ-011 |
| IMPACT OF THERAPEUTIC PATIENT EDUCATION IN THE PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER | 5PSQ-012 |
| PRESCRIPTIONS OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS ADMITTED | 5PSQ-013 |
| NOVEL ORAL ANTICOAGULANTS VS VITAMIN K ANTAGONISTS: A COST ANALYSIS | 5PSQ-014 |
| DRUG INTERACTION BETWEEN NOACs AND ITRACONAZOLE: AN ITALIAN DISTRICT ANALYSIS | 5PSQ-015 |
| UNFAVOURABLE OUTCOMES OF BLOOD TRANSFUSIONS IN HOSPITALISED ANAEMIC PATIENTS | 5PSQ-016 |
| IMPLEMENTATION AND MONITORING OF A PROTOCOL FOR THE USE OF INTRAVENOUS IRON | 5PSQ-017 |
| IMPLEMENTATION OF PARENTERAL NUTRITION PRESCRIBING SOFTWARE IN A NEONATAL INTENSIVE CARE UNIT | 5PSQ-018 |
| SWITCHING FROM INDIVIDUALISED NUTRITION TO STANDARDISED OR COMMERCIALISED NUTRITION IN NEWBORNS: ARE THERE ANY POSSIBILITIES? | 5PSQ-019 |
| SAFETY EVALUATION OF INJECTABLE POTASSIUM CHLORIDE PRESCRIPTIONS IN HOSPITAL | 5PSQ-020 |
| PHARMACOGENETIC TESTING FOR PERSONALISATION OF STATIN THERAPY | 5PSQ-021 |
| AN EVALUATION OF THE PHARMACIST INTERVENTION IN INTRAVENOUS MIXTURES’ STABILITY | 5PSQ-022 |
| ADEQUATE DIGOXIN DOSAGE IN PATIENTS WITH DIGITALIS TOXICITY | 5PSQ-023 |
| MEDICATION ERRORS – A CAUSE FOR MAJOR CARDIOVASCULAR EVENTS IN AN EMERGENCY DEPARTMENT | 5PSQ-024 |
| PULMONARY ARTERIAL HYPERTENSION DRUGS: EPIDEMIOLOGICAL ANALYSIS CONCERNING AN ITALIAN DISTRICT | 5PSQ-025 |
| IMPACT OF A SAFETY ALERT WITH VALSARTAN IN A HEALTH MANAGEMENT AREA | 5PSQ-026 |
| EFFECTIVENESS AND SAFETY OF TOLVAPTAN AND UREA FOR THE TREATMENT OF SEVERE SYMPTOMATIC HYPONATRAEMIA: A CASE SERIES | 5PSQ-027 |
| THE GOVERNANCE OF PCSK9-INHIBITORS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA: APPROPRIATENESS ANALYSIS | 5PSQ-028 |
| EFFECTIVENESS AND SAFETY OF EVOLOCUMAB IN REAL CLINICAL PRACTICE | 5PSQ-029 |
| DO WE KNOW WHICH ANTIBIOTICS SHOULD BE AVOIDED IN OUR PATIENTS? ANTIBIOTIC ALLERGY SURVEY AMONG HOSPITALISED PATIENTS | 5PSQ-030 | |
| A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS | 5PSQ-031 |
| ADMINISTRATION PROTOCOL FOR PENICILLIN G IN A PATIENT WITH A SEVERE REACTION TO BETALACTAMS AND ABDOMINAL ACTINOMYCOSIS | 5PSQ-032 | |
| EFFECTIVENESS OF COMPUTERISED DECISION SUPPORT SYSTEM-BASED INTERVENTION IN ANTIMICROBIAL USE: THE HIGEA PROJECT | 5PSQ-033 |
| LINEZOLID AND SEROTONIN SYNDROME | 5PSQ-034 |
| ANALYSIS OF THE MEDICATION TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA TREATED IN THE COMMUNITY AND HAVING RESULTED IN HOSPITALISATION | 5PSQ-035 |
| POLYPHARMACY AND DEPRESCRIBING IN HIV-INFECTED ELDERLY POPULATION | 5PSQ-036 |
| ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS POSTEXPOSURE PROPHYLAXIS IN A THIRD-LEVEL HOSPITAL | 5PSQ-037 |
| SAFETY AND EFFECTIVENESS OF HIV POST-EXPOSURE PROPHYLAXIS | 5PSQ-038 |
| GLECAPREVIR/PIBRENTASVIR ASSOCIATION FOR CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS IN HEALTH | 5PSQ-039 |
| REAL-LIFE DIRECT-ACTING ANTIVIRALS EFFECTIVENESS COMPARATIVE STUDY IN HIV-HEPATITIS C VIRUS COINFECTED PATIENTS | 5PSQ-040 |
| EFFICACY AND SAFETY OF CIDOFOVIR IN THE TREATMENT OF LARYNGEAL PAPILLOMATOSIS: CASE REPORTS | 5PSQ-041 |
| MODIFICATION ON FASTING LIPID AND RENAL PARAMETERS IN PATIENTS SWITCHING FROM TENOFOVIR DISOPROXIL TO TENOFOVIR ALAFENAMIDE | 5PSQ-042 |
| COMORBIDITIES, POLYPHARMACY AND ADHERENCE IN GERIATRIC HIV PATIENTS | 5PSQ-043 |
| ASEPTIC MENINGITIS INDUCED BY INTRAVENOUS IMMUNOGLOBULIN | 5PSQ-044 |
| SAFETY PROFILE OF SUNITINIB IN REAL CLINICAL PRACTICE | 5PSQ-045 |
| EFFICACY AND SAFETY OF PANITUMUMAB IN METASTATIC COLORECTAL CANCER TREATMENT | 5PSQ-046 |
| NIVOLUMAB FLAT DOSE, CLINICAL-ETHICAL AND ECONOMIC IMPLICATIONS | 5PSQ-047 |
| REAL-WORLD SAFETY AND TOLERABILITY OF THE RECENTLY COMMERZIALISED PALBOCICLIB | 5PSQ-048 |
| ATEZOLIZUMAB: EFFICACY AND SAFETY IN ADVANCED NON-SMALL CELL LUNG CANCER | 5PSQ-049 |
| TOXICITY WITH 5-FLUOROURACIL AND IRINOTECAN: INTEREST OF GENOTYPING IN PATIENT CARE | 5PSQ-050 |
| ANALYSIS OF CARDIOVASCULAR EVENTS ASSOCIATED WITH CARFILZOMIB IN PATIENTS WITH MULTIPLE REFRACTORY MYELOMA | 5PSQ-051 | |
| THE ERROR ROOM: A FUN TRAINING TOOL FOR THE PHARMACEUTICAL CHEMOTHERAPY UNIT | 5PSQ-052 |
| ADAPTATION OF PROPHYLAXIS AGAINST VARICELLA-ZOSTER VIRUS IN PATIENTS WITH MULTIPLE MYELOMA | 5PSQ-053 |
| NIVOLUMAB IN LUNG CANCER: FROM WEIGHT-BASED TO FLAT DOSING | 5PSQ-054 |
| DOES PALBOCICLIB MEAN NEUTROPAENIA? | 5PSQ-055 |
| SAFETY BETWEEN THE USE OF COMMERCIAL AND GENERIC IMATINIB: IS THE EXCIPIENT RELEVANT? | 5PSQ-056 |
| OLAPARIB AND NIRAPARIB SAFETY PROFILE IN THE CLINICAL PRACTICE OF A TERTIARY-LEVEL HOSPITAL | 5PSQ-057 |
| MEASURING ADHERENCE TO EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES FOR PATIENTS TREATED WITH TRASTUZUMAB | 5PSQ-058 |
| CYCLIN DEPENDENT KINASES 4/6 INHIBITORS: NEW OPTIONS IN HR+ HER2- BREAST CANCER | 5PSQ-059 |
| IMMUNOTHERAPY AND TOXICITY: EXPERIENCE IN A THIRD-LEVEL HOSPITAL | 5PSQ-060 |
| DETERMINATION OF GENETIC POLYMORPHISMS OF THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN REAL CLINICAL PRACTICE: POSOLOGICAL INDIVIDUALISATION | 5PSQ-061 |
| RALTITREXED AS AN END-OF-LIFE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER | 5PSQ-062 |
| MORE RISK OF NEUTROPAENIA IN OBESE PATIENTS TREATED WITH PACLITAXEL? | 5PSQ-063 |
| INTENSIVE MONITORING OF AFATINIB – CASE REPORT | 5PSQ-064 |
| MANIC SYMPTOMATOLOGY INDUCED BY ALECTINIB: A CASE REPORT | 5PSQ-065 |
| THE OTHER SIDE OF IMMUNOTHERAPY: SAFETY AND TOXICITY MANAGEMENT IN CLINICAL PRACTICE | 5PSQ-066 |
| DETECTION OF ADVERSE NEUROPSYCHIATRIC REACTIONS ASSOCIATED WITH ABIRATERONE AND ENZALUTAMIDE TREATMENTS IN THE HOSPITAL | 5PSQ-067 |
| ADHERENCE TO DISEASE-MODIFYING THERAPIES IN SPANISH PATIENTS WITH MULTIPLE SCLEROSIS | 5PSQ-068 |
| ABSTRACT WITHDRAWN | 5PSQ-069 | |
| INFLUENCE OF PATHOLOGY IN INJECTION PAIN REDUCTION WITH A NEW FORMULATION OF ORIGINAL ADALIMUMAB | 5PSQ-070 |
| EVALUATION OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | 5PSQ-071 |
| ACUTE PROMYELOCYTIC LEUKAEMIA AFTER INFLIXIMAB THERAPY IN A CROHN’S DISEASE PATIENT: A CASE REPORT AND A REVIEW OF THE LITERATURE | 5PSQ-072 |
| MUCORMYCOSIS INDUCED BY INAPPROPIATE USE OF ORAL CORTICOIDS – A CASE REPORT | 5PSQ-073 |
| CANAKINUMAB IN FAMILIAL MEDITERRANEAN FEVER AND SECONDARY AMYLOIDOSIS: A CASE REPORT | 5PSQ-074 |
| INTRODUCTION OF BIOSIMILAR ETANERCEPT: AN ITALIAN DISTRICT ANALYSIS | 5PSQ-075 |
| SWITCHING BIOLOGIC TREATMENTS: EXPERIENCE OF A REGIONAL HOSPITAL | 5PSQ-076 |
| COST-EFFECTIVENESS OF BIOSIMILAR ETANERCEPT IN CLINICAL PRACTICE USE | 5PSQ-077 |
| MORPHINE OVERDOSE FROM ERROR INFUSION RATE WITH INTRAVENOUS PUMP: FEEDBACK EXPERIENCE AND ACTION PLAN | 5PSQ-078 |
| THE USE OF FENTANYL SUBLINGUAL TABLETS IN A HOSPITAL | 5PSQ-079 |
| A STUDY ON RISK FACTORS ELICITING OPIOID ADVERSE REACTIONS IN ELDERLY MALES | 5PSQ-080 |
| Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY: EVALUATION OF EFFECTIVENESS AND SAFETY | 5PSQ-081 |
| ABSTRACT WITHDRAWN | 5PSQ-082 | |
| DEVELOPMENT AND VALIDATION OF QUALITY INDICATORS FOR BENZODIAZEPINE USE IN GENERAL AND MENTAL HEALTH HOSPITALS: SHORTCOMINGS OF AVAILABLE REIMBURSEMENT DATA | 5PSQ-083 |
| RISK OF QT INTERVAL PROLONGATION IN OLDER PATIENTS | 5PSQ-084 |
| METABOLIC DISORDERS IN PATIENTS TREATED WITH SECOND-GENERATION ANTIPSYCHOTICS: AN OPPORTUNITY FOR PHARMACEUTICAL INTERVENTION | 5PSQ-085 |
| PREVALENCE OF ASPIRATION PNEUMONIA FOLLOWING ANTIPSYCHOTICS: A LARGE POPULATION STUDY | 5PSQ-086 |
| INAPPROPIATE USE OF HYDROXYCINE | 5PSQ-087 |
| DEVELOPMENT OF ALZHEIMER’S DISEASE AND EXPOSITION TO BENZODIAZEPINES: A COHORT STUDY IN A HEALTH REGION OF CATALONIA BETWEEN 2002 AND 2015 | 5PSQ-088 |
| PREVALENCE OF PRESCRIPTION OF ANTIPSYCHOTIC POLYPHARMACY IN A PSYCHIATRIC HOSPITAL | 5PSQ-089 |
| ANTICHOLINERGIC DRUGS AND ACETYLCHOLINESTERASE INHIBITORS: A NON-RECOMMENDED COMBINATION | 5PSQ-090 |
| ASTHMA IN THE MOROCCAN POPULATION | 5PSQ-091 |
| PROFILE AND COMPLEXITY LEVEL OF CLINICAL TRIALS IN THE PHARMACY SERVICE | 5PSQ-092 |
| CHARACTERISATION OF PRE-FILLED SYRINGE USE IN AN ACUTE CARE SETTING: COSTS AND ADVANTAGES | 5PSQ-093 |
| USE OF EXCIPIENTS IN ORAL LIQUID COMMERCIAL MEDICINES IN A CHILDREN’S HOSPITAL | 5PSQ-094 |
| ABSTRACT WITHDRAWN | 5PSQ-095 | |
| KEY STAKEHOLDERS, PERSPECTIVES ON MEDICATION SAFETY PRACTICES AND ERROR REPORTING IN QATAR – AN EXPLORATORY SEQUENTIAL MIXED-METHOD STUDY | 5PSQ-096 | |
| TRIPLE WHAMMY INTERACTION: IMPROVING PATIENTS´ SAFETY | 5PSQ-097 |
| USING A CUSTOMISED MEDICATION VERIFICATION TOOL ON ADMISSION TO HOSPITAL IN PSYCHIATRIC PATIENTS TO REDUCE CLINICALLY RELEVANT MEDICATION DISCREPANCIES | 5PSQ-098 |
| IMPACT OF ROBOTICS ON PATIENT SAFETY AND PRODUCTIVITY | 5PSQ-099 |
| PUBLIC PERCEPTIONS AND CONCERNS INCLUDING MEDICATION AWARENESS IN LIFESTYLE HEALTH CAMPAIGNS | 5PSQ-100 | |
| LESS-CHRON FOR DEPRESCRIBING IN NURSING HOME RESIDENTS | 5PSQ-101 |
| ANTIMICROBIAL TREATMENT INADEQUACY IN AN EMERGENCY DEPARTMENT | 5PSQ-102 |
| PHARMACOLOGICAL STUDY OF HIV PATIENTS ENTERED INTO THE HOSPITAL | 5PSQ-103 |
| INVESTIGATING ERROR REPORTING RATES BY ALL PHARMACY STAFF IN THE PHARMACY DEPARTMENT OF A GENERAL HOSPITAL | 5PSQ-104 |
| EFFECTIVENESS AND TOXICITY PROFILE ANALYSIS OF ANTIFIBROTIC AGENTS IN IDIOPATHIC PULMONARY FIBROSIS | 5PSQ-105 |
| FOCUSING AUDITS ON PATIENT SAFETY | 5PSQ-106 |
| ASPIRIN AND NOVEL ORAL ANTICOAGULANTS: REPORTING OF ADVERSE DRUG REACTIONS | 5PSQ-107 |
| PROCEDURE FOR PAEDIATRIC EMERGENCY AND RESULTS OF A SURVEY ON USE | 5PSQ-108 |
| ABSTRACT WITHDRAWN | 5PSQ-109 | |
| COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEMS AND RELATED CLINICAL DECISION SUPPORT TOOLS IN INPATIENT CARE – BARRIERS OF COST-EFFECTIVENESS | 5PSQ-110 |
| EVALUATION OF THE FORM’S QUALITY OF MEDICAL PRESCRIPTIONS FROM PUBLIC HOSPITALS AND PRIVATE CLINICS | 5PSQ-111 |
| RISK ASSESSMENT OF ELEMENTAL IMPURTIES FOR MANUFACTURING THE DRUG SUBSTANCE (ICH Q3D) | 5PSQ-112 |
| HOW TO SECURE MEDICATION SELF-MANAGEMENT IN HOSPITALISED POSTPARTUM WOMEN? | 5PSQ-113 |
| EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED ON MEDICATION ERRORS DETECTED IN THE PRESCRIPTION | 5PSQ-114 |
| “PATIENT EXPERIENCE” FOR IMPROVING PATIENT CLINICAL PATHWAYS IN AN ONCOLOGY DAY HOSPITAL | 5PSQ-115 | |
| ANALYSIS AND EVALUATION OF A RENAL FUNCTION-BASED DOSAGE ADJUSTMENT SYSTEM AT A UNIVERSITY HOSPITAL | 5PSQ-116 |
| PREVENTING MEDICATION ERRORS REGARDING HIGH-ALERT MEDICATION | 5PSQ-117 |
| SURVEILLANCE AND MONITORING OF PATIENT FALLS IN A HOSPITAL SETTING BY THE HOSPITAL PHARMACIST: FOCUS ON PATIENT-RELATED RISK FACTORS AND DRUG THERAPY | 5PSQ-118 |
| A PRELIMINARY SURVEY ON DAILY DRUG INTAKE IN OLDER PATIENTS IN COMPLIANCE WITH EAHP POLICY STATEMENT ON AN AGEING SOCIETY | 5PSQ-119 | |
| APPLICATION OF INTERNATIONAL GERIATRIC CRITERIA ACCORDING TO EAHP POLICY STATEMENT ON AN AGEING SOCIETY | 5PSQ-120 |
| QUALITY ASSESSMENT WITHIN FRENCH FIRE AND RESCUE SERVICES PHARMACIES IN THE NORTH OF FRANCE: DEVELOPMENT AND EVALUATION OF A SELF-ASSESSMENT TOOL | 5PSQ-121 |
| PERIPHERIC INTRAVENOUS PERFUSION IN ANAESTHESIA: SECURING MEDICAL TREATMENT IS ALSO ABOUT THE PROPER USE OF MEDICAL DEVICES | 5PSQ-122 | |
| FAILURE MODES, EFFECTS AND CRITICALITY ANALYSIS: APPLICATION TO A HOSPITAL PHARMACY | 5PSQ-123 | |
| ABSTRACT WITHDRAWN | 5PSQ-124 | |
| QUALITY AND RISK MANAGEMENT IN HOSPITALS : EVALUATION OF IMPLANTABLE MEDICAL DEVICES’ TRACEABILITY PROCESS | 5PSQ-125 | |
| MEDICATIONS AND FALLS IN THE ELDERLY: AN EPIDEMIOLOGICAL STUDY IN A FRENCH HOSPITAL | 5PSQ-126 |
| DISPENSATION OF FINITE MEDICATION AT DISCHARGE IN THE COMPLEX CHRONIC PATIENT | 5PSQ-127 | |
| PHARMACOTHERAPEUTIC PROFILE AND RISK OF DRUG-RELATED PROBLEMS AND DRUG INTERACTIONS IN HIV+ PATIENTS OF A HEALTH AREA | 5PSQ-128 |
| BALANCE AND CLASSIFICATION OF PHARMACEUTICAL INTERVENTIONS IN A GENERAL HOSPITAL OF SPECIALTIES: THE PERSONALISED HOSPITAL PHARMACY | 5PSQ-129 |
| ANALYSIS OF RITUXIMAB OFF-LABEL USE | 5PSQ-130 |
| PHARMACOVIGILANCE 2018: SURVEY ON THE PERCEPTION OF PHARMACOVIGILANCE IN THE HOSPITAL – TOOLS TO ENHANCE ADVERSE DRUG REACTIONS REPORTING | 5PSQ-131 |
| ASSOCIATION BETWEEN ANTICHOLINERGIC BURDEN OF MEDICATIONS AND MORTALITY IN OLDER ADULTS: A SYSTEMATIC REVIEW | 5PSQ-132 | |
| DRUG-RELATED HOSPITAL ADMISSIONS IN AN ACUTE GERIATRIC UNIT AND ASSOCIATED FACTORS | 5PSQ-133 | |
| ANALYSIS OF MEDICATION DISCREPANCIES AS PART OF THE CLINICAL PHARMACY MEDICATION RECONCILIATION PROCESS | 5PSQ-134 |
| SAFETY RELATED TO PSYCHOGERIATRIC PATIENTS. ONE-YEAR PROSPECTIVE STUDY | 5PSQ-135 |
| A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY | 5PSQ-136 | |
| WHEN IS A DRUG INTERACTION NOT A DRUG INTERACTION? COMPARISON OF DRUG-DRUG INTERACTIONS-CHECKING DATABASES BETWEEN THE UK AND USA | 5PSQ-137 |
| REVIEW OF MEDICATION ERRORS IN A PAEDIATRIC HOSPITAL BASED ON AN INSTITUTIONAL REPORTING SYSTEM | 5PSQ-138 |
| ORTHOPAEDIC IMPLANT RESUPPLY CHAIN: BETTER, FASTER, STRONGER! | 5PSQ-139 |
| THE COMMUNICATION PROCESS BETWEEN PHARMACY AND OTHER DEPARTMENTS AND WARDS IN AN ACUTE HOSPITAL | 5PSQ-140 | |
| POLYPHARMACY AND TRANSCATHETER AORTIC VALVE IMPLANTATION | 5PSQ-141 |
| RISK FACTORS FOR HYPONATRAEMIA IN ELDERLY PATIENTS, BEYOND PHARMACOLOGICAL ADVERSE EFFECTS | 5PSQ-142 |
| PREVALENCE OF POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN INSTITUTIONALISED AND NON-INSTITUTIONALISED ELDERLY PATIENTS | 5PSQ-143 |
| MEDICATION RECONCILIATION PROGRAMME PERFORMED IN A GENERAL AND DIGESTIVE SURGERY SERVICE | 5PSQ-144 |
| SEVERITY OF MEDICATION RECONCILIATION ERRORS IN ELDERLY PATIENTS PRODUCED IN THE EMERGENCY DEPARTMENT | 5PSQ-145 |
| DRUGS INTERACTION ANALYSIS OF PRESCRIPTIONS OF A TEACHING HOSPITAL: FREQUENCY AND GRAVITY | 5PSQ-146 |
| THE VALSARTAN SAGA: PHARMACISTS’ COMPETENCE TO RESOLVE THE THERAPEUTIC CHALLENGE | 5PSQ-147 |
| PHARMACOVIGILANCE AND CLINICAL PHARMACY APPLIED TO MEDICAL DEVICES: SHOULD CANCER PATIENTS BE INFORMED ABOUT THEIR MEDICAL DEVICES? | 5PSQ-148 | |
| SELF-MEDICATION IN CANCER PATIENTS: SURVEY CONDUCTED IN THE PHARMACY DEPARTMENT OF A UNIVERSITY HOSPITAL | 5PSQ-149 | |
| TRADITIONAL MISUSE OF CAMPHOR POWDER: CONCERNING TWO CASES OF PAEDIATRIC POISONING | 5PSQ-150 | |
| ARE PROPOFOL EMULSIONS STABLE WHEN INTRAVENOUSLY CO-ADMINISTERED WITH REMIFENTANIL? | 5PSQ-151 | |
| DO WE KNOW THE CONTENT OF HARMFUL EXCIPIENTS IN MEDICINES THAT NEONATES RECEIVE? | 5PSQ-152 |
| DETECTION OF POTENTIALLY INAPPROPRIATE PRESCRIBING IN AN INSTITUTIONALISED POPULATION | 5PSQ-153 |
| INCIDENT REPORTS VERSUS DIRECT OBSERVATION TO IDENTIFY MEDICATION ERRORS AND RISK FACTORS IN HOSPITALISED NEWBORNS | 5PSQ-154 |
| THE EFFECT OF GERIATRIC STEWARDSHIP ON DRUG-RELATED PROBLEMS AFTER DISCHARGE | 5PSQ-155 |
| RISK ASSESSMENT AND MANAGEMENT TO IMPROVE THERMO-SENSITIVE DRUGS SAFETY | 5PSQ-156 |
| IMPACT OF ANTICHOLINERGIC BURDEN, QUANTIFIED BY ANTICHOLINERGIC RISK SCALES, ON COGNITIVE AND FUNCTIONAL STATUS AND FALLS IN PATIENTS WITH MULTIMORBIDITY: A PRELIMINARY STUDY | 5PSQ-157 | |
| INTEREST IN MEDICATION RECONCILIATION AND ESTABLISHMENT OF A PRIORITISATION SCORE IN A VASCULAR SURGERY DEPARTMENT | 5PSQ-158 |
| KEY POINTS IN IMPROVING THE RECONCILIATION PROCESS IN AN EMERGENCY DEPARTMENT | 5PSQ-159 |
| MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT IN ELDERLY PATIENTS | 5PSQ-160 |
| SECURING STORAGE OF HIGH-RISK MEDICINES IN A CARE UNIT: WHERE ARE WE NOW? | 5PSQ-161 |
| ABSTRACT WITHDRAWN | 5PSQ-162 | |
| MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT | 5PSQ-163 |
| DRUG-DRUG INTERACTIONS IN PATIENTS WITH CARDIOVASCULAR DISEASES | 5PSQ-164 |
| QUALITY CONTROL OF INFUSIONS IN PATIENT-SPECIFIC PREPARATIONS FOR ONCOLOGICAL TREATMENT | 5PSQ-165 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HIGH VERSUS LOW DOSE OF URSODEOXYCHOLIC ACID FOR THE MANAGEMENT OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY: A COHORT RETROSPECTIVE STUDY OF MATERNAL AND NEONATAL OUTCOMES | 6ER-001 | |
| EFFICACY OF A FIXED-RATIO COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS | 6ER-002 |
| COST OF VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS WITH LUNG AND PROSTATE CANCE: COSTECAT STUDY | 6ER-003 |
| USE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE | 6ER-005 |
| EFFECTS OF STATINS USE ON CLINICAL OUTCOMES IN PATIENTS ADMITTED WITH COMMUNITY-ACQUIRED PNEUMONIA | 6ER-006 |
| OFF-LABEL USE OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS: EFFECTIVENESS, SAFETY AND COST IN CLINICAL PRACTICE | 6ER-007 |
| PERSISTENCE AND REASONS FOR SWITCHING THE INITIAL ANTIRETROVIRAL TREATMENT IN A COHORT OF NAÏVE HIV-INFECTED PATIENTS | 6ER-008 |
| PATIENT SATISFACTION AND KNOWLEDGE AFTER SWITCHING FROM EVIPLERA TO ODEFSEY | 6ER-009 |
| PUBLIC KNOWLEDGE AND PERCEPTION TOWARDS VACCINES IN ITALY | 6ER-010 |
| MODELLING THE IMPACT OF DISCOUNTS ON THE REAL-LIFE COST-EFFECTIVENESS OF BIOLOGIC THERAPIES IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SPAIN | 6ER-011 |
| EFFICACY AND SAFETY ANALYSIS OF ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS | 6ER-012 |
| A PILOT RANDOMISED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL OF PROPHYLACTIC SILDENAFIL IN PRETERM INFANTS AT RISK OF BRONCHOPULMONARY DYSPLASIA | 6ER-013 |
| PLATELET-RICH PLASMA: WHAT ARE WE REALLY ADMINISTERING TO OUR PATIENTS? | 6ER-014 |
| IMPACT ON PAIN MANAGEMENT AFTER A SINGLE VISCOSUPPLEMENTATION INTRAARTICULAR INJECTION IN PATIENTS WITH HIP OSTEOARTHRITIS WHO FAILED CONVENTIONAL TREATMENT | 6ER-015 |
| CLINICAL TRIALS: THERAPEUTIC OPPORTUNITIES, ECONOMIC IMPACT AND SAVINGS FOR THE NATIONAL HEALTH SYSTEM | 6ER-016 |
| ABSTRACT WITHDRAWN | 6ER-017 | |
| DEVELOPMENT AND PERFORMANCE EVALUATION OF THE MEDICINES OPTIMISATION ASSESSMENT TOO: A PROGNOSTIC MODEL TO TARGET HOSPITAL PHARMACISTS’ INPUT TO PREVENT MEDICATION-RELATED PROBLEMS | 6ER-018 |
| INTRODUCING YOUNG HOSPITAL PHARMACISTS TO SCIENTIFIC RESEARCH: AN EDUCATIONAL PROJECT SUPPORTED BY A NATIONAL SOCIETY FOR CLINICAL PHARMACY | 6ER-019 |
| SOCIAL AUTHORITIES CONCERNING #HOSPITALPHARMACY ON TWITTER | 6ER-020 |
| WHY SUCH A LOW PARTICIPATION OF PHARMACISTS IN THE PATIENT EDUCATION PROGRAMMS IN OUR HOSPITAL? | 6ER-021 |
| WHAT IS PHARMACOVIGILANCE FOR YOU? A SURVEY OF 153 PHARMACISTS | 6ER-022 | |
| ESTABLISHMENT OF GROUP WORK: WHAT IS THE EFFECT ON THE STATE OF KNOWLEDGE AND PERCEPTION OF PHARMACOVIGILANCE AMONG OUR FUTURE MOROCCAN PHARMACISTS? | 6ER-023 | |
| ASPIRIN COMPARED TO ENOXAPARIN OR RIVAROXABAN FOR THE PREVENTION OF VTE FOLLOWING HIP AND KNEE REPLACEMENT – A RETROSPECTIVE COHORT STUDY IN IRELAND | 6ER-024 |
| IMPACT OF THE NEW EUROPEAN REGULATION ON CLINICAL TRIALS IN THE ACTIVITY AND DYNAMICS OF RESEARCH ETHICS COMMITTEES FROM CATALONIA | 6ER-025 |
| PERCEPTION OF A PEER-TO-PEER MENTORING EXPERIENCE WITH EUROPEAN PHARMACY STUDENTS IN A STUDENT-RUN FREE CLINIC | 6ER-026 |
| ABSTRACT WITHDRAWN | 6ER-027 | |
| PERCEPTION OF HOSPITAL PHARMACISTS TOWARDS PHARMACOGENETIC TESTING | 6ER-028 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| STANDARDISATION OF MEDICATION COUNSELLING MATERIAL FOR PAEDIATRIC SOLID ORGAN TRANSPLANT RECIPIENTS AND THEIR FAMILIES | INT-002 |
| PHYSICOCHAEMICAL STABILITY OF CARFILZOMIB (KYPROLIS®) CONTAINING SOLUTIONS AFTER RECONSTITUTION AND READY-TO-ADMINISTER PREPARATIONS | INT-004 |
| MORPHINE HYDROCHLORIDE SOLUTION 0.5 MG/ML: A RECONSTITUTION KIT FOR NEONATAL UNITS | INT-005 |
| MEDICINAL TREATMENT OPTIMISATION OF RESIDENTS OF ESTABLISHMENTS FOR ELDERLY DEPENDENT PERSONS: FIRST RESULTS OF A PROGRAMME IMPLEMENTED IN A GERONTOLOGICAL SECTOR | INT-007 |
| IMPLEMENTATION OF PHARMACEUTICAL CONSULTATION IN PRIMARY HEALTH CARE – PHARMACOTHERAPY FOLLOW-UP OF POLYMEDICATED ELDERLY PATIENTS IN ULSCB HEALTH CENTRE, EPE | INT-008 | |
| DEVELOPMENT AND IMPLEMENTATION OF ‘CHECK OF MEDICATION APPROPRIATENESS’ IN A LARGE TERTIARY CARE CENTRE | INT-009 |
| PREVALENCE AND PHARMACOTHERAPEUTIC COMPLEXITY OF POLYPHARMACY IN HIV+ PATIENTS IN SPAIN: POINT STUDY | INT-011 |
| THE START OF PAEDFORM – A PAN-EUROPEAN PAEDIATRIC FORMULARY | INT-012 |
| DEVELOPING A MANIPULATION GUIDELINE FOR SOLID ORAL DOSAGE FORMS TO EASE SWALLOWING | INT-013 |
| SIDE-EFFECTS AND TREATMENT RESPONSE TO METHOTREXATE ASSOCIATED WITH COMORBIDITY IN EARLY RHEUMATOID ARTHRITIS | INT-015 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKER IN HOSPITALISED PATIENT | 1ISG-002 | |
| COST SAVING IN ANTIRETROVIRAL THERAPY THROUGH BREAKING FIXED-DOSE COMBINATION AND SWITCH TO GENERIC FORMULATIONS | 1ISG-003 |
| A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB VERSUS DOCETAXEL FOR ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER IN SECOND LINE IN A HEALTHCARE SETTING | 1ISG-005 |
| CONTAMINATION OF THE BLISTER PACKS BY POMALIDOMIDE AFTER USE IN CLINICAL SITUATION | 1ISG-006 | |
| BIOSIMILAR OF INFLIXIMAB: DOES THE PENETRATION RATE MEET EXPECTATIONS? APPRAISAL IN A CENTRAL PURCHASING OFFICE | 1ISG-007 |
| ECONOMIC IMPACT OF THE USE OF BIOSIMILAR INFLIXIMAB IN A SECOND-LEVEL HOSPITAL | 1ISG-008 |
| ECONOMIC IMPACT OF AFLIBERCEPT OPTIMISATION FOR THE TREATMENT OF EYE-RELATED CONDITIONS | 1ISG-009 |
| DEVELOPMENT OF A PREDICTIVE MODEL FOR ESTIMATING FUTURE DRUG EXPENSES | 1ISG-011 |
| THE ROLE OF THE PHARMACIST IN CHOOSING THE CENTRAL VENOUS ACCESS DEVICE FOR THE PREVENTION OF COMPLICATIONS: AN EXAMPLE OF BUDGET IMPACT ANALYSIS | 1ISG-012 | |
| ECONOMIC IMPACT OF ORPHAN DRUGS USED IN PAEDIATRIC PATIENTS ATTENDING HOSPITAL OUTPATIENT PHARMACY AND DAY HOSPITAL | 1ISG-013 |
| ISO 9001 CERTIFICATION: CUSTOMER FOCUS | 1ISG-014 |
| MULTIPLE SCLEROSIS COMMITTEE: INCLUDING A PHARMACIST AS PART OF THE MULTIDISCIPLINARY TEAM | 1ISG-015 |
| EVALUATION OF SUBSTITUTION AND SWITCH TO ETANERCEPT BIOSIMILAR AND RELATED COST SAVINGS | 1ISG-016 |
| ANALYSIS OF PRESCRIBING QUALITY INDEX (PQI) IN HOSPITAL CARE AND STRATEGIES FOR IMPROVEMENT | 1ISG-017 |
| EVALUATION OF THE ECONOMIC SUSTAINABILITY OF A ROBOTIC SYSTEM FOR CHEMOTHERAPY COMPOUNDING | 1ISG-018 |
| MARKET ACCESS IN THE EU, DO WE HAVE ENOUGH EVIDENCE? | 1ISG-020 |
| PROCEDURAL KITS WITH MEDICAL DEVICES FOR EYE SURGERY: OPTIMISATION STRATEGY | 1ISG-021 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ECONOMIC ASPECTS OF THE USE OF FLUIDS IN SEPSIS | 2SPD-002 |
| MAGNETIC DOUBLE PIGTAIL STENT: AN ECONOMICALLY INTERESTING INNOVATIVE DEVICE? | 2SPD-003 |
| ANALYSIS OF PIPERACILLIN/TAZOBACTAM USE DURING ITS WORLDWIDE SHORTAGE | 2SPD-004 |
| COMPARATIVE EFFECTIVENESS AND SAFETY OF EVEROLIMUS AND AXITINIB AS SECOND-LINE THERAPY IN METASTATIC RENAL CELL CARCINOMA | 2SPD-007 |
| IMPLEMENTATION OF A SPECIFIC CIRCUIT OF HAZARDOUS DRUGS IN A PHARMACY DEPARTMENT | 2SPD-009 |
| ASSESSMENT OF PERTUZUMAB USE FOR HER2- POSITIVE BREAST CANCER TREATMENT | 2SPD-010 |
| LEAD-TIME FOR DELIVERY OF CHEMOTHERAPIES AT DAY HOSPITAL: DIFFICULTIES OF A CHEMOTHERAPY COMPOUNDING UNIT WITH TWO DAY HOSPITALS ON TWO SITES | 2SPD-011 |
| BUDGETARY IMPACT OF ULTRA-RARE DISEASES IN A THIRD-LEVEL HOSPITAL | 2SPD-012 |
| ANALYSIS OF EXPENDITURE ON ORPHAN DRUGS ACCORDING TO THE DIAGNOSIS | 2SPD-015 |
| IMPLANTABLE MEDICAL DEVICES MANAGEMENT: A CHALLENGE | 2SPD-016 |
| THE REVIEW AND CLASSIFICATION OF THE MOST COMMONLY USED SURGICAL SUTURES | 2SPD-017 |
| DETERMINATION OF TRENDS OF PRESCRIPTION AND USE OF OFF-LABEL DRUGS IN PAEDIATRIC UNITS AT A HIGH COMPLEXITY HOSPITAL | 2SPD-018 |
| EVALUATION OF THE IMPLEMENTATION OF A CENTRALISED FLOOR STOCK: WHAT CONCLUSIONS CAN BE DRAWN? | 2SPD-022 |
| IMPROVEMENTS IN WARD PHARMACY MANAGEMENT BY PHARMACEUTICAL STAFF | 2SPD-023 |
| UNIT DOSE SYSTEM EVALUATION | 2SPD-024 |
| PRACTICAL CLASSIFICATION OF MEDICAL DEVICES BASED ON ANATOMICAL SYSTEMS AND CREATION OF AN ELECTRONIC GUIDE FOR USERS IN A TEACHING HOSPITAL | 2SPD-025 |
| MEDICINES’ SHORTAGE AND HOSPITAL PHARMACISTS’ STRATEGIES | 2SPD-026 |
| CENTRALISED PURCHASING AS A STRATEGIC LINE FOR THE RATIONALISATION OF PHARMACEUTICAL EXPENDITURE IN A REGIONAL HEALTH SERVICE | 2SPD-027 |
| COMPARATIVE STUDY OF TWO METHODS OF UNITDOSE PACKAGING: ETICONFORM® AND EURAF® | 2SPD-028 |
| IMPACT OF THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE ON A HEALTHCARE INSTITUTION | 2SPD-029 |
| DRUG SHORTAGE IMPACT ON PATIENT CARE: AN INCREASING HEALTHCARE PROBLEM | 2SPD-030 |
| ECONOMIC ANALYSIS OF THE PHARMACEUTICAL SUPPLY TO A SOCIO-SANITARY CENTRE FROM THE HOSPITAL PHARMACY SERVICE | 2SPD-031 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| STABILITY OF MIXTURES OF ONDANSETRON AND HALOPERIDOL STORED IN INFUSORS AT DIFFERENT TEMPERATURES | 3PC-002 |
| PAEDIATRIC PARENTERAL NUTRITION ON WEEKENDS: WHO PREPARES? SURVEY OF COUNTRY’S HOSPITALS | 3PC-003 |
| AUTOMATION OF PARENTERAL NUTRITION ELABORATION IN A HOSPITAL PHARMACY SERVICE | 3PC-004 |
| A NEW PACKAGING OF HYPERTONIC SOLUTION TO OVERCOME AN UNAVAILABLE FORMULATION IN FRANCE | 3PC-005 |
| FORMULATION AND STABILITY STUDY OF THE EXTEMPORANEOUS ORAL SOLUTIONS OF CARDIOLOGIC DRUGS FOR PERSONALISED THERAPY OF NEWBORNS | 3PC-008 |
| PHYSICOCHEMICAL STABILITY OF INTRAVENOUS INJECTION OF A GENERIC PRODUCT OF FUROSEMIDE PREPARED IN POLYPROPYLENE SYRINGES | 3PC-009 |
| HPLC METHOD DEVELOPMENT AND VALIDATION TO DETERMINATE RESORCINOL FOR QUALITY CONTROL IN PHARMACEUTICAL FORMULATIONS | 3PC-011 |
| STABILITY OF CEFUROXIME 80 MG/ML SOLUTION IN READY-TO-ADMINISTER POLYPROPYLENE SYRINGES | 3PC-012 |
| STABILITY STUDY OF GENTAMICIN LOCK THERAPY WITH HEPARIN OR CITRATE AS ANTICOAGULANT | 3PC-014 |
| MEDIA-FILL SIMULATION TESTS OF INFUSION BAGS PREPARED IN SERIES BY THE COMPOUNDING ROBOT APOTECACHEMO | 3PC-015 |
| TIME SAVINGS AND IMPROVED QUALITY ASSURANCE OF INTRAVENOUS CYTOSTATICS WITH SEMIAUTOMATED DOSE-BANDING | 3PC-017 |
| THE ADVANTAGE OF AUTOMATION IN THE PREPARATION OF CHEMOTHERAPY DRUGS FOR THE INTERCEPTION OF ERRORS | 3PC-018 |
| APPLICATION OF A MATRIX RISK TO AN APPROPRIATE COMPOUNDING PROCESS OF AFLIBERCEPT AND RANIBIZUMAB INTRAVITREAL INJECTIONS | 3PC-024 |
| PHYSICOCHEMICAL STABILITY OF ROCURONIUM BROMIDE INJECTION SOLUTION 10 MG/ML AS BULK SOLUTION AND IN 10 ML READY-TO-ADMINISTER SYRINGES | 3PC-026 |
| AMIFAMPRIDINE AND PYRIDOSTIGMINE HARD CAPSULES FOR TREATMENT OF CONGENITAL MYASTHENIC SYNDROMES: A CASE REPORT | 3PC-027 |
| CALCULATION OF ANNUAL ECONOMIC IMPACT OF MANUFACTURING AVASTIN® SYRINGES IN THE AGERELATED MACULAR DEGENERATION TREATMENT IN OUR HOSPITAL | 3PC-029 |
| DETERMINATION OF SENSITIVITY THRESHOLD FOR STERILITY ASSAY OF THE BINARY PARENTERAL NUTRITION BAGS BY DIRECT SEEDING | 3PC-032 |
| IN VITRO PHYSICOCHEMICAL INTERACTIONS STUDY BETWEEN IRON AND ANTICANCER DRUGS ADMINISTRATED IN HOSPITAL | 3PC-033 |
| SCREENING FOR PHYSICOCHEMICAL INCOMPATIBILITIES OF CYTOTOXIC DRUGS AFTER RECONSTITUTION: THE CASE OF METHOTREXATE | 3PC-034 |
| SO, HAPPY? AUTOMATED NOMINATIVE DISPENSATION: SATISFACTION SURVEY OF THE NURSING STAFF | 3PC-035 |
| SMALL-SCALE COMPOUNDING USING A POWDER DISPENSING TOOL FOR INDIVIDUALISED SOLID DOSAGE FORM DRUG DELIVERY | 3PC-036 |
| CLEANING VALIDATION OF SOLUTION PRODUCTION IN A HOSPITAL PHARMACY | 3PC-037 |
| IFOSFAMIDE-INDUCED ENCEPHALOPATHY: QUALITY CONTROL OF INTRAVENOUS SOLUTION OF METHYLENE BLUE FORMULATED AND PREPARED IN PHARMACY USING A DISPOSABLE CLOSED SYSTEM TRANSFER DEVICE – A CASE REPORT | 3PC-038 |
| CENTRALISED NON-HAZARDOUS INTRAVENOUS COMPOUNDING: IMPROVEMENT OF CLINICAL PRACTICE | 3PC-039 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| RELEVANCE OF PROTON PUMP INHIBITOR (PPI) TREATMENTS IN 2017 IN TWO GERIATRIC DEPARTMENTS: IMPACT OF A FIRST STUDY IN 2014 ON PRESCRIBING PRACTICES | 4CPS-004 |
| INTERDISCIPLINARY TEAM IN THE FOLLOW-UP OF A PATIENT WITH TEDUGLUTIDA | 4CPS-007 |
| EFFICACY, SAFETY AND ECONOMIC IMPACT OF VEDOLIZUMAB IN ULCERATIVE COLITIS AND CROHN’S DISEASE | 4CPS-009 |
| ANALYSIS OF USE OF PROTON PUMP INHIBITORS IN PATIENTS BEFORE HOSPITAL ADMISSION AND AT HOSPITAL DISCHARGE | 4CPS-010 |
| THE PHARMACIST’S ROLE IN THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | 4CPS-011 |
| PHARMACOTHERAPEUTICAL PROFILE BEFORE AND AFTER LIVER TRANSPLANTATION | 4CPS-012 |
| DISCONTINUATION OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DUE TO RECURRENT GENITOURINARY INFECTIONS | 4CPS-013 |
| FOLLOW-UP TO RECOMMENDATIONS ABOUT RENAL FUNCTION MONITORING IN ELDERLY PATIENTS TREATED WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS | 4CPS-014 |
| PHARMACEUTICAL INTERVENTIONS IN PATIENTS TREATED WITH DIRECT-ACTING ORAL ANTICOAGULANTS ADMITTED IN INTERNAL MEDICINE | 4CPS-015 |
| MISUSE OF NOVEL ORAL ANTICOAGULANTS IN HOSPITAL SETTINGS | 4CPS-017 |
| EVALUATION OF VENOUS THROMBOEMBOLIC EVENT PROPHYLAXIS IN HOSPITALISED CANCER PATIENTS: A SINGLE-CENTRED RETROSPECTIVE STUDY | 4CPS-019 |
| USE AND EFFECTIVENESS OF CARBOXYMALTOSE IRON AND ISOMALTOSIDE IRON | 4CPS-020 |
| TREATMENT OF PREOPERATIVE ANAEMIA WITH FERRIC CARBOXYMALTOSE | 4CPS-021 |
| PREVALENCE OF POTASSIUM, PHOSPHORUS AND CALCIUM IMBALANCE IN VERY-LOW-BIRTHWEIGHTPRETERM INFANTS RECEIVING PARENTERAL NUTRITION FROM THE FIRST DAY OF LIFE | 4CPS-022 |
| IMPACT OF DRUG AND THERAPEUTIC COMMITTEE INTERVENTION ON RATIONALISATION OF ALBUMIN USE IN CANCER PATIENTS ADMITTED TO SURGERY WARDS OF A TERTIARY CARE TEACHING HOSPITAL | 4CPS-023 |
| HUMAN NORMAL IMMUNOGLOBULIN REQUIREMENTS IN PAEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCY, FOCUSING ON THE ADMINISTRATION ROUTE SWITCHING | 4CPS-024 |
| SUITABILITY OF SACUBITRIL VALSARTAN PRESCRIPTIONS IN A HEALTH MANAGEMENT AREA | 4CPS-025 |
| THE SACUBITRIL-VALSARTAN ASSOCIATION: FROM THEORY TO PRACTICE | 4CPS-026 |
| HOSPITAL PHARMACIST INTERVENTIONS IN AN ACCREDITED CARDIOLOGY DEPARTMENT | 4CPS-027 |
| EDUCATING CARDIAC REHABILITATION PATIENTS ON THEIR MEDICINES | 4CPS-028 |
| ADHERENCE TO MEDICATION AND SALT RESTRICTION AND BLOOD PRESSURE CONTROL AMONG HYPERTENSIVE PATIENTS | 4CPS-029 |
| EVALUATION OF PHARMACIST-LED CARDIOVASCULAR SERVICES WITHIN PRIMARY CARE, PROVIDED BY CARDIOVASCULAR PHARMACISTS | 4CPS-030 |
| STUDY OF THE CHARACTERISTICS OF PATIENTS TREATED WITH TOLVAPTAN | 4CPS-032 |
| EFFECTIVENESS OF THERAPEUTIC INTERCHANGE PROGRAMMES FOR ANGIOTENSIN RECEPTOR BLOCKERS IN THE HOSPITAL SETTING | 4CPS-033 |
| EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODIES AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 (PCSK9 INHIBITORS) FOR THE TREATMENT OF HYPERCHOLESTEROLAEMIA | 4CPS-034 |
| EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY PCSK9 INHIBITORS | 4CPS-035 |
| STATINS AND THE ELDERLY: IS THEIR USE APPROPRIATE? | 4CPS-036 |
| ANALYSIS OF USAGE PROFILE, EFFECTIVENESS AND SAFETY OF ALIROCUMAB IN A TERTIARY HOSPITAL | 4CPS-037 |
| INITIAL EXPERIENCE WITH THE USE OF PCSK9- INHIBITORS IN THE REAL-WORLD CLINICAL PRACTICE | 4CPS-038 |
| ALLANTOIN 6% CREAM IN EPIDERMOLYSIS BULLOSA: A CASE REPORT | 4CPS-039 |
| COST-COMPARISON OF SECUKINUMAB AND USTEKINUMAB FOR TREATMENT OF PSORIASIS | 4CPS-040 |
| DRUG SURVIVAL OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PSORIASIS | 4CPS-041 |
| APREMILAST IN PSORIATIC ARTHRITIS AND PSORIASIS: A CASE REPORT | 4CPS-042 |
| EVALUATION OF NON-FORMULARY DRUGS PRESCRIPTION AND ACCEPTANCE OF AN ALTERNATIVE DRUG | 4CPS-043 |
| GROWTH HORMONE THERAPY FOLLOW-UP PROGRAMME IN PAEDIATRIC PATIENTS | 4CPS-044 |
| PREDICTIVE FACTORS OF HYPERGLYCAEMIA IN PATIENTS WITH PARENTERAL NUTRITION | 4CPS-045 |
| GLUCOCORTICOIDS IN CHRONIC INFLAMMATORY DISEASES: ASSESSMENT OF PATIENTS’ ADHERENCE | 4CPS-046 |
| USE OF VANCOMYCIN: CURRENT PRACTICES IN A PAEDIATRIC HOSPITAL | 4CPS-047 |
| COMPARATIVE STUDY BETWEEN THREE SEQUENTIAL SEMESTERS TO EVALUATE THE IMPLEMENTATION OF ANTIBIOTICS’ STEWARDSHIP PROGRAMME IN INTENSIVE CARE UNIT OF A 500-BED GENERAL HOSPITAL | 4CPS-050 |
| MONITORING OF ANTIBIOTICS: DEGREE OF COMPLIANCE OF THE PHARMACOKINETIC SETTINGS | 4CPS-051 |
| IMPROVEMENT OPPORTUNITIES IN THE USE OF ANTIMICROBIALS | 4CPS-053 |
| EARLY LEVELS OF VANCOMYCIN IN INTENSIVE CARE UNIT (ICU) PROTOCOL DEPENDING ON ICU PATIENTS’ CHARACTERISTICS | 4CPS-054 |
| ANTIMICROBIAL STEWARDSHIP PROGRAMME IN PRIMARY HEALTHCARE EMERGENCY DEPARTMENT | 4CPS-055 |
| ANALYSIS OF INHALED COLISTIMETHATE USE IN A THIRD-LEVEL HOSPITAL | 4CPS-056 |
| DALBAVANCINA AND TEDIZOLID: ADEQUATE ALTERNATIVES FOR STRAINS WITH REDUCED SENSITIVITY TO VANCOMYCIN, DAPTOMYCIN OR LINEZOLID? | 4CPS-057 |
| IMPACT OF THE PROGRAMME FOR OPTIMISING THE USE OF ANTIBIOTICS AFTER PIPERACILIN/ TAZOBACTAM’S SHORTAGE | 4CPS-058 |
| LINEZOLID DOSING IN PATIENTS WITH LIVER CIRRHOSIS: STANDARD DOSING RISKS’ TOXICITY | 4CPS-059 |
| PHARMACEUTICAL ROLE IN AN ANTIMICROBIAL STEWARDSHIP PROGRAMME | 4CPS-060 |
| ANTIBIOTIC PROPHYLAXIS FOR PREVENTING SURGICAL WOUND INFECTION AFTER ELECTIVE CAESAREAN SECTION: META-ANALYSIS OF CLINICAL TRIALS | 4CPS-061 |
| PHARMACIST INTERVENTION FOR THE IMPROVEMENT IN THE USE OF ANTIBIOTICS IN SURGERY SERVICE | 4CPS-062 |
| APPROPRIATENESS OF ANTIBIOTIC PRESCRIBING IN URINARY TRACT INFECTIONS IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL | 4CPS-063 |
| APPROPRIATENESS OF ANTIBIOTIC PRESCRIPTIONS IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL | 4CPS-064 |
| ADEQUACY OF VANCOMYCINE DOSAGE IN THE INTENSIVE CARE UNIT OF A UNIVERSITY HOSPITAL | 4CPS-065 |
| PHARMACEUTICAL INTERVENTIONS IN A THIRD-LEVEL HOSPITAL | 4CPS-066 |
| ASSESSMENT OF THE EFFECTIVENESS OF USING VANCOMYCIN IN PATIENTS UNDERGOING HAEMODYALISIS | 4CPS-067 |
| SUB-THERAPEUTIC PLASMA LEVELS OF LINEZOLID IN THE ICU: USUAL OR UNUSUAL IN THIS SETTING? | 4CPS-068 |
| ANTIMICROBIAL STEWARDSHIP TEAM: MANAGEMENT OF PIPERACILIN/TAZOBACTAM SUPPLY SHORTAGE | 4CPS-070 |
| THERAPEUTIC DRUG MONITORING AND SAFETY OF HIGH-DOSE AMIKACIN IN CRITICALLY ILL PATIENTS | 4CPS-071 |
| ARE WE PROPERLY DOSING ANTIBIOTICS IN ENTEROCOCCUS FAECIUM BACTERAEMIA? | 4CPS-072 |
| EVALUATION OF CARBAPENAEMIC TREATMENTS AND ANTIMICROBIAL STEWARDSHIP | 4CPS-073 |
| IMPACT OF ANTIBIOTIC PROPHYLAXIS GUIDELINES IN OBSTETRIC AND GYNAECOLOGY SURGERY: A RETROSPECTIVE MULTI-CENTRE STUDY | 4CPS-074 |
| COMPLIANCE OF A PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS PROTOCOL IN CARDIAC SURGERY | 4CPS-075 |
| EVALUATION OF THE TREATMENT AND MORBIMORTALITY OF INFECTIOUS ENDOCARDITIS BY STAPHYLOCOCCUS AUREUS | 4CPS-076 |
| DO WE NEED TO ADOPT ANTIFUNGAL STEWARDSHIP PROGRAMMES? | 4CPS-077 |
| IDENTIFICATION OF CANDIDATE DUAL/ MONOTHERAPY PATIENTS IN TREATMENT WITH PROTEASE INHIBITORS: ECONOMIC SAVINGS | 4CPS-078 |
| FACTORS IMPLICATED IN LIPID PROFILE CONTROL AMONG HIV-INFECTED PATIENTS IN TREATMENT WITH PROTEASE INHIBITORS | 4CPS-079 |
| HIV POST-EXPOSURE PROPHYLAXIS PROTOCOL | 4CPS-080 |
| COMPARISON OF THE COCKCROFT–GAULT, MDRD AND CKD–EPI EQUATIONS FOR ESTIMATING GANCICLOVIR CLEARANCE | 4CPS-081 |
| EVALUATION OF EFFECTIVENESS OF DARUNAVIR/ COBICISTAT MONOTHERAPY IN HIV PATIENTS | 4CPS-082 |
| EVALUATION OF CARDIOVASCULAR RISK IN PATIENTS ON DARUNAVIR/COBICISTAT MONOTHERAPY TREATMENT | 4CPS-083 |
| IDENTIFICATION OF PATIENT CANDIDATES TO SWITCH FROM TENOFOVIR/EMTRICITABINE TO ABACAVIR/ LAMIVUDINE ANTIRETROVIRAL THERAPY: ECONOMIC SAVING | 4CPS-084 |
| ASSESSMENT OF THE DIRECT-ACTING ANTIVIRALS USED TO TREAT THE HEPATITIS C VIRUS GENOTYPE 4 INFECTION IN A TERTIARY HOSPITAL | 4CPS-085 |
| PROPOSAL TO DARUNAVIR (DRV) THE LEAST TROUGH PLASMA LEVEL (TPL) CUT-OFF TO ESTIMATE PLASMA HIV VIRAL LOAD (HVL) EQUAL OR LESS THAN 20 COPIES/ML | 4CPS-086 |
| ASSESSMENT OF THE DIRECT ACTING ANTIVIRALS USED TO TREAT THE HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN A TERTIARY HOSPITAL | 4CPS-087 |
| DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION: A REAL-WORLD DATA ANALYSIS | 4CPS-088 |
| ALL-ORAL DIRECT-ACTING ANTIVIRAL COMBINATION THERAPY: CHRONIC HEPATITIS C TREATMENT AFTER UNSUCCESSFUL THERAPY WITH DAAs AGENTS | 4CPS-089 |
| EMTRICITABINE/ELVITEGRAVIR/COBICISTAT/TENOFOVIR: EFFECTS ON LIPID METABOLISM AND RENAL FUNCTION | 4CPS-090 |
| VARIATION OF THE HIV-NAÏVE PATIENT PROFILE AND INITIAL ART RECOMMENDED REGIMENS AFTER IMPLEMENTATION OF THE UNIVERSAL TREATMENT RECOMMENDATIONS IN A UNIVERSITY HOSPITAL | 4CPS-091 |
| COLLABORATIVE APPROACH TO IMPROVE ADHERENCE AND RETENTION IN CARE AMONG ILLICIT DRUG USERS WITH HIV/AIDS | 4CPS-092 |
| LONG-TERM EFFICACY OF SECOND-GENERATION DIRECT-ACTING ANTIVIRAL AGENTS (DAAS-2) FOR HCV TREATMENT: A META-ANALYSIS | 4CPS-093 |
| IMPROVING CHRONIC HEPATITIS B VIRUS OUTCOMES USING A WEB AND SMARTPHONE-BASED MEDICATION SELF-MANAGEMENT PLATFORM | 4CPS-094 |
| DRUG-DRUG INTERACTIONS AMONG HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS | 4CPS-095 |
| EFFECTIVENESS, SAFETY AND POTENTIAL INTERACTIONS OF ELBASVIR/GRAZOPREVIR FOR CHRONIC HEPATITIS C INFECTION | 4CPS-096 |
| EXTENDED VERSUS STANDARD CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANTATION | 4CPS-097 |
| USE OF PALIVIZUMAB IN THE IMMUNOPROFILAXIS OF RESPIRATORY SYNCYTIAL VIRUS | 4CPS-098 |
| NIVOLUMAB: CLINICAL EXPERIENCE IN A TERTIARY HOSPITAL | 4CPS-099 |
| CHEMOTHERAPY DOSE ADJUSTMENT IN RELATION TO PATIENTS’ NUTRITIONAL STATUS | 4CPS-101 |
| ANALYSIS OF OFF-LABEL USE IN ONCOHAEMATOLOGY | 4CPS-102 |
| SECOND-GENERATION TYROSIN KINASE INHIBITORS IN FRONT-LINE THERAPY. COMPARING RESPONSES | 4CPS-103 |
| EFFECTIVENESS AND SAFETY OF CABAZITAXEL IN CASTRATION-RESISTANT METASTATIC PROSTATE CANCER | 4CPS-104 |
| BLINATUMOMAB FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN A PAEDIATRIC PATIENT: A CASE REPORT | 4CPS-105 |
| IMPACT OF ONCOLOGICAL CLINICAL TRIALS IN A HOSPITAL PHARMACY | 4CPS-106 |
| AN ESTIMATE OF AVOIDED COSTS FOR DRUGS IN PATIENTS INCLUDED IN NON-SMALL LUNG CANCER CLINICAL TRIALS | 4CPS-107 |
| EXPERIENCE OF REGORAFENIB USE IN METASTATIC COLORECTAL CANCER | 4CPS-109 |
| IMPACT OF PATIENTS’ CONDITIONS ON THE EFFECTIVENESS AND SAFETY OF ERLOTINIB IN PANCREATIC CANCER | 4CPS-110 |
| EFECTIVENESS AND COST OF ABIRATERONE AND ENZALUTAMIDE IN PROSTATE CANCER | 4CPS-111 |
| SYNOPTIC TABLE OF RELEVANT DRUG INTERACTIONS TO BE USED AS CLINICAL DECISION SUPPORT TOOL ON HAEMATO-ONCOLOGY WARDS | 4CPS-112 |
| EXPERIENCE WITH BRAF AND MEK INHIBITORS IN THE TREATMENT OF METASTASIC MELANOMA IN A THIRD-LEVEL UNIVERSITY HOSPITAL | 4CPS-113 |
| ALECTINIB HEPATIC-TOLERANCE IN PATIENTS WITH HEPATOTOXICITY BACKGROUND WITH OTHER ANAPLASTIC LYMPHOMA KINASE (ALK)-INHIBITORS | 4CPS-116 |
| RELATIONSHIP BETWEEN DAILY DOSE FREQUENCY AND ADHERENCE IN CHRONIC MYELOID LEUKAEMIA | 4CPS-117 |
| LONG-TERM SURVIVAL IN ALK POSITIVE LUNG CANCER: A CASE REPORT | 4CPS-118 |
| CASE REPORT: USE OF VISMODEGIB IN A PATIENT WITH GORLIN GOLTZ SYNDROME | 4CPS-120 |
| IMPACT OF PHARMACEUTICAL CONSULTATIONS FOR NEW ORAL ONCOLOGY AGENTS | 4CPS-121 |
| OF ERIBULIN IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER | 4CPS-125 |
| ANALYSIS OF THE EFFECTIVENESS OF PERTUZUMAB AS NEOADYUVANT TREATMENT IN PATIENTS WITH HER2-POSITIVE BREAST CANCER | 4CPS-126 |
| EFFECTIVENESS OF ABIRATERONE ACETATE AND ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | 4CPS-128 |
| EVALUATION OF THE REAL INFUSION TIME OF INTRAVENOUS IMMUNOGLOBULIN AND INFLUENTIAL FACTORS IN ROUTINE CLINICAL PRACTICE ANALYSIS | 4CPS-129 |
| USE OF NON-SPECIFIC IMMUNOGLOBULINS IN BURNED PAEDIATRIC PATIENTS: VALIDATION OF THE PROTOCOL OF A TERTIARY HOSPITAL | 4CPS-130 |
| DIFFERENCES IN UK HEALTHCARE PROFESSIONALS’ KNOWLEDGE, ATTITUDE AND PRACTICE TOWARDS INFLIXIMAB AND INSULIN GLARGINE BIOSIMILARS | 4CPS-131 |
| LEVEL OF EVIDENCE AND DEGREE OF RECOMMENDATION OF INTRAVENOUS IMMUNOGLOBULIN IN AUTO-IMMUNE NEUROLOGICAL DISEASES | 4CPS-132 |
| RESPONSE TO VEMURAFENIB-COBIMETINIB WITH REDUCED DOSES IN A PATIENT WITH METASTASIC MELANOMA: CONCERNING A CASE | 4CPS-133 |
| EVOLUTION AND ANALYSIS OF SPENDING ON BIOLOGICAL MEDICATION IN PSORASIS | 4CPS-134 |
| EFFECTIVENESS AND COST OF ECULIZUMAB ON PATIENTS WITH ATYPICAL (SHUA), URENIC AND HAEMOLITIC SYNDROME, WITH ENLARGEMENT OF THE FREQUENCY OF ADMINISTRATION | 4CPS-135 |
| ARE CARDIOVASCULAR ADVERSE EVENTS WITH IBRUTINIB WELL CONSIDERED? | 4CPS-136 |
| HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS | 4CPS-137 |
| QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS WITH PARENTERAL FIRST-LINE TREATMENT: EXPERIENCE IN A UNIVERSITY HOSPITAL | 4CPS-138 |
| STUDY ASSESSING THE USE OF HIGH-COST OFF-LABEL DRUGS IN THE TREATMENT OF ATOPIC DERMATITIS | 4CPS-139 |
| EFFECTIVENESS OF TOCILIZUMAB IN A TAKAYASU ARTERITIS PAEDIATRIC PATIENT: A CASE REPORT | 4CPS-140 |
| USE OF ADALIMUMAB IN PATIENTS WITH HIDRADENITIS SUPPURATIVA | 4CPS-141 |
| ANALYSIS OF PRESCRIBING AND CLINICAL OUTCOMES OF VEDOLIZUMAB TREATMENT IN A UNIVERSITY CARE HOSPITAL | 4CPS-142 |
| TOPICAL APPLICATION OF RAPAMYCIN 0.4% FOR TREATMENT OF FACIAL ANGIOKERATOMAS IN A PAEDIATRIC PATIENT | 4CPS-143 |
| EFFECTIVENESS AND SAFETY OF INDUCTION THERAPY WITH VEDOLIZUMAB IN PATIENTS WITH INTESTINAL INFLAMMATORY DISEASE | 4CPS-144 |
| TIME OF PERMANENCE IN SECOND OR SUCCESSIVE LINES OF TREATMENT WITH ANTI-TNF DRUGS VS OTHER BIOLOGICAL DRUGS IN PATIENTS WITH INFLAMMATORY ARTHROPATHIES | 4CPS-149 |
| USE OF ADALIMUMAB FOR HIDRADENITIS SUPPURATIVA | 4CPS-150 |
| OPTIMISATION PROGRAMME OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS: RESULTS OF CREATE REGISTRY AFTER 3 YEARS | 4CPS-151 |
| ECULIZUMAB FOR DENSE DEPOSIT DISEASE: INCREASED DOSAGE WITHOUT RESPONSE: A CASE REPORT | 4CPS-152 |
| CASE REPORT: PAEDIATRIC PATIENT WITH RECURRENT APHTHOUS STOMATITIS TREATED WITH THALIDOMIDE | 4CPS-153 |
| FOLLOW-UP IN THE USE OF BIOTHERAPIES IN CROHN’S DISEASE IN A FRENCH UNIVERSITY HOSPITAL | 4CPS-154 |
| COMPARATIVE STUDY FOR EVALUATION OF THE PAIN, EASE OF USE AND PREFERENCE BETWEEN TWO ADALIMUMAB ADMINISTRATION DEVICES: STUDY ADAP2017 | 4CPS-155 |
| A RARE CASE AND AN EFFECTIVE DRUG THERAPY: OFF-LABEL USE OF TACROLIMUS IN A PAEDIATRIC DYSIMMUNE DISEASE | 4CPS-156 |
| VEDOLIZUMAB: EARLY EXPERIENCE AND MEDIUMTERM OUTCOMES IN INFLAMMATORY BOWEL DISEASE | 4CPS-157 |
| OPTIMISATION OF BIOLOGICAL THERAPIES AND ECONOMIC IMPACT ANALYSIS | 4CPS-158 |
| QUALITY OF LIFE ASSESSMENT AND EFFICACY OF SECUKINUMAB IN PLAQUE PSORIASIS DISEASE | 4CPS-159 |
| USE OF APREMILAST IN PLAQUE PSORIASIS AS AN ALTERNATIVE TO BIOLOGIC TREATMENTS | 4CPS-160 |
| DETERMINATION OF DRUG SERUM LEVELS TO OPTIMISE TREATMENT OF PATIENTS WITH PSORIASIS | 4CPS-161 |
| INFLIXIMAB SERUM CONCENTRATIONS, ANTIBODY FORMATION AND CLINICAL RESPONSE IN PSORIATIC PATIENTS | 4CPS-162 |
| ECULIZUMAB THERAPY FOR ADULT RENAL TRANSPLANT IN AHUS WITH MUTATION IN THE CFH GENE: A CASE REPORT | 4CPS-163 |
| ESTIMATION OF PRECISION AND ACCURACY OF FIVE POPULATION PHARMACOKINETICS MODELS OF INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES | 4CPS-165 |
| EVALUATION OF ZOLEDRONIC ACID IN THE TREATMENT OF BONE DISEASES WITH HIGH RISK OF FRACTURES | 4CPS-170 |
| CANCER PAIN ASSESSMENT AND ASSOCIATED ANALGESICS PRESCRIPTIONS | 4CPS-173 |
| SAFE USE OF LEVETIRACETAM AT DOSES HIGHER THAN THE MAXIMUM RECOMMENDED | 4CPS-175 |
| PSYCHIATRIC DISORDERS AND CARDIOPULMONARY ARREST PROBABLY RELATED TO PRESCRIBING CASCADE | 4CPS-176 |
| ANTICHOLINERGIC RISK IN ELDERLY PATIENTS WITH DEMENTIA TAKING CHOLINESTERASE INHIBITORS | 4CPS-177 | |
| MANAGEMENT OF DELIRIUM IN AN ACUTE CARE HOSPITAL | 4CPS-178 |
| ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER IN ADULTHOOD: CONFLICT BETWEEN CLINICAL NEEDS AND PRESCRIPTION STATUS | 4CPS-179 |
| APPLYING DIFFERENT SCALES FOR CALCULATING THE ANTICHOLINERGIC BURDEN IN OLDER PATIENTS | 4CPS-180 |
| STUDY OF THE REASONS FOR THE THERAPEUTIC DISCONTINUATION OF IMMUNE-BASED THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS | 4CPS-181 |
| OFF-LABEL RITUXIMAB IN NEUROLOGY PATIENTS | 4CPS-183 |
| VISION-RELATED QUALITY OF LIFE IN PATIENTS DIAGNOSED WITH RETINAL PATHOLOGY | 4CPS-186 |
| EFFECT OF RANIBIZUMAB IN VISION-RELATED QUALITY OF LIFE IN PATIENTS DIAGNOSED WITH RETINAL PATHOLOGY | 4CPS-187 |
| HE STRUCTURES, PROCESSES AND RELATED OUTCOMES OF CLINICAL PHARMACY PRACTICE AS PART OF THE MULTIDISCIPLINARY CARE OF PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW | 4CPS-192 |
| DESCRIPTIVE ANALYSIS OF ACTIVE CLINICAL TRIALS MANAGED IN A PHARMACY DEPARTMENT OF A TERTIARY HOSPITAL | 4CPS-194 |
| MASTERING THE COLONOSCOPY BOWEL PREPARATION OF PATIENTS: A MULTIDISCIPLINARY HEALTHCARE APPROACH | 4CPS-195 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS WITH POTENTIAL TO AVOID DRUG ADVERSE EVENTS IN HOSPITALISED PATIENTS, AND CALCULATION OF AVOIDED COST | 4CPS-197 |
| ADVERSE DRUG REACTIONS REPORTING: AWARENESS, KNOWLEDGE AND REASONS FOR UNDER-REPORTING AMONG HOPITAL PHARMACISTS IN MACEDONIA | 4CPS-198 |
| INTRODUCING A CLINICAL PHARMACIST TO A CARE OF THE ELDERLY (COE) DAY HOSPITAL | 4CPS-199 |
| RISK OF CARDIOVASCULAR EVENTS DURING PREGNANCY: A PROSPECTIVE OBSERVATIONAL STUDY | 4CPS-201 |
| EVALUATION OF EFFICIENCY AND CLINICAL IMPROVEMENTS OF PHARMACEUTICAL INTERVENTIONS IN A RECENTLY IMPLEMENTED SOCIAL-SANITARY CENTRE | 4CPS-203 |
| INTRAVENOUS MEDICINE COMPATIBILITY: AN EVALUATION OF HOSPITAL PRACTICES | 4CPS-205 |
| EXPERIENCE OF IMPLEMENTATION OF A CLINICAL PHARMACY SERVICE IN A FIRST-LEVEL HOSPITAL IN PORTUGAL | 4CPS-208 |
| A CLINICAL PHARMACIST-LED MEDICATION RECONCILIATION SERVICE IN GERIATRIC PATIENTS UPON ADMISSION TO HOSPITAL | 4CPS-209 |
| EVALUATION OF THE INTERVENTIONS OF A CRITICAL CARE PHARMACIST IN ADDITION TO TEAM-BASED CARE IN AN INTENSIVE CARE UNIT | 4CPS-211 |
| ASSESSING AND COMPARING A PRE-DISCHARGE MEDICATION RECONCILIATION MODEL TO A POSTDISCHARGE MODEL | 4CPS-213 |
| IMPLEMENTATION OF A CLINICAL PHARMACIST IN AN INTERNAL MEDICINE SERVICE OF A TERTIARY REFERRAL HOSPITAL | 4CPS-214 |
| THE TRUTH ABOUT MEDICATION RECONCILIATION DOCUMENTATION | 4CPS-215 |
| ROLE OF THE HOSPITAL PHARMACIST IN THE MANAGEMENT OF DRUGS NOT ADAPTED TO PATIENTS WITH DYSPHAGIA | 4CPS-216 |
| HEPATITIS B TREATMENT: TOWARDS EFFECTIVENESS AND ADHERENCE | 4CPS-217 |
| ASSOCIATION BETWEEN ORAL SOLUTION OF 24% SUCROSE AND PROCEDURAL PAIN BY PRETERM INFANTS | 4CPS-218 |
| ANALYSIS OF PATIENTS’ INFORMATION NEEDS ATTENDING AN OUTPATIENT PHARMACEUTICAL CARE UNIT: PILOT TEST | 4CPS-219 |
| CLINICAL PHARMACIST INTERVENTIONS IN HOSPITALISED PATIENTS WITH RENAL IMPAIRMENT | 4CPS-220 |
| CUTANEOUS INFECTION CAUSED BY CORYNEBACTERIUM DIPHTHERIAE: A CASE REPORT | 4CPS-221 |
| DECREASED USE OF PIMS IN ELDERLY HOSPITALISED PATIENTS: IS IT POSSIBLE? | 4CPS-222 |
| EVALUATION OF ALLERGIES DURING VALIDATION OF PHARMACOLOGICAL THERAPY ACCORDING TO EAHP STATEMENTS | 4CPS-223 |
| ANALYSIS OF INTERVENTIONS IN POLYMEDICATED ELDERLY PATIENTS | 4CPS-224 |
| DEVELOPMENT OF A DRUG INFORMATION SHEET FOR PATIENTS TO PROMOTE APPROPRIATE USE | 4CPS-225 |
| EVALUATION OF A TARGETED MEDICATION RECONCILIATION IN PATIENTS AT THE HIGHEST RISK ADMITTED THROUGH THE EMERGENCY UNIT | 4CPS-226 |
| OBTAINING THE MOST ACCURATE LIST OF CURRENT MEDICATION FOR THE PATIENT | 4CPS-227 |
| PHARMACEUTICAL INTERVENTIONS IN THE MANAGEMENT OF PARENTERAL NUTRITION IN CRITICALLY ILL PATIENTS | 4CPS-229 |
| PROSPECTIVE STUDY TO EXPLORE THE IMPACT OF A CLINICAL PHARMACIST IN A CARDIAC SURGICAL POPULATION OR AFTER ACUTE CORONARY SYNDROME | 4CPS-230 |
| THE USE OF CANNABIS OIL IN ONCOLOGICAL PAIN: ANALYSIS OF THE OUTCOMES IN REAL PRACTICE AT A CANCER CENTRE | 4CPS-231 |
| ANALYSIS OF ORAL MEDICATION PRESCRIPTION AND ADMINISTRATION THROUGH THE JEJUNOSTOMY OR THE NASOGASTRIC TUBE IN AN INTENSIVE CARE UNIT: HOW TO IMPROVE PATIENT’S HOSPITALISATION? | 4CPS-232 |
| COVERAGE OF ENERGY AND PROTEIN NEEDS IN PATIENTS WITH KIDNEY FAILURE OR LIVER FAILURE RECEIVING TOTAL PARENTERAL NUTRITION | 4CPS-233 |
| PHARMACEUTICAL INTERVENTIONS IN THE EMERGENCY DEPARTMENT: RELEVANCE IN HIGHALERT MEDICATIONS | 4CPS-234 |
| A MOBILE TEAM OF CLINICAL PHARMACISTS IN DIGESTIVE AND UROLOGICAL SURGERY UNITS: RESULTS AND SATISFACTION AFTER 9 MONTHS | 4CPS-235 |
| MEDICATION USE DURING PREGNANCY | 4CPS-236 |
| CLINICALLY-RELEVANT DRUG-DRUG INTERACTIONS AMONG ELDERLY PEOPLE WITH DEMENTIA LIVING IN NORTHERN SWEDEN | 4CPS-237 |
| MANAGEMENT OF A MEDICATION RECONCILIATION PLAN AT ADMISSION IN DIFFERENT LEVELS OF GERIATRIC HEALTHCARE | 4CPS-238 |
| EVALUATION OF CLINICAL PHARMACIST INTERVENTIONS IN SURGICAL PATIENTS | 4CPS-239 |
| ADDING VALUE: PHARMACIST INTERVENTIONS IN THE PERIOPERATIVE SETTING | 4CPS-240 |
| METABOLIC COMPLICATIONS ASSOCIATED WITH PARENTERAL NUTRITION OF INTENSIVE CARE PATIENTS | 4CPS-241 |
| INVOLVEMENT OF A PHARMACIST IN A GERIATRIC TEAM IN PRIMARY CARE | 4CPS-242 |
| A NESTED QUALITATIVE STUDY OF MEDICATION REVIEWS WITHIN A MULTICENTRE CLUSTERRANDOMISED CROSSOVER TRIAL (MEDBRIDGE) | 4CPS-243 |
| MEDICATION RECONCILIATION IN A VISCERAL SURGERY DEPARTMENT: IS IT USEFUL FOR SURGEONS? | 4CPS-244 |
| IMPLEMENTING CLINICAL PHARMACY PRACTICES IN THE COMPREHENSIVE GERIATRIC ASSESSMENT PERFORMED BY THE MOBILE GERIATRIC MULTIDISCIPLINARY TEAM IN ORTHOPAEDIC UNITS | 4CPS-245 |
| IMPACT OF MEDICATION REVIEW TO OPTIMISE PRESCRIPTIONS OF NURSING HOME RESIDENTS | 4CPS-246 |
| COMPARATIVE ANALYSIS OF ANAESTHESIA REPORT AND MEDICATION RECONCILIATION IN AN ORTHOPAEDIC SURGERY DEPARTMENT | 4CPS-249 |
| OPTIMISATION OF PHARMACOTHERAPY IN INSTITUTIONALISED PATIENTS IN A SOCIO-HEALTH CENTRE | 4CPS-250 |
| EFFECTIVENESS OF SACRAL NEUROMODULATION IN TWO PATIENTS WITH TETHERED CORD SYNDROME OUTPUTS: A CASE REPORT | 4CPS-252 |
| LOCAL ASSESSMENT OF MEDICATION REVIEW IN AN INTERNAL MEDICINE UNIT | 4CPS-253 |
| MEDICATION REVIEW: CASE REPORT OF A FRAGILE PATIENT’S FALL | 4CPS-254 |
| EXPANDING THE PROCESS OF PHARMACEUTICAL CARE TO THE INSTITUTIONALISED PATIENT CARE UNIT | 4CPS-255 |
| DISCHARGE MEDICATION RECONCILIATION: EVALUATION OF A 7-MONTHS ACTIVITY | 4CPS-256 |
| THE EFFECTIVENESS OF DIFFERENT ORAL CARE SOLUTIONS IN THE TREATMENT OF CHEMOTHERAPYINDUCED ORAL COMPLICATIONS | 4CPS-257 |
| USEFULNESS OF CYSTATIN C AS A BIOMARKER OF RENAL FUNCTION IN DRUG DOSING IN A HAEMATOLOGIC PATIENT WITH PROTEIN MALNUTRITION | 4CPS-259 |
| GRADE OF CHRONICITY IN NONAGENARIANS: CAN WE COMPARE NUMBER AND TYPE OF DRUG INTERVENTIONS? | 4CPS-261 |
| EVALUATION OF A PHARMACIST-LED DISCHARGE SERVICE | 4CPS-262 |
| REDUCTION OF POTENTIALLY INAPPROPRIATE PRESCRIPTIONS AT DISCHARGE IN A POPULATION OF NONAGENARIANS | 4CPS-263 |
| POPULATION PHARMACOKINETIC MODEL OF ETANERCEPT IN RHEUMATIC DISEASE: PROGNOSTIC FACTORS AND DOSE RECOMMENDATIONS | 4CPS-264 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ANAEMIA AMONG HOSPITALISED ELDERLY PATIENTS | 5PSQ-001 |
| ADHERENCE TO GUIDELINES FOR TREATMENT OF UPPER AND LOWER GASTROINTESTINAL BLEEDING IN ACUTE SURGICAL WARDS | 5PSQ-002 |
| EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN ULCERATIVE COLITIS AND CROHN’S DISEASE | 5PSQ-003 |
| ADEQUACY AND EFFECTIVENESS OF LIRAGLUTIDE IN PATIENTS WITH TYPE-2 DIABETES MELLITUS | 5PSQ-004 |
| BULLOUS PHEMPHIGOID ASSOCIATED WITH GLIPTINS: REVIEW OF LITERATURE AND CASE REPORT | 5PSQ-005 |
| SAFE MANAGEMENT OF DIABETIC KETOACIDOSIS IN THE EMERGENCY SERVICE | 5PSQ-006 |
| ASSESSMENT OF THE INTERVENTION OF THE GROUP PROI ENDOCRINOLOGY-PHARMACY FOR THE IMPROVEMENT OF INSULIN THERAPY IN THE HOSPITAL | 5PSQ-007 |
| RESULTS AFTER THE IMPLANTATION OF AN INSULINISATION PROTOCOL IN NON-CRITICAL HOSPITALISED PATIENTS | 5PSQ-008 |
| ADEQUACY OF USE AND EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS IN REAL CLINICAL PRACTICE | 5PSQ-009 |
| EFFICACY AND SAFETY OF AGALSIDASE ALFA IN FABRY DISEASE | 5PSQ-010 |
| EVALUATION OF ADHERENCE TO NEW ORAL ANTICOAGULANTS THERAPY BASED ON THERAPEUTIC SWITCHES: A DESCRIPTIVE STUDY | 5PSQ-011 |
| PRESCRIPTION ERRORS OF ANTICOAGULANTS | 5PSQ-015 |
| SAFE USE OF ANTIPLATELET MEDICATION: APPROACHING THE OPTIMAL DOSE OF ASPIRIN BY PHARMACEUTICAL INTERVENTION | 5PSQ-016 |
| SAFETY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN TREATMENT OF IRON DEFICIENCY IN CHILDREN UNDER 2 YEARS WITH INTESTINAL FAILURE | 5PSQ-017 |
| AN ORGANISATIONAL APPROACH TO IMPROVE THE SAFETY OF INTRAVENOUS POTASSIUM CHLORIDE REPLACEMENT: DATA FROM A TERTIARY CARE HOSPITAL | 5PSQ-019 |
| PRESCRIPTION ERRORS ASSOCIATED WITH ONDEMAND MEDICATION RECONCILIATION AT ADMISSION: SUBLINGUAL NITROGLYCERIN AS AN EXAMPLE | 5PSQ-021 |
| PHARMACOLOGICAL CARDIOVERSION IN PATIENTS WITH RECENT-ONSET ATRIAL FIBRILLATION AT EMERGENCY DEPARTMENT: EFFICACY AND SAFETY OF VERNAKALANT | 5PSQ-022 |
| THE IMPORTANCE OF THE EVALUATION OF AMIODARONE’S PLASMATIC CONCENTRATION IN PATIENTS WITH ATRIAL FIBRILLATION | 5PSQ-023 |
| REAL-WORLD EFFECTIVENESS AND SAFETY OF EVOLOCUMAB AND ALIROCUMAB | 5PSQ-025 |
| EFFICACY AND SAFETY OF EVOLOCUMAB IN HYPERCHOLESTEROLAEMIA AND MIXED DYSLIPIDAEMIA | 5PSQ-026 |
| EARLY REAL-WORLD EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIASIS | 5PSQ-027 |
| CARDIOVASCULAR RISK FACTOR IN INDIVIDUALS WITH GENDER IDENTITY DISORDER OR CROSS-SEX HORMONE THERAPY | 5PSQ-028 |
| USE AND EFFECTIVENESS OF TIGECYCLINE IN A PRIVATE CARE HOSPITAL | 5PSQ-030 |
| PNEUMOCYSTIS CARINII PNEUMONIA PREVENTION IN LUNG TRANSPLANTATION: IS ATOVAQUONE EFFECTIVE? | 5PSQ-031 |
| HIGH DOSAGE OF TIGECYCLINE IN MULTIDRUGRESISTANT ACINETOBACTER BAUMANNII: USE ANALYSIS DURING AN OUTBREAK | 5PSQ-033 |
| ASSESSMENT OF LINEZOLID’S HAEMOTOLOGICAL TOXICITY AND RELATED RISK FACTORS IN CLINICAL PRACTICE | 5PSQ-034 |
| RELEVANCE OF FLUOROQUINOLONE PRESCRIPTION IN HOSPITAL | 5PSQ-035 |
| EVALUATION OF AN ANTIMICROBIAL STEWARDSHIP INTERVENTION IN A GENERAL HOSPITAL | 5PSQ-036 |
| EVOLUTION OF THE ANTIMICROBIAL STEWARDSHIP PROGRAMME QUALITY INDICATORS IN A THIRDLEVEL HOSPITAL | 5PSQ-037 |
| ACTION OF THE PHARMACIST ON THE ADEQUATE PRESCRIPTION OF ANTIBIOTICS | 5PSQ-038 |
| ANALYSIS OF THE QUALITY OF THE INFORMATION REGISTERED IN THE ELECTRONIC MEDICAL RECORD FOR THE CORRECT FOLLOW-UP OF THE TREATMENT WITH VANCOMYCIN | 5PSQ-039 |
| ANTIBIOTIC USE IN A TERTIARY CARE HOSPITAL | 5PSQ-040 |
| INCIDENTS DUE TO THE USE OF ANTIBIOTICS DETECTED IN THE PAEDIATRIC EMERGENCY SERVICE OF A THIRD-LEVEL HOSPITAL | 5PSQ-041 |
| ACUTE EOSINOPHILIC PNEUMONIA SECONDARY TO DAPTOMYCIN: A CASE REPORT | 5PSQ-042 |
| NEBULISED VORICONAZOLE IN LUNG TRANSPLANT RECIPIENTS: ANALYSIS OF USE, EFFICACY AND TOLERABILITY | 5PSQ-043 |
| SYSTEMIC ADMINISTRATION OF ANTIFUNGAL MEDICINES: ANALYSIS OF PRESCRIPTIONS | 5PSQ-044 |
| COST-EFFECTIVENESS ANALYSIS OF ISAVUCONAZOLE VERSUS VORICONAZOLE | 5PSQ-045 |
| DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS IN HIV CO-INFECTED PATIENTS | 5PSQ-046 |
| SERIOUS ADVERSE REACTIONS AND SUSTAINED VIRAL RESPONSE RELATED TO 3D REGIME: PURPOSE OF A CASE | 5PSQ-047 |
| DARUNAVIR/COBICISTAT PHARMACOLOGICAL INTERACTIONS: CLINICAL RELEVANCE AND ACTION MECHANISM | 5PSQ-048 |
| EFFECTIVENESS AND RENAL SAFETY OF TAF/FTC/EVG/ COBI IN REAL CLINICAL PRACTICE | 5PSQ-049 |
| NEUROPSYCHIATRIC ADVERSE EFFECTS ON DOLUTEGRAVIR: EXPERIENCE IN A THIRD-LEVEL HOSPITAL | 5PSQ-050 |
| EFFECTIVENESS AND SAFETY OF SNAKE ANTIVENOM: A CASE REPORT | 5PSQ-051 |
| OPTIMISATION OF HUMAN NORMAL IMMUNOGLOBULINS IN PAEDIATRIC CANCER: A MULTIDISCIPLINARY TEAMWORK | 5PSQ-052 |
| DRUG UTILISATION STUDY OF HUMAN NORMAL IMMUNOGLOBULIN IN HAEMATOLOGICAL AND ONCOLOGIC PATIENTS IN A TEACHING PAEDIATRIC HOSPITAL | 5PSQ-053 |
| DRUGS THAT EXTEND THE QT INTERVAL OF THE ECG: EVALUATION OF ONCOLOGICAL PATIENTS | 5PSQ-054 |
| ANALYSIS OF CHEMOTHERAPY EXTRAVASATION AND ITS MANAGEMENT IN AN OUTPATIENT CLINIC OF A TERTIARY CARE HOSPITAL | 5PSQ-055 |
| EVALUATION OF OXALIPLATIN-SPECIFIC NEUROTOXICITY BASED ON TOTAL CUMULATIVE DOSE | 5PSQ-056 |
| DEVELOPMENT OF AN ANALYSIS METHOD TO ASSESS THE OCCUPATIONAL RISK DEALING WITH THERAPEUTIC MONOCLONAL ANTIBODIES USING LIQUID CHROMATOGRAPHY AND HIGH-RESOLUTION MASS SPECTROMETRY (LC-HRMS) | 5PSQ-057 |
| COMPARATIVE EFFECTIVENESS OF REGORAFENIB VERSUS TRIFLURIDINE/TIPIRACIL IN METASTATIC COLORECTAL CANCER | 5PSQ-058 |
| TOXICITY ASSOCIATED WITH THE USE OF NIVOLUMAB IN MONOTHERAPY IN CLINICAL PRACTICE | 5PSQ-059 |
| AN ACUTE AND SEVERE EVENT IN A PATIENT TREATED WITH RAMUCIRUMAB | 5PSQ-060 |
| STABILITY OF CARBOPLATIN INFUSION SOLUTIONS USED IN DESENSITISATION PROTOCOL | 5PSQ-061 |
| MANAGEMENT AND EFFECTIVENESS OF NABPACLITAXEL IN METASTASIC PANCREATIC ADENOCARCINOMA | 5PSQ-062 |
| RESPONSE TO ABIRATERONE AND ENZALUTAMIDE IN CASTRATE-RESISTANT PROSTATE CANCER IN CLINICAL PRACTICE | 5PSQ-063 |
| USE OF SORAFENIB IN CELLULAR HEPATOCARCINOMA IN ROUTINE CLINICAL PRACTICE | 5PSQ-064 |
| CARDIOVASCULAR TOXICITY INDUCED BY TARGETED AGENTS | 5PSQ-065 |
| ANALYSIS OF ANTINEOPLASTIC DRUGS PREPARATION ERRORS AS A FIRST STEP TO IMPROVE THE QUALITY OF THE PROCESS | 5PSQ-067 |
| BASAL CELL EPITHELIOMA INDUCED BY IBRUTINIB: TWO CASE REPORTS | 5PSQ-069 |
| HAZARDOUS DRUGS DISPENSED TO OUTPATIENTS AND PROPOSALS FOR SAFE HANDLING | 5PSQ-070 |
| EFFICACY AND SAFETY EVALUATION OF TRIFLURIDINE/TIPARACIL FOR METASTATIC COLON CANCER (MCRC) | 5PSQ-071 |
| TOLERANCE PROFILE OF PLATINUM SALTS IN ANTICANCER CHEMOTHERAPY: A PROSPECTIVE STUDY | 5PSQ-072 |
| REVIEW OF METABOLIC AND ELECTROLYTIC ALTERATIONS IN PATIENTS WITH ENTERAL NUTRITION | 5PSQ-073 |
| ACTIVITY OF ENZALUTAMIDE AFTER ABIRATERONE IN CASTRATION-RESISTANT PROSTATE CANCER | 5PSQ-074 |
| FINGOLIMOD-ASSOCIATED LYMPHOPAENIA IN MULTIPLE SCLEROSIS PATIENTS | 5PSQ-075 |
| PATIENT-REPORTED OUTCOMES IN MULTIPLE SCLEROSIS | 5PSQ-076 |
| SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS AND PSORIATIC ARTHRITIS IN CLINICAL PRACTICE | 5PSQ-078 |
| ARE ANALYTICAL PARAMETERS SUITABLE PREDICTORS IN RHEUMATOLOGIC DISEASES? | 5PSQ-079 |
| EFFECTIVENESS AND SECURITY OF ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS | 5PSQ-080 |
| CYCLOPHOSPHAMIDE THERAPY IN CHILDREN WITH NEPHROTIC SYNDROME | 5PSQ-082 |
| STUDY OF THE PREVALENCE OF IMMUNOGENICITY IN PATIENTS TREATED WITH ANTI-TUMOUR NECROSIS FACTOR MONOCLONAL ANTIBODIES | 5PSQ-083 |
| OPTIMISATION OF STOCK OF LEVODOPA/CARBIDOPA INTESTINAL GEL BY USING A SEMI-AUTOMATIC PLANNING SYSTEM | 5PSQ-086 |
| EVIDENCE AND DECISION ALGORITHM FOR THE WITHDRAWAL OF ANTIPSYCHOTIC TREATMENT IN THE ELDERLY WITH DEMENTIA AND NEUROPSYCHIATRIC SYMPTOMS | 5PSQ-087 |
| PATHOPHYSIOLOGY OF OROPHARYNGEAL DYSPHAGIA IN DEMENTIA PATIENTS TAKING ANTIPSYCHOTICS USING A VIDEOFLUOROSCOPY STUDY | 5PSQ-088 |
| LACK OF ISO-APPEARANCE IN DISPENSED ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA | 5PSQ-090 |
| IDENTIFY AND PROTOCOLISE TORSADE DE POINTES RISK IN A RESIDENTIAL CENTRE | 5PSQ-091 |
| ANALYSIS OF OFF-LABEL USES OF INHALERS IN HOSPITALISED PATIENTS | 5PSQ-092 |
| ASSESSMENT TOOL FOR HOSPITAL ADMISSIONS RELATED TO MEDICATIONS, 10 QUESTIONS (ATHARM10): A VALIDATION STUDY | 5PSQ-093 |
| EFFICACY AND DURATION IN TREATMENT OF ACANTHAMOEBA KERATITIS. PREVALENCE AND RISK FACTOR OF THE INFECTION | 5PSQ-094 |
| LIKELY HYPERSENSIVILITY TO 20% AUTOLOGOUS SERUM EYE DROPS | 5PSQ-095 |
| EFFICACY AND SECURITY OF PLASMA RICH IN GROWTH FACTORS EYE DROPS FOR THE TREATMENT OF OCULAR SURFACE DISEASES | 5PSQ-096 |
| TOXICITY ASSOCIATED WITH GENE POLYMORPHISMS IN PATIENTS WITH COLORECTAL CANCER, TREATED WITH FLUOROPYRIMIDINES AND ANALOGUES, IRINOTECAN AND PLATINUM COORDINATION COMPLEXES | 5PSQ-097 |
| CYTOTOXIC PREPARATION UNIT: EVALUATION OF CLINICAL SERVICES SATISFACTION IN THREE HOSPITALS | 5PSQ-099 |
| ONCOLYTIC VIRUSES RISK AND CONTROL ASSESSMENT: TALIMOGENE LAHERPAREPVEC EXPERIENCE | 5PSQ-101 |
| HAZARDOUS DRUG COLOUR MARKS THE DIFFERENCE | 5PSQ-102 |
| STUDY ON THE USE OF OFF-LABEL DRUGS IN A GENERAL HOSPITAL | 5PSQ-104 |
| TABLET CRUSHING AND HARD CAPSULE OPENING PRACTICES IN NURSING HOME AND LONG-TERM CARE UNIT | 5PSQ-107 |
| REDUCING ERRORS OF ORAL MEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA | 5PSQ-108 |
| IMPROVING PATIENT SAFETY AND QUALITY ASSURANCE THROUGH MULTIDISCIPLINARY CLINICAL AUDITS | 5PSQ-111 | |
| UPDATED MEDICATION LISTS – A PROBLEM ANALYSIS WITH IMPROVEMENT SUGGESTIONS | 5PSQ-112 |
| RISK ASSESSMENT AND MANAGEMENT TO IMPROVE PARENTERAL NUTRITION SAFETY | 5PSQ-113 |
| FREQUENCY OF MANIPULATED MEDICINES ADMINISTERED TO PAEDIATRIC IN-PATIENTS: A REGISTER STUDY | 5PSQ-114 |
| COMPUTERISED PHYSICIAN ORDER ENTRY IMPACT ON MEDICATION ERRORS IN A PAEDIATRIC UNIT | 5PSQ-115 |
| IDENTIFICATION OF HIGH-ALERT MEDICATION FOR PAEDIATRIC PATIENTS IN A CENTRAL HOSPITAL | 5PSQ-116 |
| FAILURE MODE AND EFFECTS CRITICALITY ANALYSIS: MULTICENTRIC APPLICATION ON CANCER CHEMOTHERAPY PROCESS | 5PSQ-117 |
| A MEDICATION RECONCILIATION PROTOCOL PERFORMED BY PHARMACISTS: IMPACT ON HOSPITAL DISCHARGE SUMMARIES | 5PSQ-118 |
| PHARMACEUTICAL INTERVENTION IN CONCILIATION PERFORMED IN AN EMERGENCY DEPARTMENT | 5PSQ-121 |
| MEDICINES AND DIETARY SUPPLEMENTS PURCHASED OUTSIDE THE TRADITIONAL SUPPLY CHAIN RAISE PATIENT SAFETY CONCERNS IN HOSPITAL AND CLINICAL SETTINGS | 5PSQ-124 |
| ASSESSMENT OF NURSES’ KNOWLEDGE ABOUT CARE AND MANAGEMENT OF CENTRAL VENOUS CATHETERS | 5PSQ-125 |
| ASSESSMENT OF DRUG-DRUG INTERACTIONS IN SURGICAL INTENSIVE CARE UNIT | 5PSQ-126 |
| SATISFACTION SURVEY TO EVALUATE HOSPITAL PHARMACY SERVICES IN A TEACHING HOSPITAL | 5PSQ-127 |
| MOBILE APPLICATIONS TO CHECK DRUG INTERACTIONS: QUALITATIVE AND QUANTITATIVE ANALYSIS | 5PSQ-131 |
| CASES OF DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOM SYNDROME DUE TO ANTIINFLAMMATORY DRUGS | 5PSQ-132 |
| PREVALENCE OF UNDERPRESCRIPTION OF RECOMMENDED MEDICATIONS IN FRAIL AND ROBUST OLDER ADULTS IN NURSING HOMES | 5PSQ-133 |
| HYPERPIGMENTATION INDUCED BY PROLONGED USE OF CHLOROQUINE: A CASE REPORT | 5PSQ-134 |
| TRAINING OF HOSPITAL PHARMACY RESIDENTS IN STRATEGIES THAT IMPROVE PATIENT SAFETY IN PRIMARY CARE | 5PSQ-135 |
| COMPUTERISATION OF MEDICAL DEVICES, TRACEABILITY AND UNEXPECTED LOSS OF DATA: REPORTS AND PROSPECTS FOR IMPROVEMENT | 5PSQ-136 |
| OPTIMISATION OF THE SETTING-UP OF DATA SAFETY MONITORING BOARDS IN CLINICAL TRIALS: LESSONS OF A 6-YEARS ANALYSIS | 5PSQ-137 |
| BEST PRACTICE OF WARD-BASED RECONSTITUTION IN PAEDIATRIC HOSPITALS | 5PSQ-138 |
| ADVERSE EVENTS ASSOCIATED WITH HIGH-ALERT MEDICATIONS DETECTED BY TRIGGER METHODOLOGY IN PATIENTS WITH CHRONIC ILLNESSES | 5PSQ-139 |
| RECONSTUTION PRACTICE BY A PAEDIATRIC AND NEONATAL WARD-BASED PHARMACIST | 5PSQ-140 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ASSOCIATION BETWEEN FAECAL CALPROTECTIN VALUES AND INFLIXIMAB TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE PATIENTS | 6ER-001 |
| COMPREHENSIVE PROGRAMME FOR PREVENTION AND CONTROL OF INFECTIONS RELATED TO HEALTH CARE AND APPROPRIATE USE OF ANTIMICROBIALS: ONE MORE STEP | 6ER-005 |
| USE OF PIPERACILLIN-TAZOBACTAM IN A UNIVERSITY HOSPITAL | 6ER-006 |
| IMPACT OF OPTIMISING USE OF CARBAPENEM ANTIBIOTICS PROGRAMME | 6ER-007 |
| EVALUATION OF PATIENT, VIRUS AND TREATMENT BASELINE FACTORS AFFECTING THE EFFECTIVENESS OF DIRECT ANTIVIRAL AGENTS AGAINST THE HEPATITIS C VIRUS | 6ER-008 |
| CAN TOLERABILITY AND SAFETY OF DAA-2 FOR HEPATITIS C BE ESTIMATED ONLY BY RANDOMISED CLINICAL TRIALS? A SYSTEMATIC REVIEW WITH META-ANALYSIS | 6ER-009 |
| FOCUS ON HCV TREATMENT BASED ON SECONDGENERATION DIRECT-ACTING ANTIVIRAL AGENTS (DAAS-2): COMPARING NATIONAL AND LOCAL PRESCRIBING TRENDS | 6ER-010 |
| DRUG UTILISATION STUDY OF BEVACIZUMAB IN A TEACHING REFERRAL PAEDIATRIC HOSPITAL | 6ER-011 |
| PATIENT-REPORTED OUTCOMES REGARDING ADALIMUMAB NEW FORMULATION | 6ER-014 |
| THE RELATION BETWEEN PLACEBO EFFECT AND SEROTONIN TRANSPORTER GENETIC POLYMORPHISM: A DOUBLE-BLIND CLINICAL TRIAL IN HEALTHY ADULTS | 6ER-015 |
| ANALYSIS OF PRESCRIBED TREATMENTS FOR PATIENTS WITH PULMONARY HYPERTENSION IN A PROVINCIAL HOSPITAL | 6ER-016 |
| ASSESSMENT OF DRUG PRESCRIPTION USING THE WORLD HEALTH ORGANISATION (WHO) INDICATORS AT A PUBLIC HOSPITAL | 6ER-017 |
| THE POSSIBLE CORRELATION BETWEEN BLOOD GROUPS AND MEDICAL CONDITIONS OCCURRENCE IN PREGNANCY: A PROSPECTIVE STUDY | 6ER-020 |
| IMPACT OF ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISM G894T ON THE DEVELOPMENT OF TYPE-2 DIABETES | 6ER-023 |
| IMMUNE CHECKPONT INHIBITORS IN PHARMACOLOGICAL THERAPY | 6ER-024 |
| PHARMACIST CLINICIANS IN HOSPITALS – TRANSFORMING THE WORKFORCE WITH NEW MODELS OF PATIENT CARE | 6ER-025 |
| HOME MEDICINE STORAGE HABITS AMONG PATIENTS ATTENDING OUTPATIENT PHARMACY SERVICES | 6ER-027 |
| BECOMING AN HOSPITAL PHARMACIST: AN OBSERVATIONAL CROSS-SECTIONAL STUDY ON THE EDUCATIONAL PATHWAYS FROM STUDENTS’ PERSPECTIVE | 6ER-028 |
| SPANISH HOSPITAL PHARMACY TWITTERSPHERE: A QUANTITATIVE STUDY | 6ER-029 |
| CLINICAL INVESTIGATIONS OF MEDICAL DEVICES: AN EXAMPLE FROM A LOCAL ETHICAL COMMITTEE | 6ER-030 |
| DESIGN AND IMPLEMENTATION OF A PHARMACY TECHNICIAN TRAINING PROGRAMME TO IMPROVE OUTPATIENT DRUG DISPENSING | 6ER-032 |
| PHARMACY RESIDENTS’ TRAINING TO ON-CALL DUTIES IN HOSPITAL PHARMACIES: SURVEY OF FRENCH TRAINING PROGRAMMES AND OPTIMISATION OF A LOCAL TRAINING PROGRAMME | 6ER-033 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| MEDICATION ERRORS IN VOLUNTARY REPORTED INCIDENTS AT A UNIVERSITY HOSPITAL | CP-007 | |
| COMPARISON OF PRESCRIPTION PROFILE OF ANTIRETROVIRALS DRUGS BETWEEN 2014 AND 2016 IN A TERTIARY CARE HOSPITAL | CP-008 | |
| USE AND EFFECTIVENESS OF PLERIXAFOR FOR HEMATOPOIETIC STEM CELLS MOBILISATION | CP-010 | |
| INFLUENCE OF SURGICAL STRATEGY AND BASELINE CONDITIONS VERSUS CYP2C19 POLYMORPHISMS IN ANTIPLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS UNDERGOING PERCUTANEUS TRANSLUMINAL ANGIOPLASTY | CP-011 | |
| EFFICACY AND SAFETY OF NIVOLUMAB IN A TERTIARY HOSPITAL: EARLY ACCESS PROGRAM | CP-017 | |
| EFFECTIVENESS OF OMALIZUMAB ON ASTHMATIC PATIENTS | CP-018 | |
| RISK FACTORS FOR ANAEMIA DEVELOPMENT DURING THERAPY WITH RIBAVIRIN PLUS DIRECT-ACTING ANTIVIRALS | CP-019 | |
| SWITCHING TO DOLUTEGRAVIR IN MONOTHERAPY | CP-020 | |
| USE OF INTRAVITREAL ANTIANGIOGENIC DRUG IN A LARGE STUDY IN THE TREATMENT OF RETINOPATHY OF PREMATURITY | CP-023 | |
| FACTORS AFFECTING UPTAKE OF BIOSIMILARS | CP-024 | |
| EFFICACY OF COMPOUNDING TOPICAL TACROLIMUS FOR SUBEPITHELIAL CORNEAL INFILTRATES TREATMENT | CP-027 | |
| SAFETY AND TOLERABILITY OF COMPOUNDED TOPICAL TACROLIMUS | CP-028 | |
| INFLUENCE OF ADMINISTRATION OF ANTITHROMBIN CONCENTRATE IN CHILDREN ON HEPARIN INFUSION RATE DURING EXTRACORPOREAL MEMBRANE OXYGENATION | CP-031 |
| EVALUATION OF BOOSTED PROTEASE INHIBITOR MONOTHERAPY WITH DARUNAVIR/RITONAVIR IN HIVINFECTED PATIENTS. STUDY IN A REAL LIFE SETTING. | CP-032 | |
| EFFECTIVINESS OF THE COMBINATION LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF THE HEPATITIS C VIRUS INFECTION | CP-034 |
| EVALUATION OF THE THERAPEUTIC STRATEGIES USED FOR THE TREATMENT OF THE HEPATITIS C VIRUS GENOTYPE 3 INFECTION | CP-035 | |
| USE OF CHITOSAN FILM FOR REFRACTORY PAIN IN PERIOSTOMAL ULCER | CP-037 | |
| USE AND ECONOMIC IMPACT OF INTRAVENOUS IMMUNOGLOBULIN AT A UNIVERSITY HOSPITAL | CP-038 | |
| ANTIMICROBIALS STEWARDSHIP PROGRAMME FOCUSED ON LONG DURATION TREATMENTS: PRELIMINARY RESULTS | CP-040 | |
| APPROPRIATENESS OF ALBUMIN TREATMENT IN NON-CRITICAL AND NON – ONCOHAEMATOLOGICAL HOSPITALISED PATIENTS | CP-044 |
| AN ASSESSMENT OF PREFERENCE OF VISUAL AND MANUAL COMPLIANCE AIDS | CP-046 | |
| EVALUATION OF THE CLINICAL PHARMACISTS IMPACT ON TOTAL PARENTERAL NUTRITION PRESCRIPTION ORDER REVIEW AND PREPARATION IN NEONATAL INTENSIVE CARE UNIT | CP-047 | |
| EARLY RECOVERY AFTER CAESAREAN SECTION AND EVALUATION OF CARBETOCIN | CP-048 |
| MEDICATION DISCREPANCIES AT THE TIME OF ADMISSION TO AND TRANSFER FROM THE INTENSIVE CARE UNIT (ICU) AND THE ROLE OF A CLINICAL PHARMACIST | CP-050 |
| ECONOMIC ASPECTS OF THE USE OF CARBAPENEMS IN CRITICALLY ILL PATIENTS | CP-052 | |
| CLINICAL PREDICTORS OF RESPONSE TO TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS | CP-054 |
| PATIENT TREATMENT SATISFACTION AFTER SWITCHING TO BIWEEKLY SUBCUTANEOUS PEGINTERFERON BETA 1A FROM INTRAMUSCULAR INTERFERON BETA 1A | CP-056 |
| OPTIMIZING PHARMACOTHERAPY IN INSTITUTIONALISED ELDERLY PATIENTS: THE ROLE OF HOSPITAL PHARMACISTS | CP-057 | |
| ANALYSIS OF CHANGES IN MANAGEMENT OF CATHETER RELATED INFECTIONS IN HAEMODIALYSIS AFTER IMPLEMENTATION OF A PROTOCOL | CP-058 | |
| EFFICACY AND COST OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HCV INFECTION AMONG HCV MONOINFECTED AND HIV/HCV COINFECTED PATIENTS IN REAL LIFE SETTING | CP-059 |
| INFLIXIMAB IN REFRACTORY COELIAC DISEASE | CP-062 | |
| ASSESSMENT OF URINARY 8-HYROXYDEOXYGUANOSINE LEVEL IN DIABETIC CANCER PATIENTS | CP-063 | |
| EFFECTIVENESS OF NEW DIRECT ACTING ANTIVIRALS FOR CHRONIC HEPATITIS C DEPENDING ON GENOTYPE IN REAL MEDICAL PRACTICE | CP-064 | |
| COMPARISON OF THE DURATION OF EFFECT OF TWO HYALURONIC ACIDS IN KNEE OSTEOARTHRITIS | CP-069 |
| CURRENT VENOUS THROMBOEMBOLISM PROPHYLAXIS PERI-CORONARY ARTERY BYPASS GRAFTING AT ST. THOMAS’ HOSPITAL | CP-072 |
| SAFETY PROFILE OF GLATIRAMER ACETATE 40mg | CP-076 |
| FACTOR IX INHIBITOR DEVELOPMENT IN CONGENITAL HAEMOPHILIA B PATIENTS WITH NONACOG ALFA TREATMENT | CP-079 |
| INNOVATION AND DEVELOPMENT IMPACT OF ACTIVITIES IN ANTIMICROBIAL STEWARDSHIP PROGRAMMES (ASP) | CP-081 |
| CD69 A>G (RS11052877) GENETIC POLYMORPHISM ON THE RESPONSE OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS. | CP-086 |
| PERSISTENCE OF INTRAMUSCULAR VERSUS SUBCUTANEOUS FIRST-LINE THERAPIES IN MULTIPLE SCLEROSIS PATIENTS | CP-087 |
| DO PATIENTS RECEIVE MEDICATIONS ADJUSTED TO THEIR INDIVIDUAL REQUIREMENTS? | CP-088 |
| EVALUATION OF EFFICACY AND SAFETY OF REGORAFENIB IN METASTATIC COLON CANCER | CP-090 |
| THE IMPACT OF MYELOMA MULTIPLE CLINICAL TRIALS ON MEDICATION COST SAVINGS | CP-093 |
| TOCILIZUMAB FOR THE TREATMENT OF A CASTLEMAN’S DISEASE PAEDIATRIC PATIENT: A CASE REPORT | CP-097 |
| IMPLEMENTATION OF A STRUCTURED OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY (OPAT) SERVICE BY THE HOSPITAL PHARMACIST IN A REGIONAL HOSPITAL | CP-099 |
| NATALIZUMAB EVERY 6 WEEKS VERSUS STANDARD DOSE: EVALUATION OF EFFECTIVENESS. PRELIMINARY STUDY | CP-101 |
| USEFULNESS OF THE TRACEABILITY OF PHARMACEUTICAL ANALYSIS IN PATIENT’S MEDICAL RECORD | CP-102 |
| ADHERENCE TO PARENTERAL FIRST-LINE DISEASE-MODIFYING THERAPY FOR MULTIPLE SCLEROSIS | CP-108 |
| EVALUATION OF CLINICAL, ECONOMIC AND ORGANISATIONAL IMPACTS OF PHARMACISTS’ INTERVENTIONS IN IMMUNOSUPPRESSIVE THERAPY MANAGEMENT AMONG LUNG TRANSPLANT OUTPATIENTS | CP-109 |
| MULTIDISCIPLINARY VIEWS TOWARDS THE CLINICAL PHARMACIST: A Hospital Palliative Care Team Perspective | CP-110 |
| ASSOCIATION BETWEEN POTASSIUM CHLORIDE INTRAVENOUS CONCENTRATION AND SEVERITY OF THE PAIN | CP-111 |
| A MULTIDISCIPLINARY APPROACH TO ANTIRETROVIRAL SIMPLIFICATION IN HIV-INFECTED PATIENTS | CP-112 |
| PERSISTENCE OF BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS | CP-114 |
| OPTIMISATION OF ANTI-INTERLEUKIN BIOLOGICAL THERAPIES IN PSORIASIS PATIENT ABOVE 100 KG | CP-115 |
| EVALUATION OF THE CLINICAL SIGNIFICANCE AND VALUE OF A CLINICAL PHARMACY SERVICE AT A TEACHING HOSPITAL | CP-116 | |
| DOES A STRUCTURED PROTOCOL INCREASE IMPLEMENTATION OF BIOLOGIC THERAPY DOSE REDUCTION AMONG CLINICIANS AND PATIENTS? A PILOT STUDY | CP-118 |
| SEVERE HEPATOTOXICITY INDUCED BY CERITINIB IN A METASTATIC NON-SMALL-CELL LUNG CANCER PATIENT: A CASE RESPORT | CP-121 |
| PEMBROLIZUMAB AND INMUNE MEDIATED NEPHRITIS: A CASE REPORT | CP-122 |
| A COST EFFECTIVENESS ANALYSIS OF NIVOLUMAB COMPARED WITH PEMETREXED FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN REAL PRACTICE | CP-123 |
| SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS FORMULATION OF TRASTUZUMAB: COSTS AND SAFETY | CP-127 |
| MEDICATION ERRORS AND THEIR SEVERITY DETECTED IN THE OBSERVATION AREA OF AN EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL | CP-132 |
| DRUG RELATED PROBLEMS IN EMERGENCY DEPARTMENT PATIENTS: ROLE OF CLINICAL PHARMACIST | CP-133 |
| SPIRONOLACTONE IN PAEDIATRICS. TOXICITY UPDATE. | CP-138 |
| ANALYSIS OF DISTRIBUTION AND ACCEPTABILITY OF PHARMACEUTICAL INTERVENTIONS AFTER IMPLANTATION OF THE ELECTRONIC ASSISTED PRESCRIPTION | CP-140 |
| VENOUS THROMBOEMBOLISM PROPHYLAXIS ADEQUACY OF MEDICAL PATIENTS: CROSS SECTIONAL STUDY | CP-141 |
| FIRSTLINE TRIPLET OR DOUBLET CHEMOTHERAPY FOR HER2 NEGATIVE ADVANCED OESOPHAGOGASTRIC CANCER: AN ANALYSIS FROM A COMMUNITY PRACTICE REGISTRY | CP-144 |
| QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS: EXPERIENCE IN A UNIVERSITY HOSPITAL OUTPATIENT PHARMACY | CP-145 |
| A MEDICATION THERAPY MANAGEMENT PROGRAM FOR CHRONIC PATIENT : ABOUT PATIENT SATISFACTION IN CARDIOLOGY | CP-147 |
| ACUTE CONFUSIONAL STATE: CASE REPORT | CP-148 |
| ASSESSMENT OF AN EXPERIMENTAL CALL CENTER DEDICATED TO DRUG INFORMATION FOR OUTPATIENTS | CP-151 |
| LIRAGLUTIDE ADEQUACY AND EFFECTIVENESS IN REAL PRACTICE TYPE 2 DIABETES THERAPY | CP-153 |
| PREVALENCE AND EFFECTIVINESS OF ANTIRETROVIRAL TREATMENT COMBINATIONS USED IN HIV PATIENTS NOT COLLECTED IN GUIDELINES | CP-155 |
| CARBAPENEM DE-ESCALATION THERAPY FOR INTRA-ABDOMINAL INFECTION. | CP-160 |
| A CLINICAL AND COST ANALYSIS OF MEDICATION RECONCILIATION BY PHARMACISTS AT THE POINT OF HOSPITAL DISCHARGE | CP-161 |
| ONCO-HEMATOLOGICAL OUTPATIENTS TREATED WITH ORAL ANTINEOPLASTIC AGENTS: PHARMACIST INTERVENTIONS | CP-163 |
| AN AUDIT OF SELF-ADMINISTRATION OF MEDICINES IN CARDIOVASCULAR WARDS AND PATIENT’S PREFERENCE FOR MEDICINES ADMINISTRATION WHILE AN INPATIENT | CP-164 |
| IMPACT ON HOSPITAL READMISSION OF MEDICATION RECONCILIATION IN POST EMERGENCY GERIATRIC UNIT : A PILOT STUDY | CP-165 |
| RENAL DONOR OR RECRUDESCENCE AS ORIGIN OF MALARIA INFECTION | CP-167 |
| ECONOMIC IMPACT OF CLINICAL PHARMACISTS’ INTERVENTIONS ON ANTIMICROBIAL THERAPY IN CRITICALLY ILL PATIENTS | CP-168 |
| EVALUATION OF ANGIOTENSINOGEN M235T AND T174M POLYMORPHISMS, DEMOGRAPHIC AND CLINICAL FACTORS IN NEW-ONSET DIABETES AFTER LIVER TRANSPLANTATIONS IN IRANIAN PATIENTS | CP-170 |
| BIOLOGICAL DRUGS: PERSISTENCE RATE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIS | CP-171 |
| SUCCESSFUL DESENSITISATION IN A PATIENT WITH LENALIDOMIDE HYPERSENSITIVITY | CP-174 |
| INDIVIDUAL PARENTERAL NUTRITION: PHARMACIST WORK AS A MULTIDISCIPLINARY TEAM MEMBER | CP-177 |
| EFFECTS OF REIMBURSEMENT CHANGES ON USE OF ERYTHROPOIESIS-STIMULATING AGENTS IN DIALYSIS PATIENTS | CP-179 |
| POTENTIAL ECONOMICAL IMPACT OF BIOSIMILAR ADLIMUMAB | CP-182 |
| EFFECTIVENESS AND SAFETY OF BIOLOGICAL THERAPY OPTIMISATION IN CHRONIC PLAQUE PSORIASIS | CP-183 |
| CORRELATIONS OF VANCOMYCIN CLEARANCE DURING INTERMITTENT INFUSION WITH MEASURED AND ESTIMATED CREATININE CLEARANCE IN CRITICALLY III PATIENTS: 6-HOUR URINE COLLECTION MAY BE BENEFICIAL | CP-184 |
| AN INNOVATIVE TREATMENT ADHERENCE TOOL | CP-185 |
| EFFICACY, SAFETY AND COST OF POMALIDOMIDE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA | CP-187 |
| ADHERENCE TO ABIRATERONE AND ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | CP-189 |
| PRESCRIPTION EVALUATION OF HOSPITALISED PATIENTS AT A DISTRICT HOSPITAL, USING A PLATFORM THAT SUPPORTS ANTIMICROBIAL PRESCRIPTION: A PILOT ANALYSIS | CP-191 |
| ASSESSMENT OF MEDICAL COMPUTERISED PRESCRIPTIONS IN GERIATRICS USING STOPP/START CRITERIA | CP-192 |
| CLINICAL AND ECONOMIC IMPACT OF PHARMACISTS’ INTERVENTIONS RELATED TO ANTIMICROBIALS IN THE HOSPITAL SETTING: A SYSTEMATIC REVIEW | CP-193 |
| EVALUATION OF ACCESS TO OFF-LABEL NEW THERAPIES PHARMACOLOGICAL FIELD AND THE HOSPITAL AND ECONOMIC IMPACT | CP-194 |
| EVOLUTION OF IMMNUNO-ONCOLOGY CLINICAL TRIALS IN A TERTIARY UNIVERSITY HOSPITAL | CP-195 |
| THE IMPACT OF SOCIAL STATUS ON THE FINANCIAL EQUILIBRIUM OF ENDOVASCULAR TREATMENT OF INTRACRANIAL ANEURYSMS IN PUBLIC HOSPITAL | CP-196 |
| REVIEW OF INTRAVENOUS IRON PRESCRIPTIONS: FOCUS ON DOSING | CP-198 |
| PRESCRIPTION OF QUINOLONES, CARBAPENEMS AND ANTI-MRSA AGENTS IN THE EMERGENCY DEPARTMENT OF A DISTRICT HOSPITAL: INTERVENTIONS AND DEVELOPMENT OVER 3 YEARS | CP-199 |
| POLYPHARMACY AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN GERIATRIC OUTPATIENTS | CP-201 |
| OBSERVATIONAL STUDY ON THE USE OF THE DIFFERENT THERAPEUTIC ALTERNATIVES FOR MULTIPLE SCLEROSIS TREATMENT | CP-204 |
| ANALYSIS OF FREQUENCY OF UNDERDOSING IN OBESE PATIENTS TREATED WITH VANCOMYCIN | CP-207 |
| THE ADDED ROLE OF PHARMACEUTICAL INTERVENTION ON HEPATITIS C VIRUS DIRECT ANTIVIRAL AGENT TREATMENT: A SINGLE CENTRE OBSERVATIONAL PROSPECTIVE COHORT ANALYSIS | CP-210 |
| USING RITUXIMAB FOR OFF-LABEL INDICATIONS | CP-216 |
| EVALUATION OF ANTIVIRAL PRESCRIPTION FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION | CP-217 |
| MEDICATION DISCREPANCIES AND THEIR CLINICAL IMPACT: A STUDY AT THE EMERGENCY DEPARTMENT | CP-218 |
| UGT1A1*28 POLYMORPHISM AND IRINOTECAN EFFECTIVENESS | CP-225 |
| ANTIVITAMIN K OVERDOSE: HOW TO USE VITAMIN K1? | CP-229 |
| IMPLEMENTATION OF MEDICATION RECONCILIATION ON ADMISSION IN A PSYCHIATRIC HOSPITAL: WHO COMES FIRST? | CP-231 |
| ANALYSIS OF SURVIVAL IN PATIENTS DIAGNOSED WITH METASTATIC | CP-237 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CAN WE REDUCE OR AVOID DRUG CHANGES FOR CYTOSTATICS BY INCREASING THE BUFFER STOCK AT THE HOSPITAL PHARMACIES? | DD-002 |
| OPTIMISATION OF STORAGE AND UNIT DOSE DISPENSING CIRCUIT | DD-004 |
| EVALUATION OF INTERRUPTIONS DURING UNIT DOSE DRUG DISTRIBUTION SYSTEM IN AN HOSPITAL PHARMACY | DD-005 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| OFF-LABEL AND UNLICENSED PRESCRIBING IN PAEDIATRIC OUTPATIENTS WITH NEPHROTIC SYNDROME: AN INDONESIAN CONTEXT | DI-003 |
| BUSULFAN STABILITY DETERMINATION BY UHPLC-MS | DI-004 |
| SIROLIMUS FOR THE TREATMENT OF COMPLICATED VASCULAR ANOMALIES IN CHILDREN | DI-007 |
| A SYSTEMATIC LITERATURE REVIEW OF ANTIMICROBIAL STABILITY DATA IN ELASTOMERIC DEVICES | DI-010 |
| ANALYSIS OF OFF-LABEL USE IN BIOLOGICAL THERAPIES | DI-011 |
| COST PER RESPONDER TO USTEKINUMAB BASED ON THE FIRSTLINE ANTI-TNFαTREATMENT IN MODERATE-SEVERE PSORIASIS | DI-013 |
| CONTINUING USE OF OUTPATIENT PRESCRIPTION DRUGS IN PATIENTS HOSPITALISED ON A CARDIOLOGY WARD DOES NOT IMPROVE MEDICATION KNOWLEDGE | DI-014 |
| SAFETY OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING–REMITTING MULTIPLE SCLEROSIS: A RETROSPECTIVE STUDY | DI-015 |
| USE OF ARILOCUMAB AND EVOLOCUMAB: LIPID LOWERING THERAPIES | DI-016 |
| EFECTIVENESS AND SAFETY OF NEW ANTIVIRALS AGENTS IN HIV PATIENTS WITH CHRONIC HEPATITIS C | DI-019 |
| TOXIC EPIDERMAL NECROLYSIS RESULTING IN A FATAL OUTCOME CAUSED BY USE OF LAMOTRIGINE | DI-020 |
| USE AND CLINICAL EXPERIENCE OF DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA IN A TERTIARY HOSPITAL | DI-022 |
| UTILISATION STUDY OF ORAL ANTICOAGULANTS (2008-2015) AND BLEEDINGS DUE TO ANTICOAGULANT TREATMENT (2012 – 2015) | DI-023 |
| USE OF A NALOXONE TRIGGER TOOL AND MULTIDISCIPLINARY CAUSALITY ASSESSMENT TO IDENTIFY AND CONFIRM OPIOID RELATED ADVERSE DRUG EVENTS | DI-024 |
| INTRAVENOUS IMMUNOGLOBULIN INDUCED AGRANULOCYTOSIS | DI-025 |
| REASONS FOR CHANGING TREATMENT TO ORAL AGENTS IN MULTIPLE SCLEROSIS | DI-028 |
| ANALYSIS OF THE MODIFICATIONS IN ANTIRETROVIRAL TREATMENT | DI-029 |
| ANALYSIS OF TREATMENT WITH VEMURAFENIB AND DABRAFENIB IN PATIENTS WITH METASTASIC MELANOMA IN A TERTIARY HOSPITAL | DI-030 |
| PHARMACY INTERVENTION TO PROMOTE SAFER USE OF GLICLAZIDE | DI-034 |
| METRONOMIC CHEMOTHERAPY WITH ORAL VINORELBINE: EPIDEMIOLOGICAL ANALYSIS AND ECONOMIC EVALUATION | DI-036 |
| IMPACT OF SPANISH PHARMACOVIGILANCE LEGISLATION ON SUSPECTED ADVERSE DRUG REACTIONS REPORTED BY THE HOSPITAL PHARMACY SERVICE | DI-037 |
| FOSFOMYCIN TROMETAMOL USE IN A THIRD LEVEL HOSPITAL | DI-039 |
| EFFECTIVENESS OF THE COMBINATION SOFOSBUVIR AND DACLATASVIR FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | DI-044 |
| ANALYSIS OF THE USE OF INTRAVENOUS IMMUNOGLOBULINS | DI-045 |
| ANALYSIS OF TREATMENT DISCONTINUATION BY IATROGENESIS RELATED TO DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE | DI-046 |
| IMPACT OF PILL BURDEN ON DURATION OF FIRSTLINE ANTIRETROVIRAL THERAPY IN REAL LIFE SETTING | DI-047 |
| GOOD PRACTICE ON ANTIBIOTIC USE : TIGECYCLINE IN A MEDICAL INTENSIVE CARE UNIT | DI-049 |
| DEVELOPING AN INTERACTIVE TOOL TO EDUCATE PATIENTS ON GOOD MANAGEMENT OF DRUGS | DI-052 |
| ADHERENCE TO IMMUNOMODULATORY DRUGS IN PATIENTS WITH MULTIPLE MYELOMA | DI-053 |
| ARE PATIENTS ADHERENT TO THALIDOMIDE? | DI-054 |
| WRITTEN PATIENT INFORMATION: ANALYSING ITS QUALITY | DI-060 |
| CANCER ASSOCIATED THROMBOSIS: EVALUATION OF AN ANTICOAGULATION THERAPY APPROACH IN A MEDICAL ONCOLOGY SERVICE | DI-061 |
| NEW DIRECT ACTING ANTIVIRALS BASED THERAPIES IN HIV/HCV COINFECTED PATIENTS: MANAGEMENT AND EFFECTIVENESS IN A STUDY POPULATION | DI-062 |
| HERBAL MEDICINES IN CHILDREN: BETWEEN ADVICE GIVING AND SELF-MEDICATION | DI-066 |
| RETROSPECTIVE STUDY OF ALFUZOSIN 10mg PRESCRIPTIONS | DI-067 |
| GENDER DIFFERENCE IN ADVERSE DRUG REACTIONS: ANALYSIS IN ITALIAN POPULATION | DI-068 |
| CUTANEOUS TOLERANCE TO LONG TERM ANAKINRA THERAPY : REPORT OF A 9 YEAR EXPERIENCE AND REVIEW OF FRENCH PHARMACOVIGILANCE | DI-069 | |
| MEDICINE INFORMATION CLINICAL PHARMACY SERVICES: QUANTIFICATION AND CHARACTERISATION OF ENQUIRIES FROM GPS AND INVESTIGATION OF THEIR AWARENESS, EXPERIENCES AND VIEWS | DI-073 |
| EFFICACY AND SAFETY OF TRASTUZUMAB IN METASTATIC GASTRIC CANCER | DI-074 |
| EVALUATION OF PATIENTS’ NEEDS REGARDING INFORMATION ON ANTICANCER TREATMENTS DELIVERED TO OUR HEALTH INSTITUTION AS PART OF A THERAPEUTIC EDUCATION PROJECT | DI-075 | |
| CLINICAL EXPERIENCE WITH DARUNAVIR PLUS COBICISTAT COMBINATION IN HUMAN IMMUNODEFICIENCY VIRUS TREATMENT | DI-076 |
| A PHARMACEUTICAL CARE PROGRAM TO IMPROVE PAIN MANAGEMENT IN PATIENTS WITH ADVANCED PROSTATE CANCER | DI-077 |
| THERAPEUTIC MANAGEMENT OF LEAD POISONING: SATURNISM | DI-079 |
| EFFICACY IN CLINICAL PRACTICE OF NEW DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS | DI-082 |
| THE SWITCH FROM ORIGINATOR TO BIOSIMILAR GROWTH HORMONE: PATIENTS’ EXPERIENCES | DI-088 |
| OFF-LABEL DRUG USE IN ONCO-HAEMATOLOGY SETTING | DI-093 |
| REFRACTORY LANCE–ADAMS SYNDROME:: PHARMACOTHERAPY MANAGEMENT AND IIATROGENIIC COMPLIICATIIONS | DI-096 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PRACTICAL IMPLICATIONS IN SHELF-LIFE EXTENSION OF ANTICANCER ADMIXTURES | GM-001 |
| TRAINING OF HEALTH PROFESSIONALS IN THE GOOD USE OF INSULIN: SATISFACTION SURVEY | GM-002 |
| THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR CLASS IN HELTH CENTRES. A PROSPECTIVE ANALYSIS | GM-004 |
| AN ECONOMIC ANALYSIS OF THE INTRODUCTION OF A WARD BASED “DISPENSING FOR DISCHARGE” PHARMACY TECHNICIAN MEDICINES MANAGEMENT SERVICE | GM-007 |
| BUILDING A REALISTIC AND CHALLENGING CONTINUOUS PROFESSIONAL DEVELOPMENT PROGRAMME IN ONCOLOGY FOR HOSPITAL PHARMACY TECHNICIANS | GM-008 |
| ROLE AND IMPACT OF HOSPITAL PHARMACY TECHNICIAN: A LITERATURE REVIEW | GM-009 |
| CONTAMINATION WITH CYTOSTATICS IN PHARMACIES AND HOSPITALS IN THE CZECH REPUBLIC | GM-011 |
| PHARMACOECONOMICS EVALUATION OF IMPLANTATION THE SELECTIVE DIGESTIVE TRACT DECONTAMINATION FOR PREVENTION OF VENTILATOR-ASSOCIATED PNEUMONIA IN A CRITICAL CARE UNIT | GM-012 |
| PHARMACEUTICAL SUPPORT ROLE OF HOSPITAL PHARMACY DEPARTMENT IN CENTRAL ITALY EARTHQUAKE | GM-013 |
| THE ANNUAL COSTS OF PREPARING THE TOP 10 MOST COMMONLY USED INJECTABLE DRUGS AS PREFILLED SYRINGES IN A HOSPITAL PHARMACY | GM-017 |
| SHARING DRUG INFORMATION TO OPTIMISE PRESCRIBING AND ADMINISTRATION OF MEDICINES FOR HOSPITALISED PATIENTS: FROM THEORY TO DAILY PRACTICE | GM-018 |
| OPTIMISING THE SUPPLY CHAIN OF MEDICAL DEVICES: PHARMACEUTICAL CLASSIFICATION AND QUALITY MANAGEMENT | GM-020 |
| USING AN INTEGRATED INFORMATION SYSTEM TO REDUCE INTERRUPTIONS AND THE NUMBER OF NON-RELEVANT CONTACTS IN THE INPATIENT PHARMACY AT TERTIARY HOSPITAL | GM-022 |
| PERFORMANCE INDICATORS IN HOSPITAL PHARMACY: EXPERIENCE OF A TEACHING HOSPITAL WITH A DOCUMENTATION TOOL | GM-023 | |
| PERFORMANCE INDICATORS IN HOSPITAL PHARMACY: EXPERIENCE OF A TEACHING HOSPITAL WITH A DOCUMENTATION TOOL | GM-023 |
| EVIDENCES ABOUT THE ROLES AND THE IMPACT OF PHARMACISTS: AN ACTION PLAN OF INTERVENTIONS TO INCREASE PHARMACIST AWARENESS ABOUT THESE EVIDENCES | GM-025 |
| QUALITY MANAGEMENT SYSTEM IN CYTOTOXIC DRUGS LABORATORY: MONITORING ACTIVITY AND IMPROVEMENT ACTIONS | GM-026 |
| CHARACTERISTICS OF WORK INTERRUPTIONS DURING MEDICATION ADMINISTRATION | GM-029 |
| OPTIMISATION OF THE BLOOD DERIVED MEDICINES CIRCUIT BY COLLECTING AND ANALYZING NON-COMPLIANCES | GM-034 |
| CAN ADMINSTRATION TRACEABILITY OF BLOOD DERIVED MEDICINES BY PARAMEDICAL TEAM BE OPTIMAL WITHOUT INTERVENTION OF THE PHARMACEUTICAL TEAM? | GM-035 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EMPLOYEE ENGAGEMENT IN THE HEALTHCARE SECTOR | INT-003 |
| CHRONIC HEPATITIS C: INFORMATION BROCHURE FOR PATIENTS UNDER NEW DIRECT ACTING ANTIVIRALS | INT-004 |
| ADMINISTRATION OF SOLID DOSAGE FORMS TO PATIENTS WITH DYSPHAGIA OR VIA FEEDING TUBES | INT-007 |
| EFFICACY OF HYDROXYCHLOROQUINE IN PRIMARY HAND OSTEOARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL | INT-008 |
| IMPACT OF DRUGS ON HYPOGLYCEMIA IN HOSPITALIZED PATIENTS | INT-010 |
| ADR AND INTERACTIONS OF NEW DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C TREATMENT | INT-011 |
| PHARMACY BASED DOSING OF DARBEPOETIN: A RANDOMIZED CONTROLLED TRIAL IN HEMODIALYSIS PATIENTS | INT-012 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HOSPITAL PHARMACY TECHNICIANS IN FRANCE AND QUEBEC : DIFFERENCES IN TRAINING AND PRACTICE | OHP-001 | |
| COST OF TREATMENT ANALYSIS OF BIOSIMILAR AND INNOVATOR INFLIXIMAB IN A TERTIARY LEVEL HOSPITAL | OHP-002 |
| COST ANALYSIS OF THERAPY FOR PATIENTS WITH MULTIPLE SCLEROSIS THREE YEARS AGO AND NOW | OHP-003 | |
| PRESCRIPTION OF ORAL SUPPLEMENTS DURING A HOSPITALISATION PERIOD | OHP-007 | |
| LIPID EMULSION BASED EXCLUSIVELY ON OMEGA-3 FATTY ACIDS FOR ABNORMAL LIVER FUNCTIONING ASSOCCIATED WITH TOTAL PARENTERAL NUTRITION AT HOME | OHP-011 | |
| TECHNOLOGY AT THE SERVICE OF THE PHARMACIST: IDEA OF SOFTWARE TO SUPPORT THE ‘AGENZIA ITALIANA DEL FARMACO’ REGISTERS | OHP-012 | |
| SINGLE USE CANISTER FREE NEGATIVE PRESSURE WOUND THERAPY (NPWT): AN ALTERNATIVEAN ECONOMICAL ALTERNATIVE | OHP-018 | |
| EVALUATION OF EFFICACY AND SAFETY OF HEPATITIS C VIRUS TREATMENT WITH THE NEW DIRECT ACTING ANTIVIRALS IN THE CLINICAL PRACTICE OF A REGIONAL HOSPITAL | OHP-022 | |
| CONTROVERSY BETWEEN CYCLIC PARENTERAL NUTRITION AND TOTAL PARENTERAL NUTRITION | OHP-024 | |
| ANTICHOLINERGIC BURDEN CALCULATOR WEB TOOL | OHP-027 | |
| RATIONALISATION SCHEME FOR APPROPRIATE CONSUMPTION OF MEDICAL GLOVES IN A GENERAL HOSPITAL | OHP-028 | |
| EVOLUTION IN TREATMENT OF MULTIPLE SCLEROSIS IN A MEDIUM SIZED HOSPITAL | OHP-031 | |
| INVOLVEMENT OF PHARMACISTS FROM THE ALPES-MARITIMES FIRE & RESCUE SERVICES (SDIS 06) DURING THE TERRORIST ATTACK OF JULY 14, 2016 IN NICE (FRANCE) | OHP-032 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ANALYSIS OF DRUG RELATED PROBLEMS AND PHARMACIST’S RECOMENDATION OF HOSPITALISED PATIENTS WITH CHRONIC KIDNEY DISEASE AT A MAJOR TEACHING HOSPITAL IN JAKARTA | PS-006 |
| EVALUATION OF A CLINICAL DECISION SUPPORT SYSTEM (CDSS) TO OPTIMIZE CYTOTOXIC DRUG DOSING AND CONTINUOUS SURVEILLANCE IN OUTPATIENT CANCER PATIENTS WITH RENAL IMPAIRMENT | PS-010 |
| SURFACE CONTAMINATION IN A TEACHING HOSPITAL: A 6-YEAR PERSPECTIVE | PS-012 |
| MULTICENTER STUDY OF ENVIRONMENTAL CONTAMINATION WITH CYCLOPHOSPHAMIDE, IFOSFAMIDE AND METHOTREXATE IN 66 CANADIAN HOSPITALS: 2016 FOLLOW-UP STUDY | PS-013 |
| AN OBSERVATIONAL REVIEW AND AUDIT OF THE TREATMENT OF HYPOGLYCAEMIC EVENTS IN A UNIVERSITY TEACHING HOSPITAL | PS-014 |
| THE DEVELOPMENT OF A VIDEO TO DEMONSTRATE EXTEMPORANEOUS EYE DROP PREPARATION FOR USE BY COMMUNITY PHARMACISTS | PS-015 |
| MEDICATION SAFETY IN NEONATAL CARE: ANALYSIS OF HIGH-ALERT MEDICATIONS | PS-016 |
| CORRECTIVE ACTIONS AFTER PARTICIPATING IN THE STUDY MULTICENTRE WATCHING FOR DETECTION OF MEDICATION ERRORS (EMOPEM) | PS-017 |
| NATALIZUMAB DISCONTINUATION IN PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS | PS-021 |
| COMPLEX AUTOMATED MEDICATION SYSTEMS REDUCE MEDICATION ADMINISTRATION ERROR RATES IN AN ACUTE MEDICAL WARD | PS-022 |
| PHARMACEUTICAL RECOMMENDATIONS IN TRAUMATOLOGY DEPARTMENT | PS-024 |
| FEASIBILITY OF UTILIZATION AND PATIENT SATISFACTION WITH A NATIONWIDE STANDARDIZED ELECTRONIC MEDICATION PLAN | PS-029 |
| PHARMACEUTICAL INTERVENTIONS PERFORMED IN A SHORT STAY EMERGENCY SERVICE | PS-031 |
| IFOSFAMIDE INDUCED ENCEPHALOPATHY: PROPHYLAXIS AND THERAPY WITH METHYLENE BLUE | PS-033 |
| EVALUATION OF PHARMACIST INTERVENTION ON VANCOMYCINDOSING AND NEPHROTOXICITY PREVENTION | PS-035 |
| RISKS AND INEFFICIENCIES IN HOSPITALS CAUSED BY INADEQUATE PACKAGING OF ORAL MEDICATIONS | PS-036 |
| ESSENTIAL MEDICINES BY THE WORLD HEALTH ORGANISATION AND THEIR CONVENIENCE IN ELDERLY PATIENTS | PS-039 |
| MEDICATION REVIEW IN THE HOSPITAL PHARMACY: AN EVERYDAY CLINICAL PRACTICE OR WISHFUL THINKING? | PS-040 |
| FOR BETTER IATROGENIC LACTIC ACIDOSIS PREVENTION: LET’S BETTER MANAGE ITS RISK FACTORS! | PS-042 |
| ANALYSIS OF MEDICATION USE BY FRAIL ELDERLY PATIENTS WITH FREQUENT HOSPITAL ADMISSIONS | PS-045 |
| PHARMACEUTICAL INTERVENTION TO IMPROVE DOSE CALCULATION OF 4 MABS | PS-049 |
| PREDICTIVE MODEL OF HOSPITAL MORTALITY RISK OF COMPLEX CHRONIC PATIENTS OR PATIENTS WITH ADVANCED DISEASE IN A GERIATRIC CENTER | PS-054 |
| BENZODIAZEPINES AND Z-DRUGS DEPRESCRIPTION BY A MULTIDISCIPLINARY PHARMACOTHERAPY REVISION FOCUSED ON THE PATIENT | PS-055 |
| DRY GANGRENE TREATED WITH SILDENAFIL AND MEDICATION ERROR | PS-057 |
| EVALUATION OF CLINICAL PHARMACISTS’ INTERVENTIONS IN A CARDIOLOGY DEPARTMENT | PS-058 |
| IMPACT OF REMEDIAL ACTIONS AFTER A RISK ANALYSIS BY A FAILURE MODE EFFECTS AND CONSEQUENCES ANALYSIS ON PHARMACEUTICAL INTERVENTIONS IN A PAEDIATRIC HOSPITAL | PS-064 |
| STANDARDISATION IN THE PREPARATION OF INTRAVENOUS MIXTURES | PS-065 |
| TRACEABILITY INTENDED FOR PATIENTS: INVESTIGATION OF SUPPLIERS OF IMPLANTABLE MEDICAL DEVICES | PS-067 |
| ANALYSIS AND IMPROVEMENT OF PRESCRIPTION AND ADMINISTRATION IN HOSPITAL TRANSITIONS | PS-068 |
| SIMULATION TRAINING: AN INNOVATIVE AND EFFICIENT TOOL TO TEACH MEDICATION RECONCILIATION TO PHARMACY STUDENTS | PS-069 |
| A NEW SEMI-AUTOMATIC TOOL FOR ASSESSING TREATMENT PRESCRIBING BASED ON REAL TIME BLOOD TESTS | PS-071 |
| PATIENT RECORDS ANALYSIS FOR POTENTIALLY PREVENTABLE ADVERSE DRUG EVENTS LEADING TO ACUTE KIDNEY INJURY FOLLOWING A PROPENSITY MATCHED COHORT STUDY | PS-073 |
| EFFECT OF ELECTRONIC MEDICATION ADMINISTRATION RECORD APPLICATION ON PATIENT SAFETY | PS-074 |
| LONG TERM HEPATOTOXICITY OUTCOME OF ENDOTHELIN RECEPTOR ANTAGONISTS AS TREATMENT IN PULMONARY ARTERIAL HYPERTENSION | PS-077 |
| DEVELOPMENT OF RHEUMATOLOGY SHARED CARE GUIDELINES: IMPROVING TRANSITIONAL CARE | PS-078 |
| THE USE OF ATC CODES AS INDEX FOR DECISION SUPPORT IN COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEMS | PS-080 |
| DRUG RELATED RISK FACTORS AND FALLS IN HOSPITALISED OLDER ADULTS MEASURED WITH AN ELECTRONIC INCIDENCE REPORTING SYSTEM | PS-082 |
| MEDICATION REVIEW AND MEDICATION RECONCILIATION: MOST FREQUENT ERRORS IN ELDERLY POLYMEDICATED PATIENTS | PS-083 |
| NEGATIVE RESULTS ASOCCIATED WITH TNF ANTAGONISTS IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS | PS-084 |
| THE IMPACT OF A CLINICAL PHARMACIST’S CONSULT ON DOCTORS MANAGEMENT OF DRUG-DRUG INTERACTIONS WITH POTENTIAL QT PROLONGATION IN AN INTERNAL MEDICINE WARD | PS-088 |
| PROTOCOL BASED USE OF POTASSIUM BINDERS IN INTERNAL MEDICINE WARDS IS ASSOCIATED WITH DECREASE IN TREATMENT RELATED ADVERSE REACTIONS | PS-089 |
| THE EFFECTIVENESS OF NEW DIRECT ACTING ANTIVIRALS IN THE TREATMENT OF CHRONIC HEPATITIS C IN PREVIOUSLY TREATED PATIENTS | PS-090 |
| MEDICATION INDUCED SIADH: DISTRIBUTION AND CHARACTERIZATION ACCORDING TO MEDICATION CLASS | PS-091 |
| COLLABORATIVE EFFORT WITHIN A MULTIDISCIPLINARY HEART FAILURE TEAM | PS-093 |
| PHARMACEUTICAL VALIDATION OF MEDICATION ORDERS IN AN EMERGENCY DEPARTMENT OBSERVATION UNIT. RECOMMENDATIONS AND DEGREE OF ACCEPTANCE. | PS-094 |
| ANALYSIS OF MATERIOVIGILANCE BOTTOM UP ALERTS RELATED TO MEDICAL PERFUSION DEVICES | PS-095 |
| METHADONE AND LEVOMETHADONE: RISKS AND COSTS ANALYSES | PS-096 |
| A COMPARATIVE STUDY BETWEEN INVESTIGATOR SAFETY DATA AND A PHARMACOVIGILANCE DATABASE: A KEY ROLE OF THE PHARMACOVIGILANT IN THE RELEVANCY OF CLINICAL TRIAL PUBLICATIONS | PS-097 |
| REORGANIZATION OF MEDICATION CIRCUIT IN THE OPERATING AND DELIVERY ROOM | PS-098 |
| PROTOCOLISED MEDICATION AFTER DISCHARGE FROM AN EMERGENCY DEPARTMENT | PS-100 |
| OPTIMIZATION OF THE DRUG PRESCRIPTION PROCESS IN PATIENT ADMISSION | PS-103 |
| MEDICATION RECONCILIATION : WHICH SELECTION CRITERIA IN PSYCHIATRY? | PS-104 |
| LOOK-ALIKE AND SOUND-ALIKE DRUG INCIDENTS IN A HOSPITAL: A RETROSPECTIVE ANALYSIS | PS-106 |
| DOES THE COMPLETION OF A RISK ASSESSMENT TEMPLATE IMPROVE THE RATE OF APPROPRIATE VENOUS THROMBOEMBOLISM RISK MANAGEMENT FOR HOSPITALISED MEDICAL PATIENTS? | PS-108 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| VANCOMYCIN INTRAPERITONEAL IN PEDIATRIC PATIENTS: NEED TO MONITOR PLASMA LEVELS | PKP-001 |
| CONTINUOUS INFUSION VANCOMYCIN, A CASE REPORT | PKP-002 |
| INFLUENCE OF CYTARABINE METABOLIC PATHWAY POLYMORPHISMS IN EFFECTIVENESS OF ACUTE MYELOID LEUKAEMIA INDUCTION TREATMENT | PKP-003 |
| DETERMINATION OF GENETIC POLYMORPHISMS AFFECTING METABOLISM OF THIOPURINES | PKP-005 |
| PHARMACIST’S ROLE IN CLINICAL PHARMACOKINETIC MONITORING OF DIGOXIN: MINIMISING TOXIC EFFECTS | PKP-006 |
| DPYD SNPs AND DISEASEE FREE SURVIVAL AFTER CAPECITABINE-BASED ADJUVANT TREATMENT | PKP-007 |
| IMPLEMENTATION OF A MONITORING PROTOCOL FOR DIGOXIN | PKP-008 |
| RELATION BETWEEN CLINICAL REMISSION AND TROUGH INFLIXIMAB LEVELS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE | PKP-009 | |
| RELATION BETWEEN CLINICAL REMISSION AND TROUGH INFLIXIMAB LEVELS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE | PKP-009 |
| LEVETIRACETAM CLINICAL PHARMACOKINETICS IN ELDERLY PATIENTS WITH EPILEPSY | PKP-010 |
| METHOTREXATE LEVELS IN CEREBROSPINAL FLUID IN CHILDREN TREATED WITH HIGH-DOSE METHOTREXATE | PKP-012 |
| REVIEW OF SAFETY OUTCOMES OF MULTIPLE DAILY DOSIN OF AMIKACIN IN PAEDIATRIC FEBRILE NEUTROPENIC PATIENTS WITH CANCER | PKP-015 |
| DOXORUBICIN PLASMA DETERMINATION BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY | PKP-017 |
| COMPARISON BETWEEN ASSAYS ON THE THERAPEUTIC DRUG MONITORIN OF EVEROLIMUS | PKP-018 |
| EXPERIENCE OF ONCE DAILY TACROLIMUS INDIVIDUALISED DOSING THROUGH A BAYESIAN APPROACH IN THE NOVO LIVER TRANSPLANT RECIPIENTS | PKP-019 |
| GENETIC POLYMORPHISMS ASSOCIATED WITH COLORECTAL CANCER RISK | PKP-044 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HYPROMELLOSE PROLONGS THE DISSOLUTION OF KETAMINE OUT OF GELATINE CAPSULES | PP-001 |
| STABILITY STUDY OF BORTEZOMIB (VELCADE) WITH LIMIT TEST FOR ALL DEGRADATION PRODUCTS | PP-003 | |
| CHEMICAL CONTAMINATIONS: UNDERSTAND TO PREVENT | PP-004 |
| IMPROVING SAFE PREPARATION OF INJECTABLE MEDICINES: THE EFFECTS OF INTRODUCING A SPORICIDAL AGENT | PP-005 |
| GALENIC PROPERTIES OF PLASMA RICH IN GROWTH FACTORS EYE DROPS | PP-006 |
| STABILITY AND STERILITY OF AUTOLOGOUS SERUM-EYE-DROPS AFTER LONG-TERM STORAGE | PP-008 |
| STABILITY OF INTRAVEOUS INJECTION OF DECITABINE STORED IN POLYETHYLENE SYRINGES | PP-009 |
| EOSIN WITH ZINC COMBINATION FOR THE TREATMENT OF DIAPER RASH. A STABILITY STUDY | PP-010 |
| EOSIN WITH ALLANTOIN MIXTURE FOR THE TREATMENT OF PERIOSTOMAL ULCERS. A STABILITY STUDY | PP-011 |
| CONSERVING COLD CHAIN COMPLIANCE IN THE RECONSTITUTION OF VIDAZA® IN ISOLATORS | PP-012 |
| LONG TERM STABILITY OF 5-FLUOROURACIL AT STANDARDISED ROUNDED DOSES IN SODIUM CHLORIDE INFUSION POLYOLEFIN BAGS, STORED AT ROOM TEMPERATURE | PP-013 |
| STABILITY STUDY OF 10 MG/ML PEDIATRIC CYCLOSPORINE SOLU8ON IN OLIVE OIL | PP-014 |
| PHYSICOCHEMICAL AND MICROBIOLOGICAL STABILITY OF A NEW PAEDIATRIC ORAL SOLUTION OF CLONIDINE | PP-017 |
| LONG TERM STABILITY OF 5-FLUOROURACILE AT STANDARDISED ROUNDED DOSES IN TWO TYPES OF PORTABLE INFUSION DEVICES | PP-018 |
| MANIPULATION AND FORMULATION – THE TALE OF TWO ASPIRIN TABLETS | PP-019 |
| NEW VERSATILE DIFFUSION CELL FOR RAPID AND HANDY PERMEABILITY ASSESSMENTS IN EXPERIMENTAL MEDICINE DEVELOPMENT IN HOSPITAL PHARMACY | PP-020 |
| EVALUATION OF THE SURFACE CONTAMINATION IN A CHEMOTHERAPY PREPARATION UNIT BEFORE A PROCESS CHANGE | PP-021 |
| CONCENTRATION ACCURACY ASSESSMENT OF KETAMINE, REMIFENTANIL AND SUFENTANIL SYRINGES PREPARED IN THE PAEDIATRIC SURGERY UNIT | PP-022 |
| HOW TO IMPLEMENT IV ROBOTICS IN GMP ASEPTIC PRODUCTION | PP-024 |
| INTRANASAL BEVACIZUMAB TREATMENT ON EPISTAXIS IN HEREDITARY HAEMORRHAGIC TELANGIECTASIA: A CASE REPORT | PP-026 |
| STABILITY OF FROZEN 1% VORICONAZOLE EYE DROPS IN GLASS AND IN INNOVATIVE CONTAINERS | PP-029 |
| HAZARDOUS DRUGS: ANALYSIS OF CONSISTENCY WITH NEW RECOMMENDATIONS | PP-031 |
| ACPP PROTOCOL (ANTICIPATED CIRCUIT OF ANTICANCER INTRAVENOUS CHEMOTHERAPIES PRESCRIPTION AND PREPARATION IN A DAY HOSPITAL): OBSERVATIONAL STUDY ASSESSING THE IMPACT OF THE NEW WORKFLOW FOR HOSPITAL PHARMACY | PP-032 |
| “IMPLEMENTATION OF BACT/ALERT (BIOMERIEUX) CULTURE BOTTLES IN A HOSPITAL PHARMACY PRODUCTION UNIT FOR THE STERILITY TESTING OF CHEMOTHERAPEUTIC BATCHES” | PP-033 | |
| CLOSED SYSTEM TRANSFER DEVICE (CSTD) EVALUATION: SURFACE WIPE STUDY TO MEASURE EXPOSURE OF HEALTHCARE PERSONNEL TO CHEMOTERAPY AGENTS | PP-037 |
| IMPACT OF MASKING OF METHYLPHENIDATE DISSOLUTION FOR OVER ENCAPSULATED CAPSULES OF RITALIN LA 10 MG | PP-039 |
| EVALUATION OF THERAPY MANAGEMENT FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN A CENTRALISED INTRAVENOUS COMPOUNDING FACILITY | PP-040 |
| CENTRALISED NON-HAZARDOUS INTRAVENOUS COMPOUNDING: FROM THEORY TO CLINICAL PRACTICE | PP-041 |
| CENTRALISED NON-HAZARDOUS INTRAVENOUS COMPOUNDING: FROM THEORY TO CLINICAL PRACTICE | PP-041 | |
| STABILITY OF 50 AND 100μG/0.1ML INTRAOCULAR SOLUTIONS OF VORICONAZOLE AT 2-8°C | PP-044 |
| A STABILITY INDICATING HPLC-UV METHOD FOR QUANTIFICATION OF SIMVASTATIN AND DETECTION OF ITS IMPURITIES IN ORAL CAPSULES | PP-046 |
| AUTOMATED INTRAVENOUS CHEMOTHERAPY WORKFLOW: THE ADDED BENEFIT TO REDUCE POTENTIAL MEDICATION ERRORS | PP-047 |
| ANTINEOPLASIC: ANTICIPATED PREPARATIONS OR LONGER OPENING HOURS? | PP-048 |
| IMPACT OF IMMUNOTHERAPY ARRIVAL IN CHEMOTHERAPY PRODUCTION UNITS : RETROSPECTIVE STUDY AND PROJECTION WITH ANTI-PD-1 AGENTS | PP-049 |
| CYTOTOXIC CONTAMINATION RESEARCH IN A CENTRALISED CYTOTOXIC UNIT TO IMPROVE PROFESSIONAL PRACTICES | PP-051 |
| STABILITY STUDY OF 100 MG/ML PAEDIATRIC PYRAZINAMIDE ORAL SUSPENSION IN SYRSPEND | PP-054 |
| PHARMACEUTICAL QUALIFICATION OF BIOINVERT® 200, AN ENZYME SUBSTITUTE TO SUCRAID® | PP-057 |
| EVOLUTION OF THE PAEDIATRIC PARENTERAL NUTRITION BAG PRESCRIPTIONS FURTHER TO THE NUMETAH (THREE CHAMBER BAG) MARKETING | PP-058 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| DEPRESCRIBING PSYCHOACTIVE MEDICATION FOR GERIATRIC PATIENTS IN A MULTIDISCIPLINARY WAY | CP-003 |
| KETOCONAZOLE AND PERFORMANCE STATUS AS PREDICTIVE FACTORS OF RESPONSE TO ABIRATERONE IN METASTASIC PROSTATE CANCER IN REAL LIFE CONDITIONS | CP-006 |
| SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS FORMULATION OF ABATACEPT IN A REAL WORLD SETTING | CP-007 |
| DEOXYNUCLEOTIDES DTMP AND DCMP IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY BY MUTATIONS ON THE TK2 GENE | CP-008 |
| IMPACT OF CONCILIATION IN INSTITUTIONALISED GERIATRIC PATIENTS | CP-009 |
| PHYSICIANS’ ACCEPTANCE RATE OF PHARMACY INTERVENTIONS IN HOSPITALISED PATIENTS IN AN ABDOMINAL SURGERY WARD IN A GENERAL HOSPITAL | CP-010 |
| PARENTERAL NUTRITION IN ABDOMINAL SURGERY: IMPROVEMENT IN 2014? | CP-012 |
| IMPACT OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW | CP-013 |
| IMPACT OF DISCHARGE PHARMACEUTICAL COUNSELLING ON PATIENT ADHERENCE TO ANTIINFECTIVE TREATMENT | CP-014 |
| AN EVALUATION OF THE TYPES AND CONTRIBUTING FACTORS OF DISPENSING ERRORS IN HOSPITAL PHARMACY | CP-015 |
| RECONFIGURATION TO SINGLE BED WARDS: QUANTIFICATION OF THE TIME IMPACT ON THE WARD BASED CLINICAL PHARMACY SERVICE | CP-017 |
| OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT) – A QUALITATIVE STUDY OF PATIENT PERSPECTIVES IN THOSE CHOOSING NOT TO SELF-ADMINISTER | CP-018 |
| EFFICACY AND SAFETY OF INTERFERON ALPHA 2A IN THE TREATMENT OF LARYNGEAL PAPILLOMATOSIS: A CASE REPORT | CP-019 |
| NATIONALLY AGREED STANDARDS FOR WARD PHARMACY SERVICES – HOW ARE WE DOING? | CP-022 |
| INTRODUCTION OF A PRESCRIPTION CHART FOR PERIPROCEDURAL BRIDGING ANTICOAGULATION | CP-023 |
| INTRAVENTRICULAR COLISTIN FOR THE TREATMENT OF EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII MENINGITIS: A CASE REPORT | CP-025 |
| A NEW MANAGEMENT OF PERISTOMAL DERMATITIS: A PILOT STUDY | CP-026 |
| DEVELOPMENT OF A STROKE PATHWAY PHARMACY TEAM TO SUPPORT REABLEMENT AND MEDICATION OPTIMISATION | CP-027 |
| SOFOSBUVIR/LEDIPASVIR USE FOR HEPATITIS C VIRUS TREATMENT: OUR CLINICAL EXPERIENCE | CP-028 |
| HOW TO DEAL WITH A NEW DRUG INTERACTION? EXAMPLE OF THE CONTRAINDICATION ALFUZOSIN– STRONG CYP3A4 INHIBITORS | CP-029 |
| 25 YEARS OF CHRONIC HEPATITIS C: FROM DISCOVERY TO CURE. RETROSPECTIVE ANALYSIS OF A COHORT OF PATIENTS | CP-030 |
| CLINICAL USE OF LENALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA | CP-031 |
| SUSTAINED REMISSION OF IMMUNE THROMBOCYTOPENIA WITH THE USE OF ELTROMBOPAG | CP-032 |
| EVALUATION OF SOFOSBUVIR PLUS DACLATASVIR COMBINATION FOR HEPATITIS C VIRUS TREATMENT | CP-033 |
| ECONOMIC IMPACT OF THE INTRODUCTION OF A COMPOUNDED 50 MG/ML MERCAPTOPURINE SUSPENSION IN A TEACHING HOSPITAL | CP-034 |
| ECONOMIC IMPACT OF AFLIBERCEPT OPTIMISATION FOR THE TREATMENT OF AGE RELATED MACULAR DEGENERATION REFRACTORY TO BEVACIZUMAB AND/ OR RANIBIZUMAB | CP-035 |
| COST AND DOSAGE OF BIOLOGICAL THERAPIES IN CLINICAL PRACTICE OF RHEUMATIC DISEASES | CP-036 |
| CO-MEDICATION IN AN INFECTIOUS DISEASES CLINIC: THE RATE OF CO-MEDICATION OMISSIONS AND THE SIGNIFICANCE OF INTERACTIONS BETWEEN COMEDICATIONS AND ANTIRETROVIRALS | CP-038 |
| CREATION OF A SCORE TO ASSESS PATIENTS’ KNOWLEDGE ABOUT ADVERSE EVENTS OF LONG TERM CORTICOTHERAPY | CP-043 |
| INTERVENTIONS TO DECREASE THE MULTIDRUG RESISTANT BACTERIAS IN THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS | CP-044 |
| ROLE OF THE CLINICAL PHARMACIST IN THERAPEUTIC OPTIMISATION OF BIOLOGIC MOLECULES IN RHEUMATOLOGY, GASTROENTEROLOGY AND DERMATOLOGY | CP-045 |
| ANALYSIS OF DRUG-DRUG INTERACTIONS DURING HOSPITALISATION AT A UNIVERSITY HOSPITAL | CP-046 |
| IMPACT OF PHARMACEUTICAL INTERVENTIONS IN DIGOXIN DOSE ADJUSTMENT ACCORDING TO STOPP/ START CRITERIA | CP-047 |
| PHARMACOKINETIC ENHANCERS (COBICISTAT/ RITONAVIR) AND THE POTENTIAL FOR DRUG-DRUG INTERACTIONS (AN AUDIT OF PATIENTS ATTENDING A BUSY OUTPATIENT HIV SERVICE) | CP-048 |
| EFFECTIVENESS OF SOFOSBUVIR BASED INTERFERON FREE TREATMENT REGIMENS FOR CHRONIC HEPATITIS C VIRUS INFECTION | CP-049 |
| A COMPLIANCE WITH DIABETES MELLITUS TREATMENT STUDY IN THE CASE OF POLYMEDICATION | CP-050 |
| AN AUDIT TO DETERMINE THE IMPACT OF PHARMACIST MEDICATION RECONCILIATION ON DISCHARGE (MROD) WITHIN A TERTIARY CARDIAC CENTRE | CP-051 |
| CHRONIC KIDNEY DISEASE: DOSAGE ADJUSTMENT OF EPOETIN b AND DARBEPOETIN a | CP-052 |
| CONDITIONS OF USE OF ELVITEGRAVIR/COBICISTAT/ EMTRICITABINE/TENOFOVIR IN PATIENTS WITH HIV | CP-053 |
| VALIDATION OF SOME INDICATORS FOR MONITORING THE QUALITY OF RECONCILIATION OF MEDICATION WITHIN THE SURGERY UNIT | CP-054 |
| THE CLINICAL PHARMACIST RESOLVES MEDICATION RELATED PROBLEMS IN CRANIO, MAXILLOFACIAL AND ORAL SURGERY PATIENTS | CP-055 |
| PERSISTENCE OF BIOLOGICAL TREATMENT WITH INFLIXIMAB, ADALIMUMAB AND ETANERCEPT IN PATIENTS WITH SPONDYLOARTHROPATHY | CP-056 |
| PARTIAL ECONOMIC EVALUATION OF PHARMACEUTICAL INTERVENTIONS ON THE PRESCRIPTION OF DIRECT ORAL ANTICOAGULANTS IN A TEACHING HOSPITAL | CP-057 |
| IDENTIFICATION OF KEY AREAS FOR ANTIMICROBIAL STEWARDSHIP STRATEGIES IN A LARGE UNIVERSITY TEACHING HOSPITAL: A POINT PREVALENCE STUDY | CP-058 |
| EVALUATION OF TREATMENT WITH NATALIZUMAB THERAPY ON TRIPLE RISK PATIENTS REGARDING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | CP-059 |
| EFFECTIVENESS AND SAFETY OF FERRIC CARBOXYMALTOSE TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES | CP-060 |
| RETROSPECTIVE EVALUATION OF THE CLINICAL USE OF PROTHROMBIN COMPLEX CONCENTRATE FOR THE REVERSAL OF ORAL ANTICOAGULATION | CP-061 |
| DOSE REDUCTION AND DISCONTINUATION OF CHEMOTHERAPY IN CANCER PATIENTS EXPERIENCING DRUG-DRUG INTERACTIONS | CP-065 |
| DECREASED INR AFTER ACENOCOUMAROL AND OMBITASVIR/PARITAPREVIR/RITONAVIR COADMINISTRATION | CP-066 |
| INTRA-ARTICULAR METHOTREXATE IN THE TREATMENT OF A BAKER`S CYST | CP-068 |
| EVALUATION OF THE EFFECTIVENESS OF FAMPRIDINE AND COMPARISON WITH A CLINICAL TRIAL | CP-069 |
| COST-BENEFIT ANALYSIS OF VACCINE REJECTION: A TETANUS CASE | CP-070 |
| MIDODRINE IN REFRACTORY CHYLOTHORAX AFTER PAEDIATRIC CARDIAC SURGERY | CP-071 |
| CARDIOVASCULAR RISK ASSOCIATED WITH THE USE OF NON STEROIDAL ANTI-INFLAMMATORY DRUGS. COHORT STUDY | CP-072 |
| APPLICATION OF PARETO’S ANALYSIS ON HOSPITAL’S DISCHARGE DRUGS DISTRIBUTION | CP-074 |
| MULTIPLE SCLEROSIS THERAPY AT MACERATA’S GENERAL HOSPITAL: ECONOMIC IMPACT | CP-075 |
| ABCIXIMAB IN REFRACTORY KAWASAKI DISEASE | CP-076 |
| USE OF TRANEXAMIC ACID IN ORTHOPAEDIC SURGERY | CP-077 |
| OPTIMISATION OF BIOLOGICAL THERAPY IN ESTABLISHED RHEUMATOID ARTHRITIS PATIENTS IN REAL LIFE CLINICAL PRACTICE | CP-078 |
| CHRONIC MYELOID LEUKAEMIA AND MEDICATION ADHERENCE WITH IMATINIB. IS THERE A CUT OFF? | CP-079 |
| NUTRITIONAL SCREENING IN ONCOLOGY OUTPATIENS TREATED WITH ORAL ANTINEOPLASTIC DRUGS IN A PHARMACEUTICAL CARE CONSULTATION | CP-081 |
| OPTIMISED USE OF TUMOUR NECROSIS FACTOR INHIBITORS IN RHEUMATOLOGY | CP-082 |
| PERSISTENCE OF FIRSTLINE BIOLOGICAL AGENTS AMONG PSORIASIS PATIENTS | CP-083 |
| THE IMPACT OF PHARMACIST INTERVENTIONS ON SAFETY AND COST SAVINGS | CP-085 |
| TREATMENT OF CHRONIC HEPATITIS C WITH DIRECT ACTION ANTIVIRALS. PRELIMINARY RESULTS | CP-086 |
| USE AND EFFECTIVENESS OF PALIVIZUMAB FOR IMMUNOPROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS | CP-087 |
| ‘START SMART’: IMPROVING THE QUALITY OF EMPIRIC ANTIMICROBIAL PRESCRIBING IN A TERTIARY CHILDREN’S HOSPITAL SETTING | CP-089 |
| ADEQUACY OF OMEPRAZOLE SOLUTION PRESCRIPTION FOR ADMINISTRATION BY NASOGASTRIC TUBE APPLYING A CONTINUOUS IMPROVEMENT SYSTEM (DEMING CYCLE) | CP-090 |
| ANALYSIS OF OFF-LABEL USE OF LEVOSIMENDAN IN PAEDIATRICS | CP-091 |
| CLINICAL AND ECONOMIC OUTCOMES OF FIXED DOSE COFORMULATION RUPTURE IN HIV INFECTED PATIENTS | CP-093 |
| COMMUNICATION AMONG CENTRALISED HEALTH SERVICE AND HOSPITAL PHARMACY: WHAT CAN WE IMPROVE? | CP-094 |
| EVALUATING THE APPROPRIATENESS OF ANTIBIOTIC THERAPY: ROLE OF THE HOSPITAL PHARMACIST IN THE ANTIMICROBIAL STEWARDSHIP | CP-095 |
| FINAL RESULTS OF EFFECTIVENESS AND SAFETY OF DIRECT ACTING ANTIVIRAL AGENTS IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION | CP-096 |
| IMPACT OF DIRECT ACTING ANTIVIRALS FOR HEPATITIS C IN ANTIRETROVIRAL THERAPY IN CO-INFECTED PATIENTS | CP-097 |
| SIMEPREVIR AND SOFOSBUVIR FOR TREATMENT OF CHRONIC INFECTION WITH HEPATITIS C VIRUS | CP-101 |
| PHARMACEUTICAL CARE MONITORING OF HEPATITIS C OUTPATIENTS: GUARANTEEING SAFETY AND EFFICIENCY | CP-102 |
| ADHERENCE TO DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS | CP-104 |
| EMILIA ROMAGNA REGIONAL PROJECT CONCERNING PHARMACOVIGILANCE OF DRUG INTERACTIONS IN POLYTREATED ELDERLY PATIENTS | CP-105 |
| A CASE STUDY OF SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: ALTERNATIVE TREATMENT TO TOLVAPTAN WITH UREA AND SODIUM CHLORIDE | CP-106 |
| BIOSIMILARS: WHAT DO CLINICIANS ACTUALLY THINK? | CP-108 |
| MAXIMSING PHARMACISTS’ EFFICIENCY AND IMPROVING PATIENT CARE IN CANCER OUTPATIENT CLINICS | CP-110 |
| NEW DIRECT ANTIVIRAL AGENTS IN HEPATITIS C: PRELIMINARY RESULTS IN CLINICAL PRACTICE | CP-112 |
| SECOND GENERATION DIRECT ACTING ANTIVIRAL AGENTS IN POST-TRANSPLANT HEPATITIS C VIRUS INFECTION RECURRENCE: REAL CLINICAL PRACTICE | CP-115 |
| DRUG USE EVALUATION OF HEPARINS PRESCRIBED AS A ‘SINGLE DOSE’ IN HOSPITAL | CP-116 |
| RISKS OF SURGICAL INTERVENTION IN PATIENTS TAKING ORAL ANTICOAGULANTS | CP-117 |
| DETAILED DOCUMENTATION IN CLINICAL PHARMACY – TOO MUCH EFFORT? | CP-120 |
| ANALYSIS OF THE USE OF ANTIDOTES IN A UNIVERSITY HOSPITAL | CP-121 |
| FIRST CYCLE NEUTROPENIA AND RELATIVE DOSE INTENSITY IN LOCALISED BREAST CANCER PATIENTS TREATED WITH AN ADJUVANT AC PROTOCOL FOLLOWED BY WEEKLY PACLITAXEL | CP-122 |
| THE EFFECT OF A PHARMACIST LED INHALER TECHNIQUE ASSESSMENT, EDUCATION AND TRAINING INTERVENTION ON ASTHMA CONTROL TEST SCORES IN A PAEDIATRIC HOSPITAL OUTPATIENT SETTING | CP-125 |
| INNAPPROPRIATE PRESCRIBING IN ELDERLY PATIENTS ATTENDING THE EMERGENCY ROOM | CP-127 |
| EXPERIENCE OF USE IN HOSPITAL WITH SOFOSBUVIR: EFFICACY AND SAFETY OF TREATMENT | CP-128 |
| IMPACT OF PHARMACEUTICAL INTERVENTIONS IN A MEDICINE DEPARTMENT | CP-132 |
| A PHARMACOECONOMIC EVALUATION IN THE THERAPY EVOLUTION SETTING OF RENAL CELL CARCINOMA | CP-133 |
| ANALYSYS OF THERAPEUTIC RESPONSE AND TOLERABILITY IN PATIENTS TREATED WITH CRIZOTINIB IN ALK POSITIVE NSCLC | CP-134 |
| MONITORING AND RATIONALISATION OF ANTIBIOTICS PRESCRIBED IN HOSPITALS | CP-135 |
| INVASIVE FUNGAL INFECTIONS: OBSERVATIONAL STUDY IN TWO HOSPITALS IN ITALY (TURIN) AND FRANCE (PARIS) | CP-137 |
| ANALYSIS OF EFFECTIVENESS, SAFETY AND ADHERENCE IN PATIENTS SWITCHING TO EMTRICITABINE/RILPIVIRINE/TENOFOVIR | CP-140 |
| ERIBULIN USE IN METASTATIC BREAST CANCER | CP-141 |
| ONE STOP DISPENSING: MEDICATION-ECONOMIC PERSPECTIVES ON SELF-ADMINISTRATING ELECTIVE GASTRIC SURGERY PATIENTS | CP-142 |
| THE CHANGE IN USE OF CALCINEURIN INHIBITORS IN KIDNEY TRANSPLANT RECIPIENTS AND ITS EFFECT ON SHORT TERM GRAFT AND PATIENT OUTCOMES | CP-143 |
| DRUG INTERACTIONS WITH DIRECT ACTING ANTIVIRALS FOR HEPATITIS C: WHAT ABOUT IN PRACTICE? PHARMACEUTICAL IMPACT | CP-146 |
| PHARMACIST INTERVENTION AND ITS DOCUMENTATION IN THE COMPUTERISED MEDICAL RECORD IN SAP | CP-147 |
| IMPACT ON DRUG ADHERENCE AND VIRAL LOAD AFTER PHARMACEUTICAL INTERVENTION IN SELECTED HEPATITIS B OUTPATIENTS | CP-148 |
| REDESIGN OF THE MANAGEMENT MODEL AND PHARMACEUTICAL CARE OF PATIENTS WITH HEPATITIS C VIRUS INFECTION | CP-149 |
| EFFICACY OF 4, 12 AND 24 WEEKS OF TREATMENT WITH LEDIPASVIR/SOFOSBUVIR, SIMEPREVIR, SOFOSBUVIR, SOFOSBUVIR/SIMEPREVIR AND SOFOSBUVIR/DACLATASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS | CP-151 |
| APPLYING THE RESULTS FROM THE TOGA TRIAL INTO CLINICAL PRACTICE: DATA FROM THE AGAMENON MULTICENTRE STUDY | CP-152 |
| ACUTE CORONARY SYNDROME IN A PATIENT RECEIVING ROMIPLOSTIM | CP-154 |
| USE AND SAFETY PROFILE OF ORAL MEDICATION BEFORE SECONDLINE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS | CP-155 |
| PRESCRIBING PATTERN, TOLERABILITY AND EFFICACY STUDY (4 WEEKS) OF THE NOVEL DRUG ‘XIAPEX’ | CP-1566 |
| ANALYSIS OF THE EXPENDITURE ON THE TREATMENT OF HEPATITIS C VIRUS IN 2015 | CP-157 |
| UNCRITICAL USE OF PROTON PUMP INHIBITORS IN NON-INTENSIVE CARE UNITS OF A UNIVERSITY HOSPITAL | CP-158 |
| DIRECT ACTING ANTIVIRALS (DAAS) FOR THE TREATMENT OF HCV INFECTION IN HIV/HCV COINFECTED PATIENTS: A CLINICAL EXPERIENCE | CP-159 |
| CLINICAL PHARMACIST INTERVENTIONS IN THE CRITICAL PATIENT: EVOLUTION OF A 4 YEAR PROJECT | CP-160 |
| INCIDENCE OF ABNORMALITIES OF URINARY DIPSTICK TESTS IN PATIENTS RECEIVING BIOTHERAPIES | CP-161 |
| ANALYSIS OF THE SIDE EFFECTS AND THE TREATMENT DISCONTINUATION OF DIMETHYL FUMARATE IN A TERTIARY HOSPITAL | CP-163 | |
| QUALITY PERCEIVED BY THE PATIENTS OF A PHARMACEUTICAL CARE CONSULTATION AND STEPS TAKEN TO IMPROVE IT | CP-166 | |
| EFFECTIVENESS OF THE NEW DIRECT-ACTING ANTIVIRAL AGENTS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 | CP-167 | |
| OBESE PATIENTS: ARE DOSE ADJUSTMENTS FOR TREATMENT OF COMORBIDITIES USED? | CP-168 | |
| EFFECTIVENESS OF BIOSIMILAR FILGRASTIM VS ORIGINAL GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) IN FEBRILE NEUTROPENIA PREVENTION IN BREAST CANCER PATIENTS RECEIVING DOCETAXEL/DOXORUBICIN/CYCLOPHOSPHAMIDE (TAC) | CP-169 | |
| USE OF ERIBULIN IN METASTASIC BREAST CANCER | CP-171 |
| TYROSINE KINASE INHIBITORS IN THE TREATMENT OF RENAL CELL CARCINOMA IN ROUTINE CLINICAL PRACTICE | CP-172 | |
| TOPICAL 0.1% RAPAMYCIN FOR ANGIOFIBROMAS IN A PAEDIATRIC PATIENT WITH TUBEROUS SCLEROSIS | CP-173 |
| THERAPY EDUCATION PROGRAMME IN HEART FAILURE – 3 YEAR EVALUATION | CP-174 | |
| THE VALUE ADDED BY THE PHARMACIST : DRUG-DRUG INTERACTIONS ANALYSIS IN MULTIDISCIPLINARY MEETING FOR HEPATITIS C | CP-175 |
| THE HOSPITAL PHARMACIST AS A MEMBER OF A MULTIDISCIPLINARY TEAM IN PERIOPERATIVE MANAGEMENT OF CHRONIC MEDICATION | CP-176 | |
| PATIENTS EXCEEDING DOXORUBICIN RECOMMENDED CUMULATIVE DOSE | CP-179 | |
| QUALITY OF ARTIFICIAL NUTRITION SUPPORT IN AN INTENSIVE CARE UNIT | CP-180 | |
| PROFILE OF USE OF A MUCOSITIS COMPOUNDED SUSPENSION IN PATIENTS AFFECTED WITH MUCOSITIS | CP-181 | |
| PHARMACEUTICAL VALIDATION OF TREATMENTS: FROM THE PHARMACY OR AT THE HOSPITAL WARDS? | CP-182 |
| OVARIAN STIMULATION IN ASSISTED REPRODUCTION TECHNIQUES | CP-183 | |
| THE IMPORTANCE OF ASSESSING ASYMPTOMATIC BACTERIURIA IN HOSPITALISED PATIENTS | CP-185 | |
| CAN THE ANTIRETROVIRAL THERAPY EFFECTIVENESS BE CONNECTED WITH TREATMENT SIMPLIFICATION? | CP-186 | |
| KNOWLEDGE OF HIV INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY AND HIV INFECTION | CP-187 | |
| INTRA-ABDOMINAL INFECTIONS IN DIGESTIVE SURGERY WARDS: IS EMPIRIC ANTIBIOTIC TREATMENT IN ACCORDANCE WITH LOCAL MICROBIOLOGICAL ECOLOGY? | CP-188 | |
| INCIDENCE AND RISK FACTORS ASSOCIATED WITH TREATMENT FAILURE IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY | CP-190 | |
| IMPACT OF MEDICATION RECONCILIATION AT HOSPITAL ADMISSION IN SURGICAL PATIENTS | CP-191 | |
| DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH CHRONIC LIVER DISEASE: A SNAPSHOT BY CLINICAL PHARMACIST | CP-193 | |
| CONTRIBUTION OF CLINICAL PHARMACIST IN AN EXPERIENCE FEEDBACK COMMITTEE: OUTCOMES AT 9 MONTHS OF ANALYSIS OF DRUG PRESCRIPTIONS FOR PATIENT ‘FALLERS’ | CP-195 | |
| IVERMECTIN ENEMA ELABORATION FOR THE TREATMENT OF STRONGYLOIDES HYPERINFECTION | CP-197 | |
| EFFECTIVENESS AND SAFETY OF ECULIZUMAB IN ATYPICAL HAEMOLYTIC URAEMIC SYNDROME ANDTHROMBOTIC MICROANGIOPATHY | CP-199 | |
| RISK MANAGEMENT IN CIRCUIT OF MEDICATION: WHAT ROLE OF PHARMACIST | CP-201 | |
| SAFETY AND EFECTIVENESS OF TOPICAL 10% NACETYLCYSTEINE NACETYLCYSTEINE CONGENITAL LAMELLAR ICHTYOSIS AND EPIDERMOLYTIC ICHTYOSIS IN CHILDREN | CP-202 | |
| THERAPEUTIC OPTIMISATION OF ELDERLY PRESCRIPTIONS: TARGETED PHARMACEUTICAL DISCHARGE LETTER | CP-204 | |
| PEGYLATED LIPOSOMAL DOXORUBICIN AND CARBOPLATINE COMBINATION IN THE TREATMENT OF RECURRENT OVARIAN CARCINOMA. COMPARATIVE LONG TERM EFFECTIVENESS | CP-208 | |
| ECONOMIC IMPACT OF OBESITY AND OVERWEIGHT IN THE INFLIXIMAB TREATMENT IN A TERTIARY HOSPITAL | CP-210 | |
| EFFECTIVENESS AND SAFETY OF NEW DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C INFECTION: PRELIMINARY DATA IN A COINFECTED HIV/HCV POPULATION | CP-212 | |
| HOSPITAL PHARMACISTS INTERVENTIONS ON ANTIEMETIC APPROPRIATENESS IN PAEDIATRIC ONCOLOGY IN A UNIVERSITY HOSPITAL CENTRE | CP-213 | |
| OPTIMISATION OF RESTRICTED ANTIBIOTICS IN THE TREATMENT OF URINARY TRACT INFECTIONS | CP-215 | |
| FACTORS INFLUENCING THE SELECTION OF DIRECT ACTING ANTIVIRALS IN THE TREATMENT OF GENOTYPE 1 HEPATITIS C VIRUS INFECTION | CP-216 | |
| EVALUATION OF EFFICACY, EFFICIENCY AND PERSISTENCE RATE OF BIOLOGICAL THERAPY IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN A THIRD LEVEL REFERENCE HOSPITAL | CP-217 | |
| EFFECTIVENESS AND SAFETY OF SWITCHING TO DUAL ANTIRETROVIRAL THERAPY IN A TREATMENT EXPERIENCED HIV COHORT | CP-219 |
| EFFECTIVENESS AND SAFETY USING ERIBULIN IN METASTATIC BREAST CANCER | CP-223 |
| EVALUATION OF TWO CATHETER LOCKING SOLUTIONS IN HAEMODIALYSIS PATIENTS | CP-224 |
| KERION CELSI: AN INFECTION WITH TRICHOPHYTUN VERRUCOSUM. A CASE REPORT | CP-225 |
| SAFETY OF DIRECT ACTING ANTIVIRAL AND ANTIRETROVIRALS DRUGS IN HCV PATIENTS COINFECTED WITH HIV-1: CLINICAL PRACTICE EXPERIENCE | CP-226 |
| RISK MINIMISATION OF ADVERSE DRUG REACTIONS: ROLE OF THE PHARMACIST | CP-227 |
| IS THERE AN ADDED VALUE CONTRIBUTION OF BIOLOGICAL GLUE IN SURGERY OF CYANOTIC CONGENITAL HEART DISEASES? | CP-229 |
| HEALTH TECHNOLOGY ASSESSMENT: CHOICE BETWEEN CYTOTOXIC SAFETY CABINETS AND ISOLATORS FOR CYTOTOXIC DRUG RECONSTITUTION | CP-230 |
| EFFICACY PROFILE OF DIRECT ACTING ANTIVIRAL BASED THERAPY IN HCV MONO AND CO-INFECTED PATIENTS IN A REAL WORLD SETTING | CP-231 |
| METASTATIC PANCREATIC CANCER TREATMENT WITH NAB-PACLITAXEL: EFFECTIVENESS AND SAFETY | CP-232 |
| EFFECTIVENESS OF REGORAFENIB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SELECTED PATIENTS | CP-233 |
| ANTIMICROBIAL STEWARDSHIPS: SEMI-AUTOMATIC VALIDATION TOOL FOR ANTIMICROBIAL PRESCRIBING BASED ON REAL TIME ANTIBIOGRAMS | CP-234 |
| ANALYSIS OF PHARMACIST INTERVENTIONS’ ACCEPTANCE RATE IN A TERTIARY HOSPITAL | CP-235 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ONE STOP DISPENSING: NURSING STAFF’S INITIAL EXPERIENCE WITH BARCODE CONTROLLED BEDSIDE MEDICATION DISPENSING | DD-002 | |
| ASSESSMENT OF INDICATORS RELATED TO AUTOMATED DISPENSING SYSTEMS | DD-003 |
| ANALYSIS OF THE CAUSES OF STOCK-OUT IN SMALL AUTOMATED DISPENSING SYSTEMS | DD-004 |
| IMPLEMENTATION AND VALIDATION OF CASSETTES FOR PARTIAL TABLETS IN A BLISTER MACHINE FOR IMPROVEMENT OF MULTI-DOSE BLISTER PACKAGING IN A GOOD MANUFACTURING PRACTICE CONFORM SETTING | DD-005 |
| UNIT DOSE DRUG DISTRIBUTION SYSTEM. HOW TO IMPROVE THE PROCESS IN A TERTIARY HOSPITAL | DD-006 |
| IMPLEMENTATION OF AN ELECTRONIC COMMUNICATION SYSTEM TO DECREASE DEFICIENCIES IN REQUESTS FOR ADDITIONAL/MISSING DOSES AND IMPROVE PROCESS EFFICIENCY | DD-007 |
| DRUG SHORTAGES AND QUOTAS IN A TEACHING HOSPITAL: EVOLUTION AND CURRENT SITUATION | DD-008 |
| EVALUATION OF A FROZEN LOGISTICS CIRCUIT IMPLEMENTATION | DD-009 |
| A RISK ANALYSIS METHOD TO EVALUATE THE IMPACT OF ROBOTIC DISPENSING ON PATIENT SAFETY | DD-012 | |
| STAFF SATISFACTION AFTER THE IMPLEMENTATION OF A ROBOTIC DISPENSING SYSTEM IN AN OUTPATIENT PHARMACY | DD-014 |
| AUTOMATION: TRACKING THE ALARMS OF THE ROBOT AS A TRACER OF THE EFFICIENCY OF THE PROCESS | DD-015 |
| LEAN METHODOLOGY IN THE MEDICATION DISTRIBUTION PROCESS | DD-016 |
| THEFTS OF MEDICINES FROM HOSPITAL PHARMACIES: A EUROPEAN CHALLENGE | DD-017 |
| ‘LOCK, STOCK AND FLOW’–IMPROVING THE SUPPLY OF CONTROLLED DRUGS IN A TERTIARY REFERRAL TEACHING HOSPITAL | DD-018 |
| IMPACT OF INCOMPLETE PRESCRIPTIONS ON PATIENT WAITING TIME IN CLINICAL TRIALS | DD-019 |
| AN AUDIT OF PHARMACEUTICAL SPECIALTY MULTIDOSE USAGE IN A REGIONAL HOSPITAL’S NURSING UNIT | DD-020 |
| MEDICINE SUPPLY CHAIN OF A CENTRAL PHARMACY : RISK MAPPING OF SHORTAGE | DD-021 |
| IMPACT OF STOCK DISCREPANCIES IN AUTOMATED DISPENSING CABINETS | DD-022 |
| EVALUATION OF INFORMATION CONTENT AND CHARACTERISTICS OF PUBLICLY AVAILABLE DRUG SHORTAGE INFORMATION SOURCES | DD-023 |
| DEVELOPMENT OF AN OBJECTIVE FEEDBACK SCORE FOR THE EVALUATION OF DRUG AND MEDICAL DEVICE MANUFACTURERS/DISTRIBUTORS AS AN ADDITIONAL PARAMETER TO BE CONSIDERED IN PUBLIC PROCUREMENT | DD-024 |
| AUTOMATIC STORAGE SYSTEM: IMPACT IN REDUCING MEDICATION ERRORS IN A PAEDIATRIC HOSPITAL | DD-025 |
| NEW MARKET FOR MEDICINES: DO THE SUPPLIERS MEET THEIR COMMITMENTS? | DD-026 |
| IMPLEMENTATION AND EVALUATION OF AN APPOINTMENT BASED MODEL FOR OUTPATIENTS ATTENDING A HOSPITAL PHARMACY | DD-027 |
| EVALUATION OF A METHOD FOR PRESCRIPTION DISPENSING OF ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION SUSCEPTIBLE TO CARDIOVERSION | DD-029 |
| SETTING UP CONTROL OF DELIVERY OF RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE DEPARTMENT | DD-030 |
| SHORTAGE OF ANTI-INFECTIVES AND ITS CONSEQUENCES IN A TERTIARY HOSPITAL | DD-031 |
| THE IMPACT OF COMPUTERISED PHYSICIAN ORDER ENTRY ON MEDICATION ERRORS IN CHEMOTHERAPY | DD-032 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| NUTRITIONAL SCREENING IN ONCOLOGY OUTPATIENS TREATED WITH ORAL ANTINEOPLASTIC DRUGS IN A PHARMACEUTICAL CARE CONSULTATION | CP-081 | |
| PACLITAXEL-CARBOPLATIN INDUCED PERIPHERAL NEUROPATHY IN OVARIAN CANCER PATIENTS | DI-003 |
| CANNABINOID USE IN THERAPY: FIRST MONITORING OF ADVERSE REACTIONS | DI-005 |
| EFFECTIVENESS AND SECURITY OF SUSTAINED RELEASE FAMPRIDINE IN MULTIPLE SCLEROSIS IN THE SHORT TERM | DI-007 |
| APPS FOR PAEDIATRIC DOSING – AN EVALUATION | DI-008 |
| CLINICAL AND ECONOMIC ASSESSMENT AFTER CHANGING BASILIXIMAB PROTOCOL IN HEPATIC TRANSPLANTATION | DI-009 |
| BLEOMYCIN SCLEROTHERAPY IN VASCULAR MALFORMATIONS | DI-010 |
| BOTULINUM TOXIN TYPE A OPTIMISATION | DI-011 |
| SAFETY PROFILE OF JANUS ASSOCIATED KINASE INHIBITORS | DI-012 |
| USE OF TUBERCULOSTATIC IN PREGNANCY WITH FATAL RESULTS: A CASE REPORT | DI-013 |
| EFFICACY AND SAFETY OF FINGOLIMOD IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS | DI-014 |
| USE OF OMALIZUMAB FOR TREATMENT OF MAST CELL ACTIVATION DISEASE | DI-015 |
| PREVENTION OF TOXOPLASMIC ENCEPHALITIS AND PNEUMOCYSTIS JIROVECI PNEUMONIA IN PATIENTS INFECTED WITH HIV: EFFICACY AND SAFETY OF DAPSONE/PYRIMETHAMINE/LEUCOVORIN | DI-016 |
| MEFLOQUINE IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | DI-017 |
| ECULIZUMAB IN THE ATYPICAL HAEMOLYTIC URAEMIC SYNDROME: A CASE REPORT | DI-018 |
| EFFECT AND SAFETY OF MEXILETINE ON SIGNS AND SYMPTOMS OF MYOTONIC DISORDERS | DI-019 |
| CLINICAL EXPERIENCE WITH DOLUTEGRAVIR IN A TERTIARY HOSPITAL | DI-020 |
| SAFETY PROFILE OF THE NEW DIRECT ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS | DI-021 |
| REAL LIFE EFFECTIVENESS AND SAFETY OF LENALIDOMIDE IN THE TREATMENT OF MULTIPLE MYELOMA | DI-022 |
| ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN USE IN A TERTIARY HOSPITAL AND EVALUATION OF ITS ECONOMIC IMPACT | DI-023 |
| AN INDEPENDENT STUDY ABOUT OVER THE COUNTER MEDICINES TO ANALYSE PARENTS’ AWARENESS FOR PAEDIATRIC USE | DI-024 |
| THERAPEUTIC EDUCATION AND LONG TERM CORTICOTHERAPY: PATIENTS’ EXPECTATIONS | DI-026 |
| NOVEL ORAL ANTIPLATELET AGENTS IN ACUTE CORONARY SYNDROME. PRESCRIPTION PROFILE IN A TERTIARY HOSPITAL | DI-028 |
| SEVERE HYPONATREMIA INDUCED BY ESCITALOPRAM: A CASE REPORT | DI-029 |
| IMPACT OF LAST GUIDELINES ON ANTIEMETIC PRESCRIPTIONS IN A FRENCH UNIVERSITY HOSPITAL | DI-030 |
| ACUTE PANCREATITIS AND HYPERBILIRUBINAEMIA POSSIBLY ASSOCIATED WITH RIBAVIRIN ADMINISTRATION AND NEW DIRECT ANTIVIRAL AGENTS | DI-031 |
| STUDY OF EFFECTIVENESS AND SAFETY OF FOSCARNET IN CYTOMEGALOVIRUS TREATMENT IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS | DI-032 |
| DRUG USAGE EVALUATION OF ABIRATERONE IN METASTASIC CASTRATION RESISTANT PROSTATE CANCER: 4 YEARS OF EXPERIENCE | DI-034 |
| INTRAVITREAL AFLIBERCEPT INJECTIONS FOR TREATING WET AGE RELATED MACULAR DEGENERATION UNRESPONSIVE TO OTHER ANTIVASCULAR ENDOTHELIAL GROWTH FACTORS: INITIAL EXPERIENCE IN ROUTINE CLINICAL PRACTICE | DI-035 |
| TOXICITY IN ONCOLOGY: AN ANALYSIS | DI-036 |
| RISK OF HYPERTENSION IN PATIENTS TREATED WITH MIRABEGRON. STRATEGY FOR PRIORITISATION OF A DRUG SAFETY WARNING | DI-037 |
| OPTIMISATION OF ANTIBIOTIC USE IN A COUNTY HOSPITAL | DI-040 |
| DESIGN OF A METHODOLOGY FOR CULTURAL TRANSLATION AND ADAPTATION OF THE ADHERENCE TO REFILLS AND MEDICATIONS SCALE (ARMS) | DI-041 |
| MANAGEMENT OF LIPOSOMAL ANTHRACYCLINE EXTRAVASATIONS: USE OF DESRAZOXANE | DI-042 |
| EVALUATION OF THERAPEUTIC ADHERENCE AND RELATED FACTORS IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS | DI-043 |
| INAPPROPIATE USE OF OSELTAMIVIR IN HOSPITALISED PATIENTS | DI-044 |
| DIFFERENCES IN TREATMENT DURATION IN PANCREATIC CANCER PATIENTS TREATED WITH CHEMOTHERAPY FROM 2005 TO 2014 | DI-046 |
| PHARMACEUTICAL CARE PROGRAMME IN FERTILITY TREATMENTS: ANALYSIS OF PATIENT SATISFACTION LEVELS | DI-048 |
| DURATION OF NATALIZUMAB MAINTENANCE IN PATIENTS WITH MULTIPLE SCLEROSIS | DI-049 |
| TOLVAPTAN OFF-LABEL USE IN HYPONATRAEMIA DUE TO HEART FAILURE. A CASE SERIES | DI-051 |
| ADHERENCE, QUALITY OF LIFE AND PATIENT SATISFACTION WITH DALFAMPRIDINE IN CLINICAL PRACTICE | DI-053 |
| SAFETY RESULTS OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | DI-054 |
| EVALUATION OF TOCILIZUMAB RESPONSE IN RHEUMATOID ARTHRITIS. COMPARISION OF THE RESULTS WITH THE CLINICAL TRIAL | DI-055 |
| LINEZOLID INDUCED THROMBOCYTOPENIA IN A PATIENT WITH RENAL INSUFFICIENCY: A CASE REPORT AND A RETROSPECTIVE CASE STUDY | DI-056 | |
| LINEZOLID INDUCED THROMBOCYTOPENIA IN A PATIENT WITH RENAL INSUFFICIENCY: A CASE REPORT AND A RETROSPECTIVE CASE STUDY | DI-056 |
| UTILITY OF A NEW TOOL TO GUIDE DEPRESCRIBING IN CHRONIC PATIENTS: A CHART REVIEW | DI-057 |
| USE OF OMALIZUMAB IN A TERTIARY LEVEL HOSPITAL | DI-058 |
| USE OF DIMETHYL FUMARATE IN A TERTIARY HOSPITAL | DI-059 |
| TRANSLATING INTO ENGLISH A NEW TOOL TO GUIDE DEPRESCRIBING: A CROSS CULTURAL ADAPTATION | DI-060 |
| SUSTAINED VIROLOGIC RESPONSE RATES OF NEW DIRECT ACTING ANTIVIRAL AGENTS FOR HCV | DI-062 |
| SURVIVAL BENEFIT WITH VEMURAFENIB IN ‘BRAF’ MUTATION POSITIVE MELANOMA: AREA UNDER THE CURVE BASED REANALYSIS | DI-063 |
| STUDY CONCERNING ADVERSE DRUG REACTIONS IN ADULT PATIENTS FROM SURGICAL WARDS IN A CLINICAL EMERGENCY HOSPITAL | DI-064 |
| PERMEATION ENHANCERS: EXCIPIENTS TO BE CONSIDERED IN TOPICAL FORMULATIONS WITH SYSTEMIC ADVERSE EFFECTS | DI-066 |
| ANALYSIS OF THE USE OF TERIFLUNOMIDE IN A TERTIARY HOSPITAL | DI-067 |
| CHROMATOPSIA AND NIGHT BLINDNESS IN A PATIENT ON CAPECITABINE AND TEMOZOLOMIDE | DI-068 |
| COMPLIANCE OF ADOLESCENTS TO THE TREATMENT OF ACNE VULGARIS | DI-069 |
| INVITRO COMPARISON OF ANTACID DRUGS: APPLICATION TO SIX MARKETED FORMULATIONS | DI-071 |
| EXCIPIENTS IN PATIENTS WITH HEREDITARY FRUCTOSE INTOLERANCE | DI-073 |
| EVALUATION OF THE EFFECTIVENESS AND SAFETY OF PIRFENIDONE AND NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS | DI-075 |
| EFFECTIVENESS AND SAFETY OF BIOSIMILAR INFLIXIMAB IN ULCERATIVE COLITIS | DI-077 |
| ECONOMIC IMPACT EVALUATION OF OSELTAMIVIR ADJUSTMENT CRITERIA IN RENAL IMPAIRMENT | DI-078 |
| DEVELOPING A TEST BATTERY FOR PEOPLE’S HAND-EYE FUNCTION IN RELATION TO TABLET SUBDIVISION | DI-079 |
| SUCCESSFUL TREATMENT AND PREVENTION OF CISPLATIN/ETOPOSIDE INDUCED ENCEPHALOPATHY WITH THIAMINE | DI-080 |
| EFFECTIVENESS AND SAFETY OF PIRFENIDONE IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | DI-081 |
| ADVERSE EVENTS OF PIRFENIDONE AND CAUSE OF SUSPENSION IN CLINICAL PRACTICE | DI-082 |
| PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY ASSOCIATED WITH FINGOLIMOB USE IN A PATIENT WITH MULTIPLE SCLEROSIS WITHOUT PREVIOUS EXPOSURE TO IMMUNOSUPRESSANT DRUGS | DI-086 |
| OVERUSE OF VITAMIN K-DEPENDENT CLOTTING FACTORS AND CORRECTIVE ACTIONS | DI-087 |
| EVEROLIMUS IN TUBEROUS SCLEROSIS COMPLEX TREATMENT | DI-088 |
| NEW APPROACH TO THE MANAGEMENT OF THE HEREDITARY FRUCTOSE INTOLERANCE HYPOGLYCAEMIA: TREATMENT WITH ORAL MANNOSE | DI-089 |
| CONDITIONS OF USE AND TOLERANCE OF TRAMADOL IN THE HOSPITALIZED ELDERLY | DI-090 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ROLE OF THE PHARMACIST IN HOSPITAL: WHAT IS THE PERCEPTION OF HEALTH PROFESSIONALS? | GM-001 |
| USING EDUCATIONAL TOOLS TO INCREASE THE REPORTING RATES OF PRESCRIBING, DISPENSING AND ASSOCIATED ERRORS IN A GENERAL HOSPITAL | GM-002 |
| DO YOU NEED THE ON-CALL PHARMACIST? | GM-003 |
| EVALUATION OF THE DRUG ORDER COSTS IN A HOSPITAL PHARMACY | GM-004 |
| HOSPITAL TRANSFER IS A CRITICAL PERIOD. ONCOLOGY PHARMACY UNIT USERS’ EVALUATIONS | GM-005 |
| MONITORING OF WAITING TIMES FOR ANTICANCER CHEMOTHERAPY AS AN INDICATOR OF QUALITY PERFORMANCE | GM-006 |
| SATISFACTION OF HEALTH PROFESSIONALS ON SERVICES PROVIDED BY THE CLINIC PHARMACY MANAGEMENT UNIT | GM-007 |
| ECONOMIC VALUATION OF LOSSES DUE TO DRUG LEFTOVERS: CASE OF TENECTEPLASE | GM-008 |
| KNOWLEDGE, ATTITUDES AND SELF-CARE ACTIVITIES AMONG PATIENTS WITH TYPE II DIABETES | GM-009 |
| ECONOMIC IMPACT OF THE REVISION OF THE PHARMACOTHERAPEUTIC GUIDE IN A PRIVATE HOSPITAL | GM-010 |
| ANALYSIS OF BENCHMARKING INDICATORS TO ACHIEVE QUALITY IMPROVEMENT IN A PHARMACY DEPARTMENT | GM-011 |
| EUROPEAN PRICE COMPARISON OF HIGH COST HOSPITAL MEDICINES | GM-012 |
| QUALITY MANAGEMENT SYSTEM: ANALYSIS AND IMPROVEMENT IN AN ONCOLOGY PHARMACY UNIT | GM-013 |
| USE AND FINANCIAL IMPACT STUDY OF ENTERAL NUTRITION IN INSTITUTIONALISED PATIENTS LINKED TO A PHARMACY SERVICE | GM-014 |
| SURVEY OF THE CURRENT SITUATION IN OUR COUNTRY’S HOSPITAL PHARMACY SERVICES’ DISPENSATION AREAS | GM-015 |
| E-LEARNING PROGRAM ADAPTED TO PHARMACY STAFF: A 1 YEAR ASSESSMENT | GM-017 |
| IMPROVEMENT PLAN FOR DAA PRESCRIPTION COMPLIANCE IN THE PITIÉ-SALPÊTRIÈRE HOSPITAL | GM-018 |
| OPTIMISATION OF STOCKS AND WORKLOAD IN THE REPLACEMENT OF DRUGS IN A SEMI-AUTOMATIC SYSTEM OF STORAGE AND DISPENSING | GM-019 |
| SEAMLESS CARE: DEVELOPMENT OF A DISCHARGE COMMUNICATION TOOL FOR ELDERLY PATIENTS | GM-020 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| BUILDING FOR BETTER BONES: EVAULATION OF A CLINICAL PATHWAY IN THE SECONDARY PREVENTION OF OSTEOPOROTIC FRACTURES | INT-002 |
| IMPORTANCE OF CLINICAL PHARMACIST IN RATIONALISATION OF PHARMACOTHERAPY | INT-003 |
| THE USE OF CLINICAL PHARMACISTS AND PHARMACOECONOMISTS IN REGARDS TO MEDICATION SAFETY AND RESOURCE CONSUMPTION IN A HOSPITAL SETTING | INT-004 |
| SIMULATION METHOD IN THE DEVELOPMENT OF HOSPITAL PHARMACY’S PROCESSES | INT-005 |
| DRUGS AND CLINICAL SITUATIONS THAT OFFER THE OPPORTUNITY OF DEPRESCRIBING IN PATIENTS WITH MULTIPLE CHRONIC CONDITIONS: LESSCHRON CRITERIA | INT-010 |
| AN ANALYSIS ON SAFETY PROFILE OF BIOLOGIC AGENTS IN PAEDIATRIC PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS | INT-012 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HEALTH RELATED QUALITY OF LIFE AND ITS ASSOCIATED FACTORS AMONG SOUTH ASIAN AND MIDDLE EASTERN PATIENTS WITH CHRONIC DISEASES IN THE UK | OHP-001 | |
| SUPPLY AND DEMAND: REDUCING THE TIME TO COMPLETE THE ORAL DRUG ADMINISTRATION ROUND | OHP-002 |
| APPLYING DIFFERENT SCALES FOR CALCULATING THE PATIENT’S ANTICHOLINERGIC LOAD – FIVE CASE EXAMPLES | OHP-003 |
| DIFFERENCES IN TRAINING REQUIRED FOR HOSPITAL PHARMACY PRACTICE IN FRANCE AND EGYPT | OHP-005 |
| CONTINUOUS VENOVENOUS HAEMOFILTRATION IN CRITICALLY ILL PATIENTS: PRATICE ASSESSMENT AND COST IMPACT | OHP-006 |
| ACUTE BRONCHIOLITIS: THERAPEUTIC MANAGEMENT SUITABILITY IN A THIRD LEVEL HOSPITAL | OHP-008 |
| HOW HOSPITAL PHARMACISTS CAN PROMOTE PROPER USE OF BREATH TESTS BEYOND BUYING MEDICAL DEVICES? | OHP-009 |
| ECONOMIC ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB USE VERSUS INTRAVENOUS TRASTUZUMAB | OHP-010 |
| NURSES’ NEEDS FOR A PRACTICAL BASIC TRAINING ON ANTITHROMBOTIC DRUGS IN A UNIVERSITY HOSPITAL | OHP-011 |
| SAFETY ENGINEERED DEVICES IN THE HOSPITAL SETTING: THE ITALIAN MARKET | OHP-012 |
| CORONARY STENTS IN A REGIONAL HOSPITAL: EVOLUTION AND ANALYSIS FROM 2011 TO 2015 | OHP-013 |
| PREVENTION OF SHARP INJURIES IN HOSPITALS IN THE LOMBARDY REGION | OHP-015 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| SAFETY AND ECONOMIC OUTCOME AFTER IMPLEMENTATION OF A RESTRICTED USE ANTIBIOTIC PROTOCOL | PS-003 |
| EFFECTIVENESS AND TOXICITY OF HYPERTHERMIC ISOLATED LIMB PERFUSION WITH ANTITUMOR DRUGS IN TREATMENT OF IN-TRANSIT METASTASES OF MELANOMA AND SARCOMA | PS-005 |
| IDENTIFYING AND REPORTING MEDICATION ERRORS HELPS PHARMACISTS TO HAVE A GREAT ROLE IN PROMOTING PATIENT SAFETY | PS-006 |
| INAPPROPRIATE PRESCRIBING OF BENZODIAZEPINES IN COMORBID OLDER PATIENTS AT HOSPITAL DISCHARGE | PS-007 |
| ADVERSE DRUG EVENTS AND RISK FACTORS ASSOCIATED WITH ORAL OPIOID THERAPY IN ELDERLY PATIENTS | PS-008 |
| PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: PROGNOSIS AND TREATMENT | PS-009 |
| EXTRAVASATION OF ANTHRACYCLINES: DEVELOPMENT OF AN ACTION ALGORITHM FOR QUICK AND EFFECTIVE TREATMENT | PS-010 |
| IMPACT OF PHARMACEUTICAL INTERVENTIONS ON MEDICATION ERRORS IN PREPARATION OF CHEMOTHERAPY REGIMENS | PS-011 |
| IMPLEMENTATION OF A SUPPORT PROGRAMME FOR ANTIMICROBIAL PRESCRIPTION: A 3 MONTH EXPERIENCE | PS-012 |
| SAFETY PROGRAMME TO AVOID SKIN BURNS ASSOCIATED WITH TRANSDERMAL PATCHES | PS-013 |
| SAFETY ANALYSIS OF LEDIPASVIR/SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: ADVERSE EVENTS AND DRUG INTERACTIONS | PS-014 |
| E-LEARNING TO REDUCE INTRAVENOUS MEDICATION ERRORS? SIMULATION STUDY IN A ‘ROOM OF ERRORS’ | PS-015 |
| PERCEPTIONS OF POTENTIAL ANTIBIOTIC PRESCRIBING BY PHARMACISTS | PS-016 |
| QUALITY AND RISK MANAGEMENT IN HOSPITALS: AUDIT OF SURGICAL ANTIBIOTIC PROPHYLAXIS | PS-017 |
| CONCOMITANT USE OF DRUGS WITH ANTICHOLINERGIC EFFECTS AND ACETYLCHOLINESTERASE INHIBITORS IN ELDERLY PEOPLE WITH COGNITIVE IMPAIRMENT IN A NURSING HOME | PS-019 |
| NEW ORAL THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: SAFETY PROFILE EVALUATION | PS-02 |
| PRESCRIPTION ERRORS IN ORAL INVESTIGATIONAL PRODUCTS FOR ONCOHAEMATOLOGIC OUTPATIENTS INCLUDED IN A CLINICAL TRIAL | PS-021 |
| AROMATASE INHIBITORS INDUCED CARPAL TUNNEL SYNDROME. A CASE/NON-CASE STUDY OF SUSPECTED ADVERSE DRUG REACTIONS IN VIGIBASE | PS-023 |
| MEDICATION DISCREPANCIES AT THE TRANSFER POINT FROM ICU TO WARD: NEED TO BRIDGE SOME GAPS | PS-024 |
| ANALYSIS OF THE UTILISATION OF ZOLPIDEM IN HOSPITALISED PATIENTS | PS-025 |
| DATA MINING: PHARMACOVIGILANCE SIGNAL OF BENZODIAZEPINES AND SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PS-026 |
| ELECTRONIC PRESCRIBING SYSTEMS IN OUTPATIENT CARE. SOURCE OF INFORMATION OR SOURCE OF ERRORS? | PS-028 |
| MEDICATION NON-ADHERENCE IN ELDERLY PATIENTS | PS-029 |
| OFF-LABEL USE OF ANTICANCER DRUGS: WHICH BENEFITS AND HOW MUCH? | PS-030 |
| ON THE CLINICAL EVIDENCE LEADING TO TETRAZEPAM WITHDRAWAL | PS-031 |
| PHARMACIST INTERVENTIONS TO REDUCE RISK FACTORS IN FALLS RELATED TO THE SEDATIVE EFFECTS OF DRUGS IN ELDERLY PATIENTS | PS-034 |
| COMPLEMENTARY MEDICINE USAGE IN CANCER PATIENTS | PS-035 |
| IMPROVING PHARMACOLOGICAL TREATMENT: REAL-TIME SAFETY AUDITS | PS-036 |
| PHARMACEUTICAL INTERVENTIONS IN A TEACHING HOSPITAL | PS-037 |
| SAFE ADMINISTRATION OF MEDICATION THROUGH ENTERAL FEEDING IN HOSPITALISED PATIENTS | PS-038 |
| DRUG DOSAGE ERRORS IN THE TREATMENT OF ALZHEIMER’S DISEASE | PS-040 |
| DRUG DOSING ADJUSTMENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE ADMITTED TO HOSPITAL THROUGH THE EMERGENCY DEPARTMENT | PS-041 |
| POTENTIAL INTERACTIONS IN PATIENTS TREATED WITH DABIGATRAN, PREVALENCE AND THERAPEUTIC APPROACH | PS-042 |
| MEDICATION RECONCILIATION AT HOSPITAL ADMISSION: RESULTS EVALUATION AND FUTURE PROSPECTS | PS-043 |
| FOOD AND DRUG INTERACTIONS IN ORAL CANCER THERAPY | PS-044 |
| LOOK-ALIKE INJECTABLE DRUGS: DETECTION AND FIRST ASSESSMENT | PS-045 |
| Materiovigilance ex ante risk management | PS-046 |
| RESULTS OF AN ALLERGY DETECTION PROGRAMME OVER PREOPERATIVE ANTIBIOTIC PROPHYLAXIS | PS-047 |
| A BAR CODE ASSISTED CHEMOTHERAPY ADMINISTRATION SYSTEM IN CANCER PATIENTS | PS-048 |
| PROSPECTIVE DETECTION OF ADVERSE DRUG REACTIONS AMONG 2,263 HOSPITALISED CHILDREN OVER A 19 MONTH PERIOD | PS-049 |
| THE IMPLEMENTATION OF A RETROACTIVE MEDICATION RECONCILIATION PROCESS AT ADMISSION REDUCES THE RATE OF PRESCRIPTION ERRORS IN AN ACUTE CARDIOLOGY UNIT | PS-050 |
| SEVERE THROMBOCYTOPENIA INDUCED BY REGORAFENIB IN A METASTATIC COLON CANCER PATIENT: A CASE REPORT | PS-053 |
| USE OF CONTRAINDICATED DRUGS IN PARKINSON’S DISEASE PATIENTS | PS-054 |
| PRIORITISATION OF PATIENTS FOR MEDICATION RECONCILIATION: APPLICATION IN PATIENTS HOSPITALISED IN THE EMERGENCY UNIT | PS-056 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN THE ONCO-HAEMATOLOGY AREA IN A TERTIARY LEVEL HOSPITAL | PS-058 |
| DESENSITISATION PROTOCOL FOR CABAZITAXEL: A CASE REPORT | PS-062 |
| MEDICATION LABEL DESIGN AND PATIENT SAFETY: AN INTERACTIVE COMPARISON TEST | PS-063 |
| MEDICATION ERRORS IN AN EMERGENCY DEPARTMENT OBSERVATION UNIT | PS-064 |
| IVABRADINE PRESCRIPTION ACCORDING TO PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE RESTRICTIONS | PS-065 |
| INFUSION REACTIONS DOCUMENTED WITH DIFFERENT GENERIC PACLITAXEL FORMULATIONS BY MEANS OF AN ADVERSE DRUG REACTIONS REPORTING PROGRAMME | PS-066 |
| INAPPROPRIATE USE OF PROTON PUMP INHIBITORS AMONG ELDERLY PEOPLE: AUDIT IN A GERIATRIC HOSPITAL | PS-067 |
| EVALUATION OF THE INCIDENCE AND THE CONSEQUENCES OF THE EXTRAVASATION OF CHEMOTHERAPY DRUGS IN A TERTIARY HOSPITAL | PS-068 |
| EVALUATION OF POST-CHEMOTHERAPY TOXICITIES IN CANCER PATIENTS WHO ATTENDED THE EMERGENCY SERVICE | PS-069 |
| EVALUATION OF A PROGRAMME OF MEDICATION RECONCILIATION AT HOSPITAL ADMISSION IN TRAUMA PATIENTS REQUIRING SURGERY | PS-070 |
| DOES THE COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEM REDUCE PRESCRIBING ERRORS FOR INPATIENTS? A BEFORE AND AFTER STUDY | PS-072 |
| DOSE OPTIMISATION OF OMALIZUMAB IN PATIENTS WITH SEVERE PERSISTENT ALLERGIC ASTHMA | PS-077 |
| THERAPEUTIC EDUCATION OF THE PATIENT: THE ROLE OF THE HOSPITAL PHARMACIST | PS-078 |
| IMPORTANCE OF HYPERCHOLESTEROLAEMIA IN PATIENTS WITH BIOLOGICAL TREATMENT FOR AUTOIMMUNE INFLAMMATORY DISEASE | PS-079 |
| DRUG RELATED PROBLEMS IDENTIFIED THROUGH MEDICATION REVIEW IN ELDERLY PATIENTS IN PRIMARY HEALTHCARE | PS-080 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| INFLUENCE OF GENDER AND BODY SIZE ON 5- FLUOROURACIL PHARMACOKINETIC | PKP-001 |
| SECURITY PROFILE OF PATIENTS TREATED WITH PHENYTOIN IN A HOSPITAL | PKP-002 |
| EVALUATING PRESCRIPTIVE APPROPRIATENESS AND PHARMACOLOGICAL INTERACTION IN ELDERLY PATIENTS UNDERGOING POLYTHERAPY IN NURSING HOMES | PKP-003 | |
| ASSESSMENT OF COMPLIANCE OF PHARMACOKINETIC MONITORING REQUEST CRITERIA IN VANCOMYCIN AND AMINOGLYCOSIDE PRESCRIPTIONS | PKP-004 |
| EFFECT OF GENETIC POLYMORPHISM OF AZATHIOPRINE METABOLISING ENZYMES ON RESPONSE TO RHEUMATOID ARTHRITIS TREATMENT | PKP-005 | |
| ABCB1 AND OPRM1 POLYMORPHISMS ALTER MATERNAL EFFICACY AND NEONATAL SAFETY OF REMIFENATNIL IN WOMEN UNDERGOING CAESAREAN SECTION | PKP-006 | |
| PHARMACIST LED RAPID POINT OF CARE CYTOCHROME P 2C19 GENOTYPING FOR INDIVIDUALISATION OF ANTIPLATELET THERAPY | PKP-007 |
| EVALUATION OF A POPULATION PHARMACOKINETIC MODEL OF INFLIXIMAB IN RHEUMATOID ARTHRITIS FOR PREDICTION OF INDIVIDUAL DOSAGE REQUIREMENTS | PKP-009 |
| IMPACT OF THE RS1143634 POLYMORPHISM OF INTERLEUKIN 1b ON INFLIXIMAB EXPOSURE IN CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS | PKP-010 |
| AMIKACIN ACCUMULATION IN PATIENTS WITH NORMAL RENAL FUNCTION AND ONCE DAILY DOSING BASED ON ACCEPTED TROUGH TARGETS | PKP-011 |
| BODY SURFACE AREA, CIGARRETE SMOKING AND INFLIXIMAB RESPONSE IN PATIENTS WITH PSORIASI | PKP-012 |
| LEVETIRACETAM THERAPEUTIC MONITORING IN PATIENTS WITH EPILEPSY: EFFECT OF CONCOMITANT ANTIEPILEPTIC DRUGS | PKP-013 |
| INFLUENCE OF THE GENETIC POLYMORPHISMS ON THE RESPONSE TO CLOPIDOGREL IN PERIPHERAL ARTERY DISEASE PATIENTS FOLLOWING PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY | PKP-014 |
| ANALYSIS OF THE PREDICTIVE ABILITY OF DIFFERENT METHODS IN DOSAGE ADJUSTMENT OF DIGOXIN | PKP-015 |
| PHARMACOLOGICAL INTERACTIONS REGISTERED WITH THE USE OF NEW DIRECT ACTING ANTIVIRAL AGENTS FOR TREATMENT OF HEPATITIS C VIRUS | PKP-019 |
| IMPACT OF NADPH OXIDASE FUNCTIONAL POLYMORPHISMS IN ACUTE MYELOID LEUKAEMIA INDUCTION CHEMOTHERAPY | PKP-020 |
| RESULTS OF THE USE OF PHARMACOGENETICS IN THE CHOICE OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION WITH STENT | PKP-021 |
| THE KCNMB1 (A >G) (RS703505) GENETIC VARIANT AND THE EFFICACY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS | PKP-022 |
| INTERLEUKIN 6 G >G GENETIC POLYMORPHISM (RS1800795) AND THE RESPONSE TO TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS | PKP-023 |
| THE FCGR2A (A >G) (RS1801274) GENETIC VARIANT AND THE EFFICACY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS | PKP-024 |
| EFFECT OF ANTIANGIOGENIC TREATMENTS ON BIOMARKERS OF OXIDATIVE STRESS IN PATIENTS WITH AGE RELATED MACULAR DEGENERATION | PKP-025 |
| SIGNIFICANT INTERACTIONS IN TREATMENT OF DRAVET SYNDROME | PKP-027 |
| PHARMACOGENETIC STUDY OF THE INFLUENCE OF POLYMORPHISMS IN THE TNFR1A AND FAS GENES ON THE RESPONSE TO RITUXIMAB AND CHEMOTHERAPY IN FOLLICULAR LYMPHOMA PATIENTS | PKP-029 |
| APPROPRIATENESS OF AN INITIAL PREFIXED DOSE OF VANCOMYCIN AND RISK FACTORS FOR OVERDOSE | PKP-030 |
| CLINICAL PHARMACOKINETICS OF EVEROLIMUS IN LUNG TRANSPLANTATION: STRATEGIES OF MONITORING | PKP-031 |
| ANALYSIS OF A DESIGN TO DETECT TRIPLE WHAMMY IN PATIENTS WITH DIGOXIN THERAPY | PKP-033 |
| DETERMINATION OF METHOTREXATE IN CSF BY CHEMILUMINESCENCE USING THE ARCHITECT | PKP-034 |
| FACTORS CORRELATED TO HIGH DOSE METHOTREXATE SEVERE INTOXICATION: NAUSEA AND VOMITING | PKP-035 |
| LINEZOLID DOSE OPTIMISATION USING MONTE CARLO SIMULATION | PKP-036 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CONTAMINATION WITH CYTOTOXIC DRUGS IN THE WORKPLACE ESOP PILOT STUDY | PP-001 |
| COMPOUNDING FOR PAEDIATRIC PATIENTSINCREASING QUALITY THROUGH MECHANISATION? | PP-002 |
| RISK MATRIX FOR STERILE COMPOUNDED PRODUCTS: DESIGN AND VALIDATION | PP-003 |
| STABILITY OF HOSPITAL PHARMACY PREPARED HEPARIN SOLUTIONS | PP-005 |
| A NOVEL HALOGENATED ANAESTHETIC SOLUTION: PHYSICAL AND CHEMICAL STABILITY STUDY | PP-006 |
| EVALUATION OF AMYLASE-RESISTANT GELLAN GUM (E418) AS A RHEOLOGY AND TEXTURE MODIFIER FOR ORAL PREPARATIONS | PP-007 |
| QUALITY RISK MANAGEMENT: MICROBIOLOGIC PROCESS VALIDATION FOR SEMISOLID FORMULATIONS USING THE FAILURE MODE EFFECT ANALYSIS | PP-008 |
| IDENTIFYING AND LOCALISING MOLECULAR POLARITIES AS A BASIC PROCESS TO PREDICT COMPATIBLE AQUEOUS DRUG MIXTURES | PP-009 |
| IMPLEMENTING A STANDARD OPERATING PROCEDURE OF THIOGUANINE 40 MG/ML COMPOUNDED MEDICINE | PP-010 |
| IMPACT OF WORKLOAD ON PREPARATIONS QUALITY IN CHEMOTHERAPY: A PILOT SIMULATION STUDY | PP-011 |
| TRACEABILITY AND SAFETY IN THE PREPARATION OF CYTOTOXIC DRUGS | PP-012 |
| LONG TERM STABILITY OF A GENERIC PRODUCT OF PIPERACILLINE/TAZOBACTAM IN GLUCOSE 5% INFUSION POLYOLEFIN BAGS AT 5°C ± 3°C AFTER MICROWAVE FREEZE–THAW TREATMENT | PP-016 |
| THE PHYSICAL STABILITY OF INJECTABLE DRUGS MUST BE PROVED TO ENSURE PATIENT SAFETY | PP-017 |
| DRUG SAVINGS REALISED BY USE OF A RIGHT CLOSED SYSTEM TRANSFER DEVICE IN THE PREPARATION OF ANTINEOPLASTIC DRUGS | PP-018 |
| CENTRALISED IV COMPOUNDING: A PRE-FEASIBILITY STUDY IN CLINICAL PRACTICE | PP-019 |
| CONTROVERSIES IN THE CONDUCTING OF DRUG PATCH TESTING | PP-020 |
| QUALITY STUDY OF INTRAVENOUS MIXTURES AFTER THE IMPLEMENTATION OF DOUBLE CHECK | PP-021 |
| PAEDIATRIC CHEMOTHERAPY PREPARATION: AN A PRIORI RISK ASSESSMENT | PP-022 |
| GRAVIMETRIC AND SPECTROPHOTOMETRIC QUANTIFICATION OF PRAVASTATIN SODIUM SALT EXTEMPORANEOUS SOLUTIONS ADMINISTERED THROUGH FEEDING TUBE: EFFECT OF PREPARATION METHODS | PP-023 |
| EVALUATION OF LONG TERM BIOLOGICAL ACTIVITY OF PEGASPARGASE (ONCASPAR) AFTER DILUTION IN NACL 0.9% | PP-024 |
| 99MTC MACROAGGREGATED ALBUMIN (99MTC-MAA): VALIDATION OF PREPARATION PROTOCOLS FOR LUNG SCINTIGRAPHY IN PAEDIATRIC PATIENTS | PP-025 |
| EVALUATION OF THE QUALITY OF THE PARENTERAL NUTRITION PREPARED ON THE NEONATOLOGY WARD | PP-027 |
| ARE COMMERCIAL MULTI-DOSE FORMULATIONS THE BEST SOLUTION? A SPECTROSCOPIC QUALITY STUDY OF CYCLOPHOSPHAMIDE | PP-028 | |
| ARE COMMERCIAL MULTI-DOSE FORMULATIONS THE BEST SOLUTION? A SPECTROSCOPIC QUALITY STUDY OF CYCLOPHOSPHAMIDE | PP-028 |
| STUDY OF RADIONUCLIDE IMPURITIES IN 18F-METILCHOLINE: SETUP OF THE MEASUREMENT GEOMETRY FOR HIGH PURITY GERMANIUM GAMMA RAY SPECTROMETER | PP-029 |
| EFFECTIVENESS OF A TOPICAL SIROLIMUS FORMULATION IN PATIENTS WITH TUBEROUS SCLEROSIS | PP-030 |
| STABILITY STUDY OF 20 MG/ML PAEDIATRIC AMIODARONE ORAL SUSPENSION IN SYRSPEND | PP-033 |
| USE OF AUTOLOGOUS SERUM EYE DROPS PREPARED IN A HOSPITAL PHARMACY SERVICE | PP-034 |
| THE OUTCOME OF MICROBIOLOGICAL MONITORING IN CYTOTOXIC DRUG PREPARATION | PP-035 |
| STABILITY STUDY OF 5 MG/ML OXYBUTYNIN ORAL SUSPENSION IN SYRSPEND | PP-036 |
| RISK OF MICROBIAL CONTAMINATION OF PHARMACY STERILE PREPARATIONS: A RISK BASED DECISION MATRIX | PP-037 |
| DOUBLE CHECKING MANIPULATIONS FOR COMPLEX AND/OR HIGH RISK PREPARATIONS | PP-039 |
| SODIUM THIOSULFATE IN CUTANEOUS NECROSIS BY CALCIPHYLAXIS TREATMENT. A CASE REPORT | PP-040 |
| EXTEMPORANEOUS PREPARATION OF ORAL LIQUID FORMULATION OF CAPECITABINA | PP-041 |
| PROPRANOLOL 2 MG/ML AS SYRUP FOR SKIN ANGIOMAS. CLINICAL EVALUATION OF AN OFF-LABEL PREPARATION | PP-043 |
| EVALUATION OF THE QUANTOS® POWDER DOSING SYSTEM FOR CAPSULE MANUFACTURING IN A HOSPITAL PHARMACY | PP-044 |
| EVALUATION OF COMPOUNDING QUALITY OF INTRAVENOUS ADMIXTURES | PP-045 |
| ELABORATION OF A 10% SODIUM THIOSULFATE W/O TOPICAL CREAM FOR THE TREATMENT OF CALCINOSIS CUTIS IN TWO PREMATURE NEONATES | PP-046 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IMPACT OF A PHARMACEUTICAL CARE PROGRAMME FOCUSED ON THE SOLID ORGAN TRANSPLANT PATIENT | CP-001 |
| PHARMACEUTICAL CARE SYSTEM FOR LIVER TRANSPLANT PATIENTS USING ELECTRONIC CONSULTATION | CP-002 |
| CLINICAL PHARMACIST INTERVENTIONS ON PARENTERAL NUTRITION APPROPRIATENESS IN A TEACHING HOSPITAL | CP-003 |
| AGE-RELATED MACULAR DEGENERATION: ECONOMIC IMPACT OF IMPLEMENTING TREATMENT GUIDELINES | CP-004 |
| PRACTICAL UTILITY OF ITPA GENOTIPATION IN A TERTIARY HOSPITAL | CP-006 |
| HEPATITIS C VIRUS TREATMENT-RELATED ANEMIA AND ITS ASSOCIATION WITH HIGHER SUSTAINED VIROLOGIC RESPONSE RATE | CP-007 |
| A CLINICO-ETHICAL FRAMEWORK FOR MULTIDISCIPLINARY MEDICINES REVIEW IN NURSING HOMES: A HEALTH FOUNDATION SHINE PROJECT | CP-008 |
| ADHERENCE TO LONG-TERM MEDICINES IN HIV-INFECTED PATIENTS | CP-010 |
| LENGTH OF ANTIMICROBIAL USE AND THE ROLE OF THE PHARMACIST IN AN ACUTE HOSPITAL SETTING | CP-011 |
| MEDICINES RECONCILIATION – IMPLEMENTATION BY CLINICAL PHARMACISTS IN THE OTORHINOLARYNGOLOGY CLINIC | CP-012 |
| ETANERCEPT ON STEROID-REFRACTARY ACUTE GRAFT-VERSUS-HOST DISEASE | CP-013 |
| PARENTERAL NUTRITION, IS STANDARIZATION ACCEPTABLE? | CP-014 |
| DIFFERENCES IN VALUES OF BODY SURFACE AREA IN CHEMOTHERAPY PATIENTS | CP-017 |
| PARENTERAL NUTRITION GIVEN IN THE PEROPERATIVE PERIOD IN ABDOMINAL SURGERY: COMPLIANCE WITH GUIDELINES | CP-018 |
| ALBUMIN CONSUMPTION IN FIVE YEARS 2009-2013: AN EXAMPLE OF IMPROVED PRESCRIBING APPROPRIATENESS | CP-019 | |
| ALBUMIN CONSUMPTION IN FIVE YEARS 2009-2013: AN EXAMPLE OF IMPROVED PRESCRIBING APPROPRIATENESS | CP-022 |
| THE USE OF INTENSIVE DOSES OF STATINS AFTER ACUTE MYOCARDIAL INFARCTION IN AN EMERGENCY ROOM WITH A CLINICAL PHARMACIST | CP-023 |
| USE OF ERYTHROPOIESIS-STIMULATING AGENTS IN ANAEMIA SECONDARY TO CHRONIC KIDNEY DISEASE IN A TERTIARY HOSPITAL | CP-024 |
| PATIENTS´ADHERENCE-RELATED BELIEFS ABOUT MEDICINES PRESCRIBED FOR LONG-TERM CONDITIONS IN HIV PATIENTS | CP-025 |
| EFFICACY OF TRIPLE THERAPY WITH PROTEASE INHIBITORS FOR THE TREATMENTOF HEPATITIS C VIRUS IN CLINICAL PRACTICE | CP-026 |
| EFFICACY AND SAFETY OF RIBAVIRIN USED FOR RESPIRATORY SYNCITIAL VIRUS TREATMENT IN HEMATOLOGICAL PATIENTS | CP-027 |
| OFF-LABEL USE OF ADALIMUMAB IN BEHÇET’S DISEASE. A CASE REPORT | CP-032 |
| USE OF INFLIXIMAB IN A PREGNANT WOMAN WITH ANKYLOSING SPONDYLITIS | CP-033 |
| IPILIMUMAB EXPERIENCE IN ADVANCED MELANOMA | CP-034 |
| DRUG INTERACTIONS INVOLVING ANTIBIOTICS: DO THEY CARE? | CP-036 |
| EFICACY OF ABIRATERONE IN THE TREATMENT OF PROSTATE CANCER | CP-037 |
| ADEQUACY OF NUTRITION ENERGY DELIVERY IN SURGICAL INTENSIVE CARE | CP-038 |
| SWITCHING TO TENOFOVIR/ EMTRICITABINE/RILPIVIRINE IN HIV-1 PATIENTS PREVIOUSLY TREATED WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ | CP-040 |
| IMPLEMENTATION OF EXTENDED TOP-UP SERVICE INCREASED CORRECT RECORDING IN THE ELECTRONIC MEDICATION MODULE | CP-043 |
| EFFECTIVENESS AND SAFETY OF IMATINIB IN CHRONIC MYELOID LEUKEMIA IN A TERTIARY HOSPITAL | CP-044 |
| ELECTRONIC PRESCRIBING: THE DEVELOPMENT OF A PAEDIATRIC DRUG DATABASE | CP-045 |
| HYPERSENSITIVITY REACTIONS TO CHEMOTHERAPY: SO… WHAT DO WE DO NOW? | CP-046 |
| PHARMACIST’S CONTRIBUTION TO THE OPTIMIZATION OF DRUG THERAPY IN ONCOLOGY INPATIENTS | CP-047 |
| ANALYSIS OF THE AMBULATORY USE OF BOTULINUM TOXIN TYPE A IN A TERTIARY HOSPITAL: AUTHORIZED AND OFF-LABEL INDICATIONS | CP-048 |
| CLINICAL RELEVANCE OF RECONCILIATION ERRORS AT ADMISSION FROM EMERGENCY DEPARTMENT AVOIDED BY THE CLINICAL PHARMACIST | CP-049 |
| POSACONAZOLE AND INVASIVE FUNGAL INFECTION | CP-050 |
| EVALUATION OF ELECTRONIC DRUG INTERACTION CHECKER DATABASES – RHEUMATOID ARTHRITIS PATIENTS CASE STUDY | CP-051 |
| IDENTIFICATION OF A NATIONAL PORTFOLIO OF UNLICENSED PHARMACEUTICAL PREPARATIONS IN DENMARK | CP-053 |
| OFF-LABEL USE OF EMTRICITABINE / RILPIVIRINE / TENOFOVIR | CP-054 |
| PHARMACY INTERVENTIONS IN VENOUS THROMBOEMBOLISM PROPHYLAXIS IN MEDICAL PATIENTS | CP-055 |
| DOSAGE ADJUSTMENT OF EPOETIN ß AND DARBEPOETIN a IN CHRONIC KIDNEY DISEASE | CP-057 |
| PHARMACEUTICAL CARE SYSTEM FOR CHRONIC PAEDIATRIC PATIENTS | CP-058 |
| COMPARISON OF ETHNIC CHRISTIAN AND MUSLIM POPULATIONS ON ANTIRETROVIRAL TREATMENT | CP-060 |
| LONG-TERM COST-EFFECTIVENESS ANALYSIS OF INFLIXIMAB, ETANERCEPT AND ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS IN REAL-LIFE CLINICAL PRACTICE | CP-061 |
| COST IMPACT OF BELIMUMAB IN A HOSPITAL SETTING | CP-062 |
| PHARMACY ASSISTANCE FOR FRAIL PATIENTS WITH NASOGASTRIC TUBE | CP-063 |
| ANALYSIS OF ORAL IMMUNOSUPPRESSANT USE IN OFF-LABEL INDICATIONS IN A HOSPITAL PHARMACY SERVICE | CP-064 |
| SWITCHING ANTIRETROVIRAL THERAPY: REASONS AND ASSOCIATED COSTS IN A COHORT OF HIV-INFECTED PATIENTS | CP-065 |
| PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: A CASE REPORT | CP-066 |
| USE OF VALIDATED CARE QUALITY INDICATORS TO IDENTIFY MPROVEMENTS IN HIV PHARMACEUTICAL CARE | CP-067 |
| COMPATIBILITY ANALYSIS OF PROPOFOL – OPTIMIZATION OF DRUG TREATMENT SAFETY | CP-068 |
| QUALITY OF ANTIBIOTIC TREATMENT IN PRETERM NEONATES: A READY-TO-USE FORMULATION OF GENTAMICIN SULPHATE | CP-069 |
| GOOD PRACTICE IN COMPLEX PARENTERAL IRON REGIMENS: A SURVEY IN 5 SURGICAL DEPARTMENTS | CP-072 |
| OPTIMIZING INFLIXIMAB TREATMENT IN INFLAMMATORY BOWEL DISEASE | CP-073 |
| INTERVENTIONS TO IMPROVE MEDICINES ADHERENCE IN PATIENTS WITH SEVERAL CHRONIC CONDITIONS: AN OVERVIEW OF SYSTEMATIC REVIEWS | CP-074 |
| NATALIZUMAB: EFFECTIVENESS AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN A TERTIARY HOSPITAL. | CP-075 |
| POST-MARKETING ACTIVE PHARMACOVIGILANCE IN A CENTRAL HOSPITAL | CP-076 |
| ANALYSIS OF COSTS AND PRESCRIPTION GUIDELINES OF ETANERCEPT AND ADALIMUMAB IN PATIENTS OF RHEUMATOLOGY, DERMATOLOGY AND GASTROENTEROLOGY SERVICES ON THE PHARMACY OUTPATIENT UNIT | CP-077 |
| OPTIMISING RESOURCES IN COMPOUNDING PREPARATIONS: SIMPLE MEASURES AIMED AT REDUCING COSTS | CP-078 |
| RELATIONSHIP BETWEEN ADHERENCE TO HEPATITIS C TREATMENT AND RAPID, EARLY AND SUSTAINED VIRAL RESPONSE | CP-079 |
| THROMBOPOIETIN RECEPTOR AGONIST TREATMENT IN IDIOPATHIC THROMBOCYTOPENIC PURPURA | CP-080 |
| MANAGEMENT OF UNCONTROLLED BLOOD PRESSURE IN PATIENTS WITH MULTIPLE DRUG INTOLERANCE REFERRED TO A SPECIALIST HYPERTENSION CLINIC | CP-081 |
| PREVALENCE OF MALNUTRITION AND ASSOCIATED RISK FACTORS | CP-083 |
| USE OF INFLIXIMAB FOR STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE | CP-084 |
| COMPARISON OF BILIRUBIN LEVELS WITH TWO INTRAVENOUS LIPID EMULSIONS IN PREMATURE INFANTS REQUIRING PARENTERAL NUTRITION | CP-085 |
| ANTIRETROVIRAL THERAPY: ARE WE USING THE MOST EFFICIENT TREATMENT? | CP-087 |
| EVALUATION OF STANDAR PARENTERAL NUTRITION IN SURGICAL PATIENTS. | CP-088 |
| TIME EFFECTS OF INTRAVENOUS LIPID EMULSIONS ON PREMATURES | CP-089 |
| CLINICAL RELEVANCE OF DRUG INTERACTIONS DETECTED IN HEPATITIS C (GENOTYPE 1) TRIPLE THERAPY PATIENTS | CP-090 |
| DOSE ADJUSTMENT IN CANCER PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT | CP-091 |
| ESTIMATED RATE OF THERAPEUTIC FAILURE WITH PALIVIZUMAB IN THE PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS | CP-092 |
| USE OF FAMPRIDINE IN MULTIPLE SCLEROSIS PATIENTS | CP-093 |
| THE EFFECT OF ADDING ANTI-HCV TO ANTIRETROVIRAL TREATMENT ON ADHERENCE | CP-094 |
| KETOCONAZOLE IN CHEMO-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | CP-095 |
| FEASIBILITY STUDY ON IMPLEMENTATION OF DOSE BANDING IN A TEACHING HOSPITAL | CP-096 |
| DOSE ADJUSTMENT OF TENOFOVIR IN HIV PATIENTS WITH RENAL IMPAIRMENT | CP-097 |
| RISK FACTORS OF URINARY TRACT INFECTION IN PATIENTS TREATED WITH ABIRATERONE | CP-098 |
| FAMPRIDINE, A NEW APPROACH IN THE TREATMENT OF MULTIPLE SCLEROSIS: EFFICACY IN IMPROVING WALKING AND QUALITY OF LIFE | CP-099 |
| PHARMACEUTICAL INTERVENTION IN NUTRITIONAL SUPPORT IN POSTSURGICAL INTENSIVE CARE UNIT | CP-100 |
| COLLABORATION BETWEEN HOSPITAL PHARMACY AND PRIMARY CARE PHARMACY: ASSESMENT OF ANTIRETROVIRAL AND ANTINEOPLASTIC TREATMENT PRESCRIBED WITH ANTIULCER TREATMENT | CP-101 |
| SUCCESSFUL ANTIDEPRESSANT TREATMENT WITH AN ORAL SOLUTION OF IMIPRAMINE DURING A SHORTAGE OF IMIPRAMINE TABLETS: A CASE REPORT | CP-102 |
| OPTIMIZATION OF ANTIBIOTIC TREATMENT IN GENERAL SURGERY | CP-103 |
| OSELTAMIVIR USE | CP-106 |
| INFECTIONS CAUSED BY CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE IN A TERTIARY HOSPITAL | CP-108 |
| IMPLEMENTING CLINICAL PHARMACY ON A HEPATOLOGY WARD: FIRST STEPS | CP-109 |
| EFFICACY OF TELAPREVIR IN TREATMENT OF CHRONIC HEPATITIS C | CP-111 |
| FINANCIAL IMPACT OF THE USE OF REDUCED DOSES OF TOCILIZUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS | CP-113 |
| DIFFERENCES IN TREATMENT COMPLEXITY BETWEEN MULTIMORBIDITY PATTERNS IN THE OLDER POPULATION | CP-114 |
| CHANGING TREATMENT IN HIV PATIENTS TREATED WITH EFAVIRENZ/EMTRICITABINE/TENOFOVIR TO RILPIVIRINE/EMTRICITABINE/TENOFOVIR | CP-115 |
| WOUND INFECTION IN PATIENTS WITH SILVER DRESSINGS | CP-118 |
| EFFECT OF TREATMENT COMPLEXITY ON TREATMENT PERSISTENCE IN HIV PATIENTS | CP-119 |
| COMPARISON OF ANTIBIOTIC CONSUMPTION AND BACTERIAL RESISTANCE IN TWO TEACHING HOSPITALS: IMPACT OF A MULDISCIPLINARY ANTIBIOTIC MANAGEMENT PROGRAM | CP-120 |
| ADVERSE DRUG REACTIONS FROM ANTIPSYCHOTICS CONTRIBUTING TO ADMISSIONS IN AN ACUTE GENERAL HOSPITAL | CP-121 |
| IMPROVING ACCESS TO SPECIALIST PHARMACEUTICAL CARE: AN ALTERNATIVE MODEL TO WARD-BASED CLINICAL PHARMACY SERVICES | CP-122 |
| IMPROVING ACCESS TO MENTAL HEALTH SERVICES: A NEW PHARMACY ROLE IN GENERAL HOSPITAL PSYCHIATRY LIAISON | CP-123 |
| IMPACT OF HOSPITAL PHARMACIST INTEGRATION ON PATIENT SAFETY IN A GENERAL SURGERY SERVICE AND THE RELATED DIRECT FINANCIAL SAVINGS | CP-124 |
| EVALUATION OF COMPLIANCE AND TOLERABILITY IN TREATMENT-NAÏVE PATIENTS SUFFERING FROM IDIOPATHIC PULMONARY FIBROSIS (IPF) AND TREATED WITH PIRFENIDONE | CP-125 |
| VALIDATION OF INHALATION TECHNIQUE VIDEOTAPED IN ASTHMATIC CHILDREN UNDER 5 YEARS | CP-126 |
| ASSESSMENT OF ERROR AND PHARMACEUTICAL INTERVENTION IN PARENTERAL NUTRITION PRESCRIBING IN NEONATOLOGY | CP-128 |
| Analysis of the impact on the rates of nosocomial infection (NI) after the implantation of a Fast Track (FT) protocol in elective colon surgery | CP-129 |
| ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF INFLIXIMAB IN THE TREATMENT OF PSORIASIS IN A TERTIARY HOSPITAL | CP-130 |
| REVIEW OF NEUTROPENIC FEVER AND MUCOSITIS IN PATIENTS UNDERGOING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION | CP-131 |
| IMPACT OF IMPLEMENTING A CARBAPENEM STEWARDSHIP PROGRAM | CP-132 |
| NAME PATIENT PROGRAM WITH SILTUXIMAB IN MULTICENTRIC CASTLEMAN’S DISEASE: A CASE REPORT. | CP-133 |
| ANALYSIS OF STRUCTURED AND COMMENTED INDIVIDUALIZED DRUGS REVIEWS MADE BY HOSPITAL PHARMACY DEPARTMENT. | CP-134 |
| Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Breast Cancer patients | CP-135 |
| INAPPROPRIATE PRESCRIBING IN OLDER PATIENTS:ASSESSMENT OF A SCREENING TOOL BASED ON THE STOPP AND START CRITERIA | CP-136 |
| IMPACT OF THE PHARMACIST IN THE OPTIMIZATION OF ANTIRETROVIRAL TREATMENT IN HIV PATIENT CONSULTATIONS | CP-137 |
| SUCCESSFUL OFF-LABEL USE OF ELTROMPOBAG IN PA REGNANT WOMAN WITH CONGENITAL THROMBOPENIA | CP-138 |
| EFFECT OF CANCELLING ELECTIVE CARDIOVERSION AND CATHETER ABLATION IN PATIENTS WITH ATRIAL FIBRILLATION | CP-139 |
| IMPLEMENTATION OF ANTIBIOTIC TREATMENT PROTOCOLS IN THE ICU: RESULTS AFTER A YEAR | CP-140 |
| BOSENTAN TREATMENT FOR AUTOINMUNE DISEASES | CP-141 |
| BIOLOGICAL TREATMENTS FOR PSORIASIS: FINANCIAL IMPACT OF DOSE MODIFICATION | CP-142 |
| INVOLVEMENT OF MICROBIAL FLORA IN AETIOLOGY OF SURGICAL SITE INFECTIONS | CP-143 |
| ANALYSIS OF THE USE AND EFFECTIVENESS OF PALIVIZUMAB IN A TERTIARY HOSPITAL | CP-144 |
| EFFECT OF A TRAINING INITIATIVE TO IMPROVE ADHERENCE TO THE RECOMMENDATIONS FOR THERAPEUTIC MONITORING VANCOMYCINEFFECT OF A TRAINING INITIATIVE TO IMPROVE ADHERENCE TO THE RECOMMENDATIONS FOR THERAPEUTIC MONITORING VANCOMYCIN | CP-145 |
| SURVIVAL BENEFIT WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MYELOMA: AREA UNDER THE CURVE-BASED REANALYSIS | CP-148 |
| INFLUENCE OF CLINICAL TRIALS ON THE CONSUMPTION OF ANTIBIOTICS IN HOSPITAL | CP-149 |
| INCIDENCE OF LACTIC ACIDOSIS IN PATIENTS TREATED WITH METFORMIN | CP-150 |
| ANALYSIS OF BIOLOGICAL TREATMENTS ALLOWED BY A LOCAL DERMATOLOGY COMMITTE IN A THIRD LEVEL HOSPITAL | CP-151 |
| EFFECTIVENESS AND SAFETY OF BRENTUXIMAB IN HODGKIN’S AND NON-HODGKIN’S LYMPHOMA | CP-152 |
| EFFEDC OF REGIMEN COMPLEXITY ON THE PREMATURE DISCONTINUATION OF TREATMENT WITH BOCEPREVIR OR TELAPREVIR IN HEPATITIS C VIRUS- HIV COINFECTED PATIENTS | CP-154 |
| COMPARATIVE PHARMACOECONOMICS STUDY: TUMOR NECROSIS FACTOR -ALPHA ANTAGONITS TREATMENT FOR RHEUMATOID ARTHRITIS | CP-155 |
| EVALUATION OF THE INCIDENCE AND EFFECTIVENESS OF ANTI-TNF-a DRUG DOSE INTENSIFICATION IN CROHN´S DISEASE PATIENTS | CP-156 |
| ASSESSMENT OF EFFECTIVENESS IN WALKING ABILITY AND SAFETY OF FAMPRIDINE IN MULTIPLE SCLEROSIS PATIENTS | CP-159 |
| HOSPITAL PHARMACIST-LED PROJECT TO IMPROVE ANTIBIOTIC USE IN THE HOSPITAL SETTING | CP-160 |
| Evaluation of benzodiazepine use in HIV-positive patients | CP-162 |
| EVALUATION OF EFFECTIVENESS AND SAFETY OF RILPIVIRINE/EMTRICITABINE/ TENOFOVIR | CP-163 |
| USE OF IVERMECTIN FOR STRONGYLOIDOSIS: AN APPROACH TO CLINICAL PRACTICE | CP-164 |
| FACTORS ASSOCIATED WITH PERSISTENCE WITH ANTIRETROVIRAL TREATMENT IN HIV INFECTED PATIENTS | CP-166 |
| ADDING VALUE: PHARMACIST INTERVENTIONS IN ONCO-HAEMATOLOGICAL OUTPATIENTS | CP-168 |
| DEXMEDETOMIDINE FOR SEDATION IN CRITICALLY ILL PATIENTS: A SINGLE CENTRE EXPERIENCE | CP-169 |
| ACCEPTANCE OF PHARMACEUTICAL INTERVENTIONS IN DRUG DOSING IN RENAL DISEASE | CP-170 |
| MEDICINES RECONCILIATION ON ADMISSION: A PATIENT SAFETY STRATEGY | CP-171 |
| CYTOMEGALOVIRUS INFECTION AFTER ANTI-THYMOCYTE GLOBULIN IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION | CP-172 |
| ASSASSEMENT OF EFFICACY OF MULTIPLE ANTIRETROVIRAL THERAPY | CP-173 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EFFECT OF AUTOMATED DISPENSING CABINETS ON DRUG DISTRIBUTION IN 5 HOSPITALS | DD-001 |
| AN INTERVENTION IN AN ANTIBIOTICS DISTRIBUTION SYSTEM: UNIT-DOSE VS BULK EVALUATION IN A COUNTY HOSPITAL | DD-002 |
| ANALYSIS OF THE USE OF AUTOMATED MEDICINES DISPENSING CABINETS WITHOUT ELECTRONICALLY ASSISTED PRESCRIBING | DD-003 |
| QUALITY INDICATORS IN AN UNITARY DOSE DRUG DISPENSATION SYSTEM: MEASUREMENT, ANALYSIS AND IMPROVEMENT | DD-004 |
| DEVELOPING A MANAGEMENT STRATEGY FOR MEDICATION UNITS FREE OF SECONDARY PACKAGING IN A HOSPITAL PHARMACY | DD-005 |
| PHARMACEUTICALS INTERVENTIONS IN THE DRUGS DISPENSATION PROCESS BY AUTOMATED CABINETS IN A SPECIALTY HOSPITAL | DD-007 |
| MONITORING OF THE ADHERENCE TO THERAPIES FOR THE TREATMENT OF PULMONARY HYPERTENSION | DD-008 |
| LEAN medicine room saves time and improves patient safety | DD-009 |
| DESIGNING SUPPLY QUOTAS OF DRUGS IN CARE UNITS: HOW CAN WE IMPROVE THE METHODOLOGY FOR DOUBLE BIN REPLENISHMENT SYSTEMS? | DD-012 |
| DRUG SUPPLY CHAIN: HOW TO PREVENT OUT OF STOCK DUE TO INDUSTRIAL FAILURE? RETROSPECTIVE STUDY IN THE CENTRAL PHARMACY OF A UNIVERSITY HOSPITAL | DD-013 |
| How should drug shortages be defined? A review | DD-015 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| USAGE PROFILE, EFFECTIVENESS AND SAFETY OF COFORMULATED RILPIVIRINE/EMTRICITABINE/TENOFOVIR | CP-017 |
| ANALYSIS OF THE USE, EFFECTIVENESS AND SAFETY OF TREATMENT WITH TRASTUZUMAB-EMTANSINE IN METASTATIC BREAST CANCER | DI-001 |
| EVALUATION OF PROFESSIONAL PRACTICE ON THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | DI-003 |
| STUDY ON PRESCRIPTION PATTERN AND COST ANALYSIS OF ANTIRETROVIRAL DRUGS IN A TERTIARY CARE HOSPITAL. | DI-004 |
| RESPONSE TO REPLACEMENT ENZYME TREATMENT IN PATIENTS WITH TYPE 1 GAUCHER’S DISEASE | DI-005 |
| EVALUATING THE LEVEL OF KNOWLEDGE OF MEDICINES AND NEED FOR INFORMATION AMONG PEOPLE CARING FOR PAEDIATRIC CANCER PATIENTS | DI-008 |
| VITAMIN K ANTAGONIST / NEW ORAL ANTICOAGULANT IN ATRIAL FIBRILLATION: MONITORING OF HAEMORRHAGIC RISK | DI-009 |
| FACTORS INFLUENCING THE APPEARANCE OF HAEMATOLOGICAL AND THYROID ADVERSE EFFECTS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 TREATED WITH TELAPREVIR/BOCEPREVIR PLUS PEG-INTERFERON AND RIBAVIRIN | DI-010 |
| RITUXIMAB EFFICACY IN THE TREATMENT OF AUTOIMMUNE DISEASES | DI-012 |
| OFF LABEL USE AND ECONOMIC IMPACT OF BIOLOGIC THERAPY IN NON-INFECTIOUS UVEITIS | DI-014 |
| EVALUATION OF PHARMACOLOGICAL PAIN CONTROL MANAGEMENT IN CANCER PATIENTS; A PATIENT-CENTERED APPROACH TO PREVENT EXPOSURE TO INEFFECTIVE MEDICATION | DI-015 |
| SIMPLIFICATION TO SINGLE-DRUG REGIMEN WITH A RITONAVIR-BOOSTED PROTEASE INHIBITOR FOR HIV PATIENTS | DI-018 |
| STUDY OF ADHERENCE TO THE USE OF INHALED COLISTIN | DI-019 |
| EFFECTIVENESS OF SORAFENIB IN ADVANCED HEPATOCELLULAR CARCINOMA IN REAL-LIFE CONDITIONS | DI-020 |
| IMPROVEMENT STRATEGIES IN QUALITY PRESCRIBING INDICATORS ON A HEALTHCARE AREA | DI-021 |
| NEW CHANCES IN MULTIPLE SCLEROSIS TREATMENT: SUSTAINED-RELEASE FAMPRIDINE | DI-022 |
| EFFECT OF DIFFERENT ANTIFUGAL EYE DROPS ON HUMAN CORNEAL CELLS IN VITRO | DI-023 |
| OFF-LABEL USE OF GABAPENTIN AND PREGABALIN IN A TERTIARY HOSPITAL | DI-024 |
| DIMETHYLFUMARATE FOR THE TREATMENT OF MULTIPLE SCLEROSIS : DOSING REGIMEN AND SAFETY DATA. | DI-025 |
| IMPACT OF A TARGETED POLICY ON INTRAVENOUS OXYCODONE AND MORPHINE CONSUMPTION | DI-026 |
| PEMETREXED USE IN PATIENTS WITH STAGE IV LUNG ADENOCARCINOMA WHO UNDERGO THYMIDYLATE SYNTHASE LEVEL INVESTIGATION | DI-027 |
| OFF-LABEL USE: A DESCRIPTIVE RETROSPECTIVE ANALYSIS. | DI-028 |
| QUALITY OF INFORMATION ON MALE FERTILITY IN THE SUMMARY OF PRODUCT CHARACTERISTICS – CAUSE FOR CONCERN | DI-029 |
| ANALYSIS OF ADVERSE DRUG REACTIONS REPORTED IN A UNIVERSITY HOSPITAL FOR PREVENTABILITY | DI-031 |
| ANTIRETROVIRAL THERAPY, ADHERENCE AND QUALITY OF LIFE IN OLDER HIV-PATIENTS WITH MODERATE-HIGH CARDIOVASCULAR RISK | DI-032 |
| SHOULD WE MAKE PATIENTS AND NURSES AWARE OF THEIR DRUG ADMINISTRATION PROBLEMS AND TRAINING NEEDS? | DI-035 |
| INTRAVITREAL AFLIBERCEPT IN REFRACTORY AGE-RELATED MACULAR DEGENERATION | DI-036 |
| TOXIC EPIDERMAL NECROLYSIS PROBABLY DUE TO CHEMOTHERAPY: A CASE REPORT | DI-037 |
| APPROPRIATE USE OF ANTI-DEMENTIA DRUGS IN THE ELDERLY: PRESCRIPTION PRACTICE EVALUATION IN NURSING HOMES | DI-038 |
| PRELIMINARY STUDY TO ESTABLISH A NEW LINK BETWEEN HOSPITAL AND RETAIL PHARMACISTS TO FOLLOW UP PATIENTS TREATED WITH VITAMIN K ANTAGONISTS | DI-039 |
| LONG-TERM EFFECT OF AN INDIVIDUALIZED MEDICATION PLAN WITH DRUG ADMINISTRATION RECOMMENDATIONS ON THE PATIENTS’ DRUG KNOWLEDGE | DI-040 |
| KETACONAZOLE: MEDICAL TREATMENT OF CUSHING’S SYNDROME | DI-041 |
| ANTIBIOTIC CONSUMPTION IN PATIENTS WITH SEVERE PRESSURE ULCERS | DI-042 |
| BIOLOGICS ARE A NEW CHALLENGE FOR HOSPITAL PHARMACISTS – PILOT STUDY OF PATIENT ADHERENCE | DI-043 |
| USE OF KETAMINE RINSING SOLUTION FOR REFRACTORY PAIN IN A PAEDIATRIC ONCOLOGY PATIENT: A CASE REPORT | DI-044 |
| SHOULD PATIENTS OF THAI, HAN CHINESE AND HONG KONG CHINESE ORIGIN BE TESTED FOR THE HLA-B*1502 ALLELE PRIOR TO PHENYTOIN TREATMENT? | DI-045 |
| INTRAVITREAL BEVACIZUMAB VS LASER PHOTOCOAGULATION IN RETINOPATHY OF PREMATURITY | DI-046 |
| DRUG INTERACTION BETWEEN LINEZOLID AND SEROTONERGIC AGONISTS: THE APPEARANCE OF SEROTONIN SYNDROME | DI-049 |
| PAMIDRONATE TREATMENT FOR HYPERCALCEMIA IN A PREMATURE NEWBORN | DI-050 |
| ANALYSIS OF HEPATITIS B VIRUS REACTIVATION AFTER CYTOTOXIC CHEMOTHERAPY WITH RITUXIMAB | DI-052 |
| EVALUATION OF TREATMENT ADHERENCE WITH RILPIVIRINE/ EMTRICITABINE/TENOFOVIR | DI-053 |
| HAEMATOLOGICAL AND CUTANEOUS ADVERSE EVENTS ASSOCIATED WITH CHRONIC HEPATITIS C TREATMENT. | DI-055 |
| DYSPNEA INVOLVING DIMETHYL FUMARATE: FIRST CASE REPORT | DI-056 |
| THE CONTRIBUTION OF THE HOSPITAL PHARMACY TO THE HEALTHCARE OF PATIENTS ON ANTIRETROVIRAL THERAPY: AN IDENTIFICATION OF PATIENT NEEDS AND AN EVALUATION OF SERVICES PROVIDED | DI-057 |
| PHARMACOTHERAPEUTIC MONITORING IN GROWTH-HORMONE TREATMENT ADHERENCE | DI-059 |
| A CASE OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CIDOFOVIR TREATMENT | DI-061 |
| EVIDENCE-BASED MEDICINE AND CASE REPORTS: STUDY OF AN OPTIMIZED METHOD OF REPORTING MATERNAL DRUG EXPOSURE CASES | DI-062 |
| REVIEW OF ALZHEIMER’S TREATMENT IN ELDERLY PATIENTS | DI-063 |
| FOLLOW UP STUDY OF HIV PATIENTS WITH BOOSTED PROTEASE INHIBITOR MONOTHERAPY IN ROUTINE CLINICAL PRACTICE | DI-065 |
| TOPICAL AMPHOTERICIN B USED IN CANDIDA KRUSEI VAGINITIS REFRACTORY TREATMENT | DI-066 |
| TREATMENT WITH ERYTHROPOIETIN STIMULATING AGENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND CANCERS | DI-067 |
| BELIEFS, KNOWLEDGE AND EXPECTATIONS ABOUT MEDICINES AND PHARMACISTS IN ASTHMA AND PULMONARY ARTERIAL HYPERTENSION PATIENTS: PRELIMINARY RESULTS | DI-068 |
| REVIEW OF OFF-LABEL APPLICATIONS IN ORDER TO IMPROVE THE USE | DI-069 |
| INDIRECT COMPARISON OF CETUXIMAB VS. PANITUMUMAB IN METASTATIC COLORECTAL CANCER | DI-070 |
| EVEROLIMUS (AFINITOR): A CASE OF STEATOSIS IN THE TREATMENT OF PANCREATIC NEUROENDOCRINE TUMOURS | DI-071 |
| MOBILE PHONE TEXT MESSAGING TO IMPROVE ADHERENCE TO ANTIRETROVIRAL TREATMENT IN HIV-INFECTED PATIENTS | DI-072 |
| Off label use of psychotropic drugs in elderly patients with dementia in a psychogeriatric unit | DI-073 |
| ANALYSIS OF PERSISTENCE WITH ANTIRETROVIRAL THERAPY AMONG HIV+ PATIENTS IN THE SPANISH COHORT, PSITAR | DI-074 |
| INTERRUPTION AND DISCONTINUATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN PSITAR HIV COHORT | DI-076 |
| USE OF ROMIPLOSTIM IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA | DI-077 |
| PRESCRIPTION BY ACTIVE INGREDIENT VERSUS BRAND NAME | DI-078 |
| EFFECTIVENESS OF TREATMENT WITH IMMUNOGLOBULIN IN PATIENTS WITH ITP | DI-079 |
| ORAL CHEMOTHERAPY: INCIDENCE AND DESCRIPTION OF POTENTIAL INTERACTIONS BETWEEN DRUGS AND FOOD | DI-081 |
| IMPROVEMENT IN THE LIPID PROFILE OF HIV-INFECTED PATIENTS AFTER SWITCHING TO RILPIVIRINE/EMTRICITABINE/TENOFOVIR | DI-082 |
| AMPHOTERICIN B TOPICAL TREATMENT OF PLEURAL ASPERGILLOSIS: A CASE REPORT | DI-083 |
| COST-UTILITY OF SOFOSBUVIR-BASED TREATMENT FOR UNTREATED GENOTYPE 1 AND 3 HEPATITIS C PATIENTS | DI-084 |
| EVOLUTION OF ANTIRETROVIRAL PRESCRIPTIONS IN TREATMENT-NAÏVE HIV-INFECTED PATIENTS | DI-085 |
| INFLUENCE OF THE RECOMMENDATIONS OF THE EUROPEAN MEDICINES AGENCY REGARDING THE MODIFICATION OF THE PRESCRIPTION PATTERN OF METOCLOPRAMIDE | DI-086 |
| SPONTANEOUS REPORTING OF ADVERSE DRUG REACTIONS IN A SECOND LEVEL HOSPITAL: IS PHARMACOVIGILANCE WELL TARGETED? | DI-087 | |
| SINGLE-TABLET REGIMEN TENOFOVIR/ EMTRICITABINE/ RILPIVIRINE: ONE YEAR’S EXPERIENCE | DI-088 |
| EFFECTIVENESS OF ABIRATERONE IN PROSTATE CANCER IN CLINICAL PRACTICE | DI-089 |
| ASSESSMENT OF AN EDUCATION PROGRAM FOR PATIENTS TREATED WITH ORAL ANTICOAGULANTS IN A CARDIOLOGY DEPARTMENT: A PILOT STUDY | DI-091 |
| POPULATION ATTRIBUTABLE RISK OF HIP FRACTURES IN ANTIDEPRESSANT USERS IN HUNGARY AND ESTIMATION OF THE RELEVANT COST CONSEQUENCES | DI-092 |
| PREDICTORS OF NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS | DI-093 |
| TREATMENT OF PULMONARY EMPHYSEMA ASSOCIATED WITH ALPHA-1-ANTITRYPSIN DEFICIENCY | DI-094 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| THE USE OF PERFORMANCE INDICATORS TO IMPROVE STANDARDS, AND TO IDENTIFY ‘ PERFORMANCE CONCERNS’ IN INDIVIDUAL PHARMACISTS. | GM-001 |
| EVALUATION OF THE EFFECTIVENESS OF A BASIC TRAINING COURSE: THE PROCESS OF PHARMACEUTICAL LOGISTICS, PROSPECTS AND CHALLENGES FOR THE NATIONAL HEALTH SERVICE | GM-003 |
| IMPROVEMENT OF CUSTOMER FOCUS USING A QUALITY REQUIREMENT SELF-ASSESSMENT | GM-004 |
| FINANCIAL EVALUATION OF CATARACT SURGERY IN A PUBLIC HEALTH HOSPITAL | GM-005 |
| CRITICAL ANALYSIS OF CONVENTIONAL CUSTOMER SATISFACTION INDICATORS IN HOSPITALS | GM-006 |
| PLAN TO IMPROVE MEDICAL RECORDS AT THE OUTPATIENT PHARMACY SERVICE | GM-007 |
| IMPLEMENTATION OF AN OBJECTIVE STRUCTUTRED CLINICAL EXAMINATION AND EVALUATION CHECKLISTS AT AN INSTIUTE OF CLINICAL PHARMACY | GM-008 |
| MULTICENTER STUDY OF ENVIRONMENTAL 5-FU CONTAMINATION DURING NORMAL MIXING OF ANTINEOPLASTIC DRUGS | GM-009 |
| REDUCING THE OVERALL PARTICULATE CONTAMINATION EXPOSURE IN PAEDIATRIC PATIENTS: THE ADVANTAGE OF USING MULTILUMEN INFUSION SETS | GM-010 |
| CENTRALIZED PREPARATION OF ARGATROBAN SYRINGES: MEDICO-ECONOMIC ASSESSMENT AFTER 18 MONTHS | GM-011 |
| IMPACT OF DRUG SUPPLY DISRUPTIONS IN A TEACHING HOSPITAL: ONE YEAR ANALYSIS | GM-012 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HIGHLY ACTIVE ANTIRETROVIRAL THERAPY PRESCRIPTIONS IN NAIVE PATIENTS: IMPROVEMENT PLAN | HAM15-0325 |
| INTEGRATED ONCOLOGY PHARMACY UNIT IN MULTIDISCIPLINARY TEAM | HAM15-0564 | |
| DEVELOPING USE GUIDELINES FOR PATIENTS AT SPECIAL SITUATIONS | HAM15-0630 |
| A TARGETED STRATEGY AND TRAINING PROGRAM TO IMPROVE THE MEDICATION RECONCILIATION PROCESS | HAM15-0653 |
| INTEGRATION OF THE PHARMACEUTICAL CARE RECORD INTO THE MULTIDISCIPLINARY ELECTRONIC OUTPATIENT RECORD | HAM15-0800 | |
| A NATIONALLY COORDINATED APPROACH TO DEVELOPING HOSPITAL PHARMACY SERVICES IN DENMARK | HAM15-126 | |
| A ROBUST LEAN METHOD FOR IMPROVING THE MEDICATION MANAGEMENT PROCESS | HAM15-131 |
| IMPLEMENTING CHEMOTHERAPY DOSE-BANDING USING RETROSPECTIVE DATA ANALYSIS AND EXPONENTIAL CALCULUS | HAM15-248 |
| WHY NOT CHANGING PDCA BY PTDCA FOR REALIZING HOSPITAL PHARMACY PROJECTS | HAM15-407 |
| INNOVATING AND COLLABORATING – SYNERGY BETWEEN THE HOSPITAL PHARMACY AND THE UNIVERSITY | HAM15-423 |
| IMPLEMENTING PHARMACIST PRESCRIBING AT SCALE ACROSS A UNITED KINGDOM NHS HOSPITAL TRUST | HAM15-487 | |
| DEVELOPMENT AND IMPLEMENTATION OF GUIDELINES FOR THE SAFETY MANAGEMENT OF INTRATHECAL CHEMOTHERAPY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | HAM15-656 |
| CONTINUING EDUCATION FOR PHARMACY RESIDENTS THROUGH CASES DISCUSSION | HAM15-657 |
| PRESCRIPTION-DISPENSING SYSTEM FOR WOUND DRESSINGS | HAM15-660 |
| IMPROVING STAFF TRAINING IN A CYTOTOXICS PREPARATION UNIT | HAM15-704 | |
| CONTINUITY IN PERIOPERATIVE MEDICATION MANAGEMENT | HAM15-858 |
| BARCODESCANNING IN THE PHARMACY FOR A SAFER THERAPY | HAM15-879 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ANALYSIS OF INVESTIGATIONAL PRODUCTS EXPIRY DATES | OHP-001 |
| HEALTH PROFESSIONAL PARTICIPATION IN MOBILE APPLICATIONS RELATED TO MULTIPLE SCLEROSIS | OHP-002 | |
| DRUG SHORTAGES IN HOSPITAL PHARMACY: THE CAUSES AND THE CONSEQUENCES | OHP-003 |
| BOTULINUM TOXIN: PROFILE OF USE AND FINANCIAL ANALYSIS IN A SPANISH HOSPITAL | OHP-004 |
| PATTERNS OF USE OF BIOLOGICAL ANTI-TNF AGENTS AMONG PATIENTS WITH RHEUMATOLOGICAL DISEASES | OHP-005 |
| PARENTERAL NUTRITION IN HOSPITALIZED PATIENTS. A QUALITY CONTROL STUDY. | OHP-007 |
| ABILITY OF A SPANISH PHARMACIST REGISTRAR TO CARRY OUT THE INTEGRAL MANAGEMENT OF A PHARMACY DEPARTMENT | OHP-008 |
| OPTIMIZING USE OF RANIBIZUMAB IN THE HOSPITAL PHARMACY: FINANCIAL IMPACT STUDY | OHP-009 |
| VAC® THERAPY TO REDUCE SURGICAL WOUND COMPLICATIONS: THE OPINION OF THE PHARMACIST | OHP-010 |
| COST-EFFECTINESS STUDY OF CABAZITAXEL IN ACTUAL PRACTICE | OHP-013 |
| ELASTOMERIC INFUSION SYSTEMS: SAFE AND EFFICIENT ADMINISTRATION | OHP-014 |
| USE OF ANTIPSYCHOTICS AMONG ELDERLY NURSING HOME RESIDENTS | OHP-016 |
| ABILITY OF INFUSION DEVICES TO DELIVER THE EXPECTED VOLUME OF ANTINEOPLASTIC DRUG IN SOLUTION: AN IN VITRO ASSESSMENT | OHP-017 |
| CHEMICAL DEGRADATION OF METHOXSALEN AFTER ACID AND ALKALINE HYDROLYSIS | OHP-018 |
| BUDGET IMPACT OF FINGOLIMOD IN THE TREATMENT OF MULTIPLE SCLEROSIS | OHP-019 |
| PROSPECTIVE MONOCENTRIC STUDY: COMPLICATIONS RELATED TO PERIPHERALLY INSERTED CENTRAL CATHETERS (PICC) | OHP-020 |
| IMPACT OF HOSPITAL PHARMACIST INTEGRATION OVER A GENERAL SURGERY SERVICE STAFF | OHP-021 |
| ADVANCES IN PHARMACY EDUCATION: EVALUATION OF A WARD-BASED CLINICAL TEACHING COURSE | OHP-022 |
| IMPORTANCE OF PREVIOUS MICROBIAL CULTURES IN CARBAPENEMS USE | OHP-023 |
| PHARMACIST FOCUS GROUP ABOUT QUALITY OF MEDICINES AND RELATED ISSUES | OHP-024 |
| INVESTIGATIONS FOLLOWING INCREASING COMPLAINTS ABOUT INFUSION SETS FOR SAFE ADMINISTRATION OF CYTOSTATICS | OHP-025 |
| COSTS OF TRIPLE THERAPY AND THE HOSPITAL PHARMACIST’S ROLE | OHP-026 |
| LITERATURE ABOUT THE ROLE AND THE IMPACT OF PHARMACISTS: PERCEPTIONS OF PHARMACY STUDENTS | OHP-027 |
| COST-EFFECTIVENESS OF TRIPLE THERAPY FOR HEPATITIS C COMPARED WITH DUAL THERAPY IN CLINICAL PRACTICE | OHP-028 |
| SURVEY OF GOOD PRESCRIBING PRACTICE OF KANOKAD AND FEIBA USED AS ANTAGONISTS OF DIRECT ORAL ANTICOAGULANTS (DOAs) AFTER IMPLEMENTATION OF A VALIDATED PROTOCOL | OHP-030 |
| ANTIFUNGAL PROPHYLAXIS IN INVASIVE ASPERGILLOSIS | OHP-031 |
| PATIENTS’ HOME TREATMENT UPON HOSPITALIZATION | OHP-033 |
| TRACEABILITY OF IMPLANTABLE MEDICAL DEVICES (IMDs) IN HOSPITAL: INDUSTRIAL CODIFICATION SYSTEMS STILL INSUFFICIENT | OHP-034 |
| Interdisciplinary collaboration over naturopathic treatment to relieve the symptoms of hand-foot syndrome in cancer patients | OHP-035 |
| IMPROVING OUR PHARMACY OUTPATIENT UNIT: ARE WE GOING IN THE RIGHT DIRECTION? | OHP-036 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IMPORTANCE OF PHARMACOVIGILANCE FOR MAINTAINING HOSPITAL PROTOCOLS INCLUDING HIGHLY COMPLEX DRUGS: OUR OWN EGFR-TKI AFFAIR | PS-002 |
| PHARMACEUTICAL INTERVENTIONS IN THE FIELD OF ONCOHAEMATOLOGY | PS-003 |
| PURE RED CELL APLASIA ASSOCIATED WITH ADALIMUMAB THERAPY | PS-006 |
| MEDICATION ERROR: FEEDBACK CONCERNING THE DEATH OF A NURSING HOME RESIDENT | PS-009 |
| SCREENING OF ELECTRONICALLY PRESCRIBED CYTOSTATIC DRUG PROTOCOLS FOR MEDICATION ERRORS | PS-010 |
| IMPROVING THE SYSTEM FOR MONITORING ADVERSE DRUG REACTIONS | PS-011 |
| MEDICINES RECONCILIATION IN THE INTENSIVE CARE UNIT | PS-012 |
| ERRARE HUMANUM EST, NOT ONLY… A REVIEW OF ERRORS DUE TO COMPUTERIZED PHYSICIAN ORDER ENTRY (CPOE) | PS-013 |
| PHARMACEUTICAL INTERVENTIONS (PIs) IN ELECTRONIC PRESCRIPTIONS | PS-015 |
| DEVELOPING TOOLS FOR ELECTRONIC PRESCRIBING PROGRAM IMPROVEMENT | PS-016 |
| UNDER-DOSING OF ONCOLOGY PATIENTS DUE TO THE OVERFILLING WITH DILUENT OF CYTOSTATIC DRUG SOLUTIONS | PS-018 |
| RESULTS OF PHARMACEUTICAL INTERVENTIONS IN ELECTRONIC PRESCRIBING. | PS-019 |
| POTENTIALLY INAPPROPRIATE MEDICINES FOR THE ELDERLY IN THIRD LEVEL HOSPITAL DISCHARGES | PS-021 |
| POLYPHARMACY AND DRUG-DRUG INTERACTIONS IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION | PS-022 |
| TYPES, CAUSES AND POTENTIAL SERIOUSNESS OF MEDICINES ERRORS INTERCEPTED BY MEDICINES RECONCILIATION IN A GENERAL HOSPITAL | PS-023 |
| PREFILLED PRESCRIPTIONS:IS MORE SUPERVISION NEEDED FOR SAFETY REASONS? THE CASE OF RITUXIMAB | PS-024 |
| QUALITY METRICS FOR HYGIENE MONITORING | PS-025 |
| PERIPHERAL INFUSIONS IN NEONATAL AND PAEDIATRIC INTENSIVE CARE: EXTRAVASATION RATE AND RISK FACTORS | PS-026 |
| Potentially inappropiate prescriptions according to Beers and STOPP criteria in the University Hospital of Ferrara | PS-027 |
| SUCCESSFUL PREGNANCY OUTCOME WITH INTERFERON-ALPHA IN HAEMATOLOGICAL PATIENTS | PS-028 |
| IMPACT OF HAEMATOLOGICAL ADVERSE EVENTS OF TRIPLE THERAPY IN PATIENTS WITH HEPATITIS C | PS-029 |
| RISK OF ANTICHOLINERGIC EFFECTS ESTIMATED IN POLYPATHOLOGICAL PATIENTS. THE IMPACT PROJECT | PS-030 |
| EFFECTIVENESS AND SAFETY OF ANTIHYPERTENSIVE DRUGS IN ELDERLY PATIENTS | PS-031 |
| PHARMACEUTICAL VALIDATION AS SAFETY ASSURANCE FOR THE MANAGEMENT OF CYTOSTATICS | PS-032 |
| HYPOPHOSPHATEMIA IN HIV PATIENTS TREATED WITH ANTIRETROVIRAL TREATMENT | PS-034 |
| Are we aware of the risk of eye irritation caused by some eye drops, paradoxically, in the treatment of allergic conjunctivitis? | PS-035 |
| IMPROVING PHARMACOLOGICAL TREATMENT: REAL TIME SAFETY AUDITS | PS-036 |
| THE PLACE OF MATERIOVIGILANCE AS TOOL OF TRACEABILITY IN THE QUALITY MANAGEMENT SYSTEM (QMS) IN HOSPITAL PHARMACY | PS-036 |
| DRUG RELATED PROBLEMS IN ONCOHAEMATOLOGIC OUTPATIENTS INCLUDED IN CLINICAL TRIALS | PS-037 |
| DRUG SHORTAGES AND MEDICINES ERRORS | PS-039 |
| IMPACT OF DISPLACEMENT VALUES OF POWDERS FOR SOLUTION FOR INJECTION OR INFUSION ON DRUG DOSES ADMINISTERED TO CHILDREN | PS-040 |
| POLYPHARMACY AND COMPLIANCE WITH START CRITERIA IN PATIENTS ADMITTED TO A REFERENCE HOSPITAL | PS-041 |
| PARENTERAL NUTRITION (PN) IN PREMATURE INFANTS: RISK ANALYSIS AFTER REDESIGNING A PRODUCTION PROCESS | PS-042 |
| MEDICINES ERRORS IN CRITICALLY ILL PATIENTS | PS-043 |
| STUDY OF APPROPRIATENESS OF THE INDICATION FOR PARENTERAL NUTRITION FOR ADULT HOSPITALIZED PATIENTS | PS-045 |
| EVALUATION OF A SYSTEMATIC TOOL TO REDUCE INAPPROPRIATE PRESCRIBING (STRIP) IN ADULTS WITH INTELLECTUAL DISABILITY: A PILOT STUDY | PS-046 |
| MEDICINES SAFETY: THE INCIDENCE AND SEVERITY OF PRESCRIBING ERRORS IN PARENTERAL NUTRITION IN PAEDIATRIC INPATIENTS | PS-047 |
| USE OF ALTERNATIVE TREATMENT IN OUTPATIENTS | PS-048 |
| ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTIONS WITH IMMUNOSUPPRESSIVE DRUGS IN PATIENTS ON THE WAITING LIST FOR RENAL TRANSPLANTATION | PS-049 |
| SUBVISIBLE PARTICULATE MATTER IN INTRAVENOUS PREPARATIONS – A COMPARISON OF INNOVATOR AND GENERIC DICLOFENAC SODIUM | PS-050 |
| EVALUATION OF PHARMACEUTICAL INTERVENTIONS IN INTENSIVE CARE UNIT PRESCRIPTIONS | PS-052 |
| STORAGE AND USE OF CONCENTRATED INTRAVENOUS POTASSIUM SOLUTIONS IN A HOSPITAL COMPLEX | PS-054 |
| THE INCIDENCE OF DRUG ALLERGIES IN HOSPITALIZED PATIENTS | PS-055 |
| IMPROVING THE CULTURE OF SAFETY THROUGH AN ONLINE INCIDENT REPORTING SYSTEM: A NATIONAL PROJECT. | PS-056 |
| CISPLATIN -INDUCED HYPOMAGNESAEMIA | PS-057 |
| A SYSTEMATIC REVIEW OF TRENDS, RATES AND BURDEN OF HARM ASSOCIATED WITH INTRAVENOUS DRUG PREPARATION ERRORS IN HEALTHCARE SETTINGS | PS-058 |
| REVISION OF BENZODIAZEPINES RECONCILIATION AT ADMISSION AND DISCHARGE | PS-059 |
| AGREEMENT BETWEEN POTENTIAL DRUG INTERACTIONS IDENTIFIED BY AN ELECTRONIC TOOL AND CLINICAL JUDGMENT: INTERcheck VERSUS PHYSICIANS | PS-060 |
| THE RECOGNITION/RECONCILIATION PROCESS IN ELDERLY PATIENTS: A RETROSPECTIVE STUDY IN GERIATRIC AND INTERNAL MEDICINE WARDS. | PS-061 |
| A PILOT STUDY ON HOW NURSES MANAGE DRUG SUBSTITUTION DUE TO DRUG CHANGES AND DISCREPANCIES BETWEEN PRESCRIPTIONS AND DRUG AVAILABILITY | PS-062 |
| INTERVENTION OF HOSPITAL PHARMACISTS TO OPTIMIZE HOME TREATMENT | PS-063 |
| ANALYSIS OF MEDICINES ERRORS MADE IN A GENERAL HOSPITAL | PS-065 |
| PERIPHERAL NEUROPATHY INDUCED BY OXALIPLATIN: RISK FACTORS | PS-067 |
| UTILITY OF ROOT CAUSE ANALYSIS TO IMPROVE SAFETY IN THE USE OF IODINATED CONTRAST AGENTS | PS-068 | |
| POTENTIALLY INAPPROPRIATE MEDICATIONS IN PRIMARY CARE OLDER PATIENTS IN TOLEDO (SPAIN): THE STOPP-START CRITERIA COMPARED WITH THE BEERS CRITERIA. | PS-069 |
| SUBMANDIBULAR SIALADENITIS CAUSED BY ONDANSETRON IN A PATIENT WITH RISK FACTORS | PS-071 |
| INCIDENCE, MANAGEMENT AND COST OF TELAPREVIR/BOCEPREVIR-INDUCED THROMBOCYTOPENIA DURING THE FIRST 12 WEEKS OF TREATMENT IN PATIENTS WITH HEPATITIS C | PS-072 |
| OMISSION OR OVERPRESCRIPTION OF DRUGS DURING HOSPITAL RECONCILIATION CAUSED BY ERRORS IN THE INFORMATION SOURCES | PS-074 |
| EVALUATION OF TOXICITY OF STANDARDIZED TRIPLE INTRATHECAL CHEMOTHERAPY | PS-075 |
| REVIEW OF CLOSTRIDIUM DIFFICILE ISOLATES IN A GENERAL HOSPITAL | PS-078 |
| IMPLEMENTATION OF PROACTIVE MEDICINES RECONCILIATION TO REDUCE DRUG ERRORS AT ADMISSION | PS-079 |
| SAFETY SYSTEM IN THE ADMINISTRATION OF INTRAVENOUS CHEMOTHERAPY | PS-080 |
| ACCIDENTAL CYTOTOXIC EXPOSURE OF PAEDIATRIC PATIENTS, RELATIVES AND HEALTHCARE STAFF: IMPROVING THE SAFETY OF CYTOTOXIC SYRINGES | PS-081 |
| NEW ERRORS ASSOCIATED WITH COMPUTERIZED PHYSICIAN ORDER ENTRY SYSTEM: INCORRECT MEDICATION SCHEDULE | PS-084 |
| IMPACT OF DRUG INCIDENT REPORTING ON THE WORK OF PHARMACEUTICAL SERVICES | PS-085 |
| ERRORS ASSOCIATED WITH A COMPUTERIZED PHYSICIAN ORDER ENTRY SYSTEM: INCORRECT NON-DAILY MEDICINES REQUESTS | PS-086 |
| MEDICINES RECONCILIATION AT HOSPITAL DISCHARGE | PS-087 |
| IMPLANTATION OF A SAFETY STRATEGY FOR DRUG STORAGE IN A PHARMACY SERVICE | PS-089 |
| RESULTS OF A MEDICINES RECONCILIATION PROGRAM IN COMPLEX CHRONIC PATIENTS AT HOSPITAL DISCHARGE | PS-090 |
| BENEFITS OF MEDICINES RECONCILIATION IN AN EMERGENCY UNIT | PS-091 |
| EVALUATION OF PATIENT SAFETY CULTURE AMONG HEALTHCARE PROFESSIONALS IN A PHARMACY DEPARTMENT | PS-092 |
| PHARMACEUTICAL INTERVENTION TO PREVENT METFORMIN-ASSOCIATED LACTIC ACIDOSIS IN DIABETICS ADMITTED WITH KIDNEY FAILURE | PS-093 |
| BISPHOSPHONATE TREATMENT AND ATYPICAL FRACTURES | PS-094 |
| DRUG INTERACTIONS BETWEEN IMATINIB AND THE USUAL HOME TREATMENT | PS-095 |
| DENOSUMAB-INDUCED HYPOCALCEMIA IN PATIENTS WITH METASTATIC BONE DISEASE | PS-096 |
| ADMISSIONS CAUSED BY IATROGENIC DISEASE IN A REFERENCE HOSPITAL | PS-097 |
| ROLE OF THE PHARMACIST IN THE IMPLEMENTATION OF A COMPREHENSIVE SAFETY PROGRAM | PS-098 |
| DRUG-DRUG INTERACTIONS IN FLUOROPYRIMIDINES-BASED REGIMENS USED IN COLORECTAL CANCER TREATMENT | PS-099 |
| VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS FOR HOSPITALIZED MEDICAL PATIENTS (HMP) WITH LOW MOLECULAR WEIGHT HEPARIN (LMWH) | PS-100 |
| RISK MANAGEMENT OF HBV REACTIVATION IN HAEMATOLOGICAL PATIENTS TREATED WITH RITUXIMAB | PS-101 |
| CAN THE PATIENT BRING MEDICINE TO THE HOSPITAL? – THE USE AND RISK OF BROUGHT IN MEDICINES | PS-102 |
| PRESCRIPTION OF QUETIAPINE FROM THE PERSPECTIVE OF PATIENT SAFETY | PS-103 |
| INITIATIVE FOR IMPROVING MEDICINES SAFETY IN SURGICAL INPATIENTS | PS-104 |
| IMPLEMENTATION OF A UNIQUE AUTOMATION AND MANAGEMENT PLATFORM TO EXTEND PROCESS CONTROL TO ALL MEDICINAL PRODUCTS PREPARED FOR CANCER PATIENTS | PS-105 |
| Administration mistakes in cytostatic unit | PS-106 |
| STUDY OF POTENTIAL DRUG INTERACTIONS WITH ORAL ANTINEOPLASTIC AGENTS IN AN ONCOLOGY OUTPATIENT CLINIC. | PS-108 |
| BARRIERS AND FACILITATORS TO IMPLEMENTING DRUG CHANGES CAUSED BY DRUG TENDERS AND SHORTAGES | PS-109 |
| EXTENT AND DIVERSITY OF DAY-TO-DAY CLINICAL PHARMACISTS’ INTERVENTIONS IN HOSPITALS | PS-110 |
| EVALUATION OF THE MEDICINES RECONCILIATION AND VTE RISK ASSESSMENT ROLES OF THE PRESCRIBING PHARMACISTS ON THE ELECTIVE THEATRE ADMISSIONS UNIT | PS-111 |
| PHARMACEUTICAL ANALYSIS OF ASSISTANCE ON RECONCILIATION OF PEDIATRIC MEDICINES | PS-112 |
| BIOLOGICAL TREATMENT ALERTS PROJECT IN RHEUMATOLOGY PATIENTS’ ELECTRONIC RECORDS | PS-113 |
| EXPOSURE TO ANTICHOLINERGIC AND SEDATIVE DRUGS : RELATIONSHIP BETWEEN DRUG BURDEN INDEX (DBI), ANTICHOLINERGIC RISK SCALES (ARS) AND FALLS IN ELDERLY HOSPITALIZED PATIENTS | PS-116 |
| DATA QUALITY ANALYSIS OF ADVERSE DRUG EVENTS IN A VOLUNTARY REPORTING SYSTEM | PS-117 |
| Effect of anticoagulation and antiplatelet therapy on the incidence of intracranial bleeding after thrombolysis in patients with acute ischaemic stroke – a pharmacoepidemiological approach | PS-119 |
| CHALLENGES IN EVALUATION OF ELECTRONIC SWITCH MODULES FOR HOME TREATMENT | PS-120 |
| MODEL FOR ADVISING ON INTERACTIONS AND ADVERSE REACTIONS OF TYROSINE KINASE INHIBITOR TREATMENT | PS-121 |
| RISK MANAGEMENT OF PRESCRIPTION AND PREPARATION OF CYTOTOXIC DRUGS IN HOSPITAL PHARMACIES | PS-122 |
| Improving the prescription of benzodiazepines in an elderly population | PS-124 |
| ELECTRONIC ALERT SYSTEM FOR PRIMARY CARE DOCTORS FROM A MEDICINES RECONCILIATION APPLICATION | PS-125 |
| THE RATIONAL USE OF PROTON PUMP INHIBITORS IN A GERIATRIC CENTRE | PS-126 |
| ELEVATED TRANSAMINASE LEVELS IN PATIENTS TREATED WITH TOCILIZUMAB | PS-127 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CURRENT VANCOMYCIN DOSING RECOMMENDATIONS FOR PAEDIATRIC PATIENTS: A PHARMACOKINETIC EVALUATION | PKP-001 |
| DECREASED LINEZOLID SERUM LEVELS IN CRITICALLY ILL PATIENTS: CLINICAL CASE STUDIES OF A DRUG-DRUG-INTERACTION BETWEEN LINEZOLID AND RIFAMPICIN | PKP-002 |
| PHARMACOGENETICS IN ANTIPLATELET TREATMENT WITH CLOPIDOGREL IN VASCULAR PATHOLOGY | PKP-003 |
| CYP450 ISOENZYME-ASSOCIATED FOOD-DRUG INTERACTIONS ARE A NEGLECTED ISSUE IN MEDICINES INFORMATION | PKP-004 |
| Prognostic Impact of novel Gene Polymorphisms In Newly Diagnosed Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy | PKP-005 |
| COMPARISON BETWEEN THE USE OF TOTAL/IDEAL/ADJUSTED BODY WEIGHT FOR EMPIRICAL VANCOMYCIN DOSING IN OBESE PATIENTS | PKP-006 |
| APPROPRIATENESS OF SAMPLING TIMES FOR DRUG MONITORING IN THE EMERGENCY DEPARTMENT. | PKP-007 |
| IMPROVING THE QUALITY OF CLINICAL DECISION MAKING BASED ON TOTAL PHENYTOIN SERUM LEVELS | PKP-008 |
| GENETIC POLYMORPHISMS OF EFECTIVENESS TO INTERFERON-B TREATMENT IN MULTIPLE SCLEROSIS | PKP-009 |
| HIGHER THAN RECOMMENDED DOSES OF COLISTIMETHATE SODIUM IN PATIENTS WITH MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS: A BENEFIT OR AN INCREASED RISK OF TOXICITY? | PKP-010 |
| PHARMACOTHERAPEUTICS MONITORING ANALYSIS OF VANCOMYCIN IN THE PHARMACEUTICAL SERVICE | PKP-011 |
| MONITORING OF VANCOMYCIN IN 62 PATIENTS WITH CENTRAL NERVOUS SYSTEM INFECTIONS | PKP-012 |
| VARIABILITY OF EXPOSURE PARAMETERS OF ADULTS TREATED WITH HIGH DOSES METHOTREXATE | PKP-014 |
| PHARMACOGENETIC STUDY OF THE EFFECT OF POLYMORPHISMS IN THE TRAILR1/TRAIL SYSTEM ON THE RESPONSE TO TREATMENT WITH RITUXIMAB IN FOLLICULAR LYMPHOMA PATIENTS | PKP-015 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| Validation of cleaning in a multipurpose facility for non-sterile products | PP-001 |
| COMPATIBILITY AND STABILITY OF HYOSCINE N-BUTYL BROMIDE AND FUROSEMIDE ADMIXTURES FOR USE IN PALLIATIVE CARE | PP-002 |
| PRODUCTION AND STABILITY OF A READY-TO-USE HYDROXOCOBALAMIN SOLUTION FOR PAEDIATRIC PARENTERAL USE | PP-003 |
| QUALITY CONTROL ASSESSMENT OF CYTOTOXIC BAGS BY UV-RAMAN SPECTROMETRY | PP-004 |
| COMPLETE FORMULAE FOR PARENTERAL NUTRITION IN NEONATAL INTENSIVE CARE: A STABILITY TRIAL | PP-005 |
| MICROWAVE FREEZE-THAW TREATMENT OF INJECTABLE DRUGS: A REVIEW OF THE LITERATURE FROM 1980 TO 2014 | PP-006 |
| STABILITY OF DILUTED AND RECONSTITUTED ANTINEOPLASTIC DRUGS: UPDATED 2014 | PP-007 |
| THE IPILIMUMAB DRUG DAY: AN INSTRUMENT TO CONTAIN COSTS | PP-009 |
| OPTIMIZATION IN THE USE OF DRUGS FOR AGE-RELATED MACULAR DEGENERATION | PP-010 |
| ENVIRONMENTAL CONTAMINATION BY CYCLOPHOSPHAMIDE: COMPARISON OF MANUAL PRODUCTION IN BIOLOGICAL SAFETY CABINET AND ROBOT-ASSISTED PRODUCTION BY APOTECAchemo | PP-012 |
| DESENSITIZATION PROTOCOL FOR PEMETREXED HYSENSITIVITY: A CASE REPORT | PP-013 |
| PHYSICAL AND CHEMICAL STABILITY OF SEVOFLURANE IN POLYPROPYLENE SYRINGES | PP-014 |
| USING A CLOSED-SYSTEM TRANSFER DEVICE LEADS TO BETTER CONTROL OF OCCUPATIONAL EXPOSURE IN ROUTINE PRACTICE | PP-015 |
| VALIDATION OF A NEW METHOD OF STERILITY TESTING FOR THE VITAMIN AND LIPID MIXTURES DESTINED FOR THE NEONATALOGY DEPARTMENT | PP-016 |
| EVALUATION OF LONG-TERM BIOLOGICAL ACTIVITY OF BEVACIZUMAB 25 mg/mL BY AN AD HOC ELISA METHOD | PP-017 |
| PREPARATION OF EYE DROPS FOR VERNAL KERATOCONJUNCTIVITIS: THE PHARMACIST ADDED TO A TEAM ACTS AS A FULCRUM BETWEEN DOCTOR AND PATIENT | PP-018 |
| COMPATIBILITY OF IRINOTECAN-LOADED DC BEADS WITH DIFFERENT VOLUMES AND TYPES OF NON-IONIC CONTRAST MEDIA | PP-019 |
| IMPROVING EFFICIENCY BY EXTENDING THE STABILITY OF BORTEZOMIB | PP-020 |
| READY-TO-USE MEDICINES SAFETY?! NATIONAL EVALUATION OF STANDARDIZED DRUG SOLUTIONS IN THE INTENSIVE CARE MEDICINE | PP-021 |
| EVALUATION OF LONG-TERM BIOLOGICAL ACTIVITY OF CETUXIMAB 5.0 mg/mL (ERBITUX) BY AN AD HOC ELISA METHOD | PP-022 |
| EVALUATION OF THE PERFORMANCE OF AN AUTOMATED SYSTEM FOR THE PREPARATION OF CYTOTOXIC BAGS | PP-023 |
| NON-STERILE DRUG COMPOUNDING: PROFESSIONAL PRATICE EVALUATION | PP-024 |
| STABILITY OF INTRAVITREAL BEVACIZUMAB SOLUTION IN POLYPROPYLENE SYRINGES IN NEOVASCULAR MACULAR DEGENERATION | PP-025 |
| EVALUATION OF LONG-TERM BIOLOGICAL ACTIVITY OF TRASTUZUMAB 15.0 mg /mL(Herceptin) BY AN AD HOC ELISA METHOD | PP-026 |
| LONG-TERM STABILITY OF SOLUTIONS OF THE MONOCLONAL ANTIBODY CETUXIMAB | PP-027 |
| LONG-TERM STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY INFLIXIMAB | PP-028 |
| NON-COMEDOGENIC FORMULATION OF TOPICAL SIROLIMUS FOR TUBEROUS SCLEROSIS PATIENTS WITH FACIAL ANGIOFIBROMAS DEVELOPING ACNE COSMETICA | PP-029 |
| 100.000 TREATMENTS PREPARED BY ROBOT: WHAT HAVE WE LEARNED? | PP-030 |
| THE USE OF GUIDELINES IN THE CYTOTOXIC DRUGS PREPARATION UNIT: WHAT IS THE REAL WORKLOAD FOR PHARMACY TECHNICIANS? | PP-031 |
| CLOTTING CONTROL IN A HAEMODIALYSED PATIENT WITH ALLERGIC TO LOW MOLECULAR WEIGHT HEPARIN (LMWH). | PP-032 |
| NYSTATIN-LIDOCAINE LOZENGES: INNOVATION IN THE TREATMENT OF ORAL MUCOSITIS | PP-033 |
| ENVIRONMENTAL CONTAMINATION WITH CYTOTOXIC DRUGS IN A RECONSTITUTION UNIT | PP-034 |
| ALBUMIN DESENSITIZATION | PP-035 |
| PREPARATION OF AN EXPERIMENTAL CORD BLOOD SERUM EYE DROPS FOR TOPICAL USE IN SEVERE CORNEAL EPITHELIOPATHY | PP-036 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CHEMOTHERAPY DOSING AND HAEMATOLOGICAL TOXICITY IN GYNAECOLOGICAL CANCER PATIENTS | CP-003 |
| HAEMATOLOGICAL SIDE EFFECTS OF TELAPREVIR-BASED TRIPLE THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C MONOINFECTION | CP-007 |
| ADEQUACY OF INTRAVENOUS IMMUNOGLOBULIN PRESCRIPTION AT A TEACHING HOSPITAL | CP-009 | |
| CHEMOTHERAPY: A LOT IS STILL UNKNOWN, NEW PERSPECTIVES ON THE INFUSION SEQUENCE | CP-018 |
| HOSPITAL PHARMACISTS’ INTERVENTIONS IN A CENTRAL HOSPITAL | CP-019 |
| IMPACT OF A MEDICINES REVISION GROUP ON MEDICAL PRESCRIPTION IN A MODERN HOSPITAL | CP-024 |
| EVALUATION OF EFFECTIVENESS OF FAMPRIDINE IN WALKING CAPACITY OF MULTIPLE SCLEROSIS PATIENTS IN A UNIVERSITY HOSPITAL | CP-025 |
| IMPLEMENTATION OF QUALITY PRESCRIBING INDICATORS AND COMPLIANCE BY A RHEUMATOLOGY TEAM | CP-026 |
| PROTOCOLISED USE OF PROTEASE INHIBITORS FOR HEPATITIS C IN A HEALTH CARE AREA: 18 MONTHS OF COST SAVINGS | CP-027 |
| HEART FAILURE PATIENTS NEED HEART FAILURE TEAMS | CP-028 |
| EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE TREATMENT IN PATIENTS WITH METASTATIC PANCREATIC CANCER | CP-029 |
| CONCURRENT USE OF CO-TREATMENT WITH ANTIRETROVIRALS REDUCES ADHERENCE TO HIV MEDICINES | CP-031 |
| PREVALENCE OF COMORBIDITIES AND EFFECT ON ART ADHERENCE IN HIV-INFECTED PATIENTS | CP-032 |
| EVALUATION OF OUTPATIENT CLINIC LETTERS FOR MEDICATION ERRORS | CP-036 |
| THROMBOLYSIS PERFORMED WITHIN THREE HOURS FOLLOWING STROKE REDUCES DISABILITY AND COSTS: AN ECONOMIC MODEL TO ESTIMATE SAVINGS | CP-037 |
| EVALUATION OF THE USE OF USTEKINUMAB IN CLINICAL PRACTICE AND ITS ECONOMIC IMPACT | CP-041 |
| AUDIT OF THE PATIENT TREATMENT PROCESS IN AN ONCOLOGY OUTPATIENT CLINIC: FROM WELCOME TO THE ADMINISTRATION OF CHEMOTHERAPY | CP-044 |
| ADEQUACY OF INTRAVENOUS IMMUNOGLOBULIN PRESCRIPTION AT A TEACHING HOSPITAL | CP-045 |
| HOW TO RESPOND TO HIGH LEVELS OF SERUM POTASSIUM | CP-047 |
| MULTIDISCIPLINARY MANAGEMENT AS A RESOURCE FOR METABOLIC DISEASES: COOPERATION BETWEEN CLINICIANS AND PHARMACISTS IN AN ITALIAN CENTRE FOR RARE DISEASES | CP-048 |
| ADHERENCE TO PROTEIN TYROSINE KINASE INHIBITORS TREATMENT IN CHRONIC MYELOID LEUKAEMIA AND GASTROINTESTINAL STROMAL TUMOURS | CP-050 |
| ESTABLISHMENT OF A CLINICAL PHARMACY DEPARTMENT AT THE UNIVERSITY MEDICAL CENTRE, LJUBLJANA | CP-051 |
| EVALUATION OF PHARMACEUTICAL INTERVENTIONS IN A GENERAL MEDICAL AND A GERIATRIC UNITS | CP-056 |
| EFFICIENCY OF A PROTOCOL TO PREVENT DELAYED CHEMOTHERAPY-INDUCED EMESIS | CP-058 |
| CONGRUENCE OF SEVERITY RATINGS ASSIGNED BY TWO DRUG INTERACTION DATABASES IN HAEMOTOLOGICAL TREATMENT SHEETS | CP-059 |
| AN INVESTIGATION INTO THE IMPACT OF A CLINICAL WARD PHARMACIST ON MEDICINES RETURNED TO PHARMACY FOR RE-USE OR DESTRUCTION | CP-060 |
| SUBCUTANEOUSLY IMPLANTED PORT-CHAMBER CENTRAL VENOUS CATHETERS: PREVENTION AND CARE OF OCCLUSION | CP-062 |
| COMPARATIVE EFFICACY OF BIOLOGICAL DRUGS IN THE MAINTENANCE PHASE IN ADULT PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS | CP-064 |
| EFFECTIVENESS IN GENOTYPES 1B, 1A IN PATIENTS WITH HEPATITIS C VIRUS INFECTION TREATED WITH TELAPREVIR-BASED TREATMENT | CP-065 |
| INTERLEUKIN-28B POLYMOPHISM AS A PREDICTOR OF RESPONSE TO TELAPREVIR-BASED REGIMENS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION | CP-066 |
| ANTIRETROVIRAL TREATMENT ADHERENCE IN PAEDIATRIC PATIENTS | CP-068 |
| ECONOMIC IMPACT OF BIOLOGICAL TREATMENTS IN RHEUMATIC DISEASES | CP-069 |
| COMPARISON THE DIFFERENT INCLUSION AND EXCLUSION CRITERIA FOR TREATMENT WITH ECULIZUMAB IN SPAIN | CP-074 |
| EVALUATION OF GLUTAMINE SUPPLEMENTATION IN PARENTERAL NUTRITION IN A GENERAL HOSPITAL | CP-077 |
| ANALYSIS OF ONDANSETRON PRESCRIPTION PRACTICES IN THE CARE OF POSTOPERATIVE NAUSEA AND VOMITING | CP-080 |
| ROLE OF THE HOSPITAL PHARMACIST IN AUTOMATICALLY REMOVING PRESCRIPTION OF CONTINUOUS ANALGESIA PUMPS IN A TRAUMA SERVICE | CP-081 |
| EVALUATION OF THE SAFETY AND EFFICACY OF MITOXANTRONE IN CYPRIOT PATIENTS WITH WORSENING FORMS OF MULTIPLE SCLEROSIS | CP-087 |
| SURVIVAL TIME OF BIOLOGICAL TREATMENTS IN PSORIASIS | CP-088 |
| CLINICAL AUDIT OF PRESCRIPTIONS OF PROTHROMBIN COMPLEX CONCENTRATE IN A SMALL HOSPITAL | CP-092 |
| IS THE EMERGENCY PHARMACIST ROLE ACCEPTED BY EMERGENCY DEPARTMENT STAFF? | CP-095 |
| ECONOMIC IMPACT OF OPTIMISING BIOLOGIC THERAPIES FOR ARTHROPATHIES | CP-099 |
| STRATEGY FOR THE SIMPLIFICATION OF ANTIRETROVIRAL THERAPY: PROTEASE INHIBITOR MONOTHERAPY | CP-100 |
| CARBOPLATIN – PACLITAXEL – BEVACIZUMAB BASED TREATMENT FOR NON-SMALL CELL LUNG ADVANCED CANCER PATIENTS: USE REVIEW | CP-102 |
| COST EFFECTIVENESS OF TICAGRELOR FOR CARDIOVASCULAR PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND LOW-DOSE ASPIRIN IN SPAIN | CP-105 |
| USE OF BOTULINUM TOXIN TYPE A IN ESOPHAGEAL ACHALASIA: A CASE REPORT | CP-107 |
| EVALUATION OF CLINICAL PHARMACIST INTERVENTIONS IN A UNIVERSITY HOSPITAL LOCATED IN A RURAL AREA IN LEBANON | CP-108 |
| ACUTE CORONARY SYNDROME: USE OF THE NEW ANTIPLATELET DRUGS IN CLINICAL PRACTICE | CP-114 |
| BIOMARKERS ASSOCIATED TO TREATMENT RESPONSE AND PROGNOSIS IN GLIOBLASTOMA MULTIFORME | CP-116 |
| NEONATAL VANCOMYCIN: EXPLORING LEVELS AT NHS TAYSIDE, SCOTLAND | CP-118 |
| STUDY OF DRUG TREATMENTS SUITABLE FOR INTRAVENOUS TO ORAL SWITCHING | CP-119 |
| INCIDENCE AND RISK FACTORS FOR TENOFOVIRASSOCIATED ASSOCIATED PATIENTS | CP-127 |
| EVALUATION OF HOSPITALISED PATIENTS’ACUTE PAIN: PRELIMINARY SURVEY TO PROMOTE USE OF BEHAVIOURAL TOOLS | CP-128 |
| FACING THE CHALLENGE OF OFF-LICENCE DRUG ADMINISTRATION IN PATIENTS WITH DYSPHAGIA | CP-132 |
| EVALUATION OF PHARMACOECONOMIC INTERVENTIONS IN NEUROLOGICAL PATIENTS TREATED WITH IMMUNOGLOBULINS | CP-138 |
| A CROSS-SECTIONAL SURVEY OF ANTIMICROBIAL STEWARDSHIP STRATEGIES IN UK HOSPITALS | CP-139 |
| SPONTANEOUS RESISTANCE TO TEMOCILLIN, AN OLD AND RARELY-USED ANTIBIOTIC INDICATED FOR THE TREATMENT OF MULTIRESISTANT ENTEROBACTERIACEAE INFECTIONS: A CASE REPORT | CP-140 |
| INCREASED FOCUS ON INHALATION TECHNIQUE AFTER IMPROVEMENT OF NURSING STAFF QUALIFICATIONS: BEFORE/AFTER STUDY AT AALBORG UNIVERSITY HOSPITAL | CP-142 |
| EVALUATION OF INHALED COLISTIN TREATMENT IN PATIENTS WITHOUT CYSTIC FIBROSIS | CP-143 |
| ELECTRONIC AUTO-INJECTION DEVICE FOR b-INTERFERON ADMINISTRATION IN MULTIPLE SCLEROSIS PATIENTS: A NEW TOOL TO IMPROVE ADHERENCE | CP-144 |
| SHARED MEDICATION RECORD DISCREPANCIES IN ASSOCIATION WITH ELECTRONIC TRANSFER OF PRESCRIPTIONS | CP-146 |
| DEVELOPMENT OF A DATABASE TO SHARE INFORMATION ABOUT HOSPITAL DRUG FORMULARIES | CP-147 |
| COMPARATIVE EFFICACY AND SAFETY OF TUMOUR NECROSIS FACTOR ALPHA BLOCKERS (ANTI-TNF) IN NON-FISTULIZING CROHN’S DISEASE | CP-148 |
| IMPLEMENTATION OF AN INTEGRATED MULTIFACETED APPROACH TO IMPROVE CRUSHING PRACTICE ON HOSPITAL WARDS | CP-150 |
| COMPARISON OF 5 HEALTH CARE PROFESSIONALS’RATINGS OF THE CLINICAL SIGNIFICANCE OF DRUG RELATED PROBLEMS | CP-153 |
| MISSED AND DELAYED DOSES OF PARKINSON’S MEDICINES AT NORTH BRISTOL NHS TRUST (NBT) (UK) | CP-155 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IS THE UNIT DOSE PROCESS A TOOL FOR PATIENT SAFETY AND FOR IMPLEMENTING ‘LEAN THINKING’ IN THE DRUG SUPPLY CHAIN? | DD-007 |
| PROSPECTIVE STUDY ON RESTRICTED-USE ANTIBIOTICS: ERTAPENEM, LINEZOLID, TIGECYCLINE AND DAPTOMYCIN | DD-008 |
| THE IMPORTANT ROLE OF THE HOSPITAL PHARMACIST IN THE NORWEGIAN DRUG TENDERING PROCESS | DD-009 |
| STUDY OF THE REDUCTION IN THE RATE OF DISPENSING ERRORS FOLLOWING THE INSTALLATION OF AN AUTOMATED DELIVERY ROBOT | DD-014 |
| EVALUATION OF THE THERMAL PERFORMANCE OF A CHEMOTHERAPY TRANSPORT SYSTEM | DD-015 |
| A STUDY OF COMPLAINTS ASSOCIATED WITH MEDICINES IN A UNIT DOSE DISPENSING SYSTEM | DD-017 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EFFICACY STUDY OF ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL | DI-007 |
| PHARMACEUTICAL INTERVENTION ON SWITCHING TREATMENT FROM INTRAVENOUS TO ORAL ANTIBIOTICS | DI-013 |
| DOES BOTULINUM TOXIN SURGERY CHANGE QUALITY OF LIFE IN AXILLARY HYPERHIDROSIS? WHAT PATIENTS THINK | DI-014 |
| REGIONAL CARD FOR THE PRESCRIPTION OF BOTULINUM TOXIN BY CLOSTRIDIUM BOTULINUM TYPE A: AN INSTRUMENT FOR APPROPRIATE PRESCRIBING | DI-016 |
| SAFETY OF NAB-PACLITAXEL PLUS GEMCITABINE IN PATIENTS WITH METASTATIC PANCREATIC CANCER | DI-017 |
| INFORMATION ABOUT THE ANTICANCER CHEMOTHERAPY PROCESS: A FILM FOR PATIENTS | DI-023 |
| CETUXIMAB IN THE TREATMENT OF ADVANCED METASTATIC COLORECTAL CANCER | DI-024 |
| QUALITY OF LIFE IN OLDER HIV-INFECTED PATIENTS WITH ANTIRETROVIRAL THERAPY | DI-027 |
| PHARMACOTHERAPY PROFILE OF HIV-PATIENTS OLDER THAN 50 YEARS IN USE OF ANTIRETROVIRAL THERAPY | DI-028 |
| USE OF ERYTHROPOIESIS-STIMULATING AGENTS AFTER THE CESSATION OF SUPPLY OF CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR | DI-029 |
| PRESCRIPTION PROFILE OF ABIRATERONE IN METASTATIC PROSTATE CARCINOMA | DI-030 |
| EFFECTIVENESS AND SAFETY OF ABIRATERONE IN PROSTATE CANCER IN CLINICAL PRACTICE | DI-031 |
| OMALIZUMAB USE: OUR EXPERIENCE IN A REGIONAL HOSPITAL | DI-032 |
| SAFETY PROFILE STUDY OF PLANNED RANDOMISED CONVERSION FROM TACROLIMUS TO SIROLIMUS-BASED IMMUNOSUPPRESSIVE REGIMEN IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS | DI-033 |
| NEUROLOGICAL TOXICITY CAUSED BY IFOSFAMIDE IN CHILDREN | DI-034 |
| COMPARISON OF INDIRECT TREATMENT FOR FIRST-LINE METASTATIC PANCREATIC CANCER | DI-037 |
| APPROPRIATENESS OF TELAPREVIR TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 | DI-043 |
| EFFECT OF THE COMPLEXITY OF THE DRUG REGIMEN ON ADHERENCE IN HIV INFECTED PATIENTS | DI-047 |
| DRUG INDUCED FEVER CAUSED BY PIPERACILLIN-TAZOBACTAM IN ADULTS WITH CYSTIC FIBROSIS | DI-050 |
| RIFAMPICIN-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS | DI-051 |
| MULTICENTER STUDY TO DETERMINE THE SAFETY OF PROTEASE INHIBITORS IN PATIENTS INFECTED WITH HEPATITIS C VIRUS | DI-053 |
| OFF LABEL USE OF ADALIMUMAB IN THE MANAGEMENT OF SEVERE SUPPURATIVE HIDRADENITIS | DI-056 |
| Experience in paediatric use of dapsone for the treatment of linear IGA dermatosis | DI-058 |
| USE, EFFECTIVENESS AND SAFETY OF IVABRADINE IN PAEDIATRIC PATIENTS | DI-059 |
| DAPTOMYCIN: A DRUG USE REVIEW AT A GENERAL HOSPITAL | DI-060 |
| ROMIPLOSTIM AND ELTROMBOPAG IN THE TREATMENT OF IDIOPATIC THROMBOCYTOPENIC PURPURA | DI-062 |
| OFF-LABEL DRUG USE IN A SPANISH UNIVERSITY HOSPITAL | DI-063 |
| BOTULINUM TOXIN TYPE A: EXPERIENCE WITH 51 PATIENTS OF A NEUROLOGY DEPARTMENT | DI-064 |
| ORAL ANTICOAGULANTS AND ADVERSE EVENTS IN THE EMERGENCY ROOM | DI-065 |
| EVALUATION OF THE SAFETY OF LENALIDOMIDE IN CLINICAL PRACTICE | DI-068 |
| EFFICACY OF ECULIZUMAB IN ADULT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME RESISTANT TO PLASMA TREATMENT | DI-072 |
| EFFICACY AND SAFETY OF ELTROMBOPAG IN IMMUNE THROMBOCYTOPENIA | DI-075 |
| PIRFENIDONE: COMPASSIONATE USE IN TWO PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | DI-076 |
| STUDY OF RITUXIMAB IN OFF-LABEL SITUATIONS | DI-078 |
| BRENTUXIMAB VEDOTIN: FROM NAMED PATIENT PROGRAM (NPP) TO ITALIAN LAW 648/96 | DI-079 |
| UNINSURED PATIENTS: TOOLS AIMED AT SAFE DISPENSING | DI-081 |
| DEPRESCRIBING STRATEGIES IN ELDERLY PATIENTS OR PATIENTS WITH SEVERAL CHRONIC CONDITIONS | DI-083 |
| ACENOCOUMAROL DRUG INTERACTIONS IN HOSPITALISED PATIENTS | DI-084 |
| ADVERSE REACTIONS TO RADIOPHARMACEUTICALS: LITERATURE REVIEW OF THE PAST 70 YEARS | DI-085 |
| REVIEW OF OFF-LABEL USE AND ECONOMIC IMPACT OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN A TERTIARY HOSPITAL | DI-086 |
| DRUG USE EVALUATION: EFFECTIVENESS, SAFETY AND COST OF EMTRICITABINE/TENOFOVIR/RILPIVIRINE | DI-087 |
| ADALIMUMAB FOR THE TREATMENT OF BEHCET’S DISEASE | DI-096 |
| BUDESONIDE SUSPENSION FOR EOSINOPHILIC ESOPHAGITIS | DI-097 |
| EFFECTIVENESS AND SAFETY STUDY IN CHILDREN WITH STEROID-DEPENDENT NEPHROTIC SYNDROME TREATED WITH LEVAMISOLE | DI-099 |
| A TOOL FOR SHARING KNOWLEDGE – THE HOSPITAL PHARMACIES INFORMATION DATABASES REGARDING MEDICINES | DI-103 |
| TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKAEMIA: USE AND SAFETY PROFILE | DI-104 |
| EPIDEMIOLOGICAL MONITORING OF ADVERSE DRUG REACTIONS IN PAEDIATRIC EMERGENCY DEPARTMENTS | DI-105 |
| A PROTOCOL FOR THE SELECTION OF ANALGESIC MIXTURE DRUGS ACCORDING TO PAIN INTENSITY IN A POSTOPERATIVE PAIN UNIT | DI-106 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| COMPLIANCE WITH FDA RECOMMENDATIONS ABOUT OVERDOSING WITH CARBOPLATIN | GM-006 |
| VIDEO OBSERVED TREATMENT OF TUBERCULOSIS: STUDY OF IMPLEMENTATION | GM-012 |
| UNDERGRADUATE TEACHING IN A HOSPITAL PHARMACY SERVICE: EXPERIENCE AND IMPROVEMENT | GM-013 |
| ST SAVINGS POTENTIAL OF PHARMACY STAFF-BASED PREPARATION OF BIOLOGICALS COMPARED TO NURSE-BASED PREPARATION | GM-014 |
| SURVEY TO ASSESS OUTPATIENT SATISFACTION AS A QUALITY MEASURE TOOL IN A HOSPITAL PHARMACY | GM-018 |
| USE OF IMATINIB IN GIST AND CML: COMPARISON OF EXPENDITURE BETWEEN NATIONAL CANCER INSTITUTE OF MILAN AND NATIONAL EXPENDITURE | GM-019 |
| CHANGES CAUSED BY IMPLEMENTATION OF THE ABC (ACTIVITY BASED COSTING) METHOD FOR DRUG SUPPLY IN A FRENCH UNIVERSITY HOSPITAL | GM-021 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| National monitor for the quality of medication surveillance | |
| Safe and integrated onco-hematology workflow | |
| Medication reviews conducted by clinical pharmacist in emergency ward | |
| High Performance Medicines Management – HPMMF | |
| cation Safety Audits developed and conducted by a hospital pharmacy in Finland | |
| Home Parenteral Nutrition (HPN) Safety and Quality Assurance Project | |
| Early-stage experiences of the implementation of a large-scale robotic storage and distribution system in a hospital pharmacy service within a large UK health authority | |
| pediatric-dosages.ch | |
| eLearning Environment for Ensuring the Competence in Pharmacotherapy |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PHARMACIST-PHYSICIAN COLLABORATION TO ENSURE THE SAFE DOSING IN RENAL IMPAIRMENT AMONG PATIENTS ADMITTED TO AN EMERGENCY WARD IN FINLAND | INT-006 |
| COMPARISON OF PHARMACIST-LED MEDICATION REVIEW AT DIFFERENT STAGES DURING THE INPATIENT STAY | INT-008 |
| EFFICIENCY OF AN ANTIFUNGAL STEWARDSHIP PROGRAM (PROMULGA PROJECT) | INT-009 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PRESCRIPTION OF ORAL ANTI-DIABETIC AGENTS RECENTLY MARKETED IN A HEALTH AREA | OHP-004 |
| PHARMACOVIGILANCE IN THE CONDUCT OF CLINICAL TRIALS: THE EXPERIENCE OF AN ITALIAN ETHICS COMMITTEE | OHP-011 |
| IMPACT OF A CZT DETECTOR GAMMA CAMERA ON THE 99MTC-TETROFOSMIN ACTIVITY FOR MYOCARDIAL PERFUSION IMAGING IN NUCLEAR CARDIOLOGY | OHP-013 |
| A COMPUTERISED QUEUE MANAGEMENT SYSTEM IN THE OUTPATIENT PHARMACEUTICAL CARE UNIT OF A HOSPITAL PHARMACY SERVICE | OHP-014 |
| CURRENT USE OF ALUMINIUM AND POTASSIUM SULFATE IN THE TREATMENT OF HAEMORRHAGIC CYSTITIS: A DESCRIPTIVE STUDY | OHP-015 |
| EFFECT OF INTRODUCING CLOSTRIDIUM HYSTOLITICUM COLLAGENASE FOR TREATING DUPUYTREN DISEASE IN A HOSPITAL | OHP-017 |
| CE MARKING FOR IMPLANTABLE MEDICAL DEVICES: WHAT’S GOING ON BEHIND HOSPITAL DOORS? | OHP-018 |
| REORGANISATION OF A PERMANENT STERILE OSTEOSYNTHESIS IMPLANTS STORE | OHP-019 |
| DESCRIPTIVE STUDY OF THE ENTERAL TUBE FEEDING PRACTICES IN A TERTIARY HOSPITAL | OHP-021 |
| THE INTRODUCTION OF THE OFF-LINE METHOD FOR EXTRA-CORPOREAL PHOTOCHEMOTHERAPY (ECP) IN SIENA UNIVERSITY HOSPITAL (AOUS): THE ECONOMIC IMPACT | OHP-023 |
| IMPROVEMENT OF HEALTH CARE SERVICES FOR AMBULATORY HIV PATIENTS: PRELIMINARY DATA | OHP-025 |
| TELEMATICS PHARMACEUTICAL CARE OF SHORT BOWEL SYNDROME OUTPATIENTS | OHP-030 |
| THE USE OF HANDHELD DEVICES AMONG HEALTHCARE STAFF AND STUDENTS IN A TEACHING HOSPITAL IN QATAR | OHP-031 |
| IMPLANTATION OF A PERIOPERATIVE NUTRITIONAL SUPPORT PROGRAMME FOR PATIENTS SCHEDULED FOR MAJOR ELECTIVE LOWER GASTROINTESTINAL SURGERY | OHP-035 |
| AJUSTED INDIRECT COMPARISON OF INTRAVITREAL AFLIBERCEPT VERSUS INTRAVITREAL BEVACIZUMAB IN WET-AGE RELATED MACULAR DEGENERATION | OHP-036 |
| MONITORING OF ADVERSE REACTIONS TO DEPUY ASR DEVICES IN PATIENTS WITH METAL-ON-METAL HIP ARTHROPLASTY | OHP-040 |
| IMPACT OF THE PAEDIATRIC REGULATION ON THE ENVIRONMENT OF PAEDIATRIC MEDICINES USE: PAEDIATRIC INVESTIGATION VERSUS OFF-LABEL DRUG USE | OHP-042 |
| AUXILIARY MEDICINAL PRODUCTS PROVIDED BY SPONSOR OR THE HOSPITAL IN CLINICAL TRIALS | OHP-047 |
| COMPATIBILITY AND STABILITY OF MORPHINE AND FUROSEMIDE ADMIXTURES | OHP-048 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IMPORTANCE OF PHARMACOVIGILANCE FOR MAINTAINING HOSPITAL PROTOCOLS INCLUDING HIGHLY COMPLEX DRUGS: OUR OWN EGFR-TKI AFFAIR | PS-002 | |
| EFFICACY OF A CLOSED LOOP MEDICINES ADMINISTRATION PROCESS TO REDUCE THE PROBABILITY OF MEDICINES ERRORS | PS-004 |
| PHARMACEUTICAL INTERVENTIONS IN AN EMERGENCY DEPARTMENT UNDER A PHARMACEUTICAL CARE SYSTEM | PS-005 |
| RHABDOMYOLYSIS POSSIBLZ PROVOKED BY A SITAGLIPTIN-ATORVASTATIN INTERACTION | PS-006 |
| EXPOSURE TO VASOCONSTRICTOR NASAL DECONGESTANTS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION | PS-008 |
| ROLE OF PHARMACIST IN PREVENTING DRUG-RELATED PROBLEMS ASSOCIATED TO PRESCRIPTION OF TOTAL PARENTERAL NUTRITION BY CLINICAL STATUS | PS-010 |
| ADVERSE DRUG EVENTS (ADES) IN SPANISH HOSPITALS | PS-018 |
| MEDICAL ACCEPTANCE OF SEQUENTIAL TREATMENT | PS-023 |
| RELATIVE SAFETY OF BIOLOGICAL DRUGS IN THE MAINTENANCE PHASE IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | PS-026 |
| MEDICINES RECONCILIATION AT EMERGENCY DEPARTMENT DISCHARGE | PS-027 |
| REVIEW OF THE SYSTEM FOR RECORDING ELDERLY PATIENTS’ MEDICINES AT ADMISSION | PS-029 |
| REVIEW OF DRUG PRESCRIPTION ERRORS REPORTED TO THE HEALTH DEPARTMENT OF THE MADRID AUTONOMOUS COMMUNITY | PS-038 |
| PHARMACEUTICAL EVALUATION OF DRUG DOSAGE ADJUSTMENT ACCORDING TO RENAL FUNCTION | PS-040 |
| SAFETY PROFILE OF AMIODARONE AND DRONEDARONE IN PATIENTS TREATED WITH ORAL VITAMIN K ANTAGONISTS | PS-042 |
| STREAMLINING MEDICINES ERROR REPORTING FUNCTIONALITY WITHIN A CLINICAL PHARMACY INTERVENTION PROGRAM | PS-044 |
| ADVERSE DRUG EVENTS IN THE PRESCRIBING PROCESS | PS-045 |
| REDUCING ERRORS IN PHARMACEUTICAL CALCULATIONS – EDUCATING & TRAINING MEDICAL STAFF | PS-046 |
| CO-PRESCRIPTION OF SIMVASTATIN AND POTENT INHIBITORS OF CYP3A4; MONITORING SYSTEM IN HOSPITAL | PS-047 |
| RISKS RELATED TO DRUG RECALLS: A CASE REPORT | PS-051 |
| SYSTEM FOR IMPROVING ADHERENCE IN POLYMEDICATED PATIENTS | PS-053 |
| MEDICINES RECONCILIATION STUDY AT THE EMERGENCY DEPARTMENT | PS-055 |
| PROGRAMME FOR THE DISPENSING OF LOW MOLECULAR WEIGHT HEPARINS TO ANTICOAGULATION PATIENTS UNDERGOING MINOR OUTPATIENT SURGERY | PS-057 |
| RESULTS OF PHARMACEUTICAL INTERVENTIONS AT A HOSPITAL EMERGENCY DEPARTMENT | PS-065 |
| ANALYSIS OF PHARMACY INTERVENTIONS ON ANTIBIOTIC PRESCRIPTIONS IN MEDICAL PATIENTS | PS-068 |
| TELAPREVIR-INDUCED STEVENS-JOHNSON SYNDROME. A CASE REPORT | PS-071 |
| PRESCRIBING DEFICIENCIES: A MATTER OF LACK OF KNOWLEDGE OR NEGLIGENCE? | PS-072 | |
| PRESCRIBING DEFICIENCIES: A MATTER OF LACK OF KNOWLEDGE OR NEGLIGENCE? | PS-072 |
| HEALTHCARE ASSOCIATED INFECTIONS IN LONG-TERM CARE FACILITIES IN ASTI (ITALY) | PS-074 |
| EVALUATION OF FALL RISKS IN ELDERLY PATIENTS | PS-075 |
| ESSENTIAL THROMBOCYTHAEMIA IN PREGNANCY | PS-086 |
| RECONCILIATION OF CHRONIC MEDICINES IN PATIENTS ADMITTED TO THE UROLOGY SERVICE | PS-087 |
| MEDICINES NOT AVAILABLE IN THE HOSPITAL ARE A POTENTIAL RISK OF ADVERSE DRUG EVENTS | PS-088 |
| ANALYSIS OF THE VARIATION IN THE PLATELET COUNTS OF PATIENTS TREATED WITH LINEZOLID | PS-093 |
| COMPLICATIONS AFTER VANCOMYCIN PERFUSION BY CENTRAL VENOUS CATHETER | PS-097 |
| PHARMACEUTICAL INTERVENTION: ENOXAPARIN USE RECOMMENDATIONS IN PATIENTS WITH RENAL IMPAIRMENT | PS-099 |
| IMPLEMENTATION OF AN ELECTRONIC MEDICINES ADMINISTRATION RECORD IN A UNIVERSITY HOSPITAL | PS-102 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| GENETIC POLYMORPHISMS ASSOCIATED WITH THE DOSE OF ACENOCOUMAROL | PKP-003 |
| ASSESSMENT OF THE EFFECTIVENESS OF MONITORING VANCOMYCIN IN PATIENTS UNDERGOING HAEMODIALYSIS | PKP-008 |
| DRUG INTERACTIONS WITH AZOLE ANTIFUNGALS IN PATIENTS TREATED WITH HAEMATOPOIETIC STEM CELLS | PKP-013 |
| DRIED BLOOD SPOT SAMPLING OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: A COMPARISON WITH VENOUS BLOOD SAMPLES | PKP-014 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| DEVELOPMENT OF METHOD AND PROCESS VALIDATION FOR QUANTITATIVE ANALYSIS OF IBUPROFEN SUPPOSITORIES | PP-001 |
| PHYSICAL-CHEMICAL STABILITY OF DOCETAXEL CONCENTRATED SOLUTION DURING ONE MONTH | PP-003 |
| EXTEMPORANEOUSLY COMPOUNDED ORAL MEDICINES IN SPANISH HOSPITAL PHARMACIES | PP-006 |
| IMPLEMENTING APPROPRIATE COMPOUNDED PAEDIATRIC MIDAZOLAM 3MG/ML SYRUP IN THE CLINICAL HOSPITAL BITOLA | PP-008 |
| IMPLEMENTING APPROPRIATE COMPOUNDED PAEDIATRIC CHLORAL HYDRATE RECTAL DOSAGE FORM | PP-009 |
| IMPLEMENTATION OF A PROCESS OPTIMISATION PROTOCOL FOR THE PREPARATION OF READY-TO-USE (RTU) INTRACAMERAL CEFUROXIME FOR ENDOPHTHALMITIS PROPHYLAXIS (EP) AFTER CATARACT SURGERY | PP-011 |
| CENTRALISED PREPARATION OF METHOTREXATE SYRINGES: A COST CONTROL OPTION BETWEEN PRIMARY CARE PHARMACY AND HOSPITAL PHARMACY | PP-016 |
| ADVANCE PREPARATION OF CHEMOTHERAPY – CONSEQUENCES | PP-018 |
| VALIDATION AND IMPLEMENTATION OF AN ANALYTICAL QUALITY CONTROL METHOD IN PRETERM PARENTERAL NUTRITION | PP-021 |
| EXTENDED STABILITY OF 2.5 MG/ML BORTEZOMIB SOLUTION IN SYRINGES AND OPENED VIALS | PP-022 |
| DESIGN OF TOCILIZUMAB DESENSITISATION PROTOCOL AFTER A HYPERSENSITIVITY REACTION | PP-032 |
| PHYSICO-CHEMICAL STABILITY OF CABAZITAXEL – CONTAINING PREMIX SOLUTION AND READY-TO-ADMINISTER SOLUTIONS | PP-033 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| BUILDING UP A REGIONAL AND INTERDISCIPLINARY | BEA-001 |
| TAKING A LEAD IN WARD PATIENT SAFETY | BEA-004 |
| WHAT DO YOUR EMPLOYEES THINK ABOUT TOTAL QUALITY MANAGEMENT SYSTEMS? | BEA-007 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| A multicentricretrospective study to evaluate the economic impact of the prescribing models for Trastuzumabin the Piedmont Region (Italy) | CPC-002 |
| A RETROSPECTIVE ANALYSIS OF THE SWITCHES FROM ORIGINATOR AND BIOSIMILAR RECOMBINANT HUMAN ERYTHROPOIETINS IN CHRONIC KIDNEY DISEASE | CPC-003 | |
| A STUDY TO EVALUATE USTEKINUMAB IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | CPC-005 |
| ADHERENCE PROBLEMS IDENTIFIED BY MOTIVATIONAL INTERVIEWING AND MEDICINES REVIEW IN STROKE PATIENTS | CPC-007 |
| ADHERENCE, TOLERABILITY AND QUALITY OF LIFE ASSESSMENT IN PATIENTS TREATED WITH TELAPREVIR | CPC-008 |
| ANALYSIS OF ANTIFUNGAL USE AND COST IN A SPECIALIST HOSPITAL DURING THE LAST THREE YEARS (2009–2011) | CPC-013 |
| ANALYSIS OF ANTIRRETROVIRAL TREATMENT ADHERENCE | CPC-015 |
| ANETH: AN ORIGINAL TOOL FOR ASSESSING, PROMOTING AND IMPROVING YOUR PATIENT EDUCATION (PE) PROGRAMME | CPC-018 |
| ANTICOAGULANT THERAPEUTIC EDUCATION: A NEW MORE SUCCESSFUL METHOD? | CPC-019 |
| ASSESSMENT OF THE RELEVANCE OF FLUOROQUINOLONE PRESCRIPTIONS IN THE INTERNAL MEDICINE DEPARTMENT AND IMPACT ON ANTIBIOTIC STEWARDSHIP | CPC-022 |
| ASSESSMENT OF THE WHOLE INTERCEPTIVE AND POST-FERTILISATION EFFECTS OF POSTCOITAL LEVONORGESTREL | CPC-023 |
| ASSESSMENT OF WARD-BASED CLINICAL PHARMACY SERVICES IN JIMMA UNIVERSITY SPECIALIST HOSPITAL, ETHIOPIA: THE CASE OF INTERNAL MEDICINE | CPC-024 |
| CLINICAL CASE OF AN ADVERSE DRUG REACTION DUE TO THE ADMINISTRATION OF AN ESTROGENE/GESTAGENE COMBINATION DRUG | CPC-030 |
| CLINICAL TRIALS QUALITY: MEDICAL JOURNAL PUBLICATION INVOLVEMENT | CPC-031 |
| CLOPIDOGREL FOR THE TREATMENT OF CHILDREN WITH A SYSTEMIC-TO-PULMONARY ARTERIAL SHUNT | CPC-032 |
| CONNECTION BETWEEN BONE FRACTURES, VITAMIN D LEVEL AND LOW-ENERGY FALLS IN HOSPITALISED ELDERLY PATIENTS | CPC-036 |
| CURRENT SITUATION ON PRESCRIPTION OF CARBAPENEMS IN GERIATRIC CARE UNITS | CPC-038 |
| DELPHI APPROACH TO DEFINING AND CONTEXTUALISING MEDICINES WASTAGE IN THE MALTESE POPULATION | CPC-039 |
| DESIGN AND ASSESSMENT OF AN E-LEARNING COURSE TO TRAIN CLINICAL PHARMACISTS IN VITAMIN K ANTAGONIST (VKA) CONSULTATIONS | CPC-040 |
| DIRECT AVOIDANCE OF MEDICINES COSTS BY PHARMACEUTICAL ANALYSIS OF HOSPITAL PRESCRIPTIONS | CPC-041 |
| DRUG-RELATED PROBLEMS IN A CARDIOLOGY DEPARTMENT – IDENTIFYING TRENDS | CPC-042 |
| EPIDEMIOLOGY, SYMPTOMS AND CHEMOTHERAPY OF IMPORTED MALARIA AT MOHAMMED V MILITARY TEACHING HOSPITAL IN RABAT, MOROCCO | CPC-046 |
| EVALUATION OF A STANDARDISED THERAPEUTIC EDUCATION TRAINING SESSION FOR HYPERTENSIVE STROKE PATIENTS | CPC-049 |
| EVALUATION OF IMPLEMENTATION OF CLINICAL PHARMACY SERVICES IN CENTRAL NORWAY | CPC-051 |
| EVOLUTION IN DRUG RELATED PROBLEMS IDENTIFIED IN PHARMACIST NOTES AT THE EMERGENCY DEPARTMENT, HILLER¯D HOSPITAL DENMARK | CPC-056 |
| EVOLUTION OF CLINICAL TRIAL PRESCRIBING INCIDENTS | CPC-057 |
| FACTORS ASSOCIATED WITH ANTIRETROVIRAL MEDICINES ADHERENCE AMONG HIV-INFECTED CHILDREN | CPC-058 |
| FIRST GLOBAL ANTIMICROBIAL STEWARDSHIP SURVEY – INTERIM ANALYSIS OF NON-UK EUROPEAN DATA | CPC-059 |
| FOLLOW-UP OF PATIENTS TREATED BY PROLONGEDRELEASE OLANZAPINE IN A PSYCHIATRIC HOSPITAL | CPC-060 |
| GLOBAL ANTIMICROBIAL STEWARDSHIP SURVEY – ANALYSIS OF UK RESULTS | CPC-061 |
| HEPATITIS C AND ADHERENCE | CPC-062 |
| HOW IS IT BEST TO REPORT PHARMACEUTICAL INTERVENTIONS TO A MEDICAL TEAM? A CLINICAL RELEVANCE ASSESSMENT | CPC-064 |
| HOW TO ASSESS MEDICATION ADHERENCE AMONG PATIENTS WITH RESISTANT HYPERTENSION TREATED WITH TWO DIFFERENT PHARMACOLOGICAL INTENSIFICATION STRATEGIES | CPC-065 |
| IMPACT OF OPTIMISING PRESCRIPTIONS TO REDUCE THE RISK OF FALLS IN ELDERLY PEOPLE | CPC-068 |
| IMPORTANCE OF RESIDUAL INVESTIGATIONAL MEDICINAL PRODUCT COUNT | CPC-070 |
| INCIDENCE AND CAUSES OF CAPECITABINE DOSE ADJUSTMENT IN COLON CANCER PATIENTS | CPC-071 |
| INCLUSION OF PHARMACOGENETICS STUDIES, PATIENTREPORTED OUTCOMES AND COST MEASURES IN CLINICAL TRIALS; VARIABLES ADDED IN RECENT YEARS | CPC-072 |
| INFLUENCE OF FIRST-LINE EGFR THERAPY ON SURVIVAL AND MORTALITY RATES IN NON-SMALL CELL LUNG CANCER | CPC-073 |
| INTERDISCIPLINARY TASKFORCE BRINGS DOWN PRICE OF HIV DRUGS! | CPC-075 |
| INTERNAL AUDIT ON THE LABELLING OF INVESTIGATIONAL MEDICINAL PRODUCTS | CPC-076 |
| MANAGEMENT OF MYELODISPLASTIC SYNDROMES AND LYMPHOMAS: THE EXAMPLE OF LENALIDOMIDE | CPC-079 |
| MANAGEMENT OF POSTOPERATIVE PAIN AT MOHAMMED V MILITARY TEACHING HOSPITAL, RABAT, MOROCCO | CPC-080 |
| MANAGEMENT OF SEVERE ANAEMIA WITH RECOMBINANT HUMAN ERYTHROPOIETIN IN A JEHOVAH’S WITNESS PATIENT: CASE REPORT AND REVIEW OF LITERATURE | CPC-081 |
| MEDICATION RECONCILIATION EXPERIENCE IN PSYCHIATRIC HOSPITALS, SAUDI ARABIA | CPC-083 |
| MEDICATION REVIEWS BY CLINICAL PHARMACISTS AT HOSPITALS LEAD TO IMPROVED PATIENT OUTCOMES: A SYSTEMATIC REVIEW | CPC-084 |
| MEDICINES AND THEIR COSTS IN THE LAST SIX DAYS OF LIFE | CPC-085 |
| MIGLUSTAT OFF-LABEL IN A PAEDIATRIC FORMULATION FOR A RARE METABOLIC DISEASE: EARLY INFANTILE GM1 GANGLIOSIDOSIS | CPC-086 |
| MONITORING ANTIEMETIC REGIMENS WITH APREPITANT IN CANCER PATIENTS | CPC-087 |
| MULTIDISCIPLINARY COLLABORATION IN THE TREATMENT OF PAEDIATRIC HEMATOPOIETIC TRANSPLANT REJECTION WITH ALLOGENEIC MESENCHYMAL CELLS. A CASE REPORT | CPC-089 |
| NATALIZUMAB IN CYPRIOT PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS: THREE YEAR DATA ON SAFETY, EFFICACY AND FREQUENCY OF ANTI-JC VIRUS ANTIBODIES | CPC-091 |
| NEUROPSYCHOLOGY OF SAUDI COLON CANCER PATIENTS | CPC-092 |
| NUTRITIONAL STATUS OF HOSPITALISED PATIENTS WITH HEAD AND NECK CANCER | CPC-094 |
| OFF-LABEL USE OF ANAKINRA IN A PATIENT WITH FAMILIAL MEDITERRANEAN FEVER: A CASE REPORT | CPC-095 |
| PATIENTS ON VITAMIN K ANTAGONISTS (THE BENEFIT OF PHARMACY STUDENTS EDUCATING VKA PATIENTS IN AN UNIVERSITY HOSPITAL) | CPC-099 |
| PHARMACOKINETIC DRUG-DRUG INTERACTIONS DUE TO TREATMENT WITH AMIODARONE – A PRACTICAL APPROACH | CPC-106 |
| PHARMACISTS’ OPTIMIZATION OF THE MEDICATION PROCESS DURING ADMISSION TO HOSPITAL: A MULTICENTRE, RANDOMIZED, CONTROLLED TRIAL | CPC-111 |
| QUICK WINS – INNOVATIVE AND ECONOMIC FOCUS ON USE OF MEDICINES | CPC-118 |
| RISK FACTORS IN THE INCIDENCE OF CHEMOTHERAPYINDUCED EMESIS | CPC-122 |
| SECOND-LINE CHEMOTHERAPY WITH NAB-PACLITAXEL IN PATIENTS WITH PANCREAS CANCER | CPC-126 |
| START SMART THEN FOCUS – A SURVEY OF ANTIMICROBIAL STEWARDSHIP GUIDELINES IMPLEMENTATION IN ENGLAND | CPC-128 |
| STUDY OF A PHARMACISTS CONTRIBUTION TO MEDICINES RECONCILIATION IN CRITICALLY ILL PATIENTS | CPC-129 |
| STUDY OF A PHARMACISTS CONTRIBUTION TO MEDICINES RECONCISWITCHING FROM ADEFOVIR TO TENOFOVIR IN HEPATITIS B-INFECTED PATIENTSIATION IN CRITICALLY ILL PATIENTS | CPC-130 |
| SWITCHING STRATEGY. THE PHARMACIST’S POINT OF VIEW ON COST, ADHERENCE AND VIROLOGICAL OUTCOME | CPC-131 |
| TELAPREVIR: ADVERSE EVENTS IN CLINICAL PRACTISE | CPC-133 |
| THE EFFECT OF GENDER ON THE USE OF MEDICINES IN MULTIPLE SCLEROSIS PATIENTS | CPC-135 |
| THE PRESCRIPTION OF ANTHRACYCLINES DURING PREGNANCY IN HAEMATOLOGY: CASE REPORTS AND LITERATURE REVIEW | CPC-138 |
| THERAPEUTIC DRUG MONITORING FOR GLYCOPEPTIDES AND AMINOGLYCOSIDES: ACTUAL SITUATION AND PERSPECTIVES IN A FRENCH UNIVERSITY HOSPITAL | CPC-139 |
| THERAPEUTIC OPTIONS IN ANTI-NMDA RECEPTOR ENCEPHALITIS | CPC-140 |
| TOLERABILITY AND SAFETY OF CARBOPLATIN-BASED CHEMOTHERAPY IN A HEMODIALYSIS PATIENT WITH BREAST CANCER | CPC-141 |
| TOLERANCE TO THE BEAM PROTOCOL BEFORE AUTOLOGOUS HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN CHILDREN TREATED FOR HODGKIN’S LYMPHOMA | CPC-142 |
| TREATMENT OF CUTANEOUS CALCIPHYLAXIS WITH SODIUM THIOSULFATE: A CASE REPORT | CPC-145 |
| USE OF OMALIZUMAB IN CHRONIC COLD URTICARIA: A CASE REPORT | CPC-152 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| A systematic review of ehealth | DGI-001 |
| Analysis of clinical effectiveness of treatment with peginterferon plus ribavirin in chronic hepatitis C monoinfected patients | DGI-003 |
| ANALYSIS OF LEVOFLOXACIN USE IN GERIATRIC UNITS AT A UNIVERSITY HOSPITAL | DGI-005 |
| ANALYSIS OF SAVINGS IF THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP) IS SWITCHED | DGI-006 |
| ANALYSIS OF THE PRESCRIPTIONS OF ANTIBIOTICS AS LAST RESORT | DGI-007 |
| ANALYSIS OF THE USE OF CARBOXYMALTOSE IRON | DGI-008 |
| ANALYSIS OF THE USE OF ERYTHROPOIESIS-STIMULATING AGENTS IN A UNIVERSITY HOSPITAL | DGI-009 |
| ANALYSIS OF THE USE OF FINGOLIMOD IN PATIENTS WITH MULTIPLE SCLEROSIS IN A UNIVERSITY HOSPITAL | DGI-010 |
| ANTIBIOTICS MONITORING: THE EXPERIENCE OF LIGURIA REGION, ITALY | DGI-012 |
| ANTIRETROVIRAL TREATMENT SWITCHING IN VIROLOGICALLY UNSUPPRESSED HIV-INFECTED PATIENTS | DGI-013 |
| APPROPRIATENESS OF TREATMENT AND COST ANALYSIS IN THE TREATMENT OF SYSTEMIC FUNGAL INFECTIONS IN A TRANSPLANT CENTRE | DGI-014 |
| ASSESSMENT OF THE TREATMENT WITH A TWO-DRUG ANTIRETROVIRAL REGIMEN | DGI-015 |
| ASSESSMENT OF TOCILIZUMAB PRESCRIPTIONS AT A UNIVERSITY HOSPITAL | DGI-016 |
| BUDGET IMPACT ANALYSIS ON NEW 3-YEAR IMATINIB ADJUVANT TREATMENT FOR PATIENTS WITH OPERABLE GIST AT HIGH RISK OF RECURRENCE | DGI-018 |
| DESCRIPTION OF OMALIZUMAB USE FOR THE TREATMENT OF ASTHMA AFTER FOUR YEARS OF EXPERIENCE | DGI-023 |
| DRUG USE IN PATIENTS WITH METASTATIC BREAST CANCER | DGI-026 |
| EFFECTIVENESS AND SAFETY OF CLOFARABINE IN PAEDIATRIC PATIENTS WITH ACUTE LEUKAEMIA | DGI-027 |
| EFFECTIVENESS AND SAFETY OF RITUXIMAB IN IDIOPATHIC THROMBOCYTOPENIC PURPURA | DGI-028 |
| EFFICACY AND SAFETY OF PROPRANOLOL IN INFANTILE HAEMANGIOMA | DGI-029 |
| EFFICACY AND SAFETY OF TELAPREVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 | DGI-030 |
| EFFICACY OF ORAL THALIDOMIDE IN PATIENTS WITH RECURRENT GASTROINTESTINAL BLEEDING | DGI-031 |
| EVALUATION OF CRIZOTINIB TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER | DGI-033 |
| EVALUATION OF THE EFFICACY AND SAFETY OF MIFAMURTIDE IN OSTEOGENIC SARCOMA TREATMENT IN PAEDIATRIC PATIENTS | DGI-034 |
| GEMTUZUMAB OZOGAMICIN AS SALVAGE TREATMENT IN CHILDREN WITH ACUTE MYELOID LEUKAEMIA RELAPSE: A RETROSPECTIVE STUDY | DGI-038 |
| GUIDE TO THE PREPARATION AND ADMINISTRATION OF INJECTABLE CYTOTOXIC DRUGS | DGI-039 |
| HUMAN LUNG CARCINOMA SENSITIVITY TO PACLITAXEL: WHICH ROLE FOR BIM? | DGI-040 |
| HYPOMAGNESEMIA AS A POSSIBLE MARKER OF EFFICACY IN PATIENTS WITH HEAD AND NECK CARCINOMA IN FIRST-LINE TREATMENT WITH CETUXIMAB | DGI-042 |
| INCREASED COST OF ERYTHROPOIESIS-STIMULATING AGENTS IN SOME SPECIAL SITUATIONS | DGI-043 |
| INHALED COLISTIN IN TREATMENT OF CHRONIC COLONISATION PSEUDOMONAS AERUGINOSA IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | DGI-044 |
| OUTCOMES WITH THE USE OF NITROFURANTOIN IN RENAL IMPAIRMENT IN PRIMARY CARE – A PILOT STUDY | DGI-052 |
| REDUCED DELAY IN THE ADMINISTRATION OF CHEMOTHERAPY AFTER OPTIMISING THE PROCESS OF PREPARATION/DISPENSING OF PARENTERAL ANTINEOPLASTICS | DGI-056 |
| SAFETY OF INTRAVENOUS TREATMENT OF BREAST CANCER: INTERACTION WITH CHRONIC MEDICINES | DGI-060 |
| SAFETY OF TRIPLE TREATMENT IN CHRONIC HEPATITIS C | DGI-061 |
| STUDY USING FOSCARNET IN HAEMATOLOGICAL PATIENTS | DGI-065 |
| SURVIVAL STUDY OF PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB | DGI-066 |
| THE EFFECT OF MAIN GENE POLYMORPHISMS ON STABLE DOSES OF ACENOCOUMAROL IN LONG-TERM ANTICOAGULATION TREATMENT | DGI-068 |
| THE IMPORTANCE OF CLINICAL PHARMACIST COUNSELLING IN IMPROVING PATIENT MEDICATION ADHERENCE | DGI-069 |
| THE USE OF LINEZOLID IN NEUROSURGERY: THE EXAMPLE OF A FRENCH TEACHING HOSPITAL | DGI-072 |
| USE OF BOTULINUM TOXIN TYPE A IN POLAND: SYSTEMATIC REVIEW AND QUESTIONNAIRE SURVEY | DGI-075 |
| USE OF COLONY STIMULATING FACTORS (CSF-G) IN FEBRILE NEUTROPENIA IN PATIENTS UNDERGOING CANCER CHEMOTHERAPY | DGI-076 |
| USE OF EVEROLIMUS IN COMBINATION WITH EXEMESTANE FOR THE TREATMENT OF ADVANCED BREAST CANCER IN A TERTIARY HOSPITAL | DGI-077 |
| USE OF SGN35 OR BRENTUXIMAB VEDOTIN IN ANAPLASTIC LARGE-CELL LYMPHOMA: A CASE REPORT IN PAEDIATRICS | DGI-078 |
| VALPROIC ACID AND BEHAVIOUR DISORDERS: OBSERVATION OF EFFICIENCY AND TOXICITY IN A COGNITIVE-BEHAVIORAL UNIT | DGI-079 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| A MULTIDISCIPLINARY APPROACH TO FURTHER IMPROVEMENTS ON PATIENT SAFETY | DSL-001 |
| AUTOMATION OF STORAGE AND DISPENSING: WHAT SYSTEM SHOULD WE IMPLEMENT? | DSL-004 |
| COMPARATIVE STUDY OF THE COST OF ERYTHROPOIETIC FACTORS, ORIGINAL MEDICINES AND BIOSIMILARS IN FRENCH CARE FACILITIES | DSL-005 |
| EVALUATING THE STANDARDS OF HOSPITAL PHARMACIES IN THERAPEUTIC CENTRES AFFILIATED WITH OF KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES, IRAN | DSL-012 |
| EVALUATION OF THE LIMITS OF AUTOMATION AND IMPACT ON DRUG MANAGEMENT AT MOHAMMED V MILITARY TEACHING HOSPITAL PHARMACY, RABAT, MOROCCO | DSL-013 |
| FINANCIAL EVALUATION OF THE SURPLUS GENERATED BY THE DISPENSING OF SUNITINIB IN THE LOCAL HEALTH SERVICE OF REGGIO EMILIA | DSL-014 |
| FINANCIAL IMPACT OF ANTI-VEGF IN OPHTHALMOLOGY | DSL-015 |
| HOW WOULD PHYSICIANS AND NURSES HANDLE THE PROBLEM OF DRUG SHORTAGES? | DSL-016 |
| OPTIMIZATION OF INFLIXIMAB USE CAN SAVE MONEY | DSL-019 |
| THE COST ANALYSIS OF INTRODUCING THE TWO-BIN REPLENISHMENT SYSTEM FOR MEDICAL DEVICES, ANTISEPTICS AND INTRAVENOUS FLUIDS IN A GERIATRIC HOSPITAL | DSL-023 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| 1ST ESNEE EXCIPIENT MONOGRAPH: INFORMATION NEEDED TO FORMULATE, PREPARE AND PRESCRIBE MEDICINES FOR NEONATES CONTAINING PROPYLENE GLYCOL AS AN EXCIPIENT | GRP-001 |
| A CASE REPORT: MANAGEMENT OF PAIN AFTER SUBCUTANEOUS INJECTION OF TREPROSTINIL | GRP-002 |
| A MEDICINES RECONCILIATION PROCESS IN FRAIL ELDERLY PEOPLE | GRP-003 |
| ADHERENCE TO ORAL CANCER TREATMENT: THE ROLE OF THE HOSPITAL PHARMACIST IN THERAPEUTIC SUCCESS | GRP-010 |
| ADHERENCE, PERSISTENCE AND FINANCIAL EVALUATION IN THE TREATMENT OF PROSTATE CANCER | GRP-012 |
| ADVERSE DRUG REACTIONS IN THALIDOMIDE TREATED PATIENTS | GRP-013 |
| AN OVERVIEW OF HOSPITAL PHARMACEUTICAL EXPENDITURE IN GREECE OVER THE LAST TWO YEARS | GRP-015 |
| ANALYSIS AND CONSUMPTION OF INNOVATIVE ANTIDIABETIC DRUGS IN PIEDMONT PATIENTS | GRP-016 |
| ANALYSIS OF ANTINEOPLASTIC MEDICATION ERRORS IN A 500-BED TEACHING HOSPITAL | GRP-018 |
| ANALYSIS OF PHARMACIST INTERVENTIONS DURING THE VALIDATION OF THE ELECTRONIC PRESCRIPTIONS IN A SPANISH HOSPITAL | GRP-021 |
| ANALYSIS OF THE MEDICINES RECONCILIATION PROCESS IN DIFFERENT CLINICAL SERVICES | GRP-022 |
| ANTITHROMBOTIC PROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA BEING TREATED WITH LENALIDOMIDE | GRP-024 |
| APPLICATION OF A PRESSURE ULCER PREVENTION AND TREATMENT PROTOCOL IN THE FATEBENEFRATELLI AND OPHTHALMIC HOSPITAL IN MILAN | GRP-025 |
| ASSESSMENT OF BLOOD PRESSURE CONTROL AND ANTIHYPERTENSIVE MEDICATION ADHERENCE IN A PORTUGUESE HYPERTENSIVE POPULATION | GRP-027 |
| BENEFICIAL EFFECT OF HOSPITAL PHARMACIST PARTICIPATION IN INTENSIVE CARE ROUNDS: REDUCTION IN MEDICINES ERRORS AND HOSPITAL COSTS | GRP-032 |
| BLOOD PRESSURE CONTROL AND ANTIHYPERTENSIVE PHARMACOTHERAPY PATTERNS IN A HYPERTENSIVE PORTUGUESE POPULATION | GRP-034 |
| BOCEPREVIR AND TELAPREVIR: SAFETY | GRP-035 |
| CATHETER RELATED INFECTION TREATMENT PROTOCOL COMPLIANCE IN THE INTENSIVE CARE UNIT | GRP-037 |
| CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | GRP-038 |
| CLASSIFICATION OF THE PHARMACEUTICAL INTERVENTIONS MADE USING THE ISOFAR PROGRAMME | GRP-039 |
| COLLECTION AND ANALYSIS OF ADVERSE EFFECTS AND CO-MEDICATIONS FOR OUTPATIENTS RECEIVING BOCEPREVIR- OR TELAPREVIR-BASED TREATMENT FOR CHRONIC HEPATITIS C | GRP-041 |
| COMPUTERIZED PHYSICIAN ORDER ENTRY IN THE GERIATRIC CENTER: COLLECTION AND ANALYSIS OF PRESCRIBING ERRORS MADE OVER A 5-MONTH PERIOD | GRP-042 |
| CONFORMITY OF THE BATCH FILE IN PREPARATION: AN INTERNAL AUDIT | GRP-044 |
| CONTRADICTIONS IN THE INTERPRETATION OF DRUG/ SUPPLEMENT INTERACTIONS AND DIFFICULTIES OF THEIR MANAGEMENT IN EVERYDAY CLINICAL PRACTISE | GRP-045 |
| CORONARY PATIENTS: WHICH THERAPEUTIC APPROACH ON DISCHARGE FROM HOSPITAL? | GRP-046 |
| CYTOTOXIC DRUGS WITH THE POTENTIAL TO PROLONG THE QT INTERVAL | GRP-048 |
| DESIGN AND DEVELOPMENT OF A PRESCRIPTION MODULE OF ENTERAL DIETS FOR A NEONATAL UNIT | GRP-049 |
| DISPENSING PRACTISE IN SAUDI COMMUNITY PHARMACY | GRP-051 |
| EFFECT OF ANTIVIRAL TREATMENT, VIRAL LOAD AND STAGE OF FIBROSIS IN QUALITY OF LIFE OF HEPATITIS C-INFECTED PATIENTS | GRP-055 |
| EFFECT OF PHARMACEUTICAL FOLLOW-UP IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM TREATED WITH CINACALCET | GRP-056 |
| ERRORS IN MEDICINES PREPARATION AND ADMINISTRATION IN VIETNAMESE HOSPITALS | GRP-057 |
| ETHANOL CONTENT IN CHEMOTHERAPY | GRP-059 |
| EVALUATION OF OCCUPATIONAL EXPOSURE TO ANTINEOPLASTIC DRUGS IN PHARMACY AND ONCOLOGY DEPARTMENT | GRP-065 |
| EVALUATION OF THE PRESCRIPTION OF INTRAVENOUS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS COMPARED TO THE RECOMMENDATIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS | GRP-071 |
| EXPOSURE TO ANTINEOPLASTIC AGENTS IN ONCOLOGY DEPARTMENTS: PRACTISE SURVEY AND INFORMATION TO THE PERSONNEL OF THREE ONCOLOGY DEPARTMENTS | GRP-072 |
| GASTROPROTECTIVE AGENTS IN THE EMERGENCY ROOM OF A TERTIARY-LEVEL HOSPITAL | GRP-076 |
| GENERIC MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS: IMPLEMENTATION OF ACTIVE PHARMACOVIGILANCE | GRP-077 |
| GUIDELINES FOR CHEMOTHERAPY EXTRAVASATION | GRP-079 |
| HAEMATOLOGICAL TOXICITY SECONDARY TO TREATMENT WITH DIAZOXIDE: A CASE REPORT | GRP-080 |
| HEALTH INFORMATION TECHNOLOGY AND STRESSORS: HOW TO MEASURE AND ELIMINATE THEM | GRP-081 |
| HOSPITAL PHARMACIST INTERVENTIONS IN PATIENTS WITH ENTERAL NUTRITION FEEDING TUBES | GRP-082 |
| IDENTIFICATION OF RELEVANT DRUG INTERACTIONS IN NEONATAL INTENSIVE CARE UNITS | GRP-085 |
| IDENTIFYING NEW TUBERCULOSIS CASES THROUGH PHARMACY DISPENSING RECORDS IN PROF DR FERNANDO FONSECA HOSPITAL, PORTUGAL | GRP-086 |
| IMPACT OF AN ELECTRONIC MEDICINES RECONCILIATION PROGRAMME USED IN A GENERAL SURGERY UNIT | GRP-087 |
| IMPACT OF THE PHARMACEUTICAL VALIDATION OF PRESCRIPTIONS FOR INPATIENTS WITH RENAL IMPAIRMENT | GRP-088 |
| IMPLEMENTATION OF GRAVIMETRIC ANALYSIS IN THE PHARMACY DEPARTMENT | GRP-090 |
| INAPPROPRIATE PRESCRIBING FOR ELDERLY PEOPLE: | GRP-098 |
| INTEGRATION OF ORAL ANTICANCER DRUGS INTO STANDARDISED COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEMS | GRP-103 |
| INTERACTIONS BETWEEN MEDICINAL GASES AND OTHER MEDICINAL PRODUCTS: DEVELOPMENT OF A HOSPITAL DRUG DATABASE | GRP-104 |
| INVOLVEMENT OF THE PHARMACY AND THERAPEUTICS COMMITTEE IN CLINICAL DECISION SUPPORT SYSTEMS FOCUSED ON ANTICOAGULANTS | GRP-106 |
| LEAN CULTURE: AN OPPORTUNITY IN THE HOSPITAL PHARMACY PRODUCTION DEPARTMENT | GRP-108 |
| LINEZOLID ADVERSE REACTIONS. A ONE YEAR OVERVIEW | GRP-110 |
| MANAGEMENT OF METHOTREXATE-INDUCED RENAL FAILURE WITHOUT GLUCARPIDASE | GRP-111 |
| MEDICAL DEVICES IN MOROCCO: WHAT GUARANTEES OF QUALITY AND SAFETY? | GRP-112 |
| MEDICINES RECONCILIATION PROCESS AT ADMISSION IN PATIENTS OVER 75 YEARS OF AGE | GRP-115 |
| MEDICINES RECONCILIATION: AN INNOVATIVE COMPUTER-BASED USE OF THE MEDICINES LIST | GRP-116 |
| MOST FREQUENT DRUG-RELATED EVENTS DETECTED BY PHARMACEUTICAL ANALYSIS OF COMPUTERIZED PHYSICIAN ORDER ENTRY AND PROPOSED SOLUTIONS | GRP-119 |
| MULTIDISCIPLINARY MONITORING OF PSYCHIATRIC MORBIDITY OF HCV-INFECTED PATIENTS TREATED WITH INTERFERON AND RIBAVIRIN | GRP-121 |
| NEW PERSPECTIVES OF HOSPITAL PHARMACISTS’ ROLE IN COMMUNICATING PHARMACEUTICAL POLICY TO HEALTHCARE PROFESSIONALS AND PATIENTS IN GREECE | GRP-122 |
| PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS | GRP-129 |
| PARENTS/CAREGIVERS’ KNOWLEDGE TOWARDS MEDICINES ADMINISTRATION IN PAEDIATRIC PATIENTS | GRP-130 |
| PATIENT SAFETY – ANALYSING MEDICATION-RELATED ADVERSE EVENTS | GRP-131 |
| PATIENTS DISCHARGED FROM HOSPITAL WITH | GRP-132 |
| PHARMACEUTICAL CARE PROGRAMME IN AN EMERGENCY DEPARTMENT | GRP-133 |
| PHARMACEUTICAL INTERVENTION IN A BRAZILIAN HOSPITAL: ANALYSIS OF INTERVENTIONS FOCUSING ON PATIENT SAFETY | GRP-134 |
| PHARMACEUTICAL INTERVENTIONS AND E-PRESCRIBING TOOLS IN A TERTIARY-CARE INSTITUTION | GRP-136 |
| PHARMACIST INTERVENTIONS IN THE EMERGENCY ROOM OF A TERTIARY-LEVEL HOSPITAL | GRP-139 |
| PHARMACOVIGILANCE AND NON-MEDICAL PRESCRIBERS: EXPLORING PERCEPTIONS OF TRAINING, CONTRIBUTION AND POTENTIAL FOR ENHANCEMENT | GRP-142 |
| POTASSIUM MONITORING: DO WE GIVE IT THE ATTENTION IT DESERVES? | GRP-143 |
| POTENTIAL DRUG-DRUG INTERACTIONS IN PATIENTS ADMITTED TO A TRAUMA HOSPITAL | GRP-144 |
| PREPARATION OF A RISK MAP FOR A PHARMACY SERVICE IN A HEALTHCARE AREA | GRP-148 |
| PROGRAM INTERVENTIONS TO OPTIMISE THE DURATION OF ANTIBIOTIC TREATMENT | GRP-151 |
| RECOMMENDATION FOR ERROR PREVENTION IN ANTICANCER DRUG TREATMENT | GRP-153 |
| RECONCILIATION AND DRUG INFORMATION TO GERIATRIC POLYMEDICATED PATIENTS AT DISCHARGE USING INFORMATION TECHNOLOGY | GRP-154 |
| RECONCILIATION ERRORS ASSOCIATED WITH ANTIRETROVIRAL TREATMENT | GRP-155 |
| RECONCILIATION ERRORS AT CARDIOLOGY UNIT ADMISSION | GRP-156 |
| RISK ASSESSMENT FORMS FOR PHARMACY PREPARATION | GRP-161 |
| RIVAROXABAN VERSUS ENOXAPARIN: COMPARISON OF OUTPATIENT TREATMENT ADHERENCE IN CLINICAL PRACTISE | GRP-164 |
| SAFETY OF ADJUVANT CHEMOTHERAPY IN ELDERLY COLON CANCER PATIENTS | GRP-167 |
| SAFETY OF SUNITINIB VERSUS PAZOPANIB IN METASTATIC RENAL CANCER IN A TERTIARY HOSPITAL | GRP-168 |
| SCREENING FOR CLINICALLY RELEVANT INTERACTIONS IN LIVER TRANSPLANT PATIENTS | GRP-169 |
| SIGNIFICANCE OF POTENTIALLY INAPPROPRIATE MEDICINES FOR ELDERLY PATIENTS AT A GERMAN UNIVERSITY HOSPITAL | GRP-174 |
| STUDY OF THE IMPORTANCE OF THE PHARMACEUTICAL CONTRIBUTION IN THE DETECTION OF NON CONFORMITY (NC) IN THE MEDICATION PROCESS IN CHEMOTHERAPY | GRP-176 |
| TELAPREVIR AND BOCEPREVIR: SAFETY AND EFFICACY OF THE INITIAL TREATMENTS IN THE HOSPITAL | GRP-180 |
| THE CLINICAL IMPACT OF CALCIUM-CEFTRIAXONE INTERACTION IN PATIENTS ON TOTAL PARENTERAL NUTRITION | GRP-181 |
| THE EFFECT OF A CLINICAL PHARMACIST-LED TRAINING PROGRAMME ON INTRAVENOUS PREPARATION AND ADMINISTRATION ERRORS IN A VIETNAMESE HOSPITAL | GRP-183 |
| THE IMPACT OF PHARMACEUTICAL INTERVENTIONS ON THE TREATMENT OF GRAM POSITIVE INFECTIONS | GRP-184 |
| THE PHARMACIST’S ROLE IN EMERGENCY FIRST AID SERVICES IN A TERRORIST ATTACK WITH SARIN: EMERGENCY INTERVENTION SIMULATION | GRP-185 |
| THE RATES AND TYPES OF PRESCRIBING ERRORS IN ELECTRONIC CHEMOTHERAPY PRESCRIPTIONS FOR AMBULATORY PATIENTS | GRP-187 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| Risk of contamination in cytotoxic reconstitution | INT-010 |
| URINARY TRACT INFECTIONS – LOCAL UROPATHOGENS AND PATTERNS OF ANTIBIOTIC RESISTANCE | INT-012 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ADVANTAGES AND DISADVANTAGES OF AN ELECTRONIC PRESCRIBING SYSTEM. ASPECTS TO CONSIDER DURING PHARMACIST VALIDATION. | OHP-005 |
| ADVERSE EFFECTS OF DAY-HOSPITAL CANCER TREATMENT MONITORED AT HOME: CREATION OF A PHYSICIANÑPATIENT LOGBOOK | OHP-006 |
| ANALYSIS OF COSTS AND CONSUMPTION OF MEDICAL DEVICES FOR EXTRACORPOREAL PHOTOCHEMOTHERAPY IN SIENAÍS UNIVERSITY HOSPITAL (AOUS) | OHP-008 |
| CONSUMPTION OF OPIOID ANALGESICS IN HOSPITAL PHARMACY AND CONSULTATIVE CARE FOR PATIENTS | OHP-016 |
| DE-ESCALATION STRATEGY OF EMPIRICAL ANTIBIOTIC TREATMENT WITH CARBAPENEMS | OHP-020 |
| DEVELOPMENT AND IMPLEMENTATION OF A PERIPHERAL STANDARD PARENTERAL NUTRITION FOR A NEONATOLOGY DEPARTMENT | OHP-021 |
| DOSES OF ANTI-TUMOR NECROSIS FACTOR IN CLINICAL PRACTISE: A FOUR-YEAR RETROSPECTIVE STUDY IN ANKYLOSING SPONDYLITIS PATIENTS | OHP-024 |
| DRUG INFORMATION AND THE USE OF A PILLBOX TO IMPROVE SATISFACTION OF PATIENTS TREATED WITH TEMOZOLOMIDE | OHP-025 |
| EDUCATIONAL MODEL FOR IT SYSTEMS | OHP-027 |
| EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE IN HIV-NAIVE PATIENTS: A PHARMACOECONOMIC STUDY | OHP-032 |
| ESTIMATION OF THE ADHERENCE TO BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS | OHP-034 |
| FINANCIAL ASSESSMENT OF INTRAVENOUS MIXTURE PREPARATION | OHP-040 |
| HIP AND KNEE PROSTHESES IN REPLACEMENT SURGERY: REVIEW OF USE | OHP-043 |
| IMPLEMENTATION OF A PROTOCOL FOR SELECTION OF BIOLOGICAL THERAPIES IN RHEUMATOLOGY | OHP-048 |
| IN VITRO EVALUATION OF A NEW SAFETY CONNEXION FOR THE ADMINISTRATION OF ENTERAL NUTRITION: ENLOCK | OHP-050 |
| INTRANASAL APPLICATIONS OF CAPSAICIN TO TREAT CLUSTER HEADACHE, A CASE REPORT | OHP-053 |
| OPTIMIZATION OF HIGH-IMPACT MEDICINES IN PAEDIATRICS | OHP-059 |
| SATISFACTION WITH ELECTRONIC PRESCRIBING IN A GENERAL HOSPITAL | OHP-070 |
| STUDY OF GLUTAMINE USE IN ADULT PARENTERAL NUTRITION | OHP-071 |
| SURVEY OF INTERFACE MANAGEMENT MEASURES REGARDING MEDICINES | OHP-073 |
| THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AZIENDA SANITARIA PROVINCIALE SIRACUSA: ECONOMIC CONSIDERATIONS RELATED APPROPRIATENESS OF PRESCRIPTION | OHP-074 |
| THE COST OF MANAGING INTRACRANIAL ANEURYSMS BY EMBOLIZATION IN MOROCCO | OHP-075 |
| THE ROLE OF PHARMACISTS IN AN ITALIAN MODEL OF ECONOMIC SUSTAINABILITY AND INNOVATIVE TREATMENTS | OHP-077 |
| TREATMENT OF POSTOPERATIVE ANAEMIA IN ORTHOPAEDIC SURGERY: A BUDGET IMPACT ANALYSIS FROM A HOSPITAL PERSPECTIVE | OHP-078 |
| USE OF LOW THERAPEUTIC UTILITY DRUGS IN AN INSTITUTION BEFORE THEIR USE WAS RESTRICTED IN THE SPANISH HEALTH SYSTEM | OHP-081 |
| WHAT CONCEPTS ARE USED TO DESCRIBE THE COOPERATION MECHANISMS BETWEEN THE HOSPITAL SECTOR AND PRIMARY CARE? ANALYSIS OF TERMINOLOGY | OHP-084 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CONCOMICANT DRUGS AS A RISK FACTOR FOR THE APPEARANCE OF ADVERSE EVENTS | PHC-002 |
| ASSESSMENT OF THE IMPACT OF PHARMACOKINETICS MONITORING RECOMMENDATIONS | PHC-003 |
| BLOOD LEVELS OF IMMUNOSUPPRESSANT DRUGS IN PATIENTS WITH CYSTIC FIBROSIS AFTER LUNG TRANSPLANTATION | PHC-005 |
| DEPLOYMENT OF BAR CODE MEDICINES ADMINISTRATION TO CONTROL THE ADMINISTRATION OF MEDICINES IN GERIATRIC UNITS | PHC-007 |
| DEVELOPMENT AND APPLICATION OF A SIMPLE LC-MS METHOD FOR THE DETERMINATION OF PLASMA RILPIVIRINE CONCENTRATIONS | PHC-008 |
| DRUG INTERACTION: A CASE REPORT | PHC-010 |
| ERLOTINIB IN NON-SMALL CELL LUNG CANCER PATIENTS FROM FERNANDO FONSECA HOSPITAL | PHC-012 |
| EXPERIENCE WITH CANNABINOID TREATMENT | PHC-013 |
| IMPACT OF MDR1 POLYMORPHISMS ON THE ANALGESIC EFFICACY OF TRAMADOL IN PATIENTS AFTER MINOR SURGERY | PHC-015 |
| PHARMACOGENETIC STUDY ABOUT INFLUENCE OF A POLYMORPHISM IN GENE TRAILR1 IN RESPONSE TO INLFIXIMAB IN PATIENTS WITH CROHN’S DISEASE (CD) | PHC-017 |
| PHARMACOKINETICALLY GUIDED DOSE ADJUSTMENT OF 5-FLUOROURACIL (5-FU) IN GASTROINTESTINAL CANCER PATIENTS | PHC-020 |
| RENAL FUNCTION ESTIMATION BY DIFFERENT METHODS (CKD-EPI,COCKCROFT-GAULT AND MDRD4-IDMS) AND ITS EFFECT ON THE DOSE OF IV DEXKETOPROFEN | PHC-024 |
| SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH ADVERSE EVENTS IN TAXANE-TREATED BREAST CANCER PATIENTS | PHC-025 |
| THE PHARMACIST’S ROLE IN IMPROVING VALPROIC ACID PRESCRIPTIONS | PHC-027 |
| VANCOMYCIN PHARMACOKINETICS IN ALCOHOL AND INTRAVENOUS DRUG ABUSERS | PHC-029 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ANALYSIS OF DISPENSING LOGISTICS ACTIVITY CARRIED | TCH-002 |
| ASSESSMENT OF AUTOMATED DRUG DISPENSING SYSTEM PERFORMANCE INDICATORS | TCH-003 |
| CENTRALIZATION AND TECHNOLOGY SUPPORT THE HOSPITAL PHARMACIST IN IMPROVING SAFETY, ACCURACY AND ECONOMY IN THE MANAGEMENT OF MONOCLONAL ANTIBODIES | TCH-004 |
| DEVELOPMENT OF A HYDROCHLOROTHIAZIDE 0.5 MG/ML ORAL SOLUTION FOR CHILDREN | TCH-008 |
| DEVELOPMENT OF A STABLE NYSTATIN ORAL SUSPENSION TO OVERCOME SHORTAGES OF THE COMMERCIAL MEDICINE | TCH-009 |
| EXTENDED CHEMICAL-PHYSICAL STABILITY OF 25 mg/ml AZACITIDINE SUSPENSION | TCH-016 |
| IMPLEMENTATION OF A MONITORED INFORMATION SYSTEM PROTOCOL IN PHARMACEUTICAL MONITORING | TCH-019 |
| INCORPORATION OF IL28B POLYMORPHISM DETERMINATION INTO THE SERVICES PORTFOLIO OF THE PHARMACY DEPARTMENT AND RESULTS OBTAINED | TCH-021 |
| INTRADIALYTIC CALCIPHYLAXIS IN RENAL PATIENTS. DEVELOPMENT OF AN INJECTABLE SOLUTION OF 25% SODIUM THIOSULFATE FOR TREATMENT | TCH-022 |
| LIQUID ORAL FORMULATIONS OF PROPRANOLOL HYDROCHLORIDE FOR THE TREATMENT OF INFANTILE HAEMANGIOMAS | TCH-023 |
| LONG-TERM STABILITY OF INDOMETHACIN 0.2 MG/ML READY-TO-USE SOLUTION FOR INTRAVENOUS USE | TCH-024 |
| MEDIA FILL TO VALIDATE THE ASEPTIC PREPARATION OF SODIUM BICARBONATE INTRAVENOUS INFUSION | TCH-027 |
| NEW BULSULFAN PROCEDURE TO IMPROVE BOTH PREPARATION AND ADMINISTRATION | TCH-028 |
| PET/CT IMAGING WITH [11C]CHOLINE AS A RADIOPHARMACEUTICAL FOR THE DETECTION OF RECURRENT PROSTATE CANCER: A RELIABLE PRODUCTION METHOD AND QUALITY CONTROL | TCH-030 |
| PHARMACY PREPARATION: RETROSPECTIVE ANALYSIS OF MORPHINE BAGS USED FOR THE PREPARATION OF ELASTOMERIC INFUSION PUMPS | TCH-032 | |
| PHARMACY PREPARATION: RETROSPECTIVE ANALYSIS OF MORPHINE BAGS USED FOR THE PREPARATION OF ELASTOMERIC INFUSION PUMPS | TCH-034 |
| REPACKAGING OF DRUGS IN UNIT DOSES USING AN AUTOMATIC BLISTER PRECUTTING SYSTEM | TCH-035 |
| RESULTS OF A SYSTEMATIC LONG-TERM STABILITY STUDY FOR READY-TO-USE INJECTABLE DRUGS PRODUCED BY A CENTRALIZED INTRAVENOUS ADMIXTURE SERVICE | TCH-036 |
| SHORTAGE OF STERILE CALCIUM GLUCONATE STOCK SOLUTION FOR PARENTERAL NUTRITION: WHAT IS THE ALTERNATIVE AND HOW MUCH DOES IT COST? | TCH-038 |
| STABILITY OF TOTAL PARENTERAL NUTRITION ADMIXTURES FOR PAEDIATRIC HOME CARE IN THE PRESENCE OF HIGH CONCENTRATIONS OF ELECTROLYTES | TCH-041 |
| STABILITY STUDY OF GANCICLOVIR IN 0.9% SODIUM CHLORIDE IN DIFFERENT TYPES OF CONTAINERS: OPTIMIZATION OF RESOURCES | TCH-042 |
| STABILITY STUDY OF SILDENAFIL CAPSULES BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY | TCH-043 |
| STERILITY TESTING USING A RAPID MICROBIOLOGICAL METHOD FOR BATCH PRODUCTION OF CYTOTOXIC DRUGS IN A HOSPITAL PHARMACY | TCH-044 |
| THE ADVANTAGES OF UV-RAMAN SPECTROSCOPY FOR CHECKING THE STRENGTH OF NALBUPHINE PREPARATIONS | TCH-046 |
| THE SECURITY OF PHARMACOKINETIC INFORMATION IN ELECTRONIC HEALTH RECORDS | TCH-048 |
| VALIDATION OF AN AUTOMATED METHOD FOR COMPOUNDING MONOCLONAL ANTIBODY PATIENT DOSES: CASE STUDIES OF BEVACIZUMAB, INFLIXIMAB AND TRASTUZUMAB | TCH-052 |
| EVALUATION OF THE CHEMICAL AND PHYSICAL STABILITY OF SODIUM DICHLOROACETATE, AN ORPHAN DRUG FOR RARE METABOLIC DISEASES | THC-015 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PHARMACIST’S CONTRIBUTION ON THE WARDS | CPC-003 |
| CARDIOVASCULAR RISK ASSOCIATED WITH USE OF BIOLOGICAL THERAPY WITH ETANERCEPT AND ADALIMUMAB | CPC-004 |
| THE USEFULNESS OF COMPUTER-ASSISTED PRESCRIBING OF RESTRICTED DRUGS | CPC-007 |
| AN EPIDEMIOLOGICAL ANALYSIS OF POISONINGS IN THE ITALIAN REGION OF EMILIA ROMAGNA FROM 2005 TO 2009 | CPC-010 |
| LONG-TERM PROTEASE INHIBITORS-BASED MONOTHERAPY VERSUS REVERSE TRANSCRIPTASE INHIBITORS-BASED TRIPLE THERAPY: EXPERIENCE IN A SPANISH TERTIARY HOSPITAL | CPC-011 |
| RITUXIMAB IN THE TREATMENT OF ACQUIRED HAEMOPHILIA A: A CASE REPORT | CPC-016 |
| A PROSPECTIVE OBSERVATIONAL STUDY ON PREVALENCE OF POISONING CASES – FOCUS ON VASMOL POISONING (PARAPHENYLENEDIAMINE(PPD) POISONING) | CPC-018 |
| THE USE OF DABIGATRAN ETEXILATE IN HOSPITALISED PATIENTS | CPC-019 |
| ANTIMICROBIAL STEWARDSHIP PROGRAMME IN A MEDICAL INTENSIVE CARE UNIT AT A TERTIARY CARE HOSPITAL IN SAUDI ARABIA | CPC-021 |
| LIPID-LOWERING EFFECT OF TENOFOVIR IN PATIENTS WITH CHRONIC HEPATITIS B | CPC-025 |
| IMPLEMENTATION OF FRONT-LINE CLINICAL PHARMACY IN AN EMERGENCY DEPARTMENT | CPC-026 |
| SHORT FORM 36 AND HOSPITAL ANXIETY AND DEPRESSION SCALE AND ITS PREDICTORS IN SAUDI DIALYSIS PATIENTS AND HEALTHY CONTROLS | CPC-028 |
| KALAEMIA DISORDERS: A WARNING FOR CLINICAL PHARMACISTS? | CPC-030 |
| CLINICAL TRIALS QUALITY: MEDICAL JOURNAL PUBLICATION INVOLVEMENT | CPC-031 | |
| ASSESSMENT OF THE INFORMATION ON INVESTIGATIONAL ORAL TREATMENT PROVIDED TO PATIENTS IN CLINICAL TRIALS | CPC-031 |
| COST EFFECTIVENESS OF PHARMACOTHERAPEUTIC FOLLOW-UP IN HIV-POSITIVE PATIENTS TO IMPROVE IMMUNE RESPONSE | CPC-032 |
| PRESCRIPTION AND ADMINISTRATION OF MEDICINE IN A SURGICAL DEPARTMENT. CLINICAL PHARMACISTS INCREASE THE SAFETY OF MEDICAL TREATMENT OF SURGICAL PATIENTS | CPC-034 |
| THE USE OF MITOMYCIN C IN OPHTHALMIC PATHOLOGIES | CPC-035 |
| PHARMACEUTICAL INTERVENTIONS AT A DANISH EMERGENCY DEPARTMENT: INCIDENCE, IMPORTANCE AND SPECIAL TARGET GROUPS FOR PHARMACEUTICAL INTERVENTION | CPC-037 |
| USE OF ELTROMBOPAG IN PRIMARY IMMUNE THROMBOCYTOPENIA: REPORT OF FOUR CASES | CPC-038 |
| LOCAL INJECTION OF INFLIXIMAB FOR THE TREATMENT OF PERIANAL FISTULAS IN CROHN’S DISEASE | CPC-039 |
| THE USE OF SUNITINIB IN METASTATIC THYROID CARCINOMA: CASE REPORT OF AN OFF-LABEL TREATMENT | CPC-040 |
| STOPP AND START SCREENING TOOLS AS SUPPLEMENTS TO THE PHARMACEUTICAL MEDICINES REVIEW | CPC-043 |
| LENALIDOMIDE: SAFETY AND CLINICAL BENEFIT | CPC-045 |
| ECHINOCANDINS FOR INVASIVE FUNGAL INFECTIONS | CPC-046 |
| EVALUATION OF THE PROTHROMBIN TIME FOR MEASURING RIVAROXABAN PLASMA CONCENTRATIONS USING CALIBRATORS AND CONTROLS | CPC-047 |
| EVALUATION OF THE ANTIFACTOR XA CHROMOGENIC ASSAY FOR MEASURING RIVAROXABAN PLASMA CONCENTRATIONS USING CALIBRATORS AND CONTROLS | CPC-049 |
| EVALUATION OF PHARMACIST CLINICAL INTERVENTIONS PROFILE IN A UNIVERSITY HOSPITAL | CPC-052 |
| ANTIBIOTIC PRESCRIPTION TRENDS IN UTIS AT A HOSPITAL EMERGENCY DEPARTMENT | CPC-053 |
| TOXICITY AND RELATIVE DOSE INTENSITY (RDI) OF FOLFOX 6 CHEMOTHERAPY IN PATIENTS OF DIFFERING BODY MASS INDEX TREATED FOR COLORECTAL CANCER | CPC-054 |
| ANTIRETROVIRAL NAÏVE PATIENTS HAVE BETTER FIRST YEAR AND FOLLOW-UP ADHERENCE DATA IN OUR COHORT | CPC-056 |
| SELF-ADMINISTERED HOME PARENTERAL ANTIBIOTIC TREATMENT USING ELASTOMERIC INFUSION PUMPS IN ORTHOPAEDIC PATIENTS | CPC-057 |
| ADHERENCE TO DISEASE-MODIFYING TREATMENTS IN PATIENTS WITH MULTIPLE SCLEROSIS | CPC-058 |
| USE AND EFFECTIVENESS OF ELTROMBOPAG IN A TERTIARY HOSPITAL | CPC-059 |
| PREVALENCE OF POLYPHARMACY IN OLDER | CPC-065 |
| COMPASSIONATE DRUG USE: THE EXPERIENCE OF THE LECCE-ASL ETHICS COMMITTEE | CPC-066 |
| IMPROVING THE QUALITY OF DATA IN THE ONCOAIFA REGISTER AS A PREREQUISITE FOR OUTCOME RESEARCH STUDIES | CPC-068 |
| COMPARING ORAL RIVAROXABAN VERSUS STANDARD TREATMENT IN THE TREATMENT OF SYMPTOMATIC DEEP VEIN THROMBOSIS: A PATIENTREPORTED TREATMENT SATISFACTION STUDY | CPC-069 |
| VIROLOGICAL RESPONSE AT 24 WEEKS AND SAFETY OF DARUNAVIR/RITONAVIR IN HIV INFECTED PATIENTS | CPC-070 |
| DISCREPANCIES IN DRUG ALLERGIES RECORD IN THE COMPUTERISED PRESCRIPTION ORDER ENTRY SYSTEM | CPC-071 |
| THE EFFECT OF INTRAVITREAL BEVACIZUMAB INJECTION IN NEOVASCULAR MACULAR aDEGENERATION | CPC-074 |
| COURSE OF A PATIENT DURING IMIGLUCERASE SHORTAGE. APROPOS OF A CASE | CPC-079 |
| SUGAMMADEX FOR NEUROMUSCULAR BLOCKADE REVERSAL: A REVIEW OF ITS USE IN A GENERAL HOSPITAL | CPC-080 |
| ASSESSMENT OF HEALTH LITERACY IN PATIENTS RECEIVING WARFARIN ANTICOAGULATION THERAPY AND CORRELATION OF RESULTS WITH ANTICOAGULANT CONTROL | CPC-081 |
| RESULTS OF THE USE OF TOLVAPTAN | CPC-083 |
| DEVELOPMENT OF A PRACTICAL GUIDE TO DRUG THERAPY OF REFRACTORY PAIN IN ADVANCED PALLIATIVE SITUATION | CPC-085 |
| INITIATING THROMBOPROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN AND TRANSITIONING TO ORAL RIVAROXABAN | CPC-088 |
| DEVELOPMENT AND IMPLEMENTATION OF A PHARMACEUTICAL CONSULTATION IN A PAEDIATRIC HAEMATOLOGY UNIT: A PILOT STUDY | CPC-090 |
| PHARMACIST-DETECTED INAPPROPRIATE MEDICINES AND RECOMMENDATIONS MADE REGARDING A CHANGE OF MEDICINES IN THE EMERGENCY WARD | CPC-093 |
| A FIVE-YEARS SURVEILLANCE OF DRUG COMPASSIONATE USE IN A UNIVERSITY HOSPITAL IN ROME | CPC-094 |
| UPDATE ON COMBINED ORAL CONTRACEPTIVES: RISK OF VENOUS THROMBOEMBOLISM. DROSPIRENONE VERSUS OTHER PROGESTINS | CPC-096 |
| SMALL CELL LUNG CANCER: PATIENTS REPORT | CPC-100 |
| APPROPRIATE USE OF BISPHOSPHONATES IN OSTEOPOROSIS IN COSENZA HEALTH DISTRICT(ITALY). | CPC-102 |
| TRANSFERABILITY OF CLINICAL TRIALS RESULTS TO CLINICAL PRACTICE: THE EXAMPLE OF NEW DRUGS FOR RENAL CELL CARCINOMA | CPC-103 |
| OFF-LABEL USE OF OMALIZUMAB IN CASES REFRACTORY TO APPROVED TREATMENTS | CPC-104 |
| THE IMPACT OF PHARMACIST PARTICIPATION IN A MULTIDISCIPLINARY TEAM ON AN ONCOLOGY WARD COMPARED WITH A WARD CLINICAL PHARMACY SERVICE | CPC-109 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| FREQUENT INTERACTIONS BETWEEN CHEMOTHERAPY AND COMMUNITY-DISPENSED DRUGS IN A CONTINUOUS SCREENING PROGRAMME | DGI-007 |
| ASSESSMENT OF ANTIDOTE STOCKS IN HOSPITALS OF THE ITALIAN REGION EMILIA ROMAGNA | DGI-008 |
| EFFICACY AND SAFETY STUDY OF CETUXIMAB ASSOCIATED RADIATION THERAPY IN ADVANCED CARCINOME OF THE HEAD-NECK | DGI-009 |
| VALUE OF HOSPITAL PHARMACISTS SERVICE IN THE OPTIMISATION OF CAPECITABINE USE | DGI-011 |
| DO HIV/HCV CO-INFECTED PATIENTS NEED HAEMATOPOIETIC GROWTH FACTORS EARLIER THAN NON-CO-INFECTED DURING HCV TREATMENT? | DGI-013 |
| COST ANALYSIS OF HIV TREATMENT AND DRUG-RELATED ADVERSE EVENTS WHEN FIXED-DOSE COMBINATIONS OF ANTIRETROVIRALS (FDCAS) WERE STOPPED, VERSUS CONTINUATION WITH FDCAS | DGI-017 |
| STABILITY OF BORTEZOMIB 1 MG/ML SOLUTION IN POLYPROPYLENE SYRINGES-APPLICATION TO THE DAILY PRACTICE OF A CENTRALISED UNIT | DGI-018 |
| EFFECT OF PARENTERAL GLUTAMINE SUPPLEMENT ON BLOOD ALBUMIN LEVELS | DGI-021 |
| ANALYSIS OF DRUG ALLERGIES IN THE HOSPITAL‘PAOLO GIACCONE’ IN PALERMO | DGI-027 |
| USE OF VINFLUNINE IN UROTHELIAL BLADDER CARCINOMA | DGI-028 |
| EFFICACY AND SAFETY OF THE USE OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS | DGI-036 |
| ASSESSING THE QUALITY OF ANTIBIOTIC PRESCRIBING AT DISCHARGE FROM HOSPITAL | DGI-037 |
| BENDAMUSTINE IN LYMPHOMAS: A REVIEW OF ITS USE | DGI-038 |
| IMPROVEMENTS IN THE ACCESS AND AVAILABILITY OF GUIDELINES FOR THE ADMINISTRATION OF MEDICATION IN THE NURSESÍ UNITS OF OUR HOSPITAL. | DGI-041 |
| ORAL ANTICANCER AGENTS: A PROSPECTIVE PILOT STUDY OF A PATIENT EDUCATIONAL SURGERY RUN BY A PHARMACIST AND A NURSE | DGI-045 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| THE USE OF DC BEAD PARTICLES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF NONRESECTABLE MULTIFOCAL HEPATOCELLULAR CARCINOMA | DSL-001 |
| CARBOXYPEPTIDASE RESCUE AFTER HIGH-DOSE METHOTREXATE | DSL-006 |
| THE TREATMENT OF HEREDITARY ANGIOEDEMA: A REPORT OF TWO CASES | DSL-007 |
| DEVELOPMENT OF ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS B OVER THE PAST SIX YEARS | DSL-008 |
| ANTIRETROVIRAL PRESCRIPTION PROFILE AND ADHERENCE TO GUIDELINES | DSL-010 |
| CHANGES IN THE USE OF ANTIFUNGALS ON A HAEMATOLOGY WARD | DSL-011 |
| RECORDING MEDICINES ADMINISTRATION ERRORS | DSL-014 |
| DRUG AVAILABILITY: CONSIDERATIONS FOR THE HOSPITAL PHARMACIST | DSL-015 |
| TREATMENT SCHEMES: FROM TRIPLE THERAPY TO MONOTHERAPY IN HIV PATIENTS: ANALYSIS OF THE EFFICACY AND SAFETY | DSL-016 |
| ADHERENCE TO ORAL THERAPY IN ONCOLOGY – IMPROVING THE QUALITY OF PATIENT CARE. FROM LA SPEZIA, ITALY | DSL-017 |
| IMPLEMENTING RECOMMENDATION – AN ONGOING MULTIDISCIPLINARY QUALITY PROCESS | DSL-019 |
| VALGANCICLOVIR: AN OPTION IN THE TREATMENT OF CYTOMEGALOVIRUS DISEASE IN HAEMATOLOGICAL PATIENTS | DSL-021 |
| PHARMACOECONOMIC CONSIDERATIONS ON TREATMENT OF MULTIPLE SCLEROSIS: IMPORTANCE OF COMPUTERISATION AND ROLE OF THE DAILY DOSE RECEIVED | DSL-025 |
| ALLOCATING THE COST OF THE MEDICINES AFTER IMPLEMENTING AN AUTOMATED DISPENSING SYSTEM | DSL-027 |
| SIMPLYING THE MANAGEMENT OF PATIENTS WITH BIPOLAR DISORDER AND/OR SCHIZOPHRENIA WITH EXTENDED-RELEASE QUETIAPINE AS ADJUNCT TREATMENT | DSL-029 |
| SAFETY OF SUNITINIB IN RENAL CELL CARCINOMA | DSL-032 |
| TREATMENT WITH MONOCLONAL ANTI-TNF ANTIBODIES | DSL-033 |
| PROSPECTS OVER THE INTRODUCTION OF AN ELECTRONIC PRESCRIBING SYSTEM ASSOCIATED TO AN AUTOMATED SYSTEM OF DRUG DISPENSING | DSL-037 |
| EFFICACY AND SAFETY OF RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY IN THE TREATMENT OF NON- HODGKIN’S LYMPHOMA | DSL-13 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| SEVEN-YEAR EXPERIENCE USING AUTOMATED CABINETS WITHIN AN ONCO-HAEMATOLOGY DEPARTMENT | GRP-001 |
| MEDICATION ERRORS ASSOCIATED WITH RECONCILIATION IN A HOSPITAL WITH COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEM WITH ACCESS TO PRIMARY CARE TREATMENT | GRP-002 |
| IMPACT OF A PROGRAM TO PROMOTE SEQUENTIAL THERAPY WITH PARACETAMOL AND OMEPRAZOLE | GRP-004 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS CARRIED OUT VIA ELECTRONIC PRESCRIPTIONS | GRP-005 |
| MANAGEMENT OF CLINICAL TRIALS BY THE HOSPITAL PHARMACY DEPARTMENT | GRP-010 |
| INTRODUCING COLOUR CODES TO DRUG LABELLING TO INCREASE PATIENT SAFETY | GRP-012 |
| INVESTIGATION INTO RAPID (ALTERNATIVE) MICROBIAL DETECTION METHODS TO IMPROVE THE QUALITY ASSURANCE OF NHS MANUFACTURED ASEPTIC PRODUCTS | GRP-013 |
| INVESTIGATION INTO THE USE OF RAPID (ALTERNATIVE) MICROBIAL DETECTION METHODS TO DETERMINE BIOBURDEN OF NHS PHARMACYMANUFACTURED NON-STERILE MEDICINES† | GRP-014 |
| PHARMACOVIGILANCE IN A PUBLIC TERTIARY HOSPITAL IN BRAZIL | GRP-016 |
| IMPACT OF A MULTIDISCIPLINARY INTERVENTION PROGRAM ON QUALITY AND SAFETY OF PARENTERAL NUTRITION | GRP-017 |
| PHARMACIST EDUCATIONAL INTERVENTIONS PROGRAM FOR OUTPATIENTS WITH CHRONIC HEARTFAILURE | GRP-022 |
| EXPERIENCES WITH MEDICATION RECONCILIATION IN A DANISH HOSPITAL | GRP-023 |
| IDENTIFICATION AND PREVENTION OF DELETERIOUS EFFECTS OF SUPPLEMENTARY HEALTH PRODUCTS ON MEDICAL THERAPY: A CHALLENGE FOR CLINICAL PHARMACISTS | GRP-027 |
| DRUG-RELATED PROBLEMS CAUSE MANY ADMISSIONS TO A BRAZILIAN HOSPITAL PAEDIATRIC EMERGENCY UNIT: A PROSPECTIVE AND OBSERVATIONAL STUDY | GRP-032 |
| MEDICATION RECONCILIATION AT HOSPITAL ADMISSION IN INTERNAL MEDICINE SERVICE. A NECESSITY? | GRP-038 |
| DRUGS ADMINISTRATION IN PATIENTS WHO RECEIVE ENTERAL NUTRITION: ANALYSIS OF PHARMACEUTICAL INTERVENTIONS | GRP-039 |
| QUALITY IN PHARMACEUTICAL COMPOUNDING FOR PAEDIATRIC PATIENTS | GRP-040 |
| PRESCRIPTION OF PROPHYLACTIC PROTON PUMP INHIBITORS AT HOSPITAL DISCHARGE | GRP-043 |
| QUALITY MANAGEMENT OF ANTIMICROBIAL PROPHYLAXIS FOR SURGERY | GRP-044 |
| EVALUATION OF THE EFFICACY AND SAFETY OF ROMIPLOSTIM IN IDIOPATHIC THROMBOCYTOPENIC PURPURA: A CASE REPORT | GRP-050 |
| NURSES PERCEIVED PROBLEMS WITH ‘HIGH-ALERT DRUGS’: RESULTS FROM THE EUROPEAN INSTITUTE OF ONCOLOGY | GRP-051 |
| OPTIMISATION OF AVAILABLE RESOURCES IN THE IMPLEMENTATION OF A NUTRITIONAL SCREENING METHOD | GRP-053 |
| ANTIRETROVIRAL THERAPY IMPACT ON CARDIOVASCULAR RISK AND LIPID PROFILE HIV-INFECTED PATIENTS | GRP-054 |
| HIGH RISK DRUGS… REORGANISING THE EUROPEAN INSTITUTE OF ONCOLOGY | GRP-058 |
| POLYPHARMACY RELATED WITH INCREASED RISK OF HIP FRACTURE IN THE OLDER PATIENTS | GRP-059 |
| THROMBOEMBOLIC EVENTS ASSOCIATED WITH LENALIDOMIDE. A REVIEW AFTER THE EMA ALERT | GRP-063 |
| QUALITY RISK MANAGEMENT FOR PREPARED STERILE PRODUCTS IN HOSPITAL PHARMACY | GRP-065 |
| IMPORTANCE OF MEDICATION ERRORS IN THE ELECTRONIC HEALTH RECORD | GRP-069 |
| ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS TREATED WITH DARBEPOET IN ΑLPHA | GRP-070 |
| DURATION AND REASONS FOR CHANGING THE FIRST ANTIRETROVIRAL THERAPY: AN 8-YEAR FOLLOW-UP | GRP-076 |
| PRESCRIBING ERROR REPORTING AND PHARMACIST ORIENTED PREVENTION PROGRAM IN EMERGENCY DEPARTMENT | GRP-079 |
| DETECTION OF ADVERSE DRUG REACTIONS BY MONITORING ANALYTICAL PARAMETERS | GRP-084 |
| DRUG-DRUG INTERACTIONS IN PATIENTS ADMITTED TO AN INFECTIOUS DISEASES UNIT IN A TRAUMA HOSPITAL | GRP-085 |
| CHANGE OF DOSE OF LENALIDOMIDE IN RELATION TO RENAL FUNCTION: FOLLOWING THE SPC | GRP-087 |
| THERAPEUTIC TARGET IN PATIENTS WITH DEMENTIA | GRP-090 |
| DRUG POISONING: A REASON FOR CARE IN A HOSPITAL EMERGENCIES UNIT | GRP-092 |
| IMPLEMENTATION OF A PHARMACEUTICAL CARE PROCESS IN PATIENTS WITH ANAEMIA AND CHRONIC KIDNEY DISEASE IN TREATMENT WITH ERYTHROPOIESIS STIMULATING FACTORS | GRP-093 |
| PREVENTION OF MEDICATION ERRORS: AN OBSERVATIONAL STUDY | GRP-094 |
| ADHERENCE TO CAPECITABINE CHEMOTHERAPY | GRP-095 |
| EVALUATION OF CARDIOVASCULAR DISEASE RISK IN OLDER PATIENTS WITH HIV INFECTION ON ANTIRETROVIRAL THERAPY | GRP-098 |
| PREVALENCE OF CHRONIC KIDNEY DISEASE IN OLDER PATIENTS WITH HIV INFECTION ON ANTIRETROVIRAL TREATMENT | GRP-099 |
| CLOSING THE GAP – IMPROVING PATIENT SAFETY WITH BETTER DRUG INFORMATION | GRP-104 |
| CRITICAL APPRAISAL OF A NEW MEDICINES PRICING POLICY IN GREEK HOSPITALS | GRP-120 |
| INFORMATION TO PARENTS ABOUT PAEDIATRIC HOSPITAL-PRODUCED PREPARATIONS | GRP-122 |
| ASSESSMENT OF INAPPROPRIATE DRUG PRESCRIPTION IN OLDER PEOPLE THROUGH A SCREENING TOOL | GRP-123 |
| WEB 2.0 IN THE HOSPITAL PHARMACY | GRP-126 |
| THE IMPACT OF INTRODUCING OF CLINICAL WARD PHARMACY SERVICES | GRP-128 |
| SEVEN REASONS TO PROMOTE CIVAS-ASSEMBLED POINT-OF-CARE ACTIVATED SYSTEMS FOR INFUSION OF LABILE DRUGS INSTEAD OF ON-WARD TRADITIONAL SET METHODS | GRP-132 |
| DRUG SAFETY MONITORING IN THE NORTHERN REGION OF ZAMBIA | GRP-133 |
| PARENTERAL MEDICATION PREPARATION BY PHARMACY TECHNICIANS ON THE WARD IMPROVES MEDICATION SAFETY | GRP-134 |
| DESIGN, INTRODUCTION AND EVALUATION OF A NEW OUTPATIENT/DISCHARGE PRESCRIPTION FORM FOR BEAUMONT HOSPITAL | GRP-135 |
| CONNECTION BETWEEN THE HOSPITAL PRESCRIPTION PROGRAM AND THE PARENTERAL NUTRITION COMPOUNDING PROGRAM | GRP-136 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EVALUATION OF SOME QUALITY INDICATORS IN THE MANAGEMENT OF DRUG ACQUISITIONS | OHP-005 |
| THE RELATIONSHIP BETWEEN THE SAFETY OF PRESCRIBED CHEMOTHERAPY AND ADHERENCE TO BREAST CANCER GUIDELINES IN A LEVEL THREE HOSPITAL | OHP-007 |
| NON-FORMULARY DRUGS: SITUATION ANALYSIS | OHP-010 |
| THE APPEARANCE OF DRUG-INDUCED DIARRHOEA | OHP-012 |
| COST ANALYSIS OF SELF-INJECTABLE ANTI-TNF IN ALMERIA (SPAIN) | OHP-015 |
| COST EFFECTIVENESS OF TITANIUM NITRIDECOATED BIOACTIVE CORONARY STENTS COMPARED TO BMS AND DES | OHP-019 |
| COST-EFFECTIVENESS ANALYSIS OF PATIENTS IN PERITONEAL DIALYSIS WITH METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA VERSUS DARBEPOETIN ΑLFA IN SANTIAGO DE COMPOSTELA UNIVERSITY HOSPITAL COMPLEX, SPAIN | OHP-020 |
| GROUPING PATIENTS WITH THE SAME CANCER OR BIOLOGICAL TREATMENT ON THE SAME MEDICINES ADMINISTRATION DAY IS AN EFFICIENT TOOL | OHP-021 |
| ASSESMENT OF THE COMPLIANCE DEGREE IN NON-DEPENDANT RESIDENTS IN A NURSING-HOME AND REPERCUSIONS OF THE PHARMACEUTICAL INTERVENTIONS | OHP-023 |
| CLINICAL AND FINANCIAL EFFECTS OF DISPENSING ANTINEOPLASTIC AND INFERTILITY TREATMENTS FROM A HOSPITAL PHARMACY | OHP-026 |
| THE USE OF STABILITY CRITERIA FOR ALL IN ONE PARENTERAL NUTRITION SOLUTIONS IN PAEDIATRICS | OHP-027 |
| PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION IN A TERTIARY HOSPITAL | OHP-028 |
| DESIGNING AND IMPLEMENTING A STANDARD NUTRITIONAL STARTER SOLUTION FOR PRETERM INFANTS | OHP-031 |
| EVALUATION OF THE COST SAVING ACHIEVED BY CENTRALISING TOTAL PARENTERAL NUTRITION COMPOUNDING | OHP-032 |
| TRAINING ON PULMONARY HYPERTENSION DESIGNED BY A COLLABORATIVE PHARMACY PRACTICE | OHP-034 |
| ASSESSMENT OF ADHERENCE TO ANTIRETROVIRAL THERAPY | OHP-037 |
| EPIDEMIOLOGICAL AND SURVIVAL DATA OF PATIENTS WITH LUNG CANCER ASSOCIATED WITH SYMPTOMATIC BRAIN METASTASIS | OHP-038 |
| ANALYSIS OF PAEDIATRIC PHARMACEUTICAL COMPOUNDING IN A HOSPITAL PHARMACY DEPARTMENT | OHP-043 |
| COCAINE AND HEROIN ADULTERANTS | OHP-047 |
| THE USE OF GLUTAMINE SUPPLEMENTATION IN THE PARENTERAL NUTRITION SUPPORT IN A THIRD LEVEL HOSPITAL | OHP-048 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| MEASUREMENT OF METHOTREXATE IN CEREBROSPINAL FLUID BY FLUORESCENCE POLARISATION IMMUNOASSAY IN PATIENT WITH MEDULLOBLASTOMA | PHC-002 |
| EFFECT OF INFUSION TIME ON THE PHARMACODYNAMIC PROFILING OF MEROPENEM IN CRITICALLY ILL PATIENTS WITH PSEUDOMONAS AERUGINOSA INFECTIONS | PHC-003 |
| ATORVASTATIN: EVALUATION OF DRUG USE | PHC-004 |
| BEHIND CYP450 INTERACTION TABLES Ñ THE EFFECT OF GENDER AND AGE ON PHARMACOKINETICS | PHC-006 |
| GENETIC RISK FACTORS FOR TYPE 2 DIABETES MELLITUS AND RESPONSE TO SULFONYLUREA TREATMENT | PHC-007 |
| COST-UTILITY ANALYSIS FOR INDUCTION OF LABOUR WITH DINOPROSTONE | PHC-009 |
| DORIPENEM VERSUS IMIPENEM IN VENTILATORASSOCIATED PNEUMONIA: A COST-EFFECTIVENESS ANALYSIS | PHC-011 |
| ADJUST DOSES OF ANTIBIOTICS IN ACUTE RENAL FAILURE: THE ROLE OF HOSPITAL PHARMACIST | PHC-012 |
| THERAPEUTIC DRUG MONITORING OF CAFFEINE IN PRETERM NEONATES | PHC-015 |
| THE IMPACT OF GASTROINTESTINAL TRACT RESECTION IN ORAL DRUG ABSORPTION | PHC-016 |
| CLINICAL EVALUATION OF THE USE OF STATINS FOR DIABETIC DYSLIPIDAEMIA, ESPECIALLY IN THE SEOUL VETERANS HOSPITAL | PHC-017 |
| USE OF ERYTHROPOIESIS-STIMULATING AGENTS IN PATIENTS WITH ANAEMIA OF CHRONIC KIDNEY DISEASE | PHC-018 |
| DELAYED INTRODUCTION AT REDUCED DOSES OF PROLONGED-RELEASE TACROLIMUS IN KIDNEY TRANSPLANTS TREATED WITH QUADRUPLE IMMUNOSUPRESSIVE THERAPY | PHC-019 |
| ARE THE OFFICIAL RECOMMENDATIONS FOR AMIKACINE SERUM LEVELS SUITABLE FOR OLDER PATIENTS? | PHC-023 |
| REASONS FOR CHANGING TREATMENT IN MULTIPLE SCLEROSIS | PHC-025 |
| PATTERN OF ANTIBIOTIC USE IN A TERTIARY HOSPITAL IN NIGERIA | PHC-026 |
| EVALUATION OF THE REASONS FOR SWITCHING BIOLOGICAL DRUG TREATMENT IN RHEUMATIC DISEASES | PHC-027 |
| SAFETY OF EXPANDED THERAPEUTIC RANGE OF VALPROIC ACID | PHC-029 |
| ASSESSMENT OF PHARMACEUTICAL INTERVENTIONS IN A CLINICAL PHARMACOKINETICS UNIT | PHC-030 |
| ANALYSIS OF THE INCIDENCE OF POTENTIAL DRUG INTERACTIONS IN CARDIOLOGY AND INTERNAL HOSPITALISED PATIENTS | PHC-034 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| FINANCIAL ASSESSMENT OF ASEPTIC PREPARATION FACILITIES IN EUROPEAN HOSPITAL PHARMACIES | TCH-002 |
| AUTOMATION BY CLEANROOM ROBOTS IS CLEVER GMP | TCH-007 |
| THE DEVELOPMENT OF HOSPITAL MANUFACTURED READY TO USE HEPARIN SOLUTION TO FLUSH CATHETERS | TCH-009 |
| INTRODUCTION OF AN AUTOMATED MEDICINES STORAGE AND DISPENSING SYSTEM IN A PHARMACY DEPARTMENT | TCH-010 | |
| INTRODUCTION OF AN AUTOMATED MEDICINES STORAGE AND DISPENSING SYSTEM IN A PHARMACY DEPARTMENT | TCH-011 |
| INTRODUCTION OF AN AUTOMATED DRUG DISPENSING SYSTEM IN AN INTENSIVE CARE UNIT | TCH-013 |
| EFFECT OF BAR-CODE TECHNOLOGY ON THE SAFETY OF CYTOSTATIC DRUGS ADMINISTRATION | TCH-015 |
| HOSPITAL FORMULATIONS FOR THE TREATMENT OF NON-ALBICANS VULVOVAGINITIS | TCH-016 |
| OVERALL EQUIPMENT EFFECTIVENESS: A PRODUCTION WORK TOOL APPLIED TO A PARENTERAL NUTRITION ROBOT IN A UNIVERSITY HOSPITAL | TCH-019 |
| MICROBIOLOGICAL STABILITY OF VIALS USED IN CYTOSTATIC COMPOUNDING | TCH-022 |
| EVALUATION OF SURFACE CONTAMINATION WITH EIGHT ANTINEOPLASTIC DRUGS IN PREPARATION AND ADMINISTRATION AREAS IN POLISH HOSPITALS | TCH-023 |
| PREPARATION OF CAPSULES FOR INDIVIDUAL PATIENTS: VALIDATION OF THE OPERATOR’S ACCURACY | TCH-024 |
| PROTEOMIC APPROACH TO INVESTIGATING THE MOLECULAR INTEGRITY OF INFLIXIMAB AFTER RECONSTITUTION AND DILUTION IN TYPICAL HOSPITAL CONDITIONS | TCH-034 |
| STABILITY OF DOCETAXEL INFUSIONS | TCH-035 |
| CYTOTOXIC SURFACE CONTAMINATION IN A ROBOTIC SYSTEM COMPARED WITH MANUAL PREPARATION | TCH-039 |
| PILAR COMPARISON BETWEEN MANUAL AND AUTOMATED PROCESSES IN THE PREPARATION OF INTRAVENOUS MIXTURES | TCH-040 |
| HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ASSAY OF AMIODARONE CAPSULES | TCH-043 |
| STABILITY OF PHARMACY-PREPARED VANCOMYCIN AND CEFTAZIDIME-FORTIFIED ANTIBIOTIC EYE DROPS AND SOLUTIONS IN POLYPROPYLENE SYRINGES: A REVIEW | TCH-044 |
| STABILITY OF CEFUROXIME SOLUTION IN POLYPROPYLENE SYRINGES: A REVIEW | TCH-045 |
